<SEC-DOCUMENT>0000200406-22-000048.txt : 20220429
<SEC-HEADER>0000200406-22-000048.hdr.sgml : 20220429
<ACCEPTANCE-DATETIME>20220429160824
ACCESSION NUMBER:		0000200406-22-000048
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20220403
FILED AS OF DATE:		20220429
DATE AS OF CHANGE:		20220429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		22875344

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>jnj-20220403.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:16b74ba9-87ed-4a1d-982b-bd3712a1fa43,g:84010c2d-9ae9-41ea-8d72-e231a49d0ab7,d:89b54799c61648c0892d664696387b28--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:jnj="http://www.jnj.com/20220403" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20220403</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV80LTEtMS0xLTU5NzQw_86b9e38f-824d-4bc7-b3df-a7e96dd7c2a3">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV81LTEtMS0xLTU5NzQw_c3910bc9-ea60-478b-a857-8ecc4808d8dc">1/1</ix:nonNumeric><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV85LTEtMS0xLTU5NzQw_84cb03bb-afae-43ca-a6b5-82e6bebd537a">2022</ix:nonNumeric><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV8xMC0xLTEtMS01OTc0MA_c3da6c71-7756-4b03-9e82-d41641030966">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV8xMS0xLTEtMS01OTc0MA_b15850b3-2e81-440c-8a2c-34efd318d66c">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20220403.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1bfbdd2721a47c78e496b6496fc1e14_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied996a6da7cf4f25bd1d614be305c4fc_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902d46a64ed041188ea441b2e02dd66d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc9d571951142629fdd9f5cbbd77efa_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58cd890282c34ce19a979c568d6b2d2e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc6c7e3c97b04a4c81417695c15b5102_I20220422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2e490e1b4676470caee65dbdb296781b_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92abad263bf8419daa6c3d10a1e69673_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2336cd90b8e74beeb66f460bec6b6238_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic266b1b5dc484c669aed5ae886e3f910_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39899651e6354f279c457a156b59b4a6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5ba76506ab44498ae6e4962d624eae_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f1bd088462748abb8bf782cfcc07129_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbe0f983eea14da3b437dcf18bfa144b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i225ea33e8dbf48579d422823c0350b4f_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795ff92791494382a1d26a7b84fee3e5_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib230b0f5235943ff892ee51f02112200_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7dd50adc00246e78b4d70267adf860f_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccce36176b41451cb72ade5fd7acd620_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idab9077c64f34317815b7b3af8096958_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5b2d28a80e44d9bdcda5d265440506_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73bff5df510141c6acab233c801c6f0b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333b166f4d2f445f9cd585f8eb2f1c02_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeeeea464c1645cf8c4b046709808f46_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e4b855ab6e9400da78a4a7e4118d0c0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd4bbc39e1a4259935490333ab02382_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ebcce5ed4d4fa88b1380565ad0cd2f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i613a24ca8cd34aaf87209b0ce754c9a4_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f965bb993c84e458df2a90932f7f838_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6448f96ad7486da2e84f5da3d3c578_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4dc0429231c4601861ff53b097feae5_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c14471cebb545af9f344092e43e244d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i751430dc512846d6bd038f8d3e545317_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8427fded54d64f59a314115c202ccb4b_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca6e4c72b3b411e8e7e9c40313e1011_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i631a68382dbe4356a80463ddeb81e9e7_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbab423fd5014e1482bba4a9327c8dc4_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97cbf7df6c0c4273a06533b0d3e5c206_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic60ed3f5f8b143f28c600b4ef6f83731_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754795b41ad945a7ac5ecd6f2ea1cbe2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273a2ba53146449c8a18b08bc38532ee_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706befc122c24b74b7c46cad04eefa00_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ac3910bc9284705b8c0311e059b8e26_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6fe7c6e2f574a619178fc635b10b3b2_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic00ca16d24bf44179d8fcf374cbf27d7_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i681532a4eb3648508653f9fb60ec8408_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b8fe868a0e94657aceaf9efda5d051e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bcace6a0596406b8dd0416cfb063a83_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d4870c963ef433abc7a4fea5eba6e84_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8ab9973a5e462d9e057abf51bcf297_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eadcdc996d94731b0bc1014ca9e7fd0_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic315dcf608444a39b1cabd079a7d46cb_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bdcc356986e4b3e80fe4abf6ec3b52c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07dd6b6cd781421abf5b7b35627e6b59_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b7f48faa4c44dd8729fef7add9958e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19d4778b3c184c5b9a1268b12772f834_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab697ff2c9043c0af2d3551559c5cc6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ca621269f74333bfcea41317eb612d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ef606fc8d54064ac6785b084df413c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc4d7ef218294617ab67cdd7ff8ae201_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285862bf68fe4a1e9a5f16fb54ec99bb_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50372bc3c1fc4262a02f85583b8add01_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide7dc652d8a14e07b4a76aeb7b9c4d21_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13b350d42d74d879d6f63915693746c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fbe2ddfa5bd4c3c81d6b1a89bd6a3c6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6710a293c7049a89bd678b9ebf357ee_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8c65dce193b4085ac9029e9479cc836_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4612c0bb5e5643f0995c9a09afdf8c41_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica35e7e4a05a4bf1ae3566e17b66227a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3a21486e41041aea8b93609d24e888e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5125127475344a8bec0db5ebc5cba0d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24069a0bb5314816b75b91710ef6fb4f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fb4260113ae447a8ac220acba4cae35_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd707f3f168499dbac4bc8fb516087e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35c1225f1fc642b89ce27325e2764fe6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca0c41746e24c10a5010f5e3b375875_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906bc2f6d0734e46a265b998dfb78e1f_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a7b113cd604b97b6359f1ca89f88e9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac181bd434134d0f99d2723052ebb78c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98498dc117454edda8260632bcf14b3e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1a147f22b444088512ccac59a70251_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629d4c6fdf6e40a39dfb7d01c00f6bbc_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4edbfa092a4db08c3097d31dfde751_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5358dcc8f8d448188a6577bca61d7df2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e8ee39318f4e8b8637328665ee6121_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9976c768bbec41ceb31dd3e5aeee895b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0acd8032704810ac6c33c652bb3f4a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86deefadb42a48e9bb9ba37613cdc416_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i096bbfc984b74afe83163ab74df3e9c9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae4da99d4bba480d99292b2891dc32d9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200c16a786fd4d0d8795c1fc3f58843c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d4939c05de24312b1d31bf71b02fe56_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65442762e5c14bc1abd1248fe23d8341_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c04b36d74874be78fc77e16c8fb290e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92ed1d2317744e2fbc2c3b45e1b4d2e2_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic66d9ac41ee14e4f935d98d0f8036683_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dc14e7b1e2e4a29877dd2b95650a3ac_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice21f8d2655e4d0f8095be5911f1fd8b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4f1c2e35354c268ad4b4f0c299f46c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe06a04b32f541198cc74c4294d74b7e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ce73a23c814452a90b72fe868271de_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i977c041569204263b24ecc0054d30d6f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i581046ca0e0f48929501b5a10dbaba2f_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645a971a555b4c089758583b67f9d08c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f4dbad0006c47f48dad1e81741750fc_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3823718f66a4b499cedb42d987cd246_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80323310c7943d89e72028b427412c1_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf02920ebc8f4f46a0a1307481df3c99_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195975cd0e7f446da43714458700190f_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f60cf5f7ad40df935bf2a4865220fc_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a3783f757347e6a884c99fba04723c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05510e5c3ec344fca7b25f4799ad39c6_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ee07eab57304c94a3dfcb3ae7fbee1e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40143a9bc0fb45f6989738a947b0838e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b3a8c85a4a4df28a3c6f3b7f5df006_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad75e5d7a8d640fc9b410ca0e00b1a1a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423527772d4f4352be8af130cdc45743_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e32e93333a24edd846ce09ab84c19ef_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40bc079e1bf040d6a6c8095e02268b3f_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2153712ae1a485ab5669a52af66f1b4_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144bd07273654fd298013a92e5d0b27f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37485b7a6e8c4c1689bb2f8982088f64_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59607f6cdca645209d4015cb4e2f5619_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5cdf7b3948454394fae9e0a5c60184_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5aed6e544644ac091fcfd4f67609c7d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a4afb3d1574ea6841481a8c54e0b66_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32a07094db884448a992148a352debab_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d06754ef7e4c02b339a96da42f23d6_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c2d2898cff43b78e1d5e6035922a00_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idefc9360cf7d4a84871e4e4fd6c66079_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i612d93e077824654b25097d940711e0c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17e9a78d65144cabf6d0224cea88596_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0abb325296848eab35197c32673d301_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40df713ca2794a8f8f08885f6d2c8143_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b0e360214949eebb51638497d0ec18_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80cc25f225c142c9b2e51f9cc136f5e5_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i574a41416f664b5a90a57869a7b69d04_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10a6f23182d14a35bc979be835d03213_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic03f9d9c139545c6bf756b9af8dd04ce_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97fa957218749a5b2bbde6c2237328b_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88fb397aabc74f9d9919879a38532a66_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb107f40561b447d8a9bf98e62f3c54e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d1cab1bb8af45f486a55147f5bdbe07_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb5c763b5bb45f899c132bc31626b95_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c666c963c647308254b695cefee498_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ced426dcbd04d1f98029e772acf4b64_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b54bd64a574cf0ae8d1e57ec0bc8c6_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8afc02d95284431197455ed2c01e0b02_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1774beb33cd94056b250899436621d79_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9905446b33e44249abeae66f95c5b42_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f3e5d7909e4521b088bd43ea9303f3_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb2b18369ff14783885a3ab5d402b053_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i410644799f39419bbcdf5b89613bbc9b_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cf0299af0124017b184f3378b2e8260_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d410447a42f4d80ad241f38be44e316_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02c9f5cae6f44540a89c680000306ed9_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic108a9e12f3341939ea27c4f85b55d98_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14b3ec03d9234219b5bd925a86a41790_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic66945fc64dc4dd2b97e6ae77585e006_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22df2c32fde24c49ad70d6267b39461c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73b4ecb878554ed895e6731af84a2410_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec5b6d69f26346649c425f8e2933241b_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ae7da6e5e348d3bfd658d212535274_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4fd353404164731a511e7927bec85a8_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92d34c20152a4de3a3f77d8cb010b8de_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b80c19de72d40139ee47e1d21a6e42a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56414cfcd9cc49dd995d25343ea06a1c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafde104933164c4cad0deb69abac440e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf01842c5cf54c898543482c4a444521_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bbe50e67f15448d8798dfde818d59e8_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d10d54d1af41b08272b793afbde882_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ed4cca79f874285afd96939684875d4_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i253bb8f802eb4367b1f601f0eb271aa8_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id79227d6ca8e47c096d1f5db54292e11_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26657c8981ae46e79d22c832389a2403_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9b9d5f07bc14a4ea1751fd21547dfb0_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i050bb5d8583f4db5b7cab1781f41402a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98f5927fb8dc474187a16c8bb7a8f633_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0640760a4d046fdb9b6672981624f0a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7815fcc60b846c4bd4ae4cf64f6a1f5_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ee6a13418e74e9f97b7fce4de45eee6_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7cb32255274ae599a981a6313a0d95_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56cae7f5eeee4fc995a14d122519fdf4_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice21280ebab242638498d336fcf84a9c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25f1dd3b92e340df9e2c6814f388f614_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc07bbbd134548d4bab1577bebc273ed_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9c6f72bf20e4383ba64ecbe3c4bd15b_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a714f2428ce4aba8dc71a3ce15cc543_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c824e2faeb34de8b822a2f57f817f25_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f54a6d9c9f2407397bc4616bc6e7af9_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca5c18e09944b9b8a34ad2546775220_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdd4fbd384b84fd3a0d6693ec4c9c252_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b2afac7f2047619163d4ced5060322_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb79658f5f2d475486e1d306a4118a47_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb22c0fec5c4490384df777e042c7c81_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52075d97746b4d90bea9272a17635cd9_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia51b7240c69e498bbd44aa9775d04606_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice9f99b199274666b12ae2df91d2c820_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67077af31f114a30bffdc32fea20dfff_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i188f32b459e74d5cb0f963e4e0a3f7ed_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ca814e494941cc9558570cc4279cea_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44982952c49f4e749aabaf9dcdbec1dc_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b685ecce1643ff89bfb3895523a51e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea8fdb3616f451c90baf65707bdf669_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08457c1d48c94eff8dc2ac47bdf0c7b5_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fe81741fd58415cb3509d83ffdc5e73_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c1d9e65495e4ece85762fec2639f5dd_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12629c9f73b74eff9c5a235f547f2241_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3970f29929a24eacb55a58c7e37c52c1_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3af18d0134471c93564e5fd5f3fe0e_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a1c7715113b48dcbff2dfe6536eb602_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec5bcf102a34a1b87cf004f535337de_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6885bfb3e4984c65abbb4580fc179cba_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4d3a223ac884f86b9a206b4617aa103_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id914def5ea98451bbfd52ec51a11e6d4_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iededfd7a59eb43208e3672b72a308066_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f9a83e7716457aa17dcab50434530a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3f9d6c591e4c379b03f6a63223ff4c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc2dad290bf4b1f84e0014e807f7d22_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe07c4d0ab547cf987486709e3723ea_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a3fd14bab994cb2b98c874567c9124a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb0087669f7d433a94c2175b61948c30_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7ae03e86ec34f059e03de3ba7a0fa16_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7525d9cf9c7a4c2eb64364d6f1fe110a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife167dfbe51e4f7bba2d6c116e0acbe8_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6724f9eb2f284a7897adfe49ccf0a1bc_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e6d608431ea4c5398a0d5693ec02ce7_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1fb99008d5c46f782ebe421c09b6c86_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i809a6e12d5804dfb8ab4ace60751a5d4_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia20a226df1534401beb4ebac52ca168e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64bc3e5d158d4182ad9506d5f1a6e623_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02143dea06fb4fbbba003f6bb1395472_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i371566e0803142cea79b2a73e447ad55_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb12711ae25c499293d55bef830a1392_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9afdfa4aab43f5aec11564a7a210ec_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d981e7841b2446e99bdfd3c1765f8fd_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i655ff821171a4447a9788502f3181ca5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79fbbc6f7a9f4234af3a15aaeeaba82e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb1f6b66a0df4ab5a5db2bb2552e5b52_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3c368d3ea94156894bb15d205cbe39_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04f969ee3dd48eb9bd1be04f519efba_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1fcea51f4fa46ea9140cbab41a14eb8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ab2638f2434165b9cb7a98bca9725c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036b309881ec46189aa9470289afa49d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68eb55b964054c96a96b26b18621d7fd_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i326f78b1620b461cb2172429271e8699_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a97e3323484686a9262c40ba0b98ce_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i579a8661a8a943369207a48d2742c946_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie58211c7e72c4650b6392f3161a3bffe_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc118b408a9a4fa0a2216582ec2c57d3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea43f39e6f7e4722a355ac665f3270c0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a68fc6f7f84ab9bd6670bd40be776f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822f34b9534c4b36800cd53b915bfd96_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e49973bd224b328cb521a49bd33c14_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc09b5880e446b6b7704ca8b8c71bf9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icebf6d8f73bf4c99a24334b6c6b70834_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d1e565782ba4f77b615f220541630b5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8572638eba1747738bf792b8ccc0d65b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i106a09af4412484ab101b4dff6f6060a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30c0af8ca15849f8888a804c0a76e8f5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cfa95d8a78b40e4a7dfc45c287e5d8a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c6944ea87e4a3dafff3f45a308061f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46c50a0f6783436cb25640408523922e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e793e0192504c92a6fb0cb90815740a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i908ec40014fe4b879088ba1b344b5a37_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3aa331b4f344986bd6aefd2d877917a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c161740da694af9a2557994290040f0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b056bd57be1420eb472b82a9ad65490_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd2d0c278fd4ccb9e5f826f44c15a6b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd5fd3ed29041aeba59bb41d9957e8e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ceb1cef02743f1b6c9be2aa05040b3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acd3aa5bee74304878a6f9cbf1956ec_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie77366e1975a48bd8912cb5972f077ca_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ceadbf51b24faa9f04ba01b0a27b54_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4e3ae4eef749e986b5c6bd8d739748_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84d71c2b7b4544b1a58237715b2b3c42_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i678bfbf7014e416f8aa38a66f366d4be_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib688bd3f296d41f0b14572e3064b458d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4627a516050411dbd08c0de6091128b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d275cd215484120b60ac1c7626e17a7_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932bcfc6315d438f826521020670f715_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7411eebec7264351bf377981afe68c71_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f0f05017af45e3863ccf8b056567cb_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3d886ec05249aab4e1f0ce7760f1c8_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a5159ea7ea34a9486f467d8b275261c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b965aef16c049ca90d08a094faafdcd_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cbacfe0de454d4fa786ace56cada354_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd509ce95fe400781462e4ad6cfa01f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d4fd750dd7840a1bd8f81d424809f1a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac6c831f375741cd86628f708528bbc4_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i378ba8c96ec94703a6594ef190bcf501_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i770e070317374dd9bbc2d03a76164315_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id00933be305c4a70bc5ab93fcafbfa34_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30ecdf550ad642faad28a0a3da3a0c49_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic914d835318f4ac59e6afec0dc209943_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea83d16b7bb4bb4852dde662d6d8a03_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i355c4b8323c94982a0e7d8ad5ef02138_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fe9781715b43f6b43d02d8a29fdd61_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1de5e9029e04a3088baa1a08b8ee842_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i919b94882de1475288644c1f41c738db_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74ae7d88be64d3c866359475a6b9e4d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64b27662b65c465dbfc102823591a764_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275f4a59164a4f3cb58fd6b37c979201_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d196ab07bb74237905594d14817fae6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea6e2e05dd264470bda927b1746471f2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5baa35e48631478bb99da941854cbc28_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5218805bf34a4f8f9bca9cd6f32c57b2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f43191ea7584ff5a4538caed79690b3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80675b68ae0443c09f1f157dcafd38b5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d5eb90c90324a6c99251bc1ef4cd0b0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a3a53a0ad9046aca93e6a7542cd2283_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bae0a6534fb41dfa209ab28eb17aac8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbb41835a7214d6cbbc92d58157fea67_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7211490fa1584a8e8f0474626afbda8b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if075bf0d83ea40f880b89b7f1b810a39_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6904e2c80904427fb7a581c5096e57a2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb39ed1f03bf4875b56192f82a2d67c8_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f8d1cf7d44f47e6b575833e5e6f0d05_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff32341c0bbe4b5ea9b566ba153fbf51_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ac62a4e6cb4f948252748f571a1ff6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab0aa5e7ee2b48aba645333335c83702_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9efb7452eea34bc9898890c0842597d0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1665d864d98a4d47962732594b5b38f9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc4d03da8ff94f98aab51935db754a84_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb131415d3694db89b4c3cc631aebfad_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b92c4c34a94ef0a8c83ea08eee3b04_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d97f7b5e9e411796b79b2aed308f49_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4c0bdbeb7e481486ce84464add9cec_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8f65547983b48f38c56effa03744e71_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a180a67aa34f04985a9c36da5181f4_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i726bc4433398439cae78ea7e13f10dd7_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26e429353e64268acab78bb090eb6ee_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41cfcf4ec4d349ac965bd4f72a911528_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d87460fbbce401e9e230c449de32a04_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7518353c94d148b98920a57e3c13f558_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f3a3fff4b64c42b7391f6783fc86d0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i283ab968a33a4019bbca8dd07bb73fb5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe04729f6a041dcbcc8950cffbd70ad_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d850d220f25461faec903dbc0514f8c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0520f0e2ba8d45dbbb23db3edcb3b1ec_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9fba2a4e93645948a9ff0513bb728e3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f85b561077441a8f29c95efc82e1ff_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb33e483487440ffb0cfd196244dae1e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2104212889d4866a172b2ffa3412b5b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d54355525c45a48dcc9d5a2c07b492_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73699a20bfe4592ab11597b967e3e81_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43632776d7d241d6acebca744803b602_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8041af648d74844acd07d971cac9b88_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3003caab41114b89887d780481856b8f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieefaab0fe06d4a1d8825a8a2912d415d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c1c0146fd1e40afb97e83e53dac0b3c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113143b999484cd6b7094f5ffb7f6934_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6df7baa0a5740ee8592ff53dd67a1be_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dc562abb9fc439a87f2465b603dc878_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie870e747ed874ff9a84adcffcef46376_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23204760220240d9910ea175d94d29aa_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i337ee039b35a4dd29e3fda93f8888073_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i060264da9f6d465d94d5b31aa47981f0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e6a826272dc41a88d80ad0ce8b56bc4_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d3e119c5794d36acde2361b37d9315_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i371b019e1643431bbc3c4121387c7e9f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d4ebc5182ee44909c1d020a6781ee9b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5e99b0b04b4efeaf8272a60bfe9724_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1470034f0eb141a98c1afe534e4076cd_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a067e9da7f41b8a982801bb0a850bf_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dcdb3a4cc9d45ba8da97ec07cd15b51_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf27b40739cc4a25b5ec694c5b8c000a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b61e2b815e447c49c894f30ace4c7a6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa838e3db72457496cc39435fbf78f1_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91a06bb3ee246aa9b6beeac53b5b676_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie69adf3622ff4db8a081d1405d03154b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b076947d8349c4991ca5f8d983bb95_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57498e999f848169b4085103b58e794_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49109641ba840d7ab935c9251557fcc_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4d7ac479b54426c9c4da3f1551137ba_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e016b979bf4274a83e021809fededc_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04a88fda6b614cf0bc0a0b4fcc001282_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2982a107598a4da5a6e1a03aedec047e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e34ced22b4405fbd24f5ec2c767132_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide41d96049794347b667732daaad5f29_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice792ebb5db345a282d8d06424353702_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ba5f0fbf984535b145a1eb04807f5a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2ba44f06524718a59342b7ecc0be0a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd97dd4e710848aa948f66ce61e79d4e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i756b031800b74f1088dc4e2c1b95636e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002baa7993ed4772b35c50223b4dcc36_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic38731cd692a4b1c87ff4416775e7a6d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b7974a50c1c4182af2999542e8fdf1d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e49e3349adb4e589300bc5c59272da4_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9457829763fe4b90be78ca6d38abd305_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eaa50ccd6ea42d1be79c5484c2037fa_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4a95b9177eb4a48b5fd6f019f635f7c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9a1c9e24cc4521a4e8fd258ab91323_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7caf84ee3bdf4518b4c9c4166e4f8887_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib49af7ebdc1b4c46b17b462113ef14c1_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i602a6924da2441d3ab9cf85ee12fbb06_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc426c53b2a430092d248e6084cd03e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf7d6e57e38d42b4b47bd10b91df04e7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7798838f313f4f9e83d9c4854b30c499_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idff12de1146540caa7c4f80581344a74_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia86c98d81e2a4e789e3c6e3880743868_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1acbda17e2e04d3f9f18cad52f4e5d80_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if25efb856b06413aacf054618e7f99bd_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b5a6d2f7e6f47649ada40e475d62200_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia56ec1f9700b4dec9314c88e00ec7a74_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03297ccd7c91439abd458f48a7b57605_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e589a7b70e4b8c9ec8c56de960196c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92068e5088f447999d216d73ce8cdb46_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9791432463c54215891a18b29d7d056c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1074a5e410494804aa84259fe458782f_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fadc8348894481296db094bdc2eda3c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d635d3f096e49c9b21f9616e12851e5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic28be830ce4b48dcb3d8a7b426fae4d6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379186cc31f04dbb9749d2943a0e1ed9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida711057f67c47f1b72ad683127c4a91_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5cb6c1da36a4a4d8766dfa0e1727ff5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c47976576a747deb5a1820cec87eb07_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i802b2a8cc9be4de697db22398b60df0e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df3d2e7456f46cd95f6b08a1c33601d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc87f78159374d8bbc9c762e4102e794_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if926194c123b420385c4516a85ca9777_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d59f0918fbc414a8a87e6ccf2473d9b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id48f03c674f5473cb05d01f5147b5df3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb5e19b994341e19c1180af2eb7b115_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bea0dc705a44771a477c405cdd10da9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadbad500e92547ec9a836181ccd9e6c3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6d7f1b310549b0a446ef5d8d0aaea2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6498d554bec346f290453c23da02bd60_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb99ff4ae20743c7b4a1bc974a427a75_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79b08d56cce40828e2c38bf848ff8fd_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52cdeb0271e2486999508f7150d31fe2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7068d970c8e44a1ab1a0f2f2c4db613_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5887b0c29a144ebaa712e90100c41c32_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08831d99e88b4248b1d03a755ae3c76b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b566c9ea6ee4374bb5e2d126e55db93_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55dd11d66bb94525afadc67611182a00_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a96b70190a426784c40cbc850a392d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26fe8d48a8184400b9c1e5dce618bf41_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ca7c88cc02d4eaf88560c8548ee94ef_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0812afd8e2b348de81fda97685ddef59_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf731f09e014c3d94757d58a2be8657_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c940a55fb57493188d86966342836e0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b96b154e0074943b4b122886b03054d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i787149c50a1840428285fe2906bb98f1_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a0ca8ea65246758d0aea04a19962b9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife5cdc6b13e543ce8b0e1c2f9ffa25d3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5a3f74e1d54099823fc731564879ce_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c342b6c1941447a8365ead0b83ea272_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc76581373f04f5aa51d38fcdda40da3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie045af3f8e52486eb07c7ba39e98e056_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8eea6eeee44e8a8748c5f8411ca6a8_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i658cc2fee1f04efda949f70dfc908648_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1105c10c9a2445a198e98e2af0ac9d83_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dadb8ca74864bdda389d9aa76f05723_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d7e2f6cd3d9401f9fda49c75afe417f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f9118b127a41df8281a7b4b70328ed_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b44f394b70346ee9c246aae215158bd_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic62dc76763e348cbba7e08433976fac4_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c091791d85f44618179b9d279f48c9f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd9e9d0ec3a546c8a723d87323ac7ab7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a1e608de7843568d26a9b8fe5ffb43_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3fe1671e59d4c6a8a3250a87dd2e2cb_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f402cf66c9c43bf9d8b0155d69da95c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29def461faf7492f917e166e064b38d4_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0686bf4a5394db3864d38ab25d077e9_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i153a273ca54c4800aa20e3895cc837ed_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1154bb4afd9247c784b55466aae7d770_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0009ecb1334c43a265b7735989172d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857d98c87ac0445e9582504c037c4449_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8de874f946f841458bbfbdc60ac530c4_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ddb318fec741089c74f936f4d258c0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74673f6468f34983ba990177525051f9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f7260c372bc4cd69cc06c643d11c56c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ea854374a484fe38540c4f8a7470fe9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ebe25dea81647f0a7c2f6f7eaaa9f12_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f54f96121d4454b850945a4950be020_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd9e58933a04c87b85bedb0a3a11e3a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5388243b1444a0197156f13c035f594_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf14c9d52f00401b9b7af8c1eaaf40a2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2555b2153a3248ee8fd4e5f32f461af3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5167453e1314559964afd83c4a97121_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94504e48d701461ab9ef57de03631801_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9d91209813438cb5425bacbb2957d7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49cc1963139e40a48ba54590e9d558c2_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37a5f0e1b4645c18d5404587f248c4e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71825d51651b4f4c94dc7432c265826b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26c03d0211654555ae2faaa6bfbef7f0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b09f0f2d404dcb90ab77349fb4e6d6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c393b101be4a43a6732a4be31c57aa_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41cc552be0964064ae3332e0d4c7ef8d_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4de0d5ad9f549948fe05ce4c2e25b4a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83221080ad384b21800f5cd10f1c9fbc_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9d112bcae04f66b84e47128a5cc21f_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f9480fa6a64211bbaffb8bf7069aa5_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec92e1bd5064846ace07af1534211f5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i761be9058b0d43bf94db251536405133_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eddee4e37b042bc9c060f40341f10dd_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd8fd20f19644798d62ca131883fb7b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b87a33ea414436bb9dad4941879ae83_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8bb59b5b9cf4f78a4e291ae63400ced_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd947e6c419b48a4bda0b804eeafe4d6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd983febe9574fdfabf56cea42386e21_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8fed7991104862922245840fbbb6d8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa59186f7b14958a9b1c02f519eb369_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4bf77c080c34fcb8c7da93917014ef3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia86e1d075b324aada06b3181f83ab15c_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i372a0801e4354df09390de4a1bc1fe8a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b4bbabb621c4b65a1340f25f3b79d25_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505f40abf9134ef195fcf3699c50574e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e6f27a9bec4c019c8c57696e6bf1e8_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa62410b761147768b8c6e1d72541097_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8060def9fa5447d9f08d7bf2126beb6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9dff4050ad4ec1ad3383f53e178b09_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402913e98e314dc99d1428cd761b3db0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd2bfa4745e2435c84b3ff4622725d92_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34166c04357b40ca861f436c846dbdc3_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib41d736c9cbf4af88635765f2162af86_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica1e5574642c4970ac6c5731d2f54fcb_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736971e06954421791a102526ef927cc_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i462f6596d7e54be4b09bd4bcb7c18bad_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73eef6d7fd9b4dd2b5426cfa7104e199_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865bbce87767495d83951aa8eb044329_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ef4bc104ab4018b38aa4cdf80cf5a7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i479f5df29cba41dd8ba610461abe4e2e_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5794644b54414f8eaa877a9f828a6f9c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24a4d5dee1ac4cf28da4e534b4453f02_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3342c6f86e341f5ab416482e21b984c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4b1e669d8404534b72479a0f4e7a968_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b56dc097e104e6a9d6bf065e10288ee_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb28ec2e8cc243329eac4eaf64db5f0f_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5082af2c38dc4e9b94951ce99a46799d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d44704539114f25b07e12eb55564a99_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f23f5841b48406ab8cda610d6c44c21_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if956dbb8930a4658bd499404ec02618a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a91d5d2384349c3b9f8ba37ce939f63_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i976cfa9383c14f68936e4add9e92c113_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d224b06bb144ad871048ad6fc1df0b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd7a59ebb6304063a306b51e19b294ca_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b42f4cd0274c2cadf3f13f4563f625_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i281dec684941496ba9be125acb8ea3a6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9207f2f3c7994a8a8ecfaf008603423f_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7bcbf2c88c141309a3b412412019b86_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf66e290093647d2ac7eef16e4827efc_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8cbe17fae384b13888b74cd6b1ec015_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i769786328e84403f83835f16dd6077be_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied814a23dede4859b4dd10f99d05cfb6_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8addd19a2534d7298a26e3173b6a863_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e78ffd9d9242b9b0cd697326116473_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d97d2295755409ca589230c611d4a1c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib19f1a5dbe744c66ae815743a7372c8b_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic394e1061f43492797075bd9f149992c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf6412609614f56bce482cc6a3e294a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307797df24904531853ec0fc2169f7e0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045574b786544774882db0b6a4f87c00_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd0ee7f3ac94e1093e3d7ad447b4526_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie83976fce48a46b3b8d46aa9df8aa8b1_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a2d3e56a004f59a45bdb87953ecc0a_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ef3242829b546d9957de36a60faad96_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cf2d6ac264147d5bc7eea61f5da1000_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4649418b20f44a60bfb39416a9fe963b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7614bac3435145d3a723efd9bb087597_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d9f1ecfd5c34f7a9fd27206d4b69544_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01abbe2b4f24422780127bb041f28468_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa048d8675b4238a8d76e97c5690aef_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7843d84472f449c3bef37bc9121ca5f0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3ed337e07c472b931ca6aecf7946c3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447684ff42fa4bd582534e7299148f49_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i431d8a724aa54139ab3b857d81e71735_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic04865d6630d448b86af337d00e81758_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6511d5e0bf74508adf0aa6bdedfe8bc_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09018b2d45d249cd8716cb425feef71d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13abd60e97db49d09d10b6d9a10a6b80_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if894d62118864420a5c2c56cb58ec015_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8404f4966e9457699f55005e32abc65_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:context id="iefcbb252e7bb4f458a41283b135a86ec_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib22b3a738c7e4ab29b10ad29e3acd8a9_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice23be6cbe2746dd8d736fa8da0659cc_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37533ea8707341c89db72e8585de3a87_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e5fa8d553d4bdfac44b45081a72bad_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f89bd9fe89d4fdc8e39741b72fb0768_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeab3c5384914043b5f61dde75cfbcfc_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if160682b2ae54bd29b1935327968059a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>jnj:patient</xbrli:measure></xbrli:unit><xbrli:context id="iaecd09df5a17466f94617abfae776151_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cases"><xbrli:measure>jnj:cases</xbrli:measure></xbrli:unit><xbrli:context id="i1b15385aca15402cb972e9d0c02e804f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0487ffe3bd6846938c1d7cb60790531d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i812c90cdefa246e3bcebf7398bdb44f4_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5421e9f4d1234869a6e154317b70cd16_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339e763d52094be9ae4c3c2454a17c00_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14361e93fcc9401dad202a5affb4254d_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ab2dba81b64612b4248a3cd41c97e2_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1508c05368864604ae6acac4ed5e0fe4_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i876621f6fe4046ebafa49eee939aae65_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ba7f11cf3c6444fb13f272778b14648_D20181231-20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2019-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc133ce8aefa43cbbac33e0c79222c18_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic211f008f0c343b9b6dbe0257a30891d_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>jnj:claim</xbrli:measure></xbrli:unit><xbrli:context id="i8843c5f5a5344884a0b6d6b1eabc68b6_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb0be9010ee64ef5a74536a9b8bf4b5e_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf5bf7a3b0c4bcdba8ba036de5060bd_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab1eb6318e4a48a59682988b2dc916e0_I20150430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic71f1704f9cc4887aecf9df02c808339_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i429a51537c514c5d901ca9e7b22c4175_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77698652b7224cc1aa4d7e90f3dc8d52_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c5ffba5806541d5ba6376f4fc012752_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9829b5b0fbb446f5a0b0c27c4eb65328_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c4ee00cbdf34df08cf085ad78a22765_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide55be3475194704afb071efa17c609a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5135a58860bc4428aa25ef065e2d9395_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c4ef8d93674a29b417806bb3af7d59_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i964e0dcb3290414a948e1f7f5b6a98f0_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4afcfd6d8e427c8043eca9ef363498_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55870fa5009d42c29ee665e83387efd6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84f8b7c83d8e4a408decca1a1e440fef_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947a2e9e4d9745a88afc0f03c30a4835_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad79f71187349d286755258d2aaae39_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd52c3fe3994d508717b89e90774fc7_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d132ccbcb6c479395ae1351d7e61a30_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2eb914c66f44b7eacd607705a3c6eff_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd1e6b53d4a34fa48ef408b420626ba5_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i89b54799c61648c0892d664696387b28_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY2_9691e6df-36ee-412f-b8e9-3f77d5d4598c">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTYwOWNmNjU0ZDQ3NDJhZjhkYWZiMjEyNDBmZWNjNTcvdGFibGVyYW5nZTo1NjA5Y2Y2NTRkNDc0MmFmOGRhZmIyMTI0MGZlY2M1N18xLTAtMS0xLTU5NzQw_c20a6f87-a78f-4c60-8b5a-bf0408f36eac">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">for the quarterly period ended <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18xMjI_daf52676-b495-4ac7-9097-0a9784867270">April 3, 2022</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NmVlMzMzZDA4Y2M1NDFiNDhhOWU1ODM0N2E0NjlkOTQvdGFibGVyYW5nZTo2ZWUzMzNkMDhjYzU0MWI0OGE5ZTU4MzQ3YTQ2OWQ5NF8xLTAtMS0xLTU5NzQw_15b2c04b-0a0b-47f8-9bb6-032c07b41a8f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934<br/>for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY3_07527ef2-df53-405d-b6fe-69f9478b6c99">1-3215</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDYw_bd9107b9-fee6-4aa9-a331-27bb6b21ae19">Johnson &amp; Johnson</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NGUwYjAzYzEyNjlhNDRmYTg1ZWFmNzZmZjE2MDU3NjAvdGFibGVyYW5nZTo0ZTBiMDNjMTI2OWE0NGZhODVlYWY3NmZmMTYwNTc2MF8wLTAtMS0xLTU5NzQw_69140ed8-bbbd-40d7-869b-9f27a86d05cd">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NGUwYjAzYzEyNjlhNDRmYTg1ZWFmNzZmZjE2MDU3NjAvdGFibGVyYW5nZTo0ZTBiMDNjMTI2OWE0NGZhODVlYWY3NmZmMTYwNTc2MF8wLTItMS0xLTU5NzQw_d61d1fa3-5b08-4057-bf89-06bf99f7f25f">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDYx_54d3b06f-1d4b-4b51-abe0-4704a4ba786b">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDYy_c2f71238-b2ef-4475-b650-18518bda3329">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDYz_701958a7-57b0-44d6-ac51-842612473c92">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY4_da471979-84b1-4731-9c59-d481365cdba1">08933</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY5_9cecba3b-f955-4c3a-b512-0faf819b146a">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY0_c0eb8ba3-1e59-440d-b481-9c5313cf3e66">524-0400</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDcw_a42e3d55-b31d-4545-9e61-8df3cd8927a7">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY1_1ff70b72-18f1-47bc-84fd-e6ada0c8f4d1">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6ZmFlMWZmMjc0ODFkNDk0ZmI3ZjQxMjRkM2M3NDc4MmMvdGFibGVyYW5nZTpmYWUxZmYyNzQ4MWQ0OTRmYjdmNDEyNGQzYzc0NzgyY18wLTEtMS0xLTU5NzQw_012763e0-e7ec-47b7-91eb-b51088ff16ed">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6ZmFlMWZmMjc0ODFkNDk0ZmI3ZjQxMjRkM2M3NDc4MmMvdGFibGVyYW5nZTpmYWUxZmYyNzQ4MWQ0OTRmYjdmNDEyNGQzYzc0NzgyY18xLTQtMS0xLTU5NzQw_24549999-7148-4368-a6ab-ee63769392b0">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6ZmFlMWZmMjc0ODFkNDk0ZmI3ZjQxMjRkM2M3NDc4MmMvdGFibGVyYW5nZTpmYWUxZmYyNzQ4MWQ0OTRmYjdmNDEyNGQzYzc0NzgyY18yLTItMS0xLTU5NzQw_182d68fb-e33f-4421-8c5e-e1a32508cc45">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If&#160;an&#160;emerging&#160;growth&#160;company,&#160;indicated&#160;by&#160;check&#160;mark&#160;if&#160;the&#160;registrant&#160;has&#160;elected&#160;not&#160;to&#160;use&#160;the&#160;extended&#160;transition period&#160;for&#160;complying with&#160;any&#160;new&#160;or&#160;revised&#160;financial&#160;accounting&#160;standards&#160;provided pursuant&#160;to&#160;Section&#160;13(a)&#160;of&#160;the&#160;Exchange&#160;Act. &#9744;</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDcx_a4d10d54-6126-460b-b778-5e55b5f5dd4d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1bfbdd2721a47c78e496b6496fc1e14_D20220103-20220403" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18xLTAtMS0xLTU5NzQw_c8beb0cc-4bc0-4ce5-9a06-f94856ae625a">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1bfbdd2721a47c78e496b6496fc1e14_D20220103-20220403" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18xLTEtMS0xLTU5NzQw_3169da35-8e0e-470c-9b24-703a25baf84e">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1bfbdd2721a47c78e496b6496fc1e14_D20220103-20220403" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18xLTItMS0xLTU5NzQw_799fd5a3-ea23-4f9d-a02c-3d924b918eb7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied996a6da7cf4f25bd1d614be305c4fc_D20220103-20220403" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18zLTAtMS0xLTU5NzQw_aa4e8506-d7c3-458d-bbd4-8332827d4de4">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied996a6da7cf4f25bd1d614be305c4fc_D20220103-20220403" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18zLTEtMS0xLTU5NzQw_207f9904-cd71-46cd-a3f6-82b156d453c4">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied996a6da7cf4f25bd1d614be305c4fc_D20220103-20220403" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18zLTItMS0xLTU5NzQw_9290d8c2-c243-4d65-bed2-2de55c603a83">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i902d46a64ed041188ea441b2e02dd66d_D20220103-20220403" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM180LTAtMS0xLTU5NzQw_429235b0-1aea-4c00-b89d-0a67626547db">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i902d46a64ed041188ea441b2e02dd66d_D20220103-20220403" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM180LTEtMS0xLTU5NzQw_dbe5d544-7089-41f5-8517-a5e83c3349a5">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i902d46a64ed041188ea441b2e02dd66d_D20220103-20220403" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM180LTItMS0xLTU5NzQw_d7023c27-61ac-4b79-bb14-3f53bcb89f94">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2fc9d571951142629fdd9f5cbbd77efa_D20220103-20220403" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM181LTAtMS0xLTU5NzQw_8d63f689-1347-4629-8f8a-b601af99511c">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2fc9d571951142629fdd9f5cbbd77efa_D20220103-20220403" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM181LTEtMS0xLTU5NzQw_8b619e2e-da5b-4189-a990-75210a4c20c5">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2fc9d571951142629fdd9f5cbbd77efa_D20220103-20220403" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM181LTItMS0xLTU5NzQw_4d07038c-7b00-4cf6-a39b-aacce92bb9f0">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58cd890282c34ce19a979c568d6b2d2e_D20220103-20220403" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM182LTAtMS0xLTU5NzQw_29c837be-e9e6-4698-b83b-af38a00446c4">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58cd890282c34ce19a979c568d6b2d2e_D20220103-20220403" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM182LTEtMS0xLTU5NzQw_c8223a68-9985-4026-973a-b00fa2962c1c">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58cd890282c34ce19a979c568d6b2d2e_D20220103-20220403" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM182LTItMS0xLTU5NzQw_c8593086-fb35-4c69-953d-9c0f7d05a01c">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2022, <ix:nonFraction unitRef="shares" contextRef="ibc6c7e3c97b04a4c81417695c15b5102_I20220422" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18xOTk5_b6f60c34-05f8-4501-b0a5-fe29cfa2178e">2,631,401,804</ix:nonFraction> shares of Common Stock, $1.00 par value, were outstanding.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i89b54799c61648c0892d664696387b28_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_10"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_16">Part I &#8212; Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_19">Item&#160;1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_22">Consolidated Balance Sheets &#8212; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_22">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_22"> 3, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_22"> and January </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_22">2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">Consolidated Statements of Earnings for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">First</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28"> Quarter</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28"> Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28"> 3, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_28">2</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">Consolidated Statements of Comprehensive Income for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">First</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34"> Quarter</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34"> Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_34">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">Consolidated Statements of Equity for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">First</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40"> Quarter</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">s Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40"> 4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_40">4</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46">Consolidated Statements of Cash Flows for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46">Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46"> 3, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46">April</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46">1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_46">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_49">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_49">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_106">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_106">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_109">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_109">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_112">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_112">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_115">Part II &#8212; Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_115">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_118">Item&#160;1 - Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_118">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_121">Item&#160;2 - Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_121">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_124">Item&#160;6 - Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_124">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_127">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i89b54799c61648c0892d664696387b28_127">57</a></span></div></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i89b54799c61648c0892d664696387b28_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Johnson &amp; Johnson's other publicly available documents contain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward-looking statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.&#160;Management and representatives of Johnson &amp; Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Development, Market Success and Competition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Liability, Litigation and Regulatory Activity</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union&#8217;s Medical Devices Regulation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Company&#8217;s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company&#8217;s Consumer Health Business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s ability to consummate the planned separation of the Company&#8217;s Consumer Health business on a timely basis or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company&#8217;s ability to successfully separate the Company&#8217;s Consumer Health business and realize the anticipated benefits from the planned separation; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The New Consumer Health Company&#8217;s ability to succeed as a standalone publicly traded company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Economic Conditions, Financial Markets and Operating Internationally</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of global public health crises and pandemics, including the novel coronavirus (COVID-19) pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company&#8217;s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company&#8217;s products and operations; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Supply Chain and Operations </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Interruptions and breaches of the Company&#8217;s information technology systems or those of the Company&#8217;s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. </span></div><div><span><br/></span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022, for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i89b54799c61648c0892d664696387b28_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;I &#8212; FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions Except Share and Per Share Data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:69.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMy0yLTEtMS01OTc0MA_a0e65207-a29d-40f0-a347-5821c5c2e6fe">10,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMy00LTEtMS01OTc0MA_ce74d432-2c1a-49b6-a039-1fdcc360aa0a">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNC0yLTEtMS01OTc0MA_504c3a87-b0ea-4e43-aa9d-7d4e60a3b864">19,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNC00LTEtMS01OTc0MA_02cae481-6c6b-43a9-8016-64191e58df96">17,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, trade, less allowances for doubtful accounts and credit losses $<ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNS0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjYzMTBlOWZkNzU2ZTQ2YTJhMTk2NGFlNjIxYzNmNGQyXzg4_d819f08c-7a58-4316-9ed9-9fbb0bc5f8a6">234</ix:nonFraction> (2021, $<ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNS0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjYzMTBlOWZkNzU2ZTQ2YTJhMTk2NGFlNjIxYzNmNGQyXzk4_4e7d0439-4fe6-4d10-b824-53bfce217694">230</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNS0yLTEtMS01OTc0MA_82bf7e75-70dd-4ba6-92e7-cb815f44b4fb">15,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNS00LTEtMS01OTc0MA_89ae2a72-7fcf-4ef7-9e89-8e6060ee4022">15,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNi0yLTEtMS01OTc0MA_6e0e38ab-9ea6-47ce-bb00-4f290a7b60c9">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNi00LTEtMS01OTc0MA_cbc2ae35-36ff-4599-a035-94167daea3b0">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNy0yLTEtMS01OTc0MA_9b0b78c4-0a98-4a0f-bbc2-eff8c1607dfd">3,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNy00LTEtMS01OTc0MA_d73284cc-7c91-4fd9-89c4-217008f4e4f4">3,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfOS0yLTEtMS01OTc0MA_6e03d5aa-a1c3-4d63-9227-b2b3cbbcebdc">60,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfOS00LTEtMS01OTc0MA_344ddfcb-f56d-4af2-a2ee-8045af17c18e">60,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTAtMi0xLTEtNTk3NDA_52e07741-58d7-448f-9a98-f6b3ec5534db">47,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTAtNC0xLTEtNTk3NDA_7a146acb-cd73-4f22-8637-9d9ca4529ea6">47,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTEtMi0xLTEtNTk3NDA_15c47057-d727-434e-be7d-c6ec50d3db76">29,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTEtNC0xLTEtNTk3NDA_a9ae2994-6a30-4856-9422-0aa68333a669">28,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTItMi0xLTEtNTk3NDA_598c2e04-1a96-480b-a31d-6ea2b626a5d4">18,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTItNC0xLTEtNTk3NDA_45040070-17fd-49f4-b160-ef86983bf4ad">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTMtMi0xLTEtNTk3NDA_c5cb464a-1d47-467d-9414-7892c0d94a37">44,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTMtNC0xLTEtNTk3NDA_6a6c0d13-3b14-4396-999f-b50a4ea2f7ff">46,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTQtMi0xLTEtNTk3NDA_54cc0d8d-76a7-4d68-8070-c54ec17f8dc3">34,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTQtNC0xLTEtNTk3NDA_9ee69782-e3db-4124-bc5b-f9f803cc4120">35,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTUtMi0xLTEtNTk3NDA_aa001982-d366-48ed-90b8-0589c31a242e">9,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTUtNC0xLTEtNTk3NDA_9a33dd48-aa6a-4ea9-89c3-1cc3a64d66f3">10,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTYtMi0xLTEtNTk3NDA_664eb702-43f9-4ab0-ae89-414469a1f7dc">9,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTYtNC0xLTEtNTk3NDA_29caf809-750e-48c5-95bc-904fb381f23e">10,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTctMi0xLTEtNTk3NDA_5bebc13c-b72d-408b-a924-a99ae18afd80">178,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTctNC0xLTEtNTk3NDA_39e0be50-11db-491a-8c3e-65ffb34a0fcf">182,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans and notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjAtMi0xLTEtNTk3NDA_a4e815be-4b85-415e-9fcb-0d17e12e62c6">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjAtNC0xLTEtNTk3NDA_d6262d88-4d63-4fb6-964a-56c452cc7eb5">3,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjEtMi0xLTEtNTk3NDA_39de1606-4512-4e91-8dc5-41297127d3c2">9,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjEtNC0xLTEtNTk3NDA_9fd9aa73-72f3-4fb5-b3b2-ad5b2d393257">11,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjItMi0xLTEtNTk3NDA_935cd373-228b-438a-a056-f4a1b3df67df">13,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjItNC0xLTEtNTk3NDA_05462d16-d52d-4d73-ab86-7cd8c4c03cc8">13,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjMtMi0xLTEtNTk3NDA_05423523-8336-4bb9-b799-c1f28e69d6ad">12,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjMtNC0xLTEtNTk3NDA_e07dae86-0a0e-47a6-98a2-c2523d9a6ae1">12,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjQtMi0xLTEtNTk3NDA_47631aa9-106e-40a9-95ee-8d7b0eebe09a">2,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjQtNC0xLTEtNTk3NDA_06a13098-6248-40d0-afbd-41232b4d7518">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjUtMi0xLTEtNTk3NDA_23e76bb1-5359-44d4-8281-a85c1a5699f3">1,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjUtNC0xLTEtNTk3NDA_1f644c68-cccc-4d9d-8ac3-8288de2075cc">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjYtMi0xLTEtNTk3NDA_f8e559c1-3e95-4fce-b233-89f5588e7642">43,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjYtNC0xLTEtNTk3NDA_9e667775-a7fb-40b4-b01b-ad4d797e5326">45,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjctMi0xLTEtNTk3NDA_30fa12d9-b1e4-4279-bcce-ad938266c392">28,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjctNC0xLTEtNTk3NDA_f5a62684-8246-4551-8d77-40edbf29a83b">29,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjgtMi0xLTEtNTk3NDA_8ccad7ad-6a21-4c20-9e1c-31a947d5f2d6">6,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjgtNC0xLTEtNTk3NDA_ed44dc8c-e369-4321-bbc2-f345768072d2">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjktMi0xLTEtNTk3NDA_d72d725e-f38d-4fbc-be87-5e04b6c0e9bb">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjktNC0xLTEtNTk3NDA_8647a0e2-3508-4421-aff5-23f25b59086e">8,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term taxes payable (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzAtMi0xLTEtNTk3NDA_88ae2d69-dd19-49bc-8103-021b3b1a0237">5,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzAtNC0xLTEtNTk3NDA_20bd0cbc-e45a-4400-a3db-d664b0c1f18a">5,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzEtMi0xLTEtNTk3NDA_1e3a6f19-1ec9-4242-8326-d41ea7567fb6">10,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzEtNC0xLTEtNTk3NDA_2609abc3-9a40-4a48-92a9-ce9373766364">10,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzItMi0xLTEtNTk3NDA_42091e96-1427-49f8-a114-f1f99fa97aba">103,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzItNC0xLTEtNTk3NDA_8f38a962-1672-4841-84ef-df9fa29b7381">107,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzMtMi0xLTEtNTk3NDA_9782106c-a32b-4711-b128-e4255617de01"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzMtNC0xLTEtNTk3NDA_4d4751c4-bb97-4533-94e6-59981faf3326"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY18yOQ_3b62be13-d30b-49a9-b565-b2b4a8a739ab"><ix:nonFraction unitRef="usdPerShare" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY18yOQ_638cba20-27f2-45ab-9a31-cc83bee0ac71">1.00</ix:nonFraction></ix:nonFraction> per share (authorized <ix:nonFraction unitRef="shares" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY181NA_347527d0-0341-4061-9df2-3a7bfed0e9f9"><ix:nonFraction unitRef="shares" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY181NA_3ae0a780-4bd6-4aaf-8b71-8901a142ed04">4,320,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY183Mg_8a0bf196-707e-489c-bfbb-1c4f872bffa8"><ix:nonFraction unitRef="shares" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY183Mg_d2c30d29-8607-4b75-8206-f444dd948e71">3,119,843,000</ix:nonFraction></ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMi0xLTEtNTk3NDA_8f4d3f84-5055-4e28-89b1-b910945f2114">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtNC0xLTEtNTk3NDA_13b990a6-cf62-4cf4-b348-3ea93b46363e">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss) (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzYtMi0xLTEtNTk3NDA_cd6c1403-7304-437b-8d3e-5a709a51081f">13,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzYtNC0xLTEtNTk3NDA_bbf171e9-fead-4b18-ac6a-5ff5de3dbae5">13,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzctMi0xLTEtNTk3NDA_1578defe-0231-4bd6-a032-4d41960fb62d">124,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzctNC0xLTEtNTk3NDA_73b12e20-cef2-467d-aeac-6015b3b71d5e">123,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: common stock held in treasury, at cost (<ix:nonFraction unitRef="shares" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiNDhkNjM5OTcyODM0NTlkYjZkNmQ3MzkyMzYyMWFkZV81MA_c07fdcdd-b2bf-4ca4-a09d-668ec49cb058">490,459,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiNDhkNjM5OTcyODM0NTlkYjZkNmQ3MzkyMzYyMWFkZV81Nw_31aafcc8-6c46-4ae3-a1c1-2515d344447d">490,878,000</ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzgtMi0xLTEtNTk3NDA_88c1518b-b645-4133-8516-3f5b6d72bd4d">39,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzgtNC0xLTEtNTk3NDA_e750b035-6238-4786-9146-0f703c2858ed">39,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzktMi0xLTEtNTk3NDA_a87fa160-78df-4b24-9b2a-85ecafd686cb">74,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzktNC0xLTEtNTk3NDA_c6efaa1e-ca00-4248-9c73-6932353a5ac5">74,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNDAtMi0xLTEtNTk3NDA_148c85ab-8efe-46cb-a6b1-1176aceebd35">178,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNDAtNC0xLTEtNTk3NDA_d8aa5874-4447-497c-8685-cdb1f09c8c9a">182,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars &amp; Shares in Millions Except Per Share Amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:54.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMi0yLTEtMS01OTc0MA_ca056112-3b1e-4c4d-94da-7d08a70ef8d0">23,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMi00LTEtMS01OTc0MA_b14f7401-cd26-4685-99da-c1ca6293b9a6">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMi02LTEtMS01OTc0MA_0b381f1a-4649-4e87-9a34-8dcd001ac0d0">22,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMi04LTEtMS01OTc0MA_138fe261-ced1-429e-ad36-4d9e2f90afa9">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMy0yLTEtMS01OTc0MA_ddd9ee88-184f-4ca5-af1b-9436c1ed0c90">7,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMy00LTEtMS01OTc0MA_7cc23445-6c8e-4e5d-8c3b-ce6a39061ab9">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMy02LTEtMS01OTc0MA_ba5596fb-1d7e-4edc-82e5-7ad2c7f7edba">7,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMy04LTEtMS01OTc0MA_ec64163b-5334-4600-95a2-a16eb92eca10">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNC0yLTEtMS01OTc0MA_8bc8236b-84d5-48aa-b10e-12261f03b414">15,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNC00LTEtMS01OTc0MA_977cd2c9-eaee-4211-9332-0fa704a30408">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNC02LTEtMS01OTc0MA_8aec9c9a-de31-48bd-8807-3b3f681dad73">15,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNC04LTEtMS01OTc0MA_117f2aa4-9be2-483e-844e-9fbc3f75b93e">68.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNS0yLTEtMS01OTc0MA_d0c3217e-2ca9-493e-9ee5-9be7a8249bb8">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNS00LTEtMS01OTc0MA_139af531-44d3-472b-8cb3-b26da7cd945e">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNS02LTEtMS01OTc0MA_2b224cf6-fad5-46dd-8713-bf94b6364b1d">5,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNS04LTEtMS01OTc0MA_85db8233-47cf-4eeb-81be-7606e30e84f1">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNi0yLTEtMS01OTc0MA_2a44df57-503c-409d-b3cb-439755801587">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNi00LTEtMS01OTc0MA_bfa342a9-5b80-4b9b-a8e7-42d48a42eae5">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNi02LTEtMS01OTc0MA_cb334b49-f84b-4521-9a50-c37a5877afca">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNi04LTEtMS01OTc0MA_8deef34a-2394-470d-b7d4-3128e0005387">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNy0yLTEtMS01OTc0MA_2989edbd-615d-41e8-b725-9e31cec18985">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNy00LTEtMS01OTc0MA_ddcc954b-d819-4e62-94fa-c5a36eede252">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNy02LTEtMS01OTc0MA_a9ef2754-5c5c-4179-941a-7c836676c5c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNy04LTEtMS01OTc0MA_6db21a1d-9218-4a25-9954-52b93df188bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOC0yLTEtMS01OTc0MA_7d244ff0-72cc-4e75-a607-47058aff6011">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOC00LTEtMS01OTc0MA_3ba015ea-4c60-4a60-a994-975a3a54f9b6">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOC02LTEtMS01OTc0MA_b37a4327-6410-45cc-a1bb-70321c236bd8">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOC04LTEtMS01OTc0MA_5210c66b-7024-4077-997e-f2a8f356f626">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOS0yLTEtMS01OTc0MA_239683a1-9e9f-492a-8d40-9e1f66d27c5c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOS00LTEtMS01OTc0MA_3b4f9575-3d7e-42b0-b2f7-2462bf56f677">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOS02LTEtMS01OTc0MA_917539a9-9cbb-4645-b84f-c5bce342a076">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOS04LTEtMS01OTc0MA_b0da9c4b-20b0-483e-8bdc-f51af706632a">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTAtMi0xLTEtNTk3NDA_945cd14c-3402-49e0-aca9-8f6340153f2f">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" sign="-" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTAtNC0xLTEtNTk3NDA_fb04b973-b005-4131-870a-f633d19fdf9b">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTAtNi0xLTEtNTk3NDA_57b1ff55-8ea3-48a5-a6cb-84184b68cb51">882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" sign="-" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTAtOC0xLTEtNTk3NDA_5806fda2-fea7-4dbd-a2b3-91d7a2994b45">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTEtMi0xLTEtNTk3NDA_dea4dea9-bde6-43c7-ab60-aa42e2fce89b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTEtNC0xLTEtNTk3NDA_3d34a6a0-a526-4cf0-b166-19f9dcdd178e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTEtNi0xLTEtNTk3NDA_4955d2a7-2578-4769-b925-24fe79adc5f8">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTEtOC0xLTEtNTk3NDA_5c9a951f-c0cd-4f7f-a29d-6be84724a799">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTItMi0xLTEtNTk3NDA_9a2db576-dc94-4e02-8298-f880f0fc1e38">5,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTItNC0xLTEtNTk3NDA_8775d680-c7a9-4565-8b9e-48303151ba30">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTItNi0xLTEtNTk3NDA_afe92bf3-42d2-4b8b-93aa-ea6b0717470c">7,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTItOC0xLTEtNTk3NDA_dd212148-9e08-4495-b417-d2b2b14564fa">33.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTMtMi0xLTEtNTk3NDA_b08bafa1-e4eb-4bf4-b9be-a2591a4b727a">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTMtNC0xLTEtNTk3NDA_5e1d7e4f-7817-4981-99ce-78a0439250f3">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTMtNi0xLTEtNTk3NDA_ae4787cb-ebdb-468f-a1d9-7587dc755ab9">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTMtOC0xLTEtNTk3NDA_23c55f69-2e86-45d9-baea-f88a42237ee6">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTQtMi0xLTEtNTk3NDA_a7981d53-cbc8-45b6-ac56-a80c7bd3af92">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTQtNC0xLTEtNTk3NDA_b2b221c8-0951-460d-8817-3cadc199c9dd">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTQtNi0xLTEtNTk3NDA_eabbe06a-a729-44b8-99c8-98f76c03cc95">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTQtOC0xLTEtNTk3NDA_b1ad62a9-d248-4e26-8381-8b11070514b4">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS PER SHARE (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTctMi0xLTEtNTk3NDA_71476954-faa1-41ac-8401-6d41d626e374">1.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTctNi0xLTEtNTk3NDA_470fc064-b8f8-4253-89c5-2ca6ed3f6a46">2.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTgtMi0xLTEtNTk3NDA_19c0ad84-967e-48bb-b026-9cce676c3045">1.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTgtNi0xLTEtNTk3NDA_b9190d2a-7717-4d28-a66b-6d2fa4c0550c">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVG. SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMjEtMi0xLTEtNTk3NDA_0d21dcc1-159e-4e3b-9c43-976b9607a1a3">2,629.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMjEtNi0xLTEtNTk3NDA_004aad0b-80fc-4961-a46b-94b75762a7e3">2,631.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMjItMi0xLTEtNTk3NDA_529b1803-5b32-4247-b2ee-aa73a100eb1b">2,666.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMjItNi0xLTEtNTk3NDA_35132c18-cb5d-4cfb-bb52-c0d1ee5d1420">2,672.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.730%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.242%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMy0xLTEtMS01OTc0MA_a511aad7-87a7-4206-98b6-4d9e9f43a068">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMy0zLTEtMS01OTc0MA_0be685a4-c5ab-4aa2-8065-bd62d6456d2b">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfNi0xLTEtMS01OTc0MA_381c99dd-615f-47ef-bf4a-1945fa3389bf">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfNi0zLTEtMS01OTc0MA_53a01bf6-5097-477a-a035-74137fed3f0d">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized holding gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfOS0xLTEtMS01OTc0MA_a117cfef-dea6-475c-acac-d6df76505ba9">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfOS0zLTEtMS01OTc0MA_dc9be0e0-383c-4a89-a0ed-296aa714a886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTAtMS0xLTEtNTk3NDA_947a63f6-c941-4987-b71b-e5e488e96f9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTAtMy0xLTEtNTk3NDA_3e2de1d8-4890-46db-bf9b-9b95bf4e1b8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTItMS0xLTEtNTk3NDA_5574e616-a811-43f0-bdc5-665ad9b1dd85">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTItMy0xLTEtNTk3NDA_2810c6fd-3b89-4800-9084-e3f5e7b47e4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior service cost amortization during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTUtMS0xLTEtNTk3NDA_602ec9ee-88f1-4b5d-a2c6-d35a1216d320">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTUtMy0xLTEtNTk3NDA_bff4bbe0-20f7-441a-a19d-68aae7f56ee4">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Gain (loss) amortization during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTYtMS0xLTEtNTk3NDA_d9516412-b430-4d09-9ab4-0e519cca012a">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTYtMy0xLTEtNTk3NDA_be22c2e4-fca9-4290-9629-556e38c8dc8d">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTgtMS0xLTEtNTk3NDA_b610f611-accb-49d4-bf55-f71a52f78f71">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTgtMy0xLTEtNTk3NDA_9ff68290-2c37-4a3f-a727-771488271ee1">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives &amp; hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjEtMS0xLTEtNTk3NDA_b1b4337f-3488-4561-bab4-e8d8a7fcbc0f">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjEtMy0xLTEtNTk3NDA_0fb32db8-1df7-485e-97cc-3f304328a2e7">522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjItMS0xLTEtNTk3NDA_11def983-98dd-43d6-b676-0d7ccc10b655">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjItMy0xLTEtNTk3NDA_60498241-2c62-4792-8c0a-3a603f0de9f9">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjMtMS0xLTEtNTk3NDA_c78a97ba-ca01-449b-8329-d6bfa3e2deec">296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjMtMy0xLTEtNTk3NDA_b0b28ecb-009c-41ab-ae89-06fb05d0dbb0">595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjUtMS0xLTEtNTk3NDA_0539c017-a6ad-4bc7-a2e0-291323f6f8da">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjUtMy0xLTEtNTk3NDA_aaf81e2e-e829-44ea-bc39-9f8be9dddcde">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjctMS0xLTEtNTk3NDA_2c97fe46-d3df-4177-a635-67ef179eddd7">4,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjctMy0xLTEtNTk3NDA_5fbd4a6e-a554-46e0-bbcc-baff9f4b0a01">6,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal first quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzE1OQ_775d2d95-b731-4fd7-af29-f0ef45d9444b">145</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzE3NQ_a5a1bca3-31e0-42eb-899c-ba7aeb649801">319</ix:nonFraction> million; Securities: $<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzIxOTkwMjMyNTU4ODE_9027d67e-f6f5-42d7-88a0-133f35f23a20">3</ix:nonFraction> million in 2022; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzIxMg_e48fc63c-5ba2-4042-a646-e7bb290ecd34">19</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzIyOA_2a2da1c0-d5cc-4854-88cf-903a47fdfc38">66</ix:nonFraction> million; Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzI2Mw_f2b17f06-f458-4d11-88f0-31585845e7ae">78</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzI3OQ_99cc1dab-6141-4eb0-ab99-afdb8ad42a0f">157</ix:nonFraction> million.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal First Quarter Ended April&#160;3, 2022 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS0xLTEtMS01OTc0MA_515f5b8c-e9de-4290-b708-fdb6ed836a3a">74,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92abad263bf8419daa6c3d10a1e69673_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS0zLTEtMS01OTc0MA_4d1bfcd6-abfb-43c3-9b79-208407a08fcf">123,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2336cd90b8e74beeb66f460bec6b6238_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS01LTEtMS01OTc0MA_fc4c4610-0e43-4891-afcd-29e19e1b58bb">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic266b1b5dc484c669aed5ae886e3f910_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS03LTEtMS01OTc0MA_ee2e0ec4-ab9e-4ade-95e4-0310a34abfb1">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39899651e6354f279c457a156b59b4a6_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS05LTEtMS01OTc0MA_d4c82cb1-ab0d-4944-b7d3-f21979ce0ef9">39,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMi0xLTEtMS01OTc0MA_9beb7116-bce2-4b26-9e66-f2049ff45937">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb5ba76506ab44498ae6e4962d624eae_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMi0zLTEtMS01OTc0MA_c1966a2b-14d6-4f39-b5a2-c5bd7cbaf9b2">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMy0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjE3YjYxMDVkY2IzYTQ2MzNhMmJiZTFiNWQ1MjVmZTE0XzI2_14ef7ab3-b493-44ae-853a-ed50f9794de0">1.06</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMy0xLTEtMS01OTc0MA_7a9074c4-1ac1-4cd9-88ac-f1d016b52a76">2,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb5ba76506ab44498ae6e4962d624eae_D20220103-20220403" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMy0zLTEtMS01OTc0MA_f1248809-890d-475a-8f38-069e65d2457b">2,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNC0xLTEtMS01OTc0MA_bf1e6ce0-a5c9-4fa2-b49c-ac6daed96aad">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb5ba76506ab44498ae6e4962d624eae_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNC0zLTEtMS01OTc0MA_9ab120ea-016d-4251-a913-0bf5290a2d0b">1,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1bd088462748abb8bf782cfcc07129_D20220103-20220403" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNC05LTEtMS01OTc0MA_9ee47664-b9c7-4140-80db-4733ef81c271">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNS0xLTEtMS01OTc0MA_5c543506-c557-47ce-b422-c1a55b2084d9">1,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f1bd088462748abb8bf782cfcc07129_D20220103-20220403" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNS05LTEtMS01OTc0MA_dab4690a-d113-4203-8f94-35384299b4ae">1,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNy0xLTEtMS01OTc0MA_dfc7b452-bb0b-495d-b20b-7d15633b2028">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbe0f983eea14da3b437dcf18bfa144b_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNy01LTEtMS01OTc0MA_84610cff-8210-4ab1-a9ec-d36eda601790">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, April 3, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC0xLTEtMS01OTc0MA_8ea9676f-45e0-4dd5-8758-996cb82d9f99">74,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225ea33e8dbf48579d422823c0350b4f_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC0zLTEtMS01OTc0MA_2b56da35-1535-40bd-a716-e43a0b9fef53">124,380</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i795ff92791494382a1d26a7b84fee3e5_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC01LTEtMS01OTc0MA_2f450214-3141-4058-a487-85e9dffe3626">13,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib230b0f5235943ff892ee51f02112200_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC03LTEtMS01OTc0MA_dbf6009d-cb88-4159-a3b3-6bc678a18f1d">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7dd50adc00246e78b4d70267adf860f_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC05LTEtMS01OTc0MA_b2dc4fed-65e6-4426-b1fc-292e58cad275">39,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal First Quarter Ended April&#160;4, 2021 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:37.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccce36176b41451cb72ade5fd7acd620_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS0xLTEtMS01OTc0MA_8f43bbc2-d90f-40dd-ba3c-2bae92f6a323">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab9077c64f34317815b7b3af8096958_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS0zLTEtMS01OTc0MA_f4e40846-994d-48b3-a12a-0fefe613a825">113,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc5b2d28a80e44d9bdcda5d265440506_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS01LTEtMS01OTc0MA_6c9ce107-08f6-4f14-be04-84e8f766a3e1">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bff5df510141c6acab233c801c6f0b_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS03LTEtMS01OTc0MA_b1289b98-3a0f-4851-b446-99881460d6e3">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i333b166f4d2f445f9cd585f8eb2f1c02_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS05LTEtMS01OTc0MA_1ee432b9-83d8-4d21-a987-c17e4150a4c4">38,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMy0xLTEtMS01OTc0MA_02043b80-e64f-4093-b13e-6531fa7a99c7">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeeeea464c1645cf8c4b046709808f46_D20210104-20210404" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMy0zLTEtMS01OTc0MA_0e8e9367-2a3e-47f6-92ea-95e707c25475">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOmY2MmJlOTA2NTUzNTQxN2E4MjIzOTFlMjBmM2E1YmJmXzI2_7f6699c7-88e9-43e8-8810-53cbaf037865">1.01</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNC0xLTEtMS01OTc0MA_2597d257-6272-4a90-a67f-624429c35ce2">2,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeeeea464c1645cf8c4b046709808f46_D20210104-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNC0zLTEtMS01OTc0MA_44e40065-48ae-4fef-9bd0-45c2440f59b5">2,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNS0xLTEtMS01OTc0MA_1249bbeb-d607-4caf-8d3d-65e3187031d5">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeeeea464c1645cf8c4b046709808f46_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNS0zLTEtMS01OTc0MA_9174af65-b697-44db-9fa2-7530b8657868">920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4b855ab6e9400da78a4a7e4118d0c0_D20210104-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNS05LTEtMS01OTc0MA_6ecc2a48-d0a4-4ed0-869a-c96e703d8ff7">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNi0xLTEtMS01OTc0MA_6f936f7a-9424-4638-a951-253ac7e16e1c">1,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e4b855ab6e9400da78a4a7e4118d0c0_D20210104-20210404" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNi05LTEtMS01OTc0MA_3f775879-8d81-499e-8177-40c9e23241a8">1,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOC0xLTEtMS01OTc0MA_03ddae73-ebcf-41ee-9479-0994282d7feb">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd4bbc39e1a4259935490333ab02382_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOC01LTEtMS01OTc0MA_ed3107c0-3e29-4a8d-af1f-189ab3cd61c9">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, April 4, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ebcce5ed4d4fa88b1380565ad0cd2f_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS0xLTEtMS01OTc0MA_9fa8dcc0-7558-479d-a1c8-7d5f9229264a">65,834</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613a24ca8cd34aaf87209b0ce754c9a4_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS0zLTEtMS01OTc0MA_f131cafe-b39c-4d16-b8c8-c171cb76693c">116,508</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f965bb993c84e458df2a90932f7f838_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS01LTEtMS01OTc0MA_603a4dd9-7789-40db-9f66-f940965bb6da">15,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6448f96ad7486da2e84f5da3d3c578_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS03LTEtMS01OTc0MA_3d2f71a9-b89c-4d4a-a5ec-367884be89e9">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4dc0429231c4601861ff53b097feae5_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS05LTEtMS01OTc0MA_be676b3c-d05a-4fb6-a38a-782d1da93b5f">38,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.993%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_46"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMy0yLTEtMS01OTc0MA_6d71aa27-3c12-49f3-8130-0a8e78b0df44">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMy00LTEtMS01OTc0MA_6f77a5fa-07e1-467f-9cc6-fb37c94b04b1">6,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNS0yLTEtMS01OTc0MA_d343e7b1-6f5b-47c8-a749-fa75ac892ef3">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNS00LTEtMS01OTc0MA_131e8c19-502f-4ceb-b66d-7b8369ff874a">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNi0yLTEtMS01OTc0MA_91357beb-20bb-4a36-b862-13dfeb6219ed">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNi00LTEtMS01OTc0MA_0eec2ec6-5af9-4c89-8b52-d5bee207e6c9">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-downs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfOS0yLTEtMS01OTc0MA_360e8107-5b19-488a-8cdf-b8825646a5d4">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfOS00LTEtMS01OTc0MA_51457d5b-6ce5-48db-a3b8-bf51b2840906">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets/businesses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTEtMi0xLTEtNTk3NDA_2b234f9e-1d9e-49b1-b1f2-39436c735c81">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTEtNC0xLTEtNTk3NDA_bc11d246-1c26-4fe6-8e39-8a353b13e659">580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTMtMi0xLTEtNTk3NDA_8c4b80f9-84d2-403b-b0fe-d174802a1ab3">926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTMtNC0xLTEtNTk3NDA_2ff8c8a7-9d39-452b-846d-db75e97a90f3">730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit losses and accounts receivable allowances </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTQtMi0xLTEtNTk3NDA_99c2d5eb-1a17-45ac-b596-19673d0775fd">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTQtNC0xLTEtNTk3NDA_447db48a-9c54-4184-a926-1242a99ac9bd">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTYtMi0xLTEtNTk3NDA_538981af-fd77-4cbb-b2bc-b9d1ef04b229">427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTYtNC0xLTEtNTk3NDA_35ea0a96-321b-4f17-bcb8-57d951295357">1,604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTctMi0xLTEtNTk3NDA_7d8e0338-ccac-419c-9265-256417a81f45">600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTctNC0xLTEtNTk3NDA_7a357294-a9f7-4a84-b450-a6a1fc2e400a">695</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTgtMi0xLTEtNTk3NDA_d1de115e-d84e-4f40-ab11-fb83d5543cff">2,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTgtNC0xLTEtNTk3NDA_5767fe08-e6b0-4c3d-81db-bc977594c7ec">2,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other current and non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTktMi0xLTEtNTk3NDA_6c600a3e-19b8-4035-8c6a-002f63dca37e">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTktNC0xLTEtNTk3NDA_6745b34e-e3e6-4f73-9aea-8a092fd3eb30">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase/(Decrease) in other current and non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjAtMi0xLTEtNTk3NDA_d5f4ad5b-f4cc-4b6f-a82b-73d06ac166ab">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjAtNC0xLTEtNTk3NDA_56417a86-db9b-4abd-aec4-7314460d664d">902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjItMi0xLTEtNTk3NDA_328f33e7-e42d-4fc4-96f4-ef7a1a86f726">3,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjItNC0xLTEtNTk3NDA_3469b0f7-9f49-4038-a9c2-c31d42b28495">4,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjUtMi0xLTEtNTk3NDA_fe2d3745-1b36-4aca-8ae9-983b91840396">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjUtNC0xLTEtNTk3NDA_5674293c-301f-4b7e-bfea-e2447c801eb5">677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the disposal of assets/businesses, net (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjYtMi0xLTEtNTk3NDA_deaac64c-7c46-4cd9-9d03-ce341cb3f032">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjYtNC0xLTEtNTk3NDA_f25114e4-f1b0-4674-bb53-d2a665b96817">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjctMi0xLTEtNTk3NDA_db3f16c5-46c3-475d-8dad-738cce06b32b">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjctNC0xLTEtNTk3NDA_163ed107-0dc6-4bff-9a31-ff2758493090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjgtMi0xLTEtNTk3NDA_70285326-aa93-4df1-ad3e-11e9b4b9fec8">9,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjgtNC0xLTEtNTk3NDA_2d32f9c8-ef8e-46b9-b4ec-307f23ce9fab">5,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjktMi0xLTEtNTk3NDA_775809ec-2b46-4376-9a14-406e3eb9ce50">6,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjktNC0xLTEtNTk3NDA_9618bc51-aaa7-42a4-a75a-96ceaeab49fa">5,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzAtMi0xLTEtNTk3NDA_b1a21014-fc96-4def-9c79-e2249e06474d">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzAtNC0xLTEtNTk3NDA_118f9f87-0d6e-4f93-b8aa-39a0945466d2">751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzEtMi0xLTEtNTk3NDA_99ea7ae8-baad-4583-91a9-e3e7b1d60da0">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzEtNC0xLTEtNTk3NDA_2f514b6d-b0a1-4080-a062-378288ea2b53">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzMtMi0xLTEtNTk3NDA_c2df8467-51ea-4e3c-9d5b-17b717dc41b9">3,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzMtNC0xLTEtNTk3NDA_1d2abda6-aa15-4378-b6fa-d7570b38de79">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzYtMi0xLTEtNTk3NDA_f7de559c-3ff4-4654-bb41-98404e8966f6">2,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzYtNC0xLTEtNTk3NDA_ea173096-015b-4895-b50a-402c1e6df203">2,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzctMi0xLTEtNTk3NDA_5dc493fa-4e12-49b0-9b2e-821b4f49ad0a">1,577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzctNC0xLTEtNTk3NDA_32f3ab13-4243-43d0-afbc-6d0690a84a13">1,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzgtMi0xLTEtNTk3NDA_0c6b6703-6bb8-47ea-8271-e34f1e69cea8">3,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzgtNC0xLTEtNTk3NDA_92e8ee9e-c370-4f1c-9653-bf0c8cc6471c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzktMi0xLTEtNTk3NDA_6c2e9f79-dc4f-401a-bd9a-cac099a69b1e">856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzktNC0xLTEtNTk3NDA_9a6fd6b3-53be-4283-ac1c-0c32199b83bb">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDAtMi0xLTEtNTk3NDA_f7ea3b66-f85d-4978-b1b3-6d6675232f9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDAtNC0xLTEtNTk3NDA_f7a3beb4-a6cc-461a-ba9f-981bc67c4019">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDEtMi0xLTEtNTk3NDA_0d9ce7d2-78f4-4a61-8ade-06159e240557">2,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDEtNC0xLTEtNTk3NDA_a2ff9355-cd20-4880-81b6-9c0633204445">1,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDItMi0xLTEtNTk3NDA_bfe3e661-d04d-4d36-9776-8550d7137bd3">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDItNC0xLTEtNTk3NDA_b4c574fa-6b14-4f99-975f-eeff238ae95f">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDMtMi0xLTEtNTk3NDA_7c495eac-8a48-48f9-ab6f-cd9fc4fa4550">235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDMtNC0xLTEtNTk3NDA_bb90f902-48e8-408e-aac1-5c908bde34de">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDQtMi0xLTEtNTk3NDA_359b421a-6547-4fee-8459-484cc49fd95a">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDQtNC0xLTEtNTk3NDA_7a63709b-1a9e-4ee9-83a8-d89378e8b816">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDYtMi0xLTEtNTk3NDA_58cb41ec-1195-4e04-af9e-ef8a1f5ee492">4,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDYtNC0xLTEtNTk3NDA_932985b7-af2d-416e-a6a8-2d6b669fee48">5,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDgtMi0xLTEtNTk3NDA_f55daaac-8d33-46d6-b60d-2dba733d0fac">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDgtNC0xLTEtNTk3NDA_6631cf3d-e65b-4c48-a1f2-05b71f31611f">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDktMi0xLTEtNTk3NDA_9edcf010-3b69-4a36-8dda-5a9ea9c6fd39">4,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDktNC0xLTEtNTk3NDA_e5a3f9a1-305d-4487-98a1-7279e08c6583">1,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTAtMi0xLTEtNTk3NDA_0c98dc73-60f1-457b-94c4-49a5026b35ea">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccce36176b41451cb72ade5fd7acd620_I20210103" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTAtNC0xLTEtNTk3NDA_f67ca8d0-c2a0-4ded-a3f5-71723a93befc">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS, END OF PERIOD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTEtMi0xLTEtNTk3NDA_cc2173e1-80d4-449a-b91b-2eec0d43e191">10,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ebcce5ed4d4fa88b1380565ad0cd2f_I20210404" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTEtNC0xLTEtNTk3NDA_9424d317-782c-4b24-b7be-55f991a97633">12,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTgtMi0xLTEtNTk3NDA_db72b387-7cc2-43e2-9f89-232b9e53bb91">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTgtNC0xLTEtNTk3NDA_6e94005d-9a96-4c4b-b8e8-894cf57b0e9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed and noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTktMi0xLTEtNTk3NDA_8fc6216e-ab31-4e18-b278-edcd06926258">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTktNC0xLTEtNTk3NDA_43800075-be8e-42d8-8769-a3af023da82d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNjAtMi0xLTEtNTk3NDA_b440bd49-48ec-419d-b991-b6cd7dee97ea">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNjAtNC0xLTEtNTk3NDA_5f80250c-e905-42d4-b3f3-11eb7a3224b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NOTE 1 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81Mi9mcmFnOjI1MGI1NDA1MmZhZjQ4YWViMmRiOWJmYTVmMzZjZmM2L3RleHRyZWdpb246MjUwYjU0MDUyZmFmNDhhZWIyZGI5YmZhNWYzNmNmYzZfMjgyNQ_eccf885b-3fcb-492a-9af4-dba68ad8d1c0" continuedAt="i772cca17e5664e1db6450a76888dece0" escape="true">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i772cca17e5664e1db6450a76888dece0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81Mi9mcmFnOjI1MGI1NDA1MmZhZjQ4YWViMmRiOWJmYTVmMzZjZmM2L3RleHRyZWdpb246MjUwYjU0MDUyZmFmNDhhZWIyZGI5YmZhNWYzNmNmYzZfMjgyOA_2649cec5-b437-4ca1-89f5-28387e3c49a1" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended April&#160;3, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81Mi9mcmFnOjI1MGI1NDA1MmZhZjQ4YWViMmRiOWJmYTVmMzZjZmM2L3RleHRyZWdpb246MjUwYjU0MDUyZmFmNDhhZWIyZGI5YmZhNWYzNmNmYzZfMjgyOQ_32e1fa53-dfb4-453b-bc8e-090e20dc4487" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal first quarter of 2022 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal first quarter of 2022.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81Mi9mcmFnOjI1MGI1NDA1MmZhZjQ4YWViMmRiOWJmYTVmMzZjZmM2L3RleHRyZWdpb246MjUwYjU0MDUyZmFmNDhhZWIyZGI5YmZhNWYzNmNmYzZfMjgzNQ_e554cf5b-4e93-4a63-bbed-e11064e728d0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_55"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 2 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RleHRyZWdpb246ODk1NDI2NjJiZTlkNGMyNzgzODVkYWRlNDdiY2IzYThfMzc_5a222967-57c0-489f-a3fe-a3a59f90d25c" continuedAt="i3710d414917548b3aabf82eb64c094c5" escape="true">INVENTORIES </ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i3710d414917548b3aabf82eb64c094c5"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RleHRyZWdpb246ODk1NDI2NjJiZTlkNGMyNzgzODVkYWRlNDdiY2IzYThfMzM_fac69bb2-c6e6-4734-bde4-3229c297bee3" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:51.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMS0yLTEtMS01OTc0MA_bc13bbb4-6e37-476c-8a4e-4fd360792f1d">1,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMS00LTEtMS01OTc0MA_6ab1658b-44cd-4249-b587-9d4b24bf883b">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMi0yLTEtMS01OTc0MA_c69989ec-4e70-405b-bfba-29f1be1ba2ab">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMi00LTEtMS01OTc0MA_6e81bef7-6194-4604-aa6c-75acb8ed0da6">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMy0yLTEtMS01OTc0MA_24e73555-17a2-41b6-897c-ce40e8c7ab73">6,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMy00LTEtMS01OTc0MA_36299751-1f99-4bf3-ad3c-b522d3972ada">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfNC0yLTEtMS01OTc0MA_7de38ef8-73aa-4d5b-9f65-490967ab37e5">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfNC00LTEtMS01OTc0MA_b454f8e7-6b8b-4a31-a869-0e556ded7492">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 3 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMjAxMA_fe248bec-b51a-44e2-86f3-5cd382d59bfa" continuedAt="i496bbd47e53f4764aa0a3d0e858c1a5b" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i496bbd47e53f4764aa0a3d0e858c1a5b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMjAwNw_0207071f-d589-42aa-9b2a-a897d23471e8" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:61.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c14471cebb545af9f344092e43e244d_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMi0yLTEtMS01OTc0MA_8d2a3dc8-e6a7-48ef-8ab8-637b2ef7a6dc">37,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i751430dc512846d6bd038f8d3e545317_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMi00LTEtMS01OTc0MA_bc123373-86bb-44c0-8111-128cc1da60e4">38,572</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c14471cebb545af9f344092e43e244d_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMy0yLTEtMS01OTc0MA_232b9087-4e03-4911-aa19-4f76a3e7aca5">20,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i751430dc512846d6bd038f8d3e545317_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMy00LTEtMS01OTc0MA_61bdbbb9-f00b-4adb-99ef-18fba65e3696">20,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c14471cebb545af9f344092e43e244d_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNC0yLTEtMS01OTc0MA_5843e47b-cf8b-4965-8431-64f0098a8f83">17,468</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i751430dc512846d6bd038f8d3e545317_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNC00LTEtMS01OTc0MA_6875e875-d985-43f2-8e6d-3579c9eefd9b">18,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8427fded54d64f59a314115c202ccb4b_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNS0yLTEtMS01OTc0MA_4824c378-9cb3-49c3-914a-4544b76cfc57">22,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca6e4c72b3b411e8e7e9c40313e1011_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNS00LTEtMS01OTc0MA_9abd355c-b220-484d-ac0b-020201848ea3">23,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8427fded54d64f59a314115c202ccb4b_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNi0yLTEtMS01OTc0MA_f2678ef0-7473-4cab-bcbe-30f0c8669cdc">12,147</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ca6e4c72b3b411e8e7e9c40313e1011_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNi00LTEtMS01OTc0MA_0218dfeb-7264-4e86-974e-894c404124fd">11,925</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8427fded54d64f59a314115c202ccb4b_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNy0yLTEtMS01OTc0MA_25b1b09f-8a8e-4bd0-8525-3b1a0ce73613">10,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca6e4c72b3b411e8e7e9c40313e1011_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNy00LTEtMS01OTc0MA_c3314831-937e-4faf-91db-ca52371378d8">11,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631a68382dbe4356a80463ddeb81e9e7_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfOS0yLTEtMS01OTc0MA_8bf96e8f-9d17-4e31-b741-b9758f093bec">6,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbab423fd5014e1482bba4a9327c8dc4_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfOS00LTEtMS01OTc0MA_8c6d68ab-bddf-4f34-8d4c-b7b88239ec4e">6,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97cbf7df6c0c4273a06533b0d3e5c206_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTAtMi0xLTEtNTk3NDA_13b8fcb7-b0ff-466f-9753-8a091e7a7e93">9,242</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic60ed3f5f8b143f28c600b4ef6f83731_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTAtNC0xLTEtNTk3NDA_5068fe9a-422f-4e5f-ba4c-fe3b2dd6a5f5">9,837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTEtMi0xLTEtNTk3NDA_23f79018-30a7-45ef-88a9-ae2f8354c51c">16,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTEtNC0xLTEtNTk3NDA_cfcff3cf-5785-4779-b6a4-61691c90a437">16,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTItMi0xLTEtNTk3NDA_6a5b48b4-9e8f-4580-a3b4-1aa6e0b7c468">44,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTItNC0xLTEtNTk3NDA_fbce53b6-e123-4762-a96f-fafb47b4c00a">46,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i754795b41ad945a7ac5ecd6f2ea1cbe2_D20220103-20220403" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfNTk1_615d2341-311b-4f3c-89cc-a6741c6ff29e">0.6</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMjAwOA_98eb7cd9-b715-4265-8f98-8dc6e3b82fcf" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of April&#160;3, 2022 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:39.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273a2ba53146449c8a18b08bc38532ee_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMS0yLTEtMS01OTc0MA_e0f4f41f-77c5-401e-a7e4-b880eb539f1c">9,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706befc122c24b74b7c46cad04eefa00_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMS00LTEtMS01OTc0MA_843cbffd-f5cc-461e-a816-27476a64637a">10,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ac3910bc9284705b8c0311e059b8e26_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMS02LTEtMS01OTc0MA_f6db6569-5d85-4b76-885a-827c3fba9c06">14,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMS04LTEtMS01OTc0MA_d54249ed-9015-430c-9331-692ba9d0141f">35,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMi0yLTEtMS01OTc0MA_4993ae68-f6ed-4419-a9b0-6b66e43cf7e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMi00LTEtMS01OTc0MA_23aab6b9-9979-4b46-8fb8-5e0306688e16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMi02LTEtMS01OTc0MA_00c45908-00ba-4778-a0a0-e23ec997de7a">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMi04LTEtMS01OTc0MA_7ee37592-6521-43f2-8106-cad22aeb5314">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNC0yLTEtMS01OTc0MA_f5bc22eb-90fa-46b7-9e33-84f5b126461c">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNC00LTEtMS01OTc0MA_45c11642-b57b-42be-bc1c-e2204cf68436">170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNC02LTEtMS01OTc0MA_f984e05f-cdf2-4c58-824e-1d8a58a9af1f">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNC04LTEtMS01OTc0MA_cf95fbc0-b4e9-4f9d-96fa-c8305bf70aa3">384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at April 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fe7c6e2f574a619178fc635b10b3b2_I20220403" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNS0yLTEtMS01OTc0MA_0006f9c5-82aa-423e-8fad-3ba93c9640a8">9,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00ca16d24bf44179d8fcf374cbf27d7_I20220403" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNS00LTEtMS01OTc0MA_c044bba4-6920-4cd2-966e-b5e9c4a1d8b4">10,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681532a4eb3648508653f9fb60ec8408_I20220403" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNS02LTEtMS01OTc0MA_b7c014b0-d911-4f45-a022-20a7e2530d8c">14,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNS04LTEtMS01OTc0MA_88f1a95b-ce3b-4b9b-8b41-d9517d8504a8">34,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is <ix:nonNumeric contextRef="i9b8fe868a0e94657aceaf9efda5d051e_D20220103-20220403" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMTI3NQ_ec474807-d58a-4fb2-99d4-aef5670e6fea">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is <ix:nonNumeric contextRef="i4bcace6a0596406b8dd0416cfb063a83_D20220103-20220403" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMTM4NA_ec36233a-fe05-4225-a2b5-253914308946">21</ix:nonNumeric> years. The amortization expense of amortizable intangible assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMTQ5MA_8369af1a-2c4f-4f5a-ab84-46829fcf7a9b">1.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMTQ5Nw_bf1e0778-94f6-4046-8d05-38d754240e9b">1.2</ix:nonFraction>&#160;billion for the fiscal first quarters ended April&#160;3, 2022 and April&#160;4, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMjAxNw_12b7ac2a-ff98-4d14-be90-22203faab260" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"></td><td style="width:18.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi0wLTEtMS01OTc0MA_c6de0ba4-d2c6-4ca0-832f-41e570c9fc7c">4,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi0yLTEtMS01OTc0MA_2d5cfddf-31d2-4cbc-8d52-42aa86570ba6">4,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi00LTEtMS01OTc0MA_d5d22afb-de78-44de-9e7b-fcccbb657ec1">4,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi02LTEtMS01OTc0MA_d89d100e-4d4a-4f9c-bcb2-24f7dd9a8d19">3,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi04LTEtMS01OTc0MA_4813cf7d-8706-4067-9da1-0de2a748e1ae">3,000</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 4 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwOTg_01889c12-2c23-4364-a7cb-2308a58efd14" continuedAt="ie44ed0f94c174658b6d76f02c2f733b0" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie44ed0f94c174658b6d76f02c2f733b0" continuedAt="ie442bba926054a72870d03243cfcac16"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April&#160;3, 2022, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403" decimals="-6" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTY0Nw_d77ead34-59d5-4d5d-bfda-12c1eda53ecf">1.1</ix:nonFraction> billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April&#160;3, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjMxMg_e4900dc1-553e-489d-b13a-f9424b756744">42.5</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="i0a8ab9973a5e462d9e057abf51bcf297_I20220403" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjMxNg_ee62e863-6bda-4424-8621-89ce3f81c93a">37.4</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i5eadcdc996d94731b0bc1014ca9e7fd0_I20220403" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjMyMw_00c00f59-4630-4e0a-8244-0e9c5c1d5cf2">10.0</ix:nonFraction>&#160;billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="ic315dcf608444a39b1cabd079a7d46cb_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjQ3Nw_0874b30e-88c7-4b9c-9e06-c35031d876e0">45.8</ix:nonFraction> billion,  $<ix:nonFraction unitRef="usd" contextRef="i7bdcc356986e4b3e80fe4abf6ec3b52c_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjQ4NA_f4d4bde0-414c-4ac2-a330-b0d8712d2732">37.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i07dd6b6cd781421abf5b7b35627e6b59_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjE5OTAyMzI2NzkxMQ_f17a2e39-d492-4aec-bb97-3b146f4806bf">10.0</ix:nonFraction> billion respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;3, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfNDYxNQ_c2c5d94f-2857-42b5-96d3-d1acd5447797">632</ix:nonFraction>&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfNDg3Mw_684c0c05-ea14-42c8-b18a-d13d49bf4e6c">next 12 months</ix:nonNumeric> as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfNTAzNA_7c819589-48a6-46fa-8f8d-3a2f6e58978a">18</ix:nonNumeric> months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="ie442bba926054a72870d03243cfcac16" continuedAt="i181a2696ee7a44cba545e55f46c7dabb"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwNTE_b535d7b5-c8c6-4b9f-a38e-fad8566d33fb" continuedAt="ic039f8e20f0c4d8ab24cd2d9245cf5db" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2022 and 2021, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b7f48faa4c44dd8729fef7add9958e_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC0xLTEtMS01OTc0MA_1d256fad-fdc8-488b-a833-89058369796b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d4778b3c184c5b9a1268b12772f834_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC0yLTEtMS01OTc0MA_4b816321-d7dd-44f3-88fd-62a8bb4dc7f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab697ff2c9043c0af2d3551559c5cc6_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC0zLTEtMS01OTc0MA_93670d3d-fa4c-4fc4-9ec0-63d710eec208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ca621269f74333bfcea41317eb612d_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC00LTEtMS01OTc0MA_ad864f4b-a68c-43f3-85e3-77c7b98e87aa">531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ef606fc8d54064ac6785b084df413c_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC01LTEtMS01OTc0MA_72032d3e-1fb7-4623-a02e-1928e2180b94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4d7ef218294617ab67cdd7ff8ae201_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC02LTEtMS01OTc0MA_15b5e446-ffe3-49a0-9a19-2e430c259254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285862bf68fe4a1e9a5f16fb54ec99bb_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC03LTEtMS01OTc0MA_33ce210b-7c0b-47f1-94e0-53d381269f27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50372bc3c1fc4262a02f85583b8add01_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC04LTEtMS01OTc0MA_5d7d2ccb-e555-459d-a96d-ed2763872740">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7dc652d8a14e07b4a76aeb7b9c4d21_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC05LTEtMS01OTc0MA_5550451e-8a74-4971-8335-a3f7ddacb66a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13b350d42d74d879d6f63915693746c_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC0xMC0xLTEtNTk3NDA_115fff2f-f0e5-4b97-812b-b1e3ec3ea2d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b7f48faa4c44dd8729fef7add9958e_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS0xLTEtMS01OTc0MA_daed4cc5-5fcd-4f8e-a709-70c0672659a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d4778b3c184c5b9a1268b12772f834_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS0yLTEtMS01OTc0MA_e34392b3-151e-46f1-b6a3-9772ffae4955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab697ff2c9043c0af2d3551559c5cc6_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS0zLTEtMS01OTc0MA_e5ff2791-3aac-4151-a0ca-faafb245a933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ca621269f74333bfcea41317eb612d_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS00LTEtMS01OTc0MA_15ce752d-9b2f-4e26-b42e-18ebd454399e">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ef606fc8d54064ac6785b084df413c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS01LTEtMS01OTc0MA_f2b7154c-cc0a-4c6b-bea2-dd688df010db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4d7ef218294617ab67cdd7ff8ae201_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS02LTEtMS01OTc0MA_38068b05-de60-4c1a-a71c-ec11eaae70c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285862bf68fe4a1e9a5f16fb54ec99bb_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS03LTEtMS01OTc0MA_13330c78-814d-45b5-98b6-1936365abc1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50372bc3c1fc4262a02f85583b8add01_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS04LTEtMS01OTc0MA_42cf86cd-8e19-4c2b-bac4-a6d941111f28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7dc652d8a14e07b4a76aeb7b9c4d21_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS05LTEtMS01OTc0MA_0c524d25-1d49-4ee2-9728-15a04894c054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13b350d42d74d879d6f63915693746c_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS0xMC0xLTEtNTk3NDA_bcfe5200-d455-4e74-ae2a-c61e0575b75f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbe2ddfa5bd4c3c81d6b1a89bd6a3c6_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtMS0xLTEtNTk3NDA_4d09bdc3-23a9-41c3-9f0d-235d8522140a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6710a293c7049a89bd678b9ebf357ee_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtMi0xLTEtNTk3NDA_1d8ba734-0363-433e-a7f2-b8d4ee802ee7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c65dce193b4085ac9029e9479cc836_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtMy0xLTEtNTk3NDA_c1ffbe85-bf7d-4e0f-877b-30ccbc90b485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4612c0bb5e5643f0995c9a09afdf8c41_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtNC0xLTEtNTk3NDA_3e0ab571-185a-4769-b01a-c8435d58f482">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica35e7e4a05a4bf1ae3566e17b66227a_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtNS0xLTEtNTk3NDA_701110bf-ec5d-4b45-a350-13ef0201cf05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a21486e41041aea8b93609d24e888e_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtNi0xLTEtNTk3NDA_498d4bda-f2ad-4490-8813-bafcf785ee6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5125127475344a8bec0db5ebc5cba0d_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtNy0xLTEtNTk3NDA_cb117bc0-0f74-4215-bf32-4a6fb5bbe4fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24069a0bb5314816b75b91710ef6fb4f_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtOC0xLTEtNTk3NDA_16687cee-0350-41ff-9b4c-a3c5c2cc97e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb4260113ae447a8ac220acba4cae35_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtOS0xLTEtNTk3NDA_fa0a0d8f-40d7-4a10-934e-6ce2efad4d4a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd707f3f168499dbac4bc8fb516087e_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtMTAtMS0xLTU5NzQw_cae4c226-cf9f-4503-952d-d584a8825c09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fbe2ddfa5bd4c3c81d6b1a89bd6a3c6_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtMS0xLTEtNTk3NDA_760247ac-7fa8-4a85-b2f1-7eb3ab3ce197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6710a293c7049a89bd678b9ebf357ee_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtMi0xLTEtNTk3NDA_2e7dad8f-3de1-4fee-9c85-66df1cedccc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c65dce193b4085ac9029e9479cc836_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtMy0xLTEtNTk3NDA_a39b244d-5d10-4dda-a027-74273dcc8e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4612c0bb5e5643f0995c9a09afdf8c41_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtNC0xLTEtNTk3NDA_b352e780-1f6f-44cf-9ae1-e54f2e1549b2">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica35e7e4a05a4bf1ae3566e17b66227a_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtNS0xLTEtNTk3NDA_9ed0029e-4766-4ba6-a2ef-ab422b4c3aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a21486e41041aea8b93609d24e888e_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtNi0xLTEtNTk3NDA_c0b8950f-f795-4fea-a727-bc4b6bad34b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5125127475344a8bec0db5ebc5cba0d_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtNy0xLTEtNTk3NDA_040cff8e-93f5-4687-9348-fb0af9a31eba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24069a0bb5314816b75b91710ef6fb4f_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtOC0xLTEtNTk3NDA_fb7260ab-aa4d-4753-9963-d90a24be08c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb4260113ae447a8ac220acba4cae35_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtOS0xLTEtNTk3NDA_73cc248a-fc96-4045-86c9-5ecd8938dd86">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd707f3f168499dbac4bc8fb516087e_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtMTAtMS0xLTU5NzQw_01f57874-714f-4488-bc4d-a5ce47e95a93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35c1225f1fc642b89ce27325e2764fe6_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtMS0xLTEtNTk3NDA_5f7b6779-20e2-4401-aea5-dd74649ee9c8">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca0c41746e24c10a5010f5e3b375875_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtMi0xLTEtNTk3NDA_0ed11395-bd04-4f6e-b695-914efd33208b">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906bc2f6d0734e46a265b998dfb78e1f_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtMy0xLTEtNTk3NDA_93a91df4-7a3d-4e19-8bb9-0ac3c8a194e6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a7b113cd604b97b6359f1ca89f88e9_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtNC0xLTEtNTk3NDA_098a36b7-6e17-43d8-b68d-5555216db886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac181bd434134d0f99d2723052ebb78c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtNS0xLTEtNTk3NDA_1fc1c059-fd9e-4a43-8919-ca52cabc39be">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98498dc117454edda8260632bcf14b3e_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtNi0xLTEtNTk3NDA_9224da70-e9e7-421f-bcd3-89b836cc0300">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc1a147f22b444088512ccac59a70251_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtNy0xLTEtNTk3NDA_3f705401-144a-4191-8cfb-397827d7c859">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i629d4c6fdf6e40a39dfb7d01c00f6bbc_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtOC0xLTEtNTk3NDA_e8d6ce76-1b4b-4a63-b444-1c255e35c85f">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4edbfa092a4db08c3097d31dfde751_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtOS0xLTEtNTk3NDA_d064f1ea-d77a-4364-bdb3-5a1d240454fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5358dcc8f8d448188a6577bca61d7df2_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtMTAtMS0xLTU5NzQw_60b76d4d-1219-4ed2-82d3-df7523e4a456">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c1225f1fc642b89ce27325e2764fe6_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItMS0xLTEtNTk3NDA_3e3f1f55-1d55-45eb-b3c3-47aa9702273a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca0c41746e24c10a5010f5e3b375875_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItMi0xLTEtNTk3NDA_8b8f4e07-171f-480f-b720-def2b09dd24b">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906bc2f6d0734e46a265b998dfb78e1f_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItMy0xLTEtNTk3NDA_3ab18a16-fd50-4168-a8ab-bc26b5b2e041">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a7b113cd604b97b6359f1ca89f88e9_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItNC0xLTEtNTk3NDA_eb62e0e9-855d-46ef-ac60-d291e0fc7603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac181bd434134d0f99d2723052ebb78c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItNS0xLTEtNTk3NDA_98f62c2f-9718-493e-a940-1a91ac8f92b4">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98498dc117454edda8260632bcf14b3e_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItNi0xLTEtNTk3NDA_1739e50f-de99-4ae1-bdc1-0d5787918639">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc1a147f22b444088512ccac59a70251_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItNy0xLTEtNTk3NDA_27ce767d-031d-4974-a4c7-12b90d0bda94">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i629d4c6fdf6e40a39dfb7d01c00f6bbc_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItOC0xLTEtNTk3NDA_c0c8ee21-92f7-4a4f-8ba1-c41aed9bdced">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4edbfa092a4db08c3097d31dfde751_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItOS0xLTEtNTk3NDA_c236f2d7-cef4-4576-8f93-192a774ad570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5358dcc8f8d448188a6577bca61d7df2_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItMTAtMS0xLTU5NzQw_f8f22104-71a7-49db-b820-e24f586705d1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e8ee39318f4e8b8637328665ee6121_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtMS0xLTEtNTk3NDA_74eef1bf-d1d8-4055-8852-57f79f287186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9976c768bbec41ceb31dd3e5aeee895b_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtMi0xLTEtNTk3NDA_55cadf4d-95b6-4cec-b1e4-40477dd79d9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0acd8032704810ac6c33c652bb3f4a_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtMy0xLTEtNTk3NDA_81292113-871c-4cd3-aa8b-50bb2fe4ac4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86deefadb42a48e9bb9ba37613cdc416_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtNC0xLTEtNTk3NDA_6830ab75-2388-49f5-93ad-1f82cf55600c">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096bbfc984b74afe83163ab74df3e9c9_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtNS0xLTEtNTk3NDA_f8d92983-74f8-4c79-974d-e8a4899fb6bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae4da99d4bba480d99292b2891dc32d9_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtNi0xLTEtNTk3NDA_1d83900d-fa00-4c55-81f8-8765735f80cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i200c16a786fd4d0d8795c1fc3f58843c_D20210104-20210404" xsi:nil="true" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtNy0xLTEtNTk3NDA_901365cb-f17a-4b40-9867-b251be5374e4"></ix:nonFraction></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4939c05de24312b1d31bf71b02fe56_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtOC0xLTEtNTk3NDA_f019b33c-b15c-40c5-baa2-e0f1ddeedd91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65442762e5c14bc1abd1248fe23d8341_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtOS0xLTEtNTk3NDA_73305724-5c97-450f-b03f-1152623fce71">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c04b36d74874be78fc77e16c8fb290e_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtMTAtMS0xLTU5NzQw_69ba8e87-35ae-4789-86ef-74fcc5b3290a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e8ee39318f4e8b8637328665ee6121_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctMS0xLTEtNTk3NDA_b3b7acce-71ca-498e-bc57-11e6dabb0fc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9976c768bbec41ceb31dd3e5aeee895b_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctMi0xLTEtNTk3NDA_0e27b1de-d118-48fa-9393-fe3b47a64818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0acd8032704810ac6c33c652bb3f4a_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctMy0xLTEtNTk3NDA_70de4a4f-a753-4fc3-9a35-24dd98a8b293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86deefadb42a48e9bb9ba37613cdc416_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctNC0xLTEtNTk3NDA_5d4cd0e7-94cb-465b-b8c0-9a1c78944a73">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096bbfc984b74afe83163ab74df3e9c9_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctNS0xLTEtNTk3NDA_8fd40847-3cbc-44bc-8666-33a7d5ec787e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae4da99d4bba480d99292b2891dc32d9_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctNi0xLTEtNTk3NDA_5b3445b7-6aab-4c40-b458-096d1667c1e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i200c16a786fd4d0d8795c1fc3f58843c_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctNy0xLTEtNTk3NDA_e7f09b6a-0b8c-46f7-be95-566a7ff672d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4939c05de24312b1d31bf71b02fe56_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctOC0xLTEtNTk3NDA_3dd85412-a8cb-4079-b68f-7525dc0c644a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65442762e5c14bc1abd1248fe23d8341_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctOS0xLTEtNTk3NDA_27b9da74-c7c5-44f5-9d25-f2466269a7ed">307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c04b36d74874be78fc77e16c8fb290e_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctMTAtMS0xLTU5NzQw_1a0eb1f5-8928-4c1e-9274-5c145ea3ade9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><ix:continuation id="i181a2696ee7a44cba545e55f46c7dabb" continuedAt="i7f13799a112443f18eb43d86c586c528"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwODk_1b11ef31-2071-4032-994e-395f649c1e98" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  April&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ed1d2317744e2fbc2c3b45e1b4d2e2_I20220403" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjJhYzY3Njg5MmNiODQ4ODg4NmI2ZTEyYmZhMmRjZGE4L3RhYmxlcmFuZ2U6MmFjNjc2ODkyY2I4NDg4ODg2YjZlMTJiZmEyZGNkYThfNC0yLTEtMS01OTc0MA_2703dd17-6518-4f25-8937-ce2f3c62e8f1">9,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66d9ac41ee14e4f935d98d0f8036683_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjJhYzY3Njg5MmNiODQ4ODg4NmI2ZTEyYmZhMmRjZGE4L3RhYmxlcmFuZ2U6MmFjNjc2ODkyY2I4NDg4ODg2YjZlMTJiZmEyZGNkYThfNC00LTEtMS01OTc0MA_d1b74669-9f58-40bc-b8eb-8875a2b643a4">9,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92ed1d2317744e2fbc2c3b45e1b4d2e2_I20220403" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjJhYzY3Njg5MmNiODQ4ODg4NmI2ZTEyYmZhMmRjZGE4L3RhYmxlcmFuZ2U6MmFjNjc2ODkyY2I4NDg4ODg2YjZlMTJiZmEyZGNkYThfNC02LTEtMS01OTc0MA_b95e5d30-593e-4f52-bea8-036726266a5f">694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic66d9ac41ee14e4f935d98d0f8036683_I20220102" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjJhYzY3Njg5MmNiODQ4ODg4NmI2ZTEyYmZhMmRjZGE4L3RhYmxlcmFuZ2U6MmFjNjc2ODkyY2I4NDg4ODg2YjZlMTJiZmEyZGNkYThfNC04LTEtMS01OTc0MA_faa95730-3b15-471d-bf03-daf79d419350">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwNzM_2f82a726-3e8c-4c9e-9ca8-05dc1df3c43c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2022 and 2021: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"><tr><td style="width:1.0%"></td><td style="width:32.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.127%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc14e7b1e2e4a29877dd2b95650a3ac_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjgyYTZjNzZmOTBjMjQ5ODA4YzUwN2E3N2MxNGY5Y2RjL3RhYmxlcmFuZ2U6ODJhNmM3NmY5MGMyNDk4MDhjNTA3YTc3YzE0ZjljZGNfNC00LTEtMS01OTc0MA_2a6ede29-3663-478a-a2e3-43c25739de04">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice21f8d2655e4d0f8095be5911f1fd8b_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjgyYTZjNzZmOTBjMjQ5ODA4YzUwN2E3N2MxNGY5Y2RjL3RhYmxlcmFuZ2U6ODJhNmM3NmY5MGMyNDk4MDhjNTA3YTc3YzE0ZjljZGNfNC02LTEtMS01OTc0MA_99ebd2b9-f83a-4492-ba2d-2548eeda50af">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="ic039f8e20f0c4d8ab24cd2d9245cf5db"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal first quarters ended in 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfMy0yLTEtMS01OTc0MA_38efe80d-8ec1-4487-8c65-7fa549780c59">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfMy00LTEtMS01OTc0MA_549a0f6b-abb5-4f0e-bdf0-833e3eb245e9">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4f1c2e35354c268ad4b4f0c299f46c_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfMy04LTEtMS01OTc0MA_32e6757d-e3b2-46a4-8d4d-2ec29d228700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe06a04b32f541198cc74c4294d74b7e_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfMy0xMC0xLTEtNTk3NDA_f71e1243-0995-40ac-8b01-a06301c098df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ce73a23c814452a90b72fe868271de_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfNC0yLTEtMS01OTc0MA_7840d9a7-570c-4123-991f-6b5ec8bf3e79">560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i977c041569204263b24ecc0054d30d6f_D20210104-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfNC00LTEtMS01OTc0MA_7ca7bbc9-a0db-4cfd-9245-c48bcb68c969">361</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581046ca0e0f48929501b5a10dbaba2f_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfNC04LTEtMS01OTc0MA_a4f587af-b56f-4590-81d2-71f7f8cee9e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i645a971a555b4c089758583b67f9d08c_D20210104-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfNC0xMC0xLTEtNTk3NDA_ec62a82f-a6bb-43aa-8b74-94a13ac39f0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:24.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.265%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i7f13799a112443f18eb43d86c586c528" continuedAt="i1a3c4e2e6f494ce686828526b33002a4"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwMzc_42966425-cd61-4525-adbe-4468ba8b40f6" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:25.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.464%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4dbad0006c47f48dad1e81741750fc_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi0yLTEtMS01OTc0MA_c5399613-1901-47b2-baa3-ae8f49657cb0">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3823718f66a4b499cedb42d987cd246_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi00LTEtMS01OTc0MA_3934f03f-543a-4e99-9092-5af48178f688">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3823718f66a4b499cedb42d987cd246_D20220103-20220403" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi02LTEtMS01OTc0MA_b180733b-7f63-4014-a54d-9297a54b09e0">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80323310c7943d89e72028b427412c1_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi04LTEtMS01OTc0MA_59aa7ab2-29a1-4cb3-87b8-c0d4b9042d60">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80323310c7943d89e72028b427412c1_I20220403" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi0xMC0xLTEtNTk3NDA_d1732cf1-f295-4634-9a24-81049b15bdd8">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf02920ebc8f4f46a0a1307481df3c99_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC0yLTEtMS01OTc0MA_565629b3-065f-4116-86ea-18d0a8920d9e">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i195975cd0e7f446da43714458700190f_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC00LTEtMS01OTc0MA_3c57d007-2737-4b88-a7df-ca7701f86939">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195975cd0e7f446da43714458700190f_D20220103-20220403" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC02LTEtMS01OTc0MA_e2824550-099d-460a-8c2a-f48d19a6b663">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f60cf5f7ad40df935bf2a4865220fc_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC04LTEtMS01OTc0MA_8f4e19f3-d276-42ae-81ca-503049c776fb">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f60cf5f7ad40df935bf2a4865220fc_I20220403" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC0xMC0xLTEtNTk3NDA_dd22036c-c06c-4ab1-b8f5-8c7e588ef262">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, there was a decrease of $<ix:nonFraction unitRef="usd" contextRef="i195975cd0e7f446da43714458700190f_D20220103-20220403" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfNjc0OA_9ec5b120-91c3-4738-8fa9-cfe1903dcd3d">5</ix:nonFraction> million in the fair value reflected in net income as a result of impairments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i1a3c4e2e6f494ce686828526b33002a4" continuedAt="ic5a1aa757c034221a26664f697f62945"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwNjM_5c7eae83-400f-477c-b468-28aedd349883" continuedAt="i8d5911db8c5d40e5a011bdc16a478e0b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of April&#160;3, 2022 and January&#160;2, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:48.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a3783f757347e6a884c99fba04723c_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC0yLTEtMS01OTc0MA_5e3374c9-5519-4b19-9866-f2be8ca1cabd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC00LTEtMS01OTc0MA_3958cbf8-5999-4cb4-908a-411bd8605031">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05510e5c3ec344fca7b25f4799ad39c6_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC02LTEtMS01OTc0MA_f983db70-eee4-41c0-a815-eb448462899f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC04LTEtMS01OTc0MA_ed432170-4aab-4209-98fa-853ca3f2d58e">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC0xMC0xLTEtNTk3NDA_a085621a-e2be-4623-a3dd-0f4b49d32b3d">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee07eab57304c94a3dfcb3ae7fbee1e_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS0yLTEtMS01OTc0MA_a65dacae-e649-45ec-bf4d-783141e0d5e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40143a9bc0fb45f6989738a947b0838e_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS00LTEtMS01OTc0MA_fafc67e1-6e50-4fba-beba-0f0f2a1b3be1">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b3a8c85a4a4df28a3c6f3b7f5df006_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS02LTEtMS01OTc0MA_7a36cffa-9d9e-4720-ae22-6868a7f4d1d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad75e5d7a8d640fc9b410ca0e00b1a1a_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS04LTEtMS01OTc0MA_b90a142b-13f9-40ed-9750-7e6d7357035d">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423527772d4f4352be8af130cdc45743_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS0xMC0xLTEtNTk3NDA_ede9cf42-0c09-424b-bdd1-6e47b0510845">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy0yLTEtMS01OTc0MA_dc804fac-2524-436e-bb9d-e7a70353c5db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy00LTEtMS01OTc0MA_bc8747b1-dac5-4360-b883-ac2c92410bd3">1,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy02LTEtMS01OTc0MA_43a6415e-e16e-497a-a7ba-dea0d9fa0c56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy04LTEtMS01OTc0MA_11df5d80-2af2-46ee-a5e6-84cf13d50d9e">1,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2153712ae1a485ab5669a52af66f1b4_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy0xMC0xLTEtNTk3NDA_89f77a1d-4082-405f-ac8e-d1bf4dcb87c3">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a3783f757347e6a884c99fba04723c_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS0yLTEtMS01OTc0MA_4126ecc5-5daf-4512-803d-3a2f01c87163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS00LTEtMS01OTc0MA_d7db2732-560b-4002-a9c5-b11ca84dea47">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05510e5c3ec344fca7b25f4799ad39c6_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS02LTEtMS01OTc0MA_e7f422a1-ae3b-4151-924b-278b7ec752f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS04LTEtMS01OTc0MA_b0d4047d-6043-4c0e-af34-a8489fe41b0f">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS0xMC0xLTEtNTk3NDA_0c6ac260-2399-44c6-abb1-818feccc99ed">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee07eab57304c94a3dfcb3ae7fbee1e_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtMi0xLTEtNTk3NDA_068d7815-5571-4052-b41f-7f987cf20160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40143a9bc0fb45f6989738a947b0838e_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtNC0xLTEtNTk3NDA_eb4c1bd0-f5aa-4565-aa41-b4bfd80475b0">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b3a8c85a4a4df28a3c6f3b7f5df006_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtNi0xLTEtNTk3NDA_fb8fe7d0-2c0c-4ffc-8d23-a5d799dc9d58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad75e5d7a8d640fc9b410ca0e00b1a1a_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtOC0xLTEtNTk3NDA_dad032b9-b60c-4605-88d3-232572ae7bf2">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423527772d4f4352be8af130cdc45743_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtMTAtMS0xLTU5NzQw_797d49a8-ca38-4574-a6f7-2d28d6de7039">979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItMi0xLTEtNTk3NDA_e364b3bd-05d2-469f-b82a-db63f041ff6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItNC0xLTEtNTk3NDA_664ec61b-e9ee-443c-b7d2-0ffae75e3ac6">2,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItNi0xLTEtNTk3NDA_a6aa9f2d-fa51-40ba-a26a-aaf522cdf526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItOC0xLTEtNTk3NDA_7d82685b-52ef-4cf9-985b-80504ca05d01">2,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2153712ae1a485ab5669a52af66f1b4_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItMTAtMS0xLTU5NzQw_e53877f3-e9df-4e83-b1b9-afc7c5baf484">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a3783f757347e6a884c99fba04723c_I20220403" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtMi0xLTEtNTk3NDA_1e3ae94f-d387-4f29-94f7-bceb3e9d8f52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtNC0xLTEtNTk3NDA_c83fd755-9c72-44e8-9862-8c9d63f219b9">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05510e5c3ec344fca7b25f4799ad39c6_I20220403" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtNi0xLTEtNTk3NDA_df29ee44-3a89-4abe-97d4-213a7572efd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtOC0xLTEtNTk3NDA_09d34dc9-6256-47be-888a-6d956cceadbb">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtMTAtMS0xLTU5NzQw_5e9fe0e8-61d8-499a-b94f-141a4ef85613">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a3783f757347e6a884c99fba04723c_I20220403" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctMi0xLTEtNTk3NDA_655b2ce0-b2d5-42a6-83ab-cf71a7b1ebbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctNC0xLTEtNTk3NDA_5c95fe92-309a-4d0a-a938-1259b5635caf">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05510e5c3ec344fca7b25f4799ad39c6_I20220403" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctNi0xLTEtNTk3NDA_e6e56267-7718-47e3-a465-828901674db0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctOC0xLTEtNTk3NDA_8f2c1990-07c4-4666-9596-8965c38aab5f">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctMTAtMS0xLTU5NzQw_122247d4-cd7b-414f-9a2f-a255654131c4">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktMi0xLTEtNTk3NDA_6ae4d426-f723-4301-a1b4-b2ec7c4f2be0">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktNC0xLTEtNTk3NDA_c24e0cfd-185d-43f1-96cc-35b73032eccd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktNi0xLTEtNTk3NDA_76695ba3-8c4f-47cc-a408-b9578bb09994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktOC0xLTEtNTk3NDA_48019f63-a95a-41df-bd35-fba0c0a783c3">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktMTAtMS0xLTU5NzQw_04a72a7b-1687-4139-95e0-24377e042e46">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtMi0xLTEtNTk3NDA_60477627-ca77-4c87-bd1d-2c603f10cc5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtNC0xLTEtNTk3NDA_1274de58-01b3-40fb-8ccb-10a898d15310">19,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtNi0xLTEtNTk3NDA_c23a8f13-d14b-4f21-8949-3db104bd01cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtOC0xLTEtNTk3NDA_f3744ef7-fdb8-49a1-8237-440e8a0d301f">19,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtMTAtMS0xLTU5NzQw_98aa6d4e-edff-4445-9063-63281bb9b875">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItMi0xLTEtNTk3NDA_4c7394d3-0c1b-4a47-b9c6-b25ceabf085c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItNC0xLTEtNTk3NDA_54e676de-683d-4d63-b360-5ffec60ed340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItNi0xLTEtNTk3NDA_5291a263-11cd-43d6-ba1f-1bb9107c2cb8">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItOC0xLTEtNTk3NDA_498b152d-d3e8-4fa4-a2ea-ab1e3fbe2f19">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItMTAtMS0xLTU5NzQw_c139fa65-682c-451a-98a2-bde7630f42a6">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfMi0yLTEtMS01OTc0MA_fd5f8549-d68d-457f-a956-f7d834c50f32">1,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfMi00LTEtMS01OTc0MA_8a3f2b38-36d6-4619-96df-2305338952e3">1,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfMy0yLTEtMS01OTc0MA_ddeacc13-d99b-4240-a8d7-ac1d310db345">1,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfMy00LTEtMS01OTc0MA_35f26742-bf41-4a8f-86aa-14d3740804e4">1,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNC0yLTEtMS01OTc0MA_0e7a9483-62d8-41c4-8ca6-38d162fa1781">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNC00LTEtMS01OTc0MA_23d7cb13-7ee7-4c13-b298-2dd08b381ace">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNi0yLTEtMS01OTc0MA_413b5e88-70dd-4c7b-abd7-cfa7a4d80b19">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNi00LTEtMS01OTc0MA_a9b3bab2-4b50-41e6-ad83-83d32022ae3a">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNy0yLTEtMS01OTc0MA_cde4493d-ca8b-4f1a-aa4f-93e46e669b0d">2,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNy00LTEtMS01OTc0MA_28234090-07fb-408b-b8c4-72f9e471df2c">1,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfOC0yLTEtMS01OTc0MA_e94191b2-39a4-4cdb-9684-18be7c58263d">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfOC00LTEtMS01OTc0MA_331c2273-cbd6-4545-aad9-cc5e95881624">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><ix:continuation id="ic5a1aa757c034221a26664f697f62945" continuedAt="i0049fb83b03a423cb1ebf3721f98fca0"><ix:continuation id="i8d5911db8c5d40e5a011bdc16a478e0b" continuedAt="i2d2cea3c257543e3bca6a8683150dcca"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"></td><td style="width:41.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfMy0yLTEtMS01OTc0MA_85c69c74-ba56-4e01-be57-fbacbb3d4cdd">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccce36176b41451cb72ade5fd7acd620_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfMy00LTEtMS01OTc0MA_adffd16b-ab1f-469b-bb47-4d75ce2e1c92">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNC0yLTEtMS01OTc0MA_37382722-12a2-4eee-8af0-63d89a8569c9">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNC00LTEtMS01OTc0MA_15a40211-7e93-4df4-8aa2-0a6df50c67f2">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNS0yLTEtMS01OTc0MA_79184f9d-5c91-40a4-a3c3-1dd0bf51a30a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNS00LTEtMS01OTc0MA_9b83de0b-93cf-4818-8886-9ab92334211b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNi0yLTEtMS01OTc0MA_3b707a8f-ab0d-458b-b69b-2c9198dd65b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNi00LTEtMS01OTc0MA_4429a2bc-a703-4f45-9172-d428e0af9454">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNy0yLTEtMS01OTc0MA_54ce10b3-8aef-40ea-a532-a285bce6a4a0">486</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4ebcce5ed4d4fa88b1380565ad0cd2f_I20210404" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNy00LTEtMS01OTc0MA_288c693e-b9ed-451e-9ad1-a47b7a6caee7">600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="i144bd07273654fd298013a92e5d0b27f_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTE1Mg_55a47ec7-d826-4423-93dd-e94a3cedd946">1,884</ix:nonFraction> million, which are classified as Level 1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i37485b7a6e8c4c1689bb2f8982088f64_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTIyMA_b26a9993-5b3c-43d8-a713-5f4d6b1b57fd">533</ix:nonFraction> million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $<ix:nonFraction unitRef="usd" contextRef="i59607f6cdca645209d4015cb4e2f5619_I20220403" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTUzOQ_6e297af4-613d-40db-b862-49f86dc36342">469</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc5cdf7b3948454394fae9e0a5c60184_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTU1NA_8bb0a4f6-aa60-4d7f-ba9e-2bf722b0d5c4">520</ix:nonFraction> million, classified as non-current other liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $<ix:nonFraction unitRef="usd" contextRef="ib5aed6e544644ac091fcfd4f67609c7d_I20220403" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTY1MQ_508f82ca-8f93-4aad-bcb0-e5d8fe8f65c6">17</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i68a4afb3d1574ea6841481a8c54e0b66_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTY2Ng_bfd29a19-801c-41a3-a05e-b1fe45a49606">13</ix:nonFraction> million classified as current liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i2d2cea3c257543e3bca6a8683150dcca" continuedAt="i18a54641557048d8a2d487310d6b16ef">           (6)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i18a54641557048d8a2d487310d6b16ef">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.</ix:continuation> </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwNjk_e21c0db3-0438-493d-bde8-8f982e78678c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of April&#160;3, 2022 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:25.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.373%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/( Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a07094db884448a992148a352debab_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS0xLTEtMS01OTc0MA_19692daf-a719-4290-80a7-a7c890fc596b">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a07094db884448a992148a352debab_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS01LTEtMS01OTc0MA_8b93085b-2864-4e41-b3f4-cb93feba4c9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a07094db884448a992148a352debab_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS03LTEtMS01OTc0MA_5e58849e-83db-4c53-94cb-0c64b33cfa96">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a07094db884448a992148a352debab_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS05LTEtMS01OTc0MA_ec81a505-a2e6-4ab7-b417-4b22e2c166c8">3,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a07094db884448a992148a352debab_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS0xMS0xLTEtNTk3NDA_c725d156-836f-4478-b671-599b08485764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy0xLTEtMS01OTc0MA_cda1f6db-2d39-4866-9070-768bb612ed18">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy01LTEtMS01OTc0MA_e49cb3b8-fa21-4a2c-9811-9eace9db8c90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy03LTEtMS01OTc0MA_dd8f6e80-74dd-41cf-a8cc-6859e8db1c0b">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy05LTEtMS01OTc0MA_c3771875-57c2-4777-90a7-37927ce0596d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy0xMS0xLTEtNTk3NDA_a741e7e8-25bc-4cde-bd6f-9ddbd31379e2">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC0xLTEtMS01OTc0MA_f05e8802-599b-43ec-bef1-941cad413acf">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC01LTEtMS01OTc0MA_25651ed5-efbf-40c0-9145-c381f07b6743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC03LTEtMS01OTc0MA_696bc987-c82f-4771-85eb-2e0637184779">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC05LTEtMS01OTc0MA_6786e93a-77bf-4b39-98a8-f0918d99e323">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC0xMS0xLTEtNTk3NDA_32d36a96-322b-4f6a-82c1-98f403c32a2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi0xLTEtMS01OTc0MA_fb8da110-c6f8-4f4d-9dfb-95bfec6e9780">3,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi01LTEtMS01OTc0MA_ead89a2a-f1db-4ab6-80d7-021a7d79210b">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi03LTEtMS01OTc0MA_770c3cc4-e258-4bc9-abf9-f27c95212431">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi05LTEtMS01OTc0MA_9d823757-f86a-42d4-afab-7e3b4eb65a24">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi0xMS0xLTEtNTk3NDA_b8b827a0-4a36-48f0-a67e-0c8b4f59c43d">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy0xLTEtMS01OTc0MA_7397bcf3-f275-4494-9ce0-f22d308e0cae">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy01LTEtMS01OTc0MA_9ae9f276-7e86-40a6-9c09-4c105cc1a519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy03LTEtMS01OTc0MA_c108f2fb-2dfd-4380-a2ae-dcfc9e604ad8">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy05LTEtMS01OTc0MA_40e18094-e020-42db-ba2a-757907545e2b">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy0xMS0xLTEtNTk3NDA_59a4bbbb-80b1-4287-8b28-161ef540e876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i612d93e077824654b25097d940711e0c_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC0xLTEtMS01OTc0MA_d6c27ed6-9ea2-4567-9ec5-29fbb2533c34">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i612d93e077824654b25097d940711e0c_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC01LTEtMS01OTc0MA_a0865e9e-2ee6-4f54-b4f7-2ed8e1884333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i612d93e077824654b25097d940711e0c_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC03LTEtMS01OTc0MA_368146e4-b873-48bd-b405-f57d762fe31e">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i612d93e077824654b25097d940711e0c_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC05LTEtMS01OTc0MA_eb2d7b75-833e-4a83-ba9d-cb7aaedb43fc">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i612d93e077824654b25097d940711e0c_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC0xMS0xLTEtNTk3NDA_a803bca0-eac4-4ad5-a915-746847ec4cb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS0xLTEtMS01OTc0MA_6976a90f-4979-4439-ad9e-908b6a2ba686">10,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS01LTEtMS01OTc0MA_68de31ce-78a2-4ab4-b91d-d52ec2e986f8">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS03LTEtMS01OTc0MA_2e4b2021-2147-4acb-aa80-fe9fce73bfdc">10,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS05LTEtMS01OTc0MA_46e25075-981b-4eff-af64-a577edf1417d">7,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS0xMS0xLTEtNTk3NDA_200c4ed1-c3df-4d4e-b84d-a3771078c909">3,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0abb325296848eab35197c32673d301_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItMS0xLTEtNTk3NDA_e0c2460c-d627-4fdd-a6dd-beb36ef86bb3">19,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0abb325296848eab35197c32673d301_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItNS0xLTEtNTk3NDA_887d0818-828d-4769-b490-4ae2dea40a99">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0abb325296848eab35197c32673d301_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItNy0xLTEtNTk3NDA_b96dcfbe-eb59-41fd-8685-9b335fa7ebb5">19,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0abb325296848eab35197c32673d301_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItOS0xLTEtNTk3NDA_ff2488c3-f049-4643-b11f-ee0f9f943141">2,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0abb325296848eab35197c32673d301_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItMTEtMS0xLTU5NzQw_023c19ed-a919-44cb-bf3f-a3cc39b0d32e">16,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtMS0xLTEtNTk3NDA_579dc931-d6eb-4d0e-a346-38e5ad3e525f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtNS0xLTEtNTk3NDA_a975be18-c0d2-4deb-bf98-405700ecb057">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtNy0xLTEtNTk3NDA_beb9f410-a226-45a3-95e1-b29b7085c587">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtOS0xLTEtNTk3NDA_b55d0ced-7bf2-45d7-a634-c2878429fc62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtMTEtMS0xLTU5NzQw_00741378-ff91-42fa-af4b-9ab91c8eba23"><ix:nonFraction unitRef="usd" contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtMTEtMS0xLTU5NzQw_7ca89b32-d7e8-4021-a600-fd19557e3d29">3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b0e360214949eebb51638497d0ec18_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtMS0xLTEtNTk3NDA_38627eca-09fa-4cd1-9e84-b4e6dfb51f1a">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98b0e360214949eebb51638497d0ec18_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtNS0xLTEtNTk3NDA_791d6959-9130-4272-95f3-97c24b818f77">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b0e360214949eebb51638497d0ec18_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtNy0xLTEtNTk3NDA_aa37c8e9-76da-446e-a985-9a9cb54ff353">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b0e360214949eebb51638497d0ec18_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtOS0xLTEtNTk3NDA_bda58d60-3bad-465a-8962-f6b4a717b27a">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b0e360214949eebb51638497d0ec18_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtMTEtMS0xLTU5NzQw_9f3d9577-3d82-45ee-8fdb-ef8353b7ac31">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtMS0xLTEtNTk3NDA_04258481-b39b-4a01-9fcf-dca93197f0c6">19,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtNS0xLTEtNTk3NDA_12cf701b-6484-415c-a09c-d69c96c25710">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtNy0xLTEtNTk3NDA_892934d9-3ba4-4058-bbad-288eb034e63f">19,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtOS0xLTEtNTk3NDA_6a91748d-a37c-4678-ae73-46a2243c0f08">3,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtMTEtMS0xLTU5NzQw_a8fdc871-d960-412f-b7ad-45e4596a43c1">16,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtMS0xLTEtNTk3NDA_8ade641e-529c-47b6-a0e3-8ec6fbe733d1">30,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtNS0xLTEtNTk3NDA_cb5ced81-42e8-4dd0-af82-08da6e621563">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtNy0xLTEtNTk3NDA_4c134c60-4118-481a-924e-5677a6463b00">30,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtOS0xLTEtNTk3NDA_dea5ba02-12b2-4b10-aad0-baf80e0cdcaf">10,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtMTEtMS0xLTU5NzQw_7c0e2a35-c56a-4ebc-ae27-55661523505b">19,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i0049fb83b03a423cb1ebf3721f98fca0" continuedAt="i730dfa3ab2e84564b883bec6da81dea1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;2, 2022 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwODU_135c222f-e8cf-4bf1-a5a9-839d4ad55b48" escape="true">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwMjg_7c8b2f3b-3f08-4cb8-a247-75bf4ea69037" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of April&#160;3, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"></td><td style="width:43.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMS0yLTEtMS01OTc0MA_c14e90ba-7308-4185-9bab-0641b5ef5cfa">19,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMS00LTEtMS01OTc0MA_7b019d63-3df8-488c-9d04-4a13629fad93">19,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMi0yLTEtMS01OTc0MA_35b6ff56-6724-418d-90ec-2b9c1abcb130">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMi00LTEtMS01OTc0MA_f1de03fc-593a-4466-ba10-112533710f10">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMy0yLTEtMS01OTc0MA_a479a1cc-04a0-424b-9df5-01f6784ad845">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMy00LTEtMS01OTc0MA_6621898a-c850-4876-8ea9-86417aeaa7a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfNC0yLTEtMS01OTc0MA_60972d80-dfd2-45f7-97f4-36e57ca9d102">19,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfNC00LTEtMS01OTc0MA_09ffc8f3-832c-4a14-9161-7fc06f748b0f">19,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i730dfa3ab2e84564b883bec6da81dea1" continuedAt="i51d82a413909424f94500c495bcdcd55"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIxMDQ_00b18075-34a5-43ff-b5ed-a84809a2232c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;3, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.259%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80cc25f225c142c9b2e51f9cc136f5e5_I20220403" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNC0yLTEtMS01OTc0MA_c7a73e62-0bb3-4a9c-91f1-0d9e18ef4577">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574a41416f664b5a90a57869a7b69d04_I20220403" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNC00LTEtMS01OTc0MA_21a1f75b-8f41-4af7-b624-49a0820ed9f5">4,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10a6f23182d14a35bc979be835d03213_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNy0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjhiNDU4MWQxYTFkMzQyYWQ4ODU5YjBmNTcyNWRiNDI2XzQ_cd1d130f-ed3c-4523-bc72-ce1f582102e0">6.73</ix:nonFraction>% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03f9d9c139545c6bf756b9af8dd04ce_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNy0yLTEtMS01OTc0MA_dccb2c31-4eee-4375-8e63-e36e7569c833">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97fa957218749a5b2bbde6c2237328b_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNy00LTEtMS01OTc0MA_bec5eadc-f42a-4467-8b08-c14dbcadffec">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88fb397aabc74f9d9919879a38532a66_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfOC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjg5YTY0MmQzMzhjYzQzMDFhY2UxYzkyMGRjNTBiZjMzXzQ_b83794b5-5031-4bdf-9ddd-055ff1f278ef">3.375</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb107f40561b447d8a9bf98e62f3c54e_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfOC0yLTEtMS01OTc0MA_051250ee-363b-4c53-9a35-a230a36d23da">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1cab1bb8af45f486a55147f5bdbe07_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfOC00LTEtMS01OTc0MA_46d2012a-c288-4ba1-8fd7-d294be56f8b7">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafb5c763b5bb45f899c132bc31626b95_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTAtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjowNTBjNWIwNTY5ZjA0MGI1YWM2ZDA2NDk1NTkyNjhhZF80_db23e159-cb54-403e-b35a-5fdf8151ba62">0.650</ix:nonFraction>% Notes due 2024 (750MM Euro 1.1311)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c666c963c647308254b695cefee498_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTAtMi0xLTEtNTk3NDA_78087391-3520-466b-a4ae-dfceffa8bb50">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ced426dcbd04d1f98029e772acf4b64_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTAtNC0xLTEtNTk3NDA_1e12e997-a82c-4f2b-ae82-a6bc42351aba">829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53b54bd64a574cf0ae8d1e57ec0bc8c6_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTEtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo2MGMwZDhiNzY1YTk0MWM4YTg1ZjdiYzcyYjdmYzM3NV80_5e9cb233-0ac5-481b-9319-a4d928fbd40d">5.50</ix:nonFraction>% Notes due 2024 (500 MM GBP 1.3485)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8afc02d95284431197455ed2c01e0b02_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTEtMi0xLTEtNTk3NDA_d52f3237-fbf3-4a2d-be09-467356ae1e7c">654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1774beb33cd94056b250899436621d79_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTEtNC0xLTEtNTk3NDA_d614e260-f2be-42be-9978-983b289cd1be">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9905446b33e44249abeae66f95c5b42_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTItMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo1MjE2MDI0ZTcwNzM0NzhiOTJkNmM3NjgwNDJjZmMwOV80_a0f68679-92c6-41c7-ab27-85b0826dc25e">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f3e5d7909e4521b088bd43ea9303f3_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTItMi0xLTEtNTk3NDA_526edded-4da6-4fe3-baf8-097a4304f54e">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2b18369ff14783885a3ab5d402b053_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTItNC0xLTEtNTk3NDA_40afbd06-8217-46f8-ab77-80ea7a92c8cd">762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i410644799f39419bbcdf5b89613bbc9b_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTQtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozOWI5NWFkY2FmN2U0OGEwYTg4N2M1ODIzMDM4MDEwY180_ed49b6e8-012b-40a5-959a-d6acbee8b3ac">0.55</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf0299af0124017b184f3378b2e8260_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTQtMi0xLTEtNTk3NDA_22dc5104-874f-4f41-9f97-624b92ebcabc">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d410447a42f4d80ad241f38be44e316_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTQtNC0xLTEtNTk3NDA_e3019ecb-c1de-4596-9633-db4cbbed1763">886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c9f5cae6f44540a89c680000306ed9_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiMjIwNzgyMWNiMjY0YWJiOWFhYzRiYWViYmZlNTg4M180_a4076bc3-2bfe-4843-9e45-b349408b4855">2.45</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic108a9e12f3341939ea27c4f85b55d98_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTUtMi0xLTEtNTk3NDA_b59b53db-70b1-4695-a630-848ec1f2ee4b">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b3ec03d9234219b5bd925a86a41790_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTUtNC0xLTEtNTk3NDA_1fc2921f-748c-4a4e-b446-8e2881143c32">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic66945fc64dc4dd2b97e6ae77585e006_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTYtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozZTc1NDRkYTM0YTI0ZTlmODZiYWU4NmJjZDhlYzM3MV80_4e04ef28-cbda-4694-b5ca-6cd3afe06879">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22df2c32fde24c49ad70d6267b39461c_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTYtMi0xLTEtNTk3NDA_601d99a1-e8ce-4d2d-9779-1145d2d59f81">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73b4ecb878554ed895e6731af84a2410_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTYtNC0xLTEtNTk3NDA_cd6cd845-89ee-47d1-8bba-e6794a6e0acc">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec5b6d69f26346649c425f8e2933241b_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo3MjhmOTEzYjIzZmM0NDZkOTA5NGRkN2NkOWE2MWYyNV80_e6c71da5-ccd2-403b-8406-d5aed4045c25">0.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ae7da6e5e348d3bfd658d212535274_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTgtMi0xLTEtNTk3NDA_729a104a-a11d-473c-b184-08890f987f7e">1,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4fd353404164731a511e7927bec85a8_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTgtNC0xLTEtNTk3NDA_0c6624f7-3f22-4c3b-9c1f-6568ff55a866">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92d34c20152a4de3a3f77d8cb010b8de_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTktMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4YzQwZjkzNzU1NDc0OGZhOThiNTQ2ZDA3YmEwN2JiM180_67bb8188-144d-4f99-9166-7d753805a790">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b80c19de72d40139ee47e1d21a6e42a_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTktMi0xLTEtNTk3NDA_c344f19a-5f05-4676-9133-d317e35da90e">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56414cfcd9cc49dd995d25343ea06a1c_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTktNC0xLTEtNTk3NDA_498d3eb4-078d-480e-b7df-628c0e7a9f0b">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafde104933164c4cad0deb69abac440e_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjAtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo5MGRkM2YzZDUxMjQ0NTMwOTQyNmMwNzJlYzg5ZDhmOV80_0b748bde-f446-4480-8f85-3f5e66fe652e">1.150</ix:nonFraction>% Notes due 2028 (750MM Euro 1.1311)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf01842c5cf54c898543482c4a444521_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjAtMi0xLTEtNTk3NDA_a176156a-6a71-4c27-90f7-108529ee8738">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbe50e67f15448d8798dfde818d59e8_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjAtNC0xLTEtNTk3NDA_18b4ebee-0817-47e1-9772-f2233e4d13d8">829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4d10d54d1af41b08272b793afbde882_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjEtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiZTU4MDU5NWM0N2I0YzczODk5ZGM3ZmNhNzMxNmYwOV80_39186a1a-15f7-4069-aada-a6fdcf3b4ac7">6.95</ix:nonFraction>% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed4cca79f874285afd96939684875d4_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjEtMi0xLTEtNTk3NDA_7c882419-2201-4fbd-96f2-2ac013e6eb96">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253bb8f802eb4367b1f601f0eb271aa8_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjEtNC0xLTEtNTk3NDA_64d4127c-a7d7-4e40-ab06-6a8c50421530">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id79227d6ca8e47c096d1f5db54292e11_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjMtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpkZWNmNWVhNzc1OTY0NTM4ODRjMzk4Zjc1YjNjZTU3OV80_7a9c03fa-f0c9-43dc-bd90-701dcda83454">1.30</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26657c8981ae46e79d22c832389a2403_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjMtMi0xLTEtNTk3NDA_0c37c9ea-0439-4f24-8213-e31eb255a1ff">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b9d5f07bc14a4ea1751fd21547dfb0_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjMtNC0xLTEtNTk3NDA_c6f6ae48-fcc1-4ac3-90e5-da747c015eb2">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i050bb5d8583f4db5b7cab1781f41402a_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjQtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozMTNhNTRiOTVjNDg0OTU3OWJlNDcxZTJkM2Q5MTUzMl80_03a66410-3472-4858-9520-5046cdd61384">4.95</ix:nonFraction>% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f5927fb8dc474187a16c8bb7a8f633_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjQtMi0xLTEtNTk3NDA_e300f689-f9ad-40bb-ab3b-bb065a58a0af">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0640760a4d046fdb9b6672981624f0a_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjQtNC0xLTEtNTk3NDA_82e7c550-6067-4c54-a8b5-82be7e6fd175">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7815fcc60b846c4bd4ae4cf64f6a1f5_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozNTBiOGU2YzY5MTY0ODMzOTAxZjA4MmY3ZmI5N2FiZl80_897f19ac-9173-446c-9fec-391675702135">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee6a13418e74e9f97b7fce4de45eee6_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjUtMi0xLTEtNTk3NDA_18d3ccb1-6217-4127-8911-0dd92ce33ce1">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7cb32255274ae599a981a6313a0d95_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjUtNC0xLTEtNTk3NDA_1740139d-b66f-44a9-a57f-a8df5977756d">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56cae7f5eeee4fc995a14d122519fdf4_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjYtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo0MzY4OTcyZDY0YTE0MzZmODdlNTk3MjAwMGNkYjgzOF80_4e9e5aa2-5b3e-46dd-967f-44de4038ca50">1.650</ix:nonFraction>% Notes due 2035 (1.5B Euro 1.1311)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice21280ebab242638498d336fcf84a9c_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjYtMi0xLTEtNTk3NDA_d846644e-07d5-4a3b-8ef7-5fcbf1856ad8">1,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f1dd3b92e340df9e2c6814f388f614_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjYtNC0xLTEtNTk3NDA_71ff2848-64ad-4495-bdf2-4bb310e4b924">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc07bbbd134548d4bab1577bebc273ed_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjctMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpkZGRmNDk4NWM5ZDg0ZmJjOThkZjNkZWZhMjdkNTBmMF80_f9c50d6c-78c0-42ec-b453-7fd8fff257e0">3.55</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9c6f72bf20e4383ba64ecbe3c4bd15b_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjctMi0xLTEtNTk3NDA_4a1e641f-8cfd-4013-b64e-4f719d9ef69c">917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a714f2428ce4aba8dc71a3ce15cc543_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjctNC0xLTEtNTk3NDA_bb61071c-e1b2-4338-806a-4ccdf5c231c3">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c824e2faeb34de8b822a2f57f817f25_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpmOWJjNTY5ZWY5MjU0ZmFkYWM2OGU5ODk4ZjkyOWFjZV80_b25b2a27-613a-42bd-8b90-4d6182b611ea">5.95</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f54a6d9c9f2407397bc4616bc6e7af9_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjgtMi0xLTEtNTk3NDA_8daf794c-2d1c-4443-b889-04000cb64673">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca5c18e09944b9b8a34ad2546775220_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjgtNC0xLTEtNTk3NDA_b107d125-a13a-4ac5-b1d8-7c839ef4897c">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifdd4fbd384b84fd3a0d6693ec4c9c252_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjktMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo5MjM2YzM1MjcyNzk0OTE2ODMzMjM1ODU0NmE1YjM5Y180_4e26baef-ccf2-4418-9df9-bb8529b27ff2">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b2afac7f2047619163d4ced5060322_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjktMi0xLTEtNTk3NDA_7300d8ff-7bdd-497e-be89-8bdac7c3e8ff">1,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb79658f5f2d475486e1d306a4118a47_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjktNC0xLTEtNTk3NDA_a220541c-696c-4f25-81ad-14d3c9473ceb">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb22c0fec5c4490384df777e042c7c81_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzAtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozZTcyM2IwODlkZDg0N2JkOWVlMGUyZmQ1ODJkZWZjNl80_cc2de636-4d4a-4d4a-a922-53a1e4dae326">3.40</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52075d97746b4d90bea9272a17635cd9_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzAtMi0xLTEtNTk3NDA_f8009b0c-3de4-4162-9d59-dcffcadc3369">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia51b7240c69e498bbd44aa9775d04606_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzAtNC0xLTEtNTk3NDA_85cb8e00-2593-45e9-acc9-ad412348f9d9">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice9f99b199274666b12ae2df91d2c820_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzEtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo5NWY1YTFiZTJkNWM0ZmIzYTNkZDZkNjZiZjFhMjNjZF80_e166317e-3e1d-4d79-ab51-0ca66818f163">5.85</ix:nonFraction>% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67077af31f114a30bffdc32fea20dfff_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzEtMi0xLTEtNTk3NDA_3a66ecd0-bd0b-4b84-a041-ab63ab28322a">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i188f32b459e74d5cb0f963e4e0a3f7ed_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzEtNC0xLTEtNTk3NDA_43343dbc-693b-4d69-ace1-2f706b517ed8">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3ca814e494941cc9558570cc4279cea_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzItMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjoxZGNhNmRiYTE4MDY0OTA1YTcyM2U4OTUxNjk2NWVkYl80_52c16c0a-96b3-4cf9-be50-fcd7346be452">4.50</ix:nonFraction>% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44982952c49f4e749aabaf9dcdbec1dc_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzItMi0xLTEtNTk3NDA_e1355641-ecbe-493f-be9c-143e59232468">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b685ecce1643ff89bfb3895523a51e_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzItNC0xLTEtNTk3NDA_95b5e23c-426b-4051-9765-c93c2ca90647">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibea8fdb3616f451c90baf65707bdf669_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzQtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiMWQ5MTVmNjY2Njk0NTJhODIwMDBiYjQwOWM1YWNjOV80_02176a37-423a-49fd-a5e2-d881dfd3cd01">2.10</ix:nonFraction>% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08457c1d48c94eff8dc2ac47bdf0c7b5_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzQtMi0xLTEtNTk3NDA_04ffcb4f-8c25-4be1-b726-65929a73bee7">914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe81741fd58415cb3509d83ffdc5e73_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzQtNC0xLTEtNTk3NDA_faf729dd-9287-4285-b300-11c7e69c2f98">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c1d9e65495e4ece85762fec2639f5dd_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4YzZkMzNjN2FlNGQ0NGJkYTZiOWEzMzgwMTczNjU4MV80_26e5cb05-865f-4baa-b202-cd16daf8e6f2">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12629c9f73b74eff9c5a235f547f2241_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzUtMi0xLTEtNTk3NDA_fb79fb94-caad-46a8-9079-f0db8b692d90">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3970f29929a24eacb55a58c7e37c52c1_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzUtNC0xLTEtNTk3NDA_72e9a331-c91b-4889-94e6-f1c4774b580b">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a3af18d0134471c93564e5fd5f3fe0e_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzYtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo3OGFmNGY3OGZlNDI0Yzc2OTkwMzkyZDllNTI2MGNjZF80_8f831ffa-314f-42b9-98f3-edf7e1bc9967">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1c7715113b48dcbff2dfe6536eb602_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzYtMi0xLTEtNTk3NDA_6cd3bbaf-2ce5-446d-88e1-8e6ce0e145ff">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec5bcf102a34a1b87cf004f535337de_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzYtNC0xLTEtNTk3NDA_2a73c304-5695-4c95-9c55-e5b8ef17ec8d">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6885bfb3e4984c65abbb4580fc179cba_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzctMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo2ZDE0ZjY2NGUyYTQ0Y2ZjODExMGE2ODIzYmMyMDc0OV80_f30642d9-6055-4257-baff-51269446167d">3.70</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d3a223ac884f86b9a206b4617aa103_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzctMi0xLTEtNTk3NDA_623afbb8-e92b-4c65-80b6-c42349af4c4b">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id914def5ea98451bbfd52ec51a11e6d4_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzctNC0xLTEtNTk3NDA_5cad65c0-b82c-4beb-86d9-99c9813a4cf4">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iededfd7a59eb43208e3672b72a308066_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiODFjNzhmODgyOGQ0YTQ0OGM0ZGExNGI0MTU1NWY5Ml80_1dd96832-e6ab-4356-a694-a24871c3f10a">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f9a83e7716457aa17dcab50434530a_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzgtMi0xLTEtNTk3NDA_b7e97d73-40a2-4fa8-93cc-e8ca721e5609">906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3f9d6c591e4c379b03f6a63223ff4c_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzgtNC0xLTEtNTk3NDA_88caf3ae-f3f7-49f4-bc31-7ad2fb3f7264">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffc2dad290bf4b1f84e0014e807f7d22_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzktMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjoyZDczODA0YjA5MDg0MjAwYWYwMjliM2U2NDQ4NDg1ZF80_56d6f0a9-c61a-4df1-b233-538a91f3cf81">3.50</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe07c4d0ab547cf987486709e3723ea_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzktMi0xLTEtNTk3NDA_6e87d001-3d3d-475f-af42-02e03563de26">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3fd14bab994cb2b98c874567c9124a_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzktNC0xLTEtNTk3NDA_337eff8b-b5a1-4895-a357-5218b89e2a58">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb0087669f7d433a94c2175b61948c30_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDAtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo2ZDUxZmQ2ZDIzOTM0YjUwOWM2MGFhNTc5NTA1ODlkZV80_ef2f6031-a6c8-4c98-880f-f7a89524ac3b">2.25</ix:nonFraction>% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ae03e86ec34f059e03de3ba7a0fa16_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDAtMi0xLTEtNTk3NDA_ef132c54-f44b-4a27-b333-c3182ef01afa">914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7525d9cf9c7a4c2eb64364d6f1fe110a_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDAtNC0xLTEtNTk3NDA_067375d4-7c10-4640-83f0-bd8658edbb31">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife167dfbe51e4f7bba2d6c116e0acbe8_I20220403" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDEtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo5NTQzY2ZiMmY3ZjU0ZjI4YTU4ZjI2MDU4ZTM0NWM5ZF80_14b9a2e4-4465-436e-8dc1-58636321ef8e">2.45</ix:nonFraction>% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6724f9eb2f284a7897adfe49ccf0a1bc_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDEtMi0xLTEtNTk3NDA_5be761f7-dfc6-484a-b835-750f6fd669b2">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6d608431ea4c5398a0d5693ec02ce7_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDEtNC0xLTEtNTk3NDA_60d598f2-85a4-4c73-a542-bf5bf0b55b03">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1fb99008d5c46f782ebe421c09b6c86_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDItMi0xLTEtNTk3NDA_15f64e30-4035-4c11-bce7-b4ab090c1919">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809a6e12d5804dfb8ab4ace60751a5d4_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDItNC0xLTEtNTk3NDA_244fbe29-d860-4419-a956-6a0bcd15f3c6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80cc25f225c142c9b2e51f9cc136f5e5_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDMtMi0xLTEtNTk3NDA_91df9965-0f20-48cc-a1d6-b3f4e626cab9">28,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574a41416f664b5a90a57869a7b69d04_I20220403" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDMtNC0xLTEtNTk3NDA_cdb4b00b-ef5a-490b-904b-59e9a848254c">29,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is <ix:nonFraction unitRef="number" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE1ODg_6dd65f77-9e9e-478f-83f7-c34f6525fbe9">3.04</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $<ix:nonFraction unitRef="usd" contextRef="ia20a226df1534401beb4ebac52ca168e_D20210104-20220102" decimals="-8" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE2Njg_8803a906-5642-49b7-98ce-21d593082401">3.2</ix:nonFraction> billion at January 2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of April&#160;3, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i64bc3e5d158d4182ad9506d5f1a6e623_I20220403" decimals="-8" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE3MzU_eb5403e7-f2d7-4871-82a9-8e942a764253">3.8</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="i64bc3e5d158d4182ad9506d5f1a6e623_I20220403" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE4MDQ_e35f6c6a-a8f0-4894-9da6-270ac6572c72">0.37</ix:nonFraction>% and a weighted average maturity of approximately <ix:nonNumeric contextRef="i02143dea06fb4fbbba003f6bb1395472_D20220103-20220403" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE4NTY_4dff14b9-b416-43e6-a270-ac9a738aea90">three months</ix:nonNumeric>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i51d82a413909424f94500c495bcdcd55">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</ix:continuation></span></div><div id="i89b54799c61648c0892d664696387b28_70"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 5 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83MC9mcmFnOjRiNTJhZjFkOWQwNDRiOTk5Mzc5NzRhOTU4MjlmZjY5L3RleHRyZWdpb246NGI1MmFmMWQ5ZDA0NGI5OTkzNzk3NGE5NTgyOWZmNjlfNDU4MA_ef86c3ca-4af6-49e5-91c3-30067edb1949" continuedAt="id4671681aca043e1bc35cbc7660fab9e" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id4671681aca043e1bc35cbc7660fab9e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal first quarters of 2022 and 2021 were <ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83MC9mcmFnOjRiNTJhZjFkOWQwNDRiOTk5Mzc5NzRhOTU4MjlmZjY5L3RleHRyZWdpb246NGI1MmFmMWQ5ZDA0NGI5OTkzNzk3NGE5NTgyOWZmNjlfMTE1_4bfbca15-3b98-4346-ad22-8cbd39bcdca2">12.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83MC9mcmFnOjRiNTJhZjFkOWQwNDRiOTk5Mzc5NzRhOTU4MjlmZjY5L3RleHRyZWdpb246NGI1MmFmMWQ5ZDA0NGI5OTkzNzk3NGE5NTgyOWZmNjlfMTIy_f6f00f7a-84d2-4c77-ab7f-455ce6cef073">16.6</ix:nonFraction>%, respectively. This decrease in the consolidated tax rate is primarily due to lower income in higher tax jurisdictions, primarily in the U.S., compared to the same period in the prior year. This lower income in the first fiscal quarter of 2022 was caused by a mark to market adjustment to the Company&#8217;s investment portfolio and the impairment of the bermekimab AD IPR&amp;D (for further information see Note 3 of the Consolidated Financial Statements), both at the U.S. statutory rate. The impact of the income mix was partially offset by incremental tax costs directly related to the planned separation of the Company&#8217;s Consumer Health business.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also had tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal first quarters. Additionally, the Company&#8217;s effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal year 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of April&#160;3, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83MC9mcmFnOjRiNTJhZjFkOWQwNDRiOTk5Mzc5NzRhOTU4MjlmZjY5L3RleHRyZWdpb246NGI1MmFmMWQ5ZDA0NGI5OTkzNzk3NGE5NTgyOWZmNjlfMzc0Mg_c63f48b4-4ac4-4bcc-8d2d-6cabb850d825">3.3</ix:nonFraction> billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.  In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 6 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RleHRyZWdpb246MTBjNTkzNTUwYzc4NDUxMTk1MmJhZTI4ZWQ0MjhhNTdfODk5_cd288301-308b-4449-a7a2-362d00f9af6d" continuedAt="i31e56f34ccc043999e18363d9179d542" escape="true">PENSIONS AND OTHER BENEFIT PLANS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i31e56f34ccc043999e18363d9179d542"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RleHRyZWdpb246MTBjNTkzNTUwYzc4NDUxMTk1MmJhZTI4ZWQ0MjhhNTdfODg3_f97a55b4-58d2-4db2-a401-7079022fa0a8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"><tr><td style="width:1.0%"></td><td style="width:45.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMy0yLTEtMS01OTc0MA_6e705d13-a5ff-40d7-a4e9-1ea8a69ea2ff">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMy00LTEtMS01OTc0MA_ba1876d2-52a8-4ef4-999a-a98b734612b0">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMy02LTEtMS01OTc0MA_4cd9058c-10b6-4b17-9cae-684f022a121a">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMy04LTEtMS01OTc0MA_8ed28a55-4948-4a76-b33a-508ea90b103e">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNC0yLTEtMS01OTc0MA_cc02ba82-59ae-4058-8f8c-a687a796d984">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNC00LTEtMS01OTc0MA_c7463490-cbad-452a-90f9-83fd6174e643">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNC02LTEtMS01OTc0MA_26763d2d-3fde-4e05-aca3-af2682377f68">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNC04LTEtMS01OTc0MA_dab70431-61a5-4318-8734-0e0477216cc2">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNS0yLTEtMS01OTc0MA_7e06e7eb-6486-4ea7-a382-6fafdad143a9">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNS00LTEtMS01OTc0MA_c29e8746-a7a1-4a6c-90b0-e95510489eda">680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNS02LTEtMS01OTc0MA_4132e31e-d183-483a-89d4-6af85a2d277a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNS04LTEtMS01OTc0MA_6af45dc4-05c4-4ebd-be87-58321e5cd94c">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNi0yLTEtMS01OTc0MA_cbd3c129-9bde-45a4-93d8-4d051a427358">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNi00LTEtMS01OTc0MA_1bd1d53f-0347-438f-a33c-dc6741151ab5">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNi02LTEtMS01OTc0MA_a329dcca-25dc-4b2e-b074-a05903cf5373">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNi04LTEtMS01OTc0MA_fdce7869-d81e-4632-8a99-a63571401cba">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOC0yLTEtMS01OTc0MA_d7300a9e-00c0-4148-a999-1f6294695036">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOC00LTEtMS01OTc0MA_c958a94f-d555-4dcb-8f57-d2e85e4a4ff0">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOC02LTEtMS01OTc0MA_27ef7a17-3b16-4bf9-bf0e-63675b023e8c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOC04LTEtMS01OTc0MA_3c1ba08b-f030-47df-bfcf-6c2114ba1002">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOS0yLTEtMS01OTc0MA_47a29318-edfb-4ebf-a7af-f646a789c1df">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOS00LTEtMS01OTc0MA_6d23c5f1-8358-47e5-a840-98e90f7e92de">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOS02LTEtMS01OTc0MA_face1e08-1b0b-4676-93a0-92f5beef034c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOS04LTEtMS01OTc0MA_3b62c454-556d-4fea-870a-3dd918c8cfb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMTAtMi0xLTEtNTk3NDA_31c6fdbb-0212-4fc5-8c26-abb18e167fdd">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMTAtNC0xLTEtNTk3NDA_cbcadc8e-a80f-4434-b11b-9b4dd0ae2125">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMTAtNi0xLTEtNTk3NDA_c6e60789-2b56-4be3-b8ab-c8a0bf2f4dfd">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMTAtOC0xLTEtNTk3NDA_78d9e077-3e63-48fb-ae0a-234a647cf40b">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal three months ended April&#160;3, 2022, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="ifd9afdfa4aab43f5aec11564a7a210ec_D20220103-20220403" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RleHRyZWdpb246MTBjNTkzNTUwYzc4NDUxMTk1MmJhZTI4ZWQ0MjhhNTdfNjIz_6050e08f-1d8a-48e1-af69-6e2dc5e8cbb6">29</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9d981e7841b2446e99bdfd3c1765f8fd_D20220103-20220403" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RleHRyZWdpb246MTBjNTkzNTUwYzc4NDUxMTk1MmJhZTI4ZWQ0MjhhNTdfNjMw_ccf2e3f8-7498-48c4-b3cf-c917ebad4a15">5</ix:nonFraction> million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div></ix:continuation><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_76"></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 7 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RleHRyZWdpb246N2U0MDU0Y2M1ZDI1NDM0ODhhNzFkOWRlNzA4MDdjY2RfOTI1_7fd33335-cac1-4edd-9ca3-dedac86d1212" continuedAt="idaf6b9e6dc7b4f52ac4092fa20e206ea" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idaf6b9e6dc7b4f52ac4092fa20e206ea"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RleHRyZWdpb246N2U0MDU0Y2M1ZDI1NDM0ODhhNzFkOWRlNzA4MDdjY2RfOTM3_c6b03e5a-1112-4495-b302-36154a5695aa" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.991%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i655ff821171a4447a9788502f3181ca5_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC0yLTEtMS01OTc0MA_0ca29a67-6e3d-45d4-a66c-aa673f086064">10,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79fbbc6f7a9f4234af3a15aaeeaba82e_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC00LTEtMS01OTc0MA_cff46b52-3663-4a7b-9ee5-a87f36c6afa3">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb1f6b66a0df4ab5a5db2bb2552e5b52_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC02LTEtMS01OTc0MA_1a0e309b-c87c-40ce-91ac-47eb259b1499">2,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b3c368d3ea94156894bb15d205cbe39_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC04LTEtMS01OTc0MA_205ad5eb-ad1c-49f9-a419-33525ff023af">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2336cd90b8e74beeb66f460bec6b6238_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC0xMC0xLTEtNTk3NDA_12899e42-0d26-4d5f-b336-d39dbca36c4b">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id04f969ee3dd48eb9bd1be04f519efba_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS0yLTEtMS01OTc0MA_cb8be334-1054-452a-acee-4e4f25cf3fd2">554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1fcea51f4fa46ea9140cbab41a14eb8_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS00LTEtMS01OTc0MA_374573cd-4e49-4c5c-b71a-b07bff872d0e">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ab2638f2434165b9cb7a98bca9725c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS02LTEtMS01OTc0MA_5b535199-4b40-473a-ba90-72e07e69041a">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i036b309881ec46189aa9470289afa49d_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS04LTEtMS01OTc0MA_ea1cce0c-db5a-4542-867e-75ab012127a3">296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbe0f983eea14da3b437dcf18bfa144b_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS0xMC0xLTEtNTk3NDA_ce80ad71-3b45-41d5-9a40-e10a2c01b350">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68eb55b964054c96a96b26b18621d7fd_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy0yLTEtMS01OTc0MA_b46bf5d2-301e-49d0-adc6-cd2e8d466dea">10,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i326f78b1620b461cb2172429271e8699_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy00LTEtMS01OTc0MA_ce7eb60f-8236-4fad-a908-a2077e1408b4">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49a97e3323484686a9262c40ba0b98ce_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy02LTEtMS01OTc0MA_d2961795-3320-42b2-9850-15f8993796d7">2,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i579a8661a8a943369207a48d2742c946_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy04LTEtMS01OTc0MA_63759510-38a6-4623-98bc-233246fad092">632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i795ff92791494382a1d26a7b84fee3e5_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy0xMC0xLTEtNTk3NDA_778ce9f7-13f6-4e84-9c25-5d4f374ad033">13,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 8 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RleHRyZWdpb246NzE1YWY5MGNkYWViNGY2NGIyNDkwM2EyNmJiZmJhMTlfOTkz_f34541d4-4d37-49d9-9556-22f5047b093d" continuedAt="i74c56260e738407ebce480682b6ee818" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i74c56260e738407ebce480682b6ee818" continuedAt="id4e199d488f641969701b5e62ef1cedc"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RleHRyZWdpb246NzE1YWY5MGNkYWViNGY2NGIyNDkwM2EyNmJiZmJhMTlfMTAwMQ_a77c00a6-ff68-4a32-87d2-d66697d6aee6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.011%"><tr><td style="width:1.0%"></td><td style="width:69.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.335%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfMi0yLTEtMS01OTc0MA_ac8d6b56-b77c-4f9d-9ac4-464f87c51089">1.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfMi00LTEtMS01OTc0MA_21658fe7-6828-4700-8a78-182930066711">2.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfMy0yLTEtMS01OTc0MA_cd876ad2-1d1d-4a5e-95f5-667712632925">2,629.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfMy00LTEtMS01OTc0MA_6995128d-dff2-4f4f-b824-8226174eb768">2,631.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNC0yLTEtMS01OTc0MA_1fbd7950-ee3e-4b1c-b772-23823a98da19">140.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNC00LTEtMS01OTc0MA_b590dba2-be9b-48b8-8b51-0c3e851c5d99">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNS0yLTEtMS01OTc0MA_ea0870c4-cf3d-4244-a65e-c8e7cb3c7b1d">102.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNS00LTEtMS01OTc0MA_4f3b1961-bb87-4cd5-811e-98218a27f25a">87.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNy0yLTEtMS01OTc0MA_a1b38437-f40e-4376-8750-df09d85a68c2">2,666.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNy00LTEtMS01OTc0MA_2f3f67cb-bc24-4623-8aef-c44c5a133d7d">2,672.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfOC0yLTEtMS01OTc0MA_69e164be-68e0-41da-8c31-20e9b2070e96">1.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfOC00LTEtMS01OTc0MA_11dc7c24-05a5-468a-92f4-800cf9052e5e">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="id4e199d488f641969701b5e62ef1cedc">The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;4, 2021 excluded <ix:nonFraction unitRef="shares" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RleHRyZWdpb246NzE1YWY5MGNkYWViNGY2NGIyNDkwM2EyNmJiZmJhMTlfNDYw_df378649-d1fd-4503-9219-bda8ab8dd134">9</ix:nonFraction>&#160;million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 9 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzczOA_55c3c6d2-2e29-4b29-8d14-14e957fef0e2" continuedAt="i0558d722e6a6492fb5d789815308c877" escape="true">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0558d722e6a6492fb5d789815308c877" continuedAt="ia77a72a777a647e8845b8163a5de5e8c"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzc0Ng_a5603c06-0eee-4b51-b43a-9e51e3cc2247" continuedAt="ibf66f4333e5544ad9c547b616e4115d6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58211c7e72c4650b6392f3161a3bffe_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNS0yLTEtMS01OTc0MA_5f3c4578-5c16-4710-9dc2-077d0d92e926">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc118b408a9a4fa0a2216582ec2c57d3_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNS00LTEtMS01OTc0MA_2e79e29e-8007-4a7b-85d7-63cba963ac03">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie58211c7e72c4650b6392f3161a3bffe_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNS02LTEtMS01OTc0MA_13fd33be-d047-48cf-8fa8-54d85f4ad14f">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea43f39e6f7e4722a355ac665f3270c0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNi0yLTEtMS01OTc0MA_0e1c51f6-5dee-4331-91ea-974e59de20f3">791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a68fc6f7f84ab9bd6670bd40be776f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNi00LTEtMS01OTc0MA_ef72179b-2079-4379-a036-0bac5f0dc6af">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea43f39e6f7e4722a355ac665f3270c0_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNi02LTEtMS01OTc0MA_cfeada2c-be27-4392-92d5-6ef9a608651f">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i822f34b9534c4b36800cd53b915bfd96_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNy0yLTEtMS01OTc0MA_0910f3f8-13f7-4a5c-a903-71b840804a39">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e49973bd224b328cb521a49bd33c14_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNy00LTEtMS01OTc0MA_7332e281-df07-4a71-801e-a2311b9cbba2">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i822f34b9534c4b36800cd53b915bfd96_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNy02LTEtMS01OTc0MA_4f98e118-e837-48a8-b2e0-fbfc9ca67928">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc09b5880e446b6b7704ca8b8c71bf9_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOS0yLTEtMS01OTc0MA_831b4d79-ab3d-4c6f-ac9e-c75c5b0b6329">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icebf6d8f73bf4c99a24334b6c6b70834_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOS00LTEtMS01OTc0MA_89eb3555-ea1d-4f99-bf40-28b965cdea46">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7cc09b5880e446b6b7704ca8b8c71bf9_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOS02LTEtMS01OTc0MA_946ce16f-9997-4fa0-b3d2-631d6da2585f">14.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d1e565782ba4f77b615f220541630b5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAtMi0xLTEtNTk3NDA_b2b0e5a7-4f06-42a9-b2b1-f60f1f406fb9">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8572638eba1747738bf792b8ccc0d65b_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAtNC0xLTEtNTk3NDA_178c4f31-e352-46f8-a9b2-38fec933d2c8">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0d1e565782ba4f77b615f220541630b5_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAtNi0xLTEtNTk3NDA_c989731f-e238-4c69-9b70-0c5d15fb1123">11.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106a09af4412484ab101b4dff6f6060a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEtMi0xLTEtNTk3NDA_0e05e384-f8b8-41fa-ab73-2d00a12a4a6f">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c0af8ca15849f8888a804c0a76e8f5_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEtNC0xLTEtNTk3NDA_97b23d9e-0717-438f-89c2-c6cc482d38ff">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i106a09af4412484ab101b4dff6f6060a_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEtNi0xLTEtNTk3NDA_26999e3b-49bf-4381-9002-fae74a0ffcd9">13.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfa95d8a78b40e4a7dfc45c287e5d8a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMtMi0xLTEtNTk3NDA_9cdf2387-28e2-4224-a927-fb53e2909c9c">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c6944ea87e4a3dafff3f45a308061f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMtNC0xLTEtNTk3NDA_cc3f4ad0-566b-45af-b476-78a89e052be8">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1cfa95d8a78b40e4a7dfc45c287e5d8a_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMtNi0xLTEtNTk3NDA_df14d5b3-6da7-498e-a3e3-96f6d7efc4b4">12.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c50a0f6783436cb25640408523922e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQtMi0xLTEtNTk3NDA_48a26bc2-4653-4454-aecc-0b075e8cc37c">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e793e0192504c92a6fb0cb90815740a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQtNC0xLTEtNTk3NDA_9fe3377e-757a-48a4-8ff2-06bf95b30e0c">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i46c50a0f6783436cb25640408523922e_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQtNi0xLTEtNTk3NDA_b058d6d6-c8a0-4889-9a1b-61b7a5b197a4">12.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908ec40014fe4b879088ba1b344b5a37_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUtMi0xLTEtNTk3NDA_73bbbe55-1ac0-441a-935a-19a69e78b7f4">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3aa331b4f344986bd6aefd2d877917a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUtNC0xLTEtNTk3NDA_d945756e-2a0b-436e-92fc-b92d51cb54c8">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i908ec40014fe4b879088ba1b344b5a37_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUtNi0xLTEtNTk3NDA_d76895f7-6505-478f-b03b-88409af4cf81">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c161740da694af9a2557994290040f0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTctMi0xLTEtNTk3NDA_471dc47c-0eea-4095-96bf-2a968e51b9ea">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b056bd57be1420eb472b82a9ad65490_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTctNC0xLTEtNTk3NDA_a8cce880-0d44-4699-a275-42a61aded944">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4c161740da694af9a2557994290040f0_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTctNi0xLTEtNTk3NDA_e1a55253-a3e9-4e78-afa1-3abfa0f15301">11.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd2d0c278fd4ccb9e5f826f44c15a6b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgtMi0xLTEtNTk3NDA_688b271f-a44b-457f-bfb1-f7688417b8ca">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd5fd3ed29041aeba59bb41d9957e8e_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgtNC0xLTEtNTk3NDA_42950506-659a-4bf5-9cec-f977d1462869">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9cd2d0c278fd4ccb9e5f826f44c15a6b_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgtNi0xLTEtNTk3NDA_412433bf-8a3f-481c-b79c-e7bc0fa6d404">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ceb1cef02743f1b6c9be2aa05040b3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTktMi0xLTEtNTk3NDA_3286727f-87db-4862-8791-a57604f59c09">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acd3aa5bee74304878a6f9cbf1956ec_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTktNC0xLTEtNTk3NDA_7492ccf7-3a46-40b6-9f42-a3c38edc28f1">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i43ceb1cef02743f1b6c9be2aa05040b3_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTktNi0xLTEtNTk3NDA_05778f8c-297f-4349-aa60-61bf7c111597">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77366e1975a48bd8912cb5972f077ca_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEtMi0xLTEtNTk3NDA_ac93c4b2-9593-48e3-8350-d1bdabace9b4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ceadbf51b24faa9f04ba01b0a27b54_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEtNC0xLTEtNTk3NDA_61295424-c86d-42ad-8404-8154d5b63e14">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie77366e1975a48bd8912cb5972f077ca_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEtNi0xLTEtNTk3NDA_99650182-a6ce-4c9a-8b13-02f91b22b0f8">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4e3ae4eef749e986b5c6bd8d739748_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjItMi0xLTEtNTk3NDA_d8538e52-0566-475e-b717-de18084b8db6">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84d71c2b7b4544b1a58237715b2b3c42_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjItNC0xLTEtNTk3NDA_4627dbac-49a7-47cf-9cdc-8120dfbfc9ab">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d4e3ae4eef749e986b5c6bd8d739748_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjItNi0xLTEtNTk3NDA_bd95cf60-ab34-4a67-b53f-75421acde98a">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678bfbf7014e416f8aa38a66f366d4be_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMtMi0xLTEtNTk3NDA_e5208ea9-ebdf-44cf-859b-1e88d350828d">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib688bd3f296d41f0b14572e3064b458d_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMtNC0xLTEtNTk3NDA_a058c63c-508c-4836-b0e9-754801d3b387">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i678bfbf7014e416f8aa38a66f366d4be_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMtNi0xLTEtNTk3NDA_75c5e1bf-7300-465d-b21f-2402ce32154a">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4627a516050411dbd08c0de6091128b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjUtMi0xLTEtNTk3NDA_43025c11-013d-412d-ad94-e3400b43b8fe">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d275cd215484120b60ac1c7626e17a7_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjUtNC0xLTEtNTk3NDA_703dd018-f9f0-4472-b088-dfddf3e52f21">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia4627a516050411dbd08c0de6091128b_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjUtNi0xLTEtNTk3NDA_d6b12e10-86fe-4675-989a-6b9783101da1">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932bcfc6315d438f826521020670f715_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjYtMi0xLTEtNTk3NDA_27219204-7304-451e-8867-3281cf8e4cf7">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7411eebec7264351bf377981afe68c71_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjYtNC0xLTEtNTk3NDA_84b7f3d1-c65e-47a2-a19b-47d730852046">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i932bcfc6315d438f826521020670f715_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjYtNi0xLTEtNTk3NDA_def1c44e-555f-44c5-9017-95f0e396e89a">15.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f0f05017af45e3863ccf8b056567cb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjctMi0xLTEtNTk3NDA_833df720-86a1-4967-86e7-161d37900970">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3d886ec05249aab4e1f0ce7760f1c8_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjctNC0xLTEtNTk3NDA_38d3f10b-a06e-45b6-a85d-af83ae70ab07">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41f0f05017af45e3863ccf8b056567cb_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjctNi0xLTEtNTk3NDA_f80ddef3-c5e8-472a-a47e-3f67a5adf125">7.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5159ea7ea34a9486f467d8b275261c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjktMi0xLTEtNTk3NDA_8ef4accc-75b0-4982-ad61-822543a5517f">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b965aef16c049ca90d08a094faafdcd_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjktNC0xLTEtNTk3NDA_1e9b541e-b8db-4069-ae3c-cc5677a6cb0c">1,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7a5159ea7ea34a9486f467d8b275261c_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjktNi0xLTEtNTk3NDA_c11252f2-a7b9-4e82-a1dc-3e558366d08c">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbacfe0de454d4fa786ace56cada354_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzAtMi0xLTEtNTk3NDA_7f4f623a-91e1-453b-adca-3e8a3965bbe9">2,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd509ce95fe400781462e4ad6cfa01f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzAtNC0xLTEtNTk3NDA_0606b9f7-9d8d-4742-9247-b76b739edfd8">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cbacfe0de454d4fa786ace56cada354_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzAtNi0xLTEtNTk3NDA_a9be7090-09b0-4f3b-bb68-24c9a52020e5">0.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzEtMi0xLTEtNTk3NDA_ff50784b-673a-4ec6-bf49-e0aaae4bfd42">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4fd750dd7840a1bd8f81d424809f1a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzEtNC0xLTEtNTk3NDA_e9fa37f2-632f-4a06-bcd2-7bf53d0c6f4b">3,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzEtNi0xLTEtNTk3NDA_1a5ca81d-1e9c-43c1-84db-c8772c12a1bf">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="ia77a72a777a647e8845b8163a5de5e8c" continuedAt="ie6421d30753f41c285f8340bfdc41457"><ix:continuation id="ibf66f4333e5544ad9c547b616e4115d6" continuedAt="ia6801fce1ce84db8b68a88be28d1f4d2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6c831f375741cd86628f708528bbc4_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzYtMi0xLTEtNTk3NDA_be50017a-fbe9-4cde-947c-ad4a7892a97e">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378ba8c96ec94703a6594ef190bcf501_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzYtNC0xLTEtNTk3NDA_2724975b-0fb1-4dca-ae6b-0a9aca977e9d">2,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac6c831f375741cd86628f708528bbc4_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzYtNi0xLTEtNTk3NDA_6deb535f-c836-42df-9e4c-b341da429756">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770e070317374dd9bbc2d03a76164315_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzctMi0xLTEtNTk3NDA_113b5543-b7f2-4859-98f9-d3901577611b">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00933be305c4a70bc5ab93fcafbfa34_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzctNC0xLTEtNTk3NDA_b194d787-7f4e-4e46-8ac8-429a59a72954">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i770e070317374dd9bbc2d03a76164315_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzctNi0xLTEtNTk3NDA_20b9b330-9ae5-4b9d-9560-00a6fc0db3a4">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ecdf550ad642faad28a0a3da3a0c49_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzgtMi0xLTEtNTk3NDA_ba9639a3-a6a2-4663-80bc-5369c6d8b95e">4,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic914d835318f4ac59e6afec0dc209943_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzgtNC0xLTEtNTk3NDA_882be0b4-a7f8-4009-85bc-19e1787b657e">3,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30ecdf550ad642faad28a0a3da3a0c49_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzgtNi0xLTEtNTk3NDA_4c308ae3-3d40-4390-8e34-57d2cc47a7d4">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea83d16b7bb4bb4852dde662d6d8a03_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDAtMi0xLTEtNTk3NDA_e4cbd040-ef1c-4772-a990-38f0714048fa">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i355c4b8323c94982a0e7d8ad5ef02138_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDAtNC0xLTEtNTk3NDA_f4eacda8-7342-4044-acf8-346d38697d2f">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9ea83d16b7bb4bb4852dde662d6d8a03_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDAtNi0xLTEtNTk3NDA_2d6e59de-0e29-4f92-9241-b38159ccd010">26.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5fe9781715b43f6b43d02d8a29fdd61_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDEtMi0xLTEtNTk3NDA_a8f02b5f-f6f9-452b-b384-e593854ca103">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1de5e9029e04a3088baa1a08b8ee842_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDEtNC0xLTEtNTk3NDA_7ca271aa-606c-4b1a-827d-86981f336999">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5fe9781715b43f6b43d02d8a29fdd61_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDEtNi0xLTEtNTk3NDA_d3e31da8-dd19-4f4d-b691-115d82f0ef9d">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919b94882de1475288644c1f41c738db_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDItMi0xLTEtNTk3NDA_44a45c1a-25b8-4e32-8a51-4e8d6cc99a0b">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74ae7d88be64d3c866359475a6b9e4d_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDItNC0xLTEtNTk3NDA_ffe6f391-d267-4ba4-8523-0bfbdce609ba">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i919b94882de1475288644c1f41c738db_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDItNi0xLTEtNTk3NDA_9defe84a-a8af-4a7f-b762-3f620ff383e0">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b27662b65c465dbfc102823591a764_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDMtMi0xLTEtNTk3NDA_0022d349-155b-4cec-8da8-c625f09d171a">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275f4a59164a4f3cb58fd6b37c979201_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDMtNC0xLTEtNTk3NDA_d5056e88-4e9d-4cc3-b69a-d11e34317377">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i64b27662b65c465dbfc102823591a764_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDMtNi0xLTEtNTk3NDA_a98c59bf-0385-4bcf-9ef4-3f1c85adcf69">14.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d196ab07bb74237905594d14817fae6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDUtMi0xLTEtNTk3NDA_2fa2c70a-94fe-4323-a755-2e407251162a">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6e2e05dd264470bda927b1746471f2_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDUtNC0xLTEtNTk3NDA_63706bee-58d0-428e-9998-9db827fe0c3a">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d196ab07bb74237905594d14817fae6_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDUtNi0xLTEtNTk3NDA_e448d8c4-7b7b-4bca-b299-4606c51885fa">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5baa35e48631478bb99da941854cbc28_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDYtMi0xLTEtNTk3NDA_da494422-8335-4c1c-beee-e8b188228813">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5218805bf34a4f8f9bca9cd6f32c57b2_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDYtNC0xLTEtNTk3NDA_e6abe4ad-625e-46f3-99a0-b4b159d970c5">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5baa35e48631478bb99da941854cbc28_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDYtNi0xLTEtNTk3NDA_a3822aae-ad9a-4508-848a-db6f9f959f07">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f43191ea7584ff5a4538caed79690b3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDctMi0xLTEtNTk3NDA_167865f5-4bde-4f9a-849c-8f2da8b1a7fe">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80675b68ae0443c09f1f157dcafd38b5_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDctNC0xLTEtNTk3NDA_e69ebc55-d0c4-4d76-a7ad-0b38d52c7cba">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f43191ea7584ff5a4538caed79690b3_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDctNi0xLTEtNTk3NDA_6ea4b2f7-b70f-4d96-853b-4f2063a2587e">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d5eb90c90324a6c99251bc1ef4cd0b0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDktMi0xLTEtNTk3NDA_5d785131-8149-4972-a5cb-8528265c3c2d">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3a53a0ad9046aca93e6a7542cd2283_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDktNC0xLTEtNTk3NDA_8e5a84b6-0134-43d3-9c86-ee1e60705b5c">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d5eb90c90324a6c99251bc1ef4cd0b0_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDktNi0xLTEtNTk3NDA_4efbe509-2d5a-47f6-baca-0b00acea54ed">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bae0a6534fb41dfa209ab28eb17aac8_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTAtMi0xLTEtNTk3NDA_5788dfa0-22b3-49d9-8954-9a610e792e75">909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb41835a7214d6cbbc92d58157fea67_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTAtNC0xLTEtNTk3NDA_f7335adb-78b5-48fe-bd0d-c7f16a350b50">817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3bae0a6534fb41dfa209ab28eb17aac8_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTAtNi0xLTEtNTk3NDA_a57a7736-2c68-4a53-8f95-f3ccb6b26d75">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7211490fa1584a8e8f0474626afbda8b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTEtMi0xLTEtNTk3NDA_b9c63713-9406-462c-b3ac-b7409c3731e4">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if075bf0d83ea40f880b89b7f1b810a39_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTEtNC0xLTEtNTk3NDA_7512e13f-20fd-425a-9e6a-90d328a39473">2,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7211490fa1584a8e8f0474626afbda8b_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTEtNi0xLTEtNTk3NDA_75faa9ec-7074-4beb-a4f8-94e40f13bb78">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6904e2c80904427fb7a581c5096e57a2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTMtMi0xLTEtNTk3NDA_f2f9c663-982c-4775-9a02-99663bda94f4">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb39ed1f03bf4875b56192f82a2d67c8_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTMtNC0xLTEtNTk3NDA_645b60cc-dcac-4545-b1e3-5dacd34206a6">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6904e2c80904427fb7a581c5096e57a2_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTMtNi0xLTEtNTk3NDA_9810b18c-ad92-4af4-b364-59339a9d8ffe">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8d1cf7d44f47e6b575833e5e6f0d05_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTQtMi0xLTEtNTk3NDA_3aa230f8-b4ef-42a8-ba7b-13b0938b50f0">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff32341c0bbe4b5ea9b566ba153fbf51_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTQtNC0xLTEtNTk3NDA_8e8e14d4-c327-4fe6-ac12-4b6b92aa6d62">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f8d1cf7d44f47e6b575833e5e6f0d05_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTQtNi0xLTEtNTk3NDA_4b2f80ae-ce0a-479a-a51f-2c8cd49c4be9">38.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ac62a4e6cb4f948252748f571a1ff6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTUtMi0xLTEtNTk3NDA_686bc5c5-5d2d-4ab7-a7e8-0621ace31f16">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab0aa5e7ee2b48aba645333335c83702_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTUtNC0xLTEtNTk3NDA_15a2a560-6923-41ed-b6bf-82e0197e1169">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11ac62a4e6cb4f948252748f571a1ff6_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTUtNi0xLTEtNTk3NDA_75d8f29c-cfe5-4892-9be1-1b9f4f1f4507">41.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9efb7452eea34bc9898890c0842597d0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTctMi0xLTEtNTk3NDA_fb4cb15c-ed60-40af-808c-6492bafdc601">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1665d864d98a4d47962732594b5b38f9_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTctNC0xLTEtNTk3NDA_848bec08-9142-4e2d-8b6c-59cc2a94c6dd">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9efb7452eea34bc9898890c0842597d0_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTctNi0xLTEtNTk3NDA_a9af4b7d-a0da-4e63-a0c6-bf45b23d9baa">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc4d03da8ff94f98aab51935db754a84_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTgtMi0xLTEtNTk3NDA_3dcf68b9-489d-4787-aed6-260ce70d18a3">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb131415d3694db89b4c3cc631aebfad_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTgtNC0xLTEtNTk3NDA_13621bab-fb17-4a25-88bf-713ee37aa930">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b92c4c34a94ef0a8c83ea08eee3b04_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTktMi0xLTEtNTk3NDA_88af2fce-e666-4695-a488-6cdc8963cdea">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d97f7b5e9e411796b79b2aed308f49_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTktNC0xLTEtNTk3NDA_286a7b67-c673-4106-bb8c-ac47872c55bd">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i04b92c4c34a94ef0a8c83ea08eee3b04_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTktNi0xLTEtNTk3NDA_9f08de1d-348a-4096-ac9c-4459d5c9f3fe">22.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4c0bdbeb7e481486ce84464add9cec_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjItMi0xLTEtNTk3NDA_5fa3eb28-c593-426f-8033-9235c2af5cf6">461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f65547983b48f38c56effa03744e71_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjItNC0xLTEtNTk3NDA_b0ba0484-3a02-4c6a-9483-8b6a746224e5">512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifd4c0bdbeb7e481486ce84464add9cec_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjItNi0xLTEtNTk3NDA_e641f5ec-db8b-4069-966f-639ae334cc87">10.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a180a67aa34f04985a9c36da5181f4_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjMtMi0xLTEtNTk3NDA_e4492dd6-5101-4886-aead-5067d3474208">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i726bc4433398439cae78ea7e13f10dd7_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjMtNC0xLTEtNTk3NDA_e6ac2055-77c4-4944-8a3e-a3d19de25741">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42a180a67aa34f04985a9c36da5181f4_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjMtNi0xLTEtNTk3NDA_3b37fac1-3642-4725-80d1-b500fd05fc7a">72.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic26e429353e64268acab78bb090eb6ee_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjQtMi0xLTEtNTk3NDA_f3334be9-95ba-4e37-85dd-53e4470d8f09">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cfcf4ec4d349ac965bd4f72a911528_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjQtNC0xLTEtNTk3NDA_069fd7fe-c337-40d5-becc-cb53604a7083">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic26e429353e64268acab78bb090eb6ee_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjQtNi0xLTEtNTk3NDA_f80809a3-dabe-4706-9936-4b2e912c9a8c">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d87460fbbce401e9e230c449de32a04_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjYtMi0xLTEtNTk3NDA_670b8e45-f319-4d38-b611-ac39114be807">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7518353c94d148b98920a57e3c13f558_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjYtNC0xLTEtNTk3NDA_4ec25e74-7352-44c7-89f2-dfe8b1025121">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8d87460fbbce401e9e230c449de32a04_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjYtNi0xLTEtNTk3NDA_d863304c-8166-40a8-aeb7-f3149748a3db">24.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f3a3fff4b64c42b7391f6783fc86d0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjctMi0xLTEtNTk3NDA_290a5805-3323-4efe-820a-d73b6e2e4be9">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283ab968a33a4019bbca8dd07bb73fb5_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjctNC0xLTEtNTk3NDA_186be3e1-60aa-4ee9-b0fc-b5a78d233854">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe04729f6a041dcbcc8950cffbd70ad_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjgtMi0xLTEtNTk3NDA_a2bb6869-9f7c-4031-b4c5-ad9699bd7362">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d850d220f25461faec903dbc0514f8c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjgtNC0xLTEtNTk3NDA_5cca2e36-f8a8-4557-996c-3705c86b32e3">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0520f0e2ba8d45dbbb23db3edcb3b1ec_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzAtMi0xLTEtNTk3NDA_6e7ade17-94d2-49ef-9273-268518a59432">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9fba2a4e93645948a9ff0513bb728e3_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzAtNC0xLTEtNTk3NDA_d5764ebd-d33b-4036-8491-853b23e66095">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0520f0e2ba8d45dbbb23db3edcb3b1ec_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzAtNi0xLTEtNTk3NDA_537cab0b-4539-45de-9565-26ee5bdbba1d">12.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f85b561077441a8f29c95efc82e1ff_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzEtMi0xLTEtNTk3NDA_98ce671d-b9ee-4cab-986c-4050486a0ca8">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb33e483487440ffb0cfd196244dae1e_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzEtNC0xLTEtNTk3NDA_cd0b1476-8e7d-46a8-a587-b6fd5d6820bd">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78f85b561077441a8f29c95efc82e1ff_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzEtNi0xLTEtNTk3NDA_423520d3-38ff-42b0-ab2a-a24a80b007e4">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2104212889d4866a172b2ffa3412b5b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzItMi0xLTEtNTk3NDA_4492c5fb-c361-4c78-982c-88e68533580f">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d54355525c45a48dcc9d5a2c07b492_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzItNC0xLTEtNTk3NDA_8c55f454-6302-4152-8d88-4932f3da5c0d">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2104212889d4866a172b2ffa3412b5b_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzItNi0xLTEtNTk3NDA_fa7197a2-0169-4914-a635-3f0a4699c9ed">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73699a20bfe4592ab11597b967e3e81_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzQtMi0xLTEtNTk3NDA_94946ab4-f6da-4749-98d6-059a0dfe1bd9">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43632776d7d241d6acebca744803b602_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzQtNC0xLTEtNTk3NDA_a5373a0c-83de-4988-bbb9-5c6a170ac8aa">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic73699a20bfe4592ab11597b967e3e81_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzQtNi0xLTEtNTk3NDA_8bff0da5-0d0e-4747-b724-c0a8cf0185ac">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8041af648d74844acd07d971cac9b88_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzUtMi0xLTEtNTk3NDA_a037e7b5-dcec-4956-8a4f-9790c33570ed">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3003caab41114b89887d780481856b8f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzUtNC0xLTEtNTk3NDA_0450bb4f-458c-4734-8444-55573fb06b85">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie8041af648d74844acd07d971cac9b88_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzUtNi0xLTEtNTk3NDA_3262d955-64d4-45bc-aea1-25d4064b77ab">20.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieefaab0fe06d4a1d8825a8a2912d415d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzYtMi0xLTEtNTk3NDA_0a2f4ca6-c8f9-4265-8c25-9f075dcf0172">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1c0146fd1e40afb97e83e53dac0b3c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzYtNC0xLTEtNTk3NDA_5f605593-55a9-4dae-83c4-88d711ed3883">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ieefaab0fe06d4a1d8825a8a2912d415d_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzYtNi0xLTEtNTk3NDA_4436578e-4f6d-473c-80bb-c422c11c54e3">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="ie6421d30753f41c285f8340bfdc41457" continuedAt="i219e0fd42833446ab0fbdea7207ae068"><ix:continuation id="ia6801fce1ce84db8b68a88be28d1f4d2" continuedAt="if84928d57a8f4b53a954a0e534c48346"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113143b999484cd6b7094f5ffb7f6934_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODAtMi0xLTEtNTk3NDA_758a492b-3bb3-4ea1-b7b4-7a6d1e0c0f9e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6df7baa0a5740ee8592ff53dd67a1be_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODAtNC0xLTEtNTk3NDA_9b0ae23f-ab1c-4de2-bf2d-9abdabaa2e38">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i113143b999484cd6b7094f5ffb7f6934_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODAtNi0xLTEtNTk3NDA_c8dc9a3e-1d3e-492a-b0a4-250c10a2c12d">62.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dc562abb9fc439a87f2465b603dc878_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODEtMi0xLTEtNTk3NDA_22768fbf-b3f2-4fdc-a8b2-d76f7b597b77">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie870e747ed874ff9a84adcffcef46376_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODEtNC0xLTEtNTk3NDA_80aedf41-ca7c-4c53-b84e-e9a9bf6d69d6">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4dc562abb9fc439a87f2465b603dc878_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODEtNi0xLTEtNTk3NDA_74ba15c9-9e5f-438b-a82a-6e8d5eab31ab">3.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23204760220240d9910ea175d94d29aa_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODItMi0xLTEtNTk3NDA_9da19b5f-f7b5-4b14-81fd-3c7d516f3e0a">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i337ee039b35a4dd29e3fda93f8888073_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODItNC0xLTEtNTk3NDA_83b9f636-ac1b-428f-8790-94fa256493c2">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i23204760220240d9910ea175d94d29aa_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODItNi0xLTEtNTk3NDA_c8c13ccf-2050-4c98-b307-13f4cce6e135">15.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i060264da9f6d465d94d5b31aa47981f0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODUtMi0xLTEtNTk3NDA_1cbc67cb-2b12-4927-8ae0-d32dea02a166">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6a826272dc41a88d80ad0ce8b56bc4_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODUtNC0xLTEtNTk3NDA_164078cc-2d6d-46d1-92be-aa6b10b53911">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i060264da9f6d465d94d5b31aa47981f0_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODUtNi0xLTEtNTk3NDA_f3ce7595-273c-402d-ab1b-947ba9cdb683">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d3e119c5794d36acde2361b37d9315_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODYtMi0xLTEtNTk3NDA_28b8e91e-b43c-4a99-bbcc-84972f069ddc">898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371b019e1643431bbc3c4121387c7e9f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODYtNC0xLTEtNTk3NDA_fd98acd2-ceba-4bdb-b7b8-c796956cd9c2">943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26d3e119c5794d36acde2361b37d9315_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODYtNi0xLTEtNTk3NDA_41d0c586-4497-4350-9ab4-d5073c04e1e4">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4ebc5182ee44909c1d020a6781ee9b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODctMi0xLTEtNTk3NDA_66118e80-5408-4d52-acbf-a51b196edeab">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5e99b0b04b4efeaf8272a60bfe9724_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODctNC0xLTEtNTk3NDA_c981db91-c8fb-4a4c-a35d-8b26a365b92e">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d4ebc5182ee44909c1d020a6781ee9b_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODctNi0xLTEtNTk3NDA_f6943179-c3b8-4fa6-9992-4fb4c02d8da1">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1470034f0eb141a98c1afe534e4076cd_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODktMi0xLTEtNTk3NDA_c21f1cfd-7b83-46e5-945e-4b62768b348a">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a067e9da7f41b8a982801bb0a850bf_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODktNC0xLTEtNTk3NDA_3fc96922-ea41-40dc-918c-7d8495fad04e">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1470034f0eb141a98c1afe534e4076cd_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODktNi0xLTEtNTk3NDA_3179bfab-8b0f-4be2-914f-8cc923aa0a16">26.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dcdb3a4cc9d45ba8da97ec07cd15b51_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTAtMi0xLTEtNTk3NDA_1e9ec652-5143-4dbc-b50f-7976d77e067d">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf27b40739cc4a25b5ec694c5b8c000a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTAtNC0xLTEtNTk3NDA_2ddc37cd-7792-4c8a-94da-6c74c8021ecf">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0dcdb3a4cc9d45ba8da97ec07cd15b51_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTAtNi0xLTEtNTk3NDA_69a2ba4c-4655-4970-aed0-07890162e478">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b61e2b815e447c49c894f30ace4c7a6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTEtMi0xLTEtNTk3NDA_9d9bd0cb-f8c1-4672-bf8d-802e99256549">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa838e3db72457496cc39435fbf78f1_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTEtNC0xLTEtNTk3NDA_2340a83f-d90b-4701-989d-b3ef0cf9b6b0">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4b61e2b815e447c49c894f30ace4c7a6_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTEtNi0xLTEtNTk3NDA_f260bdb1-97d6-474f-9284-074654290bd9">8.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91a06bb3ee246aa9b6beeac53b5b676_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTMtMi0xLTEtNTk3NDA_84894f8d-23d4-4ddf-9beb-fb157095c15a">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie69adf3622ff4db8a081d1405d03154b_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTMtNC0xLTEtNTk3NDA_4c48bd9b-3318-480b-b20d-1c53adb97b06">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic91a06bb3ee246aa9b6beeac53b5b676_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTMtNi0xLTEtNTk3NDA_c540abee-744c-45d4-bd9f-ceffccc27f0f">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b076947d8349c4991ca5f8d983bb95_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTQtMi0xLTEtNTk3NDA_59b7a608-9acc-44ce-aa1b-9f1488f380b3">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic57498e999f848169b4085103b58e794_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTQtNC0xLTEtNTk3NDA_6269ec32-3ba9-496c-9f91-3c331fedc047">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib8b076947d8349c4991ca5f8d983bb95_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTQtNi0xLTEtNTk3NDA_dedbe8f3-634d-4c26-9e42-22c8623e187d">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49109641ba840d7ab935c9251557fcc_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTUtMi0xLTEtNTk3NDA_8d03df07-d0bc-4e99-ae10-4897888b3794">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4d7ac479b54426c9c4da3f1551137ba_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTUtNC0xLTEtNTk3NDA_0716e895-8e29-49ed-89f9-6fd9a070d803">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie49109641ba840d7ab935c9251557fcc_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTUtNi0xLTEtNTk3NDA_e0989afd-7a8e-4ccf-8dde-c69069657823">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e016b979bf4274a83e021809fededc_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTctMi0xLTEtNTk3NDA_25c1c78d-b24b-4b5e-82b9-804f8d1aa88a">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04a88fda6b614cf0bc0a0b4fcc001282_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTctNC0xLTEtNTk3NDA_54305ac4-d3e1-449b-a5bc-53efc4003dd6">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i80e016b979bf4274a83e021809fededc_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTctNi0xLTEtNTk3NDA_a58629dd-85cb-4b3a-956f-2ac3f55b4562">6.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2982a107598a4da5a6e1a03aedec047e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTgtMi0xLTEtNTk3NDA_94e6a1c8-84d2-4de7-8226-2bcca8b584a4">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e34ced22b4405fbd24f5ec2c767132_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTgtNC0xLTEtNTk3NDA_2a3f886d-d251-4946-bef5-117712534006">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2982a107598a4da5a6e1a03aedec047e_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTgtNi0xLTEtNTk3NDA_2b2f9177-5ded-4bc8-86bf-bc434960615e">26.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide41d96049794347b667732daaad5f29_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTktMi0xLTEtNTk3NDA_2f58b519-a33a-4edf-a95e-d140b1efc721">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice792ebb5db345a282d8d06424353702_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTktNC0xLTEtNTk3NDA_090f5957-0608-40d0-affd-26ef4b289664">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide41d96049794347b667732daaad5f29_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTktNi0xLTEtNTk3NDA_2a2d42bc-ff58-4a5f-bd0a-5918a84c28d6">17.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ba5f0fbf984535b145a1eb04807f5a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAxLTItMS0xLTU5NzQw_14aa2edc-4627-4919-a2dc-d38ebb3c6d8a">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2ba44f06524718a59342b7ecc0be0a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAxLTQtMS0xLTU5NzQw_7083a40f-28a2-4d93-bfdb-551809511851">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46ba5f0fbf984535b145a1eb04807f5a_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAxLTYtMS0xLTU5NzQw_f357c3f1-696c-45d0-9942-3e346a4693e2">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd97dd4e710848aa948f66ce61e79d4e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAyLTItMS0xLTU5NzQw_0b2e6c40-c8af-43f9-aa0b-97417157103a">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756b031800b74f1088dc4e2c1b95636e_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAyLTQtMS0xLTU5NzQw_1c7aa7ad-6ef5-4e36-bfca-2e1f7c8ccd49">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibd97dd4e710848aa948f66ce61e79d4e_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAyLTYtMS0xLTU5NzQw_d30a6c80-aec5-413e-8ddb-00503f9c6fe3">8.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002baa7993ed4772b35c50223b4dcc36_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAzLTItMS0xLTU5NzQw_4909ff78-9739-4818-9dcd-d9d6c8a489dd">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38731cd692a4b1c87ff4416775e7a6d_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAzLTQtMS0xLTU5NzQw_2dfaed66-8bfa-452b-af5c-f39c4f6ea540">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i002baa7993ed4772b35c50223b4dcc36_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAzLTYtMS0xLTU5NzQw_eff589d7-ffca-4166-8bc4-8035029d76f5">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7974a50c1c4182af2999542e8fdf1d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA2LTItMS0xLTU5NzQw_e39ddb9a-a04e-4eb9-be85-08bdb148bf7a">1,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e49e3349adb4e589300bc5c59272da4_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA2LTQtMS0xLTU5NzQw_ce3a816b-05e8-486b-958f-e9e13ed5d721">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b7974a50c1c4182af2999542e8fdf1d_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA2LTYtMS0xLTU5NzQw_20139e09-35cc-4366-bff2-f410f9eac5e7">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9457829763fe4b90be78ca6d38abd305_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA3LTItMS0xLTU5NzQw_a5cac74a-cd62-48eb-8898-bf5fe59ef19d">2,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eaa50ccd6ea42d1be79c5484c2037fa_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA3LTQtMS0xLTU5NzQw_99434c46-5922-4475-ad69-59934d7ec592">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9457829763fe4b90be78ca6d38abd305_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA3LTYtMS0xLTU5NzQw_c8be07c1-1707-419b-a67f-dd1197c47e26">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a95b9177eb4a48b5fd6f019f635f7c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA4LTItMS0xLTU5NzQw_8b5ee9df-51d4-4484-8b96-f1e51b2a68d0">3,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9a1c9e24cc4521a4e8fd258ab91323_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA4LTQtMS0xLTU5NzQw_f8ff73f4-5e42-408c-938d-e30552fbd878">3,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4a95b9177eb4a48b5fd6f019f635f7c_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA4LTYtMS0xLTU5NzQw_b9613500-9996-4ec5-8440-6cd30980abe8">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7caf84ee3bdf4518b4c9c4166e4f8887_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEwLTItMS0xLTU5NzQw_a60709bb-751c-4426-900d-d2cc8be4daf8">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49af7ebdc1b4c46b17b462113ef14c1_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEwLTQtMS0xLTU5NzQw_7d693f86-bacb-4909-9d81-ec9d45b0ac89">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7caf84ee3bdf4518b4c9c4166e4f8887_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEwLTYtMS0xLTU5NzQw_b904c77e-afed-48a2-94d9-c37d5ee60525">37.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602a6924da2441d3ab9cf85ee12fbb06_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTExLTItMS0xLTU5NzQw_e3a60734-6d57-4951-bdfc-373fff6afca7">903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc426c53b2a430092d248e6084cd03e_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTExLTQtMS0xLTU5NzQw_c295dd9f-a599-4cbc-83c0-77298c4bf7f8">674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i602a6924da2441d3ab9cf85ee12fbb06_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTExLTYtMS0xLTU5NzQw_370a5221-da5a-49ac-962a-67ac24173734">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf7d6e57e38d42b4b47bd10b91df04e7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEyLTItMS0xLTU5NzQw_354aad3b-1d33-4293-bb62-80f827968967">1,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7798838f313f4f9e83d9c4854b30c499_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEyLTQtMS0xLTU5NzQw_542e4286-5f26-4abc-a5ee-2db6f98c72de">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf7d6e57e38d42b4b47bd10b91df04e7_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEyLTYtMS0xLTU5NzQw_8a6335c0-e6bb-4ed9-b92e-ca9eeea9a1d9">36.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff12de1146540caa7c4f80581344a74_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE0LTItMS0xLTU5NzQw_3d7675c6-af0f-473c-a1e0-13fa1d55151c">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86c98d81e2a4e789e3c6e3880743868_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE0LTQtMS0xLTU5NzQw_5cca7e6c-ff4e-4248-921b-3315107eb783">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idff12de1146540caa7c4f80581344a74_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE0LTYtMS0xLTU5NzQw_c6999825-e401-4d48-963b-7c61d308893d">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1acbda17e2e04d3f9f18cad52f4e5d80_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE1LTItMS0xLTU5NzQw_df87efe0-7fe8-44ad-b3c0-39c7939e9df8">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25efb856b06413aacf054618e7f99bd_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE1LTQtMS0xLTU5NzQw_9c45f23a-6a27-46fe-81b8-3293fbddea26">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5a6d2f7e6f47649ada40e475d62200_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE2LTItMS0xLTU5NzQw_1662748a-5cdd-46e8-827b-08c119245981">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56ec1f9700b4dec9314c88e00ec7a74_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE2LTQtMS0xLTU5NzQw_2a2ba94d-20d7-4c44-8df1-cd8b96fdab75">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b5a6d2f7e6f47649ada40e475d62200_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE2LTYtMS0xLTU5NzQw_d7541497-8f1d-4d07-a881-97d6e67b6d09">53.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03297ccd7c91439abd458f48a7b57605_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE4LTItMS0xLTU5NzQw_7787aa0c-483f-4ed7-9692-3ebbf3f5b158">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e589a7b70e4b8c9ec8c56de960196c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE4LTQtMS0xLTU5NzQw_d8a681fe-098f-4fcf-8a50-2801392fbadc">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i03297ccd7c91439abd458f48a7b57605_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE4LTYtMS0xLTU5NzQw_e1fa2859-13a1-4221-a13f-972769e593fd">16.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92068e5088f447999d216d73ce8cdb46_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE5LTItMS0xLTU5NzQw_92282f23-ef10-4c7f-90de-710607b1bdd2">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9791432463c54215891a18b29d7d056c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE5LTQtMS0xLTU5NzQw_69b6cbcf-b159-4749-bfe9-f3e9b3bb4e6d">680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i92068e5088f447999d216d73ce8cdb46_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE5LTYtMS0xLTU5NzQw_268ba9ad-69e4-43cb-843b-6702119b0335">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1074a5e410494804aa84259fe458782f_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIwLTItMS0xLTU5NzQw_482d431b-220a-4879-bacd-378e94606b30">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fadc8348894481296db094bdc2eda3c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIwLTQtMS0xLTU5NzQw_4e500311-eff4-46bb-93ba-f05e358ad063">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1074a5e410494804aa84259fe458782f_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIwLTYtMS0xLTU5NzQw_226a8673-764e-4b05-a558-7c30d9820034">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d635d3f096e49c9b21f9616e12851e5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIyLTItMS0xLTU5NzQw_f6d8d068-3ee8-4530-9cab-740e365d478b">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28be830ce4b48dcb3d8a7b426fae4d6_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIyLTQtMS0xLTU5NzQw_0869f643-6009-454e-9ef3-a09bb5861e75">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8d635d3f096e49c9b21f9616e12851e5_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIyLTYtMS0xLTU5NzQw_0f38c4fe-7bdd-4dd0-be6a-50f8ad6436fe">62.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379186cc31f04dbb9749d2943a0e1ed9_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIzLTItMS0xLTU5NzQw_8f03f357-d3dd-45aa-b646-c9c0af74af5d">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida711057f67c47f1b72ad683127c4a91_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIzLTQtMS0xLTU5NzQw_b473be17-4294-4622-85cf-6142db987853">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i379186cc31f04dbb9749d2943a0e1ed9_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIzLTYtMS0xLTU5NzQw_8d042f6f-d4ba-4061-943a-f3c422e77bd8">11.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5cb6c1da36a4a4d8766dfa0e1727ff5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI0LTItMS0xLTU5NzQw_55955f7f-ecdc-45d3-a85f-56ce0d913c6e">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c47976576a747deb5a1820cec87eb07_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI0LTQtMS0xLTU5NzQw_4e838905-a10a-413b-bf40-368d3d3a3bd2">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if5cb6c1da36a4a4d8766dfa0e1727ff5_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI0LTYtMS0xLTU5NzQw_4859eeea-8d2c-4280-943c-3e574bd8108d">15.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i219e0fd42833446ab0fbdea7207ae068" continuedAt="i96c4e5cd11424d0b826c5eb745620d49"><ix:continuation id="if84928d57a8f4b53a954a0e534c48346" continuedAt="i757bccc77fdf4347ac659bf24a6e568d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i802b2a8cc9be4de697db22398b60df0e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI3LTItMS0xLTU5NzQw_f44b5c75-1854-49fb-aa37-ba73fd56ae44">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5df3d2e7456f46cd95f6b08a1c33601d_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI3LTQtMS0xLTU5NzQw_749a8cac-a85a-4cae-90e6-cf5833077b5d">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i802b2a8cc9be4de697db22398b60df0e_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI3LTYtMS0xLTU5NzQw_a6a23461-aef1-41b0-83b4-c2fe86e10886">63.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc87f78159374d8bbc9c762e4102e794_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI4LTItMS0xLTU5NzQw_7431998a-628c-444d-b0c3-5ebf209b8566">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if926194c123b420385c4516a85ca9777_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI4LTQtMS0xLTU5NzQw_c8cd8d72-5cc9-4a66-85d9-e35dbb469347">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibc87f78159374d8bbc9c762e4102e794_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI4LTYtMS0xLTU5NzQw_fa9ee8e1-efbb-4c91-8e4f-ecf4c78ad577">47.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d59f0918fbc414a8a87e6ccf2473d9b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI5LTItMS0xLTU5NzQw_b4b37090-0032-4969-8c3c-fccb674b8995">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id48f03c674f5473cb05d01f5147b5df3_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI5LTQtMS0xLTU5NzQw_0e83fac2-4cfc-4075-a999-125be9dd7f53">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7d59f0918fbc414a8a87e6ccf2473d9b_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI5LTYtMS0xLTU5NzQw_941b9399-29ff-435f-9de0-3bfd7284f45d">35.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb5e19b994341e19c1180af2eb7b115_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMyLTItMS0xLTU5NzQw_264719a4-2b29-4d3c-a913-20b827891087">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bea0dc705a44771a477c405cdd10da9_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMyLTQtMS0xLTU5NzQw_d622f849-aa4c-4229-a643-be20b09b20a6">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3fb5e19b994341e19c1180af2eb7b115_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMyLTYtMS0xLTU5NzQw_3668bc2b-9ac3-4798-935e-58e496d9b7f9">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadbad500e92547ec9a836181ccd9e6c3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMzLTItMS0xLTU5NzQw_81c75a31-e82f-49d9-8d53-f6fc27a70be9">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6d7f1b310549b0a446ef5d8d0aaea2_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMzLTQtMS0xLTU5NzQw_2149c384-9341-4491-ad5e-146a820ff383">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iadbad500e92547ec9a836181ccd9e6c3_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMzLTYtMS0xLTU5NzQw_abc16b66-26d1-4eb3-a4fc-77d78f4b54ce">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6498d554bec346f290453c23da02bd60_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM0LTItMS0xLTU5NzQw_becf258a-bb6b-43a3-9223-a4397b430e04">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb99ff4ae20743c7b4a1bc974a427a75_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM0LTQtMS0xLTU5NzQw_d2c1328c-9621-4c06-9103-63df93687eed">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6498d554bec346f290453c23da02bd60_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM0LTYtMS0xLTU5NzQw_af66a973-d0f2-4fed-9fa0-a8cfa94a159f">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79b08d56cce40828e2c38bf848ff8fd_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM2LTItMS0xLTU5NzQw_fb857140-162f-46e1-ba81-e085324ad962">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52cdeb0271e2486999508f7150d31fe2_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM2LTQtMS0xLTU5NzQw_0faabfef-8468-4d28-9c55-b47cabdabdca">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie79b08d56cce40828e2c38bf848ff8fd_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM2LTYtMS0xLTU5NzQw_de230850-fa72-4825-80a4-ea23669fcb08">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7068d970c8e44a1ab1a0f2f2c4db613_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM3LTItMS0xLTU5NzQw_bd936952-9510-4d2a-95fc-223bfbed544d">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5887b0c29a144ebaa712e90100c41c32_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM3LTQtMS0xLTU5NzQw_fd2a30d2-eaa4-4eff-ae08-37a78f307e21">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if7068d970c8e44a1ab1a0f2f2c4db613_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM3LTYtMS0xLTU5NzQw_75208c52-005e-40a3-87e3-08ea03a0fa72">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08831d99e88b4248b1d03a755ae3c76b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM4LTItMS0xLTU5NzQw_ff24a7b9-7936-4c50-a321-a1af05e3b978">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b566c9ea6ee4374bb5e2d126e55db93_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM4LTQtMS0xLTU5NzQw_483c3a3f-fe86-4fa3-842d-90d4b1a1924e">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i08831d99e88b4248b1d03a755ae3c76b_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM4LTYtMS0xLTU5NzQw_baad295c-3165-4f8c-bc5e-e157fcd7ca3e">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd11d66bb94525afadc67611182a00_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQwLTItMS0xLTU5NzQw_e34330e4-1ba6-4636-9ec5-3510634c3f57">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62a96b70190a426784c40cbc850a392d_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQwLTQtMS0xLTU5NzQw_767160de-4509-4b60-b805-2eb29274a725">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55dd11d66bb94525afadc67611182a00_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQwLTYtMS0xLTU5NzQw_d3861ed3-8d5c-4ac4-a8f5-2acf6f1a3133">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26fe8d48a8184400b9c1e5dce618bf41_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQxLTItMS0xLTU5NzQw_a06c2d66-4358-411e-8eee-6e3e771bd37e">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ca7c88cc02d4eaf88560c8548ee94ef_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQxLTQtMS0xLTU5NzQw_cf1a510c-221d-4af4-bb44-22af21bcdcd8">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26fe8d48a8184400b9c1e5dce618bf41_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQxLTYtMS0xLTU5NzQw_19c60adb-e9c1-415c-ac72-19643ea2a0b3">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0812afd8e2b348de81fda97685ddef59_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQyLTItMS0xLTU5NzQw_05614449-3c81-488f-8601-b7c77c726dfd">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf731f09e014c3d94757d58a2be8657_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQyLTQtMS0xLTU5NzQw_da25d7a5-0a43-4461-86d9-81afc9b18b87">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0812afd8e2b348de81fda97685ddef59_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQyLTYtMS0xLTU5NzQw_0b5aecbf-3a42-4015-8e26-ca3177a0ca50">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c940a55fb57493188d86966342836e0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ0LTItMS0xLTU5NzQw_22dfb9da-db07-46eb-baff-de37ecaf702c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b96b154e0074943b4b122886b03054d_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ0LTQtMS0xLTU5NzQw_e1c4411b-051b-4c9e-83b7-e116fd155250">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6c940a55fb57493188d86966342836e0_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ0LTYtMS0xLTU5NzQw_306566dc-607d-4e9d-a2dd-2fb6b3b5c3a4">29.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787149c50a1840428285fe2906bb98f1_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ1LTItMS0xLTU5NzQw_2e595ca7-5bcc-44c2-a71a-20befa4ef549">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a0ca8ea65246758d0aea04a19962b9_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ1LTQtMS0xLTU5NzQw_518a6d73-e239-4e7a-aca3-79576034ad81">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i787149c50a1840428285fe2906bb98f1_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ1LTYtMS0xLTU5NzQw_cc28b1d9-8a8f-413e-b3e2-487cbfba2358">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5cdc6b13e543ce8b0e1c2f9ffa25d3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ2LTItMS0xLTU5NzQw_afa9f392-1ae3-41bf-83bd-894d366a2733">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5a3f74e1d54099823fc731564879ce_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ2LTQtMS0xLTU5NzQw_b64c1c15-cba7-485f-8418-9dda723ca3bc">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ife5cdc6b13e543ce8b0e1c2f9ffa25d3_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ2LTYtMS0xLTU5NzQw_e42da077-1196-43d3-868d-471ef0ac299b">20.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c342b6c1941447a8365ead0b83ea272_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ5LTItMS0xLTU5NzQw_7a9880df-7f7f-43a3-a868-04817e76eb1e">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc76581373f04f5aa51d38fcdda40da3_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ5LTQtMS0xLTU5NzQw_db1f1cfb-1bfe-490c-a3eb-8a0e48b95b4e">799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5c342b6c1941447a8365ead0b83ea272_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ5LTYtMS0xLTU5NzQw_72926043-529f-416e-9815-7fde80bdabcd">15.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie045af3f8e52486eb07c7ba39e98e056_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUwLTItMS0xLTU5NzQw_d17b20b2-e6a9-4492-b59f-a31efcdd615d">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8eea6eeee44e8a8748c5f8411ca6a8_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUwLTQtMS0xLTU5NzQw_53e00622-04d0-4dc8-984d-79a643c90e4a">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie045af3f8e52486eb07c7ba39e98e056_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUwLTYtMS0xLTU5NzQw_2ab0d097-ee67-40c9-a1f7-7f99b7dc7b85">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658cc2fee1f04efda949f70dfc908648_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUxLTItMS0xLTU5NzQw_0e03551a-4d6c-4d8e-a740-04c479204511">910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1105c10c9a2445a198e98e2af0ac9d83_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUxLTQtMS0xLTU5NzQw_8dafb3c4-442b-4269-bc58-f11bac5fe6f1">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i658cc2fee1f04efda949f70dfc908648_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUxLTYtMS0xLTU5NzQw_fba0e8c4-46c3-474d-8fcd-cad91d1ada26">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dadb8ca74864bdda389d9aa76f05723_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUzLTItMS0xLTU5NzQw_10368b89-03d6-4300-9905-427cc7965ad7">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d7e2f6cd3d9401f9fda49c75afe417f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUzLTQtMS0xLTU5NzQw_225814f8-ec6e-4853-ab14-a122a4492a56">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3dadb8ca74864bdda389d9aa76f05723_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUzLTYtMS0xLTU5NzQw_e3c5ee9c-2595-45a8-a312-539271d97c9c">13.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f9118b127a41df8281a7b4b70328ed_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU0LTItMS0xLTU5NzQw_02e6e3b2-99b4-4b57-adc2-28eb9a437e1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b44f394b70346ee9c246aae215158bd_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU0LTQtMS0xLTU5NzQw_25835392-2196-4f08-836c-66580ab1c1c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21f9118b127a41df8281a7b4b70328ed_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU0LTYtMS0xLTU5NzQw_8f070058-4727-4eca-926d-d5ad6a4bdee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62dc76763e348cbba7e08433976fac4_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU1LTItMS0xLTU5NzQw_8e8d89f1-48bd-4b36-b1df-e120e0d246b2">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c091791d85f44618179b9d279f48c9f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU1LTQtMS0xLTU5NzQw_fdfca982-5843-4a0a-812f-a3263fac771d">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic62dc76763e348cbba7e08433976fac4_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU1LTYtMS0xLTU5NzQw_88dc6c72-34f7-44b4-9497-12eb847b9f6f">13.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA / INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9e9d0ec3a546c8a723d87323ac7ab7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU3LTItMS0xLTU5NzQw_9688b24b-70d6-46ce-bcdc-f044573bb653">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a1e608de7843568d26a9b8fe5ffb43_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU3LTQtMS0xLTU5NzQw_6cd959fd-a17a-4d46-9121-d5c1049974b2">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibd9e9d0ec3a546c8a723d87323ac7ab7_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU3LTYtMS0xLTU5NzQw_741f632c-f154-46f9-b3ff-454adcb27982">30.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3fe1671e59d4c6a8a3250a87dd2e2cb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU4LTItMS0xLTU5NzQw_162cd91c-411e-4931-a132-40b03304cf69">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f402cf66c9c43bf9d8b0155d69da95c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU4LTQtMS0xLTU5NzQw_3db2f7a7-7ccd-48b6-a78d-e21f35672891">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3fe1671e59d4c6a8a3250a87dd2e2cb_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU4LTYtMS0xLTU5NzQw_c96f8384-bda9-4729-8ada-7d26ea6d1640">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29def461faf7492f917e166e064b38d4_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU5LTItMS0xLTU5NzQw_ea669faf-7a01-4da4-95f0-6ebd6192c2c6">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0686bf4a5394db3864d38ab25d077e9_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU5LTQtMS0xLTU5NzQw_9ff10e2e-9fb2-4146-83e7-1cc4ef15b091">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29def461faf7492f917e166e064b38d4_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU5LTYtMS0xLTU5NzQw_26edd692-3e69-4d5a-ba2a-7e6d5dcb63f1">14.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1,2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a273ca54c4800aa20e3895cc837ed_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY1LTItMS0xLTU5NzQw_4daa4d0f-f831-4794-aa63-45befcbfd9d0">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1154bb4afd9247c784b55466aae7d770_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY1LTQtMS0xLTU5NzQw_a46418ca-88cc-49bf-b570-69820ea167d9">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i153a273ca54c4800aa20e3895cc837ed_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY1LTYtMS0xLTU5NzQw_d1a05f5b-4424-45ab-b3aa-1e1fd220c369">14.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0009ecb1334c43a265b7735989172d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY2LTItMS0xLTU5NzQw_0e15e964-3ff4-4fe0-8ec3-9ff546b6fb97">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857d98c87ac0445e9582504c037c4449_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY2LTQtMS0xLTU5NzQw_2cdc09f0-5b6b-4bcd-967a-925b3c4e159b">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icf0009ecb1334c43a265b7735989172d_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY2LTYtMS0xLTU5NzQw_4e482576-dbe3-40c9-8ee9-9572d22b3a05">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de874f946f841458bbfbdc60ac530c4_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY3LTItMS0xLTU5NzQw_e7292310-68ab-4f21-bcaf-a1a44b4f9e04">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ddb318fec741089c74f936f4d258c0_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY3LTQtMS0xLTU5NzQw_b990cf9e-9a16-48da-b68f-a7c677309eb3">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8de874f946f841458bbfbdc60ac530c4_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY3LTYtMS0xLTU5NzQw_4d7cc9ab-ccf7-4536-8321-22cf32429d0c">10.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74673f6468f34983ba990177525051f9_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcwLTItMS0xLTU5NzQw_5b45b610-a76f-4311-9f0c-b1b03068c591">6,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f7260c372bc4cd69cc06c643d11c56c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcwLTQtMS0xLTU5NzQw_36cb527a-fe75-4032-b9e3-d38f318a0089">6,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74673f6468f34983ba990177525051f9_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcwLTYtMS0xLTU5NzQw_45b91839-cca5-457e-96bc-d52f3dd45427">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea854374a484fe38540c4f8a7470fe9_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcxLTItMS0xLTU5NzQw_1e12746e-d944-48ce-b861-d60ffa718fdf">6,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ebe25dea81647f0a7c2f6f7eaaa9f12_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcxLTQtMS0xLTU5NzQw_78d9cd39-41da-41f1-b5ca-0934084bfa04">5,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ea854374a484fe38540c4f8a7470fe9_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcxLTYtMS0xLTU5NzQw_750a7430-c7d3-43db-bb52-294d039041a4">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcyLTItMS0xLTU5NzQw_cb9bb189-8bf6-475b-abce-0df96aea996a">12,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f54f96121d4454b850945a4950be020_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcyLTQtMS0xLTU5NzQw_ce9a31f3-2bd5-4485-a77b-3eca0c24fd3e">12,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcyLTYtMS0xLTU5NzQw_c71d7598-4efc-497c-b4b1-3359757450a9">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i96c4e5cd11424d0b826c5eb745620d49" continuedAt="i0c10a1de220c42e492ed1809bd816b14"><ix:continuation id="i757bccc77fdf4347ac659bf24a6e568d" continuedAt="ic85ad0df8f2b4b7a98ce8f745cb97e61"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd9e58933a04c87b85bedb0a3a11e3a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgzLTItMS0xLTU5NzQw_1781a1e0-3813-4d37-bd53-c4a7704ea2c8">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5388243b1444a0197156f13c035f594_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgzLTQtMS0xLTU5NzQw_dea11967-cdc3-4b81-ab1f-aaec9ec421ac">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1dd9e58933a04c87b85bedb0a3a11e3a_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgzLTYtMS0xLTU5NzQw_0d368194-be07-4442-9684-bc7900610c1d">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf14c9d52f00401b9b7af8c1eaaf40a2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg0LTItMS0xLTU5NzQw_e4f9035b-1ca6-44e0-b550-7689d84254a8">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2555b2153a3248ee8fd4e5f32f461af3_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg0LTQtMS0xLTU5NzQw_f6dc1df9-4365-4248-92fe-bb3a9d84db3f">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf14c9d52f00401b9b7af8c1eaaf40a2_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg0LTYtMS0xLTU5NzQw_00f420c2-2fde-4a69-8dd5-9b050f6d41e8">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5167453e1314559964afd83c4a97121_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg1LTItMS0xLTU5NzQw_93e079b8-ffbd-43a0-8b77-7cbe35b2d0b6">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94504e48d701461ab9ef57de03631801_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg1LTQtMS0xLTU5NzQw_4e9c4476-7093-4a5e-adb0-c05ab967aee6">949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5167453e1314559964afd83c4a97121_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg1LTYtMS0xLTU5NzQw_d9ba0058-2a78-4757-b8bc-b5269524d71e">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9d91209813438cb5425bacbb2957d7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg3LTItMS0xLTU5NzQw_2d063a4e-f098-4f9d-a735-d38f7ff9e402">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49cc1963139e40a48ba54590e9d558c2_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg3LTQtMS0xLTU5NzQw_718b4a72-a965-4ec9-9d7c-8e1ef6e18845">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd9d91209813438cb5425bacbb2957d7_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg3LTYtMS0xLTU5NzQw_c5a3ba14-feb3-4519-b85e-7c41cb8f877f">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37a5f0e1b4645c18d5404587f248c4e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg4LTItMS0xLTU5NzQw_d0a02cb1-004e-42c4-8806-1a1987cdd047">899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71825d51651b4f4c94dc7432c265826b_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg4LTQtMS0xLTU5NzQw_636e9ce1-c50f-40c8-a0f3-24fee948c690">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic37a5f0e1b4645c18d5404587f248c4e_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg4LTYtMS0xLTU5NzQw_d6aead4f-eb59-44d6-af47-867750782ee9">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c03d0211654555ae2faaa6bfbef7f0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg5LTItMS0xLTU5NzQw_81bdae81-e365-4ba2-bcc4-9fd9b26d6eca">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b09f0f2d404dcb90ab77349fb4e6d6_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg5LTQtMS0xLTU5NzQw_aa5835ab-1016-435e-a8d3-13201e9194e8">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26c03d0211654555ae2faaa6bfbef7f0_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg5LTYtMS0xLTU5NzQw_aec46fde-506d-4940-9323-c57d4b6da09f">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c393b101be4a43a6732a4be31c57aa_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkxLTItMS0xLTU5NzQw_d21770ed-c2a5-4c5d-adac-8088eabe4a3d">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cc552be0964064ae3332e0d4c7ef8d_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkxLTQtMS0xLTU5NzQw_4950d14d-27f0-41c7-80d2-b140e227a476">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94c393b101be4a43a6732a4be31c57aa_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkxLTYtMS0xLTU5NzQw_7913733e-5456-4c4d-ae18-8c96fa080010">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4de0d5ad9f549948fe05ce4c2e25b4a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkyLTItMS0xLTU5NzQw_be4ea8ee-4630-4df9-9a2e-ee8494d15928">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83221080ad384b21800f5cd10f1c9fbc_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkyLTQtMS0xLTU5NzQw_f03a2562-5c45-4d73-bcb9-293dc21ec8a7">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4de0d5ad9f549948fe05ce4c2e25b4a_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkyLTYtMS0xLTU5NzQw_58f9bb9f-e809-4ba5-ba2d-bcd37e5a3583">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9d112bcae04f66b84e47128a5cc21f_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkzLTItMS0xLTU5NzQw_e7d9ae56-1c2a-4b24-9d96-c43db807ce45">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f9480fa6a64211bbaffb8bf7069aa5_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkzLTQtMS0xLTU5NzQw_3f13ef6b-9c16-423b-b7c3-547faa5f55b4">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a9d112bcae04f66b84e47128a5cc21f_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkzLTYtMS0xLTU5NzQw_d30ef2e7-3050-4c04-a2b1-f88285d27f1f">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ec92e1bd5064846ace07af1534211f5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk1LTItMS0xLTU5NzQw_8c97dd38-ba89-469b-b378-74b70bb50525">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i761be9058b0d43bf94db251536405133_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk1LTQtMS0xLTU5NzQw_336e0cab-4933-46a6-a018-a18f754e3170">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ec92e1bd5064846ace07af1534211f5_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk1LTYtMS0xLTU5NzQw_3249e294-ce78-4d4f-ad8c-b9395b8bf8ed">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eddee4e37b042bc9c060f40341f10dd_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk2LTItMS0xLTU5NzQw_16158d14-ca29-4fc4-b90a-74dd4ade272f">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd8fd20f19644798d62ca131883fb7b_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk2LTQtMS0xLTU5NzQw_99313beb-bd99-4961-bb8b-6428326b09d3">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6eddee4e37b042bc9c060f40341f10dd_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk2LTYtMS0xLTU5NzQw_f78396c2-b1fa-4810-a987-d170bb0a7f99">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b87a33ea414436bb9dad4941879ae83_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk3LTItMS0xLTU5NzQw_1e168f6b-391f-4383-bb0a-0fd14e0ca784">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bb59b5b9cf4f78a4e291ae63400ced_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk3LTQtMS0xLTU5NzQw_5e51d7e8-925d-41a6-8468-8351c57259da">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b87a33ea414436bb9dad4941879ae83_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk3LTYtMS0xLTU5NzQw_78f767de-5ce3-4054-9592-73b36e96420a">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd947e6c419b48a4bda0b804eeafe4d6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk5LTItMS0xLTU5NzQw_a2c5db66-df87-4fa5-82bc-d0403fced614">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd983febe9574fdfabf56cea42386e21_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk5LTQtMS0xLTU5NzQw_901dd0ea-25b1-4111-86af-bd40dfa57776">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd947e6c419b48a4bda0b804eeafe4d6_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk5LTYtMS0xLTU5NzQw_0b060326-bff5-47f7-8386-2c93ea295fc7">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8fed7991104862922245840fbbb6d8_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAwLTItMS0xLTU5NzQw_ec622ed3-4cf1-468b-8b5b-84c93900edb8">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa59186f7b14958a9b1c02f519eb369_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAwLTQtMS0xLTU5NzQw_9a11876a-8da1-47b4-8876-86302543394e">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifc8fed7991104862922245840fbbb6d8_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAwLTYtMS0xLTU5NzQw_47631d65-5474-4d61-95a5-6c605fd620e8">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4bf77c080c34fcb8c7da93917014ef3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAxLTItMS0xLTU5NzQw_9d5b762e-fa97-4630-9447-727afd4d9b28">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86e1d075b324aada06b3181f83ab15c_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAxLTQtMS0xLTU5NzQw_a82c37e4-f83c-4b44-aef6-275f68daff87">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4bf77c080c34fcb8c7da93917014ef3_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAxLTYtMS0xLTU5NzQw_4b8a023a-4522-4bfa-99b5-49b71ba45943">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i372a0801e4354df09390de4a1bc1fe8a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAzLTItMS0xLTU5NzQw_65260991-2798-4e16-955d-1f77bdca2130">387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4bbabb621c4b65a1340f25f3b79d25_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAzLTQtMS0xLTU5NzQw_fd74883a-da91-4df9-901d-09078d179328">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i372a0801e4354df09390de4a1bc1fe8a_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAzLTYtMS0xLTU5NzQw_61e6a15f-e9f5-41be-bb4b-1fd0febefc55">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505f40abf9134ef195fcf3699c50574e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA0LTItMS0xLTU5NzQw_cdd0cafd-f9f2-4118-90ba-5c9eeb67edc3">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e6f27a9bec4c019c8c57696e6bf1e8_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA0LTQtMS0xLTU5NzQw_9474cb0d-ff7c-4f9b-a0b1-788dc2ac1cbc">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i505f40abf9134ef195fcf3699c50574e_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA0LTYtMS0xLTU5NzQw_6dd09916-7585-47e8-a281-1701c482b837">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa62410b761147768b8c6e1d72541097_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA1LTItMS0xLTU5NzQw_d3ee3048-9521-4594-8096-5b33b5a5bfc2">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8060def9fa5447d9f08d7bf2126beb6_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA1LTQtMS0xLTU5NzQw_675903e1-fdc2-4160-bb1f-dba4929f8873">707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa62410b761147768b8c6e1d72541097_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA1LTYtMS0xLTU5NzQw_2e2c3a80-f18c-492a-8331-8f364fa763ba">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9dff4050ad4ec1ad3383f53e178b09_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA3LTItMS0xLTU5NzQw_4caa354f-7d5b-4cd7-9bc2-b589c4a164ea">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402913e98e314dc99d1428cd761b3db0_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA3LTQtMS0xLTU5NzQw_219b14e0-b50c-4fd5-af09-e2d52d74134b">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b9dff4050ad4ec1ad3383f53e178b09_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA3LTYtMS0xLTU5NzQw_ac846b26-6c18-41b3-963b-f72a848d3f1a">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2bfa4745e2435c84b3ff4622725d92_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA4LTItMS0xLTU5NzQw_a8c9a125-0910-4078-8035-80664734e5c0">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34166c04357b40ca861f436c846dbdc3_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA4LTQtMS0xLTU5NzQw_a25ac796-8c7d-49b4-b58c-c3451cdec2af">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd2bfa4745e2435c84b3ff4622725d92_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA4LTYtMS0xLTU5NzQw_9f48f88f-01e3-480b-ab69-87c9fb527c7a">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib41d736c9cbf4af88635765f2162af86_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA5LTItMS0xLTU5NzQw_dbe17c42-829c-4906-b140-5de0612899a4">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1e5574642c4970ac6c5731d2f54fcb_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA5LTQtMS0xLTU5NzQw_d18f863f-c562-40ad-b5d3-cb5d6f77231b">2,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib41d736c9cbf4af88635765f2162af86_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA5LTYtMS0xLTU5NzQw_836d7bc7-606c-440b-b959-d21070b1ab46">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736971e06954421791a102526ef927cc_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjExLTItMS0xLTU5NzQw_f11c87d4-a81d-4994-af6c-cdfcae18d76b">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462f6596d7e54be4b09bd4bcb7c18bad_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjExLTQtMS0xLTU5NzQw_19efb3fc-407f-4412-8a1d-2396c8952c39">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i736971e06954421791a102526ef927cc_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjExLTYtMS0xLTU5NzQw_5eabec7a-8b81-4aac-b8fb-8373d6c3b1b9">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73eef6d7fd9b4dd2b5426cfa7104e199_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEyLTItMS0xLTU5NzQw_3812bdc3-d429-4140-94c8-1b571d3183f2">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865bbce87767495d83951aa8eb044329_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEyLTQtMS0xLTU5NzQw_4f8e691f-e193-493a-b4f8-7d38452d63d8">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i73eef6d7fd9b4dd2b5426cfa7104e199_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEyLTYtMS0xLTU5NzQw_53d7c92b-0041-4db5-82fa-3682c77c5f4d">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ef4bc104ab4018b38aa4cdf80cf5a7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEzLTItMS0xLTU5NzQw_c1189b1e-3d35-4188-907f-8117a08a001a">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479f5df29cba41dd8ba610461abe4e2e_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEzLTQtMS0xLTU5NzQw_4a0b2809-af9a-4b2f-b5fd-b43c4feaecfd">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9ef4bc104ab4018b38aa4cdf80cf5a7_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEzLTYtMS0xLTU5NzQw_364c2af6-72b6-47d1-8e20-49caabf37713">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5794644b54414f8eaa877a9f828a6f9c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE1LTItMS0xLTU5NzQw_2292f232-b8c3-4c23-b0fc-e5b640c186b1">504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24a4d5dee1ac4cf28da4e534b4453f02_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE1LTQtMS0xLTU5NzQw_00ece192-d182-4743-acd9-cce3129c2928">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5794644b54414f8eaa877a9f828a6f9c_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE1LTYtMS0xLTU5NzQw_bcc3acac-f128-4e22-8931-992138dcda64">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3342c6f86e341f5ab416482e21b984c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE2LTItMS0xLTU5NzQw_fdaf9085-13ed-444d-bf9c-e66320067b39">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4b1e669d8404534b72479a0f4e7a968_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE2LTQtMS0xLTU5NzQw_5e275c2e-77a8-4bf0-875e-ef22ee2b6f01">761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3342c6f86e341f5ab416482e21b984c_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE2LTYtMS0xLTU5NzQw_d842f715-b47a-46ab-82d7-22c8072e1f70">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b56dc097e104e6a9d6bf065e10288ee_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE3LTItMS0xLTU5NzQw_6f655861-c2bc-4f32-87b5-e120b0945254">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb28ec2e8cc243329eac4eaf64db5f0f_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE3LTQtMS0xLTU5NzQw_1803cc2f-d4d0-43ac-9a0c-f439159f0b0a">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b56dc097e104e6a9d6bf065e10288ee_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE3LTYtMS0xLTU5NzQw_1e28d9e5-d636-4d6a-a76b-a8daa8eb2ce2">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5082af2c38dc4e9b94951ce99a46799d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE5LTItMS0xLTU5NzQw_726d422d-0b0d-443f-8f40-126dbdf81b96">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d44704539114f25b07e12eb55564a99_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE5LTQtMS0xLTU5NzQw_a545e1b4-a2b7-4e6a-8dfd-1dfdf3765e0b">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5082af2c38dc4e9b94951ce99a46799d_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE5LTYtMS0xLTU5NzQw_ea007548-815c-4c91-b15c-e09457c44c7a">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f23f5841b48406ab8cda610d6c44c21_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIwLTItMS0xLTU5NzQw_113b467c-6c7e-472f-9818-0e8b79520feb">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if956dbb8930a4658bd499404ec02618a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIwLTQtMS0xLTU5NzQw_8d307620-55ea-46f4-be95-442f35ce4b70">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f23f5841b48406ab8cda610d6c44c21_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIwLTYtMS0xLTU5NzQw_21e01cb6-606b-461d-a878-252f01fe9ad6">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a91d5d2384349c3b9f8ba37ce939f63_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIxLTItMS0xLTU5NzQw_5580d04d-7600-466d-b161-fb7ed191a6fe">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i976cfa9383c14f68936e4add9e92c113_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIxLTQtMS0xLTU5NzQw_4740f963-8634-4757-b91e-55694d1c9907">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a91d5d2384349c3b9f8ba37ce939f63_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIxLTYtMS0xLTU5NzQw_265a1b06-440a-44d1-9332-066867c55b51">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d224b06bb144ad871048ad6fc1df0b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIzLTItMS0xLTU5NzQw_d30c0efe-5eae-4252-ac9b-23bdaa723738">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7a59ebb6304063a306b51e19b294ca_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIzLTQtMS0xLTU5NzQw_fc8cd768-2666-4247-9fd5-5baeb10c8a2f">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45d224b06bb144ad871048ad6fc1df0b_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIzLTYtMS0xLTU5NzQw_123f8e65-6fbb-4c69-b44c-7c2dbeeed820">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b42f4cd0274c2cadf3f13f4563f625_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI0LTItMS0xLTU5NzQw_08e66514-07cd-4046-b49d-d8e7239c7fee">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281dec684941496ba9be125acb8ea3a6_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI0LTQtMS0xLTU5NzQw_aa1762ea-720e-411a-8b76-e9b7faf04048">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0b42f4cd0274c2cadf3f13f4563f625_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI0LTYtMS0xLTU5NzQw_eccea045-9526-48e2-91fb-9131870dfbf4">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9207f2f3c7994a8a8ecfaf008603423f_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI1LTItMS0xLTU5NzQw_c5c65d80-0bf5-41c3-a796-c3c10970e945">910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bcbf2c88c141309a3b412412019b86_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI1LTQtMS0xLTU5NzQw_107d0c0b-e2a8-4393-a092-15d3f06f1432">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9207f2f3c7994a8a8ecfaf008603423f_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI1LTYtMS0xLTU5NzQw_fd070124-44cb-44c5-a11e-35619c7e7899">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i0c10a1de220c42e492ed1809bd816b14" continuedAt="i7d18fabb2c96483c88af4a480a79c7d0"><ix:continuation id="ic85ad0df8f2b4b7a98ce8f745cb97e61"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf66e290093647d2ac7eef16e4827efc_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI4LTItMS0xLTU5NzQw_6fc9b39e-f443-43f8-b1da-f8cc1b83eb3b">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8cbe17fae384b13888b74cd6b1ec015_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI4LTQtMS0xLTU5NzQw_46b01893-6f0c-41f0-a984-34cb6cb6c24f">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf66e290093647d2ac7eef16e4827efc_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI4LTYtMS0xLTU5NzQw_959fab59-42ec-4a10-a151-389614c9ba77">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769786328e84403f83835f16dd6077be_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI5LTItMS0xLTU5NzQw_5813f506-37d5-4e3b-87ad-2c843ba645a3">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied814a23dede4859b4dd10f99d05cfb6_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI5LTQtMS0xLTU5NzQw_877dc40f-8fb2-46fb-adef-f54c1f1938a5">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i769786328e84403f83835f16dd6077be_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI5LTYtMS0xLTU5NzQw_02c31548-86a9-4f38-9993-0e21a326149a">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8addd19a2534d7298a26e3173b6a863_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMwLTItMS0xLTU5NzQw_e0648171-16d3-4933-8c52-0cf5639692d3">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e78ffd9d9242b9b0cd697326116473_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMwLTQtMS0xLTU5NzQw_010c51dc-a8f2-47a1-b63b-0a0fefb7359d">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8addd19a2534d7298a26e3173b6a863_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMwLTYtMS0xLTU5NzQw_60664fbd-5508-44c7-9b5d-b48d97c59cbb">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d97d2295755409ca589230c611d4a1c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMzLTItMS0xLTU5NzQw_f31eac28-b928-4dba-b716-3b4f9ea9f5a1">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19f1a5dbe744c66ae815743a7372c8b_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMzLTQtMS0xLTU5NzQw_2b610965-fc76-42df-8735-48b4a577e31b">3,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d97d2295755409ca589230c611d4a1c_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMzLTYtMS0xLTU5NzQw_4d50ce3e-f57c-41b6-962d-c76af6a8c573">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic394e1061f43492797075bd9f149992c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM0LTItMS0xLTU5NzQw_e1ffee1a-906d-49c7-bff2-275017aeee38">3,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf6412609614f56bce482cc6a3e294a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM0LTQtMS0xLTU5NzQw_bf236c13-b3a6-41f7-8690-a67d0d6caef8">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic394e1061f43492797075bd9f149992c_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM0LTYtMS0xLTU5NzQw_857b6ba8-ec42-45cc-a082-0e869d79ba54">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM1LTItMS0xLTU5NzQw_16894f52-cebc-4b56-8240-13011aabb76c">6,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307797df24904531853ec0fc2169f7e0_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM1LTQtMS0xLTU5NzQw_0b595376-6bdc-481c-a46a-c6b6867d26e1">6,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM1LTYtMS0xLTU5NzQw_b791742c-27d0-43dc-a280-146d676fd2c1">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM4LTItMS0xLTU5NzQw_16a73af4-57c1-4675-93f2-8b5326b07a74">11,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045574b786544774882db0b6a4f87c00_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM4LTQtMS0xLTU5NzQw_f371b304-7a22-4d2c-9657-91bafe2e8b48">11,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM4LTYtMS0xLTU5NzQw_b431352b-8b30-4473-a8e9-972f0d75faf5">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd0ee7f3ac94e1093e3d7ad447b4526_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM5LTItMS0xLTU5NzQw_143a7330-14e8-4941-8ab7-7648f892d94c">12,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie83976fce48a46b3b8d46aa9df8aa8b1_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM5LTQtMS0xLTU5NzQw_3a9cdfd1-50c8-4e0b-81c8-013204aea1cb">11,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd0ee7f3ac94e1093e3d7ad447b4526_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM5LTYtMS0xLTU5NzQw_9be4e34a-7778-44ff-aa08-4adc52535bb5">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjQwLTItMS0xLTU5NzQw_4699138b-1ff4-424e-8d16-e00f44f79764">23,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjQwLTQtMS0xLTU5NzQw_0579bbad-dca5-46cc-8033-068fdbc46658">22,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjQwLTYtMS0xLTU5NzQw_1d968fb0-d0f2-41c9-bbca-b331e1e9b27b">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In the fiscal first quarter of 2021, approximately $<ix:nonFraction unitRef="usd" contextRef="i53a2d3e56a004f59a45bdb87953ecc0a_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMjc0ODc3OTA4MDI0OQ_0e24f868-ec32-4767-bd28-5bd355622abc">0.1</ix:nonFraction>&#160;billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Previously referred to as Medical Devices</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzczMQ_8eb97d55-a432-4a55-b1b0-f86d680bedfb" continuedAt="if4abbe871980412c92d8cc59139401b1" escape="true"><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzczMQ_9d0ab5a7-df88-480c-b6a2-843c49a0103a" continuedAt="i6b9d01db3179477880c66417d8ad2ef9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.251%"><tr><td style="width:1.0%"></td><td style="width:53.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.891%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMi0yLTEtMS01OTc0MA_b40fc36c-8bd0-4ec1-80ff-2fdd0db8f6e0">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef3242829b546d9957de36a60faad96_D20210104-20210404" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMi00LTEtMS01OTc0MA_cd0337ba-d2da-45b7-bfa9-1f7aab99f810">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMi02LTEtMS01OTc0MA_38a47b79-01ca-41a0-a160-c4ad2d880799">18.5</ix:nonFraction>)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMy0yLTEtMS01OTc0MA_ebd663df-6705-4d81-b04b-447c0c5d557c">3,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf2d6ac264147d5bc7eea61f5da1000_D20210104-20210404" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMy00LTEtMS01OTc0MA_91191794-07fa-4e50-a9db-17cdbe5a1d6e">5,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMy02LTEtMS01OTc0MA_ba1331d8-17ee-43b1-b8b2-b8d45496dc5e">24.1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4649418b20f44a60bfb39416a9fe963b_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNC0yLTEtMS01OTc0MA_04e38c98-2907-4fe0-becb-cec86cf91a1d">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7614bac3435145d3a723efd9bb087597_D20210104-20210404" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNC00LTEtMS01OTc0MA_787c4016-246c-434a-9bb0-14cca2e16355">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4649418b20f44a60bfb39416a9fe963b_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNC02LTEtMS01OTc0MA_a93554a9-3f5f-4384-ace9-7739334a573b">9.3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d9f1ecfd5c34f7a9fd27206d4b69544_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNS0yLTEtMS01OTc0MA_73d1a520-4f40-4ef7-a153-c07f98f04f5e">6,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01abbe2b4f24422780127bb041f28468_D20210104-20210404" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNS00LTEtMS01OTc0MA_ad27c00a-0063-4df4-994f-4eea6640e79e">7,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0d9f1ecfd5c34f7a9fd27206d4b69544_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNS02LTEtMS01OTc0MA_95d8b8c7-ed93-4ae9-8cf9-426b12972de5">20.3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa048d8675b4238a8d76e97c5690aef_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNi0yLTEtMS01OTc0MA_d6c72718-3374-484b-8193-62d79eab19ca">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7843d84472f449c3bef37bc9121ca5f0_D20210104-20210404" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNi00LTEtMS01OTc0MA_7e56606b-005c-4bf9-bbb2-98b94a0d4137">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy0yLTEtMS02NjIxOQ_132c9cc7-487f-4804-ad78-59e08088dfef">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef3242829b546d9957de36a60faad96_D20210104-20210404" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy00LTEtMS02NjIyNg_4e19606e-c57e-42ca-9627-d7414c683ece">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy0yLTEtMS01OTc0MA_485ba0a5-46af-4273-a90c-1f8dc53c9717">5,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy00LTEtMS01OTc0MA_1d2db8bb-4f62-476c-8f8f-f607a110516f">7,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy02LTEtMS01OTc0MA_c9b76f1d-4d1b-4544-acb4-1b78b3e914c7">21.1</ix:nonFraction>)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*Fiscal first quarter 2021 earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzY5_d651d87d-c36c-4c37-8610-9d0962bca2c4"><ix:nonFraction unitRef="usd" contextRef="i7ef3242829b546d9957de36a60faad96_D20210104-20210404" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzY5_e728ffc5-a14b-4ff1-8e62-9ae9d10a7d87">0.1</ix:nonFraction></ix:nonFraction> billion in both the fiscal first quarter of 2022 and 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $<ix:nonFraction unitRef="usd" contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403" decimals="-8" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfODU2_30b2f794-0704-45bf-b660-8b1b0f40c104">0.6</ix:nonFraction>&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfOTc2_42c5bfe8-b097-4492-a23e-011ce2cd2e10">0.8</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i7cf2d6ac264147d5bc7eea61f5da1000_D20210104-20210404" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfNDM5ODA0NjUxOTEzMw_1e5e6f4c-bb00-44e9-b42f-712fe8b53f08">0.9</ix:nonFraction>&#160;billion in the fiscal first quarter of 2022 and 2021, respectively</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i1a3ed337e07c472b931ca6aecf7946c3_D20220103-20220403" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfNDM5ODA0NjUxOTE0Nw_7a2a1f4d-07e1-4f5b-aa58-2aab0e5b95c1">0.6</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A loss of $<ix:nonFraction unitRef="usd" contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403" decimals="-8" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMTQ3NA_b9316760-dbb2-4790-9f6b-01af4a197212">0.4</ix:nonFraction>&#160;billion related to the change in the fair value of securities in the fiscal first quarter of 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $<ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-8" name="jnj:AmountPrepaidAndDueToManufacturers" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMjE4Nw_568dab4a-e4db-442a-ac17-ba04040dd3c6">0.9</ix:nonFraction>&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities </span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i7d18fabb2c96483c88af4a480a79c7d0"><ix:continuation id="if4abbe871980412c92d8cc59139401b1" continuedAt="iea00151236c841238d4e55084bf59ae4"><ix:continuation id="i6b9d01db3179477880c66417d8ad2ef9" continuedAt="i708054e3b2394b0a9478031956a93f76"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMjgxNg_32b33118-0ebe-4697-b97c-bc789d22baea"><ix:nonFraction unitRef="usd" contextRef="i307797df24904531853ec0fc2169f7e0_D20210104-20210404" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMjgxNg_b9a9a365-0137-4636-91e9-83060ff629f3">0.1</ix:nonFraction></ix:nonFraction> billion in both the fiscal first quarter of 2022 and 2021 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i4649418b20f44a60bfb39416a9fe963b_D20220103-20220403" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzAyMQ_4c6d8479-26ba-43df-895d-f7914cc487aa"><ix:nonFraction unitRef="usd" contextRef="i7614bac3435145d3a723efd9bb087597_D20210104-20210404" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzAyMQ_748ab3f8-f635-4e79-8abc-f99eb149fa62">0.3</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal first quarter of 2022 and 2021 </span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="iea00151236c841238d4e55084bf59ae4" continuedAt="i8adca063b7b3433aa381a45d16bd4d15"><ix:continuation id="i708054e3b2394b0a9478031956a93f76" continuedAt="ief088a0104064587afefef74b3ddad45">(4)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8adca063b7b3433aa381a45d16bd4d15"><ix:continuation id="ief088a0104064587afefef74b3ddad45"> Amounts not allocated to segments include interest income/expense and general corporate income/expense.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:10pt"><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzcxNg_a39706af-15f4-4e0c-83b9-adc874311706" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.190%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMi0yLTEtMS01OTc0MA_2a0d06e2-a16e-4379-8a80-9e592c50a00b">11,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045574b786544774882db0b6a4f87c00_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMi00LTEtMS01OTc0MA_6f5340af-9a05-4125-8a17-3e685c79057d">11,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMi02LTEtMS01OTc0MA_1d75fdfc-af99-4447-becb-72c5f21683fe">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447684ff42fa4bd582534e7299148f49_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMy0yLTEtMS01OTc0MA_8a08780c-e6fc-437a-ac27-fbe8f2158b90">6,024</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i431d8a724aa54139ab3b857d81e71735_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMy00LTEtMS01OTc0MA_8c275727-70b3-42a3-8f24-3bffa4517ebe">5,414</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i447684ff42fa4bd582534e7299148f49_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMy02LTEtMS01OTc0MA_7a1c6f92-94fd-4e62-8a71-e70048bcd8fc">11.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04865d6630d448b86af337d00e81758_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNC0yLTEtMS01OTc0MA_07b39fb4-8bc7-499b-81d2-1521b549c920">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6511d5e0bf74508adf0aa6bdedfe8bc_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNC00LTEtMS01OTc0MA_b163fa53-25d7-4bcd-9cf6-f0b1a3790200">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic04865d6630d448b86af337d00e81758_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNC02LTEtMS01OTc0MA_ad8bdeff-3882-4744-bb5d-7d37609d2109">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09018b2d45d249cd8716cb425feef71d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNS0yLTEtMS01OTc0MA_3f002c0f-859d-4a41-aee9-2b7907d76844">4,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13abd60e97db49d09d10b6d9a10a6b80_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNS00LTEtMS01OTc0MA_548ab5d6-7fd6-4b4c-af45-2e656882633c">4,372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i09018b2d45d249cd8716cb425feef71d_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNS02LTEtMS01OTc0MA_ec825972-ac71-451c-93a3-107f60097c18">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNi0yLTEtMS01OTc0MA_bd928573-92ff-4a1f-bf4b-e1e96c04d0f7">23,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNi00LTEtMS01OTc0MA_4aebbd80-8516-45b5-a585-49d079b02500">22,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNi02LTEtMS01OTc0MA_026fddce-e1f5-4381-89af-8b9a38bb9a97">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 10&#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84NS9mcmFnOjdiNDA5OTdiN2VlMTQwOTBhNjJiNTRjYmQ0MTgzNTg1L3RleHRyZWdpb246N2I0MDk5N2I3ZWUxNDA5MGE2MmI1NGNiZDQxODM1ODVfMTUxMw_40339ce8-d6c4-4728-b20a-c2a703730876" continuedAt="ibbb96c7bc63a4f75941340331817a4f2" escape="true">ACQUISITIONS AND DIVESTITURES</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ibbb96c7bc63a4f75941340331817a4f2" continuedAt="i123ab8c7398e4819848052fcf139334e">There were no material acquisitions in the fiscal first quarter of 2022. </ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i123ab8c7398e4819848052fcf139334e">During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="if894d62118864420a5c2c56cb58ec015_D20210104-20210404" decimals="-8" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84NS9mcmFnOjdiNDA5OTdiN2VlMTQwOTBhNjJiNTRjYmQ0MTgzNTg1L3RleHRyZWdpb246N2I0MDk5N2I3ZWUxNDA5MGE2MmI1NGNiZDQxODM1ODVfMjky_f0008236-581d-41d0-bdb4-fbf43e696417">0.6</ix:nonFraction>&#160;billion.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 11 &#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfOTUyMDk_fb6b9487-2d7f-4610-8b73-f5da8538377b" continuedAt="i62e2d309870d4d969269a415d1c61d08" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i62e2d309870d4d969269a415d1c61d08" continuedAt="i5494e2cd62744fcdb5d562b422997894"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of  April&#160;3, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i5494e2cd62744fcdb5d562b422997894" continuedAt="i564dfa5a379e434f8fb3c395a5b09630"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON&#8217;S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of April&#160;3, 2022, in the United States there were approximately <ix:nonFraction unitRef="claimant" contextRef="if8404f4966e9457699f55005e32abc65_I20220403" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDYxNA_4c92a201-368c-40b0-96ae-ed0a92614853">230</ix:nonFraction> plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; <ix:nonFraction unitRef="claimant" contextRef="iefcbb252e7bb4f458a41283b135a86ec_I20220403" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDc3OA_ff2a333d-d189-41d2-9ca4-407bff8921c8">3,900</ix:nonFraction> with respect to the PINNACLE Acetabular Cup System; <ix:nonFraction unitRef="claimant" contextRef="ib22b3a738c7e4ab29b10ad29e3acd8a9_I20220403" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDgzNA_ee9f80b5-19c6-4699-84c1-3804ba398ce9">9,800</ix:nonFraction> with respect to pelvic meshes; <ix:nonFraction unitRef="claimant" contextRef="ice23be6cbe2746dd8d736fa8da0659cc_I20220403" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDg2OA_1a6985f8-e953-4b81-bc2c-a95c7390b70c">8,600</ix:nonFraction> with respect to RISPERDAL; <ix:nonFraction unitRef="claimant" contextRef="i37533ea8707341c89db72e8585de3a87_I20220403" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDg5OQ_64adfb6f-afa1-40b1-b31b-26c89175c378">4,300</ix:nonFraction> with respect to XARELTO; <ix:nonFraction unitRef="claimant" contextRef="if5e5fa8d553d4bdfac44b45081a72bad_I20220403" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDkyOA_55da0cf6-ab53-47dd-8357-2edea964eeec">40,400</ix:nonFraction> with respect to body powders containing talc; <ix:nonFraction unitRef="claimant" contextRef="i4f89bd9fe89d4fdc8e39741b72fb0768_I20220403" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDk3Nw_b12720d3-5df6-489a-a0d1-5a46c9970729">80</ix:nonFraction> with respect to INVOKANA;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and <ix:nonFraction unitRef="claimant" contextRef="ifeab3c5384914043b5f61dde75cfbcfc_I20220403" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNTAxMg_a36e9bef-d840-40c4-a9cc-a973b3d77672">4,800</ix:nonFraction> with respect to ETHICON PHYSIOMESH Flexible Composite Mesh. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than <ix:nonFraction unitRef="patient" contextRef="if160682b2ae54bd29b1935327968059a_I20220403" decimals="0" name="jnj:Numberofpatientsinsettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjQwMg_415eb85a-e468-4d02-a383-be58d53b8838">10,000</ix:nonFraction> claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i564dfa5a379e434f8fb3c395a5b09630" continuedAt="ia862d9e93be54c629c4a754e27ec67f2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. In March 2022, the Court appointed a barrister to prepare a written report and recommendation on the form and mechanism of the individual case assessment process, due by August 2022, with a court hearing on those findings later that month. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement is expected to be filed with the Court by May 2022. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately <ix:nonFraction unitRef="cases" contextRef="iaecd09df5a17466f94617abfae776151_I20210531" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTIxMTg_76a287e9-2710-47ac-8912-f0283ca9cd15">3,600</ix:nonFraction> Physiomesh cases (covering approximately <ix:nonFraction unitRef="claimant" contextRef="iaecd09df5a17466f94617abfae776151_I20210531" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDM5ODA0Njk3MjM3Mg_2b0ea660-089e-430d-88d4-20cc8687faca">4,300</ix:nonFraction> plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes <ix:nonFraction unitRef="cases" contextRef="i1b15385aca15402cb972e9d0c02e804f_I20210930" decimals="0" name="jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDM5ODA0Njk3MjM3OQ_b6ca6dba-bd8d-44fd-9391-db0f5931eb06">3,729</ix:nonFraction> cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The deadline for issuance of Individual Allocation amounts by the Special Master was March 2022. Plaintiffs requested an extension of the deadline. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of April 2022, there are approximately <ix:nonFraction unitRef="cases" contextRef="i0487ffe3bd6846938c1d7cb60790531d_I20220403" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDM5ODA0Njk3MjM4Ng_576ab563-b5c8-49c7-9584-3c57184c89e1">105</ix:nonFraction> active cases subject to these orders which are being reviewed and evaluated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Discovery is underway in the MCL proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="i812c90cdefa246e3bcebf7398bdb44f4_D20191001-20191031" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTQ0MDg_aee6390d-f0fd-453e-b64e-5a2b779c3a05">8.0</ix:nonFraction>&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $<ix:nonFraction unitRef="usd" contextRef="i5421e9f4d1234869a6e154317b70cd16_D20200101-20200131" decimals="-5" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTQ0OTA_b4e6f6a4-ca34-4400-b66e-39348eb41a66">6.8</ix:nonFraction>&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ia862d9e93be54c629c4a754e27ec67f2" continuedAt="i02185f2650304e5ba54520aa4ddcade0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp; Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $<ix:nonFraction unitRef="usd" contextRef="i339e763d52094be9ae4c3c2454a17c00_D20180701-20180731" decimals="-8" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTY3NzQ_44764696-a61d-4a12-8f64-b60b395258bb">4.7</ix:nonFraction>&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No. ED 207476 (Mo. App.), reducing the overall award to  $<ix:nonFraction unitRef="usd" contextRef="i14361e93fcc9401dad202a5affb4254d_D20200601-20200630" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTY4NzM_584421b0-43d5-4107-829e-2f0362e39e5f">2.1</ix:nonFraction>&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="if0ab2dba81b64612b4248a3cd41c97e2_D20210601-20210630" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTcxOTQ_26510f1b-9552-4174-8674-80b85b771ed4">2.5</ix:nonFraction>&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay, and also asked the New Jersey Bankruptcy Court for leave to pursue direct appeals to the Third Circuit Court of Appeals, which was granted. In April 2022, claimants filed a request with Third Circuit Court of Appeals to hear the case, and LTL filed its opposition to the request. While the New Jersey Bankruptcy Court&#8217;s order effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $<ix:nonFraction unitRef="usd" contextRef="i1508c05368864604ae6acac4ed5e0fe4_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTk1NTQ_13751d39-c0a6-4113-9be1-c405d6f4103c">2</ix:nonFraction>&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $<ix:nonFraction unitRef="usd" contextRef="i1508c05368864604ae6acac4ed5e0fe4_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTk2NTE_21b68a9a-b02a-41f6-abf9-b05c0c96ae29">2</ix:nonFraction>&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i02185f2650304e5ba54520aa4ddcade0" continuedAt="i10395c708d2541fd980d7c03ee14f1aa"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn as improperly voted. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#8217;s insurers (the Mediation Parties) have since agreed to engage in mediation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding). The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the stay applied to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs&#8217; motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. In February 2022, the Court granted Johnson &amp; Johnson&#8217;s cross motion to dismiss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i10395c708d2541fd980d7c03ee14f1aa" continuedAt="i4ee1b61b289548db9d7c2dad8c02c342"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In November 2021, at the Court&#8217;s request, the parties submitted supplemental briefing on Plaintiff&#8217;s motion for discovery. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i4ee1b61b289548db9d7c2dad8c02c342" continuedAt="i8f01d40e84ca4154bd70b908541e89ea"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MedTech</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit. In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid. In March 2022, the U.S. Court of Appeals for the Federal Circuit affirmed the finding of invalidity of the &#8217;601 patent. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris has appealed that decision. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. Trial is scheduled to begin in December 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 and 10,517,583 (&#8217;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#8217;180 patent, and awarding damages in the amount of $20 million. DePuy is challenging the verdict in its post-trial motions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i8f01d40e84ca4154bd70b908541e89ea" continuedAt="ib64a3ec6a47f4c8785aabba201157268"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc. and Janssen Oncology, Inc. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#8217;310). The following generic drug companies are named defendants:  Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. No trial date has been set in this lawsuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Micro Labs Ltd. and Micro Labs USA Inc. (collectively, Micro) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In March 2022, the case against Micro was consolidated for all purposes, including trial, with the consolidated Delaware lawsuits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Parties Review with the United States Patent and Trademark Office, seeking to invalidate the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, Janssen Pharmaceuticals, Inc. (JPI), Bayer Intellectual Property GmbH and Bayer AG filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Changzhou Pharmaceutical Factory, which filed an ANDA seeking approval to market generic a version of XARELTO (10 mg, 15 mg, and 20 mg) before expiration of U.S. Patent No. 9,539,218 (&#8217;218). In this lawsuit, JPI, Bayer Intellectual Property GmbH and Bayer AG are seeking an order enjoining Changzhou from marketing its generic version of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA/INVOKAMET/INVOKAMET XR</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788) relating to INVOKAMET. In this lawsuit, Janssen and MTPC are seeking an order enjoining DRL from marketing its generic version of INVOKAMET before the expiration of the &#8217;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR before expiration of MTPC&#8217;s United States Patent </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ib64a3ec6a47f4c8785aabba201157268" continuedAt="iaff55332f4f2499ba1b8b1712a41fa0f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKAMET XR. In February 2022, the case was dismissed by stipulation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA before the expiration of the relevant patents. The trial is scheduled to begin in August 2022. In February 2022, the case was discontinued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial against Sandoz concluded in February 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial against Apotex concluded in March 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). In April 2022, the parties entered a confidential settlement agreement, and the case was discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of United States Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. A trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="iaff55332f4f2499ba1b8b1712a41fa0f" continuedAt="i7f524b1e8f814b59906bf3e5ca1add88"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. The action has been consolidated with the November 2020 action for trial, which is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Trial is scheduled to begin in October 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i7f524b1e8f814b59906bf3e5ca1add88" continuedAt="iedf2ad7ca7064b219452b505874b51d6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. The trial is scheduled to begin in July 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SYMTUZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of United States Patent Nos. 10,039,718 (the &#8217;718 patent) and 10,786,518 (the &#8217;518 patent). Janssen is seeking an order enjoining Lupin from marketing its generic version of SYMTUZA before the expiration of the &#8217;718 and &#8217;518 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Other Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#8217; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#8217; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in responses to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to <ix:nonFraction unitRef="claimant" contextRef="i876621f6fe4046ebafa49eee939aae65_I20220403" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjIzNzg_34235476-2ea3-44a5-8501-602e3a9d9da0">3,500</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="iedf2ad7ca7064b219452b505874b51d6" continuedAt="i2721d80b3c2a4c02b2ef2422678ddc14"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1ba7f11cf3c6444fb13f272778b14648_D20181231-20191229" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjU2OTE_4aaae1d0-32cd-4ef0-828e-b0815e7895c8">465</ix:nonFraction>&#160;million. Johnson &amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment and directed entry of judgment for Defendants. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#8217; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $<ix:nonFraction unitRef="usd" contextRef="ibc133ce8aefa43cbbac33e0c79222c18_I20191031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjkzOTA_5275fb97-6735-47ab-90fe-d6f750be5608">4</ix:nonFraction>&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $<ix:nonFraction unitRef="usd" contextRef="ic211f008f0c343b9b6dbe0257a30891d_I20201031" decimals="-9" name="jnj:LossContingencyEstimateOfAdditionalPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjk0OTU_6ca7c639-7121-4a79-a74d-6726a2224a8f">1</ix:nonFraction>&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of  $<ix:nonFraction unitRef="usd" contextRef="ic211f008f0c343b9b6dbe0257a30891d_I20201031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjk2NTU_6dd36b0a-7048-47fb-b5d3-14ffacea085f">5</ix:nonFraction>&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and up to one-third of the all-in settlement is expected to be paid within the next 12 months, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022 and initial payments are set for July 2022. In April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are approximately <ix:nonFraction unitRef="claim" contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMjc0ODc3OTQ1NTMyOA_250b3f2d-6c31-4b51-996a-49f342862b1e">100</ix:nonFraction> cases remaining post-settlement in various state courts. There are approximately <ix:nonFraction unitRef="claim" contextRef="i8843c5f5a5344884a0b6d6b1eabc68b6_I20220403" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMjc0ODc3OTQ1NTM0Nw_996d5604-e9cd-4ff1-874b-d9033dd63c63">1,000</ix:nonFraction> remaining federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i2721d80b3c2a4c02b2ef2422678ddc14" continuedAt="icfa102365da5451993417bc8087a0407"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.  By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted Johnson &amp; Johnson&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The Relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit, and the Relators&#8217; brief is due in May 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. Janssen&#8217;s motion to dismiss was denied in December 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for May 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $<ix:nonFraction unitRef="usd" contextRef="idb0be9010ee64ef5a74536a9b8bf4b5e_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDM5ODA0Njk3MjM5MQ_55d64c7e-585e-4f2c-ada0-8078626b6358">344</ix:nonFraction>&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $<ix:nonFraction unitRef="usd" contextRef="idb0be9010ee64ef5a74536a9b8bf4b5e_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNzY0OTk_9d855644-69b6-4a15-bb6e-da098a94c84c">344</ix:nonFraction>&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $<ix:nonFraction unitRef="usd" contextRef="i7bf5bf7a3b0c4bcdba8ba036de5060bd_D20220401-20220430" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMjc0ODc3OTUyNjQyMQ_d0fbb3ff-7c7c-48e4-8ea6-d87602d24eab">302</ix:nonFraction>&#160;million, but otherwise denied the appeal. The Company is pursuing an appeal to the Supreme Court of California.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="icfa102365da5451993417bc8087a0407" continuedAt="ia7ef4f9398014c1f81feb86f4189bc80"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting and in January 2022, the Court granted plaintiff&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to enter into negotiations to determine if they would resolve their claims through the LTL Bankruptcy Case.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products, LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ia7ef4f9398014c1f81feb86f4189bc80" continuedAt="ia256157da956440cb17233b032924c52"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over <ix:nonFraction unitRef="claim" contextRef="iab1eb6318e4a48a59682988b2dc916e0_I20150430" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfODM2OTk_fe4168d8-a97d-42d4-8120-3a5ad0e89530">30</ix:nonFraction> putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. This case was settled in March 2022, subject to Court approval. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022, subject to Court approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. This case was settled in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2022, defendants petitioned for rehearing en banc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ia256157da956440cb17233b032924c52"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for February 2023.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In March 2022, the Court granted preliminary approval of the settlement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 12&#8212; <ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMjU2NQ_da7a38f9-9c5d-4e2b-9955-f7b9498c2350" continuedAt="ibc12fb21e4604ae99eeb9cc17592e1b5" escape="true">RESTRUCTURING</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ibc12fb21e4604ae99eeb9cc17592e1b5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal first quarter of 2022, the Company recorded a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="ic71f1704f9cc4887aecf9df02c808339_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfNjYw_a5d34c0a-3175-4647-a41c-9602bdaa817d">72</ix:nonFraction> million, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="i429a51537c514c5d901ca9e7b22c4175_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfNzQ4_7e19f47a-4687-45b8-a738-99b037fb8d23">70</ix:nonFraction> million in restructuring, $<ix:nonFraction unitRef="usd" contextRef="i77698652b7224cc1aa4d7e90f3dc8d52_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfNzY5_580756cc-fb22-406f-8a6c-8b42707e733c">16</ix:nonFraction> million in cost of products sold and income of $<ix:nonFraction unitRef="usd" contextRef="i3c5ffba5806541d5ba6376f4fc012752_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfODAx_91e2fcf1-e076-4192-857c-3ebf07c19e68">14</ix:nonFraction> million (from property sales) in other (income) expense, net. Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i9829b5b0fbb446f5a0b0c27c4eb65328_I20220403" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTEwOQ_c3e8068b-b711-442e-822e-fe4d687dc032">1.8</ix:nonFraction> billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In total, the Company expects the Global Supply Chain actions to generate approximately $<ix:nonFraction unitRef="usd" contextRef="i8c4ee00cbdf34df08cf085ad78a22765_I20220403" decimals="-8" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTMzNw_aee8b364-b171-435e-9c5a-f2ebd8627af3">0.6</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="ide55be3475194704afb071efa17c609a_I20220403" decimals="-8" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTM0Mw_813d4b04-3829-4a56-9fc3-66ea7cd0915e">0.8</ix:nonFraction> billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i8c4ee00cbdf34df08cf085ad78a22765_I20220403" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTUwMA_e33a2133-6619-4268-8f60-85071089e406">2.1</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="ide55be3475194704afb071efa17c609a_I20220403" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTUwNg_66fe8503-7548-4081-9b95-169f66d276bb">2.3</ix:nonFraction> billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMjU2MQ_dbdf782f-a263-4777-bf84-d83e8672ec50" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:32.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5135a58860bc4428aa25ef065e2d9395_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfMS0xLTEtMS01OTc0MA_f320e07e-e17f-4e6e-a3d8-fa2fc85b395b">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c4ef8d93674a29b417806bb3af7d59_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfMS0yLTEtMS01OTc0MA_19fc4a67-08fb-478f-94c5-7813cc0ee84c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964e0dcb3290414a948e1f7f5b6a98f0_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfMS0zLTEtMS01OTc0MA_e51554d0-4c18-4a09-9f96-e0caa1954d96">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4afcfd6d8e427c8043eca9ef363498_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfMS01LTEtMS01OTc0MA_7d035790-7e95-4cc7-8607-97fdf5b42226">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55870fa5009d42c29ee665e83387efd6_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNC0xLTEtMS01OTc0MA_52f34de6-89a1-4f06-9ff6-98a3fae92c5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84f8b7c83d8e4a408decca1a1e440fef_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNC0yLTEtMS01OTc0MA_ff08dd66-16b6-49e0-97db-099a6ee712cc">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947a2e9e4d9745a88afc0f03c30a4835_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNC0zLTEtMS01OTc0MA_7f8d88ff-1f6d-48bb-af94-5480fdadd8e1">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad79f71187349d286755258d2aaae39_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNC01LTEtMS01OTc0MA_cb6d4128-d5df-4346-a234-e056724d43a8">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55870fa5009d42c29ee665e83387efd6_D20220103-20220403" decimals="-6" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNS0xLTEtMS01OTc0MA_d2e2e314-725d-4127-a63c-bebb0184f83b">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f8b7c83d8e4a408decca1a1e440fef_D20220103-20220403" decimals="-6" sign="-" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNS0yLTEtMS01OTc0MA_db63d08d-8cc6-4da9-b247-b6355c048d0f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i947a2e9e4d9745a88afc0f03c30a4835_D20220103-20220403" decimals="-6" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNS0zLTEtMS01OTc0MA_ceea4eae-1e76-424b-befb-76ed8bcc23a1">107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifad79f71187349d286755258d2aaae39_D20220103-20220403" decimals="-6" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNS01LTEtMS01OTc0MA_7a8ccbd6-4b6d-4d31-a5b2-351aa5444690">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55870fa5009d42c29ee665e83387efd6_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNi0xLTEtMS01OTc0MA_841ea045-0231-4d67-8ac2-1ce832868f93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84f8b7c83d8e4a408decca1a1e440fef_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNi0yLTEtMS01OTc0MA_18f2626c-8a32-4b40-99ea-c2a526fb79d5">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947a2e9e4d9745a88afc0f03c30a4835_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNi0zLTEtMS01OTc0MA_d0f3d77c-ec92-4dd7-8fa5-94fbe0ecafb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifad79f71187349d286755258d2aaae39_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNi01LTEtMS01OTc0MA_b157d43f-af9e-40ea-bf80-92f755ea9b4a">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, April 3, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd52c3fe3994d508717b89e90774fc7_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfOS0xLTEtMS01OTc0MA_8955a0ab-af1e-4462-a0e8-9b2b7b1bfefe">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d132ccbcb6c479395ae1351d7e61a30_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfOS0yLTEtMS01OTc0MA_766ab0b5-06ec-4366-8e88-fae8b5ab1092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2eb914c66f44b7eacd607705a3c6eff_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfOS0zLTEtMS01OTc0MA_d8b9fb64-67cd-40bd-ae67-842f575deff3">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1e6b53d4a34fa48ef408b420626ba5_I20220403" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfOS01LTEtMS01OTc0MA_619f11a9-605a-435c-87bf-454bf82fdcd6">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_106"></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Consolidated Sales</span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal first quarter of 2022, worldwide sales were $23.4 billion, a total increase of 5.0%, which included operational growth of 7.7%  and a negative currency impact of 2.7% as compared to 2021 fiscal first quarter sales of $22.3 billion. In the fiscal first quarter of 2022, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.2%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S. companies were $11.4 billion in the fiscal first quarter of 2022, which represented an increase of 2.7% as compared to the prior year. In the fiscal first quarter of 2022, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a negative 0.1%.  Sales by international companies were $12.0 billion, a total increase of 7.2%, which included operational growth of 12.6% and a negative currency impact of 5.4%. In the fiscal first quarter of 2022, the net impact of acquisitions and divestitures on the international operational sales growth was a negative 0.3%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal first quarter of 2022, sales by companies in Europe achieved growth of 11.3%, which included operational growth of 19.5% and a negative currency impact of 8.2%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 4.1%, including operational growth of 5.1% and a negative currency impact of 1.0%. Sales by companies in the Asia-Pacific, Africa region achieved growth 3.1%, including operational growth of 6.6% and a negative currency impact of 3.5%.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20220403_g1.jpg" alt="jnj-20220403_g1.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/><img src="jnj-20220403_g2.jpg" alt="jnj-20220403_g2.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Sales by Business Segments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:42.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consumer Health segment sales in the fiscal first quarter of 2022 were $3.6 billion, a decrease of 1.5% as compared to the same period a year ago, including operational growth of 0.8% offset by a negative currency impact of 2.3%. U.S. Consumer Health segment sales decreased by 3.4%. International Consumer Health segment sales were flat including operational growth of 4.1% and a negative currency impact of 4.1%. In the fiscal first quarter of 2022, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was a negative 0.8% primarily due to the DR. CI:LABO - Sedona divestiture in Asia Pacific. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Major Consumer Health Franchise Sales* &#8212; Fiscal First Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:43.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal first quarter of 2021, approximately $0.1 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OTC franchise achieved operational growth of 17.1% as compared to the prior year fiscal first quarter. Growth was driven by upper respiratory products, TYLENOL and MOTRIN  and IMODIUM and PEPCID products in digestive health.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skin Health/Beauty franchise experienced an operational decline of 11.0% as compared to the prior year fiscal first quarter. The decline was driven by external supply constraints, the DR. CI:LABO - Sedona divestiture in Asia Pacific and competitive pressures. The decline was partially offset by U.S. category recovery and strength in the Latin America and Asia Pacific regions.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oral Care franchise experienced an operational decline of 10.2% as compared to the prior year fiscal first quarter. The decline was primarily driven by strategic SKU rationalization in the U.S. and lapping prior year COVID-19 related increased demand outside the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Baby Care franchise experienced an operational decline of 6.4% as compared to the prior year fiscal first quarter. The decline was driven by supply constraints in the U.S. and EMEA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Women&#8217;s Health franchise achieved operational growth of 8.3% as compared to the prior year fiscal first quarter primarily driven by growth in EMEA due to increased stocking and LATAM due to price increases.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Wound Care/Other franchise experienced an operational decline of 7.2% as compared to the prior year fiscal first quarter primarily driven by the professional tape divestiture along with comparison to prior year COVID-19 recovery for NEOSPORIN in the U.S. and BAND-AID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Brand Adhesive Bandages outside the U.S. This decline was partially offset by growth of U.S. BAND-AID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Brand Adhesive Bandages.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business, with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after the initial announcement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:48.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.017%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pharmaceutical segment sales in the fiscal first quarter of 2022 were $12.9 billion, an increase of 6.3% as compared to the same period a year ago, including an operational increase of 9.3% and a negative currency impact of 3.0%. U.S. Pharmaceutical sales increased 2.9% as compared to the same period a year ago. International Pharmaceutical sales increased by 10.3%, including operational growth of 16.7% and a negative currency impact of 6.4%. In the fiscal first quarter of 2022, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was negligible. Adjustments to previous sales reserve estimates were negligible in the fiscal first quarter of 2022 and approximately $0.2 billion in the fiscal first quarter of 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Pharmaceutical Therapeutic Area Sales** &#8212; Fiscal First Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:47.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,914</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI/ SIMPONI ARIA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">998</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT/rilpivirine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA/ PREZCOBIX/ REZOLSTA/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,715</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA/ methylphenidate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,570</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA/ abiraterone acetate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA/ INVOKAMET</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1,2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,869</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal first quarter of 2021, approximately $0.1 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunology products achieved operational growth of 7.5% as compared to the same period a year ago driven by continued strong uptake of STELARA (ustekinumab) in Crohn's disease and Ulcerative Colitis partially offset by share declines in Psoriasis and Psoriatic Arthritis and strength of TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(guselkumab) in Psoriasis and uptake in Psoriatic Arthritis. This was partially offset by lower sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(infliximab) due to biosimilar competition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The latest expiring United States patent for STELARA (ustekinumab) will expire in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2021 were approximately $5.9 billion. The expiration of a product patent or loss of market exclusivity is likely to result in a reduction in sales.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease products achieved operational growth of 33.1% as compared to the same period a year ago. Growth was primarily driven by the contribution of the COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This was partially offset by lower sales of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PREZCOBIX/REZOLSTA (darunavir/cobicistat) due to increased competition and loss of exclusivity of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries outside the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience products achieved operational sales growth of 5.0% as compared to the same period a year ago. Growth of Paliperidone long-acting injectables INVEGA SUSTENNA/XEPLION (paliperidone palmitate) and INVEGA TRINZA/TREVICTA was due to patient mix, new patient starts and persistence of treatment as well as the launch of INVEGA HAFYERA. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology products achieved operational sales growth of 14.9% as compared to the same period a year ago. Contributors to the growth were strong sales of DARZALEX (daratumumab) driven by share gains in all regions, continued strong market growth, and solid uptake of the subcutaneous formulation; the continued global launch uptake of ERLEADA (apalutamide) and IMBRUVICA (ibrutinib) growth in all regions outside the U.S. In the U.S. IMBRUVICA (ibrutinib) declined due to competitive pressures from novel oral agents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pulmonary Hypertension achieved operational sales growth of 1.2% as compared to the same period a year ago. Sales growth of OPSUMIT (macitentan) and UPTRAVI (selexipag) were due to demand and share gains partially offset by COVID-19 related market constraints as well as entrants in Other Pulmonary Hypertension.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular / Metabolism / Other products experienced an operational decline of 11.9% as compared to the same period a year ago. The decline was primarily attributable to lower sales of XARELTO due to a one-time favorable prior period pricing adjustment in the fiscal first quarter of 2021 and INVOKANA/INVOKAMET (canagliflozin) due to continued share erosion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Starting in the second quarter of fiscal 2022, the Company updated its policy so that no end customer will be permitted to direct delivery of product to a location other than the billing location. The updated policy will impact contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company&#8217;s drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain unlimited contract pharmacy arrangements under policy exceptions. The Company will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy update could have potential discount and volume implications going forward. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech*</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:228.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment sales in the fiscal first quarter of 2022 were $7.0 billion, an increase of 5.9% as compared to the same period a year ago, which included operational growth of 8.5% and a negative currency impact of 2.6%. U.S. MedTech sales increased 5.6%. International MedTech sales increased by 6.3%, including operational growth of 11.1% and a negative currency impact of 4.8%. In the fiscal first quarter of 2022, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a negative 0.1%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Major MedTech Franchise Sales &#8212; Fiscal First Quarter Ended</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:235.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,372</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,113</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,257</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">949</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total MedTech Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Previously referred to as Medical Devices</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Surgery franchise achieved operational sales growth of 5.0% as compared to the prior year fiscal first quarter. The operational growth in Advanced Surgery was primarily driven by Endocutter and Biosurgery products attributable to market recovery, market expansion and the success of new products. Growth of Endocutter products was offset by COVID-19 market slow down in the Asia Pacific region and competitive pressures in the U.S. Energy products growth was flat to the prior year fiscal first quarter with market recovery and new product penetration mostly offset by COVID-19 market slow downs in Asia Pacific. The operational growth in General Surgery was primarily driven by market recovery, strength of the Suture portfolio, and technology penetration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Orthopaedics franchise achieved operational sales growth of 5.6% as compared to the prior year fiscal first quarter. The operational growth in hips reflects the market recovery, continued strength of the portfolio including the ACTIS stem and enabling technologies &#8211; KINCISE and VELYS Hip Navigation and momentum in the U.S. Ambulatory Surgery Center channel. The operational growth in knees was primarily driven by market recovery and uptake of new products and momentum in the U.S. Ambulatory Surgery Center channel. The operational growth in Trauma was driven by global market recovery and uptake of new products. The operational growth in Spine, Sports &amp; Other was driven by recovery across most specialties, new products in Sports, Spine &amp; VELYS Digital Solutions and a prior year China distribution channel change. Growth was partially offset by market softness and competitive pressures in Spine.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vision franchise achieved operational sales growth of 13.9% as compared to the prior year fiscal first quarter. The Contact Lenses/Other operational growth was due to market recovery, new products and the U.S. benefit related to a current year forward buy ahead of a list price increase. The growth was partially offset by the negative impact from prior year stocking. The Surgical operational growth was primarily due to market recovery and uptake of recently launched products.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interventional Solutions franchise achieved operational sales growth of 17.4% as compared to the prior year fiscal first quarter driven by the market recovery, success of new products and commercial strategies.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANALYSIS OF CONSOLIDATED EARNINGS BEFORE PROVISION FOR TAXES ON INCOME </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income for the fiscal first quarter of 2022 was $5.9 billion representing 25.0% of sales as compared to $7.4 billion in the fiscal first quarter of 2021, representing 33.3% of sales. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="text-align:center"><img src="jnj-20220403_g3.jpg" alt="jnj-20220403_g3.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2022 versus Q1 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Unfavorable volume/mix in the MedTech segment </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commodity inflation in the Consumer Health segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intangible asset amortization expense included in cost of products sold for the fiscal first quarters of 2022 and 2021 was $1.1 billion and $1.2&#160;billion, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, Marketing and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:center"><img src="jnj-20220403_g4.jpg" alt="jnj-20220403_g4.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Q1 2022 versus Q1 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher brand marketing expenses in the Pharmaceutical and Consumer Health businesses</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="text-align:center"><img src="jnj-20220403_g5.jpg" alt="jnj-20220403_g5.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2022 versus Q1 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">General portfolio progression in the Pharmaceutical business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Process Research and Development (IPR&amp;D)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Interest (Income) Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (Income) Expense in the fiscal first quarter of 2022 was a net interest income of $12 million as compared to interest expense of $48 million in the same period a year ago primarily due to the benefit from net investment hedging, a higher average cash balance and a lower average debt balance. The balance of cash, cash equivalents and current marketable securities was $30.4&#160;billion at the end of the fiscal first quarter of 2022 as compared to $24.6 billion at the end of the fiscal first quarter of 2021. The Company&#8217;s debt position was $33.1 billion as of April&#160;3, 2022 as compared to $33.6 billion the same period a year ago. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income) Expense, Net*</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2022 versus Q1 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal first quarter of 2022 was unfavorable by $0.8 billion as compared to the prior year primarily due to the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal First Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, integration and divestiture related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health separation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Primarily related to divestiture gains of two pharmaceutical brands outside the U.S. in the fiscal first quarter of 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income (loss) before tax by segment of business for the fiscal first quarters were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,862&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consumer Health segment income/(loss) before tax as a percent of sales in the fiscal first quarter of 2022 was 19.1% versus 23.1% for the same period a year ago. The decrease in the income before tax as a percent of sales in the fiscal first quarter of 2022 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">An increase in brand marketing expenses</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commodity inflation </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment income before tax as a percent of sales in the fiscal first quarter of 2022 was 30.5% versus 42.7% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal first quarter of 2021 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An IPR&amp;D charge of $0.6 billion in 2022 related to bermekimab (JnJ-77474462), an investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS) </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6 billion in 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net mark-to-market loss related to the change in the fair value of securities ($0.4 billion in 2022 vs. $0.0 billion in 2021)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased Research &amp; Development investment for general portfolio progression </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher brand marketing expenses</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment income before tax as a percent of sales in the fiscal first quarter of 2022 was 21.2% versus 24.8% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal first quarter was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Product mix within the MedTech franchises</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                          </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement actions across its Global Supply Chain that are intended to enable the Company to focus resources and increase investments in critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio of the future, enhance agility and drive growth. The Company expects these supply chain actions will include expanding its use of strategic collaborations, and bolstering its initiatives to reduce complexity, improving cost-competitiveness, enhancing capabilities and optimizing its network.&#160;Discussions regarding specific future actions are ongoing and are subject to all relevant consultation requirements before they are finalized. In total, the Company expects these actions to generate approximately $0.6 to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.1 to $2.3 billion by the completion of the program in December 2022. In the fiscal first quarter of 2022, the Company recorded a net pre-tax charge of $72 million, which is included on the following lines of the Consolidated Statement of Earnings, $70 million in restructuring, $16 million in cost of products sold and income of $14 million (from property sales) in other (income) expense, net. In the fiscal first quarter of 2021, the Company recorded a pre-tax charge of $104 million, which is included on the following lines of the Consolidated Statement of Earnings, $53 million in restructuring, $27 million in cost of products sold and $24 million in other (income) expense, net. Restructuring charges of approximately $1.8 billion have been recorded since the restructuring was announced. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;12 to the Consolidated Financial Statements for additional details related to the restructuring.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Taxes on Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rate was 12.2% in 2022 and 16.6% in 2021. During fiscal year 2022, the Company is expected to incur significant additional international tax costs related to the legal separation of the Consumer Health businesses.</span></div><div><span><br/></span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion related to the fiscal first quarter of 2022 provision for taxes refer to Note&#160;5 to the Consolidated Financial Statements. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20220403_g6.jpg" alt="jnj-20220403_g6.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20220403_g7.jpg" alt="jnj-20220403_g7.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20220403_g8.jpg" alt="jnj-20220403_g8.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents were $10.5 billion at the end of the fiscal first quarter of 2022 as compared with $14.5 billion at the end of fiscal year 2021. The primary sources and uses of cash that contributed to the $4.0&#160;billion decrease were:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:21.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2021 Cash and cash equivalents balance</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash generated from operating activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by investing activities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by financing activities</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2022 Cash and cash equivalents balance</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company had $19.9 billion in marketable securities at the end of the fiscal first quarter of 2022 and $17.1 billion at the end of fiscal year 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operations of $4.0&#160;billion was the result of:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts receivable and inventories </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in accounts payable and accrued liabilities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in other current and non-current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in other current and non-current liabilities</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow from operations</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities use of $3.6 billion of cash was primarily used for:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">additions to property, plant and equipment</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from the disposal of assets/businesses, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">acquisitions, net of cash acquired and other</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net purchases of investments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities use of $4.4 billion of cash was primarily used for: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dividends to shareholders </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">repurchase of common stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net repayment of short and long term debt</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from stock options exercised/employee withholding tax on stock awards, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other and rounding</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for financing activities</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2021, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10&#160;billion, which expires on September&#160;8, 2022.  Interest charged on borrowings under the credit line agreement is based on either Term Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreement are not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal first quarter of 2022, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of April&#160;3, 2022, the net debt position was $2.8 billion as compared to the prior year of $9.0 billion. Considering recent market conditions and the on-going COVID-19 crisis, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's approximate $0.9 billion in contractual supply commitments associated with its development of the COVID-19 vaccine, the agreement to settle opioid litigation for $5 billion and the establishment of the $2 billion trust for talc related liabilities (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. Subsequent to April 3, 2022, the Company paid approximately $1.0 billion to the U.S. Treasury including $0.8 billion related to the current installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January 2, 2022) and $0.2 billion primarily related to the normal estimated payment for the fiscal first quarter of 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2022, the Board of Directors declared a regular cash dividend of $1.06 per share, payable on March 8, 2022 to shareholders of record as of February 22, 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2022, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on June 7, 2022 to shareholders of record as of May 24, 2022. The Company expects to continue the practice of paying regular quarterly cash dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic and Market Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 considerations and business continuity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered various internal and external factors in assessing the potential impact of COVID-19 on its business and financial results based upon information available at this time, as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Operating Model: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations and commercial capabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory at major distribution centers away from high-risk areas to ensure adequate and effective distribution. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business Continuity: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The robust, active business continuity plans across the Company's network have been instrumental in preparing the Company for events like COVID-19 and the ability to meet the majority of patient and consumer needs remains uninterrupted.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Workforce: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has put procedures in place to protect its essential workforce in manufacturing, distribution, commercial and research operations while ensuring appropriate remote working protocols have been established for other employees. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's high-quality credit rating allows the Company superior access to the financial capital markets for the foreseeable future. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Domestic and Foreign Legislation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess and evaluate the on-going global legislative efforts to combat the COVID-19 impact on economies and the sectors in which it participates. Currently, the recent legislative acts put in place are not expected to have a material impact on the Company&#8217;s operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the Covid-19 vaccine and its related supply.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to evaluate and monitor both its internal and external supply arrangements, including its contract with Emergent BioSolutions and related production activities at its Bayview, Maryland facility. The Company has established a global vaccine supply network, where, in addition to its internal manufacturing site in Leiden, the Netherlands, ten other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing sites will be involved in the production of vaccine across different countries and continents. The Company does not believe that a disruption at a vaccine manufacturing site, or the resulting delay would have a material financial impact on the Company&#8217;s consolidated financial statements or results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the long-term implications of Russia&#8217;s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal first quarter of 2022, including accounts receivable or inventory reserves, was not material. As of both the 2021 fiscal year ending January 2, 2022, and the fiscal first quarter ending April 3, 2022, the business of the Company&#8217;s Ukraine subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and revenues. As of both the 2021 fiscal year ending January 2, 2022, and the fiscal first quarter ending April 3, 2022, the business of the Company&#8217;s Russian subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and represented 1% of revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company continued to supply its products throughout the first quarter as patients rely on many of the products for healthcare purposes. However, in early March, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. Additionally, at the end of March, the Company made the decision to suspend supply of personal care products in Russia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela and Argentina as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. Beginning in the fiscal second quarter of 2022, the Company will account for operations in Turkey as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This will not have a material impact on the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160;This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160; The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, as a result of the current global economic downturn, may continue to impact the Company&#8217;s businesses.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;3 &#8212; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the Company&#8217;s assessment of its sensitivity to market risk since its presentation set forth in Item&#160;7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; in its Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;4 &#8212; CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Duato and Wolk concluded that, as of the end of the period covered by this report, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal control. During the period covered by this report, there were no changes in the Company&#8217;s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company has not experienced any material impact to its internal controls over financial reporting despite the fact that most of its employees are working remotely due to the COVID-19 pandemic. The Company proactively took actions to re-evaluate and refine its financial reporting process through additional monitoring controls to provide reasonable assurance that the financial results are reported accurately and timely. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part II &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to Note 11 included in Part&#160;I, Item&#160;1, Financial Statements (unaudited) &#8212; Notes to Consolidated Financial Statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i89b54799c61648c0892d664696387b28_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to Common Stock purchases by the Company during the fiscal first quarter of 2022. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal first quarter.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:497.25pt"><tr><td style="width:1.0pt"></td><td style="width:210.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:84.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:57pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Month Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avg. Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2022 through January 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 31, 2022 through February 27, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,728,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022 through April 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,596,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,243,529&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;During the fiscal first quarter of 2022, the Company repurchased an aggregate of 9,243,529 shares of Johnson &amp; Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;6 &#8212; EXHIBITS</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20221qex311ceocertificati.htm">Exhibit&#160;31.1  </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20221qex312cfocertificati.htm">Exhibit&#160;31.2 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20221qex321ceocertificati.htm">Exhibit&#160;32.1 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div style="text-indent:11.25pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20221qex322cfocertificati.htm">Exhibit&#160;32.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certification of Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 101: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i89b54799c61648c0892d664696387b28_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:51.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JOHNSON &amp; JOHNSON<br/>(Registrant)&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April 29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/ J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer (Principal Financial Officer)&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April 29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/&#160;R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller (Principal Accounting Officer)&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a20221qex311ceocertificati.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie021d224236e4bdeb5cdfa79b7ce3e67_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joaquin Duato, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended April&#160;3, 2022 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joaquin Duato</font></div><div style="padding-left:288pt"><font style="color:#7d7d7d;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">__________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joaquin Duato </font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;   April&#160;29, 2022</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a20221qex312cfocertificati.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i766899f7130e4468a7dbb9347bcb2175_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended April&#160;3, 2022 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joseph J. Wolk</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">______________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph J. Wolk</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;29, 2022</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a20221qex321ceocertificati.htm
<DESCRIPTION>EX-32.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4b5d6f260bfa4544926e4ec24e0f2140_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:11pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended April 3, 2022 (the&#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joaquin Duato</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;  April&#160;29, 2022</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a20221qex322cfocertificati.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic7706b15cc85447a88690cfcc6caf1a2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.2</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended April 3, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Dated&#58;  April&#160;29, 2022</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>jnj-20220403.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:16b74ba9-87ed-4a1d-982b-bd3712a1fa43,g:84010c2d-9ae9-41ea-8d72-e231a49d0ab7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20220403" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20220403">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220403_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220403_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220403_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20220403_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.jnj.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>1003004 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1006007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1008009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>2103102 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>2304301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>2405401 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2106103 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillBySegmentDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
        <link:definition>2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails">
        <link:definition>2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.jnj.com/role/FairValueMeasurements">
        <link:definition>2112104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.jnj.com/role/FairValueMeasurementsTables">
        <link:definition>2313303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDerivativesBalanceSheetLocationDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
        <link:definition>2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails">
        <link:definition>2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
        <link:definition>2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.jnj.com/role/IncomeTaxes">
        <link:definition>2124105 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncomeTaxesDetails">
        <link:definition>2425416 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlans" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans">
        <link:definition>2126106 - Disclosure - Pensions and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansTables" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables">
        <link:definition>2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails">
        <link:definition>2429418 - Disclosure - Pensions and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncome" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome">
        <link:definition>2130107 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeTables" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables">
        <link:definition>2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.jnj.com/role/EarningsPerShare">
        <link:definition>2133108 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.jnj.com/role/EarningsPerShareTables">
        <link:definition>2334306 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.jnj.com/role/EarningsPerShareDetails">
        <link:definition>2435420 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreas" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas">
        <link:definition>2136109 - Disclosure - Segments of Business and Geographic Areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasTables" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables">
        <link:definition>2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
        <link:definition>2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
        <link:definition>2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
        <link:definition>2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures">
        <link:definition>2141110 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails">
        <link:definition>2443425 - Disclosure - Business Combinations and Divestitures - Schedule of Pro Forma Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.jnj.com/role/LegalProceedings">
        <link:definition>2144111 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.jnj.com/role/LegalProceedingsDetails">
        <link:definition>2445426 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.jnj.com/role/Restructuring">
        <link:definition>2146112 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.jnj.com/role/RestructuringTables">
        <link:definition>2347308 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails">
        <link:definition>2448427 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringReserveDetails" roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails">
        <link:definition>2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InvestmentIncomeInterestPercentToSales" abstract="false" name="InvestmentIncomeInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherNonOperatingIncomeExpensePercentToSales" abstract="false" name="OtherNonOperatingIncomeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" abstract="false" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_NetIncomeAttributableToParentPercentToSales" abstract="false" name="NetIncomeAttributableToParentPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ExcessOfFairValueOverCarryingValueOfDebt" abstract="false" name="ExcessOfFairValueOverCarryingValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InvokanaMember" abstract="true" name="InvokanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GrossProfitPercentToSales" abstract="false" name="GrossProfitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" abstract="true" name="OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NotesDuePeriodFifteenMember" abstract="true" name="NotesDuePeriodFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentImpairmentLoss" abstract="false" name="EquityFairValueAdjustmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterventionalSolutionsMember" abstract="true" name="InterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PaymentsForRestructuringNet" abstract="false" name="PaymentsForRestructuringNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_WoundCareandOtherMember" abstract="true" name="WoundCareandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_MedicalDevicesMember" abstract="true" name="MedicalDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" abstract="false" name="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesByGeographicArea" abstract="false" name="PercentageChangeInSalesByGeographicArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AmountPrepaidAndDueToManufacturers" abstract="false" name="AmountPrepaidAndDueToManufacturers" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ContactLensesMember" abstract="true" name="ContactLensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.375Notesdue2023Member" abstract="true" name="A3.375Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IncomeTaxExpenseBenefitPercentToSales" abstract="false" name="IncomeTaxExpenseBenefitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_CostOfGoodsSoldPercentToSales" abstract="false" name="CostOfGoodsSoldPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" abstract="true" name="CONSUMERHEALTHAndPHARMACEUTICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyEstimateOfAdditionalPossibleLoss" abstract="false" name="LossContingencyEstimateOfAdditionalPossibleLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A1300NotesDue2030Member" abstract="true" name="A1300NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" abstract="false" name="LossContingencyNumberOfClaimsWithinSettlementAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentInProcessPercentToSales" abstract="false" name="ResearchAndDevelopmentInProcessPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OralCareMember" abstract="true" name="OralCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WomensHealthMember" abstract="true" name="WomensHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterestExpensePercentToSales" abstract="false" name="InterestExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyReserveEstablishedWithinTrust" abstract="false" name="LossContingencyReserveEstablishedWithinTrust" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BeautyMember" abstract="true" name="BeautyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_Restructuringchargepercenttosales" abstract="false" name="Restructuringchargepercenttosales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ERLEADAMember" abstract="true" name="ERLEADAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SPINEOTHERMember" abstract="true" name="SPINEOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A0550NotesDue2025Member" abstract="true" name="A0550NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RISPERDALCONSTAMember" abstract="true" name="RISPERDALCONSTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesDomain" abstract="true" name="LitigationSettlementByCompaniesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SurgicalMeshProductsMarketingMember" abstract="true" name="SurgicalMeshProductsMarketingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A6.73Debenturesdue2023Member" abstract="true" name="A6.73Debenturesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesAxis" abstract="true" name="LitigationSettlementByCompaniesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SellingGeneralAndAdministrativeExpensePercentToSales" abstract="false" name="SellingGeneralAndAdministrativeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SalesRevenueGoodsNetPercentToSales" abstract="false" name="SalesRevenueGoodsNetPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_RestructuringandRelatedCostExpectedFutureSavings" abstract="false" name="RestructuringandRelatedCostExpectedFutureSavings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AurisHealthMember" abstract="true" name="AurisHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AssetWriteoffMember" abstract="true" name="AssetWriteoffMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_INVOKANAINVOKAMETMember" abstract="true" name="INVOKANAINVOKAMETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInOperatingIncomeLoss" abstract="false" name="PercentageChangeInOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OpioidMember" abstract="true" name="OpioidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LegalProceedingTextualsAbstract" abstract="true" name="LegalProceedingTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EvraAndDoxilMember" abstract="true" name="EvraAndDoxilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SupplyChainMember" abstract="true" name="SupplyChainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTCMember" abstract="true" name="OTCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BabyCareMember" abstract="true" name="BabyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>jnj-20220403_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:16b74ba9-87ed-4a1d-982b-bd3712a1fa43,g:84010c2d-9ae9-41ea-8d72-e231a49d0ab7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37e7c1db-7b5a-4788-bcb2-3a08fea8459c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8c535653-2499-4766-887f-51f53c83297a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37e7c1db-7b5a-4788-bcb2-3a08fea8459c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8c535653-2499-4766-887f-51f53c83297a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_722b6218-b701-4276-bf2d-bd9d49fcc205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37e7c1db-7b5a-4788-bcb2-3a08fea8459c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_722b6218-b701-4276-bf2d-bd9d49fcc205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7697bd7b-b371-4f9d-b434-800752309602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37e7c1db-7b5a-4788-bcb2-3a08fea8459c" xlink:to="loc_us-gaap_CommonStockValue_7697bd7b-b371-4f9d-b434-800752309602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_20d8b9b8-dbcf-4ed7-8188-80edc6ab83ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37e7c1db-7b5a-4788-bcb2-3a08fea8459c" xlink:to="loc_us-gaap_TreasuryStockValue_20d8b9b8-dbcf-4ed7-8188-80edc6ab83ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9bf52019-4132-4349-b027-ca70a6019000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5c4643e5-87d8-4ae4-978a-d67b1ce8f333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9bf52019-4132-4349-b027-ca70a6019000" xlink:to="loc_us-gaap_Liabilities_5c4643e5-87d8-4ae4-978a-d67b1ce8f333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b1eb442-5f33-4898-9070-7966a99eb6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9bf52019-4132-4349-b027-ca70a6019000" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b1eb442-5f33-4898-9070-7966a99eb6c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bf4fd05c-c95a-4e95-8e0a-4fdb18ecbb82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9bf52019-4132-4349-b027-ca70a6019000" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bf4fd05c-c95a-4e95-8e0a-4fdb18ecbb82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b0762a57-1500-4689-84cc-eb8fcc0d2dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_7e5a5195-41d7-403f-a3f6-2f4725c596f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0762a57-1500-4689-84cc-eb8fcc0d2dd5" xlink:to="loc_us-gaap_ShortTermBorrowings_7e5a5195-41d7-403f-a3f6-2f4725c596f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b072d37a-df35-4b8f-90f3-29c4ba2d2d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0762a57-1500-4689-84cc-eb8fcc0d2dd5" xlink:to="loc_us-gaap_AccountsPayableCurrent_b072d37a-df35-4b8f-90f3-29c4ba2d2d39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_31f6b8ca-c4ee-4704-a942-27e634ea81f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0762a57-1500-4689-84cc-eb8fcc0d2dd5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_31f6b8ca-c4ee-4704-a942-27e634ea81f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_64964a8c-2c1a-4789-a044-50d8351f01ba" xlink:href="jnj-20220403.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0762a57-1500-4689-84cc-eb8fcc0d2dd5" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_64964a8c-2c1a-4789-a044-50d8351f01ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ad361dfc-2d7f-472d-9544-58391acfaa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0762a57-1500-4689-84cc-eb8fcc0d2dd5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ad361dfc-2d7f-472d-9544-58391acfaa1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_c9df98a6-b4d5-471f-a353-662891e85fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0762a57-1500-4689-84cc-eb8fcc0d2dd5" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_c9df98a6-b4d5-471f-a353-662891e85fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9bd54cf8-a2b4-4ef6-b9a0-02a7610e06c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4054a4ff-60ac-4685-97a2-5bc6f5ad2e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bd54cf8-a2b4-4ef6-b9a0-02a7610e06c5" xlink:to="loc_us-gaap_LiabilitiesCurrent_4054a4ff-60ac-4685-97a2-5bc6f5ad2e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcd56cbd-c427-45e6-85aa-11d360f42dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bd54cf8-a2b4-4ef6-b9a0-02a7610e06c5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcd56cbd-c427-45e6-85aa-11d360f42dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d99ffbab-aece-4e0c-927d-48a6198dd93d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bd54cf8-a2b4-4ef6-b9a0-02a7610e06c5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d99ffbab-aece-4e0c-927d-48a6198dd93d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_c461ddd5-4fbc-43c3-86ca-77a41e8b52f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bd54cf8-a2b4-4ef6-b9a0-02a7610e06c5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_c461ddd5-4fbc-43c3-86ca-77a41e8b52f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_a39755a4-4125-4afc-8206-51779afcf4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bd54cf8-a2b4-4ef6-b9a0-02a7610e06c5" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_a39755a4-4125-4afc-8206-51779afcf4c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_10ee53d5-9747-45bd-b1fb-0fa65c46a8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9bd54cf8-a2b4-4ef6-b9a0-02a7610e06c5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_10ee53d5-9747-45bd-b1fb-0fa65c46a8a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_096c9c93-8fc0-4375-b5f1-3e311a63f9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3eb5d8c7-ffe0-47a8-b39d-ecdf5ff66cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_096c9c93-8fc0-4375-b5f1-3e311a63f9e1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3eb5d8c7-ffe0-47a8-b39d-ecdf5ff66cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_fec20b09-fc4f-4fe3-9186-b92b251358d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_096c9c93-8fc0-4375-b5f1-3e311a63f9e1" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_fec20b09-fc4f-4fe3-9186-b92b251358d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ce1616ca-b836-4029-9cce-55b14a867c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_096c9c93-8fc0-4375-b5f1-3e311a63f9e1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ce1616ca-b836-4029-9cce-55b14a867c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_af97581e-3a50-4593-bbcf-fcfa8119e6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_096c9c93-8fc0-4375-b5f1-3e311a63f9e1" xlink:to="loc_us-gaap_InventoryNet_af97581e-3a50-4593-bbcf-fcfa8119e6e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_df6579ce-c6d9-4876-bb50-3e14cd462da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_096c9c93-8fc0-4375-b5f1-3e311a63f9e1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_df6579ce-c6d9-4876-bb50-3e14cd462da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2e27c11b-6b80-4df5-94ca-fc6c8bb43e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2fdcefc3-b085-4de3-85aa-d2610e1d1317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2e27c11b-6b80-4df5-94ca-fc6c8bb43e8f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2fdcefc3-b085-4de3-85aa-d2610e1d1317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6b5e8523-1980-4554-b73e-8d403d2c70c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2e27c11b-6b80-4df5-94ca-fc6c8bb43e8f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6b5e8523-1980-4554-b73e-8d403d2c70c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_977dcc13-63c8-45e5-99e5-2c53410fb235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9561d8b6-0db9-45aa-a167-5f387e7589bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_977dcc13-63c8-45e5-99e5-2c53410fb235" xlink:to="loc_us-gaap_AssetsCurrent_9561d8b6-0db9-45aa-a167-5f387e7589bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5c79b815-713e-416b-a878-dc1ca04eb302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_977dcc13-63c8-45e5-99e5-2c53410fb235" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5c79b815-713e-416b-a878-dc1ca04eb302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_55ad9251-96d5-4948-8e92-62a9fb0e3d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_977dcc13-63c8-45e5-99e5-2c53410fb235" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_55ad9251-96d5-4948-8e92-62a9fb0e3d19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_06b04f1a-149b-4e3d-bbc5-50868188948e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_977dcc13-63c8-45e5-99e5-2c53410fb235" xlink:to="loc_us-gaap_Goodwill_06b04f1a-149b-4e3d-bbc5-50868188948e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_dac413cf-da2c-493d-b438-167ab3c07ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_977dcc13-63c8-45e5-99e5-2c53410fb235" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_dac413cf-da2c-493d-b438-167ab3c07ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_05516796-d176-4fa0-bba9-75e066d9a78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_977dcc13-63c8-45e5-99e5-2c53410fb235" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_05516796-d176-4fa0-bba9-75e066d9a78c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b26d00b4-5092-4228-ab0b-d5c73085aa18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f4d50806-086c-4d5b-a860-eb9f9f785b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b26d00b4-5092-4228-ab0b-d5c73085aa18" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f4d50806-086c-4d5b-a860-eb9f9f785b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8d491223-4a7e-4243-bbc4-277189656347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b26d00b4-5092-4228-ab0b-d5c73085aa18" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8d491223-4a7e-4243-bbc4-277189656347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_698fee93-677f-4373-84cd-63644e7f6297" xlink:href="jnj-20220403.xsd#jnj_GrossProfitPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_c2c9d7a9-216d-4320-b120-a6beb08843ca" xlink:href="jnj-20220403.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_698fee93-677f-4373-84cd-63644e7f6297" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_c2c9d7a9-216d-4320-b120-a6beb08843ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_ef07568e-eab4-4a14-8081-400a2868eb9e" xlink:href="jnj-20220403.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_698fee93-677f-4373-84cd-63644e7f6297" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_ef07568e-eab4-4a14-8081-400a2868eb9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7728e2-912b-4ceb-bd86-01359f01510d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77fa7c94-aed4-4b95-8ed7-a91652ff0d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7728e2-912b-4ceb-bd86-01359f01510d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77fa7c94-aed4-4b95-8ed7-a91652ff0d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b6f8c4c1-ae4e-4ba7-bd8b-d75c42930305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7728e2-912b-4ceb-bd86-01359f01510d" xlink:to="loc_us-gaap_GrossProfit_b6f8c4c1-ae4e-4ba7-bd8b-d75c42930305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8dae8d4d-794b-4f84-a7ac-4628ba8c6bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7728e2-912b-4ceb-bd86-01359f01510d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8dae8d4d-794b-4f84-a7ac-4628ba8c6bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5bd38975-43fe-474a-b57b-9524d3552643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7728e2-912b-4ceb-bd86-01359f01510d" xlink:to="loc_us-gaap_RestructuringCharges_5bd38975-43fe-474a-b57b-9524d3552643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_05b6a864-9dbb-4e5c-95c7-05c1099fea89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7728e2-912b-4ceb-bd86-01359f01510d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_05b6a864-9dbb-4e5c-95c7-05c1099fea89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e74e82d0-b425-4155-aeeb-c7bce26dcf76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7728e2-912b-4ceb-bd86-01359f01510d" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e74e82d0-b425-4155-aeeb-c7bce26dcf76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_60a7347e-0de1-4b3f-8906-f95e5ca55fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7728e2-912b-4ceb-bd86-01359f01510d" xlink:to="loc_us-gaap_InterestExpense_60a7347e-0de1-4b3f-8906-f95e5ca55fed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_51b000a8-ae7c-466b-af9b-e343a2c769a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d7728e2-912b-4ceb-bd86-01359f01510d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_51b000a8-ae7c-466b-af9b-e343a2c769a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_f398703d-decb-46da-a739-a5893ef02ed0" xlink:href="jnj-20220403.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_47f096d3-bf2d-482f-b9b0-8adc21a3dce4" xlink:href="jnj-20220403.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_f398703d-decb-46da-a739-a5893ef02ed0" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_47f096d3-bf2d-482f-b9b0-8adc21a3dce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_88001afe-c773-42f8-885a-21790841fcbb" xlink:href="jnj-20220403.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_f398703d-decb-46da-a739-a5893ef02ed0" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_88001afe-c773-42f8-885a-21790841fcbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c96fe838-4b15-4993-8230-91303606715b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f0c7e76e-34d0-4fe9-a3b1-b2ba5e7a6299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c96fe838-4b15-4993-8230-91303606715b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f0c7e76e-34d0-4fe9-a3b1-b2ba5e7a6299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_43f57813-be5b-4d13-9ab8-b76d2d86431c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c96fe838-4b15-4993-8230-91303606715b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_43f57813-be5b-4d13-9ab8-b76d2d86431c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4144a62d-67bd-4a2e-ac9b-3fe0e5cb3659" xlink:href="jnj-20220403.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_378ce04b-4bad-4faa-9620-fa461b3a3f0f" xlink:href="jnj-20220403.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4144a62d-67bd-4a2e-ac9b-3fe0e5cb3659" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_378ce04b-4bad-4faa-9620-fa461b3a3f0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_251ad0cf-d657-4803-92be-0f309139e257" xlink:href="jnj-20220403.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4144a62d-67bd-4a2e-ac9b-3fe0e5cb3659" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_251ad0cf-d657-4803-92be-0f309139e257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_83b9543f-13a4-4b98-aeb3-105b19ebb716" xlink:href="jnj-20220403.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4144a62d-67bd-4a2e-ac9b-3fe0e5cb3659" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_83b9543f-13a4-4b98-aeb3-105b19ebb716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_d720f3f6-432a-4886-84e9-4a952445091b" xlink:href="jnj-20220403.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4144a62d-67bd-4a2e-ac9b-3fe0e5cb3659" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_d720f3f6-432a-4886-84e9-4a952445091b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_959c76c2-a6c6-4cd9-8ac6-403bf259fde6" xlink:href="jnj-20220403.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4144a62d-67bd-4a2e-ac9b-3fe0e5cb3659" xlink:to="loc_jnj_Restructuringchargepercenttosales_959c76c2-a6c6-4cd9-8ac6-403bf259fde6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_132773c2-0fdf-4402-ac7e-c7b6ab488fdc" xlink:href="jnj-20220403.xsd#jnj_InterestExpensePercentToSales"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4144a62d-67bd-4a2e-ac9b-3fe0e5cb3659" xlink:to="loc_jnj_InterestExpensePercentToSales_132773c2-0fdf-4402-ac7e-c7b6ab488fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_e8b1f70d-1c83-40ba-aebe-3d0a73f601a8" xlink:href="jnj-20220403.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4144a62d-67bd-4a2e-ac9b-3fe0e5cb3659" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_e8b1f70d-1c83-40ba-aebe-3d0a73f601a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_5527933c-8eac-4076-b062-26d7e1a451d9" xlink:href="jnj-20220403.xsd#jnj_GrossProfitPercentToSales"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4144a62d-67bd-4a2e-ac9b-3fe0e5cb3659" xlink:to="loc_jnj_GrossProfitPercentToSales_5527933c-8eac-4076-b062-26d7e1a451d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_83752d9f-958e-4cf8-89f4-f5c259bcec23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_7eff1635-6e75-4d39-857d-38aa7313efe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_83752d9f-958e-4cf8-89f4-f5c259bcec23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_7eff1635-6e75-4d39-857d-38aa7313efe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2ca69d6e-afd0-425b-ab93-f4ab4bb6ab85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_83752d9f-958e-4cf8-89f4-f5c259bcec23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2ca69d6e-afd0-425b-ab93-f4ab4bb6ab85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_cf2f0ce8-34dc-4438-b56a-a7ce12cb022b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c5b06f0d-a738-49e8-98a3-d2259c850935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_cf2f0ce8-34dc-4438-b56a-a7ce12cb022b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c5b06f0d-a738-49e8-98a3-d2259c850935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6ec9f20b-6094-4e10-b427-4aa2a0909b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_cf2f0ce8-34dc-4438-b56a-a7ce12cb022b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6ec9f20b-6094-4e10-b427-4aa2a0909b27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d6d2988c-a362-4348-a018-53ea959a5e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_9fbf65a5-9020-4447-83dc-55fb1da4446f" xlink:href="jnj-20220403.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d6d2988c-a362-4348-a018-53ea959a5e4f" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_9fbf65a5-9020-4447-83dc-55fb1da4446f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_c01ac097-a864-46a2-8aa0-e3d81ff27831" xlink:href="jnj-20220403.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d6d2988c-a362-4348-a018-53ea959a5e4f" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_c01ac097-a864-46a2-8aa0-e3d81ff27831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_aec3c089-bf40-4177-852f-b512a1d27175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d9e1bb72-ef04-4f56-9cb0-9b48cf1b7a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_aec3c089-bf40-4177-852f-b512a1d27175" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d9e1bb72-ef04-4f56-9cb0-9b48cf1b7a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f2d1030-c88b-402a-b84f-aca0b98ee4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_aec3c089-bf40-4177-852f-b512a1d27175" xlink:to="loc_us-gaap_NetIncomeLoss_7f2d1030-c88b-402a-b84f-aca0b98ee4b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_05e37ce4-ec7f-41a7-bd9c-4584640e18e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_af88d8c4-669e-4859-a301-f3e8f437ed06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_05e37ce4-ec7f-41a7-bd9c-4584640e18e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_af88d8c4-669e-4859-a301-f3e8f437ed06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6019070d-125f-4798-b52b-0bcd822700f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_05e37ce4-ec7f-41a7-bd9c-4584640e18e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6019070d-125f-4798-b52b-0bcd822700f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_bc88d830-3f22-472c-bf4a-a46ac0921d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_05e37ce4-ec7f-41a7-bd9c-4584640e18e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_bc88d830-3f22-472c-bf4a-a46ac0921d73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a45e35bd-8138-48c0-a502-42979fe8910f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_05e37ce4-ec7f-41a7-bd9c-4584640e18e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a45e35bd-8138-48c0-a502-42979fe8910f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b23e6f1-7667-4e82-84d0-dde553f2a2be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_68d8c98a-6d0b-41fe-998a-aa15fdc3e531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b23e6f1-7667-4e82-84d0-dde553f2a2be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_68d8c98a-6d0b-41fe-998a-aa15fdc3e531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_507c22a4-ed55-456d-88d8-6c0f02e82f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b23e6f1-7667-4e82-84d0-dde553f2a2be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_507c22a4-ed55-456d-88d8-6c0f02e82f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e6d4528-a0f7-4b45-8427-223bf6078d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b23e6f1-7667-4e82-84d0-dde553f2a2be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e6d4528-a0f7-4b45-8427-223bf6078d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc057562-9104-4739-aff6-ff16d9edffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b23e6f1-7667-4e82-84d0-dde553f2a2be" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc057562-9104-4739-aff6-ff16d9edffdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1083e9f-2c8b-4666-bca7-48d2a8a1a87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_178bdbfc-c32e-4840-b170-83e250295282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1083e9f-2c8b-4666-bca7-48d2a8a1a87e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_178bdbfc-c32e-4840-b170-83e250295282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b09b5894-15f2-4108-9495-aa7bd239e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1083e9f-2c8b-4666-bca7-48d2a8a1a87e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b09b5894-15f2-4108-9495-aa7bd239e13c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_13909175-00c4-4568-b43e-bd320df6332d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1083e9f-2c8b-4666-bca7-48d2a8a1a87e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_13909175-00c4-4568-b43e-bd320df6332d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0aa3fe56-28a0-4c75-bd20-a16662ec6f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1083e9f-2c8b-4666-bca7-48d2a8a1a87e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0aa3fe56-28a0-4c75-bd20-a16662ec6f02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_67fb48d6-d276-4a36-9f79-1893f62a5cfd" xlink:href="jnj-20220403.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1083e9f-2c8b-4666-bca7-48d2a8a1a87e" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_67fb48d6-d276-4a36-9f79-1893f62a5cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1cd5803e-3fe6-472d-8879-dedbad661f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1083e9f-2c8b-4666-bca7-48d2a8a1a87e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1cd5803e-3fe6-472d-8879-dedbad661f67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_83af0760-a0c3-46bb-a461-c7753f3ad300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1083e9f-2c8b-4666-bca7-48d2a8a1a87e" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_83af0760-a0c3-46bb-a461-c7753f3ad300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_6d513334-910f-42aa-95d7-b1c8855a12a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_a5b79276-0fa2-4537-9a4f-8ee05c5c6f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_6d513334-910f-42aa-95d7-b1c8855a12a5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_a5b79276-0fa2-4537-9a4f-8ee05c5c6f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_802b5baf-25f0-4193-a61e-04042831f6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_6d513334-910f-42aa-95d7-b1c8855a12a5" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_802b5baf-25f0-4193-a61e-04042831f6fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_e2226231-5240-4a91-b118-d049b61dc98c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_e2226231-5240-4a91-b118-d049b61dc98c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d8672a42-19f6-4147-b47d-a4f3a654d618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d8672a42-19f6-4147-b47d-a4f3a654d618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_b16a75a3-6545-454f-bcdd-103abb3d71b7" xlink:href="jnj-20220403.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_b16a75a3-6545-454f-bcdd-103abb3d71b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_30e206f3-fe56-4643-910a-acb216fc7e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_30e206f3-fe56-4643-910a-acb216fc7e0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_e4c992cb-a389-4dc6-9506-ed3ddd31d5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_e4c992cb-a389-4dc6-9506-ed3ddd31d5ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f442221e-6848-4d76-9087-77ba94c0010b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f442221e-6848-4d76-9087-77ba94c0010b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_e1b1c2cc-16fa-476c-8039-346be137dd22" xlink:href="jnj-20220403.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_e1b1c2cc-16fa-476c-8039-346be137dd22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3abb9325-c1cb-48be-ae59-c464ae01d961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3abb9325-c1cb-48be-ae59-c464ae01d961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_162d0f86-01bb-4346-9b3f-42a4ab1a624d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_400554c7-2fec-4278-abf6-280ef894f11c" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_162d0f86-01bb-4346-9b3f-42a4ab1a624d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fed8c2b1-97e1-4fce-a1c8-0d7c850a74eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_NetIncomeLoss_fed8c2b1-97e1-4fce-a1c8-0d7c850a74eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9c77b356-98d6-4f5c-980d-57e2122de4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9c77b356-98d6-4f5c-980d-57e2122de4aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4d4227fa-bc36-4e7d-9721-e55a8e9b1a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_ShareBasedCompensation_4d4227fa-bc36-4e7d-9721-e55a8e9b1a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_418a7072-f4db-413a-8756-6a5981ee59dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_AssetImpairmentCharges_418a7072-f4db-413a-8756-6a5981ee59dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_d4bf5273-77ae-44dd-877b-cfed0d3a10cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_d4bf5273-77ae-44dd-877b-cfed0d3a10cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_34b13a03-ff78-409c-bc0e-f711c23d45b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_34b13a03-ff78-409c-bc0e-f711c23d45b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_aaaa932d-d86d-490d-b4b1-e59acdfb9a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_aaaa932d-d86d-490d-b4b1-e59acdfb9a8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6d3ac3d8-9eeb-4fc3-9d2e-ae1f99a2cfce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6d3ac3d8-9eeb-4fc3-9d2e-ae1f99a2cfce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_39892a15-97e6-47b8-af8c-595e6550b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_39892a15-97e6-47b8-af8c-595e6550b5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_327b276b-1268-4f0d-a0e6-9687f63c6826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_327b276b-1268-4f0d-a0e6-9687f63c6826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cf63f9e6-ff60-421a-9d32-5e490cb55225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cf63f9e6-ff60-421a-9d32-5e490cb55225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f76f3f8c-0a15-403b-94f8-66ac9ed861bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e52e0298-bc5c-43d0-ad38-7647be36fb8e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f76f3f8c-0a15-403b-94f8-66ac9ed861bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_00bdfd71-4e25-493c-9f4a-80b151233053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_e1b16cbc-f4e8-46aa-be69-b621b1b10bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_00bdfd71-4e25-493c-9f4a-80b151233053" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_e1b16cbc-f4e8-46aa-be69-b621b1b10bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_36228929-a5b1-409e-aa2b-83a82791c835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_00bdfd71-4e25-493c-9f4a-80b151233053" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_36228929-a5b1-409e-aa2b-83a82791c835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_95ba062f-97b3-4695-a787-7dbc13a51b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_00bdfd71-4e25-493c-9f4a-80b151233053" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_95ba062f-97b3-4695-a787-7dbc13a51b38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f4639fbf-b529-4c8f-a3fe-228926d39c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a5d72eb7-a5b3-40df-9d4a-bcaf870072b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f4639fbf-b529-4c8f-a3fe-228926d39c07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a5d72eb7-a5b3-40df-9d4a-bcaf870072b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f426a337-6b50-4774-aea2-f7d22b33f5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f4639fbf-b529-4c8f-a3fe-228926d39c07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f426a337-6b50-4774-aea2-f7d22b33f5dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_df7acd67-14f2-4971-bb11-1a1715f3df59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_a7926871-3a44-48d9-88b2-93349a53c1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_df7acd67-14f2-4971-bb11-1a1715f3df59" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_a7926871-3a44-48d9-88b2-93349a53c1ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_e6a71cc1-3095-4392-89c5-95163ff133a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_df7acd67-14f2-4971-bb11-1a1715f3df59" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_e6a71cc1-3095-4392-89c5-95163ff133a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_9e2de3e9-7d9b-4a10-98ea-54a3cebd1b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bbecc5e2-a7a0-4abf-a3ee-686600a1fe45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_9e2de3e9-7d9b-4a10-98ea-54a3cebd1b1e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bbecc5e2-a7a0-4abf-a3ee-686600a1fe45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_85259c66-0264-46ea-91f2-0af201f5d8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_9e2de3e9-7d9b-4a10-98ea-54a3cebd1b1e" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_85259c66-0264-46ea-91f2-0af201f5d8d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dfdba4b8-bd50-4ed4-8ac5-bed046b5b4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa61cf92-7029-4264-8d9b-2dc97bae2d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dfdba4b8-bd50-4ed4-8ac5-bed046b5b4f2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa61cf92-7029-4264-8d9b-2dc97bae2d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_baf78b36-96bc-4dd2-bcac-c6f66a6d68ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dfdba4b8-bd50-4ed4-8ac5-bed046b5b4f2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_baf78b36-96bc-4dd2-bcac-c6f66a6d68ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_c02fe10d-352c-4c72-a19e-2c211e5e13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_6746f40e-3502-4c5b-9a66-6daa63f2a506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_c02fe10d-352c-4c72-a19e-2c211e5e13d4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_6746f40e-3502-4c5b-9a66-6daa63f2a506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a22c1095-09fd-4581-aa2c-76d78202fc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_c02fe10d-352c-4c72-a19e-2c211e5e13d4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a22c1095-09fd-4581-aa2c-76d78202fc6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_0c7ae3ea-9731-4cb5-8402-5cbf1a2dc6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_36e34cd0-8530-4d59-ac42-8d6370c13ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_0c7ae3ea-9731-4cb5-8402-5cbf1a2dc6cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_36e34cd0-8530-4d59-ac42-8d6370c13ed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b451bbd5-ff69-4038-9e4a-7a8a2b6992d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_0c7ae3ea-9731-4cb5-8402-5cbf1a2dc6cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b451bbd5-ff69-4038-9e4a-7a8a2b6992d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_44c41b5f-5459-455a-a752-4ef28d057f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_0c7ae3ea-9731-4cb5-8402-5cbf1a2dc6cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_44c41b5f-5459-455a-a752-4ef28d057f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_532cf7dc-afc7-4010-8f72-aa127120f6be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_68ffa9f9-4b18-443d-8b40-b4f78f99bfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_532cf7dc-afc7-4010-8f72-aa127120f6be" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_68ffa9f9-4b18-443d-8b40-b4f78f99bfc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0d85527f-7d97-42ca-8686-5cdb25377b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_532cf7dc-afc7-4010-8f72-aa127120f6be" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0d85527f-7d97-42ca-8686-5cdb25377b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_73a011c2-84a4-4252-a3cc-02a02d14bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_532cf7dc-afc7-4010-8f72-aa127120f6be" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_73a011c2-84a4-4252-a3cc-02a02d14bb3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e3f5efda-b5f5-4a1f-8db1-070dd295f74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_ffa1814a-6dcd-4a43-be50-f948767fc0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e3f5efda-b5f5-4a1f-8db1-070dd295f74d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_ffa1814a-6dcd-4a43-be50-f948767fc0fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_87aa8ee2-d8a1-4364-9068-f80ecbfe4a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e3f5efda-b5f5-4a1f-8db1-070dd295f74d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_87aa8ee2-d8a1-4364-9068-f80ecbfe4a56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_36e2b43e-a9ed-4f31-b6bf-06fba03ef406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e3f5efda-b5f5-4a1f-8db1-070dd295f74d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_36e2b43e-a9ed-4f31-b6bf-06fba03ef406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_23a59659-4a8b-4161-851b-5512d260f90a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e3f5efda-b5f5-4a1f-8db1-070dd295f74d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_23a59659-4a8b-4161-851b-5512d260f90a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_4ac66996-def4-4ed3-a76a-103fc56a10bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e3f5efda-b5f5-4a1f-8db1-070dd295f74d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_4ac66996-def4-4ed3-a76a-103fc56a10bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_cde14c52-54bb-464c-bb22-fbac8b014e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e3f5efda-b5f5-4a1f-8db1-070dd295f74d" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_cde14c52-54bb-464c-bb22-fbac8b014e62" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_60aa4b85-7e86-4d86-8e06-35a1c6ad8166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_83224082-f73e-438d-98ee-0c517caf7a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_60aa4b85-7e86-4d86-8e06-35a1c6ad8166" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_83224082-f73e-438d-98ee-0c517caf7a5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9db848ec-c6af-41be-8df4-e887012e0f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_60aa4b85-7e86-4d86-8e06-35a1c6ad8166" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9db848ec-c6af-41be-8df4-e887012e0f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_60ba6cde-7827-4255-a58a-1b5c3fcd7f13" xlink:href="jnj-20220403.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_60aa4b85-7e86-4d86-8e06-35a1c6ad8166" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_60ba6cde-7827-4255-a58a-1b5c3fcd7f13" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>jnj-20220403_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:16b74ba9-87ed-4a1d-982b-bd3712a1fa43,g:84010c2d-9ae9-41ea-8d72-e231a49d0ab7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20220403.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended" id="ib3f8249669ce4468aa82fa3292b3818b_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cc7fb2fa-0c42-4d99-a69d-b3ac063d6aa1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentType_cc7fb2fa-0c42-4d99-a69d-b3ac063d6aa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1a8fd566-5275-4cc5-b58f-1a03bc9f9243" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentQuarterlyReport_1a8fd566-5275-4cc5-b58f-1a03bc9f9243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d45b6994-48a3-4f7a-b33f-1a296f0f7f68" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentPeriodEndDate_d45b6994-48a3-4f7a-b33f-1a296f0f7f68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0d219af0-6769-4072-9aa5-0ae143ea3221" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentTransitionReport_0d219af0-6769-4072-9aa5-0ae143ea3221" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_acefd08e-18c9-4ef2-9d7c-c8d259331b55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityFileNumber_acefd08e-18c9-4ef2-9d7c-c8d259331b55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_74b7897a-2d2c-41cd-a01d-f1f4fcb751f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityRegistrantName_74b7897a-2d2c-41cd-a01d-f1f4fcb751f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7fc081ed-1330-4dd7-9201-720906788513" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7fc081ed-1330-4dd7-9201-720906788513" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_32a361c8-eaf7-4471-928d-0aa3b616d492" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityTaxIdentificationNumber_32a361c8-eaf7-4471-928d-0aa3b616d492" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6244456a-da3e-4a3a-ad30-344254d3cb38" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityAddressAddressLine1_6244456a-da3e-4a3a-ad30-344254d3cb38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a1f5605f-5617-413a-8a9b-2d97ab36053e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityAddressCityOrTown_a1f5605f-5617-413a-8a9b-2d97ab36053e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2ae3a606-c54d-4983-8515-25ced9ba37b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityAddressStateOrProvince_2ae3a606-c54d-4983-8515-25ced9ba37b3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_431592ea-ae1f-4119-b205-d12fba6c767b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityAddressPostalZipCode_431592ea-ae1f-4119-b205-d12fba6c767b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_298b5765-a141-42de-bd13-0152605e2287" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_CityAreaCode_298b5765-a141-42de-bd13-0152605e2287" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_155160c6-29b4-42ce-a72f-1f4b3bda5f06" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_LocalPhoneNumber_155160c6-29b4-42ce-a72f-1f4b3bda5f06" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1a211c8e-fe14-436f-9f53-a660cf4fd73f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityCurrentReportingStatus_1a211c8e-fe14-436f-9f53-a660cf4fd73f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_abea8c09-7d75-47f0-af7d-a00b2ef18d00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityInteractiveDataCurrent_abea8c09-7d75-47f0-af7d-a00b2ef18d00" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cb9a2974-176a-4c6f-a221-2bd08c25c032" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityFilerCategory_cb9a2974-176a-4c6f-a221-2bd08c25c032" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c1b217c2-0483-462c-8b71-4c492d4274f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntitySmallBusiness_c1b217c2-0483-462c-8b71-4c492d4274f6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_33e990c0-eb4c-4c24-b811-c7570ecf81a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityEmergingGrowthCompany_33e990c0-eb4c-4c24-b811-c7570ecf81a4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4e20a3c0-424b-4a3b-9d43-c008b3ce3140" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityShellCompany_4e20a3c0-424b-4a3b-9d43-c008b3ce3140" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8fc55980-51d2-4d44-8bdf-9101765269b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_Security12bTitle_8fc55980-51d2-4d44-8bdf-9101765269b8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_31910e87-5b72-4e40-8a0b-ca2e66553814" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_TradingSymbol_31910e87-5b72-4e40-8a0b-ca2e66553814" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8b12d685-e258-40f7-a4ad-3ac6e62326f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_SecurityExchangeName_8b12d685-e258-40f7-a4ad-3ac6e62326f7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3dcc0ee4-eeac-4f18-a596-ba4a509fe276" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3dcc0ee4-eeac-4f18-a596-ba4a509fe276" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_59534dfa-1bde-4e64-be88-5b10d5b7597f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityCentralIndexKey_59534dfa-1bde-4e64-be88-5b10d5b7597f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9c537066-cbff-4b43-8c6c-86deb20c058a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_CurrentFiscalYearEndDate_9c537066-cbff-4b43-8c6c-86deb20c058a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_30eeb518-15f9-46db-a842-03bdfc56ec6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentFiscalYearFocus_30eeb518-15f9-46db-a842-03bdfc56ec6c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ac04b4e4-8bef-4c3c-bfdb-ff08c2f374a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ac04b4e4-8bef-4c3c-bfdb-ff08c2f374a9" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_67ca3915-20a3-4b22-a944-7ed208704eba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_AmendmentFlag_67ca3915-20a3-4b22-a944-7ed208704eba" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_6f2b9c23-cfb3-4fff-8032-6a31dfb2841d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntitiesTable_6f2b9c23-cfb3-4fff-8032-6a31dfb2841d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50341a03-ca7c-442e-ba3b-cf33f570874f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_6f2b9c23-cfb3-4fff-8032-6a31dfb2841d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50341a03-ca7c-442e-ba3b-cf33f570874f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_50341a03-ca7c-442e-ba3b-cf33f570874f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50341a03-ca7c-442e-ba3b-cf33f570874f" xlink:to="loc_us-gaap_ClassOfStockDomain_50341a03-ca7c-442e-ba3b-cf33f570874f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50341a03-ca7c-442e-ba3b-cf33f570874f" xlink:to="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5c94b758-8e06-4832-9bab-c89a5e0f2c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_us-gaap_CommonStockMember_5c94b758-8e06-4832-9bab-c89a5e0f2c9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_40b88db0-341d-4a29-ae14-dd126b23fdfc" xlink:href="jnj-20220403.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_jnj_A0.650NotesDue2024Member_40b88db0-341d-4a29-ae14-dd126b23fdfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_f22db868-9b4f-44ae-99db-4f6edd63d515" xlink:href="jnj-20220403.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_jnj_A5.50NotesDue2024Member_f22db868-9b4f-44ae-99db-4f6edd63d515" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_fcf195d2-77aa-4090-8982-d3f82748c75b" xlink:href="jnj-20220403.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_jnj_A1.150NotesDue2028Member_fcf195d2-77aa-4090-8982-d3f82748c75b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_68a14f87-e55f-4d01-b86e-20896bbea68c" xlink:href="jnj-20220403.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_jnj_A1.650NotesDue2035Member_68a14f87-e55f-4d01-b86e-20896bbea68c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i01023d0d53554652afd0338eccd8e71a_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_012871b7-c727-410f-8f33-1492d4f0e6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_012871b7-c727-410f-8f33-1492d4f0e6df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a4e773b-66f1-4891-9d3c-af6058f24c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_NetIncomeLoss_6a4e773b-66f1-4891-9d3c-af6058f24c73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_9aff432e-6b7b-4c3c-9ba3-6f912edbb87c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_DividendsCommonStockCash_9aff432e-6b7b-4c3c-9ba3-6f912edbb87c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_cb9dc10c-3e87-4f1c-b894-2daa581bafb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_cb9dc10c-3e87-4f1c-b894-2daa581bafb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c9def021-431b-4915-adaa-22da45f980e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c9def021-431b-4915-adaa-22da45f980e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5f9db8d7-4576-4c59-a59a-8d359309be62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5f9db8d7-4576-4c59-a59a-8d359309be62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_be022401-9705-41ba-9d58-3445afa0ab64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2a7f7dc3-3f10-4ffa-b7cf-46b282d1c90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_StatementTable_2a7f7dc3-3f10-4ffa-b7cf-46b282d1c90d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7d2cc9f5-d137-46f9-8233-c7295ee01b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2a7f7dc3-3f10-4ffa-b7cf-46b282d1c90d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7d2cc9f5-d137-46f9-8233-c7295ee01b74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d2cc9f5-d137-46f9-8233-c7295ee01b74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d2cc9f5-d137-46f9-8233-c7295ee01b74" xlink:to="loc_us-gaap_EquityComponentDomain_7d2cc9f5-d137-46f9-8233-c7295ee01b74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d2cc9f5-d137-46f9-8233-c7295ee01b74" xlink:to="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_04442965-79c2-43ff-9538-fd42b77b1204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:to="loc_us-gaap_RetainedEarningsMember_04442965-79c2-43ff-9538-fd42b77b1204" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8e70132e-26c0-4211-842c-38d7dd6f5996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8e70132e-26c0-4211-842c-38d7dd6f5996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4ed15d70-92dd-4cf6-bc6b-dcaf44d1d4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:to="loc_us-gaap_CommonStockMember_4ed15d70-92dd-4cf6-bc6b-dcaf44d1d4b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_1b7b8c35-3a61-44c5-a016-48fff3559f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:to="loc_us-gaap_TreasuryStockMember_1b7b8c35-3a61-44c5-a016-48fff3559f32" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i6e1b3bb465334512a915975cbafb56ce_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1162af6d-09d9-4f05-a818-9fb683e0870b" xlink:href="jnj-20220403.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_30dbe849-6085-4a61-8309-a477f7bfd38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1162af6d-09d9-4f05-a818-9fb683e0870b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_30dbe849-6085-4a61-8309-a477f7bfd38f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_30dbe849-6085-4a61-8309-a477f7bfd38f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0cf85c2d-9a35-49b4-b5d3-8a62ff52ed9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0cf85c2d-9a35-49b4-b5d3-8a62ff52ed9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b9e99743-1363-42fb-8a65-d62ce8f9c805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b9e99743-1363-42fb-8a65-d62ce8f9c805" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0efd69f6-114e-45d2-891a-a477549fb2de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0efd69f6-114e-45d2-891a-a477549fb2de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_96f4c962-d0a6-4062-bcbd-6ad036f2a234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_30dbe849-6085-4a61-8309-a477f7bfd38f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_96f4c962-d0a6-4062-bcbd-6ad036f2a234" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1e4a34a0-bd1c-4cc6-b188-05651021b88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_96f4c962-d0a6-4062-bcbd-6ad036f2a234" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1e4a34a0-bd1c-4cc6-b188-05651021b88a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f2eca44-29c4-48fb-aee2-7e4cab0e9334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_96f4c962-d0a6-4062-bcbd-6ad036f2a234" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f2eca44-29c4-48fb-aee2-7e4cab0e9334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0f499cdf-b771-4cf2-95a4-8d370c18b8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1162af6d-09d9-4f05-a818-9fb683e0870b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0f499cdf-b771-4cf2-95a4-8d370c18b8ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:href="jnj-20220403.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1162af6d-09d9-4f05-a818-9fb683e0870b" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bdfff477-fece-42da-8a9c-9cc24a7607d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bdfff477-fece-42da-8a9c-9cc24a7607d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bdfff477-fece-42da-8a9c-9cc24a7607d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bdfff477-fece-42da-8a9c-9cc24a7607d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bdfff477-fece-42da-8a9c-9cc24a7607d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bdfff477-fece-42da-8a9c-9cc24a7607d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_5f4eea05-65fd-41be-8804-04b26144da1f" xlink:href="jnj-20220403.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:to="loc_jnj_PatentsAndTrademarksMember_5f4eea05-65fd-41be-8804-04b26144da1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_86bf1757-d283-4208-8646-2b8ee9714314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_86bf1757-d283-4208-8646-2b8ee9714314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_50ceda55-9d42-4c5a-8e93-f2594ecd8404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_50ceda55-9d42-4c5a-8e93-f2594ecd8404" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1820d6ce-9550-4b21-ad13-c35174db6790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1820d6ce-9550-4b21-ad13-c35174db6790" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1820d6ce-9550-4b21-ad13-c35174db6790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1820d6ce-9550-4b21-ad13-c35174db6790" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1820d6ce-9550-4b21-ad13-c35174db6790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce45cf8a-f08b-498b-b3dd-64990c7c7155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1820d6ce-9550-4b21-ad13-c35174db6790" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce45cf8a-f08b-498b-b3dd-64990c7c7155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_4ec341bb-1996-47d7-92b3-364e13c7bb58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce45cf8a-f08b-498b-b3dd-64990c7c7155" xlink:to="loc_us-gaap_TrademarksMember_4ec341bb-1996-47d7-92b3-364e13c7bb58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_36896eb1-f051-41df-b989-fddd27335aeb" xlink:href="jnj-20220403.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce45cf8a-f08b-498b-b3dd-64990c7c7155" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_36896eb1-f051-41df-b989-fddd27335aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_25916f09-a3a2-4620-8b64-b0a7107d56ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_25916f09-a3a2-4620-8b64-b0a7107d56ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25916f09-a3a2-4620-8b64-b0a7107d56ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25916f09-a3a2-4620-8b64-b0a7107d56ea" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25916f09-a3a2-4620-8b64-b0a7107d56ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9104d9fe-4df5-4819-8f5c-f095f909fe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25916f09-a3a2-4620-8b64-b0a7107d56ea" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9104d9fe-4df5-4819-8f5c-f095f909fe1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_2c5c383e-8bca-4367-8e2d-31dfb42e2fef" xlink:href="jnj-20220403.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9104d9fe-4df5-4819-8f5c-f095f909fe1c" xlink:to="loc_jnj_BermekimabMember_2c5c383e-8bca-4367-8e2d-31dfb42e2fef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended" id="id5bc1cc058c541b49e60c0d736e53657_IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_b452167d-91e8-4a5a-ab90-ee1498c206d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_b452167d-91e8-4a5a-ab90-ee1498c206d8" xlink:to="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0b834e5a-a26b-4aaf-8207-b3d486fc6f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:to="loc_us-gaap_Goodwill_0b834e5a-a26b-4aaf-8207-b3d486fc6f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_89d527e0-7e39-4e67-9d89-a4dbbacd4b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_89d527e0-7e39-4e67-9d89-a4dbbacd4b0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_47bcc51b-1c86-42f4-a851-33e348d07831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_47bcc51b-1c86-42f4-a851-33e348d07831" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_07c5b471-6fd3-42ec-a9c8-f84755b2b6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_20b59908-6375-41f4-8c9f-91e65cd5f7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_b452167d-91e8-4a5a-ab90-ee1498c206d8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_20b59908-6375-41f4-8c9f-91e65cd5f7d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d3509c32-cd86-4b84-968f-289ddec0c730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_20b59908-6375-41f4-8c9f-91e65cd5f7d9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d3509c32-cd86-4b84-968f-289ddec0c730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d3509c32-cd86-4b84-968f-289ddec0c730_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d3509c32-cd86-4b84-968f-289ddec0c730" xlink:to="loc_us-gaap_SegmentDomain_d3509c32-cd86-4b84-968f-289ddec0c730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d3509c32-cd86-4b84-968f-289ddec0c730" xlink:to="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_5c83150c-7479-4658-b7c6-3fe64a3aa279" xlink:href="jnj-20220403.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:to="loc_jnj_ConsumerMember_5c83150c-7479-4658-b7c6-3fe64a3aa279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_ffa95ed9-a430-4fee-b399-959d0b568fb4" xlink:href="jnj-20220403.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:to="loc_jnj_PharmaceuticalMember_ffa95ed9-a430-4fee-b399-959d0b568fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_41fa1365-8413-4864-a9ec-94b2d6e45fbc" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:to="loc_jnj_MedicalDevicesMember_41fa1365-8413-4864-a9ec-94b2d6e45fbc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="i02f2710f7b034e5f8d136cf2e64c5bc8_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6128d685-62d0-49cd-9c4f-8b35abaa2543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2b36a665-bc19-4670-86b4-fd0e1ed22f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6128d685-62d0-49cd-9c4f-8b35abaa2543" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2b36a665-bc19-4670-86b4-fd0e1ed22f19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f6d0d551-a85d-47ca-b6d4-dac355eab056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6128d685-62d0-49cd-9c4f-8b35abaa2543" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f6d0d551-a85d-47ca-b6d4-dac355eab056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9fcbfe47-a21b-49be-bf09-348726fe0604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6128d685-62d0-49cd-9c4f-8b35abaa2543" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9fcbfe47-a21b-49be-bf09-348726fe0604" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_06edd12b-b29d-4a1b-b0a9-4da7bc585a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9fcbfe47-a21b-49be-bf09-348726fe0604" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_06edd12b-b29d-4a1b-b0a9-4da7bc585a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_06edd12b-b29d-4a1b-b0a9-4da7bc585a89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_06edd12b-b29d-4a1b-b0a9-4da7bc585a89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_06edd12b-b29d-4a1b-b0a9-4da7bc585a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c097cbdc-182b-4bc3-9f36-21c3d5dd0b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_06edd12b-b29d-4a1b-b0a9-4da7bc585a89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c097cbdc-182b-4bc3-9f36-21c3d5dd0b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_2ec4983e-ef5b-461d-a109-d8ef034867be" xlink:href="jnj-20220403.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c097cbdc-182b-4bc3-9f36-21c3d5dd0b16" xlink:to="loc_jnj_PatentsAndTrademarksMember_2ec4983e-ef5b-461d-a109-d8ef034867be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_72f5c172-f375-4967-b34f-284bfbef1c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c097cbdc-182b-4bc3-9f36-21c3d5dd0b16" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_72f5c172-f375-4967-b34f-284bfbef1c2f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="ife83864c9d2842d4a134de87e5e5380d_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_175a2eb2-fa1d-4cd4-9965-93c0fa51a63c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_175a2eb2-fa1d-4cd4-9965-93c0fa51a63c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_604caf74-647d-40b8-b477-d75a1a164297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_604caf74-647d-40b8-b477-d75a1a164297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_98235439-bd3f-4548-95ce-2e8383ebe7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_98235439-bd3f-4548-95ce-2e8383ebe7c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_9562ab58-99ae-4df7-827f-90e1a17da6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_9562ab58-99ae-4df7-827f-90e1a17da6bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_61239d54-5993-4dbe-bed7-bd698cc417c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_61239d54-5993-4dbe-bed7-bd698cc417c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_d5bf9f52-18f2-484c-b5c4-466ed2143c61" xlink:href="jnj-20220403.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_d5bf9f52-18f2-484c-b5c4-466ed2143c61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_a545459b-a5cd-4ff2-a293-260a761c2133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_EquityFairValueAdjustment_a545459b-a5cd-4ff2-a293-260a761c2133" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_537c0f1d-190c-4e9a-990e-654428e7ef69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_537c0f1d-190c-4e9a-990e-654428e7ef69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_605eef7c-00f6-4758-a767-bdb98cc71908" xlink:href="jnj-20220403.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_605eef7c-00f6-4758-a767-bdb98cc71908" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_f003cee6-a8de-4a57-b03e-7609c06f0d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_ShortTermBorrowings_f003cee6-a8de-4a57-b03e-7609c06f0d2c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_6b9ea8d6-edef-4f15-ac00-f8ac53cb2e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_6b9ea8d6-edef-4f15-ac00-f8ac53cb2e07" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_59d6c4fa-cb58-43a9-884c-052d74f90423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_DebtInstrumentTerm_59d6c4fa-cb58-43a9-884c-052d74f90423" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_ab0c6476-6076-48ce-bcc1-34a0be994a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_ab0c6476-6076-48ce-bcc1-34a0be994a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_ab0c6476-6076-48ce-bcc1-34a0be994a51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_ab0c6476-6076-48ce-bcc1-34a0be994a51" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_ab0c6476-6076-48ce-bcc1-34a0be994a51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_ade3555a-d297-4842-b9e5-998bf3b7e802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_ab0c6476-6076-48ce-bcc1-34a0be994a51" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_ade3555a-d297-4842-b9e5-998bf3b7e802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_c8d1837c-cba7-471b-a42f-12d3e42fa8d7" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_ade3555a-d297-4842-b9e5-998bf3b7e802" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_c8d1837c-cba7-471b-a42f-12d3e42fa8d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5d2b491e-ae54-4c24-8238-35d3da87d3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5d2b491e-ae54-4c24-8238-35d3da87d3a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d2b491e-ae54-4c24-8238-35d3da87d3a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5d2b491e-ae54-4c24-8238-35d3da87d3a2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5d2b491e-ae54-4c24-8238-35d3da87d3a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8131fe45-d2b3-4228-b6d0-cec2e883c073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5d2b491e-ae54-4c24-8238-35d3da87d3a2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8131fe45-d2b3-4228-b6d0-cec2e883c073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a850621e-420d-41cc-950b-a758ca7eb5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8131fe45-d2b3-4228-b6d0-cec2e883c073" xlink:to="loc_us-gaap_EquitySecuritiesMember_a850621e-420d-41cc-950b-a758ca7eb5ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_de686e62-00ac-4e2f-ae9b-607522a0bb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_de686e62-00ac-4e2f-ae9b-607522a0bb97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_de686e62-00ac-4e2f-ae9b-607522a0bb97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_de686e62-00ac-4e2f-ae9b-607522a0bb97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_de686e62-00ac-4e2f-ae9b-607522a0bb97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_de686e62-00ac-4e2f-ae9b-607522a0bb97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_489e9c5d-d972-4981-85e8-6cb78250b138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:to="loc_us-gaap_ForeignExchangeContractMember_489e9c5d-d972-4981-85e8-6cb78250b138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_111e9125-a1d0-4a03-acaa-ff1fe8e22d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_111e9125-a1d0-4a03-acaa-ff1fe8e22d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f35a5450-2e68-4def-9940-41b9f9785c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:to="loc_us-gaap_InterestRateSwapMember_f35a5450-2e68-4def-9940-41b9f9785c94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_fee9b42f-dcaf-4681-bf7a-20d24e7632de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_fee9b42f-dcaf-4681-bf7a-20d24e7632de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_fee9b42f-dcaf-4681-bf7a-20d24e7632de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_fee9b42f-dcaf-4681-bf7a-20d24e7632de" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_fee9b42f-dcaf-4681-bf7a-20d24e7632de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7f4f7b9f-55c1-4a8e-9e06-91b602d84e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_fee9b42f-dcaf-4681-bf7a-20d24e7632de" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7f4f7b9f-55c1-4a8e-9e06-91b602d84e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_23e27304-0cd4-430b-96c3-2f9a2af103b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7f4f7b9f-55c1-4a8e-9e06-91b602d84e8f" xlink:to="loc_us-gaap_CommercialPaperMember_23e27304-0cd4-430b-96c3-2f9a2af103b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended" id="i6becc097ab1b47b9b8713d1f780fa7b0_FairValueMeasurementsSummaryofDerivativeActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_c7348390-2aa9-44ab-9b0f-000e8117ad2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_c7348390-2aa9-44ab-9b0f-000e8117ad2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_469dacd2-1b86-4cb6-a699-6e71622046f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_469dacd2-1b86-4cb6-a699-6e71622046f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_b22a06c1-fbec-4e89-a116-20654d30fb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_b22a06c1-fbec-4e89-a116-20654d30fb72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b2cbb856-10f0-4444-ae8b-94c4e8bb64dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b2cbb856-10f0-4444-ae8b-94c4e8bb64dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b2cbb856-10f0-4444-ae8b-94c4e8bb64dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b2cbb856-10f0-4444-ae8b-94c4e8bb64dd" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b2cbb856-10f0-4444-ae8b-94c4e8bb64dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b2cbb856-10f0-4444-ae8b-94c4e8bb64dd" xlink:to="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_83abf491-2d1a-4077-b4e5-cdde210c797c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:to="loc_us-gaap_FairValueHedgingMember_83abf491-2d1a-4077-b4e5-cdde210c797c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f9134303-6e8a-445e-927b-8d602142983a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f9134303-6e8a-445e-927b-8d602142983a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_bef043dd-cf45-469f-85d7-0558df7d47ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:to="loc_us-gaap_CashFlowHedgingMember_bef043dd-cf45-469f-85d7-0558df7d47ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_aef838f6-8cf5-40fd-962a-5ace4326772d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_aef838f6-8cf5-40fd-962a-5ace4326772d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_aef838f6-8cf5-40fd-962a-5ace4326772d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_aef838f6-8cf5-40fd-962a-5ace4326772d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_aef838f6-8cf5-40fd-962a-5ace4326772d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_aef838f6-8cf5-40fd-962a-5ace4326772d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_197fed7e-0080-4b5f-8ed5-b43674c7b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_InterestRateContractMember_197fed7e-0080-4b5f-8ed5-b43674c7b34c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7a9f3a3a-ffbf-49c6-a0c7-a1faec38f4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7a9f3a3a-ffbf-49c6-a0c7-a1faec38f4c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_a4907566-a0a5-41c9-b3c9-5014fb941858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_a4907566-a0a5-41c9-b3c9-5014fb941858" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a3e44d2a-7ad8-4dbb-8d90-7ff9273eb681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_InterestRateSwapMember_a3e44d2a-7ad8-4dbb-8d90-7ff9273eb681" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ebc62fd5-c2ba-4ced-a308-49b3ae022542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ebc62fd5-c2ba-4ced-a308-49b3ae022542" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19423514-d7df-41d5-92c5-1d20a519292d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19423514-d7df-41d5-92c5-1d20a519292d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19423514-d7df-41d5-92c5-1d20a519292d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19423514-d7df-41d5-92c5-1d20a519292d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19423514-d7df-41d5-92c5-1d20a519292d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19423514-d7df-41d5-92c5-1d20a519292d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_9b5f67f8-e443-4f73-b14c-6c9871d044d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_us-gaap_SalesMember_9b5f67f8-e443-4f73-b14c-6c9871d044d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_01a5fd9b-5fb3-4599-a98c-8cb772267b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_us-gaap_CostOfSalesMember_01a5fd9b-5fb3-4599-a98c-8cb772267b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3b7f2931-23c1-45e0-b5d3-04e7e00cee03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3b7f2931-23c1-45e0-b5d3-04e7e00cee03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_2cc2c75d-a86e-4cf8-8326-3984bb2b23bb" xlink:href="jnj-20220403.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_2cc2c75d-a86e-4cf8-8326-3984bb2b23bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_4da068fa-349b-4ebf-af00-ce68eb28ec28" xlink:href="jnj-20220403.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_4da068fa-349b-4ebf-af00-ce68eb28ec28" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended" id="i2ee67410841242afb282f675fe5c1672_FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_54f49817-b740-4575-b0f4-5ff208a6dac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d09206a9-23e1-496c-ad69-b450d22c67dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_54f49817-b740-4575-b0f4-5ff208a6dac2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d09206a9-23e1-496c-ad69-b450d22c67dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e0627303-9ac6-4dbd-ba6c-8bc7d9325129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_54f49817-b740-4575-b0f4-5ff208a6dac2" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e0627303-9ac6-4dbd-ba6c-8bc7d9325129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2fcb31fe-55dd-4fa5-8e94-c3fe1efbd504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_54f49817-b740-4575-b0f4-5ff208a6dac2" xlink:to="loc_us-gaap_DerivativeTable_2fcb31fe-55dd-4fa5-8e94-c3fe1efbd504" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e224f1bf-f632-4199-a70d-3e4fdf11850c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2fcb31fe-55dd-4fa5-8e94-c3fe1efbd504" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e224f1bf-f632-4199-a70d-3e4fdf11850c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e224f1bf-f632-4199-a70d-3e4fdf11850c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e224f1bf-f632-4199-a70d-3e4fdf11850c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e224f1bf-f632-4199-a70d-3e4fdf11850c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0c10f6b8-b98a-4078-8df6-ef3d37004d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e224f1bf-f632-4199-a70d-3e4fdf11850c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0c10f6b8-b98a-4078-8df6-ef3d37004d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_89612ebf-330d-4458-89c8-a0b7d7d7a6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0c10f6b8-b98a-4078-8df6-ef3d37004d96" xlink:to="loc_us-gaap_LongTermDebtMember_89612ebf-330d-4458-89c8-a0b7d7d7a6ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a6e83779-9ee7-4f83-b017-35aff8aaea78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_2fcb31fe-55dd-4fa5-8e94-c3fe1efbd504" xlink:to="loc_us-gaap_HedgingDesignationAxis_a6e83779-9ee7-4f83-b017-35aff8aaea78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a6e83779-9ee7-4f83-b017-35aff8aaea78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a6e83779-9ee7-4f83-b017-35aff8aaea78" xlink:to="loc_us-gaap_HedgingDesignationDomain_a6e83779-9ee7-4f83-b017-35aff8aaea78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_85311ef4-86ad-4301-8a8c-a8f2bdb09af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a6e83779-9ee7-4f83-b017-35aff8aaea78" xlink:to="loc_us-gaap_HedgingDesignationDomain_85311ef4-86ad-4301-8a8c-a8f2bdb09af8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fbe5c235-c5de-48ee-85af-b9fc938423bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_85311ef4-86ad-4301-8a8c-a8f2bdb09af8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fbe5c235-c5de-48ee-85af-b9fc938423bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i37ad51c93e994e389caefbc83c06ea84_FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_910220b9-9cce-4a9d-96c8-d2eae7ef63ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_bcb99e5f-bbc6-4226-a735-99780b23866b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_910220b9-9cce-4a9d-96c8-d2eae7ef63ed" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_bcb99e5f-bbc6-4226-a735-99780b23866b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_910220b9-9cce-4a9d-96c8-d2eae7ef63ed" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_705e5efe-f3db-4bb5-9b43-67964cbbb143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:to="loc_us-gaap_HedgingDesignationAxis_705e5efe-f3db-4bb5-9b43-67964cbbb143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_705e5efe-f3db-4bb5-9b43-67964cbbb143_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_705e5efe-f3db-4bb5-9b43-67964cbbb143" xlink:to="loc_us-gaap_HedgingDesignationDomain_705e5efe-f3db-4bb5-9b43-67964cbbb143_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2b29fe96-8103-46ce-8720-97f5f5c3a980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_705e5efe-f3db-4bb5-9b43-67964cbbb143" xlink:to="loc_us-gaap_HedgingDesignationDomain_2b29fe96-8103-46ce-8720-97f5f5c3a980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_725b5060-45e5-4d06-b377-ea3c4e59b15e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2b29fe96-8103-46ce-8720-97f5f5c3a980" xlink:to="loc_us-gaap_NondesignatedMember_725b5060-45e5-4d06-b377-ea3c4e59b15e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_69a7f607-498a-466a-887d-3616b38077a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_69a7f607-498a-466a-887d-3616b38077a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_69a7f607-498a-466a-887d-3616b38077a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_69a7f607-498a-466a-887d-3616b38077a3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_69a7f607-498a-466a-887d-3616b38077a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_15838806-40cf-4ba0-bac1-7c387391847e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_69a7f607-498a-466a-887d-3616b38077a3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_15838806-40cf-4ba0-bac1-7c387391847e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ea02f27f-cbf3-4263-80f1-9254e15411f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_15838806-40cf-4ba0-bac1-7c387391847e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ea02f27f-cbf3-4263-80f1-9254e15411f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_611001e6-e914-444b-9428-fc8dcc255bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_611001e6-e914-444b-9428-fc8dcc255bf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_611001e6-e914-444b-9428-fc8dcc255bf6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_611001e6-e914-444b-9428-fc8dcc255bf6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_611001e6-e914-444b-9428-fc8dcc255bf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20a54774-4355-4c4b-9b60-a4d9d7744882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_611001e6-e914-444b-9428-fc8dcc255bf6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20a54774-4355-4c4b-9b60-a4d9d7744882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_554b3a96-d616-46c8-a809-8023bd249f84" xlink:href="jnj-20220403.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20a54774-4355-4c4b-9b60-a4d9d7744882" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_554b3a96-d616-46c8-a809-8023bd249f84" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="idc6fe0c5db1d4d819d41cc13100e4ca0_FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e3f9a144-f6f4-441a-9c05-70758134d49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_5022f8eb-de51-46db-b92b-536f30630d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e3f9a144-f6f4-441a-9c05-70758134d49b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_5022f8eb-de51-46db-b92b-536f30630d25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_ee93bfe7-0222-4a24-9ed5-86cf2de13e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e3f9a144-f6f4-441a-9c05-70758134d49b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_ee93bfe7-0222-4a24-9ed5-86cf2de13e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d6ec4d57-e2f7-4701-9785-9f92bcead350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e3f9a144-f6f4-441a-9c05-70758134d49b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d6ec4d57-e2f7-4701-9785-9f92bcead350" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d59f638e-eba4-4b1d-b5c0-83eb5112690b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d6ec4d57-e2f7-4701-9785-9f92bcead350" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d59f638e-eba4-4b1d-b5c0-83eb5112690b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d59f638e-eba4-4b1d-b5c0-83eb5112690b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d59f638e-eba4-4b1d-b5c0-83eb5112690b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d59f638e-eba4-4b1d-b5c0-83eb5112690b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2920ec55-ef9f-406c-a93e-68e2cddcf564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d59f638e-eba4-4b1d-b5c0-83eb5112690b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2920ec55-ef9f-406c-a93e-68e2cddcf564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_6e4906f6-d5e7-44f2-baa7-0c8206cc2f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2920ec55-ef9f-406c-a93e-68e2cddcf564" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_6e4906f6-d5e7-44f2-baa7-0c8206cc2f50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c35ea95f-741d-470a-a7ca-c55d03231ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d6ec4d57-e2f7-4701-9785-9f92bcead350" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c35ea95f-741d-470a-a7ca-c55d03231ff6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c35ea95f-741d-470a-a7ca-c55d03231ff6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c35ea95f-741d-470a-a7ca-c55d03231ff6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c35ea95f-741d-470a-a7ca-c55d03231ff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3dda9949-8369-4f46-98a9-bb38a3545bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c35ea95f-741d-470a-a7ca-c55d03231ff6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3dda9949-8369-4f46-98a9-bb38a3545bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_b64741c0-1839-4250-88fc-278da34d9701" xlink:href="jnj-20220403.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3dda9949-8369-4f46-98a9-bb38a3545bbb" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_b64741c0-1839-4250-88fc-278da34d9701" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended" id="ie55160a9924c4347991e51889e187e86_FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a02d645c-5e8e-4eea-95d1-94a424d439d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a02d645c-5e8e-4eea-95d1-94a424d439d8" xlink:to="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_7936517b-f446-4268-9b5e-1102f1a6f8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_7936517b-f446-4268-9b5e-1102f1a6f8f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_2adf37e2-666e-430f-94ee-100770d6ee89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_2adf37e2-666e-430f-94ee-100770d6ee89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_0bc4697f-4e91-4a40-9e54-5233be4270c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_EquityFairValueAdjustment_0bc4697f-4e91-4a40-9e54-5233be4270c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_f786be37-ef03-4073-a289-c936233b03e9" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_f786be37-ef03-4073-a289-c936233b03e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_1095c702-c6f5-4e05-bbdb-47cf8154689d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_d59af116-792d-430f-95df-15fc6a90df1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d922e77b-6957-4226-9148-2046c261ce1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d922e77b-6957-4226-9148-2046c261ce1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f539018b-f5a2-46df-b367-e6254260843d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a02d645c-5e8e-4eea-95d1-94a424d439d8" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f539018b-f5a2-46df-b367-e6254260843d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c781451a-7cc5-4aa2-8874-9f151d3c200f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f539018b-f5a2-46df-b367-e6254260843d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c781451a-7cc5-4aa2-8874-9f151d3c200f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c781451a-7cc5-4aa2-8874-9f151d3c200f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c781451a-7cc5-4aa2-8874-9f151d3c200f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c781451a-7cc5-4aa2-8874-9f151d3c200f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1576a3bc-51fb-41ec-bc0d-6bcf16a84e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c781451a-7cc5-4aa2-8874-9f151d3c200f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1576a3bc-51fb-41ec-bc0d-6bcf16a84e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_75671947-6c80-4afc-ba93-1b0a7b69f68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1576a3bc-51fb-41ec-bc0d-6bcf16a84e5e" xlink:to="loc_us-gaap_EquitySecuritiesMember_75671947-6c80-4afc-ba93-1b0a7b69f68a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_7c36ea75-0273-4754-9560-07de5c10fd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f539018b-f5a2-46df-b367-e6254260843d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_7c36ea75-0273-4754-9560-07de5c10fd0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_7c36ea75-0273-4754-9560-07de5c10fd0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_7c36ea75-0273-4754-9560-07de5c10fd0c" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_7c36ea75-0273-4754-9560-07de5c10fd0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_457578b8-8c42-4380-9a4a-7cc0fc09a370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_7c36ea75-0273-4754-9560-07de5c10fd0c" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_457578b8-8c42-4380-9a4a-7cc0fc09a370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_36a5ff71-7a85-44f7-9d9a-a945563fff8b" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_457578b8-8c42-4380-9a4a-7cc0fc09a370" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_36a5ff71-7a85-44f7-9d9a-a945563fff8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_e983f298-d948-492d-93f8-ed1c84b8ce55" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_457578b8-8c42-4380-9a4a-7cc0fc09a370" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_e983f298-d948-492d-93f8-ed1c84b8ce55" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="i8aabcf78815242ca9b4d2653d0caeda3_FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_01c0df4f-7494-4510-8c87-8e24077dab7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_01c0df4f-7494-4510-8c87-8e24077dab7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_418ffb84-a20b-46bc-b255-78968c65690c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_418ffb84-a20b-46bc-b255-78968c65690c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_2c341c14-2de8-4362-8fbf-1aa1c333bcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_2c341c14-2de8-4362-8fbf-1aa1c333bcfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_d96b0c57-4215-4b7b-a20e-f43547148e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_d96b0c57-4215-4b7b-a20e-f43547148e52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_2d9f9922-7089-419c-8387-b56a81bf6512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_2d9f9922-7089-419c-8387-b56a81bf6512" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40d5180e-099a-41e7-b49a-6396f8e96ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40d5180e-099a-41e7-b49a-6396f8e96ab2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9bd62094-ad6e-40d3-b021-05813fc74648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9bd62094-ad6e-40d3-b021-05813fc74648" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ec621a71-f07e-4252-bfca-dbcda508e1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ec621a71-f07e-4252-bfca-dbcda508e1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_bdbdb897-ee20-4341-a13c-d0a7673866cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_bdbdb897-ee20-4341-a13c-d0a7673866cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_cb39ccb1-766d-425b-a21e-711b647ca790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeAssets_cb39ccb1-766d-425b-a21e-711b647ca790" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_588fc556-cc1d-4b32-9ea0-d283e652b748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_588fc556-cc1d-4b32-9ea0-d283e652b748" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5bcd7dc4-d616-425a-9487-55729e7dff5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5bcd7dc4-d616-425a-9487-55729e7dff5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8f97cda4-e092-46e0-a361-889c4241b463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeLiabilities_8f97cda4-e092-46e0-a361-889c4241b463" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_41d3eaef-5aca-48ea-8da9-3909d3e9ba33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_41d3eaef-5aca-48ea-8da9-3909d3e9ba33" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_079c321b-fe36-4a3c-bff8-3b56d725b1ab" xlink:href="jnj-20220403.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_079c321b-fe36-4a3c-bff8-3b56d725b1ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_971694d6-568e-424c-9cd7-0e9481c32a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_971694d6-568e-424c-9cd7-0e9481c32a7b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_18f7fc71-71f6-4790-a7dc-4c34a74ff32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_18f7fc71-71f6-4790-a7dc-4c34a74ff32a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1176093b-e27a-4895-be75-72b38ee3fcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_637bccb5-9884-438c-b4a0-0ef52de6e1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_637bccb5-9884-438c-b4a0-0ef52de6e1b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_637bccb5-9884-438c-b4a0-0ef52de6e1b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_637bccb5-9884-438c-b4a0-0ef52de6e1b9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_637bccb5-9884-438c-b4a0-0ef52de6e1b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_637bccb5-9884-438c-b4a0-0ef52de6e1b9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_eb7f8c47-f06d-4df4-9aa3-e2dc28286fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_eb7f8c47-f06d-4df4-9aa3-e2dc28286fa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7d1892ea-1e91-460c-96ed-c71fcf74d568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7d1892ea-1e91-460c-96ed-c71fcf74d568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_d17ac5e9-a1b9-40d1-9466-458cad0586f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:to="loc_us-gaap_LongTermDebtMember_d17ac5e9-a1b9-40d1-9466-458cad0586f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f262f4d7-d917-4785-a0b1-02eb4f63e255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f262f4d7-d917-4785-a0b1-02eb4f63e255" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f262f4d7-d917-4785-a0b1-02eb4f63e255_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f262f4d7-d917-4785-a0b1-02eb4f63e255" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f262f4d7-d917-4785-a0b1-02eb4f63e255_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0a56edf0-b911-4933-a803-06053ed28197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f262f4d7-d917-4785-a0b1-02eb4f63e255" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0a56edf0-b911-4933-a803-06053ed28197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_a38c65f6-0e1f-4690-b4ae-114aef08d9bf" xlink:href="jnj-20220403.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0a56edf0-b911-4933-a803-06053ed28197" xlink:to="loc_jnj_AurisHealthMember_a38c65f6-0e1f-4690-b4ae-114aef08d9bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3be205cf-0e76-4ea3-ab3c-9a3504d0615e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_InvestmentTypeAxis_3be205cf-0e76-4ea3-ab3c-9a3504d0615e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3be205cf-0e76-4ea3-ab3c-9a3504d0615e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_3be205cf-0e76-4ea3-ab3c-9a3504d0615e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3be205cf-0e76-4ea3-ab3c-9a3504d0615e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3f737335-e0f4-4f31-b7e7-1115e3e258a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_3be205cf-0e76-4ea3-ab3c-9a3504d0615e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3f737335-e0f4-4f31-b7e7-1115e3e258a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_66aa3525-dd8a-4036-8b1d-10f74014e45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3f737335-e0f4-4f31-b7e7-1115e3e258a3" xlink:to="loc_us-gaap_EquitySecuritiesMember_66aa3525-dd8a-4036-8b1d-10f74014e45b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d5d09575-9672-4c98-a1f1-4df069adf3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d5d09575-9672-4c98-a1f1-4df069adf3eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d5d09575-9672-4c98-a1f1-4df069adf3eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5d09575-9672-4c98-a1f1-4df069adf3eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d5d09575-9672-4c98-a1f1-4df069adf3eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5d09575-9672-4c98-a1f1-4df069adf3eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_775bc1ce-97e0-484b-9c51-5cfc7b88bbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:to="loc_us-gaap_InterestRateContractMember_775bc1ce-97e0-484b-9c51-5cfc7b88bbb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b27c9254-7568-42e8-bf2e-be9ab5c8964b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b27c9254-7568-42e8-bf2e-be9ab5c8964b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_334555b4-107d-47b2-b2c3-4eba943c8017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_334555b4-107d-47b2-b2c3-4eba943c8017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_84239e2e-e920-4536-a1a7-9f73ea1a469d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_84239e2e-e920-4536-a1a7-9f73ea1a469d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84239e2e-e920-4536-a1a7-9f73ea1a469d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_84239e2e-e920-4536-a1a7-9f73ea1a469d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84239e2e-e920-4536-a1a7-9f73ea1a469d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_84239e2e-e920-4536-a1a7-9f73ea1a469d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6f1725b7-f739-4b77-8fb1-8140fca7f4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6f1725b7-f739-4b77-8fb1-8140fca7f4d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1a6de4ef-c89a-4f67-ace7-8582a071b618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1a6de4ef-c89a-4f67-ace7-8582a071b618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_aba6d517-e731-4bdf-bee0-e71a348bf71c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_aba6d517-e731-4bdf-bee0-e71a348bf71c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8ddc5cdb-aadd-4bdc-8cab-81d7bf028a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8ddc5cdb-aadd-4bdc-8cab-81d7bf028a4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8ddc5cdb-aadd-4bdc-8cab-81d7bf028a4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8ddc5cdb-aadd-4bdc-8cab-81d7bf028a4c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8ddc5cdb-aadd-4bdc-8cab-81d7bf028a4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_73fd1661-eebb-4ae5-99ef-7777655bfb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8ddc5cdb-aadd-4bdc-8cab-81d7bf028a4c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_73fd1661-eebb-4ae5-99ef-7777655bfb80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_93555dc8-c0ea-44df-af98-e58b76be4aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_73fd1661-eebb-4ae5-99ef-7777655bfb80" xlink:to="loc_us-gaap_FairValueHedgingMember_93555dc8-c0ea-44df-af98-e58b76be4aa3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="i052ec2de59e940edb2cfd27b21279aee_FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_0dc1ecd6-6404-47e2-9ef6-f9ebb83e8660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:to="loc_us-gaap_HeldToMaturitySecurities_0dc1ecd6-6404-47e2-9ef6-f9ebb83e8660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_0c8b1b91-1815-46f0-bc93-54b0ee427dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_0c8b1b91-1815-46f0-bc93-54b0ee427dd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_bc13bcb6-d0b8-454b-b318-f875634a3f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_bc13bcb6-d0b8-454b-b318-f875634a3f68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c70857cf-f075-4616-a5cd-65bb23262071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c70857cf-f075-4616-a5cd-65bb23262071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a556dda3-0be0-4c85-82f3-8dcfb7901777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a556dda3-0be0-4c85-82f3-8dcfb7901777" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7f6a170-288d-43a2-8bd2-fea5f82c468d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7f6a170-288d-43a2-8bd2-fea5f82c468d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72a2235f-159b-47ed-bf58-41888edc4e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72a2235f-159b-47ed-bf58-41888edc4e1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_693fa2a0-aa85-4625-8129-a92c381f9a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_693fa2a0-aa85-4625-8129-a92c381f9a89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_327b4487-7dc0-4266-b986-393a09abafc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_327b4487-7dc0-4266-b986-393a09abafc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_bfe2ed5c-8e41-4638-a7e0-ae192493d7c0" xlink:href="jnj-20220403.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_bfe2ed5c-8e41-4638-a7e0-ae192493d7c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_e8627493-aa26-46f5-8746-40911048cd6b" xlink:href="jnj-20220403.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_e8627493-aa26-46f5-8746-40911048cd6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_f9e20aee-f856-4cc1-8bb9-7eabe7ec9c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_f9e20aee-f856-4cc1-8bb9-7eabe7ec9c0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_a4726f5c-2c37-4880-ae2e-ccd20ffc7464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_f9e20aee-f856-4cc1-8bb9-7eabe7ec9c0a" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_a4726f5c-2c37-4880-ae2e-ccd20ffc7464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a4726f5c-2c37-4880-ae2e-ccd20ffc7464_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_a4726f5c-2c37-4880-ae2e-ccd20ffc7464" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a4726f5c-2c37-4880-ae2e-ccd20ffc7464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_edb93beb-a424-42af-852a-524075ea29e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_a4726f5c-2c37-4880-ae2e-ccd20ffc7464" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_edb93beb-a424-42af-852a-524075ea29e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_4c620ccc-07c1-4640-b072-1a0272378e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_edb93beb-a424-42af-852a-524075ea29e2" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_4c620ccc-07c1-4640-b072-1a0272378e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_e70465e9-7e25-41e0-ae67-ab8d3a463341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_edb93beb-a424-42af-852a-524075ea29e2" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_e70465e9-7e25-41e0-ae67-ab8d3a463341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_21782828-011d-4644-bce6-5a2ae3c79031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_f9e20aee-f856-4cc1-8bb9-7eabe7ec9c0a" xlink:to="loc_us-gaap_InvestmentTypeAxis_21782828-011d-4644-bce6-5a2ae3c79031" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_21782828-011d-4644-bce6-5a2ae3c79031_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_21782828-011d-4644-bce6-5a2ae3c79031" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_21782828-011d-4644-bce6-5a2ae3c79031_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_21782828-011d-4644-bce6-5a2ae3c79031" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_808a1b25-d95e-406d-817e-648cad85a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_CashMember_808a1b25-d95e-406d-817e-648cad85a59a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_9f11915c-fab1-4794-a805-5bc120cecf77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_9f11915c-fab1-4794-a805-5bc120cecf77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_f7f1050d-aa60-438b-ab90-8534bde9e8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_f7f1050d-aa60-438b-ab90-8534bde9e8c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fba57377-f332-4c96-988e-4c112c7e11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fba57377-f332-4c96-988e-4c112c7e11e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_114b1df3-bb45-4ebf-b4b4-ae5dd05ddd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_MoneyMarketFundsMember_114b1df3-bb45-4ebf-b4b4-ae5dd05ddd6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_e853f959-bfab-4b18-9daf-7aa5c5cdf0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_BankTimeDepositsMember_e853f959-bfab-4b18-9daf-7aa5c5cdf0d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_825f911e-10c5-4617-bf23-294411cb207d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_825f911e-10c5-4617-bf23-294411cb207d" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended" id="ieaebb4a7f8e34fbda51e75de39602bf9_FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_950ed505-6253-48b4-b709-8fb3edd8064f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_950ed505-6253-48b4-b709-8fb3edd8064f" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_a241d5c1-9d8e-4c8c-8d9f-d16fcb12beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_a241d5c1-9d8e-4c8c-8d9f-d16fcb12beaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_42453d95-685b-441b-ae46-1671585633a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_a241d5c1-9d8e-4c8c-8d9f-d16fcb12beaf" xlink:to="loc_us-gaap_ShortTermBorrowings_42453d95-685b-441b-ae46-1671585633a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_34f167b6-c2de-47f8-9475-778e7b7230ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_34f167b6-c2de-47f8-9475-778e7b7230ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_95debf1f-3c37-496c-9e89-4dbf2567ffc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_34f167b6-c2de-47f8-9475-778e7b7230ef" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_95debf1f-3c37-496c-9e89-4dbf2567ffc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b25a5bb9-b4be-404a-98ae-de19a9c72dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b25a5bb9-b4be-404a-98ae-de19a9c72dda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1b8da7df-fc37-4c0c-bca9-71c5017c37c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_950ed505-6253-48b4-b709-8fb3edd8064f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1b8da7df-fc37-4c0c-bca9-71c5017c37c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c1c9f6af-3491-4706-bd34-34c2d420a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1b8da7df-fc37-4c0c-bca9-71c5017c37c5" xlink:to="loc_us-gaap_DebtInstrumentAxis_c1c9f6af-3491-4706-bd34-34c2d420a9a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c1c9f6af-3491-4706-bd34-34c2d420a9a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1c9f6af-3491-4706-bd34-34c2d420a9a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c1c9f6af-3491-4706-bd34-34c2d420a9a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1c9f6af-3491-4706-bd34-34c2d420a9a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_fa51de57-7bfc-4a0a-b61e-b2463862c1ed" xlink:href="jnj-20220403.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_fa51de57-7bfc-4a0a-b61e-b2463862c1ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_b700294c-dc4a-4af4-aa2b-e536cd5ccbcb" xlink:href="jnj-20220403.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.375Notesdue2023Member_b700294c-dc4a-4af4-aa2b-e536cd5ccbcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_0fce3dca-28b8-4b28-89a4-fc6cb197c738" xlink:href="jnj-20220403.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A0.650NotesDue2024Member_0fce3dca-28b8-4b28-89a4-fc6cb197c738" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_070878ac-9677-499a-a043-ebe56e519870" xlink:href="jnj-20220403.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A5.50NotesDue2024Member_070878ac-9677-499a-a043-ebe56e519870" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_c86fb1ef-4108-45bd-be3c-cf247c21bd0f" xlink:href="jnj-20220403.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2.625Notesdue2025Member_c86fb1ef-4108-45bd-be3c-cf247c21bd0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_4e044516-dae3-40cf-92cc-b431f76e0c20" xlink:href="jnj-20220403.xsd#jnj_A0550NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A0550NotesDue2025Member_4e044516-dae3-40cf-92cc-b431f76e0c20" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_91f0ea23-c0cd-4cde-b2d1-5acecabe1be4" xlink:href="jnj-20220403.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2.45Notesdue2026Member_91f0ea23-c0cd-4cde-b2d1-5acecabe1be4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_b178d0e8-b93b-4ea1-8bfc-84d2d3bca0f6" xlink:href="jnj-20220403.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2.95Notesdue2027Member_b178d0e8-b93b-4ea1-8bfc-84d2d3bca0f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_a091b5fc-c41f-4a9d-a28e-3697780e5273" xlink:href="jnj-20220403.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A095NotesDue2027Member_a091b5fc-c41f-4a9d-a28e-3697780e5273" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_fa9cb00b-e881-4f7b-9323-c66a8a6fe206" xlink:href="jnj-20220403.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2.900Notesdue2028Member_fa9cb00b-e881-4f7b-9323-c66a8a6fe206" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_593cc6fc-0ce5-4ac9-8ce8-6e369d472fd3" xlink:href="jnj-20220403.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A1.150NotesDue2028Member_593cc6fc-0ce5-4ac9-8ce8-6e369d472fd3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_3d571c40-2967-4169-b598-1bb1266457cc" xlink:href="jnj-20220403.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A6.95Notesdue2029Member_3d571c40-2967-4169-b598-1bb1266457cc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_6a5152e1-20a3-4f78-ac36-2ebb214a2eb2" xlink:href="jnj-20220403.xsd#jnj_A1300NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A1300NotesDue2030Member_6a5152e1-20a3-4f78-ac36-2ebb214a2eb2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_d8c3f3b9-2f1c-43db-a497-a79957def22a" xlink:href="jnj-20220403.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_d8c3f3b9-2f1c-43db-a497-a79957def22a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_a486e694-7769-4f3d-ac4f-38231d51f157" xlink:href="jnj-20220403.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.375Notesdue2033Member_a486e694-7769-4f3d-ac4f-38231d51f157" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_1dac0cf1-7ac2-4662-8fe4-a8c33e64585e" xlink:href="jnj-20220403.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A1.650NotesDue2035Member_1dac0cf1-7ac2-4662-8fe4-a8c33e64585e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_ae06ce3e-69a1-408b-a837-54bbe2102c85" xlink:href="jnj-20220403.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.55Notesdue2036Member_ae06ce3e-69a1-408b-a837-54bbe2102c85" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_16dd8cea-5942-48bd-a430-70266fcf3c4b" xlink:href="jnj-20220403.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A5.95Notesdue2037Member_16dd8cea-5942-48bd-a430-70266fcf3c4b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_58c61daf-a0fc-46a0-8045-694ee3f94c52" xlink:href="jnj-20220403.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.625Notesdue2037Member_58c61daf-a0fc-46a0-8045-694ee3f94c52" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_525b44ca-bde8-46fc-addf-1aea3504cbc5" xlink:href="jnj-20220403.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.400Notesdue2038Member_525b44ca-bde8-46fc-addf-1aea3504cbc5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_76ebafec-2e9b-41a1-826a-2e9718270d7a" xlink:href="jnj-20220403.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_76ebafec-2e9b-41a1-826a-2e9718270d7a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_2711400e-0c5c-4d08-a538-d6cd0cac75da" xlink:href="jnj-20220403.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_2711400e-0c5c-4d08-a538-d6cd0cac75da" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_d2a20bf2-a140-400e-bd11-774f14483781" xlink:href="jnj-20220403.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A210NotesDue2040Member_d2a20bf2-a140-400e-bd11-774f14483781" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_a60f7194-6fea-46dd-acf5-e1a039ae2eef" xlink:href="jnj-20220403.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.85Notesdue2041Member_a60f7194-6fea-46dd-acf5-e1a039ae2eef" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_24280a9e-28d1-42b8-a5d8-5c8a0cbbf10f" xlink:href="jnj-20220403.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.50Notesdue2043Member_24280a9e-28d1-42b8-a5d8-5c8a0cbbf10f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_41386c07-a765-44cc-9aff-913513dc64b9" xlink:href="jnj-20220403.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.70Notesdue2046Member_41386c07-a765-44cc-9aff-913513dc64b9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_6b53c8fa-f9d5-4b5a-895b-e5789c7c4f37" xlink:href="jnj-20220403.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.75Notesdue2047Member_6b53c8fa-f9d5-4b5a-895b-e5789c7c4f37" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_d20b9797-e3fb-4b50-9447-4a71184d6e67" xlink:href="jnj-20220403.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.500Notesdue2048Member_d20b9797-e3fb-4b50-9447-4a71184d6e67" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_cd2c14a6-aa11-4b15-9867-8f75f37be743" xlink:href="jnj-20220403.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2250NotesDue2050Member_cd2c14a6-aa11-4b15-9867-8f75f37be743" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_020149b1-8ff4-4df4-8b92-f8166d4435e0" xlink:href="jnj-20220403.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2450NotesDue2060Member_020149b1-8ff4-4df4-8b92-f8166d4435e0" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_d619f511-da79-4641-8193-012cf193954d" xlink:href="jnj-20220403.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_d619f511-da79-4641-8193-012cf193954d" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_d74874f8-7903-461f-9814-312eae955291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1b8da7df-fc37-4c0c-bca9-71c5017c37c5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_d74874f8-7903-461f-9814-312eae955291" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d74874f8-7903-461f-9814-312eae955291_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_d74874f8-7903-461f-9814-312eae955291" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d74874f8-7903-461f-9814-312eae955291_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c5749035-567b-4520-89c7-eebf27cbf44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_d74874f8-7903-461f-9814-312eae955291" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c5749035-567b-4520-89c7-eebf27cbf44f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b05563c-45f1-4cae-bb46-7e8b5d0d4e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c5749035-567b-4520-89c7-eebf27cbf44f" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b05563c-45f1-4cae-bb46-7e8b5d0d4e88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9c96aac1-5db7-4bdd-b23c-668e26a1473a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b05563c-45f1-4cae-bb46-7e8b5d0d4e88" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9c96aac1-5db7-4bdd-b23c-668e26a1473a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1e3d228a-1d34-42d2-b917-d3431430e144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b05563c-45f1-4cae-bb46-7e8b5d0d4e88" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1e3d228a-1d34-42d2-b917-d3431430e144" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="if46d04c1b2f141e693ab09c1ea67f26e_PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1c1330a-a893-422d-92c3-7590746c9ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1c1330a-a893-422d-92c3-7590746c9ecd" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5d26953a-908e-4735-9a92-ffb791282f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5d26953a-908e-4735-9a92-ffb791282f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_98c30cbf-edf5-4bee-a9cc-1007fde7eb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_98c30cbf-edf5-4bee-a9cc-1007fde7eb7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_000d1f35-3b67-4bc9-86ab-aadc1d3b4851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_000d1f35-3b67-4bc9-86ab-aadc1d3b4851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_927f7e12-22ff-4aed-8ad2-cb4544ab078b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_927f7e12-22ff-4aed-8ad2-cb4544ab078b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_9fa9c3c8-0900-4747-aa37-aa422e939fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_9fa9c3c8-0900-4747-aa37-aa422e939fcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_e32c33bd-ff75-4e46-a0e2-979a86201413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_e32c33bd-ff75-4e46-a0e2-979a86201413" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3f537afb-7d3c-41c4-9483-ef7637ed7459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3f537afb-7d3c-41c4-9483-ef7637ed7459" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_635abaec-6668-4f05-8dff-66a82c43ec0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1c1330a-a893-422d-92c3-7590746c9ecd" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_635abaec-6668-4f05-8dff-66a82c43ec0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e2112d30-19f7-411c-bd1c-15c0d58e9d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_635abaec-6668-4f05-8dff-66a82c43ec0f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e2112d30-19f7-411c-bd1c-15c0d58e9d8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e2112d30-19f7-411c-bd1c-15c0d58e9d8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e2112d30-19f7-411c-bd1c-15c0d58e9d8b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e2112d30-19f7-411c-bd1c-15c0d58e9d8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_36d46f54-593c-47ad-b010-3f0d0fe12fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e2112d30-19f7-411c-bd1c-15c0d58e9d8b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_36d46f54-593c-47ad-b010-3f0d0fe12fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f30a0db5-1aeb-4798-a2fe-7ab91b603477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_36d46f54-593c-47ad-b010-3f0d0fe12fd9" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f30a0db5-1aeb-4798-a2fe-7ab91b603477" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e30b1bb-c5df-4600-b875-72a0864dfdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_36d46f54-593c-47ad-b010-3f0d0fe12fd9" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e30b1bb-c5df-4600-b875-72a0864dfdb5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended" id="ia9d49008651f4135b2702f67dd06aafc_PensionsandOtherBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2de4ed01-4329-4fb0-a084-786fdcabaf22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_8717a943-34de-4c2f-a774-3e86afd4b275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2de4ed01-4329-4fb0-a084-786fdcabaf22" xlink:to="loc_us-gaap_PensionContributions_8717a943-34de-4c2f-a774-3e86afd4b275" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2bc36d73-73b7-4554-8c36-adc777fd100c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2de4ed01-4329-4fb0-a084-786fdcabaf22" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2bc36d73-73b7-4554-8c36-adc777fd100c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_1d01e60d-163d-41a8-a07c-284314ee6b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2bc36d73-73b7-4554-8c36-adc777fd100c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_1d01e60d-163d-41a8-a07c-284314ee6b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d01e60d-163d-41a8-a07c-284314ee6b4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1d01e60d-163d-41a8-a07c-284314ee6b4d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d01e60d-163d-41a8-a07c-284314ee6b4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9908a468-399a-439a-a670-b9ea41a49fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1d01e60d-163d-41a8-a07c-284314ee6b4d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9908a468-399a-439a-a670-b9ea41a49fc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a287a0ea-8bec-45d5-8d7f-1a5a0bc6bf3f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9908a468-399a-439a-a670-b9ea41a49fc5" xlink:to="loc_country_US_a287a0ea-8bec-45d5-8d7f-1a5a0bc6bf3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ce7bd3a5-cad2-4d6c-98aa-9f8ef98a928f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9908a468-399a-439a-a670-b9ea41a49fc5" xlink:to="loc_us-gaap_ForeignPlanMember_ce7bd3a5-cad2-4d6c-98aa-9f8ef98a928f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="i51c78535cf2f463ca004344032b10c7d_AccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_40363502-9bb1-460d-a80a-b1c9f42b57b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_aa4a7803-c2d9-4b73-a577-fe6536f3a1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_40363502-9bb1-460d-a80a-b1c9f42b57b4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_aa4a7803-c2d9-4b73-a577-fe6536f3a1a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b1c80bb7-f034-4e5e-bc2c-2a98040b57b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_aa4a7803-c2d9-4b73-a577-fe6536f3a1a2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b1c80bb7-f034-4e5e-bc2c-2a98040b57b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5b90231c-d660-4e88-8cbb-9facde64f7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_aa4a7803-c2d9-4b73-a577-fe6536f3a1a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5b90231c-d660-4e88-8cbb-9facde64f7d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_236adc68-849e-4eea-83e7-11e101598730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25d51add-5965-4dd7-bb7f-9c4f15624207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_40363502-9bb1-460d-a80a-b1c9f42b57b4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25d51add-5965-4dd7-bb7f-9c4f15624207" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d6616e20-2836-4db9-b1c9-926d00321e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25d51add-5965-4dd7-bb7f-9c4f15624207" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d6616e20-2836-4db9-b1c9-926d00321e2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6616e20-2836-4db9-b1c9-926d00321e2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d6616e20-2836-4db9-b1c9-926d00321e2a" xlink:to="loc_us-gaap_EquityComponentDomain_d6616e20-2836-4db9-b1c9-926d00321e2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d6616e20-2836-4db9-b1c9-926d00321e2a" xlink:to="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9f8a29cf-0acd-4a31-baf5-e8134e27d19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9f8a29cf-0acd-4a31-baf5-e8134e27d19e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6d283834-cf4b-4eba-8787-006e272d536c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6d283834-cf4b-4eba-8787-006e272d536c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f305843b-d0cc-4281-aff9-c1d1b73b52a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f305843b-d0cc-4281-aff9-c1d1b73b52a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_447caff5-4496-421a-bdcc-1467af720ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_447caff5-4496-421a-bdcc-1467af720ab7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e879c52c-d1f1-4e01-a6c7-bd33a6f0bfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e879c52c-d1f1-4e01-a6c7-bd33a6f0bfe3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended" id="ia4cc830baa644cfda3ed4864cd110041_SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c59499f2-fbde-49df-8f9c-970b99007724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_248ca836-ca94-4dd7-85eb-3cbb0e52f95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c59499f2-fbde-49df-8f9c-970b99007724" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_248ca836-ca94-4dd7-85eb-3cbb0e52f95b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83ffc267-a5b4-49f4-9d29-7f6ee243ca38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_248ca836-ca94-4dd7-85eb-3cbb0e52f95b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83ffc267-a5b4-49f4-9d29-7f6ee243ca38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_c00ca36c-8772-4bde-badf-56915424dd59" xlink:href="jnj-20220403.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_248ca836-ca94-4dd7-85eb-3cbb0e52f95b" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_c00ca36c-8772-4bde-badf-56915424dd59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c59499f2-fbde-49df-8f9c-970b99007724" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_68694745-3967-4a54-bdef-68ca453f3a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_68694745-3967-4a54-bdef-68ca453f3a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68694745-3967-4a54-bdef-68ca453f3a90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68694745-3967-4a54-bdef-68ca453f3a90" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68694745-3967-4a54-bdef-68ca453f3a90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c421901-6ebf-4d87-af55-6c3a36eeeb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68694745-3967-4a54-bdef-68ca453f3a90" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c421901-6ebf-4d87-af55-6c3a36eeeb35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5c68dca2-9b19-400c-b64b-30ffa8af3c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5c68dca2-9b19-400c-b64b-30ffa8af3c3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5c68dca2-9b19-400c-b64b-30ffa8af3c3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5c68dca2-9b19-400c-b64b-30ffa8af3c3b" xlink:to="loc_us-gaap_SegmentDomain_5c68dca2-9b19-400c-b64b-30ffa8af3c3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5c68dca2-9b19-400c-b64b-30ffa8af3c3b" xlink:to="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_7364e0f8-2d84-42d9-a2ab-3537e20a5a43" xlink:href="jnj-20220403.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:to="loc_jnj_ConsumerMember_7364e0f8-2d84-42d9-a2ab-3537e20a5a43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_c7552a25-dd09-491d-910e-11fad424ea39" xlink:href="jnj-20220403.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:to="loc_jnj_PharmaceuticalMember_c7552a25-dd09-491d-910e-11fad424ea39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_e9c1aaed-7272-47c8-a8f2-323f854d6717" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:to="loc_jnj_MedicalDevicesMember_e9c1aaed-7272-47c8-a8f2-323f854d6717" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_4128803b-ec77-48c0-8b5f-ce4a623f8d7d" xlink:href="jnj-20220403.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_4128803b-ec77-48c0-8b5f-ce4a623f8d7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_e31b801c-3315-4479-b7e3-852ff21da0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_us-gaap_SubsegmentsAxis_e31b801c-3315-4479-b7e3-852ff21da0ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_e31b801c-3315-4479-b7e3-852ff21da0ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_e31b801c-3315-4479-b7e3-852ff21da0ff" xlink:to="loc_us-gaap_SubsegmentsDomain_e31b801c-3315-4479-b7e3-852ff21da0ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_e31b801c-3315-4479-b7e3-852ff21da0ff" xlink:to="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_b585711c-4c74-498a-9dbe-813ec59d1c68" xlink:href="jnj-20220403.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_ImmunologyMember_b585711c-4c74-498a-9dbe-813ec59d1c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_0ccaf6f1-0907-49ce-be8e-c7d63139ff1f" xlink:href="jnj-20220403.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_InfectiousDiseasesMember_0ccaf6f1-0907-49ce-be8e-c7d63139ff1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_8e74d193-a34a-4d67-8700-a874dd028307" xlink:href="jnj-20220403.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_NeuroscienceMember_8e74d193-a34a-4d67-8700-a874dd028307" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_9d0b6ea3-24eb-4503-aa57-631eb7bcc304" xlink:href="jnj-20220403.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_OncologyMember_9d0b6ea3-24eb-4503-aa57-631eb7bcc304" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_a0440070-2a61-4c40-abe5-ed830fc2c8cd" xlink:href="jnj-20220403.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_PulmonaryHypertensionMember_a0440070-2a61-4c40-abe5-ed830fc2c8cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_56d10b93-7188-49d6-8217-95fd2b3b5aff" xlink:href="jnj-20220403.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_56d10b93-7188-49d6-8217-95fd2b3b5aff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_daf55cd1-5d47-4b35-babb-4143f5b1a544" xlink:href="jnj-20220403.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_InterventionalSolutionsMember_daf55cd1-5d47-4b35-babb-4143f5b1a544" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_8f5d0d92-fe31-4466-9176-807db93915d7" xlink:href="jnj-20220403.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_OrthopaedicsMember_8f5d0d92-fe31-4466-9176-807db93915d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_37a423f4-7404-49d4-bca7-d8474ea65cdd" xlink:href="jnj-20220403.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_SurgeryMember_37a423f4-7404-49d4-bca7-d8474ea65cdd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_6e515e5f-6b1e-4678-a118-b49897f11977" xlink:href="jnj-20220403.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_VisionMember_6e515e5f-6b1e-4678-a118-b49897f11977" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_70359ad7-9c50-4e5e-8c16-da54d357f95b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_srt_ProductOrServiceAxis_70359ad7-9c50-4e5e-8c16-da54d357f95b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_70359ad7-9c50-4e5e-8c16-da54d357f95b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_70359ad7-9c50-4e5e-8c16-da54d357f95b" xlink:to="loc_srt_ProductsAndServicesDomain_70359ad7-9c50-4e5e-8c16-da54d357f95b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_70359ad7-9c50-4e5e-8c16-da54d357f95b" xlink:to="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_4499e498-9be1-4510-8d3b-617c27be7be7" xlink:href="jnj-20220403.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OTCMember_4499e498-9be1-4510-8d3b-617c27be7be7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_ead9d862-de27-42e7-b217-d5fbdcb88c1e" xlink:href="jnj-20220403.xsd#jnj_BeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_BeautyMember_ead9d862-de27-42e7-b217-d5fbdcb88c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_a03d31ef-4fe9-4ac3-a9a8-9f2f8b2831a4" xlink:href="jnj-20220403.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OralCareMember_a03d31ef-4fe9-4ac3-a9a8-9f2f8b2831a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_9f7d03ee-6217-48ac-90fa-8f4479108a1c" xlink:href="jnj-20220403.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_BabyCareMember_9f7d03ee-6217-48ac-90fa-8f4479108a1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_78e2bd6a-01df-4d11-b57b-4e050fd9e588" xlink:href="jnj-20220403.xsd#jnj_WomensHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_WomensHealthMember_78e2bd6a-01df-4d11-b57b-4e050fd9e588" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_6cfc2451-7000-4b85-9b1f-dc6342e8ea3f" xlink:href="jnj-20220403.xsd#jnj_WoundCareandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_WoundCareandOtherMember_6cfc2451-7000-4b85-9b1f-dc6342e8ea3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_d2b3cc72-1a9f-47c2-930c-8c02feaaa540" xlink:href="jnj-20220403.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_RemicadeMember_d2b3cc72-1a9f-47c2-930c-8c02feaaa540" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_a74d5b2a-479f-45c7-97aa-1ad803c812c6" xlink:href="jnj-20220403.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_SimponiSimponiAriaMember_a74d5b2a-479f-45c7-97aa-1ad803c812c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_21159a05-f3a1-4c56-a10a-c50f76b5e0b4" xlink:href="jnj-20220403.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_StelaraMember_21159a05-f3a1-4c56-a10a-c50f76b5e0b4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_7c2f82b2-6ce6-4ea3-b64a-4061f21f8ee5" xlink:href="jnj-20220403.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_TremfyaMember_7c2f82b2-6ce6-4ea3-b64a-4061f21f8ee5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_404dffac-03fb-430e-9c28-9f2a46deca9e" xlink:href="jnj-20220403.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OtherImmunologyMember_404dffac-03fb-430e-9c28-9f2a46deca9e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_7b63b267-7187-4d8f-b327-33005a6519a3" xlink:href="jnj-20220403.xsd#jnj_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_COVID19Member_7b63b267-7187-4d8f-b327-33005a6519a3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_8e45d759-9c67-4e40-8e17-de33d9e44b7a" xlink:href="jnj-20220403.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_EDURANTrilpivirineMember_8e45d759-9c67-4e40-8e17-de33d9e44b7a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_a273aa3c-6cc9-4dfc-aef9-61eba18803fd" xlink:href="jnj-20220403.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_a273aa3c-6cc9-4dfc-aef9-61eba18803fd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_9812320b-3ab6-488a-a064-bdda7e529ddb" xlink:href="jnj-20220403.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_9812320b-3ab6-488a-a064-bdda7e529ddb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_f2ccb912-b0be-4c54-9787-13f4a230cd44" xlink:href="jnj-20220403.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_f2ccb912-b0be-4c54-9787-13f4a230cd44" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_ed163233-fdaf-4794-94d8-11fa1f9658a4" xlink:href="jnj-20220403.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_ed163233-fdaf-4794-94d8-11fa1f9658a4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_c257620b-166b-426a-9d25-0b801bac3cdc" xlink:href="jnj-20220403.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_RISPERDALCONSTAMember_c257620b-166b-426a-9d25-0b801bac3cdc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_59561e43-4918-40d0-ad2e-8841ece7871d" xlink:href="jnj-20220403.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_59561e43-4918-40d0-ad2e-8841ece7871d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_53b02aac-f31b-49a4-b650-07e5f7b19788" xlink:href="jnj-20220403.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_DARZALEXMember_53b02aac-f31b-49a4-b650-07e5f7b19788" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_01138f55-53e9-4f27-bf63-f74b59368388" xlink:href="jnj-20220403.xsd#jnj_ERLEADAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_ERLEADAMember_01138f55-53e9-4f27-bf63-f74b59368388" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_3b8990f4-e4ea-4e18-8417-d7ca4634b0ff" xlink:href="jnj-20220403.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_IMBRUVICAMember_3b8990f4-e4ea-4e18-8417-d7ca4634b0ff" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_512785da-2a07-4277-883e-fbdacb6eddb4" xlink:href="jnj-20220403.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_ZYTIGAMember_512785da-2a07-4277-883e-fbdacb6eddb4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_17c1fdee-850f-4325-b27a-6073ed938139" xlink:href="jnj-20220403.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OtherOncologyMember_17c1fdee-850f-4325-b27a-6073ed938139" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_f0baea75-7427-4963-b169-ea21456826b6" xlink:href="jnj-20220403.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OPSUMITMember_f0baea75-7427-4963-b169-ea21456826b6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_474aa0a8-1a37-4034-813b-9f962a374b7f" xlink:href="jnj-20220403.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_UPTRAVIMember_474aa0a8-1a37-4034-813b-9f962a374b7f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_40679af9-1afa-42d2-ac28-5eb89d385b49" xlink:href="jnj-20220403.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_XareltoMember_40679af9-1afa-42d2-ac28-5eb89d385b49" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_3477ce53-cbe0-4ff6-8764-2dba5b4ad351" xlink:href="jnj-20220403.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_3477ce53-cbe0-4ff6-8764-2dba5b4ad351" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_2360e756-e0cb-4aeb-bd3a-2e752104ae53" xlink:href="jnj-20220403.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OtherMember_2360e756-e0cb-4aeb-bd3a-2e752104ae53" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_d20b394b-8a00-419b-be13-c157a589e567" xlink:href="jnj-20220403.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_HIPSMember_d20b394b-8a00-419b-be13-c157a589e567" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_e497c206-fc2a-45b8-90b6-6b4c575ff5b6" xlink:href="jnj-20220403.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_KNEESMember_e497c206-fc2a-45b8-90b6-6b4c575ff5b6" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_4ec52741-0d0d-4d06-b62e-0d559f816869" xlink:href="jnj-20220403.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_TRAUMAMember_4ec52741-0d0d-4d06-b62e-0d559f816869" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_b2d885f6-563d-40b0-a847-6c0ab260f710" xlink:href="jnj-20220403.xsd#jnj_SPINEOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_SPINEOTHERMember_b2d885f6-563d-40b0-a847-6c0ab260f710" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_c659baef-51a1-4afa-b19b-33f067fc9292" xlink:href="jnj-20220403.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_ADVANCEDMember_c659baef-51a1-4afa-b19b-33f067fc9292" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_0e2db870-d393-4fdb-860c-a1bb1e3cad94" xlink:href="jnj-20220403.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_GENERALMember_0e2db870-d393-4fdb-860c-a1bb1e3cad94" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_63af1560-1b09-407f-a683-f4f49cf2f903" xlink:href="jnj-20220403.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_63af1560-1b09-407f-a683-f4f49cf2f903" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_308ef074-bc91-4aaa-97f9-ba0658886411" xlink:href="jnj-20220403.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_SURGICALMember_308ef074-bc91-4aaa-97f9-ba0658886411" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0f108814-2fe3-47e5-ad9a-79e6b0f8ad24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_srt_StatementGeographicalAxis_0f108814-2fe3-47e5-ad9a-79e6b0f8ad24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0f108814-2fe3-47e5-ad9a-79e6b0f8ad24_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0f108814-2fe3-47e5-ad9a-79e6b0f8ad24" xlink:to="loc_srt_SegmentGeographicalDomain_0f108814-2fe3-47e5-ad9a-79e6b0f8ad24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0f108814-2fe3-47e5-ad9a-79e6b0f8ad24" xlink:to="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_22e63a32-9c49-4dd7-a68d-82b7c33e0447" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:to="loc_country_CN_22e63a32-9c49-4dd7-a68d-82b7c33e0447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7b0a71d8-4b75-4984-98ef-e54c1b6d09df" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:to="loc_country_US_7b0a71d8-4b75-4984-98ef-e54c1b6d09df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_de3cb3ac-3b2c-455f-8154-aa8cb1d64a95" xlink:href="jnj-20220403.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:to="loc_jnj_UNITEDSTATESExportsMember_de3cb3ac-3b2c-455f-8154-aa8cb1d64a95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1df031d2-856f-4efb-b0e6-2c6ab10fc4da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:to="loc_us-gaap_NonUsMember_1df031d2-856f-4efb-b0e6-2c6ab10fc4da" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended" id="i16d2222e407e41f3a712f53b8bccd291_SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a5dd137-c1e7-4aee-81b0-ce625e4aee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a5dd137-c1e7-4aee-81b0-ce625e4aee3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_6bdb7c13-bae2-40d6-b5df-bd30a38cf320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_BusinessExitCosts1_6bdb7c13-bae2-40d6-b5df-bd30a38cf320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3f70bff-2dc1-4ffa-be65-fdded239de7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3f70bff-2dc1-4ffa-be65-fdded239de7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_2e477054-8859-4f67-ace9-5d16feac822c" xlink:href="jnj-20220403.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_2e477054-8859-4f67-ace9-5d16feac822c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_0dc61df0-3f25-4de8-b523-e455dcac86b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_AdjustmentForAmortization_0dc61df0-3f25-4de8-b523-e455dcac86b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_433a194c-91aa-462c-9024-032ce4510e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_433a194c-91aa-462c-9024-032ce4510e64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9b614e77-e318-4c60-ab8a-f57fa4094e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9b614e77-e318-4c60-ab8a-f57fa4094e35" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_500e5cc6-e735-4fc1-9f6f-35b1106e9a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_500e5cc6-e735-4fc1-9f6f-35b1106e9a80" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_dae63a83-5057-4cf4-86eb-c88c0cf07d31" xlink:href="jnj-20220403.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_dae63a83-5057-4cf4-86eb-c88c0cf07d31" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_482cf2a2-28f2-41fb-b5ec-78505b5f12cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_RestructuringCharges_482cf2a2-28f2-41fb-b5ec-78505b5f12cb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ecdd10e0-40a4-49b0-b178-62b1489b66c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:to="loc_srt_ConsolidationItemsAxis_ecdd10e0-40a4-49b0-b178-62b1489b66c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ecdd10e0-40a4-49b0-b178-62b1489b66c9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_ecdd10e0-40a4-49b0-b178-62b1489b66c9" xlink:to="loc_srt_ConsolidationItemsDomain_ecdd10e0-40a4-49b0-b178-62b1489b66c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b36b129c-414a-4489-a083-da31abb5c9ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_ecdd10e0-40a4-49b0-b178-62b1489b66c9" xlink:to="loc_srt_ConsolidationItemsDomain_b36b129c-414a-4489-a083-da31abb5c9ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e4dfe154-0ad3-4b52-b7e7-92aa99a9a306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b36b129c-414a-4489-a083-da31abb5c9ec" xlink:to="loc_us-gaap_OperatingSegmentsMember_e4dfe154-0ad3-4b52-b7e7-92aa99a9a306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e6359919-2fbf-470e-b05d-5e8a5234a7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b36b129c-414a-4489-a083-da31abb5c9ec" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e6359919-2fbf-470e-b05d-5e8a5234a7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de02331e-8858-4ad4-8871-cc6e12f3fb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de02331e-8858-4ad4-8871-cc6e12f3fb2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_de02331e-8858-4ad4-8871-cc6e12f3fb2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de02331e-8858-4ad4-8871-cc6e12f3fb2d" xlink:to="loc_us-gaap_SegmentDomain_de02331e-8858-4ad4-8871-cc6e12f3fb2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de02331e-8858-4ad4-8871-cc6e12f3fb2d" xlink:to="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_65e75910-7026-4af3-8af1-bac7b87240b9" xlink:href="jnj-20220403.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:to="loc_jnj_ConsumerMember_65e75910-7026-4af3-8af1-bac7b87240b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_12fcab79-72dc-413f-af1d-eb36ad542f1c" xlink:href="jnj-20220403.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:to="loc_jnj_PharmaceuticalMember_12fcab79-72dc-413f-af1d-eb36ad542f1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a8fe3675-65f5-4ab6-9ea4-413b263c932e" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:to="loc_jnj_MedicalDevicesMember_a8fe3675-65f5-4ab6-9ea4-413b263c932e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b5c4196b-840a-42a2-8e8b-7fdf7873bcd6" xlink:href="jnj-20220403.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b5c4196b-840a-42a2-8e8b-7fdf7873bcd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7da7deb0-cf0d-46ab-a01f-8afd836fc63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7da7deb0-cf0d-46ab-a01f-8afd836fc63a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7da7deb0-cf0d-46ab-a01f-8afd836fc63a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7da7deb0-cf0d-46ab-a01f-8afd836fc63a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7da7deb0-cf0d-46ab-a01f-8afd836fc63a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b75a1a95-4a3a-4466-9b10-279aa972e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7da7deb0-cf0d-46ab-a01f-8afd836fc63a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b75a1a95-4a3a-4466-9b10-279aa972e5f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_eac5890b-69a7-49e0-a96d-e1d3d310a6e4" xlink:href="jnj-20220403.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b75a1a95-4a3a-4466-9b10-279aa972e5f4" xlink:to="loc_jnj_BermekimabMember_eac5890b-69a7-49e0-a96d-e1d3d310a6e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended" id="idae6c2cd0a384a1a8924e7664bf85d88_SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_159515a2-b273-45e4-9f67-6f86997808f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_d3066a79-3e8b-4476-91b6-0e6d9f8674bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_159515a2-b273-45e4-9f67-6f86997808f0" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_d3066a79-3e8b-4476-91b6-0e6d9f8674bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b716e90a-e9f4-451c-b669-aeb59d849e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_d3066a79-3e8b-4476-91b6-0e6d9f8674bc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b716e90a-e9f4-451c-b669-aeb59d849e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_62deb3c0-f7fc-4537-aaed-f9eeeec906ba" xlink:href="jnj-20220403.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_d3066a79-3e8b-4476-91b6-0e6d9f8674bc" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_62deb3c0-f7fc-4537-aaed-f9eeeec906ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d1e7b62b-44ad-4610-9484-35a551e50371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_159515a2-b273-45e4-9f67-6f86997808f0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d1e7b62b-44ad-4610-9484-35a551e50371" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6e31962e-83c2-4eee-8334-6d82264277c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d1e7b62b-44ad-4610-9484-35a551e50371" xlink:to="loc_srt_StatementGeographicalAxis_6e31962e-83c2-4eee-8334-6d82264277c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6e31962e-83c2-4eee-8334-6d82264277c5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6e31962e-83c2-4eee-8334-6d82264277c5" xlink:to="loc_srt_SegmentGeographicalDomain_6e31962e-83c2-4eee-8334-6d82264277c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6e31962e-83c2-4eee-8334-6d82264277c5" xlink:to="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c077128f-332c-4f62-8d19-80d56278ecbe" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:to="loc_country_US_c077128f-332c-4f62-8d19-80d56278ecbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c30375d8-ede4-4969-93a9-97defae5b98c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:to="loc_srt_EuropeMember_c30375d8-ede4-4969-93a9-97defae5b98c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_59928870-e857-4b37-ba98-1a155faf0934" xlink:href="jnj-20220403.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_59928870-e857-4b37-ba98-1a155faf0934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_915bab6b-85f0-4be3-918a-2369ac3017fb" xlink:href="jnj-20220403.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:to="loc_jnj_AsiaPacificAfricaMember_915bab6b-85f0-4be3-918a-2369ac3017fb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="i2bcad3066b9a4533ae762b23c48db2d4_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1009d72e-a151-4cb7-ad43-828525f287e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a67df2ae-3d7f-48c9-a18e-6e9a2ee94a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1009d72e-a151-4cb7-ad43-828525f287e5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a67df2ae-3d7f-48c9-a18e-6e9a2ee94a87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_238d3289-3626-45f5-831a-2c12e9121cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1009d72e-a151-4cb7-ad43-828525f287e5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_238d3289-3626-45f5-831a-2c12e9121cab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00be8f68-034a-4eb7-ac77-f3ca1c2cc3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_238d3289-3626-45f5-831a-2c12e9121cab" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00be8f68-034a-4eb7-ac77-f3ca1c2cc3d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00be8f68-034a-4eb7-ac77-f3ca1c2cc3d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00be8f68-034a-4eb7-ac77-f3ca1c2cc3d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00be8f68-034a-4eb7-ac77-f3ca1c2cc3d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf5cd404-834f-4940-bfa4-a4f9bdced21f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00be8f68-034a-4eb7-ac77-f3ca1c2cc3d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf5cd404-834f-4940-bfa4-a4f9bdced21f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_bc3819f9-83ed-4b4f-bd08-77d310c237b3" xlink:href="jnj-20220403.xsd#jnj_EvraAndDoxilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf5cd404-834f-4940-bfa4-a4f9bdced21f" xlink:to="loc_jnj_EvraAndDoxilMember_bc3819f9-83ed-4b4f-bd08-77d310c237b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#LegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended" id="i68a1d7c6b12a477098feb856fc59bbd9_LegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_428363d6-4ea9-4d8c-882f-8539645dc886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:href="jnj-20220403.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_428363d6-4ea9-4d8c-882f-8539645dc886" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_bfc65192-9fc1-40b5-b069-a0f4231d864e" xlink:href="jnj-20220403.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_bfc65192-9fc1-40b5-b069-a0f4231d864e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_190d3d00-cb72-486d-81d7-7bf87376c5d5" xlink:href="jnj-20220403.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_Numberofpatientsinsettlement_190d3d00-cb72-486d-81d7-7bf87376c5d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_a47717dc-e604-4c3e-a1b0-af93cebbbef0" xlink:href="jnj-20220403.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_a47717dc-e604-4c3e-a1b0-af93cebbbef0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_3977f62e-ed9b-4334-9ebd-26b2dbec47b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_3977f62e-ed9b-4334-9ebd-26b2dbec47b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_b6187af3-be3c-4d33-bd74-0af8caa136c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_b6187af3-be3c-4d33-bd74-0af8caa136c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_5371443d-d5df-472d-ae22-3cab3605a8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_5371443d-d5df-472d-ae22-3cab3605a8b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_b96e3c33-4243-4acc-a4ad-337f0e6f8027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_b96e3c33-4243-4acc-a4ad-337f0e6f8027" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_8369ea2f-a64e-4929-90a8-62ffc8281dc4" xlink:href="jnj-20220403.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_8369ea2f-a64e-4929-90a8-62ffc8281dc4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5ffb94b1-7ba7-40a8-908d-90209b0fc42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5ffb94b1-7ba7-40a8-908d-90209b0fc42d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_d40e2c9d-e802-411d-b7bb-bfcf7f87e032" xlink:href="jnj-20220403.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_d40e2c9d-e802-411d-b7bb-bfcf7f87e032" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_428363d6-4ea9-4d8c-882f-8539645dc886" xlink:to="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c4354a74-ce91-45d7-a937-59ff92a36c99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_srt_LitigationCaseAxis_c4354a74-ce91-45d7-a937-59ff92a36c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c4354a74-ce91-45d7-a937-59ff92a36c99_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c4354a74-ce91-45d7-a937-59ff92a36c99" xlink:to="loc_srt_LitigationCaseTypeDomain_c4354a74-ce91-45d7-a937-59ff92a36c99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c4354a74-ce91-45d7-a937-59ff92a36c99" xlink:to="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_8fe39f79-0972-4bc1-9d8c-367fb5f7b2a4" xlink:href="jnj-20220403.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_DePuyASRU.S.Member_8fe39f79-0972-4bc1-9d8c-367fb5f7b2a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_d17bf823-2e1c-45a2-a84c-3a995f10b717" xlink:href="jnj-20220403.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_RisperdalMember_d17bf823-2e1c-45a2-a84c-3a995f10b717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_9cdcd855-36b7-4a1d-b999-be5a59ae37cf" xlink:href="jnj-20220403.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_BabyPowderMember_9cdcd855-36b7-4a1d-b999-be5a59ae37cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_5e6d4e47-6945-42d8-b6cb-0a9f6dd181a5" xlink:href="jnj-20220403.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_5e6d4e47-6945-42d8-b6cb-0a9f6dd181a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_7607f22c-fcad-4130-8e23-ce960518f231" xlink:href="jnj-20220403.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_7607f22c-fcad-4130-8e23-ce960518f231" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_7b7c4777-9ef0-4a58-b412-7461a95428fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_us-gaap_LitigationStatusAxis_7b7c4777-9ef0-4a58-b412-7461a95428fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7b7c4777-9ef0-4a58-b412-7461a95428fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_7b7c4777-9ef0-4a58-b412-7461a95428fb" xlink:to="loc_us-gaap_LitigationStatusDomain_7b7c4777-9ef0-4a58-b412-7461a95428fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_7b7c4777-9ef0-4a58-b412-7461a95428fb" xlink:to="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_de4802a6-7d29-46da-bc38-a232cc8387d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:to="loc_us-gaap_SettledLitigationMember_de4802a6-7d29-46da-bc38-a232cc8387d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_9c5caeed-b3b3-44b1-96e6-8fd98d2645c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:to="loc_us-gaap_JudicialRulingMember_9c5caeed-b3b3-44b1-96e6-8fd98d2645c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_3406be62-b2a1-475a-b83c-38fd087bb07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:to="loc_us-gaap_PendingLitigationMember_3406be62-b2a1-475a-b83c-38fd087bb07c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b2b870d-83b2-4609-8465-25bd7d63369e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_srt_ProductOrServiceAxis_9b2b870d-83b2-4609-8465-25bd7d63369e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b2b870d-83b2-4609-8465-25bd7d63369e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9b2b870d-83b2-4609-8465-25bd7d63369e" xlink:to="loc_srt_ProductsAndServicesDomain_9b2b870d-83b2-4609-8465-25bd7d63369e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9b2b870d-83b2-4609-8465-25bd7d63369e" xlink:to="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_4c9f88f2-951a-46ed-8e55-6d0b1dfdb03c" xlink:href="jnj-20220403.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_AsrMember_4c9f88f2-951a-46ed-8e55-6d0b1dfdb03c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_5305defa-386c-4d8a-9f6d-4d9939f4d888" xlink:href="jnj-20220403.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_5305defa-386c-4d8a-9f6d-4d9939f4d888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_4fbd3fb0-449f-46b9-b55d-808c909d2ed6" xlink:href="jnj-20220403.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_PelvicMeshesMember_4fbd3fb0-449f-46b9-b55d-808c909d2ed6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_c942521c-6c23-4474-b6f6-6fd1778140d6" xlink:href="jnj-20220403.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_RisperdalMember_c942521c-6c23-4474-b6f6-6fd1778140d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_1d0b19ba-9b05-40c8-9ad2-2027ebfdd2e0" xlink:href="jnj-20220403.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_XareltoMember_1d0b19ba-9b05-40c8-9ad2-2027ebfdd2e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_a3577cd3-1f71-4cfb-a2b1-98c3c9763ebb" xlink:href="jnj-20220403.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_TalcMember_a3577cd3-1f71-4cfb-a2b1-98c3c9763ebb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_1b8d7e78-653f-4f34-a998-5ee4ea93ba90" xlink:href="jnj-20220403.xsd#jnj_InvokanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_InvokanaMember_1b8d7e78-653f-4f34-a998-5ee4ea93ba90" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_9100795c-514c-40f9-96fa-5084054d442d" xlink:href="jnj-20220403.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_PhysiomeshMember_9100795c-514c-40f9-96fa-5084054d442d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_fe4ef257-e54f-4aca-b8ef-749ec7f38728" xlink:href="jnj-20220403.xsd#jnj_OpioidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_OpioidMember_fe4ef257-e54f-4aca-b8ef-749ec7f38728" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_97264319-4a05-4e10-8700-e6e3b080501f" xlink:href="jnj-20220403.xsd#jnj_ContactLensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_ContactLensesMember_97264319-4a05-4e10-8700-e6e3b080501f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_4f0fcb8f-911e-4a75-962a-3bf6dc133b0a" xlink:href="jnj-20220403.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_4f0fcb8f-911e-4a75-962a-3bf6dc133b0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_4f0fcb8f-911e-4a75-962a-3bf6dc133b0a_default" xlink:href="jnj-20220403.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_4f0fcb8f-911e-4a75-962a-3bf6dc133b0a" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_4f0fcb8f-911e-4a75-962a-3bf6dc133b0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_6511659e-56ea-4dc9-a143-e4aba16f7680" xlink:href="jnj-20220403.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_4f0fcb8f-911e-4a75-962a-3bf6dc133b0a" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_6511659e-56ea-4dc9-a143-e4aba16f7680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_c73eef29-afec-4ea0-a531-f5df799810d1" xlink:href="jnj-20220403.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_6511659e-56ea-4dc9-a143-e4aba16f7680" xlink:to="loc_jnj_RisperdalMember_c73eef29-afec-4ea0-a531-f5df799810d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ace4d949-e9b1-41f3-8797-5a490c07fa32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ace4d949-e9b1-41f3-8797-5a490c07fa32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ace4d949-e9b1-41f3-8797-5a490c07fa32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ace4d949-e9b1-41f3-8797-5a490c07fa32" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ace4d949-e9b1-41f3-8797-5a490c07fa32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_39ec7bd5-440d-4149-9097-155864c10e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ace4d949-e9b1-41f3-8797-5a490c07fa32" xlink:to="loc_us-gaap_LossContingencyNatureDomain_39ec7bd5-440d-4149-9097-155864c10e07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_decd7068-19e6-470f-acba-c5755d869a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_39ec7bd5-440d-4149-9097-155864c10e07" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_decd7068-19e6-470f-acba-c5755d869a19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_70b6646d-485f-4672-8384-64ae82fd7637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_70b6646d-485f-4672-8384-64ae82fd7637" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_70b6646d-485f-4672-8384-64ae82fd7637_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_70b6646d-485f-4672-8384-64ae82fd7637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_70b6646d-485f-4672-8384-64ae82fd7637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61092031-4ed4-4c1e-b627-ddba036ef1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_70b6646d-485f-4672-8384-64ae82fd7637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61092031-4ed4-4c1e-b627-ddba036ef1e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c22fa67f-6d34-4fbb-a77d-0576b11c65c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_61092031-4ed4-4c1e-b627-ddba036ef1e7" xlink:to="loc_us-gaap_SubsequentEventMember_c22fa67f-6d34-4fbb-a77d-0576b11c65c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i13933f1d6d8a43c6ae6b1efe637879e7_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e0470c57-f882-4d91-8951-ef9cc076ee33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:to="loc_us-gaap_RestructuringCharges_e0470c57-f882-4d91-8951-ef9cc076ee33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_f601eb5a-893b-4b61-909a-9045294150c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_f601eb5a-893b-4b61-909a-9045294150c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_be1d433c-4892-4fca-9f13-676966fb9ca0" xlink:href="jnj-20220403.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_be1d433c-4892-4fca-9f13-676966fb9ca0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_74e31e5e-e0dd-4e27-877b-2a42eac3fd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_74e31e5e-e0dd-4e27-877b-2a42eac3fd96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_813c53e6-7130-493a-895c-51a5d82b3d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_813c53e6-7130-493a-895c-51a5d82b3d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_813c53e6-7130-493a-895c-51a5d82b3d93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_813c53e6-7130-493a-895c-51a5d82b3d93" xlink:to="loc_us-gaap_SegmentDomain_813c53e6-7130-493a-895c-51a5d82b3d93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bc719fae-42e5-4fc9-a726-b149f179fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_813c53e6-7130-493a-895c-51a5d82b3d93" xlink:to="loc_us-gaap_SegmentDomain_bc719fae-42e5-4fc9-a726-b149f179fe31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_adb03b90-911d-4341-b520-66fcffb61c69" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bc719fae-42e5-4fc9-a726-b149f179fe31" xlink:to="loc_jnj_MedicalDevicesMember_adb03b90-911d-4341-b520-66fcffb61c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_1ef96637-0384-4974-9758-39dd18d46a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:to="loc_us-gaap_RestructuringPlanAxis_1ef96637-0384-4974-9758-39dd18d46a58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_1ef96637-0384-4974-9758-39dd18d46a58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_1ef96637-0384-4974-9758-39dd18d46a58" xlink:to="loc_us-gaap_RestructuringPlanDomain_1ef96637-0384-4974-9758-39dd18d46a58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_441667b8-a04f-4314-871e-a165d9c12a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_1ef96637-0384-4974-9758-39dd18d46a58" xlink:to="loc_us-gaap_RestructuringPlanDomain_441667b8-a04f-4314-871e-a165d9c12a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_5b0ddc15-a2a9-42fa-9e73-46580386bd6c" xlink:href="jnj-20220403.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_441667b8-a04f-4314-871e-a165d9c12a67" xlink:to="loc_jnj_SupplyChainMember_5b0ddc15-a2a9-42fa-9e73-46580386bd6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_176da74e-b9d9-40e1-8888-4d02c858b6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_176da74e-b9d9-40e1-8888-4d02c858b6b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_176da74e-b9d9-40e1-8888-4d02c858b6b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_176da74e-b9d9-40e1-8888-4d02c858b6b2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_176da74e-b9d9-40e1-8888-4d02c858b6b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_176da74e-b9d9-40e1-8888-4d02c858b6b2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_f6014ce6-1c42-47c3-be6f-b765a304a2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:to="loc_us-gaap_RestructuringChargesMember_f6014ce6-1c42-47c3-be6f-b765a304a2b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7e4c73ea-38ce-451e-b6d9-5123885bb85c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:to="loc_us-gaap_CostOfSalesMember_7e4c73ea-38ce-451e-b6d9-5123885bb85c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_82fbadbe-6fd0-43fb-8c58-5ecea2d35fc5" xlink:href="jnj-20220403.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_82fbadbe-6fd0-43fb-8c58-5ecea2d35fc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e750cb26-3435-4764-9ce6-83d677c1378e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:to="loc_srt_RangeAxis_e750cb26-3435-4764-9ce6-83d677c1378e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e750cb26-3435-4764-9ce6-83d677c1378e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e750cb26-3435-4764-9ce6-83d677c1378e" xlink:to="loc_srt_RangeMember_e750cb26-3435-4764-9ce6-83d677c1378e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0110ffdd-b64c-4033-9a12-553259e2cc71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e750cb26-3435-4764-9ce6-83d677c1378e" xlink:to="loc_srt_RangeMember_0110ffdd-b64c-4033-9a12-553259e2cc71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2ac9b42a-618f-44f1-a11c-820adaa11e03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0110ffdd-b64c-4033-9a12-553259e2cc71" xlink:to="loc_srt_MaximumMember_2ac9b42a-618f-44f1-a11c-820adaa11e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07421bf6-460e-436a-bf37-f7835d8b5125" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0110ffdd-b64c-4033-9a12-553259e2cc71" xlink:to="loc_srt_MinimumMember_07421bf6-460e-436a-bf37-f7835d8b5125" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended" id="i1ccd5a24c57d4dc691e42ff3b5106a46_RestructuringScheduleofRestructuringReserveDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9a23b56c-2ef9-4d68-af83-68e8e01cc6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9a23b56c-2ef9-4d68-af83-68e8e01cc6cd" xlink:to="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4693373b-4c2e-43ef-af4c-9e245238b565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:to="loc_us-gaap_RestructuringReserve_4693373b-4c2e-43ef-af4c-9e245238b565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_54b49c7c-af2a-4ef6-a258-c49d57a6d4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:to="loc_us-gaap_RestructuringCharges_54b49c7c-af2a-4ef6-a258-c49d57a6d4fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsForRestructuringNet_43fc73c3-5c00-4102-82d9-e238254d6509" xlink:href="jnj-20220403.xsd#jnj_PaymentsForRestructuringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:to="loc_jnj_PaymentsForRestructuringNet_43fc73c3-5c00-4102-82d9-e238254d6509" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5d3eba74-711a-4c31-8eae-14300b54bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5d3eba74-711a-4c31-8eae-14300b54bc78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6f691169-5a23-4593-8074-66da3253d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f20d41fe-68c3-4e84-ad5b-3822fd799685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9a23b56c-2ef9-4d68-af83-68e8e01cc6cd" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f20d41fe-68c3-4e84-ad5b-3822fd799685" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_39345fab-9a50-40a5-a290-955079fe9656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f20d41fe-68c3-4e84-ad5b-3822fd799685" xlink:to="loc_us-gaap_RestructuringPlanAxis_39345fab-9a50-40a5-a290-955079fe9656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_39345fab-9a50-40a5-a290-955079fe9656_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_39345fab-9a50-40a5-a290-955079fe9656" xlink:to="loc_us-gaap_RestructuringPlanDomain_39345fab-9a50-40a5-a290-955079fe9656_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b8520b69-e653-431d-a9f0-6806aa06903e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_39345fab-9a50-40a5-a290-955079fe9656" xlink:to="loc_us-gaap_RestructuringPlanDomain_b8520b69-e653-431d-a9f0-6806aa06903e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_dcb0330c-940f-4d42-9703-9fe04f0972c7" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_b8520b69-e653-431d-a9f0-6806aa06903e" xlink:to="loc_jnj_MedicalDevicesMember_dcb0330c-940f-4d42-9703-9fe04f0972c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_dd0bb7ee-b3ae-4b78-9994-52cc54b4faca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f20d41fe-68c3-4e84-ad5b-3822fd799685" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_dd0bb7ee-b3ae-4b78-9994-52cc54b4faca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_dd0bb7ee-b3ae-4b78-9994-52cc54b4faca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_dd0bb7ee-b3ae-4b78-9994-52cc54b4faca" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_dd0bb7ee-b3ae-4b78-9994-52cc54b4faca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_dd0bb7ee-b3ae-4b78-9994-52cc54b4faca" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_688e18a5-8641-492d-8e7b-c613bae6fee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:to="loc_us-gaap_EmployeeSeveranceMember_688e18a5-8641-492d-8e7b-c613bae6fee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_b7338122-800f-4f9d-a20e-90b162f439e4" xlink:href="jnj-20220403.xsd#jnj_AssetWriteoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:to="loc_jnj_AssetWriteoffMember_b7338122-800f-4f9d-a20e-90b162f439e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_b4dafa15-c1c5-462b-b9d9-64f2a9dddebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:to="loc_us-gaap_OtherRestructuringMember_b4dafa15-c1c5-462b-b9d9-64f2a9dddebc" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>jnj-20220403_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:16b74ba9-87ed-4a1d-982b-bd3712a1fa43,g:84010c2d-9ae9-41ea-8d72-e231a49d0ab7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9442a47e-fe9b-4c85-85db-19622522c4fc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_a52b42cd-bd5d-4251-b477-7093e864d3ca_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_9ec2789a-c86d-4fd6-8134-bdf08b4b7188_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_08e35d47-bed2-4b4f-877b-9abdfe0ff6dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_f951f122-6c09-4566-9842-3e92816190af_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_d4e63092-4e11-4640-beb2-4be8b05a96c0_terseLabel_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_label_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_documentation_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:href="jnj-20220403.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:to="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_422d8d0f-b277-4728-a781-e4235500e972_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20220403.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07a8eeb2-0692-48b5-8f70-97175955d27e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3d7e42b3-0672-4c2c-9bda-9d67204e0b7a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0be291cf-e7c3-42f4-8f33-da35bcb9061b_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_21c08a76-2e68-4bdf-a9a7-460f7d72cfc5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_4e693d8e-262e-4c62-ba79-1c7e191373d8_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value (6)</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20220403.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_dc27e619-3089-4ba4-a148-14fe6508152a_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_264c9ea9-3f6f-40e3-8376-b8b7f8641b9d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_30fb429b-5748-4c49-9bcb-053196e0df5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6d3e040d-4aac-4125-859a-1cf969f596fa_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_34c81c6b-f5be-4080-851c-54735f1e22f0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_794bca98-5d02-4c1a-ac02-7f38835057ed_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20220403.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5d4968a4-6ec8-4506-be92-3fd54134081d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_faf08deb-1192-40fc-83c1-9a48f7cb1ca0_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20220403.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_bf69087d-9d24-425c-bd20-2894f6538827_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4350ef7f-ffd5-4b02-b5fa-1b80f7050d99_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_5f7f9351-8203-47c8-b94e-d695ff4e5949_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_79b61106-dc9d-4077-9c2c-b6b75d0bb05a_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_ec9a3b98-88be-492e-bd57-888e137629c0_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20220403.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_197e8aa6-ddb6-4ee7-b1e7-2aeccc13931f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b0ab01fc-9b21-41f1-8b74-1d41faccf92e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_0044429c-e41e-4068-bde3-082a347fb50b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_454f1c4d-8bb7-44f1-8a0a-49f779b45d41_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_05d76d44-70a0-4f69-bd5d-839742de3dc7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_64fb759b-0981-4586-8140-cc33282a2c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0fb63a0b-98f0-4741-95a4-01dc88c228db_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_b7617de0-f9b8-487a-a72b-795c157b2748_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_05314a61-e527-4c98-8c23-b099d8093b32_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_1a21fbad-7e13-42dc-ae58-00e8b961ac8e_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_label_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in operating income loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:href="jnj-20220403.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:to="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_040e7bca-7017-47bb-aad8-a4da26db1d8e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_fe645113-7147-4679-aeb6-bc0fc4aab422_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_9d3128bb-ec91-4395-bbae-dc209f60ecf4_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_925df538-ca74-4591-a90d-cdbd25a6bc1d_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_a0bde412-6e27-45fe-9f28-f5be55ec1635_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Business Segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_3c7d5516-9831-4b1e-b61c-e5f1e5431422_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_a3b52068-78a0-4590-b4db-ed1811d21904_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_62a833e9-c293-4f41-9038-b7dd561ee6b7_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cefaaf01-38f4-4401-8bd7-d94b4682c27c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_1f81c761-8a2c-446a-b7bf-2aa5e0fc1dc2_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_2f56237e-dde1-4acf-bad5-8f73c2a42639_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20220403.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a15e4af5-1aaa-416c-9b5c-6fecc74349b5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_32ed05a6-e5c3-4e44-9637-d56434af63d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_c77d8c8d-873b-48a2-97cf-af9ce0a117a6_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES / OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20220403.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6944a5d7-ad49-4b27-8c99-85211eaab49c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for Sale Securities Maturities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_49c16ab1-2142-4f56-bc85-a36397227704_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on disposition of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_34c74a16-2405-47f4-a2ff-1a8146db8fcd_negatedTerseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:href="jnj-20220403.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_8be75ac1-2513-4d89-8615-2de488fd6256_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_891c7779-841d-4f75-97b2-aec183fb0474_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: shares which could be repurchased under treasury stock method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20220403.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a597180f-bbe7-4fb6-98c5-9acffd0fba16_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_eea82b5f-0af3-41e1-aba2-16ebbc0bc67b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_a293a310-6335-4a0f-98c3-4180badf4d90_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20220403.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5fb709ea-73fe-468b-bbd4-4ceea114a3bf_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_121a7943-f307-4b39-a921-062067f8f533_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_0fe23f97-29b2-41dc-bc21-a733b663aa4f_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_49813009-e839-4355-9de9-3f57e8518483_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_060c4742-d16b-4f59-8f61-0b67c60605bc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_08b6f571-b7f4-4f3b-a07c-c1f542579636_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_2475e4b6-7b8e-4e0d-9233-e81d1dc8c64a_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_a8ba4c3a-2b4d-4557-8f2e-9a4718481ba9_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_e860c6d7-1e75-4df8-8830-3bdd9de56fc6_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes due 2035 (1.5B Euro 1.1311)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20220403.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_b576508f-8b8b-4ded-8b36-2d422f85afc2_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20220403.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e947a497-0c27-4f03-9df7-4256e82714cc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_e7a95fc4-603b-4b10-8e0b-30d9ff23d6e5_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims within settlement agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_label_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_documentation_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:href="jnj-20220403.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:to="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_4f762249-df4c-4fa8-ba5d-a029535cb4cc_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_3bf22de9-c43a-4958-933e-84b3d61e7880_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_09f8a994-9254-46e0-8882-613f53e20762_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20220403.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f74673f8-692a-41f6-b269-22f9fd6d598d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fde38578-0991-4b44-b19d-43e6dc0e155f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_26674e05-4cc4-420e-9291-9526b2c6418f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_040c1a3a-13f8-4f0c-aa1d-2d1077e36d7e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_dab1175a-692a-4062-ba37-9639aca283ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_451541af-8b60-485e-bb29-4cb256c1c786_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_f0545cca-45e3-49e5-894d-ca3193265ec0_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20220403.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b1117485-9767-4c5a-9751-0f9a30f037ff_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_1ec33c17-1846-435d-b43d-0e9d32190cfb_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20220403.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_407d42a9-539d-4091-9c76-becae1622112_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20220403.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ab907cf8-dfe4-4b15-b50f-0f4245b371ed_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_cb3050a3-11d7-4e18-951a-234b52804bff_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_c88f1c66-cbd7-470a-93fb-b16f48097eba_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvokanaMember_9e914738-af75-4921-9049-567f50d8152b_terseLabel_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana</link:label>
    <link:label id="lab_jnj_InvokanaMember_label_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:label id="lab_jnj_InvokanaMember_documentation_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember" xlink:href="jnj-20220403.xsd#jnj_InvokanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvokanaMember" xlink:to="lab_jnj_InvokanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_37a6d139-fd71-4bfa-a997-fa4ea53390b3_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_b795d558-0443-45a5-9e59-e3366410f0cc_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f4cc4375-4fe5-4c0d-8e9c-b0b051482074_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_a7a16a5f-cbf0-4f61-9a34-9b8eb20f3182_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S.</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20220403.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f4bd3f36-91bb-498c-96da-ab15d5ac562a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_6bba33e0-26db-47ac-a293-23853d7002d7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_1c506ff7-a83f-47f7-83bf-fa6896e3f304_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_77c241a8-863c-4e26-bc5b-9a41980f443b_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_e910086d-5a54-412d-89db-6aeae5ff7e9e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_f66140d4-b062-490d-ab37-a6e947b36a4d_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_8ea894f0-be30-4d7c-85de-78d667f5ec92_terseLabel_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income percent to sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_label_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income interest percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:href="jnj-20220403.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:to="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_37f40fb3-2706-45ff-ab43-a6ddc1c8a133_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost/(credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5312ef1b-90f2-4523-b9e7-43a211a58110_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_20aaa01c-f4bd-4a1b-a0e1-036aa12ec878_terseLabel_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net percent to sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Operating Income Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non operating income expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:href="jnj-20220403.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:to="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_2eca18e5-6c46-415d-b342-22f61663eb3d_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b5a97617-88ab-421d-b750-b7cff80031bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BeautyMember_7c458025-a81d-4010-ad93-c22835e537fb_terseLabel_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin Health/Beauty</link:label>
    <link:label id="lab_jnj_BeautyMember_label_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:label id="lab_jnj_BeautyMember_documentation_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember" xlink:href="jnj-20220403.xsd#jnj_BeautyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BeautyMember" xlink:to="lab_jnj_BeautyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_6f765055-9127-40c2-9284-a7e970c37c11_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8706194d-d6cd-4e17-a761-2006a3a988a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_0054f3fb-d2f1-4cbc-b166-65d6dd0b85a6_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_a6033b6f-ad94-46dd-ac6e-2f9f72194bd5_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_COVID19Member_322a64c0-268f-44f1-bf20-d515ac0e71ca_terseLabel_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_jnj_COVID19Member_label_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_jnj_COVID19Member_documentation_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member" xlink:href="jnj-20220403.xsd#jnj_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_COVID19Member" xlink:to="lab_jnj_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_45ac8d00-ed5a-4852-9905-63b6642757fb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3dd749b5-c774-4ced-9b84-42f1b40f224c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_90c7708e-0759-4d62-ab2b-fe271f9b3bb4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_06577e1c-1e0b-40c2-85cb-fabebd2ea308_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e098e035-704c-4b9a-8954-49192a43a91e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_e666719d-1b6a-4719-b229-cdbebbb24097_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov't securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_0a7898fe-0472-4fa9-815e-cb22ba060e09_terseLabel_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL [Member]</link:label>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_label_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL [Member]</link:label>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_documentation_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:href="jnj-20220403.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:to="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_44f241c1-23de-40d7-9381-dc3f38b59323_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_434f8927-3238-43b1-8797-32b1845d30de_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_8978d2ad-57c3-4ccd-9259-4d3279179977_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d7aaedea-584e-46c3-bfbc-82eb0d9bf410_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_56fb3945-485e-4939-b3e4-883618d26d96_terseLabel_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member" xlink:href="jnj-20220403.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.375Notesdue2023Member" xlink:to="lab_jnj_A3.375Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_c883e5b3-43d4-4a56-97b2-b34e69f0309b_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20220403.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_82992f0a-51f7-4c81-82d3-1ef17fe9f3b0_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20220403.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_dbfde6b9-096b-444a-9f6f-64fc2cb8f260_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_07b1ce86-250b-4182-8f56-dad099680bae_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20220403.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_68360e36-8400-4c13-ba0b-c678b14e1c48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_7364732d-3c50-4260-907f-1e19859bf5b6_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development in process percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">research and development in process percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:href="jnj-20220403.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplyChainMember_33ec163c-49ee-4c3b-b78a-1961872cdb39_terseLabel_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:label id="lab_jnj_SupplyChainMember_label_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain [Member]</link:label>
    <link:label id="lab_jnj_SupplyChainMember_documentation_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember" xlink:href="jnj-20220403.xsd#jnj_SupplyChainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplyChainMember" xlink:to="lab_jnj_SupplyChainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_67f06e04-ddbc-43ee-8b53-753830d243a8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_82e2ced5-81d6-4e96-b424-fa6f94ca7776_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_76eb6035-152f-485e-b5a6-c38e6fb8d56f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_c1427caf-2aed-407c-9007-6c2855af3f6e_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20220403.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_79871744-9bdb-479e-b3c4-501c44abeb8f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_d0cc69b8-e71d-4e8d-a677-214ce50d3c79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_f728aa0b-e5fa-44a7-a359-bba4629966dc_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_845bd87c-39f5-4818-88b3-f3c2f7aeb8aa_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_80f14a0c-61ac-43f2-82c9-24576c17f2f0_terseLabel_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_label_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing [Member]</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_documentation_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:href="jnj-20220403.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:to="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_79f7ea5e-d715-4d84-96a9-d9d8702cae2b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets and liabilities Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae5c848a-e214-4dcd-be20-49e5e37cdc03_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8f75042f-bc2a-4a98-9a2f-b83c1b7c520e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_994663bd-a6f2-4379-a38e-739069d18b01_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_5366c6b8-a95a-4ed6-9b75-e3f44b462980_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_7ba302f1-2c10-4d9f-acde-09d774c517e7_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0612d205-6196-4b53-a874-85bb8d6bc566_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_18bc1e4a-3df5-4826-907d-5308aa7ecabe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_ee752256-362b-4c12-8a62-20e5291ab19d_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_7748b082-ba35-4006-9446-f768e1c24ed3_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b03a1b82-d771-499e-9efc-413a5fad3e23_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1300NotesDue2030Member_710f50b0-10b1-4580-b72b-3c988e42a429_terseLabel_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member" xlink:href="jnj-20220403.xsd#jnj_A1300NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1300NotesDue2030Member" xlink:to="lab_jnj_A1300NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_5639a571-89fa-474d-a487-7db435b5d49a_totalLabel_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:href="jnj-20220403.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:to="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_4320e57e-6520-43e6-9770-3ca6e6289dc3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e61afbbc-f11e-4494-97d4-104582e58c9e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_1ced2eff-be5e-496e-a6d4-1441a57d6265_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular / Metabolism / Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20220403.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_ea3efcf3-b820-4b9b-a005-b0b77980fc33_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_cb1ea1b0-a5cf-48fe-bb30-17aa673d7899_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_afc643b6-ffa6-4ff4-91af-fec4f8484264_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_c811a3c9-0cff-4eda-ae7e-58f7a3e1236e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_89db7457-4e0b-4868-9482-15c61514be66_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_379137b8-d5c4-4ede-9e44-7c8daf6989c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4912ce45-aca0-4ee7-9010-ce69c2f270aa_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_e4c41123-849d-40ca-891d-6b62edc244f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7a353145-73e0-42d5-8cf5-6c7c1c9751ed_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_6971457f-f035-4917-bdcc-8723a7a9b913_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International retirement plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_060ad0ae-5b00-486b-b4be-6b1f0ce7f6a1_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20220403.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_6c8e00cd-6c8c-45c6-987c-e056f2acc56b_terseLabel_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals)</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_label_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract" xlink:href="jnj-20220403.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalProceedingTextualsAbstract" xlink:to="lab_jnj_LegalProceedingTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c54a6b41-369f-4d53-a82b-127814b9d592_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_c14f60b2-ed01-4ed8-8019-6cb7083b3b2e_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20220403.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_4296237d-c132-43bc-a0bb-a1d2692d5269_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20220403.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_eb01630e-15e1-471f-8624-f6ebda72ad22_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_f1ee855c-6638-48da-b68a-a49b4dfbd3db_terseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20220403.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyCareMember_44ed49ce-9b7c-40fe-9a0b-670734579664_terseLabel_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care</link:label>
    <link:label id="lab_jnj_BabyCareMember_label_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:label id="lab_jnj_BabyCareMember_documentation_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember" xlink:href="jnj-20220403.xsd#jnj_BabyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyCareMember" xlink:to="lab_jnj_BabyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_b4d2bf53-673e-41ae-b576-fdf889c1657d_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20220403.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_cceb4731-9ab4-4ede-b1eb-288bb4249c4b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_5d93c03b-b822-4b89-b4cc-1dd157dc12ac_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f2b92289-e576-499b-b6c3-c9f39f4aeb74_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_262abb14-849d-4b61-8848-8c29aabc4fd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_519c983e-550d-4d27-beb7-3274f39e8044_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_05293239-370e-42b4-9c97-6454784798a0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ed69743d-89d6-4e46-aa96-472f5f4f0638_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_c909f730-c84e-4742-b0b2-f5b9a816b044_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5c1a438d-4bbc-4c3a-8af9-774dfab3eef4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_1226530d-7c34-4951-807c-0964818e8945_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net (Note 10)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_510f4478-ad7f-4175-85da-56b08ed686b7_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20220403.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_07f6e3d1-dd61-4bf5-bcee-e6828317556a_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20220403.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_613ce78f-0741-4520-b8b2-b68fd54e5bc5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_518bd25d-f41b-44cc-838c-c9faa2274176_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20220403.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c587cc53-26d4-434c-beca-cacb67c90bea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_951682cb-c3d4-4866-a145-be5728cfb75c_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_24c9db0a-70ea-4f83-92aa-209a261f54eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_f76180dc-21ec-4560-a942-c458bc5bca8b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_f7384d5d-57f7-49ba-b442-43bcf59d9c33_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20220403.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_22bef31a-b35a-4e3b-a39d-cf882d482ccc_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_84ba7a90-e253-44d0-aec3-49b63c9216de_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_1df70482-db27-4d70-8e48-a54dfe63f766_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIMPONI / SIMPONI ARIA</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20220403.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_05d53fbd-1d5e-4a35-ab08-b8ad7419b975_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20220403.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_101d5980-f3c7-4866-b450-6b99acc954f1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired (Note 10)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_1a120326-ffed-4fb3-8468-6f222be967cf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_7f7d54e1-2cdc-4c8c-aa58-8972e58b0f69_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_44162643-c442-4ca6-a0c6-01706c46a2e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_43526895-f6c1-4617-a36e-41b2529f9ac7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_ae1ed96b-2ec7-4d8c-a9c1-4445507ee659_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled non cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_52505a9a-2552-464b-9381-af3beb42f545_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XARELTO</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20220403.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_49abc35b-4156-4787-9a3a-017aedf40546_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_2c6e477e-0a31-4831-a7b5-8fb85a40675e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_010fb0ba-624b-4468-a5ee-4cc53c533ba9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_eb612f27-5a7c-4895-8a58-4765f57089b2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_72a7d45f-da26-49c1-8566-efe907e02282_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_4d52e604-d3f2-47b5-b8bd-981292cf940a_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20220403.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9d1a573d-8b53-4b21-8eb3-4d3dd00bb970_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d864e78b-b499-4cd2-ba50-2f64007eda53_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_d3d49e42-93c2-4afd-b3b6-6bef2fcb46a6_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20220403.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_b193d49d-40ba-47e5-b0b2-81c06a9948bb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_66558758-f9fd-4655-be3b-70cf2bfc0725_terseLabel_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense Benefit Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense benefit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:href="jnj-20220403.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:to="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0ecbae67-d715-4724-8a20-fd19e6fe1e54_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_82f93379-b4e8-4a70-b30b-ec8edd22f520_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a507e400-50fb-41d6-9081-792f88ef6be3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_b7f4e6ae-d8ae-42d3-b399-7a9448711961_terseLabel_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers percent to sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_label_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue Goods Net Percent To Sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_documentation_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue goods net percentage to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:href="jnj-20220403.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:to="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d7e4f858-00b5-473d-9074-b9fd30e10c3b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss) (Note 7)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1b444d43-80da-4291-9359-ff30f2f00ad1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4890b96e-efb0-4033-9ce8-76d5a7a56273_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5ddecb04-0af8-4563-bd04-94fa877c1d0b_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_b5351e90-e98d-4fd6-acdb-6767c9430b02_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term taxes payable (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_52285852-1750-4c03-b442-bce0c9f42a69_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales/ Purchases/Other</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_f46b95c7-050b-41e7-b338-22508d3011c7_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA / abiraterone acetate</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20220403.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_a75320c6-38ab-434d-8e60-509bcdff0620_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_143d557c-ef29-4d85-8a16-2a1ec239f832_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20220403.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4588ca33-e20a-4497-9e73-e1d483ecfd14_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0b66e8cd-acc2-4a8b-9590-d0a0d444b470_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares exercisable under stock option plans</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f68b42d5-643a-4b32-9cc0-387adeef6d84_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_e9465732-a0a8-4793-aafe-e6f2b65550c4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3e2df523-20b8-415d-838c-e4063552bcc9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_bea63122-aa69-49b9-8b67-e8eaded0d633_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_edef5fbe-46a5-457f-8b31-8ce26bfe3e18_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_48219a8f-854a-4654-ab4d-a77a69f7f6e5_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_f550385c-5fb5-4337-9c8e-bd12bcd8c937_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_47cd667c-136e-4c07-bc77-d3d3e2636c63_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:href="jnj-20220403.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:to="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_47a0e09c-87b8-443c-a4fc-ee6fb1b1ac90_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_3ae8f175-ea95-429d-9dc4-3c899f80770a_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PHARMACEUTICAL</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20220403.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_a8060765-fad5-4a02-a10a-4547237b15db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4a5eea90-3669-4424-8a3c-c741629f4815_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_26945555-d25e-440a-9597-a866a378d048_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c56122b0-b57f-445c-b8fa-509d33e323bd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb27fee9-f78a-448e-8a5e-29e92f25b39c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a5c7a348-6b1b-40b1-aca0-db9937f2403d_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_f1020002-039b-4ff3-933a-6f66fc1c91ee_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_93823875-938f-4828-9121-6082aa6ca465_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by geographic area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:href="jnj-20220403.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:to="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_d875ae54-cff5-4cfb-9f8e-a120b04eaf01_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20220403.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_5472fda4-f56e-46a0-bb91-c1bcbd97e958_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_cc201df2-ef78-4166-bdf4-159536b4872c_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_a8b6439b-4c82-478e-95e0-0a7d5e7f52f2_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REMICADE</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20220403.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_1352f5c8-0549-4ccc-b02a-fe1b1fe7ca07_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_db216e93-da32-4489-b1a5-fdd20e4309eb_verboseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c235027b-d62f-4df7-8d21-f050f2274679_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_93481a4b-e192-40fb-9e65-19024755528e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_da193edc-11d0-42f4-932b-8e56f767ba12_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_ab5cdc1e-11db-4128-b010-eb2d26b284d7_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TREMFYA</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20220403.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_97a67fa6-f552-41b7-b1d5-64c7d1170a25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0f2bdaf6-0235-42f5-aec0-5c23c4f16609_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_96d89c87-060f-429c-8d66-5e733b7960ff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PaymentsForRestructuringNet_cad064d1-bbe7-43fe-9d62-a1b6ba2d5af6_negatedTerseLabel_en-US" xlink:label="lab_jnj_PaymentsForRestructuringNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settlements</link:label>
    <link:label id="lab_jnj_PaymentsForRestructuringNet_label_en-US" xlink:label="lab_jnj_PaymentsForRestructuringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Net</link:label>
    <link:label id="lab_jnj_PaymentsForRestructuringNet_documentation_en-US" xlink:label="lab_jnj_PaymentsForRestructuringNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsForRestructuringNet" xlink:href="jnj-20220403.xsd#jnj_PaymentsForRestructuringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PaymentsForRestructuringNet" xlink:to="lab_jnj_PaymentsForRestructuringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_aab6f2d3-08ec-4ead-95f4-741a259c3522_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Segment Operating Income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_9c4ddfdf-6ffd-46e0-8553-27d455fa0b3d_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business and Geographic Areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_14158bb6-cfd3-4286-a7dd-0bcf118a6920_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20220403.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_14a45ab4-00e6-4dd8-8586-9bfe891bfe9e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_739b48cc-61ef-4375-a3e0-36b991d7799d_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3568acd3-f9a0-44e2-9128-593fb354f455_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5d595b16-d7ef-40ac-8cbd-d09bc41e877d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_7df4b9f0-7beb-47c8-851a-f1f509f59f98_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_9f0f2e52-d0b8-4de9-b2b9-7d0314f44787_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6986feec-10e9-4bb3-8669-a95be92b26bb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_616b41fe-733b-4b55-ad6e-cdc3004b4a5f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_62ac740f-9014-497f-8b2b-c2dccdade2fb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_2a9972f8-297d-4cb3-91ad-e9882afb575c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9b2074e5-6ce2-42fa-b2cd-6e783f515098_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_588f9f21-ddba-4458-9cf1-9e16b3c9c163_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_7f9396a9-95f8-4005-8b72-6700cc0653da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_f1e75b78-a62b-45b9-a37b-11240d3679f0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_f31c4b98-bb16-4670-ae4d-98f5f0667b7a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_35876456-3176-4699-bdef-b9fca3d395d3_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20220403.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_8b28510c-3ea0-4022-b176-321ef161afed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_420b57a7-32e8-43c0-8550-220591fc83a5_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_95e51c59-45d3-41d9-9962-4c94ff9b187a_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_9843abde-0cfe-4be6-a3fa-75f9a22ae697_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5adbb925-baf1-4c1d-9da6-173a0fe3a2b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_51ecae0a-c41d-467e-b353-047f8e2057a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(Decrease) in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3e8159c6-e229-4983-9e98-8ac29e351871_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13343ee8-0eed-4ea0-9103-fc930422e025_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_8f0367c3-cd1a-423a-a82a-aea6f36dee69_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e56c4483-2d71-46af-8b85-ba35a894fbed_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_e8c7aad1-9c79-4276-a890-f5d26f3865cd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9b9e88f0-dd33-48cb-a053-6cb7eabba5e0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_7a4904c6-4de2-4755-8557-208daa1bf209_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_a4b7e7db-dd6a-4c13-84ff-b03fa9751089_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20220403.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_842cdd6f-ad38-4f57-9cc1-016d660292b6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6d742a94-fc9c-498f-b00d-78147bbae61a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a840ea43-4b34-48ef-bac2-efaaf80953b9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_192acb5a-03b2-4f28-bdf7-00f41b297b41_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_64937e99-da70-4997-a9d2-27b2311302da_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_96dbe573-5583-447a-af71-d22d8c904f0c_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_8dd40608-0b2b-4ea0-8aeb-e20a5469071a_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20220403.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0550NotesDue2025Member_aee39601-765d-43c3-a527-08b354985e61_terseLabel_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member" xlink:href="jnj-20220403.xsd#jnj_A0550NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0550NotesDue2025Member" xlink:to="lab_jnj_A0550NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9175b8d6-1291-4f0e-acd8-3c516db4505d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_50068684-1348-49ad-b42c-f700adc6c3f1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_42756486-78b3-4346-9735-4f183c38b6e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_21a1b38a-1d7b-467f-87f0-a93f2f133f56_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_6227111a-4f3d-43aa-b545-d33192d354f0_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, impairment loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:href="jnj-20220403.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:to="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b2e0b948-e797-49f4-8559-1546c9c996ee_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_12b71225-790a-4ac3-ae8a-2b5b0ac209dc_terseLabel_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_label_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_documentation_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales" xlink:href="jnj-20220403.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Restructuringchargepercenttosales" xlink:to="lab_jnj_Restructuringchargepercenttosales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7c0632c6-7816-495e-896d-de67aeb1996f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5d055ce3-8eb1-4523-aed6-b73e54e844b7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_c40dc24f-680e-421b-9b7b-7ff4268f8d0a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5f34e08f-5ec7-4cd9-a86f-25b8de9e64ef_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d567f552-0471-4f8f-b623-048beca2bd03_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a5065321-513e-49d0-bd17-8ca361f4eedb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_483624ce-2e30-46ce-a190-517abc4ec145_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_a94b9757-19ff-4c30-adae-636c03979380_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_3a8a2ef8-c984-46aa-b1d2-b0363a06dfd5_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINEOTHERMember_9e33ef5a-f6f3-4c5a-b210-e7850bd2272f_terseLabel_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE, SPORTS &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_label_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember" xlink:href="jnj-20220403.xsd#jnj_SPINEOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINEOTHERMember" xlink:to="lab_jnj_SPINEOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e3201000-fa16-4513-a4f8-50bf631b66c2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_ef8b93a1-2a7d-4641-bcb2-4dcdadc113ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_ae9af5b0-04be-4992-985e-286c2b5dc68b_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20220403.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_1603b02e-bc0e-4b1c-bef0-8088fc09bb74_terseLabel_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold percent to sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_label_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold Percent To Sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_documentation_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:href="jnj-20220403.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:to="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9c92bfbc-3a01-4e15-9bc6-6a06112bd8b3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_6a505dd5-4577-4138-8b3a-d46cb5a3242a_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_a79750b9-7b70-47d0-a10e-73ed4d67e70e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_c213dfd1-ad70-430b-a82a-34738ff38c6a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_f750ae5c-76f9-41f8-8577-8f2434981345_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20220403.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_04f68746-8fa2-4042-9d8b-67e3f5b260ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ce9b8d48-ffb1-4864-b7f8-78260c1ae6e0_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_00eef7aa-e3e9-409f-9ee5-272e617c6ece_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2de3a56d-39d6-4bfa-8829-16a8714b0fba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_a6264480-2bb5-4549-8795-bec10a149245_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_1027f5e9-796c-4aad-b59f-19a8b061b8a5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1b158294-960b-46fe-b91e-d5d1915109f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_03a722e1-2616-41ac-9d41-d09a797598aa_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_77990778-66cd-4846-9315-98e3043476f5_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_44bfc929-fc56-4b1b-9c48-6850f965f399_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_e47c078c-375b-4da5-bd9f-24eb035d1f05_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7e56110f-6d6d-435d-a968-7695730af408_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d206fea3-c903-4d2a-b0c5-5b496cdf4b6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7bfda0a5-5234-4374-a69e-eab6d921c316_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6080b640-b599-43d8-b0cf-58573602dc7f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8abcd564-3cd4-4d0c-95f2-1f20e1637e3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_ff806b5e-461e-45de-8538-3c3b5fc0309c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_499eb938-3f29-4dd5-9eb6-1bb9820d075d_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20220403.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_250f0ff9-c78e-43dd-8667-15772f4135d8_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20220403.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_87aa607d-d483-43ba-b8e7-427661cfc5ff_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_1c8f6d9f-94b0-414a-a565-4f526939248a_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes due 2028 (750MM Euro 1.1311)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20220403.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_adea5732-7d43-4682-a511-4e5c0a651f2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_ae63e4dd-5ddc-485b-ab3e-b53aef44e9ca_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ea705e66-d58e-482b-96fb-579cd4c55064_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0c4c2d3a-8e40-48b4-a925-08875a0fa27a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5c20ed38-ac18-46ca-b755-7a32e98b9391_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc19e427-0a51-4484-8345-424912bf70ec_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_959c7590-4fc6-44a9-a6d6-302222652714_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30cd5109-1cd4-4afb-a4ab-ed3981a8efa6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_3da70119-ddd1-4924-8d08-2c860987e0ff_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation/Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2e0b1641-9196-4f0d-92f6-4180f40d153d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, trade, less allowances for doubtful accounts and credit losses $234 (2021, $230)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cc3ab3ae-2f6b-458b-80c5-2a23f4d8cdc7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_a9592dcd-a8eb-4746-a1ec-5a526d42d25a_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT / rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20220403.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e6c380d7-f9bb-4a71-be26-55669ea4ffc2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cd172b77-44ce-46b8-a1eb-aba6dac22dbd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5cb7ff69-1fab-48d1-b309-bf81df902c10_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3bf68d4f-02b5-4a4d-b329-5ea4d76df03e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3e34c8fe-12dd-4c71-8c86-8dfb2132d4e3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_849e818e-bedb-4ce7-b32b-b38fc15a8343_verboseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_f0a90a1b-3fe3-4f33-aaaf-70ba378b62e0_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 1.1311)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20220403.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3848febf-e753-43ee-9db1-01cbfe7a4152_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_2e55c30f-3387-4fc2-aacc-e6a7a36559a0_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of additional possible loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_label_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_documentation_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:href="jnj-20220403.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:to="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_d68bbaa0-8b9e-4448-98ad-52314ab55871_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_label_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Loaned or Sold under Agreements to Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:to="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_1ba06053-ee7c-4bc1-9bfb-1b25559e91b0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7f2b1c41-5e41-41d0-9cad-a09532ee40d6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ff90e2dd-8003-413d-b994-b1ddf1abd83b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4fce56b0-4233-4251-8507-5822947ba869_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Note 2)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_3d3d4af3-9f37-4e7a-99f7-02ab384582d4_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_22494c8d-8d68-4c71-a81a-9e5212c9cbce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_973f42e0-9d63-4753-8389-566b6e544980_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Profit by Segment of Business</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_7566487d-71ea-43cf-830f-35074e89c60d_terseLabel_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount prepaid and due to manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_label_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_documentation_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:href="jnj-20220403.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:to="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WomensHealthMember_90f3e2a9-d793-498b-b574-679d1fd3f5d5_terseLabel_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health</link:label>
    <link:label id="lab_jnj_WomensHealthMember_label_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:label id="lab_jnj_WomensHealthMember_documentation_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember" xlink:href="jnj-20220403.xsd#jnj_WomensHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WomensHealthMember" xlink:to="lab_jnj_WomensHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_f95d8377-c0ca-487c-b251-b682b2ff05b1_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Revenue for Reportable Segment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_4803acce-2d03-4b47-912e-20fd056101a4_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations (Note 6)</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_22cdab6a-1584-44ec-9d15-f879a0b8eef0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_d017b916-3ad9-4273-97de-52bc3bccec7b_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20220403.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_e9d24113-64c0-4822-9781-556294bcc70d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_42a3dc89-dfa1-4442-b003-335dee8b348f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_876898ec-e421-49df-8e07-548d4ae2d92b_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20220403.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_a099ac3b-3be8-46d9-a7c6-be58ef766327_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_675264e5-a3c8-4a47-8ce9-02aba976ce46_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_5be1306d-0732-4ad5-a194-97973bec305b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_706d24d3-8f43-40f5-9692-34e5f8689a1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b7853222-1818-45eb-8ecb-39079dcaf9ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9fbae2a7-ff27-402c-9438-55fa481b6fa9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OralCareMember_d9302545-263e-48fd-a9f7-743aee6f11de_terseLabel_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care</link:label>
    <link:label id="lab_jnj_OralCareMember_label_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:label id="lab_jnj_OralCareMember_documentation_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember" xlink:href="jnj-20220403.xsd#jnj_OralCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OralCareMember" xlink:to="lab_jnj_OralCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_054fdccd-462e-4c5d-9ef7-6dc16cab6168_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20220403.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_535e97d3-36a1-4c3f-978c-2503e094ccad_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20220403.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_8b052c48-fc06-4b64-a873-5b11d8dcbe71_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_1879e0d5-505b-468e-aead-b7ab64858ce3_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0787f820-4c67-4adf-ae10-0256b46f0464_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_18259f3a-ce83-4462-b169-474fa0152f31_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_c04c422e-bd50-458e-ac4c-7e7a30208153_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_245bd54d-d9b1-46b0-9a48-cb2d78827cb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_60b094d2-0b73-466c-9715-ac9df1c82abc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_bbe28470-a2d9-4561-97af-b75b57961096_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_025f9771-9373-454e-b665-6e0169a2ba5b_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20220403.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_c1960706-12ba-4da4-a890-45db5033b0de_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20220403.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_5fe960db-da24-47ba-b1f6-cabd9f9d6291_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_9b67957c-c9b9-4d2b-9f02-33897fe9a3ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92763b60-ab79-4e9c-a1c8-16eeab473ca0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9df37e1d-3d1d-4f3f-838f-96572d1f0f56_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e0309ce4-9f0b-4528-99d6-9047e1a15b5a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AssetWriteoffMember_ec8abd32-1770-48e6-b29c-672c7b572ee4_terseLabel_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-offs/Sales</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_label_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_documentation_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember" xlink:href="jnj-20220403.xsd#jnj_AssetWriteoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AssetWriteoffMember" xlink:to="lab_jnj_AssetWriteoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_103672c6-5b8a-40eb-b459-869a6cfbce55_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d14cac7c-7f3d-4c45-9ffb-02c72f1ad13e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide income before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6df20faa-2bc1-46c4-8194-ad1ba79e3c59_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_2ec5b11f-70dc-4cd1-9aa9-885c3e9848ff_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20220403.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_33b55ea4-9a90-4875-a352-51af18b7ad5b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_123f4e6c-962e-47e4-811f-b37cd395812b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_6568aee9-2d0d-4476-8c92-d002ef0b2f2e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_6913101b-dbeb-4352-aa50-bf2f3d439117_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_a41f4ad2-ca26-4cad-a1e6-17925e21998f_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of the estimated fair value over the carrying value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Fair Value Over Carrying Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:href="jnj-20220403.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:to="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0169b0c2-4141-4094-9a49-50e206b182dc_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GrossProfitPercentToSales_038d65da-909e-4436-a7d5-6f59fd906e85_totalLabel_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_label_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_documentation_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales" xlink:href="jnj-20220403.xsd#jnj_GrossProfitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GrossProfitPercentToSales" xlink:to="lab_jnj_GrossProfitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9425975a-d64b-4da0-8a4f-f13bd22d742a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Weighted-Average Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_17aef275-4051-4842-8a1f-dc9a42de4fcc_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve established</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_label_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_documentation_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:href="jnj-20220403.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:to="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_4263fb7e-1ffe-4f52-89af-300a5681aed0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c86b9032-76cf-4411-bd66-1d14bcfc8ed5_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_b2e7a018-a2d7-4700-8bfe-59fcd4c5a600_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20220403.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6c15b6ff-3df5-424e-aa6b-1e804e85c695_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_3e872213-ec36-48b2-a8c8-b3126ab2e280_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20220403.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bcde386e-9838-47ef-8a29-26f4080bbc11_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b682cb07-f61d-4e8b-a0ca-7a1e8e117e06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_b162fd1c-967d-4643-a1e4-297002895ebd_terseLabel_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling marketing and administrative expenses percent to sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling general and administrative expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:href="jnj-20220403.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:to="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_9e5d2c2f-979d-4835-bc27-ca9414ade0f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3b1c9b6c-cbd6-45da-a718-72a97bfbb123_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5557780c-b36c-4433-93e6-cc7586962c4f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3a94f949-754d-4f0c-b8ff-f314ce2c8d6c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_1c0d0f12-776d-4d65-8eee-4a09e0ea74fc_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by geographic area</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_6dd18e18-7158-48b5-a722-28c93f122928_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring estimated cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_6b59df50-016e-4f1d-9ac4-6c1adcbf1991_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_2f3b9585-a639-402f-90bc-86e316cc4119_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2af8f38f-ec33-4434-a391-749352632fc9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7d4d46a1-9f16-49c8-ba61-8a04e49b0b7e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5e035751-3f1a-4f1a-9671-da31024d0eb0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_73ed8d7f-d467-44ff-ae06-1f07b97dfb78_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_6c5aed7a-5ba4-4e09-a076-960a096671cf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_70a44510-ef89-4e63-8ecc-e95d169dd55d_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency, number of claimants</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20220403.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_75ff433f-f193-4222-ac4a-c3c64f27bd2f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_a46d9538-5c3a-431d-8916-d3d60146ab5a_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f9c7d520-a1f5-4f8f-bcb3-866d8c9dde6c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_d263ce68-fe81-4e7c-9c09-c2d2e5c0eebe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_bb43c96f-f1a9-4931-8a9c-0b2e3cfead1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_a86d5041-21b1-4da5-a2c9-3516fb513d49_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_3bbe2091-5f27-4874-bff5-ff1ba9db9a1d_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_313069f8-774f-4666-a66e-e43b41b0ecca_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_26f5ed4a-5390-4baa-a32b-b9281b2c7ee2_terseLabel_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA / INVOKAMET</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_label_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_documentation_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember" xlink:href="jnj-20220403.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVOKANAINVOKAMETMember" xlink:to="lab_jnj_INVOKANAINVOKAMETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_f79687af-a33f-45f4-8929-56a6f0e1ff6f_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20220403.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_411d04c1-101c-4961-bb0f-940d30ce87f0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_241911bf-59ba-4d60-b60a-a2b5bd55a98e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6f42d469-b072-4609-9876-a600df0f10b6_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1cf7f236-4715-4bf1-b61a-4726053aa4ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_b6d891fd-8773-446d-9b5d-d549160fd14e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c9ff537-96eb-47fa-a5a6-7ddf1bf4f691_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ebcdec2d-20b7-4e25-90de-96ed1e61d0ac_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_22d345f8-a91c-4f23-9b7d-2e20f8b606fa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7327058f-ec21-4f83-a403-f622ef154466_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_2435dbc1-645c-4d65-b8cf-3d80a2144965_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_43a66b48-c4cd-4819-aa22-93a899e529ba_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_449d9176-3a9c-4ec3-95f4-c0a8cc990dc4_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AurisHealthMember_7ae5e955-6b4a-4ddc-a961-85e000b4369d_terseLabel_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:label id="lab_jnj_AurisHealthMember_label_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health [Member]</link:label>
    <link:label id="lab_jnj_AurisHealthMember_documentation_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember" xlink:href="jnj-20220403.xsd#jnj_AurisHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AurisHealthMember" xlink:to="lab_jnj_AurisHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_82ebe445-48bb-4f47-a9b8-b1f48c7644f8_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_c0a9d075-dafd-4618-951e-28c51a085055_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_83cd8ebd-ef79-49f5-a812-54a09bed1eed_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_d0ea1182-a15f-4ff7-9431-ee0309201267_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate on non-current debt</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_6d751bf9-94f3-4816-b9f8-e29eecad35ab_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_9e615531-62c8-4c7d-91a5-509718b61ee9_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_eb17295c-df6f-4b95-9692-64325c906379_verboseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ac89c93d-8b8b-4f64-b6f9-0be57c912e18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_effd90c0-6c0a-47e4-a7fe-a267881ced86_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_265ef789-2dbf-4c50-abd1-88b2722eebb1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1b68a70c-f39b-42f8-b891-cf7f1d3deae4_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (Note 3)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4f14fc52-403d-4b75-b9b3-23a5ca8b3cf1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets - net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_89c7e680-ab60-4cb4-8e15-a1f5a0ffe04a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_39427d43-d504-498e-b810-01a6c5dc07bb_terseLabel_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_label_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due Period Fifteen Member</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_documentation_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due period fifteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember" xlink:href="jnj-20220403.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NotesDuePeriodFifteenMember" xlink:to="lab_jnj_NotesDuePeriodFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4f7beb1f-1985-4d3e-9219-da66fd385eb6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_09dda269-20d5-478d-8aad-fd6e70e476f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_7193b3f4-0464-4be0-a672-ea5a6f9b583a_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: common stock held in treasury, at cost (490,459,000 and 490,878,000 shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_67290548-7dae-471b-bd2c-29fab4548bcc_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_259daf48-f00c-4f3b-b337-0bbe6f5452c2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVG. SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_c83f71d8-1c6c-4594-9943-ac8e451da130_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_ab10e003-a4f9-4d52-90c2-f5befb9caaa2_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20220403.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_6538d6ff-fc02-473c-8f54-f8d320961645_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_3e26f494-21cc-4675-bb1f-11f1de9e3b17_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral already posted, aggregate fair value</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_241c06c5-ddc6-48c9-bbd3-d0fada629114_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a1988760-f3b4-4c97-8489-dff3123293e0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities(1)</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_77085d48-f78b-4766-aa2b-5592aa213d2c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_46bf37b1-f745-4dba-a93e-557eb41845a9_verboseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_616ea319-4544-45af-96d6-4e1cefd81611_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes due 2024 (500 MM GBP 1.3485)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20220403.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_d2e29014-8f0b-4f3b-ae82-4f48bcd6383f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_078bbb8b-d0f2-4611-85fa-76f025c8ebef_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring (Note 12)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_58482c78-3e9c-44a7-909a-ff388b2fb4bb_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2cdc24d4-21dd-48a1-a9e8-1db99bb28c56_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_822b16eb-0af5-4661-bd1b-a57db96d153b_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_245fd01a-fbcd-4a26-8ece-be451f7520e3_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20220403.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_a06ec3f8-51c6-4576-b450-c04d03413097_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20220403.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0a0fd4d5-3d4a-4655-a4af-67233eaab992_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_2d8d9f35-4c4e-4162-9387-f1e10000d394_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f888bd10-7b3c-4827-b542-2c9b8b7611b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2892a035-914c-44ea-9726-6d0e124772d9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e53b5aa3-1f9d-4b22-b128-00c25a21320c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_69f9fa45-e39e-45ef-aa5d-a8daaf8ded70_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedicalDevicesMember_f2844fee-eb6a-4f33-bfdb-9533aea9601e_verboseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MedTech</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_1433b3b3-849f-4bd7-9043-5b9ce6913b1b_terseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEDTECH(3)</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_label_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_documentation_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedicalDevicesMember" xlink:to="lab_jnj_MedicalDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_832dc335-ece9-4474-9d3a-c0e2818637d9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_cfff69ba-8c4d-40a0-9983-eb29d70e7fa2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_cfbe27b3-bef7-4dc8-9c30-91aea840f511_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_c32d0c83-c356-466a-8aa0-873cba7b832f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_ee06371f-2ebb-40e2-9924-36362ffe655a_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER ONCOLOGY</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20220403.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_22e9ce52-4094-4b68-8edd-3bbdac31894a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_77512fd9-6098-484d-b89c-9a2ff69ad1d2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_33301169-9729-4954-8ea2-bda59b2fb7a6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_e0b02e4b-4891-4c5a-a859-24b0b33ec29a_terseLabel_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_label_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member" xlink:href="jnj-20220403.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.73Debenturesdue2023Member" xlink:to="lab_jnj_A6.73Debenturesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_031e1d61-0777-4ebb-b4ec-de48a1797bae_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ERLEADAMember_a0d37c43-0a52-4ef0-a322-708b5fc617b2_terseLabel_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:label id="lab_jnj_ERLEADAMember_label_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA [Member]</link:label>
    <link:label id="lab_jnj_ERLEADAMember_documentation_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember" xlink:href="jnj-20220403.xsd#jnj_ERLEADAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ERLEADAMember" xlink:to="lab_jnj_ERLEADAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_25bb7377-d672-4d86-b228-b9ee280d0107_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_f32a1c4a-8b38-4210-bbbe-473a1a869963_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20220403.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_c66060f8-2c3e-471f-9fc8-a1ca6eea2a83_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20220403.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_f5235252-35a3-4230-90b8-f7deeb82517f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_217795ec-72da-4210-90a6-9461ac84058d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_fadcb4cf-36ba-44d0-a229-2a334dfbd3a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_5ac1c2cc-ca9a-4791-bae4-08158705def7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_746384db-000a-47b7-b6c4-e6032216df90_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER IMMUNOLOGY</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20220403.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_4cc733c5-33ff-4fde-a68c-402f3c28f945_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_6a436f64-99ac-4ef5-b879-acb88be942db_terseLabel_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_label_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_documentation_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember" xlink:href="jnj-20220403.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RISPERDALCONSTAMember" xlink:to="lab_jnj_RISPERDALCONSTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_d18bf2cb-a704-428f-b04c-f0cca6e1113b_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20220403.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_78e56860-d657-4186-9b7d-a487f0f5ccec_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_222361b6-243e-4db6-ba97-328b03c292d2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1e992304-b2c9-4d5d-9565-f53349f3275c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EvraAndDoxilMember_c61e6bb6-a82a-4cf4-94b9-f6626caa9116_terseLabel_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_label_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil [Member]</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_documentation_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember" xlink:href="jnj-20220403.xsd#jnj_EvraAndDoxilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EvraAndDoxilMember" xlink:to="lab_jnj_EvraAndDoxilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_9d629363-1692-4cf7-a29e-2bffd9603165_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_f0f7060b-733a-4803-8ca6-d918e4d8d98e_terseLabel_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects</link:label>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_label_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_5603f665-6f94-457d-a08d-05be9711c8ba_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum length of time for hedge exposure</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_66abdef0-102d-447e-8e97-5a8de256f574_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_70caed4e-19d9-491a-b5ec-6e3d156f57f1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_cf2b5147-ec12-4034-a855-03db96c0d76e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_00f0cab3-591f-4b10-a4c2-8d2810bbb40a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_dffc24d5-a9cb-4b84-b9cb-486cbb73bfd2_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e10473d8-9b24-49a5-97a8-46aa96349a90_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterventionalSolutionsMember_9352b3b2-49dd-43ad-b8fa-977185de0978_verboseLabel_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember" xlink:href="jnj-20220403.xsd#jnj_InterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterventionalSolutionsMember" xlink:to="lab_jnj_InterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_406c8c37-62d1-41ee-bb00-e7ea1b81dde3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income on derivatives, after tax</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_883b776b-0a6b-4375-afad-cd24894b2f8b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_00d850d4-1d1a-4df5-a6c4-31a9f56e6df8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_94f51f1e-e923-457f-9337-8326d3f489c9_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_e47adc5d-6a99-46f1-b841-bb6c5abfa087_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestExpensePercentToSales_3ca96be0-49dd-4f05-bd90-09bfa4c48512_terseLabel_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized percent to sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_label_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales" xlink:href="jnj-20220403.xsd#jnj_InterestExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestExpensePercentToSales" xlink:to="lab_jnj_InterestExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_7fadb6bd-e433-4443-b52d-20ff1d6fad11_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits(1)</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_70160fd1-6686-4986-8332-90f8fe6320ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_d557d6bb-7dcc-4195-b48d-6ad33bb2c873_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20220403.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_310d9fa2-0272-44d1-8d37-7c82f7d11659_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 4)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c9521df2-4ef5-4dff-86d5-b50105d3c920_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_d4520c9b-fd3d-4df1-8f23-0ccd9c77c157_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20220403.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_05b6dfcf-f8c4-4261-b1b2-4f9d371ba2de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_bfcf8306-4f69-4dea-957a-d6758daf70fb_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cbcd91e2-4f86-4678-afec-d773400ea6ec_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_140fadee-68c7-471f-9474-39832536c27c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide effective income tax rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_6ccc7d93-54ba-4c4b-81db-fb2439c3ef8a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpioidMember_78b15b87-717f-489c-a455-68436a4698a4_terseLabel_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:label id="lab_jnj_OpioidMember_label_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">opioid [Member]</link:label>
    <link:label id="lab_jnj_OpioidMember_documentation_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember" xlink:href="jnj-20220403.xsd#jnj_OpioidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpioidMember" xlink:to="lab_jnj_OpioidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_ac3263a8-7305-4b3d-a5e9-bad15c5090ff_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_ec0dbb8f-d7cc-4bb4-be11-a715dcbc179b_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20220403.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a0744ea9-1455-4721-893d-0cbfdbfcc654_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_e953dcf0-3584-4059-8ed7-2eadd015fde6_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20220403.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_917440c8-3456-4b9f-ac27-4086a779e835_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dce1ad3b-fa34-49e2-a6ac-3f7374693bed_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_02e60916-4b97-4560-b222-94dc2e4c1c77_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. sovereign securities(1)</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_d439e715-88c6-40c8-8321-8bb9f32aac16_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20220403.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_dc2a38b2-eeb5-4b6f-acd8-887aa383ad05_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_da07137e-9ae1-42d0-8074-e9ea67fb574f_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_17b45bd5-039d-43f8-8c6c-2f041520f2de_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_b99c7c88-f767-43ad-8653-f4d180434900_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_e732a49d-4934-48fb-9b3d-7659104a43e9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2523f713-b85a-45f8-a147-67f43ad9d17e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_54bf1d02-0281-4bad-881b-eb4af159f640_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_37abe33e-761a-41a5-b955-cc39c50e0731_verboseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income)/Interest expense, net</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20220403.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_804285a3-63dd-410b-97d6-5dd82cf6e69b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0f9ff41a-24f8-484f-a860-551bb976d8cc_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7ce150f2-e69d-48ad-bcb8-bdf19a445d0a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a73cca7b-d450-4028-b5a5-2c7e112f8b6c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_e4500222-d16a-4f8f-9fd4-d8d8b910692a_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20220403.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_428b9e9c-5c9d-4cbb-a6d3-f77d95cca017_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_e058e974-7506-4160-8755-16f2e51e52cc_verboseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20220403.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_61a8234f-d4a1-4402-a20c-162b982ed264_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_edd7961c-4bbd-426c-a6d7-82e6d1df5da8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_daad54d4-57a7-43b1-8b66-8522ac70ca11_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6ba3ed37-40c8-40e6-baf7-bb5f9c576182_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c5794f1b-8961-4f9b-92fe-f11d2f994e3c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_63755b79-fc31-4a45-bb4d-d9a0ef7f2761_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_52f4ed93-30bd-49f5-9c37-244e935d9010_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_a3f62cce-b51b-4402-a178-e067d54f0417_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20220403.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e959bbf2-f19f-47af-b29c-b3f2fbbac26f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_920e99e5-0e62-4825-a253-fe2eb22e7b6f_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTCMember_ac6e5a94-c7c3-4bf0-a884-58881855a5aa_terseLabel_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_label_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_documentation_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember" xlink:href="jnj-20220403.xsd#jnj_OTCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTCMember" xlink:to="lab_jnj_OTCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_51d0c806-61f9-45e0-98c4-a5ae464d2cfa_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_ab3f72d9-c0ad-49ab-a9db-0d84ec78486f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_27c7ae9c-04f5-434b-a797-704198bfd361_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_e9fdb2f4-8758-48e4-9bde-bf5f9472d8ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_ea05f31c-f992-47fd-afa7-6bd7771f06a3_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Excluding Acquired In Process Cost Percent To Sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense excluding acquired in process cost percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:href="jnj-20220403.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_479f1298-d922-4e4c-aac1-8a1c166715af_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_35adbd66-2f4f-476b-9c8c-85d85cb22125_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_31e4959b-e371-4183-b0a0-b6e16af1dd71_terseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:href="jnj-20220403.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_e55bb6fc-32fc-4f81-b983-46e68e8bfe5e_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20220403.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_0498067f-db02-4008-aebf-094a8173b118_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_deadf24a-9e31-4ffb-8a92-7c24b0a35a44_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d35761d9-fba1-495f-a00e-11dcd09dcbc9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6f557212-6409-4f57-a116-0355791d7426_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b36f712-af0d-46fb-a628-6553198b6fa5_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_170a07ab-ed70-4f56-8dc9-fe89da4e9e4b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_4be04ba7-bcea-47ac-81f3-99caa07c42d5_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9bf65a89-0bed-4772-aff0-09ee14bd2ec0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_873d467e-39d4-4224-bf55-8793df0a7ae9_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_135d44d8-ede9-4e44-889e-6e29306bb46a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_0ec10de1-8119-4f06-a155-a900ee8aabba_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Fair Value Reflected in Net Income</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_bc5a69eb-884b-4463-8e84-6d4f050f9512_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_48548de4-743a-4b7a-9835-63976487b73e_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4d1333e4-7f4c-43c1-a142-0a0c3d144a69_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_6a176dac-4a72-44cb-ae52-96808d459290_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_24feee17-1448-48e8-a2c5-ad57731ee521_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_519748aa-5d73-47f2-b518-fe3a1e2c75a1_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20220403.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_2972a271-5a25-43f2-837b-ef529eb7bf35_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:href="jnj-20220403.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:to="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_b1e4ee84-ed47-4162-b8e1-2d863c9ca20d_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA / methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20220403.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_c38e533c-64da-4a87-b98f-415ae1a4fe48_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STELARA</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20220403.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_8e78ec80-591c-4129-962f-033b8e26c935_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20220403.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_63a13a9b-3727-4937-90cb-4aa696a811b3_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_4c79b869-f7a1-41bb-af48-01d93a193b97_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_ffcebe8b-9e67-4a1f-aaef-7bbab9641a6a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_dc1989da-ff5a-4e40-9146-44024b1b1490_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_f0b902f2-fcc8-479a-b38d-5e51e0c282ad_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20220403.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_c61f7353-2798-42e9-a6a1-071a2107e4fc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_66115bd1-59e4-49c2-b328-bb8d09cc5dfb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_b8a32e61-2088-4606-bbc8-0e451d1759d8_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20220403.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_010b0584-ab89-4ccf-b9bb-a8b46911cf67_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20220403.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c18561a7-30e9-4285-89d0-67f7f1556d6f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_990f377f-2d0f-4aef-98f8-08fa2319e7b6_verboseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of foreign exchange contracts into earnings, period</link:label>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_label_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Reclassification of Cash Flow Hedge Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:to="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_989dc83f-f8fd-4e7d-82f2-36ee53dee3c6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ac89f556-6292-4f01-8138-3fad3f113bb7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New and Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_64defd73-560e-4194-ada2-d7b33f59b221_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges recorded to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_480d089b-89b0-4f2e-ab80-dd5bb81d2c02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_30df64d7-2edf-4ad6-b740-6861c7320c40_totalLabel_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings percent to sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_label_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_documentation_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:href="jnj-20220403.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:to="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_fe9819c7-4a9a-4c01-8670-2452ae4fe85d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_f4b847fb-3ec9-4898-a6c7-7f6d8cb4d300_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_48b122db-f6b2-4ae9-933d-61946766dad8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c6a45c66-27e5-4ac9-8ee1-b8c82a37096d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9fc8df4c-5aac-4f75-82e3-38da545fcdff_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_a3a6b565-9fa8-40c3-8d64-edfdb2993cd2_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Note 3)</link:label>
    <link:label id="lab_us-gaap_Goodwill_feefad76-6723-44c4-9934-f819c0776449_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Beginning of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_5c74365d-6c7d-477a-82f0-f0878ccb78e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill End of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_1cb4e520-ed1a-41d4-916d-0c741fac1d49_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Change (as a percent)</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20220403.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_fc9c6e35-34f0-4942-af5f-2d366e91d475_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20220403.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_79162387-340e-4d95-8557-31f223376559_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_92b1ed5a-2362-4d2f-b6be-a74ad0a20f8b_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20220403.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_b5279ba0-ea4a-44b6-86ab-5788290ea2a5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_51a37ab8-a8b2-4980-b9b3-adf5ba7021b5_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20220403.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_043ea548-610f-4dd3-b408-adcf223e8fb7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cc36f8c8-8df1-40e1-9605-905c3835057e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_7c67071d-b3f4-49a1-a4a9-4c98ddd37bb2_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_fc776847-2b24-4a68-83a3-87074133dc5a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WoundCareandOtherMember_f8212f64-d996-4a4f-8ce9-1d6dcfc1cee5_terseLabel_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care/Other</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_label_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_documentation_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember" xlink:href="jnj-20220403.xsd#jnj_WoundCareandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WoundCareandOtherMember" xlink:to="lab_jnj_WoundCareandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e6aed2df-fe9c-45f7-adeb-454a02cb071d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_eaf25aa5-2c65-45b5-9839-787b71095531_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_72a86b4e-5083-4712-b88c-426a6c222ae9_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INFECTIOUS DISEASES(</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20220403.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_948f1da9-e71a-406e-be38-760864d95f3d_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost savings expected</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:href="jnj-20220403.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:to="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2934df10-c633-42ee-9698-0aab08159e1c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ContactLensesMember_5756b8bc-d15a-47ed-922c-b2ec450c44e7_terseLabel_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:label id="lab_jnj_ContactLensesMember_label_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses [Member]</link:label>
    <link:label id="lab_jnj_ContactLensesMember_documentation_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember" xlink:href="jnj-20220403.xsd#jnj_ContactLensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ContactLensesMember" xlink:to="lab_jnj_ContactLensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8f09ea8-ffd8-4266-b4fa-aeca079598d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_33870776-8fc2-4edb-825c-af6023446ec7_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>jnj-20220403_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:16b74ba9-87ed-4a1d-982b-bd3712a1fa43,g:84010c2d-9ae9-41ea-8d72-e231a49d0ab7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20220403.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_eb6b0bb6-c338-488d-9565-6541f00cb12c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_6f2b9c23-cfb3-4fff-8032-6a31dfb2841d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b0bb6-c338-488d-9565-6541f00cb12c" xlink:to="loc_dei_EntitiesTable_6f2b9c23-cfb3-4fff-8032-6a31dfb2841d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50341a03-ca7c-442e-ba3b-cf33f570874f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_6f2b9c23-cfb3-4fff-8032-6a31dfb2841d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50341a03-ca7c-442e-ba3b-cf33f570874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50341a03-ca7c-442e-ba3b-cf33f570874f" xlink:to="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5c94b758-8e06-4832-9bab-c89a5e0f2c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_us-gaap_CommonStockMember_5c94b758-8e06-4832-9bab-c89a5e0f2c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_40b88db0-341d-4a29-ae14-dd126b23fdfc" xlink:href="jnj-20220403.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_jnj_A0.650NotesDue2024Member_40b88db0-341d-4a29-ae14-dd126b23fdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_f22db868-9b4f-44ae-99db-4f6edd63d515" xlink:href="jnj-20220403.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_jnj_A5.50NotesDue2024Member_f22db868-9b4f-44ae-99db-4f6edd63d515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_fcf195d2-77aa-4090-8982-d3f82748c75b" xlink:href="jnj-20220403.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_jnj_A1.150NotesDue2028Member_fcf195d2-77aa-4090-8982-d3f82748c75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_68a14f87-e55f-4d01-b86e-20896bbea68c" xlink:href="jnj-20220403.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3f883f99-0848-49e0-9980-460d1167aaf0" xlink:to="loc_jnj_A1.650NotesDue2035Member_68a14f87-e55f-4d01-b86e-20896bbea68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_6f2b9c23-cfb3-4fff-8032-6a31dfb2841d" xlink:to="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cc7fb2fa-0c42-4d99-a69d-b3ac063d6aa1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentType_cc7fb2fa-0c42-4d99-a69d-b3ac063d6aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1a8fd566-5275-4cc5-b58f-1a03bc9f9243" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentQuarterlyReport_1a8fd566-5275-4cc5-b58f-1a03bc9f9243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d45b6994-48a3-4f7a-b33f-1a296f0f7f68" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentPeriodEndDate_d45b6994-48a3-4f7a-b33f-1a296f0f7f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0d219af0-6769-4072-9aa5-0ae143ea3221" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentTransitionReport_0d219af0-6769-4072-9aa5-0ae143ea3221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_acefd08e-18c9-4ef2-9d7c-c8d259331b55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityFileNumber_acefd08e-18c9-4ef2-9d7c-c8d259331b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_74b7897a-2d2c-41cd-a01d-f1f4fcb751f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityRegistrantName_74b7897a-2d2c-41cd-a01d-f1f4fcb751f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7fc081ed-1330-4dd7-9201-720906788513" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7fc081ed-1330-4dd7-9201-720906788513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_32a361c8-eaf7-4471-928d-0aa3b616d492" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityTaxIdentificationNumber_32a361c8-eaf7-4471-928d-0aa3b616d492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6244456a-da3e-4a3a-ad30-344254d3cb38" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityAddressAddressLine1_6244456a-da3e-4a3a-ad30-344254d3cb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a1f5605f-5617-413a-8a9b-2d97ab36053e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityAddressCityOrTown_a1f5605f-5617-413a-8a9b-2d97ab36053e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2ae3a606-c54d-4983-8515-25ced9ba37b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityAddressStateOrProvince_2ae3a606-c54d-4983-8515-25ced9ba37b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_431592ea-ae1f-4119-b205-d12fba6c767b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityAddressPostalZipCode_431592ea-ae1f-4119-b205-d12fba6c767b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_298b5765-a141-42de-bd13-0152605e2287" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_CityAreaCode_298b5765-a141-42de-bd13-0152605e2287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_155160c6-29b4-42ce-a72f-1f4b3bda5f06" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_LocalPhoneNumber_155160c6-29b4-42ce-a72f-1f4b3bda5f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1a211c8e-fe14-436f-9f53-a660cf4fd73f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityCurrentReportingStatus_1a211c8e-fe14-436f-9f53-a660cf4fd73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_abea8c09-7d75-47f0-af7d-a00b2ef18d00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityInteractiveDataCurrent_abea8c09-7d75-47f0-af7d-a00b2ef18d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cb9a2974-176a-4c6f-a221-2bd08c25c032" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityFilerCategory_cb9a2974-176a-4c6f-a221-2bd08c25c032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c1b217c2-0483-462c-8b71-4c492d4274f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntitySmallBusiness_c1b217c2-0483-462c-8b71-4c492d4274f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_33e990c0-eb4c-4c24-b811-c7570ecf81a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityEmergingGrowthCompany_33e990c0-eb4c-4c24-b811-c7570ecf81a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4e20a3c0-424b-4a3b-9d43-c008b3ce3140" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityShellCompany_4e20a3c0-424b-4a3b-9d43-c008b3ce3140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8fc55980-51d2-4d44-8bdf-9101765269b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_Security12bTitle_8fc55980-51d2-4d44-8bdf-9101765269b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_31910e87-5b72-4e40-8a0b-ca2e66553814" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_TradingSymbol_31910e87-5b72-4e40-8a0b-ca2e66553814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8b12d685-e258-40f7-a4ad-3ac6e62326f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_SecurityExchangeName_8b12d685-e258-40f7-a4ad-3ac6e62326f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3dcc0ee4-eeac-4f18-a596-ba4a509fe276" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3dcc0ee4-eeac-4f18-a596-ba4a509fe276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_59534dfa-1bde-4e64-be88-5b10d5b7597f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_EntityCentralIndexKey_59534dfa-1bde-4e64-be88-5b10d5b7597f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9c537066-cbff-4b43-8c6c-86deb20c058a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_CurrentFiscalYearEndDate_9c537066-cbff-4b43-8c6c-86deb20c058a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_30eeb518-15f9-46db-a842-03bdfc56ec6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentFiscalYearFocus_30eeb518-15f9-46db-a842-03bdfc56ec6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ac04b4e4-8bef-4c3c-bfdb-ff08c2f374a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ac04b4e4-8bef-4c3c-bfdb-ff08c2f374a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_67ca3915-20a3-4b22-a944-7ed208704eba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_40c32615-7534-4e34-8c4a-dd59dc25ea88" xlink:to="loc_dei_AmendmentFlag_67ca3915-20a3-4b22-a944-7ed208704eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b3076c0e-89c4-4581-88de-c781b7723aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b3076c0e-89c4-4581-88de-c781b7723aff" xlink:to="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_31ad88a3-73e2-4c5e-98db-b30882c93abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_31ad88a3-73e2-4c5e-98db-b30882c93abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfe3be93-964c-4f07-989a-3a8195c3a5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_31ad88a3-73e2-4c5e-98db-b30882c93abd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfe3be93-964c-4f07-989a-3a8195c3a5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d86ea8e8-2460-449a-8c3f-52b15410f02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_31ad88a3-73e2-4c5e-98db-b30882c93abd" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d86ea8e8-2460-449a-8c3f-52b15410f02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_da85a9e3-cb83-48d7-8683-5ff34a0edaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_31ad88a3-73e2-4c5e-98db-b30882c93abd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_da85a9e3-cb83-48d7-8683-5ff34a0edaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6eff405d-e6a8-4a38-91e5-62b55c2351ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_31ad88a3-73e2-4c5e-98db-b30882c93abd" xlink:to="loc_us-gaap_InventoryNet_6eff405d-e6a8-4a38-91e5-62b55c2351ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ade795a-e673-4ee4-bc6d-a5b130605055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_31ad88a3-73e2-4c5e-98db-b30882c93abd" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ade795a-e673-4ee4-bc6d-a5b130605055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_64971e13-3b92-4526-8d54-f6f96e79ea16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_31ad88a3-73e2-4c5e-98db-b30882c93abd" xlink:to="loc_us-gaap_AssetsCurrent_64971e13-3b92-4526-8d54-f6f96e79ea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_19ff903b-4c1a-42da-8b3f-7fee93d50e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_19ff903b-4c1a-42da-8b3f-7fee93d50e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b26b6266-06b1-48c9-95ed-eb1cd8edcb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b26b6266-06b1-48c9-95ed-eb1cd8edcb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_659b37da-b287-4a42-a862-ed861de47fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_659b37da-b287-4a42-a862-ed861de47fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_18aea55b-ef11-40a0-a868-5d9eea5102c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_18aea55b-ef11-40a0-a868-5d9eea5102c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ad87cc4d-82bd-4d87-b070-f4cfda15fefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:to="loc_us-gaap_Goodwill_ad87cc4d-82bd-4d87-b070-f4cfda15fefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8678b944-c64f-4979-9942-9f07e404fa09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8678b944-c64f-4979-9942-9f07e404fa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7a30f97e-8d22-46be-b882-b9a20d20785f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7a30f97e-8d22-46be-b882-b9a20d20785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0ccdb1f0-06dd-49b8-8ef3-b0574d96f97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ddb8347f-6cd5-41b6-bd8b-74216c702eb9" xlink:to="loc_us-gaap_Assets_0ccdb1f0-06dd-49b8-8ef3-b0574d96f97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b3076c0e-89c4-4581-88de-c781b7723aff" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b1b09cb0-12b8-47ec-8adf-b76c21c86add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b1b09cb0-12b8-47ec-8adf-b76c21c86add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_55642e95-35f3-4fdc-8ce8-259584fca325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1b09cb0-12b8-47ec-8adf-b76c21c86add" xlink:to="loc_us-gaap_ShortTermBorrowings_55642e95-35f3-4fdc-8ce8-259584fca325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_80e71eac-829d-45f0-afe5-4b3527006fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1b09cb0-12b8-47ec-8adf-b76c21c86add" xlink:to="loc_us-gaap_AccountsPayableCurrent_80e71eac-829d-45f0-afe5-4b3527006fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1b71c1f9-1378-4550-aeb6-ee11e532531c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1b09cb0-12b8-47ec-8adf-b76c21c86add" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1b71c1f9-1378-4550-aeb6-ee11e532531c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_386ae3bb-aac5-4e97-890e-ac36f9509170" xlink:href="jnj-20220403.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1b09cb0-12b8-47ec-8adf-b76c21c86add" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_386ae3bb-aac5-4e97-890e-ac36f9509170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3e233c1-2b10-450b-bb3a-79d77b93e60c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1b09cb0-12b8-47ec-8adf-b76c21c86add" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c3e233c1-2b10-450b-bb3a-79d77b93e60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_e09bee70-c74c-4a32-ab63-03d0f2c510c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1b09cb0-12b8-47ec-8adf-b76c21c86add" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_e09bee70-c74c-4a32-ab63-03d0f2c510c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6ff18ab4-e2f1-4fcf-80b2-a59365e2c186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b1b09cb0-12b8-47ec-8adf-b76c21c86add" xlink:to="loc_us-gaap_LiabilitiesCurrent_6ff18ab4-e2f1-4fcf-80b2-a59365e2c186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2b888450-8022-47e6-b5bb-5280663d3932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2b888450-8022-47e6-b5bb-5280663d3932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c3be417f-0ea8-4d9f-81c6-3f4f9eb796c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c3be417f-0ea8-4d9f-81c6-3f4f9eb796c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_eb419106-5883-45b2-9545-0e645eb4d258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_eb419106-5883-45b2-9545-0e645eb4d258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_99a69d07-0d50-4d3a-b10d-3c0b5368d6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_99a69d07-0d50-4d3a-b10d-3c0b5368d6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a6bae48f-e8be-4678-ac18-5721760a9abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a6bae48f-e8be-4678-ac18-5721760a9abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c948ab1b-f6d5-4bc5-8cbb-0db6d20d5267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_Liabilities_c948ab1b-f6d5-4bc5-8cbb-0db6d20d5267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fedcade0-a3cf-44dc-b6a9-b2c8a6bd3ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fedcade0-a3cf-44dc-b6a9-b2c8a6bd3ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8357f937-3f31-402f-9429-2193c4f37382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8357f937-3f31-402f-9429-2193c4f37382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3754b5c3-14f2-4b05-93de-5ad96c60bc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8357f937-3f31-402f-9429-2193c4f37382" xlink:to="loc_us-gaap_CommonStockValue_3754b5c3-14f2-4b05-93de-5ad96c60bc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41c4d864-61bf-4714-91f4-f56810a7de18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8357f937-3f31-402f-9429-2193c4f37382" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_41c4d864-61bf-4714-91f4-f56810a7de18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_75f41682-6286-421c-861f-a55c2585a22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8357f937-3f31-402f-9429-2193c4f37382" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_75f41682-6286-421c-861f-a55c2585a22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_23fb6179-7f6d-4a82-83af-20d39313cf47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8357f937-3f31-402f-9429-2193c4f37382" xlink:to="loc_us-gaap_TreasuryStockValue_23fb6179-7f6d-4a82-83af-20d39313cf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19f9e743-3312-4fcb-93eb-020a4a593b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8357f937-3f31-402f-9429-2193c4f37382" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19f9e743-3312-4fcb-93eb-020a4a593b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6ed539c1-66da-42dd-837a-2b239018deb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e9bb7156-1b83-468b-93b0-d4b195429637" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6ed539c1-66da-42dd-837a-2b239018deb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_433182de-5238-497a-89c9-ff5efefe1708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_07c3c22e-cb17-48c1-bcf9-a52e63498f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_433182de-5238-497a-89c9-ff5efefe1708" xlink:to="loc_us-gaap_AssetsCurrentAbstract_07c3c22e-cb17-48c1-bcf9-a52e63498f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2c33ed24-cbc6-4f0c-894a-31139ad244e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07c3c22e-cb17-48c1-bcf9-a52e63498f50" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2c33ed24-cbc6-4f0c-894a-31139ad244e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7da9de8d-be95-4ac2-a462-f51e6d7b6b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_433182de-5238-497a-89c9-ff5efefe1708" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7da9de8d-be95-4ac2-a462-f51e6d7b6b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_48014672-a7e3-4a08-af2c-74380a2297a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7da9de8d-be95-4ac2-a462-f51e6d7b6b71" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_48014672-a7e3-4a08-af2c-74380a2297a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_084bb86b-a695-49bf-a45a-482386faaac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7da9de8d-be95-4ac2-a462-f51e6d7b6b71" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_084bb86b-a695-49bf-a45a-482386faaac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_57fa90e6-9e50-4455-a38c-057bd3a6dec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7da9de8d-be95-4ac2-a462-f51e6d7b6b71" xlink:to="loc_us-gaap_CommonStockSharesIssued_57fa90e6-9e50-4455-a38c-057bd3a6dec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_9824a0df-2b66-4e89-916f-9cc5a08b0c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7da9de8d-be95-4ac2-a462-f51e6d7b6b71" xlink:to="loc_us-gaap_TreasuryStockShares_9824a0df-2b66-4e89-916f-9cc5a08b0c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_202e7045-4c83-4e46-9ddf-7ca21dbdf76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_202e7045-4c83-4e46-9ddf-7ca21dbdf76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_15c1512a-5158-4c8a-96b7-a11afe27d271" xlink:href="jnj-20220403.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_15c1512a-5158-4c8a-96b7-a11afe27d271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8457f734-d131-46f4-8392-7d91c55c2b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8457f734-d131-46f4-8392-7d91c55c2b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_25ff96a8-5800-4091-a6d9-e6c5f940c865" xlink:href="jnj-20220403.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_25ff96a8-5800-4091-a6d9-e6c5f940c865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ab1ac466-00c8-4283-8b31-28e581cbf1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_GrossProfit_ab1ac466-00c8-4283-8b31-28e581cbf1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_4b1794f5-f17d-428a-9ca9-65ca6c2a4b5b" xlink:href="jnj-20220403.xsd#jnj_GrossProfitPercentToSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_GrossProfitPercentToSales_4b1794f5-f17d-428a-9ca9-65ca6c2a4b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db89cde0-dbd9-4c37-b426-4e3855e695c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db89cde0-dbd9-4c37-b426-4e3855e695c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_765cef49-a8c9-4f52-991e-1d6c00a9f3c4" xlink:href="jnj-20220403.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_765cef49-a8c9-4f52-991e-1d6c00a9f3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9c17c689-6511-45e9-81ab-3917c5f808fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9c17c689-6511-45e9-81ab-3917c5f808fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_61059013-c8dc-457d-bb3a-85c910b55519" xlink:href="jnj-20220403.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_61059013-c8dc-457d-bb3a-85c910b55519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_6062b5d9-4883-4487-8455-0493310a1e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_6062b5d9-4883-4487-8455-0493310a1e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_e6c81dba-c30b-4056-9fe3-798eab49993e" xlink:href="jnj-20220403.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_e6c81dba-c30b-4056-9fe3-798eab49993e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c79be51d-1696-4cf0-a8d1-d580ba3aed21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c79be51d-1696-4cf0-a8d1-d580ba3aed21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_7d5f5350-2e73-4bd4-9b44-4859947f4a93" xlink:href="jnj-20220403.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_7d5f5350-2e73-4bd4-9b44-4859947f4a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b298824e-cfd5-467b-b539-2eaca12f40b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_InterestExpense_b298824e-cfd5-467b-b539-2eaca12f40b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_b9fd7250-6af4-4cdd-a89f-1ac938b12d87" xlink:href="jnj-20220403.xsd#jnj_InterestExpensePercentToSales"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_InterestExpensePercentToSales_b9fd7250-6af4-4cdd-a89f-1ac938b12d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e4409984-a77d-49d1-8b86-f3bf2b4aebfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e4409984-a77d-49d1-8b86-f3bf2b4aebfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_617fe88b-c6b1-464b-801c-3f7bc686a68a" xlink:href="jnj-20220403.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_617fe88b-c6b1-464b-801c-3f7bc686a68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1383415c-7e61-43f2-b760-e7363efa4a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_RestructuringCharges_1383415c-7e61-43f2-b760-e7363efa4a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_539b8f2f-1399-4f9b-81ef-4cb626cbd41f" xlink:href="jnj-20220403.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_Restructuringchargepercenttosales_539b8f2f-1399-4f9b-81ef-4cb626cbd41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8e1454a0-58de-40a5-be9e-5d863f041dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8e1454a0-58de-40a5-be9e-5d863f041dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_7ba9c947-afac-4801-a8f2-64702122fc63" xlink:href="jnj-20220403.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_7ba9c947-afac-4801-a8f2-64702122fc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1439dca3-9959-4aaa-8178-0c574e578767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1439dca3-9959-4aaa-8178-0c574e578767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_6351c113-8217-4592-91fc-2f15634fb91e" xlink:href="jnj-20220403.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_6351c113-8217-4592-91fc-2f15634fb91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_95409094-9e1b-4088-aea4-487d683508cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_NetIncomeLoss_95409094-9e1b-4088-aea4-487d683508cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_a2c19815-2f69-4ecf-a259-8bbb8debf521" xlink:href="jnj-20220403.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_jnj_NetIncomeAttributableToParentPercentToSales_a2c19815-2f69-4ecf-a259-8bbb8debf521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3626ae4d-fcb0-4a36-b941-68efcf20e0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_EarningsPerShareAbstract_3626ae4d-fcb0-4a36-b941-68efcf20e0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7b5ff658-507d-42c9-b558-1783391fdf56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3626ae4d-fcb0-4a36-b941-68efcf20e0be" xlink:to="loc_us-gaap_EarningsPerShareBasic_7b5ff658-507d-42c9-b558-1783391fdf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1f21c9c4-02c7-4b83-a96b-6b2c39167c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3626ae4d-fcb0-4a36-b941-68efcf20e0be" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1f21c9c4-02c7-4b83-a96b-6b2c39167c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_873daf97-224a-436c-85e8-2a0c21e64c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_58378008-1aaa-4430-91bc-32f97c49b8fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_873daf97-224a-436c-85e8-2a0c21e64c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b94a72e7-062f-4ca0-8a27-27760ac519d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_873daf97-224a-436c-85e8-2a0c21e64c34" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b94a72e7-062f-4ca0-8a27-27760ac519d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2076bdf8-31ae-4cb8-976d-859d4401b9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_873daf97-224a-436c-85e8-2a0c21e64c34" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2076bdf8-31ae-4cb8-976d-859d4401b9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d576aa58-0949-4544-b073-91e06f730e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a102a4ea-4bae-41f8-be1c-1dfe81bae226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d576aa58-0949-4544-b073-91e06f730e69" xlink:to="loc_us-gaap_NetIncomeLoss_a102a4ea-4bae-41f8-be1c-1dfe81bae226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3ab9cbce-8e94-43ad-85ec-0c3dbad99c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d576aa58-0949-4544-b073-91e06f730e69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3ab9cbce-8e94-43ad-85ec-0c3dbad99c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_7b7c459a-38a3-4ec9-8947-b16748ae54f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3ab9cbce-8e94-43ad-85ec-0c3dbad99c4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_7b7c459a-38a3-4ec9-8947-b16748ae54f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_af791be2-4286-47aa-be5d-fe77e9ac4f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3ab9cbce-8e94-43ad-85ec-0c3dbad99c4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_af791be2-4286-47aa-be5d-fe77e9ac4f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0cff814d-7779-4af8-af9f-6327de718613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_af791be2-4286-47aa-be5d-fe77e9ac4f49" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0cff814d-7779-4af8-af9f-6327de718613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_250b772a-7bbc-46b7-a4e5-fe0ac7e12db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_af791be2-4286-47aa-be5d-fe77e9ac4f49" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_250b772a-7bbc-46b7-a4e5-fe0ac7e12db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a22038da-31fc-4418-a2cd-b3ddafe37321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_af791be2-4286-47aa-be5d-fe77e9ac4f49" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a22038da-31fc-4418-a2cd-b3ddafe37321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_b621ae5f-5192-4f18-995f-730efdb2f9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3ab9cbce-8e94-43ad-85ec-0c3dbad99c4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_b621ae5f-5192-4f18-995f-730efdb2f9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_ee24cfe5-1f52-455c-b597-a9566d0dd609" xlink:href="jnj-20220403.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_b621ae5f-5192-4f18-995f-730efdb2f9c3" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_ee24cfe5-1f52-455c-b597-a9566d0dd609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_efa7323d-efaf-492d-a93b-00a77173b52a" xlink:href="jnj-20220403.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_b621ae5f-5192-4f18-995f-730efdb2f9c3" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_efa7323d-efaf-492d-a93b-00a77173b52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_6fddffa9-3a66-4335-b78a-4d5907e9e28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_b621ae5f-5192-4f18-995f-730efdb2f9c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_6fddffa9-3a66-4335-b78a-4d5907e9e28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_428ca8f1-b2b0-43ed-b32d-7dd21d4ab85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3ab9cbce-8e94-43ad-85ec-0c3dbad99c4a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_428ca8f1-b2b0-43ed-b32d-7dd21d4ab85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_852b9502-e2c3-4a35-93c9-81c6b52178d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_428ca8f1-b2b0-43ed-b32d-7dd21d4ab85b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_852b9502-e2c3-4a35-93c9-81c6b52178d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_0cdd7c0d-c60c-41b3-8687-46e0c5d32088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_428ca8f1-b2b0-43ed-b32d-7dd21d4ab85b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_0cdd7c0d-c60c-41b3-8687-46e0c5d32088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f209088b-9ed3-425b-b917-7cc3a2c29bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_428ca8f1-b2b0-43ed-b32d-7dd21d4ab85b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f209088b-9ed3-425b-b917-7cc3a2c29bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8718f39b-cc25-4e1c-81b5-ea5eda32ab1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d576aa58-0949-4544-b073-91e06f730e69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8718f39b-cc25-4e1c-81b5-ea5eda32ab1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_edaf377e-a74d-4f4e-bb47-bcce2865d347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d576aa58-0949-4544-b073-91e06f730e69" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_edaf377e-a74d-4f4e-bb47-bcce2865d347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfaf50e4-74a9-44c8-8ea1-9908ae40f63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_d4d92ae3-5c34-4d95-89a2-f4826e50c525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfaf50e4-74a9-44c8-8ea1-9908ae40f63b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_d4d92ae3-5c34-4d95-89a2-f4826e50c525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b7f4868e-86b5-47f4-87e9-1eac22217562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfaf50e4-74a9-44c8-8ea1-9908ae40f63b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b7f4868e-86b5-47f4-87e9-1eac22217562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_d4cbe2a0-5600-4ae0-b068-9230a3836ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfaf50e4-74a9-44c8-8ea1-9908ae40f63b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_d4cbe2a0-5600-4ae0-b068-9230a3836ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_1e9829a3-8c04-46bc-95b9-6e5a061bfdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfaf50e4-74a9-44c8-8ea1-9908ae40f63b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_1e9829a3-8c04-46bc-95b9-6e5a061bfdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_54460bb7-9408-4b58-a837-8921a333cfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2a7f7dc3-3f10-4ffa-b7cf-46b282d1c90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_54460bb7-9408-4b58-a837-8921a333cfc3" xlink:to="loc_us-gaap_StatementTable_2a7f7dc3-3f10-4ffa-b7cf-46b282d1c90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7d2cc9f5-d137-46f9-8233-c7295ee01b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2a7f7dc3-3f10-4ffa-b7cf-46b282d1c90d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7d2cc9f5-d137-46f9-8233-c7295ee01b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d2cc9f5-d137-46f9-8233-c7295ee01b74" xlink:to="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_04442965-79c2-43ff-9538-fd42b77b1204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:to="loc_us-gaap_RetainedEarningsMember_04442965-79c2-43ff-9538-fd42b77b1204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8e70132e-26c0-4211-842c-38d7dd6f5996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8e70132e-26c0-4211-842c-38d7dd6f5996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4ed15d70-92dd-4cf6-bc6b-dcaf44d1d4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:to="loc_us-gaap_CommonStockMember_4ed15d70-92dd-4cf6-bc6b-dcaf44d1d4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_1b7b8c35-3a61-44c5-a016-48fff3559f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9776ab28-579f-4ea1-90fc-644fd13f3a61" xlink:to="loc_us-gaap_TreasuryStockMember_1b7b8c35-3a61-44c5-a016-48fff3559f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2a7f7dc3-3f10-4ffa-b7cf-46b282d1c90d" xlink:to="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_012871b7-c727-410f-8f33-1492d4f0e6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_012871b7-c727-410f-8f33-1492d4f0e6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a4e773b-66f1-4891-9d3c-af6058f24c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_NetIncomeLoss_6a4e773b-66f1-4891-9d3c-af6058f24c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_9aff432e-6b7b-4c3c-9ba3-6f912edbb87c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_DividendsCommonStockCash_9aff432e-6b7b-4c3c-9ba3-6f912edbb87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_cb9dc10c-3e87-4f1c-b894-2daa581bafb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_cb9dc10c-3e87-4f1c-b894-2daa581bafb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c9def021-431b-4915-adaa-22da45f980e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_c9def021-431b-4915-adaa-22da45f980e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5f9db8d7-4576-4c59-a59a-8d359309be62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5f9db8d7-4576-4c59-a59a-8d359309be62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_be022401-9705-41ba-9d58-3445afa0ab64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c22490f4-2175-47a2-91ed-fcaff5ec0715" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_be022401-9705-41ba-9d58-3445afa0ab64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0f9dc8f8-2785-49b8-9569-5977679f445c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_716682e1-98db-445e-b1c5-a422d16f5517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0f9dc8f8-2785-49b8-9569-5977679f445c" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_716682e1-98db-445e-b1c5-a422d16f5517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20220403.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fd401806-6522-4b42-8e56-7e735354f374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0e460f23-83cf-45f4-aca3-53e215253e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd401806-6522-4b42-8e56-7e735354f374" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0e460f23-83cf-45f4-aca3-53e215253e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_842e8d85-19c9-4fed-b263-2beebe1adb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0e460f23-83cf-45f4-aca3-53e215253e3f" xlink:to="loc_us-gaap_NetIncomeLoss_842e8d85-19c9-4fed-b263-2beebe1adb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a964c76-3b25-4632-bb04-efc1bb324d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0e460f23-83cf-45f4-aca3-53e215253e3f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a964c76-3b25-4632-bb04-efc1bb324d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebe7e957-5318-4305-99a1-5d680d8ccbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a964c76-3b25-4632-bb04-efc1bb324d0f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebe7e957-5318-4305-99a1-5d680d8ccbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d5ccb46b-6f54-45fe-b65b-14605f562e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a964c76-3b25-4632-bb04-efc1bb324d0f" xlink:to="loc_us-gaap_ShareBasedCompensation_d5ccb46b-6f54-45fe-b65b-14605f562e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1a5cbe5c-752d-4a2a-8083-6a0b3895b684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a964c76-3b25-4632-bb04-efc1bb324d0f" xlink:to="loc_us-gaap_AssetImpairmentCharges_1a5cbe5c-752d-4a2a-8083-6a0b3895b684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_66c02df5-e387-49db-a28e-4c2651dec772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a964c76-3b25-4632-bb04-efc1bb324d0f" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_66c02df5-e387-49db-a28e-4c2651dec772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_97da4e83-d557-40b1-92ac-b1c9e7c7b1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a964c76-3b25-4632-bb04-efc1bb324d0f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_97da4e83-d557-40b1-92ac-b1c9e7c7b1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_070f124b-3910-422b-8159-5402f05e3407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9a964c76-3b25-4632-bb04-efc1bb324d0f" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_070f124b-3910-422b-8159-5402f05e3407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7c4a4566-0e00-48bc-ba8a-9b7cc5b6839e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0e460f23-83cf-45f4-aca3-53e215253e3f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7c4a4566-0e00-48bc-ba8a-9b7cc5b6839e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_15678fde-a02c-4fe0-9523-5545d1fd4739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7c4a4566-0e00-48bc-ba8a-9b7cc5b6839e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_15678fde-a02c-4fe0-9523-5545d1fd4739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7748c87a-9556-4656-b34f-947d3e18bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7c4a4566-0e00-48bc-ba8a-9b7cc5b6839e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7748c87a-9556-4656-b34f-947d3e18bed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_799731e2-b218-4eb9-87b0-c6ddce1adf70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7c4a4566-0e00-48bc-ba8a-9b7cc5b6839e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_799731e2-b218-4eb9-87b0-c6ddce1adf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_38a0bbe2-eab4-4d39-a4fd-5c193ac8679b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7c4a4566-0e00-48bc-ba8a-9b7cc5b6839e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_38a0bbe2-eab4-4d39-a4fd-5c193ac8679b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_918059b2-cd49-472e-9c75-c62a5ef78bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7c4a4566-0e00-48bc-ba8a-9b7cc5b6839e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_918059b2-cd49-472e-9c75-c62a5ef78bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16d0999e-c6a0-43fe-bb59-f442facf01e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0e460f23-83cf-45f4-aca3-53e215253e3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16d0999e-c6a0-43fe-bb59-f442facf01e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd401806-6522-4b42-8e56-7e735354f374" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fbed9c50-eb1d-4c68-986f-a100c37f78c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fbed9c50-eb1d-4c68-986f-a100c37f78c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_265377ac-979b-4197-80bd-00121fc949a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_265377ac-979b-4197-80bd-00121fc949a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5ee75ed8-eaaf-4213-964c-d7d2d99c3316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5ee75ed8-eaaf-4213-964c-d7d2d99c3316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_9d83090b-6eb6-46b4-8f4e-a4c011cce03c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_9d83090b-6eb6-46b4-8f4e-a4c011cce03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_39f25e76-c5cc-4f34-9e26-39985edf3fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_39f25e76-c5cc-4f34-9e26-39985edf3fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_319c93a7-e783-4fa8-abf0-528f6e9c4387" xlink:href="jnj-20220403.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_319c93a7-e783-4fa8-abf0-528f6e9c4387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_52333ee1-0d35-4d58-bd4e-83d64b6f3edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_52333ee1-0d35-4d58-bd4e-83d64b6f3edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1174a675-7e8e-4e82-bd39-cad3eac64383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ef5e9d-985e-4fba-899b-e1876b66b3dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1174a675-7e8e-4e82-bd39-cad3eac64383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd401806-6522-4b42-8e56-7e735354f374" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_f88a079c-cd16-408b-803b-887ae9397c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_f88a079c-cd16-408b-803b-887ae9397c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b942e499-3f0b-407c-b493-f52e3e0e2c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b942e499-3f0b-407c-b493-f52e3e0e2c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_52379777-7551-4ced-bf3f-1d12fea154c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_52379777-7551-4ced-bf3f-1d12fea154c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_e8ccbffb-6be2-4597-aa5b-14c94e042fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_e8ccbffb-6be2-4597-aa5b-14c94e042fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e41f4f1c-6714-41b7-9473-76c67024d0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e41f4f1c-6714-41b7-9473-76c67024d0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f5f334ef-6667-4a7a-9dd8-35b9d1f6d00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f5f334ef-6667-4a7a-9dd8-35b9d1f6d00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_2a0a4870-4d22-4624-a970-493fc3cb2fb1" xlink:href="jnj-20220403.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_2a0a4870-4d22-4624-a970-493fc3cb2fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_81291339-6aa4-49f3-b149-eb282fbc0f16" xlink:href="jnj-20220403.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_81291339-6aa4-49f3-b149-eb282fbc0f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_17b14ddc-8104-4352-9ffb-9728cdd9e37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_17b14ddc-8104-4352-9ffb-9728cdd9e37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_06d6a47b-0865-4c47-bfa7-275b9b593d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fccbd217-ddb3-451b-bb96-7f8070e0bad6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_06d6a47b-0865-4c47-bfa7-275b9b593d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef717e61-725a-444f-9050-81187d34ee42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd401806-6522-4b42-8e56-7e735354f374" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef717e61-725a-444f-9050-81187d34ee42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a7b5de8f-a9bd-4726-88a2-332e7daa303d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd401806-6522-4b42-8e56-7e735354f374" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a7b5de8f-a9bd-4726-88a2-332e7daa303d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8538cb3-5ba2-4c80-a66e-c77020dc7790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd401806-6522-4b42-8e56-7e735354f374" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8538cb3-5ba2-4c80-a66e-c77020dc7790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60e18b26-34d5-4f06-b912-a9ce65c5c234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd401806-6522-4b42-8e56-7e735354f374" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60e18b26-34d5-4f06-b912-a9ce65c5c234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_28522ee1-8e59-4146-9304-0bccf0953d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fd401806-6522-4b42-8e56-7e735354f374" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_28522ee1-8e59-4146-9304-0bccf0953d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_db0006e4-3ae9-48c3-b688-524d883f1957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_28522ee1-8e59-4146-9304-0bccf0953d5a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_db0006e4-3ae9-48c3-b688-524d883f1957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ef9ad237-b598-4cb5-8cc0-18688b88070e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_28522ee1-8e59-4146-9304-0bccf0953d5a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_ef9ad237-b598-4cb5-8cc0-18688b88070e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_6aba82ef-fdf0-4159-95cb-685a089b2445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_28522ee1-8e59-4146-9304-0bccf0953d5a" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_6aba82ef-fdf0-4159-95cb-685a089b2445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20220403.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_66fcf57f-4d30-41e6-8592-429d9d2cda16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5e8c02c3-a41c-4e10-bdac-d142f4a2fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66fcf57f-4d30-41e6-8592-429d9d2cda16" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5e8c02c3-a41c-4e10-bdac-d142f4a2fb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20220403.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_08a6a1a8-2f76-41b0-b50c-5c709a71ffd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_528e9845-3819-44ab-b18e-46b9d9094695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_08a6a1a8-2f76-41b0-b50c-5c709a71ffd9" xlink:to="loc_us-gaap_UseOfEstimates_528e9845-3819-44ab-b18e-46b9d9094695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fd3ef112-3455-4c8b-bc8f-c226bec48769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_08a6a1a8-2f76-41b0-b50c-5c709a71ffd9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fd3ef112-3455-4c8b-bc8f-c226bec48769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f20889a5-20a9-4f1e-9304-88498e530b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_08a6a1a8-2f76-41b0-b50c-5c709a71ffd9" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f20889a5-20a9-4f1e-9304-88498e530b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_590ae9a0-2f67-439a-8653-1c0d626e463d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_08a6a1a8-2f76-41b0-b50c-5c709a71ffd9" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_590ae9a0-2f67-439a-8653-1c0d626e463d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20220403.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4377aa7e-e2a2-4e67-acda-3c1c92bd5e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_2fda77da-234e-4120-a8c7-5e241b161d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4377aa7e-e2a2-4e67-acda-3c1c92bd5e2f" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_2fda77da-234e-4120-a8c7-5e241b161d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20220403.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3b481c2c-9cac-4732-b140-eb5f3d212eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e2253d77-b236-4dd0-8308-2ac39f8e20d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3b481c2c-9cac-4732-b140-eb5f3d212eb9" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e2253d77-b236-4dd0-8308-2ac39f8e20d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2bf2279e-9516-49dd-b186-7a34f0a19dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_0757e5c4-bde8-4aca-b555-9eee8d462391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2bf2279e-9516-49dd-b186-7a34f0a19dc9" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_0757e5c4-bde8-4aca-b555-9eee8d462391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d3c3b9fd-9dc6-4bc9-93ee-7cf94aa15548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2bf2279e-9516-49dd-b186-7a34f0a19dc9" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d3c3b9fd-9dc6-4bc9-93ee-7cf94aa15548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d2598004-2fe3-4d2c-8f74-2677ad4c768d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2bf2279e-9516-49dd-b186-7a34f0a19dc9" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d2598004-2fe3-4d2c-8f74-2677ad4c768d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ec18ced4-10ff-4bb4-b448-c238c480571a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2bf2279e-9516-49dd-b186-7a34f0a19dc9" xlink:to="loc_us-gaap_InventoryNet_ec18ced4-10ff-4bb4-b448-c238c480571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c6ec4acb-c16f-4a5f-9f30-b8efc00f69d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4a69850a-60ca-4f33-9952-d6920a8a9b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c6ec4acb-c16f-4a5f-9f30-b8efc00f69d8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4a69850a-60ca-4f33-9952-d6920a8a9b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6242f42f-b7d3-4bce-9647-ce181b6bd756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_a6985b71-0404-4161-8088-783d4004ef88" xlink:href="jnj-20220403.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6242f42f-b7d3-4bce-9647-ce181b6bd756" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_a6985b71-0404-4161-8088-783d4004ef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_ea38d9a6-a3a1-4cf9-9757-9ac0f3599e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6242f42f-b7d3-4bce-9647-ce181b6bd756" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_ea38d9a6-a3a1-4cf9-9757-9ac0f3599e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_290a10eb-6ed2-45cb-9694-193d806a7146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6242f42f-b7d3-4bce-9647-ce181b6bd756" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_290a10eb-6ed2-45cb-9694-193d806a7146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6afa0bd8-1209-4ce4-bc31-2110bd1d7406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:href="jnj-20220403.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6afa0bd8-1209-4ce4-bc31-2110bd1d7406" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bdfff477-fece-42da-8a9c-9cc24a7607d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bdfff477-fece-42da-8a9c-9cc24a7607d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bdfff477-fece-42da-8a9c-9cc24a7607d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_5f4eea05-65fd-41be-8804-04b26144da1f" xlink:href="jnj-20220403.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:to="loc_jnj_PatentsAndTrademarksMember_5f4eea05-65fd-41be-8804-04b26144da1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_86bf1757-d283-4208-8646-2b8ee9714314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_86bf1757-d283-4208-8646-2b8ee9714314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_50ceda55-9d42-4c5a-8e93-f2594ecd8404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eb1126ca-4559-417f-a524-21e234d0a7a2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_50ceda55-9d42-4c5a-8e93-f2594ecd8404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1820d6ce-9550-4b21-ad13-c35174db6790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1820d6ce-9550-4b21-ad13-c35174db6790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce45cf8a-f08b-498b-b3dd-64990c7c7155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1820d6ce-9550-4b21-ad13-c35174db6790" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce45cf8a-f08b-498b-b3dd-64990c7c7155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_4ec341bb-1996-47d7-92b3-364e13c7bb58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce45cf8a-f08b-498b-b3dd-64990c7c7155" xlink:to="loc_us-gaap_TrademarksMember_4ec341bb-1996-47d7-92b3-364e13c7bb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_36896eb1-f051-41df-b989-fddd27335aeb" xlink:href="jnj-20220403.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce45cf8a-f08b-498b-b3dd-64990c7c7155" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_36896eb1-f051-41df-b989-fddd27335aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_25916f09-a3a2-4620-8b64-b0a7107d56ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_25916f09-a3a2-4620-8b64-b0a7107d56ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9104d9fe-4df5-4819-8f5c-f095f909fe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25916f09-a3a2-4620-8b64-b0a7107d56ea" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9104d9fe-4df5-4819-8f5c-f095f909fe1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_2c5c383e-8bca-4367-8e2d-31dfb42e2fef" xlink:href="jnj-20220403.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9104d9fe-4df5-4819-8f5c-f095f909fe1c" xlink:to="loc_jnj_BermekimabMember_2c5c383e-8bca-4367-8e2d-31dfb42e2fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1162af6d-09d9-4f05-a818-9fb683e0870b" xlink:href="jnj-20220403.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_4fb3c16e-a428-4c9a-bd49-6516e63f461d" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1162af6d-09d9-4f05-a818-9fb683e0870b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_30dbe849-6085-4a61-8309-a477f7bfd38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1162af6d-09d9-4f05-a818-9fb683e0870b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_30dbe849-6085-4a61-8309-a477f7bfd38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_30dbe849-6085-4a61-8309-a477f7bfd38f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0cf85c2d-9a35-49b4-b5d3-8a62ff52ed9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0cf85c2d-9a35-49b4-b5d3-8a62ff52ed9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b9e99743-1363-42fb-8a65-d62ce8f9c805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b9e99743-1363-42fb-8a65-d62ce8f9c805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0efd69f6-114e-45d2-891a-a477549fb2de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_45d73dbb-dbe5-4044-9099-1171edea753f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0efd69f6-114e-45d2-891a-a477549fb2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_96f4c962-d0a6-4062-bcbd-6ad036f2a234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_30dbe849-6085-4a61-8309-a477f7bfd38f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_96f4c962-d0a6-4062-bcbd-6ad036f2a234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1e4a34a0-bd1c-4cc6-b188-05651021b88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_96f4c962-d0a6-4062-bcbd-6ad036f2a234" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1e4a34a0-bd1c-4cc6-b188-05651021b88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f2eca44-29c4-48fb-aee2-7e4cab0e9334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_96f4c962-d0a6-4062-bcbd-6ad036f2a234" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f2eca44-29c4-48fb-aee2-7e4cab0e9334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0f499cdf-b771-4cf2-95a4-8d370c18b8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1162af6d-09d9-4f05-a818-9fb683e0870b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0f499cdf-b771-4cf2-95a4-8d370c18b8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1fcbd60a-654c-432c-b041-65e810f740e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_20b59908-6375-41f4-8c9f-91e65cd5f7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1fcbd60a-654c-432c-b041-65e810f740e7" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_20b59908-6375-41f4-8c9f-91e65cd5f7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d3509c32-cd86-4b84-968f-289ddec0c730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_20b59908-6375-41f4-8c9f-91e65cd5f7d9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d3509c32-cd86-4b84-968f-289ddec0c730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d3509c32-cd86-4b84-968f-289ddec0c730" xlink:to="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_5c83150c-7479-4658-b7c6-3fe64a3aa279" xlink:href="jnj-20220403.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:to="loc_jnj_ConsumerMember_5c83150c-7479-4658-b7c6-3fe64a3aa279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_ffa95ed9-a430-4fee-b399-959d0b568fb4" xlink:href="jnj-20220403.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:to="loc_jnj_PharmaceuticalMember_ffa95ed9-a430-4fee-b399-959d0b568fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_41fa1365-8413-4864-a9ec-94b2d6e45fbc" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d1903253-4a42-4b3a-af32-c81026e0a41e" xlink:to="loc_jnj_MedicalDevicesMember_41fa1365-8413-4864-a9ec-94b2d6e45fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_b452167d-91e8-4a5a-ab90-ee1498c206d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_20b59908-6375-41f4-8c9f-91e65cd5f7d9" xlink:to="loc_us-gaap_GoodwillLineItems_b452167d-91e8-4a5a-ab90-ee1498c206d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_b452167d-91e8-4a5a-ab90-ee1498c206d8" xlink:to="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0b834e5a-a26b-4aaf-8207-b3d486fc6f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:to="loc_us-gaap_Goodwill_0b834e5a-a26b-4aaf-8207-b3d486fc6f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_89d527e0-7e39-4e67-9d89-a4dbbacd4b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_89d527e0-7e39-4e67-9d89-a4dbbacd4b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_47bcc51b-1c86-42f4-a851-33e348d07831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_47bcc51b-1c86-42f4-a851-33e348d07831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_07c5b471-6fd3-42ec-a9c8-f84755b2b6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_cb0c78bf-c632-441f-b827-51b452c4da11" xlink:to="loc_us-gaap_Goodwill_07c5b471-6fd3-42ec-a9c8-f84755b2b6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d6762f53-9de0-49a0-ab2a-ca6ed0ba2a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9fcbfe47-a21b-49be-bf09-348726fe0604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d6762f53-9de0-49a0-ab2a-ca6ed0ba2a1f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9fcbfe47-a21b-49be-bf09-348726fe0604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_06edd12b-b29d-4a1b-b0a9-4da7bc585a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9fcbfe47-a21b-49be-bf09-348726fe0604" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_06edd12b-b29d-4a1b-b0a9-4da7bc585a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c097cbdc-182b-4bc3-9f36-21c3d5dd0b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_06edd12b-b29d-4a1b-b0a9-4da7bc585a89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c097cbdc-182b-4bc3-9f36-21c3d5dd0b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_2ec4983e-ef5b-461d-a109-d8ef034867be" xlink:href="jnj-20220403.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c097cbdc-182b-4bc3-9f36-21c3d5dd0b16" xlink:to="loc_jnj_PatentsAndTrademarksMember_2ec4983e-ef5b-461d-a109-d8ef034867be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_72f5c172-f375-4967-b34f-284bfbef1c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c097cbdc-182b-4bc3-9f36-21c3d5dd0b16" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_72f5c172-f375-4967-b34f-284bfbef1c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6128d685-62d0-49cd-9c4f-8b35abaa2543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9fcbfe47-a21b-49be-bf09-348726fe0604" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6128d685-62d0-49cd-9c4f-8b35abaa2543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2b36a665-bc19-4670-86b4-fd0e1ed22f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6128d685-62d0-49cd-9c4f-8b35abaa2543" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2b36a665-bc19-4670-86b4-fd0e1ed22f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f6d0d551-a85d-47ca-b6d4-dac355eab056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6128d685-62d0-49cd-9c4f-8b35abaa2543" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f6d0d551-a85d-47ca-b6d4-dac355eab056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_383b4802-f18c-40bb-9dd3-419316cf399c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5f3bed26-3a32-4fd0-bc8b-a6ce6edd6358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_383b4802-f18c-40bb-9dd3-419316cf399c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5f3bed26-3a32-4fd0-bc8b-a6ce6edd6358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5f5ea4cf-3594-4f8b-a29e-e7bae36d62ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_383b4802-f18c-40bb-9dd3-419316cf399c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5f5ea4cf-3594-4f8b-a29e-e7bae36d62ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1f12e431-839d-458b-abfb-f57c248e6fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_383b4802-f18c-40bb-9dd3-419316cf399c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1f12e431-839d-458b-abfb-f57c248e6fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_16b513fa-50b7-44fa-81b5-b2868045e3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_383b4802-f18c-40bb-9dd3-419316cf399c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_16b513fa-50b7-44fa-81b5-b2868045e3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d33d279d-036c-41fb-a4cd-66ad819b7e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_383b4802-f18c-40bb-9dd3-419316cf399c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d33d279d-036c-41fb-a4cd-66ad819b7e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1172757c-ff35-4afe-a909-212f447eb254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_46f786c4-8fb8-4da4-a462-b442b1d70efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1172757c-ff35-4afe-a909-212f447eb254" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_46f786c4-8fb8-4da4-a462-b442b1d70efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b2dcea47-b990-4f4f-ba2a-90ab46696fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c9acec0e-3841-4a5c-8917-8a28b9238259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2dcea47-b990-4f4f-ba2a-90ab46696fed" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c9acec0e-3841-4a5c-8917-8a28b9238259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f4ccc61a-b59e-4213-ac25-2ce750f5f338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2dcea47-b990-4f4f-ba2a-90ab46696fed" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f4ccc61a-b59e-4213-ac25-2ce750f5f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1b2b6831-ad6f-4273-bdc3-2f8f46055c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2dcea47-b990-4f4f-ba2a-90ab46696fed" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1b2b6831-ad6f-4273-bdc3-2f8f46055c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d844fa62-149b-49fe-93de-649feaee8a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2dcea47-b990-4f4f-ba2a-90ab46696fed" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d844fa62-149b-49fe-93de-649feaee8a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_17ec5d9e-e668-40a2-b04e-b966fe54630a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2dcea47-b990-4f4f-ba2a-90ab46696fed" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_17ec5d9e-e668-40a2-b04e-b966fe54630a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5c5be14f-e6e6-4369-8663-2ebe8d578478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2dcea47-b990-4f4f-ba2a-90ab46696fed" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5c5be14f-e6e6-4369-8663-2ebe8d578478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2416a108-49f1-4785-888a-f0d682c8453f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2dcea47-b990-4f4f-ba2a-90ab46696fed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2416a108-49f1-4785-888a-f0d682c8453f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_eb17a4dd-743d-43b4-bd89-356bb20681dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2dcea47-b990-4f4f-ba2a-90ab46696fed" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_eb17a4dd-743d-43b4-bd89-356bb20681dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8ab2de0a-6a29-4505-8f0c-783dfc6dbbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ab2de0a-6a29-4505-8f0c-783dfc6dbbbd" xlink:to="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_ab0c6476-6076-48ce-bcc1-34a0be994a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_ab0c6476-6076-48ce-bcc1-34a0be994a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_ade3555a-d297-4842-b9e5-998bf3b7e802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_ab0c6476-6076-48ce-bcc1-34a0be994a51" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_ade3555a-d297-4842-b9e5-998bf3b7e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_c8d1837c-cba7-471b-a42f-12d3e42fa8d7" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_ade3555a-d297-4842-b9e5-998bf3b7e802" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_c8d1837c-cba7-471b-a42f-12d3e42fa8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5d2b491e-ae54-4c24-8238-35d3da87d3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5d2b491e-ae54-4c24-8238-35d3da87d3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8131fe45-d2b3-4228-b6d0-cec2e883c073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5d2b491e-ae54-4c24-8238-35d3da87d3a2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8131fe45-d2b3-4228-b6d0-cec2e883c073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a850621e-420d-41cc-950b-a758ca7eb5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8131fe45-d2b3-4228-b6d0-cec2e883c073" xlink:to="loc_us-gaap_EquitySecuritiesMember_a850621e-420d-41cc-950b-a758ca7eb5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_de686e62-00ac-4e2f-ae9b-607522a0bb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_de686e62-00ac-4e2f-ae9b-607522a0bb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_de686e62-00ac-4e2f-ae9b-607522a0bb97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_489e9c5d-d972-4981-85e8-6cb78250b138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:to="loc_us-gaap_ForeignExchangeContractMember_489e9c5d-d972-4981-85e8-6cb78250b138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_111e9125-a1d0-4a03-acaa-ff1fe8e22d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_111e9125-a1d0-4a03-acaa-ff1fe8e22d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f35a5450-2e68-4def-9940-41b9f9785c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5388566-6474-4c3b-b0a6-1c2ebaa352d7" xlink:to="loc_us-gaap_InterestRateSwapMember_f35a5450-2e68-4def-9940-41b9f9785c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_fee9b42f-dcaf-4681-bf7a-20d24e7632de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_fee9b42f-dcaf-4681-bf7a-20d24e7632de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7f4f7b9f-55c1-4a8e-9e06-91b602d84e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_fee9b42f-dcaf-4681-bf7a-20d24e7632de" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7f4f7b9f-55c1-4a8e-9e06-91b602d84e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_23e27304-0cd4-430b-96c3-2f9a2af103b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7f4f7b9f-55c1-4a8e-9e06-91b602d84e8f" xlink:to="loc_us-gaap_CommercialPaperMember_23e27304-0cd4-430b-96c3-2f9a2af103b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_93a48e87-0ebe-4f3d-aa0d-d8b15d6a9e5b" xlink:to="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_175a2eb2-fa1d-4cd4-9965-93c0fa51a63c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_175a2eb2-fa1d-4cd4-9965-93c0fa51a63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_604caf74-647d-40b8-b477-d75a1a164297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_DerivativeNotionalAmount_604caf74-647d-40b8-b477-d75a1a164297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_98235439-bd3f-4548-95ce-2e8383ebe7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_98235439-bd3f-4548-95ce-2e8383ebe7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_9562ab58-99ae-4df7-827f-90e1a17da6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_9562ab58-99ae-4df7-827f-90e1a17da6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_61239d54-5993-4dbe-bed7-bd698cc417c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_61239d54-5993-4dbe-bed7-bd698cc417c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_d5bf9f52-18f2-484c-b5c4-466ed2143c61" xlink:href="jnj-20220403.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_d5bf9f52-18f2-484c-b5c4-466ed2143c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_a545459b-a5cd-4ff2-a293-260a761c2133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_EquityFairValueAdjustment_a545459b-a5cd-4ff2-a293-260a761c2133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_537c0f1d-190c-4e9a-990e-654428e7ef69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_537c0f1d-190c-4e9a-990e-654428e7ef69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_605eef7c-00f6-4758-a767-bdb98cc71908" xlink:href="jnj-20220403.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_605eef7c-00f6-4758-a767-bdb98cc71908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_f003cee6-a8de-4a57-b03e-7609c06f0d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_ShortTermBorrowings_f003cee6-a8de-4a57-b03e-7609c06f0d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_6b9ea8d6-edef-4f15-ac00-f8ac53cb2e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_6b9ea8d6-edef-4f15-ac00-f8ac53cb2e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_59d6c4fa-cb58-43a9-884c-052d74f90423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a94a0a93-d467-4d27-8378-2a000dc2388a" xlink:to="loc_us-gaap_DebtInstrumentTerm_59d6c4fa-cb58-43a9-884c-052d74f90423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2b5540d2-ccf2-4498-8ad5-611ebd3d9e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2b5540d2-ccf2-4498-8ad5-611ebd3d9e21" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b2cbb856-10f0-4444-ae8b-94c4e8bb64dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b2cbb856-10f0-4444-ae8b-94c4e8bb64dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b2cbb856-10f0-4444-ae8b-94c4e8bb64dd" xlink:to="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_83abf491-2d1a-4077-b4e5-cdde210c797c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:to="loc_us-gaap_FairValueHedgingMember_83abf491-2d1a-4077-b4e5-cdde210c797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f9134303-6e8a-445e-927b-8d602142983a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f9134303-6e8a-445e-927b-8d602142983a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_bef043dd-cf45-469f-85d7-0558df7d47ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_183f8aa8-85a2-4fef-8ee2-12ed68fded74" xlink:to="loc_us-gaap_CashFlowHedgingMember_bef043dd-cf45-469f-85d7-0558df7d47ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_aef838f6-8cf5-40fd-962a-5ace4326772d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_aef838f6-8cf5-40fd-962a-5ace4326772d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_aef838f6-8cf5-40fd-962a-5ace4326772d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_197fed7e-0080-4b5f-8ed5-b43674c7b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_InterestRateContractMember_197fed7e-0080-4b5f-8ed5-b43674c7b34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7a9f3a3a-ffbf-49c6-a0c7-a1faec38f4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7a9f3a3a-ffbf-49c6-a0c7-a1faec38f4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_a4907566-a0a5-41c9-b3c9-5014fb941858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_a4907566-a0a5-41c9-b3c9-5014fb941858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a3e44d2a-7ad8-4dbb-8d90-7ff9273eb681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_InterestRateSwapMember_a3e44d2a-7ad8-4dbb-8d90-7ff9273eb681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ebc62fd5-c2ba-4ced-a308-49b3ae022542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7daa8a8-8628-498f-b8ae-bed508dda067" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ebc62fd5-c2ba-4ced-a308-49b3ae022542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_19423514-d7df-41d5-92c5-1d20a519292d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_19423514-d7df-41d5-92c5-1d20a519292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_19423514-d7df-41d5-92c5-1d20a519292d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_9b5f67f8-e443-4f73-b14c-6c9871d044d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_us-gaap_SalesMember_9b5f67f8-e443-4f73-b14c-6c9871d044d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_01a5fd9b-5fb3-4599-a98c-8cb772267b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_us-gaap_CostOfSalesMember_01a5fd9b-5fb3-4599-a98c-8cb772267b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3b7f2931-23c1-45e0-b5d3-04e7e00cee03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3b7f2931-23c1-45e0-b5d3-04e7e00cee03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_2cc2c75d-a86e-4cf8-8326-3984bb2b23bb" xlink:href="jnj-20220403.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_2cc2c75d-a86e-4cf8-8326-3984bb2b23bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_4da068fa-349b-4ebf-af00-ce68eb28ec28" xlink:href="jnj-20220403.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_17804238-80c6-41ea-b0d3-9e0581ac0fd9" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_4da068fa-349b-4ebf-af00-ce68eb28ec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ced2be07-5e3f-4372-8bc9-74d748a82277" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_c7348390-2aa9-44ab-9b0f-000e8117ad2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_c7348390-2aa9-44ab-9b0f-000e8117ad2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_469dacd2-1b86-4cb6-a699-6e71622046f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_469dacd2-1b86-4cb6-a699-6e71622046f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_b22a06c1-fbec-4e89-a116-20654d30fb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_6e246b62-5219-4f52-a739-30a2aebddc1e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_b22a06c1-fbec-4e89-a116-20654d30fb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_72c10733-9d5f-44ba-9142-cc5e33ff1482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_2fcb31fe-55dd-4fa5-8e94-c3fe1efbd504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_72c10733-9d5f-44ba-9142-cc5e33ff1482" xlink:to="loc_us-gaap_DerivativeTable_2fcb31fe-55dd-4fa5-8e94-c3fe1efbd504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e224f1bf-f632-4199-a70d-3e4fdf11850c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2fcb31fe-55dd-4fa5-8e94-c3fe1efbd504" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e224f1bf-f632-4199-a70d-3e4fdf11850c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0c10f6b8-b98a-4078-8df6-ef3d37004d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e224f1bf-f632-4199-a70d-3e4fdf11850c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0c10f6b8-b98a-4078-8df6-ef3d37004d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_89612ebf-330d-4458-89c8-a0b7d7d7a6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0c10f6b8-b98a-4078-8df6-ef3d37004d96" xlink:to="loc_us-gaap_LongTermDebtMember_89612ebf-330d-4458-89c8-a0b7d7d7a6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a6e83779-9ee7-4f83-b017-35aff8aaea78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2fcb31fe-55dd-4fa5-8e94-c3fe1efbd504" xlink:to="loc_us-gaap_HedgingDesignationAxis_a6e83779-9ee7-4f83-b017-35aff8aaea78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_85311ef4-86ad-4301-8a8c-a8f2bdb09af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a6e83779-9ee7-4f83-b017-35aff8aaea78" xlink:to="loc_us-gaap_HedgingDesignationDomain_85311ef4-86ad-4301-8a8c-a8f2bdb09af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fbe5c235-c5de-48ee-85af-b9fc938423bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_85311ef4-86ad-4301-8a8c-a8f2bdb09af8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fbe5c235-c5de-48ee-85af-b9fc938423bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_54f49817-b740-4575-b0f4-5ff208a6dac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_2fcb31fe-55dd-4fa5-8e94-c3fe1efbd504" xlink:to="loc_us-gaap_DerivativeLineItems_54f49817-b740-4575-b0f4-5ff208a6dac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d09206a9-23e1-496c-ad69-b450d22c67dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_54f49817-b740-4575-b0f4-5ff208a6dac2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d09206a9-23e1-496c-ad69-b450d22c67dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e0627303-9ac6-4dbd-ba6c-8bc7d9325129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_54f49817-b740-4575-b0f4-5ff208a6dac2" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_e0627303-9ac6-4dbd-ba6c-8bc7d9325129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_15b7c379-a9f3-420b-9e97-5637f6af89ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_15b7c379-a9f3-420b-9e97-5637f6af89ca" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_705e5efe-f3db-4bb5-9b43-67964cbbb143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:to="loc_us-gaap_HedgingDesignationAxis_705e5efe-f3db-4bb5-9b43-67964cbbb143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2b29fe96-8103-46ce-8720-97f5f5c3a980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_705e5efe-f3db-4bb5-9b43-67964cbbb143" xlink:to="loc_us-gaap_HedgingDesignationDomain_2b29fe96-8103-46ce-8720-97f5f5c3a980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_725b5060-45e5-4d06-b377-ea3c4e59b15e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2b29fe96-8103-46ce-8720-97f5f5c3a980" xlink:to="loc_us-gaap_NondesignatedMember_725b5060-45e5-4d06-b377-ea3c4e59b15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_69a7f607-498a-466a-887d-3616b38077a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_69a7f607-498a-466a-887d-3616b38077a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_15838806-40cf-4ba0-bac1-7c387391847e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_69a7f607-498a-466a-887d-3616b38077a3" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_15838806-40cf-4ba0-bac1-7c387391847e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ea02f27f-cbf3-4263-80f1-9254e15411f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_15838806-40cf-4ba0-bac1-7c387391847e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ea02f27f-cbf3-4263-80f1-9254e15411f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_611001e6-e914-444b-9428-fc8dcc255bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_611001e6-e914-444b-9428-fc8dcc255bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20a54774-4355-4c4b-9b60-a4d9d7744882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_611001e6-e914-444b-9428-fc8dcc255bf6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20a54774-4355-4c4b-9b60-a4d9d7744882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_554b3a96-d616-46c8-a809-8023bd249f84" xlink:href="jnj-20220403.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20a54774-4355-4c4b-9b60-a4d9d7744882" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_554b3a96-d616-46c8-a809-8023bd249f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_910220b9-9cce-4a9d-96c8-d2eae7ef63ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7e9330b9-929c-41ac-b088-f489a99a8140" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_910220b9-9cce-4a9d-96c8-d2eae7ef63ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_bcb99e5f-bbc6-4226-a735-99780b23866b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_910220b9-9cce-4a9d-96c8-d2eae7ef63ed" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_bcb99e5f-bbc6-4226-a735-99780b23866b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2e6d5959-bbba-4030-89f3-55c6ef95fed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d6ec4d57-e2f7-4701-9785-9f92bcead350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2e6d5959-bbba-4030-89f3-55c6ef95fed3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d6ec4d57-e2f7-4701-9785-9f92bcead350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d59f638e-eba4-4b1d-b5c0-83eb5112690b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d6ec4d57-e2f7-4701-9785-9f92bcead350" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d59f638e-eba4-4b1d-b5c0-83eb5112690b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2920ec55-ef9f-406c-a93e-68e2cddcf564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d59f638e-eba4-4b1d-b5c0-83eb5112690b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2920ec55-ef9f-406c-a93e-68e2cddcf564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_6e4906f6-d5e7-44f2-baa7-0c8206cc2f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2920ec55-ef9f-406c-a93e-68e2cddcf564" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_6e4906f6-d5e7-44f2-baa7-0c8206cc2f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c35ea95f-741d-470a-a7ca-c55d03231ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d6ec4d57-e2f7-4701-9785-9f92bcead350" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c35ea95f-741d-470a-a7ca-c55d03231ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3dda9949-8369-4f46-98a9-bb38a3545bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c35ea95f-741d-470a-a7ca-c55d03231ff6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3dda9949-8369-4f46-98a9-bb38a3545bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_b64741c0-1839-4250-88fc-278da34d9701" xlink:href="jnj-20220403.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3dda9949-8369-4f46-98a9-bb38a3545bbb" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_b64741c0-1839-4250-88fc-278da34d9701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e3f9a144-f6f4-441a-9c05-70758134d49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d6ec4d57-e2f7-4701-9785-9f92bcead350" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e3f9a144-f6f4-441a-9c05-70758134d49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_5022f8eb-de51-46db-b92b-536f30630d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e3f9a144-f6f4-441a-9c05-70758134d49b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_5022f8eb-de51-46db-b92b-536f30630d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_ee93bfe7-0222-4a24-9ed5-86cf2de13e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e3f9a144-f6f4-441a-9c05-70758134d49b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_ee93bfe7-0222-4a24-9ed5-86cf2de13e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc46b904-ed5f-40c4-8ece-a53aca37f23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f539018b-f5a2-46df-b367-e6254260843d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc46b904-ed5f-40c4-8ece-a53aca37f23a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f539018b-f5a2-46df-b367-e6254260843d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_c781451a-7cc5-4aa2-8874-9f151d3c200f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f539018b-f5a2-46df-b367-e6254260843d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_c781451a-7cc5-4aa2-8874-9f151d3c200f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1576a3bc-51fb-41ec-bc0d-6bcf16a84e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_c781451a-7cc5-4aa2-8874-9f151d3c200f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1576a3bc-51fb-41ec-bc0d-6bcf16a84e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_75671947-6c80-4afc-ba93-1b0a7b69f68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1576a3bc-51fb-41ec-bc0d-6bcf16a84e5e" xlink:to="loc_us-gaap_EquitySecuritiesMember_75671947-6c80-4afc-ba93-1b0a7b69f68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_7c36ea75-0273-4754-9560-07de5c10fd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f539018b-f5a2-46df-b367-e6254260843d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_7c36ea75-0273-4754-9560-07de5c10fd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_457578b8-8c42-4380-9a4a-7cc0fc09a370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_7c36ea75-0273-4754-9560-07de5c10fd0c" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_457578b8-8c42-4380-9a4a-7cc0fc09a370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_36a5ff71-7a85-44f7-9d9a-a945563fff8b" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_457578b8-8c42-4380-9a4a-7cc0fc09a370" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_36a5ff71-7a85-44f7-9d9a-a945563fff8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_e983f298-d948-492d-93f8-ed1c84b8ce55" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_457578b8-8c42-4380-9a4a-7cc0fc09a370" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_e983f298-d948-492d-93f8-ed1c84b8ce55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a02d645c-5e8e-4eea-95d1-94a424d439d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f539018b-f5a2-46df-b367-e6254260843d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a02d645c-5e8e-4eea-95d1-94a424d439d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_a02d645c-5e8e-4eea-95d1-94a424d439d8" xlink:to="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_7936517b-f446-4268-9b5e-1102f1a6f8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_7936517b-f446-4268-9b5e-1102f1a6f8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_2adf37e2-666e-430f-94ee-100770d6ee89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_2adf37e2-666e-430f-94ee-100770d6ee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_0bc4697f-4e91-4a40-9e54-5233be4270c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_EquityFairValueAdjustment_0bc4697f-4e91-4a40-9e54-5233be4270c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_f786be37-ef03-4073-a289-c936233b03e9" xlink:href="jnj-20220403.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_f786be37-ef03-4073-a289-c936233b03e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_1095c702-c6f5-4e05-bbdb-47cf8154689d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_1095c702-c6f5-4e05-bbdb-47cf8154689d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_d59af116-792d-430f-95df-15fc6a90df1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_d59af116-792d-430f-95df-15fc6a90df1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d922e77b-6957-4226-9148-2046c261ce1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_768ca756-a093-4be3-9e35-98acf11de240" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d922e77b-6957-4226-9148-2046c261ce1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5edbf237-a12b-416b-9bca-f9b27d15d7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5edbf237-a12b-416b-9bca-f9b27d15d7ac" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_637bccb5-9884-438c-b4a0-0ef52de6e1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_637bccb5-9884-438c-b4a0-0ef52de6e1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_637bccb5-9884-438c-b4a0-0ef52de6e1b9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_eb7f8c47-f06d-4df4-9aa3-e2dc28286fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_eb7f8c47-f06d-4df4-9aa3-e2dc28286fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7d1892ea-1e91-460c-96ed-c71fcf74d568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7d1892ea-1e91-460c-96ed-c71fcf74d568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_d17ac5e9-a1b9-40d1-9466-458cad0586f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ab0e1584-933a-4286-8602-b86e449d66ea" xlink:to="loc_us-gaap_LongTermDebtMember_d17ac5e9-a1b9-40d1-9466-458cad0586f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f262f4d7-d917-4785-a0b1-02eb4f63e255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f262f4d7-d917-4785-a0b1-02eb4f63e255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0a56edf0-b911-4933-a803-06053ed28197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f262f4d7-d917-4785-a0b1-02eb4f63e255" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0a56edf0-b911-4933-a803-06053ed28197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_a38c65f6-0e1f-4690-b4ae-114aef08d9bf" xlink:href="jnj-20220403.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0a56edf0-b911-4933-a803-06053ed28197" xlink:to="loc_jnj_AurisHealthMember_a38c65f6-0e1f-4690-b4ae-114aef08d9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3be205cf-0e76-4ea3-ab3c-9a3504d0615e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_InvestmentTypeAxis_3be205cf-0e76-4ea3-ab3c-9a3504d0615e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3f737335-e0f4-4f31-b7e7-1115e3e258a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_3be205cf-0e76-4ea3-ab3c-9a3504d0615e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3f737335-e0f4-4f31-b7e7-1115e3e258a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_66aa3525-dd8a-4036-8b1d-10f74014e45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_3f737335-e0f4-4f31-b7e7-1115e3e258a3" xlink:to="loc_us-gaap_EquitySecuritiesMember_66aa3525-dd8a-4036-8b1d-10f74014e45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d5d09575-9672-4c98-a1f1-4df069adf3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d5d09575-9672-4c98-a1f1-4df069adf3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5d09575-9672-4c98-a1f1-4df069adf3eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_775bc1ce-97e0-484b-9c51-5cfc7b88bbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:to="loc_us-gaap_InterestRateContractMember_775bc1ce-97e0-484b-9c51-5cfc7b88bbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b27c9254-7568-42e8-bf2e-be9ab5c8964b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b27c9254-7568-42e8-bf2e-be9ab5c8964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_334555b4-107d-47b2-b2c3-4eba943c8017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb2f4cf4-cccf-44f7-99f7-fcc36b90ff95" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_334555b4-107d-47b2-b2c3-4eba943c8017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_84239e2e-e920-4536-a1a7-9f73ea1a469d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_84239e2e-e920-4536-a1a7-9f73ea1a469d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_84239e2e-e920-4536-a1a7-9f73ea1a469d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6f1725b7-f739-4b77-8fb1-8140fca7f4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6f1725b7-f739-4b77-8fb1-8140fca7f4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1a6de4ef-c89a-4f67-ace7-8582a071b618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1a6de4ef-c89a-4f67-ace7-8582a071b618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_aba6d517-e731-4bdf-bee0-e71a348bf71c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4df44df4-b660-4b2d-b744-880225d4a3e1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_aba6d517-e731-4bdf-bee0-e71a348bf71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8ddc5cdb-aadd-4bdc-8cab-81d7bf028a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8ddc5cdb-aadd-4bdc-8cab-81d7bf028a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_73fd1661-eebb-4ae5-99ef-7777655bfb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8ddc5cdb-aadd-4bdc-8cab-81d7bf028a4c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_73fd1661-eebb-4ae5-99ef-7777655bfb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_93555dc8-c0ea-44df-af98-e58b76be4aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_73fd1661-eebb-4ae5-99ef-7777655bfb80" xlink:to="loc_us-gaap_FairValueHedgingMember_93555dc8-c0ea-44df-af98-e58b76be4aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_401192c3-1c10-4dff-8489-5e24244e09cc" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_01c0df4f-7494-4510-8c87-8e24077dab7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_01c0df4f-7494-4510-8c87-8e24077dab7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_418ffb84-a20b-46bc-b255-78968c65690c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_418ffb84-a20b-46bc-b255-78968c65690c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_2c341c14-2de8-4362-8fbf-1aa1c333bcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_2c341c14-2de8-4362-8fbf-1aa1c333bcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_d96b0c57-4215-4b7b-a20e-f43547148e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_d96b0c57-4215-4b7b-a20e-f43547148e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_2d9f9922-7089-419c-8387-b56a81bf6512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_2d9f9922-7089-419c-8387-b56a81bf6512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40d5180e-099a-41e7-b49a-6396f8e96ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_40d5180e-099a-41e7-b49a-6396f8e96ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9bd62094-ad6e-40d3-b021-05813fc74648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_f769678e-4e0e-489a-8aa0-49c52be81497" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9bd62094-ad6e-40d3-b021-05813fc74648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ec621a71-f07e-4252-bfca-dbcda508e1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ec621a71-f07e-4252-bfca-dbcda508e1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_bdbdb897-ee20-4341-a13c-d0a7673866cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_bdbdb897-ee20-4341-a13c-d0a7673866cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_cb39ccb1-766d-425b-a21e-711b647ca790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeAssets_cb39ccb1-766d-425b-a21e-711b647ca790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_588fc556-cc1d-4b32-9ea0-d283e652b748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_588fc556-cc1d-4b32-9ea0-d283e652b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5bcd7dc4-d616-425a-9487-55729e7dff5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5bcd7dc4-d616-425a-9487-55729e7dff5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8f97cda4-e092-46e0-a361-889c4241b463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_DerivativeLiabilities_8f97cda4-e092-46e0-a361-889c4241b463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_41d3eaef-5aca-48ea-8da9-3909d3e9ba33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_41d3eaef-5aca-48ea-8da9-3909d3e9ba33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_079c321b-fe36-4a3c-bff8-3b56d725b1ab" xlink:href="jnj-20220403.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_079c321b-fe36-4a3c-bff8-3b56d725b1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_971694d6-568e-424c-9cd7-0e9481c32a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_971694d6-568e-424c-9cd7-0e9481c32a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_18f7fc71-71f6-4790-a7dc-4c34a74ff32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_18f7fc71-71f6-4790-a7dc-4c34a74ff32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1176093b-e27a-4895-be75-72b38ee3fcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_38ffc975-f917-43dc-8f13-82df7481ea73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1176093b-e27a-4895-be75-72b38ee3fcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b8385f40-b4bc-4830-95b3-74f09619b01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_f9e20aee-f856-4cc1-8bb9-7eabe7ec9c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b8385f40-b4bc-4830-95b3-74f09619b01a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_f9e20aee-f856-4cc1-8bb9-7eabe7ec9c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_a4726f5c-2c37-4880-ae2e-ccd20ffc7464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_f9e20aee-f856-4cc1-8bb9-7eabe7ec9c0a" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_a4726f5c-2c37-4880-ae2e-ccd20ffc7464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_edb93beb-a424-42af-852a-524075ea29e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_a4726f5c-2c37-4880-ae2e-ccd20ffc7464" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_edb93beb-a424-42af-852a-524075ea29e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_4c620ccc-07c1-4640-b072-1a0272378e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_edb93beb-a424-42af-852a-524075ea29e2" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_4c620ccc-07c1-4640-b072-1a0272378e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_e70465e9-7e25-41e0-ae67-ab8d3a463341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_edb93beb-a424-42af-852a-524075ea29e2" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_e70465e9-7e25-41e0-ae67-ab8d3a463341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_21782828-011d-4644-bce6-5a2ae3c79031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_f9e20aee-f856-4cc1-8bb9-7eabe7ec9c0a" xlink:to="loc_us-gaap_InvestmentTypeAxis_21782828-011d-4644-bce6-5a2ae3c79031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_21782828-011d-4644-bce6-5a2ae3c79031" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_808a1b25-d95e-406d-817e-648cad85a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_CashMember_808a1b25-d95e-406d-817e-648cad85a59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_9f11915c-fab1-4794-a805-5bc120cecf77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_9f11915c-fab1-4794-a805-5bc120cecf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_f7f1050d-aa60-438b-ab90-8534bde9e8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_f7f1050d-aa60-438b-ab90-8534bde9e8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fba57377-f332-4c96-988e-4c112c7e11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fba57377-f332-4c96-988e-4c112c7e11e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_114b1df3-bb45-4ebf-b4b4-ae5dd05ddd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_MoneyMarketFundsMember_114b1df3-bb45-4ebf-b4b4-ae5dd05ddd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_e853f959-bfab-4b18-9daf-7aa5c5cdf0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_BankTimeDepositsMember_e853f959-bfab-4b18-9daf-7aa5c5cdf0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_825f911e-10c5-4617-bf23-294411cb207d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_142b5893-5a95-4a69-bcaa-12a5085a80da" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_825f911e-10c5-4617-bf23-294411cb207d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_f9e20aee-f856-4cc1-8bb9-7eabe7ec9c0a" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_0dc1ecd6-6404-47e2-9ef6-f9ebb83e8660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:to="loc_us-gaap_HeldToMaturitySecurities_0dc1ecd6-6404-47e2-9ef6-f9ebb83e8660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_0c8b1b91-1815-46f0-bc93-54b0ee427dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_0c8b1b91-1815-46f0-bc93-54b0ee427dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_bc13bcb6-d0b8-454b-b318-f875634a3f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_76bf6ee0-aea8-4a63-b906-59e92d3630f7" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_bc13bcb6-d0b8-454b-b318-f875634a3f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c70857cf-f075-4616-a5cd-65bb23262071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c70857cf-f075-4616-a5cd-65bb23262071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a556dda3-0be0-4c85-82f3-8dcfb7901777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a556dda3-0be0-4c85-82f3-8dcfb7901777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7f6a170-288d-43a2-8bd2-fea5f82c468d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b4ac087-c763-4aab-9284-39648a4f0dd1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c7f6a170-288d-43a2-8bd2-fea5f82c468d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9893dbd1-db22-40e2-a342-f22ce6c510a9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72a2235f-159b-47ed-bf58-41888edc4e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72a2235f-159b-47ed-bf58-41888edc4e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_693fa2a0-aa85-4625-8129-a92c381f9a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_693fa2a0-aa85-4625-8129-a92c381f9a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_327b4487-7dc0-4266-b986-393a09abafc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_327b4487-7dc0-4266-b986-393a09abafc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_bfe2ed5c-8e41-4638-a7e0-ae192493d7c0" xlink:href="jnj-20220403.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_bfe2ed5c-8e41-4638-a7e0-ae192493d7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_e8627493-aa26-46f5-8746-40911048cd6b" xlink:href="jnj-20220403.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_e8946421-abe7-4d3b-a6e1-4675bf2b2525" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_e8627493-aa26-46f5-8746-40911048cd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c737919a-6694-4387-9e99-a670c2cce94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6f417f28-8b9d-4c11-a48e-3b8c8ca1a314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c737919a-6694-4387-9e99-a670c2cce94f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6f417f28-8b9d-4c11-a48e-3b8c8ca1a314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_aef8c2e6-17e9-49b3-9261-e7252f3fa221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6f417f28-8b9d-4c11-a48e-3b8c8ca1a314" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_aef8c2e6-17e9-49b3-9261-e7252f3fa221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7dd0902c-4414-411b-86ef-4971abe695a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6f417f28-8b9d-4c11-a48e-3b8c8ca1a314" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_7dd0902c-4414-411b-86ef-4971abe695a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_880152d2-fa4c-42b2-b7a1-894d392334f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6f417f28-8b9d-4c11-a48e-3b8c8ca1a314" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_880152d2-fa4c-42b2-b7a1-894d392334f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_ec346a6c-e14a-4f02-abaa-987e33327681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_6f417f28-8b9d-4c11-a48e-3b8c8ca1a314" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_ec346a6c-e14a-4f02-abaa-987e33327681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e1d7831d-2cfe-494e-99c3-fe8490fc7e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c737919a-6694-4387-9e99-a670c2cce94f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e1d7831d-2cfe-494e-99c3-fe8490fc7e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a01014b8-3ccc-479d-819c-444b88dac65d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e1d7831d-2cfe-494e-99c3-fe8490fc7e21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a01014b8-3ccc-479d-819c-444b88dac65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ba089598-44dd-418a-a987-b7a980699db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e1d7831d-2cfe-494e-99c3-fe8490fc7e21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ba089598-44dd-418a-a987-b7a980699db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_3709bfd9-089b-400d-8cf1-84ada883e998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e1d7831d-2cfe-494e-99c3-fe8490fc7e21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_3709bfd9-089b-400d-8cf1-84ada883e998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_9a5dd0d0-67d2-491e-a915-784760e40f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e1d7831d-2cfe-494e-99c3-fe8490fc7e21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_9a5dd0d0-67d2-491e-a915-784760e40f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8b6b9475-ef92-40de-b05d-2db4e4fc6452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1b8da7df-fc37-4c0c-bca9-71c5017c37c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8b6b9475-ef92-40de-b05d-2db4e4fc6452" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1b8da7df-fc37-4c0c-bca9-71c5017c37c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c1c9f6af-3491-4706-bd34-34c2d420a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1b8da7df-fc37-4c0c-bca9-71c5017c37c5" xlink:to="loc_us-gaap_DebtInstrumentAxis_c1c9f6af-3491-4706-bd34-34c2d420a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c1c9f6af-3491-4706-bd34-34c2d420a9a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_fa51de57-7bfc-4a0a-b61e-b2463862c1ed" xlink:href="jnj-20220403.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_fa51de57-7bfc-4a0a-b61e-b2463862c1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_b700294c-dc4a-4af4-aa2b-e536cd5ccbcb" xlink:href="jnj-20220403.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.375Notesdue2023Member_b700294c-dc4a-4af4-aa2b-e536cd5ccbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_0fce3dca-28b8-4b28-89a4-fc6cb197c738" xlink:href="jnj-20220403.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A0.650NotesDue2024Member_0fce3dca-28b8-4b28-89a4-fc6cb197c738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_070878ac-9677-499a-a043-ebe56e519870" xlink:href="jnj-20220403.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A5.50NotesDue2024Member_070878ac-9677-499a-a043-ebe56e519870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_c86fb1ef-4108-45bd-be3c-cf247c21bd0f" xlink:href="jnj-20220403.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2.625Notesdue2025Member_c86fb1ef-4108-45bd-be3c-cf247c21bd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_4e044516-dae3-40cf-92cc-b431f76e0c20" xlink:href="jnj-20220403.xsd#jnj_A0550NotesDue2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A0550NotesDue2025Member_4e044516-dae3-40cf-92cc-b431f76e0c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_91f0ea23-c0cd-4cde-b2d1-5acecabe1be4" xlink:href="jnj-20220403.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2.45Notesdue2026Member_91f0ea23-c0cd-4cde-b2d1-5acecabe1be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_b178d0e8-b93b-4ea1-8bfc-84d2d3bca0f6" xlink:href="jnj-20220403.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2.95Notesdue2027Member_b178d0e8-b93b-4ea1-8bfc-84d2d3bca0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_a091b5fc-c41f-4a9d-a28e-3697780e5273" xlink:href="jnj-20220403.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A095NotesDue2027Member_a091b5fc-c41f-4a9d-a28e-3697780e5273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_fa9cb00b-e881-4f7b-9323-c66a8a6fe206" xlink:href="jnj-20220403.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2.900Notesdue2028Member_fa9cb00b-e881-4f7b-9323-c66a8a6fe206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_593cc6fc-0ce5-4ac9-8ce8-6e369d472fd3" xlink:href="jnj-20220403.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A1.150NotesDue2028Member_593cc6fc-0ce5-4ac9-8ce8-6e369d472fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_3d571c40-2967-4169-b598-1bb1266457cc" xlink:href="jnj-20220403.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A6.95Notesdue2029Member_3d571c40-2967-4169-b598-1bb1266457cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_6a5152e1-20a3-4f78-ac36-2ebb214a2eb2" xlink:href="jnj-20220403.xsd#jnj_A1300NotesDue2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A1300NotesDue2030Member_6a5152e1-20a3-4f78-ac36-2ebb214a2eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_d8c3f3b9-2f1c-43db-a497-a79957def22a" xlink:href="jnj-20220403.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_d8c3f3b9-2f1c-43db-a497-a79957def22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_a486e694-7769-4f3d-ac4f-38231d51f157" xlink:href="jnj-20220403.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.375Notesdue2033Member_a486e694-7769-4f3d-ac4f-38231d51f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_1dac0cf1-7ac2-4662-8fe4-a8c33e64585e" xlink:href="jnj-20220403.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A1.650NotesDue2035Member_1dac0cf1-7ac2-4662-8fe4-a8c33e64585e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_ae06ce3e-69a1-408b-a837-54bbe2102c85" xlink:href="jnj-20220403.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.55Notesdue2036Member_ae06ce3e-69a1-408b-a837-54bbe2102c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_16dd8cea-5942-48bd-a430-70266fcf3c4b" xlink:href="jnj-20220403.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A5.95Notesdue2037Member_16dd8cea-5942-48bd-a430-70266fcf3c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_58c61daf-a0fc-46a0-8045-694ee3f94c52" xlink:href="jnj-20220403.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.625Notesdue2037Member_58c61daf-a0fc-46a0-8045-694ee3f94c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_525b44ca-bde8-46fc-addf-1aea3504cbc5" xlink:href="jnj-20220403.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.400Notesdue2038Member_525b44ca-bde8-46fc-addf-1aea3504cbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_76ebafec-2e9b-41a1-826a-2e9718270d7a" xlink:href="jnj-20220403.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_76ebafec-2e9b-41a1-826a-2e9718270d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_2711400e-0c5c-4d08-a538-d6cd0cac75da" xlink:href="jnj-20220403.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_2711400e-0c5c-4d08-a538-d6cd0cac75da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_d2a20bf2-a140-400e-bd11-774f14483781" xlink:href="jnj-20220403.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A210NotesDue2040Member_d2a20bf2-a140-400e-bd11-774f14483781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_a60f7194-6fea-46dd-acf5-e1a039ae2eef" xlink:href="jnj-20220403.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.85Notesdue2041Member_a60f7194-6fea-46dd-acf5-e1a039ae2eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_24280a9e-28d1-42b8-a5d8-5c8a0cbbf10f" xlink:href="jnj-20220403.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A4.50Notesdue2043Member_24280a9e-28d1-42b8-a5d8-5c8a0cbbf10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_41386c07-a765-44cc-9aff-913513dc64b9" xlink:href="jnj-20220403.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.70Notesdue2046Member_41386c07-a765-44cc-9aff-913513dc64b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_6b53c8fa-f9d5-4b5a-895b-e5789c7c4f37" xlink:href="jnj-20220403.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.75Notesdue2047Member_6b53c8fa-f9d5-4b5a-895b-e5789c7c4f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_d20b9797-e3fb-4b50-9447-4a71184d6e67" xlink:href="jnj-20220403.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A3.500Notesdue2048Member_d20b9797-e3fb-4b50-9447-4a71184d6e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_cd2c14a6-aa11-4b15-9867-8f75f37be743" xlink:href="jnj-20220403.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2250NotesDue2050Member_cd2c14a6-aa11-4b15-9867-8f75f37be743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_020149b1-8ff4-4df4-8b92-f8166d4435e0" xlink:href="jnj-20220403.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_A2450NotesDue2060Member_020149b1-8ff4-4df4-8b92-f8166d4435e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_d619f511-da79-4641-8193-012cf193954d" xlink:href="jnj-20220403.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_191f851c-7109-4df3-94ba-22fd4e4349f2" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_d619f511-da79-4641-8193-012cf193954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_d74874f8-7903-461f-9814-312eae955291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1b8da7df-fc37-4c0c-bca9-71c5017c37c5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_d74874f8-7903-461f-9814-312eae955291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c5749035-567b-4520-89c7-eebf27cbf44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_d74874f8-7903-461f-9814-312eae955291" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c5749035-567b-4520-89c7-eebf27cbf44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b05563c-45f1-4cae-bb46-7e8b5d0d4e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c5749035-567b-4520-89c7-eebf27cbf44f" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b05563c-45f1-4cae-bb46-7e8b5d0d4e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9c96aac1-5db7-4bdd-b23c-668e26a1473a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b05563c-45f1-4cae-bb46-7e8b5d0d4e88" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9c96aac1-5db7-4bdd-b23c-668e26a1473a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1e3d228a-1d34-42d2-b917-d3431430e144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b05563c-45f1-4cae-bb46-7e8b5d0d4e88" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1e3d228a-1d34-42d2-b917-d3431430e144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_950ed505-6253-48b4-b709-8fb3edd8064f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1b8da7df-fc37-4c0c-bca9-71c5017c37c5" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_950ed505-6253-48b4-b709-8fb3edd8064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_950ed505-6253-48b4-b709-8fb3edd8064f" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_a241d5c1-9d8e-4c8c-8d9f-d16fcb12beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_a241d5c1-9d8e-4c8c-8d9f-d16fcb12beaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_42453d95-685b-441b-ae46-1671585633a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_a241d5c1-9d8e-4c8c-8d9f-d16fcb12beaf" xlink:to="loc_us-gaap_ShortTermBorrowings_42453d95-685b-441b-ae46-1671585633a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_34f167b6-c2de-47f8-9475-778e7b7230ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_34f167b6-c2de-47f8-9475-778e7b7230ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_95debf1f-3c37-496c-9e89-4dbf2567ffc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_34f167b6-c2de-47f8-9475-778e7b7230ef" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_95debf1f-3c37-496c-9e89-4dbf2567ffc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b25a5bb9-b4be-404a-98ae-de19a9c72dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1d704fa2-4c9f-490d-a71f-0eadcd1b6a54" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b25a5bb9-b4be-404a-98ae-de19a9c72dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20220403.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_59664ccb-9a63-4711-8cfd-750179c5440d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_dba43aa8-e1f0-4a46-a713-8376cc265c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_59664ccb-9a63-4711-8cfd-750179c5440d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_dba43aa8-e1f0-4a46-a713-8376cc265c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cfa2f9c0-4639-4a48-96e8-395393e78dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_36d3cdd5-2762-436e-bbab-c37ea2a2ac99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cfa2f9c0-4639-4a48-96e8-395393e78dbb" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_36d3cdd5-2762-436e-bbab-c37ea2a2ac99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_306e6aad-fa32-4390-bdab-bcb10a08d4db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cfa2f9c0-4639-4a48-96e8-395393e78dbb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_306e6aad-fa32-4390-bdab-bcb10a08d4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20220403.xsd#PensionsandOtherBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3ef1d74e-c265-4e81-921c-eaf5030994e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ff6e8d15-514a-44cc-a687-e94f7e39ee85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3ef1d74e-c265-4e81-921c-eaf5030994e9" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ff6e8d15-514a-44cc-a687-e94f7e39ee85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20220403.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8495fb64-e131-488d-ae69-480fd5486afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_65d64115-a86b-492f-8fe1-71a6222104dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8495fb64-e131-488d-ae69-480fd5486afd" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_65d64115-a86b-492f-8fe1-71a6222104dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a8dc9307-f229-4225-b81c-85443b43a175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_635abaec-6668-4f05-8dff-66a82c43ec0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a8dc9307-f229-4225-b81c-85443b43a175" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_635abaec-6668-4f05-8dff-66a82c43ec0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e2112d30-19f7-411c-bd1c-15c0d58e9d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_635abaec-6668-4f05-8dff-66a82c43ec0f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e2112d30-19f7-411c-bd1c-15c0d58e9d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_36d46f54-593c-47ad-b010-3f0d0fe12fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e2112d30-19f7-411c-bd1c-15c0d58e9d8b" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_36d46f54-593c-47ad-b010-3f0d0fe12fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f30a0db5-1aeb-4798-a2fe-7ab91b603477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_36d46f54-593c-47ad-b010-3f0d0fe12fd9" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f30a0db5-1aeb-4798-a2fe-7ab91b603477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e30b1bb-c5df-4600-b875-72a0864dfdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_36d46f54-593c-47ad-b010-3f0d0fe12fd9" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7e30b1bb-c5df-4600-b875-72a0864dfdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1c1330a-a893-422d-92c3-7590746c9ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_635abaec-6668-4f05-8dff-66a82c43ec0f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1c1330a-a893-422d-92c3-7590746c9ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1c1330a-a893-422d-92c3-7590746c9ecd" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5d26953a-908e-4735-9a92-ffb791282f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5d26953a-908e-4735-9a92-ffb791282f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_98c30cbf-edf5-4bee-a9cc-1007fde7eb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_98c30cbf-edf5-4bee-a9cc-1007fde7eb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_000d1f35-3b67-4bc9-86ab-aadc1d3b4851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_000d1f35-3b67-4bc9-86ab-aadc1d3b4851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_927f7e12-22ff-4aed-8ad2-cb4544ab078b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_927f7e12-22ff-4aed-8ad2-cb4544ab078b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_9fa9c3c8-0900-4747-aa37-aa422e939fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_9fa9c3c8-0900-4747-aa37-aa422e939fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_e32c33bd-ff75-4e46-a0e2-979a86201413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_e32c33bd-ff75-4e46-a0e2-979a86201413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3f537afb-7d3c-41c4-9483-ef7637ed7459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6bf291a4-3dfb-4c0c-9af0-66afdd0dd87a" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3f537afb-7d3c-41c4-9483-ef7637ed7459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3aaa3d3a-8075-41d1-a781-2cc09318ed6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2bc36d73-73b7-4554-8c36-adc777fd100c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3aaa3d3a-8075-41d1-a781-2cc09318ed6e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2bc36d73-73b7-4554-8c36-adc777fd100c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_1d01e60d-163d-41a8-a07c-284314ee6b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2bc36d73-73b7-4554-8c36-adc777fd100c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_1d01e60d-163d-41a8-a07c-284314ee6b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9908a468-399a-439a-a670-b9ea41a49fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_1d01e60d-163d-41a8-a07c-284314ee6b4d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9908a468-399a-439a-a670-b9ea41a49fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a287a0ea-8bec-45d5-8d7f-1a5a0bc6bf3f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9908a468-399a-439a-a670-b9ea41a49fc5" xlink:to="loc_country_US_a287a0ea-8bec-45d5-8d7f-1a5a0bc6bf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ce7bd3a5-cad2-4d6c-98aa-9f8ef98a928f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9908a468-399a-439a-a670-b9ea41a49fc5" xlink:to="loc_us-gaap_ForeignPlanMember_ce7bd3a5-cad2-4d6c-98aa-9f8ef98a928f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2de4ed01-4329-4fb0-a084-786fdcabaf22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2bc36d73-73b7-4554-8c36-adc777fd100c" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2de4ed01-4329-4fb0-a084-786fdcabaf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_8717a943-34de-4c2f-a774-3e86afd4b275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2de4ed01-4329-4fb0-a084-786fdcabaf22" xlink:to="loc_us-gaap_PensionContributions_8717a943-34de-4c2f-a774-3e86afd4b275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20220403.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ebd013fd-a2ec-4161-b9c3-fc4f63a07229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_909ea679-ec7f-4d06-b961-e9fdc4ea2552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ebd013fd-a2ec-4161-b9c3-fc4f63a07229" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_909ea679-ec7f-4d06-b961-e9fdc4ea2552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="jnj-20220403.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c280e3bc-e4c6-4e6f-90e0-1fe2f3a6a3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1ca891cc-a312-457b-a8c3-0221695cc90a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c280e3bc-e4c6-4e6f-90e0-1fe2f3a6a3b6" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1ca891cc-a312-457b-a8c3-0221695cc90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cae8e1f7-aa68-4281-8f2b-d6f7c7528ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25d51add-5965-4dd7-bb7f-9c4f15624207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cae8e1f7-aa68-4281-8f2b-d6f7c7528ba3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25d51add-5965-4dd7-bb7f-9c4f15624207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d6616e20-2836-4db9-b1c9-926d00321e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25d51add-5965-4dd7-bb7f-9c4f15624207" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d6616e20-2836-4db9-b1c9-926d00321e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d6616e20-2836-4db9-b1c9-926d00321e2a" xlink:to="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9f8a29cf-0acd-4a31-baf5-e8134e27d19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9f8a29cf-0acd-4a31-baf5-e8134e27d19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6d283834-cf4b-4eba-8787-006e272d536c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6d283834-cf4b-4eba-8787-006e272d536c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f305843b-d0cc-4281-aff9-c1d1b73b52a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f305843b-d0cc-4281-aff9-c1d1b73b52a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_447caff5-4496-421a-bdcc-1467af720ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_447caff5-4496-421a-bdcc-1467af720ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e879c52c-d1f1-4e01-a6c7-bd33a6f0bfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c720253-9428-4cb0-8d8d-49789120a643" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e879c52c-d1f1-4e01-a6c7-bd33a6f0bfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_40363502-9bb1-460d-a80a-b1c9f42b57b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25d51add-5965-4dd7-bb7f-9c4f15624207" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_40363502-9bb1-460d-a80a-b1c9f42b57b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_aa4a7803-c2d9-4b73-a577-fe6536f3a1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_40363502-9bb1-460d-a80a-b1c9f42b57b4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_aa4a7803-c2d9-4b73-a577-fe6536f3a1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b1c80bb7-f034-4e5e-bc2c-2a98040b57b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_aa4a7803-c2d9-4b73-a577-fe6536f3a1a2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b1c80bb7-f034-4e5e-bc2c-2a98040b57b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5b90231c-d660-4e88-8cbb-9facde64f7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_aa4a7803-c2d9-4b73-a577-fe6536f3a1a2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5b90231c-d660-4e88-8cbb-9facde64f7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_236adc68-849e-4eea-83e7-11e101598730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_aa4a7803-c2d9-4b73-a577-fe6536f3a1a2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_236adc68-849e-4eea-83e7-11e101598730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20220403.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_376627e6-db79-4c90-a96e-4afdfda9086e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_218a02ab-4a01-41b5-9a1f-3b65950ab7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_376627e6-db79-4c90-a96e-4afdfda9086e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_218a02ab-4a01-41b5-9a1f-3b65950ab7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20220403.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84a25eff-8fd2-41f6-910b-72365ddf3870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d9ac0baf-566d-49ae-b53c-57755e664e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84a25eff-8fd2-41f6-910b-72365ddf3870" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d9ac0baf-566d-49ae-b53c-57755e664e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_731490f6-be39-426b-aff8-7263a632012e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_7b0ce6d4-d04d-4162-a3ea-59bfb3de8232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_731490f6-be39-426b-aff8-7263a632012e" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_7b0ce6d4-d04d-4162-a3ea-59bfb3de8232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_778f481b-89f1-41ea-befd-d728eb5791bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_7b0ce6d4-d04d-4162-a3ea-59bfb3de8232" xlink:to="loc_us-gaap_EarningsPerShareBasic_778f481b-89f1-41ea-befd-d728eb5791bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c3584719-29ba-4d2e-a6d5-a3e5653071c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_7b0ce6d4-d04d-4162-a3ea-59bfb3de8232" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c3584719-29ba-4d2e-a6d5-a3e5653071c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ba42cff2-f5d8-44c0-9166-42d8bb849df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_7b0ce6d4-d04d-4162-a3ea-59bfb3de8232" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ba42cff2-f5d8-44c0-9166-42d8bb849df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_a4fef8f5-4f0c-4f6a-b5a0-227e2b3f4cc4" xlink:href="jnj-20220403.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_7b0ce6d4-d04d-4162-a3ea-59bfb3de8232" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_a4fef8f5-4f0c-4f6a-b5a0-227e2b3f4cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_307249b9-d4d7-4ae5-913c-9a4cf59d9822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_7b0ce6d4-d04d-4162-a3ea-59bfb3de8232" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_307249b9-d4d7-4ae5-913c-9a4cf59d9822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_34b2803e-bad3-48c6-af00-91de01fedfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_7b0ce6d4-d04d-4162-a3ea-59bfb3de8232" xlink:to="loc_us-gaap_EarningsPerShareDiluted_34b2803e-bad3-48c6-af00-91de01fedfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_188700eb-76f6-419e-8f0c-5136bdbde98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_731490f6-be39-426b-aff8-7263a632012e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_188700eb-76f6-419e-8f0c-5136bdbde98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20220403.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_dcca0eed-7697-454a-beb4-3a974178acdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_692403ca-f434-44fc-b5b7-e5c371fd2073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_dcca0eed-7697-454a-beb4-3a974178acdf" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_692403ca-f434-44fc-b5b7-e5c371fd2073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20220403.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a149611d-7af5-4134-9c45-87b42056981e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_146b6456-8173-401e-bf35-4ba63376c73c" xlink:href="jnj-20220403.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a149611d-7af5-4134-9c45-87b42056981e" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_146b6456-8173-401e-bf35-4ba63376c73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52c7a676-ca6b-49b0-987a-0b5a516ac07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a149611d-7af5-4134-9c45-87b42056981e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_52c7a676-ca6b-49b0-987a-0b5a516ac07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_58d6cbf8-23ae-487e-b291-3e79626ea00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a149611d-7af5-4134-9c45-87b42056981e" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_58d6cbf8-23ae-487e-b291-3e79626ea00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_69ffb683-b4e3-4e73-adad-48995dd2e4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_69ffb683-b4e3-4e73-adad-48995dd2e4ab" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_68694745-3967-4a54-bdef-68ca453f3a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_68694745-3967-4a54-bdef-68ca453f3a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c421901-6ebf-4d87-af55-6c3a36eeeb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68694745-3967-4a54-bdef-68ca453f3a90" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c421901-6ebf-4d87-af55-6c3a36eeeb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5c68dca2-9b19-400c-b64b-30ffa8af3c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5c68dca2-9b19-400c-b64b-30ffa8af3c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5c68dca2-9b19-400c-b64b-30ffa8af3c3b" xlink:to="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_7364e0f8-2d84-42d9-a2ab-3537e20a5a43" xlink:href="jnj-20220403.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:to="loc_jnj_ConsumerMember_7364e0f8-2d84-42d9-a2ab-3537e20a5a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_c7552a25-dd09-491d-910e-11fad424ea39" xlink:href="jnj-20220403.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:to="loc_jnj_PharmaceuticalMember_c7552a25-dd09-491d-910e-11fad424ea39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_e9c1aaed-7272-47c8-a8f2-323f854d6717" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:to="loc_jnj_MedicalDevicesMember_e9c1aaed-7272-47c8-a8f2-323f854d6717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_4128803b-ec77-48c0-8b5f-ce4a623f8d7d" xlink:href="jnj-20220403.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c0fb106f-a860-4684-91c9-a293cd565713" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_4128803b-ec77-48c0-8b5f-ce4a623f8d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_e31b801c-3315-4479-b7e3-852ff21da0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_us-gaap_SubsegmentsAxis_e31b801c-3315-4479-b7e3-852ff21da0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_e31b801c-3315-4479-b7e3-852ff21da0ff" xlink:to="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_b585711c-4c74-498a-9dbe-813ec59d1c68" xlink:href="jnj-20220403.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_ImmunologyMember_b585711c-4c74-498a-9dbe-813ec59d1c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_0ccaf6f1-0907-49ce-be8e-c7d63139ff1f" xlink:href="jnj-20220403.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_InfectiousDiseasesMember_0ccaf6f1-0907-49ce-be8e-c7d63139ff1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_8e74d193-a34a-4d67-8700-a874dd028307" xlink:href="jnj-20220403.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_NeuroscienceMember_8e74d193-a34a-4d67-8700-a874dd028307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_9d0b6ea3-24eb-4503-aa57-631eb7bcc304" xlink:href="jnj-20220403.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_OncologyMember_9d0b6ea3-24eb-4503-aa57-631eb7bcc304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_a0440070-2a61-4c40-abe5-ed830fc2c8cd" xlink:href="jnj-20220403.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_PulmonaryHypertensionMember_a0440070-2a61-4c40-abe5-ed830fc2c8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_56d10b93-7188-49d6-8217-95fd2b3b5aff" xlink:href="jnj-20220403.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_56d10b93-7188-49d6-8217-95fd2b3b5aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_daf55cd1-5d47-4b35-babb-4143f5b1a544" xlink:href="jnj-20220403.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_InterventionalSolutionsMember_daf55cd1-5d47-4b35-babb-4143f5b1a544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_8f5d0d92-fe31-4466-9176-807db93915d7" xlink:href="jnj-20220403.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_OrthopaedicsMember_8f5d0d92-fe31-4466-9176-807db93915d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_37a423f4-7404-49d4-bca7-d8474ea65cdd" xlink:href="jnj-20220403.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_SurgeryMember_37a423f4-7404-49d4-bca7-d8474ea65cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_6e515e5f-6b1e-4678-a118-b49897f11977" xlink:href="jnj-20220403.xsd#jnj_VisionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_a4824ac7-fd67-4399-bffb-1b701d3c9ba2" xlink:to="loc_jnj_VisionMember_6e515e5f-6b1e-4678-a118-b49897f11977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_70359ad7-9c50-4e5e-8c16-da54d357f95b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_srt_ProductOrServiceAxis_70359ad7-9c50-4e5e-8c16-da54d357f95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_70359ad7-9c50-4e5e-8c16-da54d357f95b" xlink:to="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_4499e498-9be1-4510-8d3b-617c27be7be7" xlink:href="jnj-20220403.xsd#jnj_OTCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OTCMember_4499e498-9be1-4510-8d3b-617c27be7be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_ead9d862-de27-42e7-b217-d5fbdcb88c1e" xlink:href="jnj-20220403.xsd#jnj_BeautyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_BeautyMember_ead9d862-de27-42e7-b217-d5fbdcb88c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_a03d31ef-4fe9-4ac3-a9a8-9f2f8b2831a4" xlink:href="jnj-20220403.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OralCareMember_a03d31ef-4fe9-4ac3-a9a8-9f2f8b2831a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_9f7d03ee-6217-48ac-90fa-8f4479108a1c" xlink:href="jnj-20220403.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_BabyCareMember_9f7d03ee-6217-48ac-90fa-8f4479108a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_78e2bd6a-01df-4d11-b57b-4e050fd9e588" xlink:href="jnj-20220403.xsd#jnj_WomensHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_WomensHealthMember_78e2bd6a-01df-4d11-b57b-4e050fd9e588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_6cfc2451-7000-4b85-9b1f-dc6342e8ea3f" xlink:href="jnj-20220403.xsd#jnj_WoundCareandOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_WoundCareandOtherMember_6cfc2451-7000-4b85-9b1f-dc6342e8ea3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_d2b3cc72-1a9f-47c2-930c-8c02feaaa540" xlink:href="jnj-20220403.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_RemicadeMember_d2b3cc72-1a9f-47c2-930c-8c02feaaa540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_a74d5b2a-479f-45c7-97aa-1ad803c812c6" xlink:href="jnj-20220403.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_SimponiSimponiAriaMember_a74d5b2a-479f-45c7-97aa-1ad803c812c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_21159a05-f3a1-4c56-a10a-c50f76b5e0b4" xlink:href="jnj-20220403.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_StelaraMember_21159a05-f3a1-4c56-a10a-c50f76b5e0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_7c2f82b2-6ce6-4ea3-b64a-4061f21f8ee5" xlink:href="jnj-20220403.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_TremfyaMember_7c2f82b2-6ce6-4ea3-b64a-4061f21f8ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_404dffac-03fb-430e-9c28-9f2a46deca9e" xlink:href="jnj-20220403.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OtherImmunologyMember_404dffac-03fb-430e-9c28-9f2a46deca9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_7b63b267-7187-4d8f-b327-33005a6519a3" xlink:href="jnj-20220403.xsd#jnj_COVID19Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_COVID19Member_7b63b267-7187-4d8f-b327-33005a6519a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_8e45d759-9c67-4e40-8e17-de33d9e44b7a" xlink:href="jnj-20220403.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_EDURANTrilpivirineMember_8e45d759-9c67-4e40-8e17-de33d9e44b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_a273aa3c-6cc9-4dfc-aef9-61eba18803fd" xlink:href="jnj-20220403.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_a273aa3c-6cc9-4dfc-aef9-61eba18803fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_9812320b-3ab6-488a-a064-bdda7e529ddb" xlink:href="jnj-20220403.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_9812320b-3ab6-488a-a064-bdda7e529ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_f2ccb912-b0be-4c54-9787-13f4a230cd44" xlink:href="jnj-20220403.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_f2ccb912-b0be-4c54-9787-13f4a230cd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_ed163233-fdaf-4794-94d8-11fa1f9658a4" xlink:href="jnj-20220403.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_ed163233-fdaf-4794-94d8-11fa1f9658a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_c257620b-166b-426a-9d25-0b801bac3cdc" xlink:href="jnj-20220403.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_RISPERDALCONSTAMember_c257620b-166b-426a-9d25-0b801bac3cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_59561e43-4918-40d0-ad2e-8841ece7871d" xlink:href="jnj-20220403.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_59561e43-4918-40d0-ad2e-8841ece7871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_53b02aac-f31b-49a4-b650-07e5f7b19788" xlink:href="jnj-20220403.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_DARZALEXMember_53b02aac-f31b-49a4-b650-07e5f7b19788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_01138f55-53e9-4f27-bf63-f74b59368388" xlink:href="jnj-20220403.xsd#jnj_ERLEADAMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_ERLEADAMember_01138f55-53e9-4f27-bf63-f74b59368388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_3b8990f4-e4ea-4e18-8417-d7ca4634b0ff" xlink:href="jnj-20220403.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_IMBRUVICAMember_3b8990f4-e4ea-4e18-8417-d7ca4634b0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_512785da-2a07-4277-883e-fbdacb6eddb4" xlink:href="jnj-20220403.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_ZYTIGAMember_512785da-2a07-4277-883e-fbdacb6eddb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_17c1fdee-850f-4325-b27a-6073ed938139" xlink:href="jnj-20220403.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OtherOncologyMember_17c1fdee-850f-4325-b27a-6073ed938139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_f0baea75-7427-4963-b169-ea21456826b6" xlink:href="jnj-20220403.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OPSUMITMember_f0baea75-7427-4963-b169-ea21456826b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_474aa0a8-1a37-4034-813b-9f962a374b7f" xlink:href="jnj-20220403.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_UPTRAVIMember_474aa0a8-1a37-4034-813b-9f962a374b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_40679af9-1afa-42d2-ac28-5eb89d385b49" xlink:href="jnj-20220403.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_XareltoMember_40679af9-1afa-42d2-ac28-5eb89d385b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_3477ce53-cbe0-4ff6-8764-2dba5b4ad351" xlink:href="jnj-20220403.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_3477ce53-cbe0-4ff6-8764-2dba5b4ad351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_2360e756-e0cb-4aeb-bd3a-2e752104ae53" xlink:href="jnj-20220403.xsd#jnj_OtherMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_OtherMember_2360e756-e0cb-4aeb-bd3a-2e752104ae53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_d20b394b-8a00-419b-be13-c157a589e567" xlink:href="jnj-20220403.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_HIPSMember_d20b394b-8a00-419b-be13-c157a589e567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_e497c206-fc2a-45b8-90b6-6b4c575ff5b6" xlink:href="jnj-20220403.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_KNEESMember_e497c206-fc2a-45b8-90b6-6b4c575ff5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_4ec52741-0d0d-4d06-b62e-0d559f816869" xlink:href="jnj-20220403.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_TRAUMAMember_4ec52741-0d0d-4d06-b62e-0d559f816869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_b2d885f6-563d-40b0-a847-6c0ab260f710" xlink:href="jnj-20220403.xsd#jnj_SPINEOTHERMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_SPINEOTHERMember_b2d885f6-563d-40b0-a847-6c0ab260f710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_c659baef-51a1-4afa-b19b-33f067fc9292" xlink:href="jnj-20220403.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_ADVANCEDMember_c659baef-51a1-4afa-b19b-33f067fc9292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_0e2db870-d393-4fdb-860c-a1bb1e3cad94" xlink:href="jnj-20220403.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_GENERALMember_0e2db870-d393-4fdb-860c-a1bb1e3cad94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_63af1560-1b09-407f-a683-f4f49cf2f903" xlink:href="jnj-20220403.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_63af1560-1b09-407f-a683-f4f49cf2f903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_308ef074-bc91-4aaa-97f9-ba0658886411" xlink:href="jnj-20220403.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2c95984c-03e7-46ed-bf9f-81fb3f484969" xlink:to="loc_jnj_SURGICALMember_308ef074-bc91-4aaa-97f9-ba0658886411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0f108814-2fe3-47e5-ad9a-79e6b0f8ad24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_srt_StatementGeographicalAxis_0f108814-2fe3-47e5-ad9a-79e6b0f8ad24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0f108814-2fe3-47e5-ad9a-79e6b0f8ad24" xlink:to="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_22e63a32-9c49-4dd7-a68d-82b7c33e0447" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:to="loc_country_CN_22e63a32-9c49-4dd7-a68d-82b7c33e0447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7b0a71d8-4b75-4984-98ef-e54c1b6d09df" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:to="loc_country_US_7b0a71d8-4b75-4984-98ef-e54c1b6d09df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_de3cb3ac-3b2c-455f-8154-aa8cb1d64a95" xlink:href="jnj-20220403.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:to="loc_jnj_UNITEDSTATESExportsMember_de3cb3ac-3b2c-455f-8154-aa8cb1d64a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1df031d2-856f-4efb-b0e6-2c6ab10fc4da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_57a50d5a-f780-4a4a-8704-6fc56a6d31c1" xlink:to="loc_us-gaap_NonUsMember_1df031d2-856f-4efb-b0e6-2c6ab10fc4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c59499f2-fbde-49df-8f9c-970b99007724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9fbd1d2a-e9ef-44f7-8ac0-ef6675eae735" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c59499f2-fbde-49df-8f9c-970b99007724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_248ca836-ca94-4dd7-85eb-3cbb0e52f95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c59499f2-fbde-49df-8f9c-970b99007724" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_248ca836-ca94-4dd7-85eb-3cbb0e52f95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83ffc267-a5b4-49f4-9d29-7f6ee243ca38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_248ca836-ca94-4dd7-85eb-3cbb0e52f95b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83ffc267-a5b4-49f4-9d29-7f6ee243ca38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_c00ca36c-8772-4bde-badf-56915424dd59" xlink:href="jnj-20220403.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_248ca836-ca94-4dd7-85eb-3cbb0e52f95b" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_c00ca36c-8772-4bde-badf-56915424dd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_661b1bfb-9690-4015-85a1-c4dcb1bad05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_661b1bfb-9690-4015-85a1-c4dcb1bad05d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ecdd10e0-40a4-49b0-b178-62b1489b66c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:to="loc_srt_ConsolidationItemsAxis_ecdd10e0-40a4-49b0-b178-62b1489b66c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b36b129c-414a-4489-a083-da31abb5c9ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_ecdd10e0-40a4-49b0-b178-62b1489b66c9" xlink:to="loc_srt_ConsolidationItemsDomain_b36b129c-414a-4489-a083-da31abb5c9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e4dfe154-0ad3-4b52-b7e7-92aa99a9a306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b36b129c-414a-4489-a083-da31abb5c9ec" xlink:to="loc_us-gaap_OperatingSegmentsMember_e4dfe154-0ad3-4b52-b7e7-92aa99a9a306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e6359919-2fbf-470e-b05d-5e8a5234a7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b36b129c-414a-4489-a083-da31abb5c9ec" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e6359919-2fbf-470e-b05d-5e8a5234a7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de02331e-8858-4ad4-8871-cc6e12f3fb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de02331e-8858-4ad4-8871-cc6e12f3fb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de02331e-8858-4ad4-8871-cc6e12f3fb2d" xlink:to="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_65e75910-7026-4af3-8af1-bac7b87240b9" xlink:href="jnj-20220403.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:to="loc_jnj_ConsumerMember_65e75910-7026-4af3-8af1-bac7b87240b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_12fcab79-72dc-413f-af1d-eb36ad542f1c" xlink:href="jnj-20220403.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:to="loc_jnj_PharmaceuticalMember_12fcab79-72dc-413f-af1d-eb36ad542f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a8fe3675-65f5-4ab6-9ea4-413b263c932e" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:to="loc_jnj_MedicalDevicesMember_a8fe3675-65f5-4ab6-9ea4-413b263c932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b5c4196b-840a-42a2-8e8b-7fdf7873bcd6" xlink:href="jnj-20220403.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0871527e-13fe-4d2d-9359-644bc9c2bed2" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b5c4196b-840a-42a2-8e8b-7fdf7873bcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7da7deb0-cf0d-46ab-a01f-8afd836fc63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7da7deb0-cf0d-46ab-a01f-8afd836fc63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b75a1a95-4a3a-4466-9b10-279aa972e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7da7deb0-cf0d-46ab-a01f-8afd836fc63a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b75a1a95-4a3a-4466-9b10-279aa972e5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_eac5890b-69a7-49e0-a96d-e1d3d310a6e4" xlink:href="jnj-20220403.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b75a1a95-4a3a-4466-9b10-279aa972e5f4" xlink:to="loc_jnj_BermekimabMember_eac5890b-69a7-49e0-a96d-e1d3d310a6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7937f149-095b-4d14-8f97-4588a5697711" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a5dd137-c1e7-4aee-81b0-ce625e4aee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a5dd137-c1e7-4aee-81b0-ce625e4aee3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_6bdb7c13-bae2-40d6-b5df-bd30a38cf320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_BusinessExitCosts1_6bdb7c13-bae2-40d6-b5df-bd30a38cf320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3f70bff-2dc1-4ffa-be65-fdded239de7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3f70bff-2dc1-4ffa-be65-fdded239de7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_2e477054-8859-4f67-ace9-5d16feac822c" xlink:href="jnj-20220403.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_2e477054-8859-4f67-ace9-5d16feac822c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_0dc61df0-3f25-4de8-b523-e455dcac86b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_AdjustmentForAmortization_0dc61df0-3f25-4de8-b523-e455dcac86b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_433a194c-91aa-462c-9024-032ce4510e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_433a194c-91aa-462c-9024-032ce4510e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9b614e77-e318-4c60-ab8a-f57fa4094e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9b614e77-e318-4c60-ab8a-f57fa4094e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_500e5cc6-e735-4fc1-9f6f-35b1106e9a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_500e5cc6-e735-4fc1-9f6f-35b1106e9a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_dae63a83-5057-4cf4-86eb-c88c0cf07d31" xlink:href="jnj-20220403.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_dae63a83-5057-4cf4-86eb-c88c0cf07d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_482cf2a2-28f2-41fb-b5ec-78505b5f12cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0c69d250-d522-4961-8dfd-432b9ef5bb00" xlink:to="loc_us-gaap_RestructuringCharges_482cf2a2-28f2-41fb-b5ec-78505b5f12cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6e6dcd6f-e5e8-4805-be12-16bfd6ede7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d1e7b62b-44ad-4610-9484-35a551e50371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6e6dcd6f-e5e8-4805-be12-16bfd6ede7c5" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d1e7b62b-44ad-4610-9484-35a551e50371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6e31962e-83c2-4eee-8334-6d82264277c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d1e7b62b-44ad-4610-9484-35a551e50371" xlink:to="loc_srt_StatementGeographicalAxis_6e31962e-83c2-4eee-8334-6d82264277c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6e31962e-83c2-4eee-8334-6d82264277c5" xlink:to="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c077128f-332c-4f62-8d19-80d56278ecbe" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:to="loc_country_US_c077128f-332c-4f62-8d19-80d56278ecbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c30375d8-ede4-4969-93a9-97defae5b98c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:to="loc_srt_EuropeMember_c30375d8-ede4-4969-93a9-97defae5b98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_59928870-e857-4b37-ba98-1a155faf0934" xlink:href="jnj-20220403.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_59928870-e857-4b37-ba98-1a155faf0934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_915bab6b-85f0-4be3-918a-2369ac3017fb" xlink:href="jnj-20220403.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f014aa9-7c17-4668-9543-20e6857bbc8f" xlink:to="loc_jnj_AsiaPacificAfricaMember_915bab6b-85f0-4be3-918a-2369ac3017fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_159515a2-b273-45e4-9f67-6f86997808f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_d1e7b62b-44ad-4610-9484-35a551e50371" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_159515a2-b273-45e4-9f67-6f86997808f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_d3066a79-3e8b-4476-91b6-0e6d9f8674bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_159515a2-b273-45e4-9f67-6f86997808f0" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_d3066a79-3e8b-4476-91b6-0e6d9f8674bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b716e90a-e9f4-451c-b669-aeb59d849e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_d3066a79-3e8b-4476-91b6-0e6d9f8674bc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b716e90a-e9f4-451c-b669-aeb59d849e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_62deb3c0-f7fc-4537-aaed-f9eeeec906ba" xlink:href="jnj-20220403.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_d3066a79-3e8b-4476-91b6-0e6d9f8674bc" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_62deb3c0-f7fc-4537-aaed-f9eeeec906ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20220403.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b7703311-1e56-4c3f-bb97-df9ea1ae4738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_2e0d56d7-1228-4f2b-bfc2-cc00930227f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b7703311-1e56-4c3f-bb97-df9ea1ae4738" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_2e0d56d7-1228-4f2b-bfc2-cc00930227f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b0e92c3a-f7ef-4d05-a3ea-b4577e78e047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_238d3289-3626-45f5-831a-2c12e9121cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b0e92c3a-f7ef-4d05-a3ea-b4577e78e047" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_238d3289-3626-45f5-831a-2c12e9121cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00be8f68-034a-4eb7-ac77-f3ca1c2cc3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_238d3289-3626-45f5-831a-2c12e9121cab" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00be8f68-034a-4eb7-ac77-f3ca1c2cc3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf5cd404-834f-4940-bfa4-a4f9bdced21f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00be8f68-034a-4eb7-ac77-f3ca1c2cc3d4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf5cd404-834f-4940-bfa4-a4f9bdced21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_bc3819f9-83ed-4b4f-bd08-77d310c237b3" xlink:href="jnj-20220403.xsd#jnj_EvraAndDoxilMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cf5cd404-834f-4940-bfa4-a4f9bdced21f" xlink:to="loc_jnj_EvraAndDoxilMember_bc3819f9-83ed-4b4f-bd08-77d310c237b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1009d72e-a151-4cb7-ad43-828525f287e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_238d3289-3626-45f5-831a-2c12e9121cab" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1009d72e-a151-4cb7-ad43-828525f287e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a67df2ae-3d7f-48c9-a18e-6e9a2ee94a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1009d72e-a151-4cb7-ad43-828525f287e5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a67df2ae-3d7f-48c9-a18e-6e9a2ee94a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20220403.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63c67580-3cd8-4515-9b1e-08964f792fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4adb88a4-87f6-4fa3-91ba-5a4547c68079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63c67580-3cd8-4515-9b1e-08964f792fe4" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4adb88a4-87f6-4fa3-91ba-5a4547c68079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4d93b6f6-e0c2-47d7-8221-a547d7d6e470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4d93b6f6-e0c2-47d7-8221-a547d7d6e470" xlink:to="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c4354a74-ce91-45d7-a937-59ff92a36c99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_srt_LitigationCaseAxis_c4354a74-ce91-45d7-a937-59ff92a36c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c4354a74-ce91-45d7-a937-59ff92a36c99" xlink:to="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_8fe39f79-0972-4bc1-9d8c-367fb5f7b2a4" xlink:href="jnj-20220403.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_DePuyASRU.S.Member_8fe39f79-0972-4bc1-9d8c-367fb5f7b2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_d17bf823-2e1c-45a2-a84c-3a995f10b717" xlink:href="jnj-20220403.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_RisperdalMember_d17bf823-2e1c-45a2-a84c-3a995f10b717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_9cdcd855-36b7-4a1d-b999-be5a59ae37cf" xlink:href="jnj-20220403.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_BabyPowderMember_9cdcd855-36b7-4a1d-b999-be5a59ae37cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_5e6d4e47-6945-42d8-b6cb-0a9f6dd181a5" xlink:href="jnj-20220403.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_5e6d4e47-6945-42d8-b6cb-0a9f6dd181a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_7607f22c-fcad-4130-8e23-ce960518f231" xlink:href="jnj-20220403.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_55b673f2-e40c-46aa-912e-8fc28f9bc3fd" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_7607f22c-fcad-4130-8e23-ce960518f231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_7b7c4777-9ef0-4a58-b412-7461a95428fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_us-gaap_LitigationStatusAxis_7b7c4777-9ef0-4a58-b412-7461a95428fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_7b7c4777-9ef0-4a58-b412-7461a95428fb" xlink:to="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_de4802a6-7d29-46da-bc38-a232cc8387d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:to="loc_us-gaap_SettledLitigationMember_de4802a6-7d29-46da-bc38-a232cc8387d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_9c5caeed-b3b3-44b1-96e6-8fd98d2645c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:to="loc_us-gaap_JudicialRulingMember_9c5caeed-b3b3-44b1-96e6-8fd98d2645c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_3406be62-b2a1-475a-b83c-38fd087bb07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a406fecb-1937-46eb-b80d-c235a8839f1f" xlink:to="loc_us-gaap_PendingLitigationMember_3406be62-b2a1-475a-b83c-38fd087bb07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b2b870d-83b2-4609-8465-25bd7d63369e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_srt_ProductOrServiceAxis_9b2b870d-83b2-4609-8465-25bd7d63369e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9b2b870d-83b2-4609-8465-25bd7d63369e" xlink:to="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_4c9f88f2-951a-46ed-8e55-6d0b1dfdb03c" xlink:href="jnj-20220403.xsd#jnj_AsrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_AsrMember_4c9f88f2-951a-46ed-8e55-6d0b1dfdb03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_5305defa-386c-4d8a-9f6d-4d9939f4d888" xlink:href="jnj-20220403.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_5305defa-386c-4d8a-9f6d-4d9939f4d888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_4fbd3fb0-449f-46b9-b55d-808c909d2ed6" xlink:href="jnj-20220403.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_PelvicMeshesMember_4fbd3fb0-449f-46b9-b55d-808c909d2ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_c942521c-6c23-4474-b6f6-6fd1778140d6" xlink:href="jnj-20220403.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_RisperdalMember_c942521c-6c23-4474-b6f6-6fd1778140d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_1d0b19ba-9b05-40c8-9ad2-2027ebfdd2e0" xlink:href="jnj-20220403.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_XareltoMember_1d0b19ba-9b05-40c8-9ad2-2027ebfdd2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_a3577cd3-1f71-4cfb-a2b1-98c3c9763ebb" xlink:href="jnj-20220403.xsd#jnj_TalcMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_TalcMember_a3577cd3-1f71-4cfb-a2b1-98c3c9763ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_1b8d7e78-653f-4f34-a998-5ee4ea93ba90" xlink:href="jnj-20220403.xsd#jnj_InvokanaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_InvokanaMember_1b8d7e78-653f-4f34-a998-5ee4ea93ba90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_9100795c-514c-40f9-96fa-5084054d442d" xlink:href="jnj-20220403.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_PhysiomeshMember_9100795c-514c-40f9-96fa-5084054d442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_fe4ef257-e54f-4aca-b8ef-749ec7f38728" xlink:href="jnj-20220403.xsd#jnj_OpioidMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_OpioidMember_fe4ef257-e54f-4aca-b8ef-749ec7f38728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_97264319-4a05-4e10-8700-e6e3b080501f" xlink:href="jnj-20220403.xsd#jnj_ContactLensesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32ef0f4f-9b42-418c-a205-48036a386ef4" xlink:to="loc_jnj_ContactLensesMember_97264319-4a05-4e10-8700-e6e3b080501f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_4f0fcb8f-911e-4a75-962a-3bf6dc133b0a" xlink:href="jnj-20220403.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_4f0fcb8f-911e-4a75-962a-3bf6dc133b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_6511659e-56ea-4dc9-a143-e4aba16f7680" xlink:href="jnj-20220403.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_4f0fcb8f-911e-4a75-962a-3bf6dc133b0a" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_6511659e-56ea-4dc9-a143-e4aba16f7680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_c73eef29-afec-4ea0-a531-f5df799810d1" xlink:href="jnj-20220403.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_6511659e-56ea-4dc9-a143-e4aba16f7680" xlink:to="loc_jnj_RisperdalMember_c73eef29-afec-4ea0-a531-f5df799810d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ace4d949-e9b1-41f3-8797-5a490c07fa32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ace4d949-e9b1-41f3-8797-5a490c07fa32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_39ec7bd5-440d-4149-9097-155864c10e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_ace4d949-e9b1-41f3-8797-5a490c07fa32" xlink:to="loc_us-gaap_LossContingencyNatureDomain_39ec7bd5-440d-4149-9097-155864c10e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_decd7068-19e6-470f-acba-c5755d869a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_39ec7bd5-440d-4149-9097-155864c10e07" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_decd7068-19e6-470f-acba-c5755d869a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_70b6646d-485f-4672-8384-64ae82fd7637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_70b6646d-485f-4672-8384-64ae82fd7637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61092031-4ed4-4c1e-b627-ddba036ef1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_70b6646d-485f-4672-8384-64ae82fd7637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61092031-4ed4-4c1e-b627-ddba036ef1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c22fa67f-6d34-4fbb-a77d-0576b11c65c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_61092031-4ed4-4c1e-b627-ddba036ef1e7" xlink:to="loc_us-gaap_SubsequentEventMember_c22fa67f-6d34-4fbb-a77d-0576b11c65c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_428363d6-4ea9-4d8c-882f-8539645dc886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_24d4161b-7189-4f93-965c-9a035a4fa603" xlink:to="loc_us-gaap_LossContingenciesLineItems_428363d6-4ea9-4d8c-882f-8539645dc886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:href="jnj-20220403.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_428363d6-4ea9-4d8c-882f-8539645dc886" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_bfc65192-9fc1-40b5-b069-a0f4231d864e" xlink:href="jnj-20220403.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_bfc65192-9fc1-40b5-b069-a0f4231d864e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_190d3d00-cb72-486d-81d7-7bf87376c5d5" xlink:href="jnj-20220403.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_Numberofpatientsinsettlement_190d3d00-cb72-486d-81d7-7bf87376c5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_a47717dc-e604-4c3e-a1b0-af93cebbbef0" xlink:href="jnj-20220403.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_a47717dc-e604-4c3e-a1b0-af93cebbbef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_3977f62e-ed9b-4334-9ebd-26b2dbec47b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_3977f62e-ed9b-4334-9ebd-26b2dbec47b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_b6187af3-be3c-4d33-bd74-0af8caa136c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_b6187af3-be3c-4d33-bd74-0af8caa136c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_5371443d-d5df-472d-ae22-3cab3605a8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_5371443d-d5df-472d-ae22-3cab3605a8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_b96e3c33-4243-4acc-a4ad-337f0e6f8027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_b96e3c33-4243-4acc-a4ad-337f0e6f8027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_8369ea2f-a64e-4929-90a8-62ffc8281dc4" xlink:href="jnj-20220403.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_8369ea2f-a64e-4929-90a8-62ffc8281dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5ffb94b1-7ba7-40a8-908d-90209b0fc42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5ffb94b1-7ba7-40a8-908d-90209b0fc42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_d40e2c9d-e802-411d-b7bb-bfcf7f87e032" xlink:href="jnj-20220403.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_fac5d851-8b8f-44fa-b19a-dfef24810207" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_d40e2c9d-e802-411d-b7bb-bfcf7f87e032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20220403.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3fce287a-793c-488e-bd1a-79fd62a5da4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_be7aca4a-4404-4262-a1e3-5707b75bc801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3fce287a-793c-488e-bd1a-79fd62a5da4c" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_be7aca4a-4404-4262-a1e3-5707b75bc801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20220403.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a17a2668-b387-4e5b-8295-7e8833f533f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_4fdddc64-b04c-4604-8409-b0b3a685801f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a17a2668-b387-4e5b-8295-7e8833f533f0" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_4fdddc64-b04c-4604-8409-b0b3a685801f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_78991a54-5203-4541-93fe-af278ca4ab23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_78991a54-5203-4541-93fe-af278ca4ab23" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_813c53e6-7130-493a-895c-51a5d82b3d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_813c53e6-7130-493a-895c-51a5d82b3d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bc719fae-42e5-4fc9-a726-b149f179fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_813c53e6-7130-493a-895c-51a5d82b3d93" xlink:to="loc_us-gaap_SegmentDomain_bc719fae-42e5-4fc9-a726-b149f179fe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_adb03b90-911d-4341-b520-66fcffb61c69" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bc719fae-42e5-4fc9-a726-b149f179fe31" xlink:to="loc_jnj_MedicalDevicesMember_adb03b90-911d-4341-b520-66fcffb61c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_1ef96637-0384-4974-9758-39dd18d46a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:to="loc_us-gaap_RestructuringPlanAxis_1ef96637-0384-4974-9758-39dd18d46a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_441667b8-a04f-4314-871e-a165d9c12a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_1ef96637-0384-4974-9758-39dd18d46a58" xlink:to="loc_us-gaap_RestructuringPlanDomain_441667b8-a04f-4314-871e-a165d9c12a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_5b0ddc15-a2a9-42fa-9e73-46580386bd6c" xlink:href="jnj-20220403.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_441667b8-a04f-4314-871e-a165d9c12a67" xlink:to="loc_jnj_SupplyChainMember_5b0ddc15-a2a9-42fa-9e73-46580386bd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_176da74e-b9d9-40e1-8888-4d02c858b6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_176da74e-b9d9-40e1-8888-4d02c858b6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_176da74e-b9d9-40e1-8888-4d02c858b6b2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_f6014ce6-1c42-47c3-be6f-b765a304a2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:to="loc_us-gaap_RestructuringChargesMember_f6014ce6-1c42-47c3-be6f-b765a304a2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7e4c73ea-38ce-451e-b6d9-5123885bb85c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:to="loc_us-gaap_CostOfSalesMember_7e4c73ea-38ce-451e-b6d9-5123885bb85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_82fbadbe-6fd0-43fb-8c58-5ecea2d35fc5" xlink:href="jnj-20220403.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3ca964a3-a990-420e-b8b3-f93df9dcfcd7" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_82fbadbe-6fd0-43fb-8c58-5ecea2d35fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e750cb26-3435-4764-9ce6-83d677c1378e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:to="loc_srt_RangeAxis_e750cb26-3435-4764-9ce6-83d677c1378e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0110ffdd-b64c-4033-9a12-553259e2cc71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e750cb26-3435-4764-9ce6-83d677c1378e" xlink:to="loc_srt_RangeMember_0110ffdd-b64c-4033-9a12-553259e2cc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2ac9b42a-618f-44f1-a11c-820adaa11e03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0110ffdd-b64c-4033-9a12-553259e2cc71" xlink:to="loc_srt_MaximumMember_2ac9b42a-618f-44f1-a11c-820adaa11e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_07421bf6-460e-436a-bf37-f7835d8b5125" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0110ffdd-b64c-4033-9a12-553259e2cc71" xlink:to="loc_srt_MinimumMember_07421bf6-460e-436a-bf37-f7835d8b5125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f0790e25-52fa-4719-b6ed-0db29c1f229f" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e0470c57-f882-4d91-8951-ef9cc076ee33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:to="loc_us-gaap_RestructuringCharges_e0470c57-f882-4d91-8951-ef9cc076ee33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_f601eb5a-893b-4b61-909a-9045294150c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_f601eb5a-893b-4b61-909a-9045294150c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_be1d433c-4892-4fca-9f13-676966fb9ca0" xlink:href="jnj-20220403.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_be1d433c-4892-4fca-9f13-676966fb9ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_74e31e5e-e0dd-4e27-877b-2a42eac3fd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c4592503-d140-47d8-84e2-8fb4ebbe2c00" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_74e31e5e-e0dd-4e27-877b-2a42eac3fd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20220403.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dd3e2ee1-aeaf-4c54-a2b5-b626c70acba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f20d41fe-68c3-4e84-ad5b-3822fd799685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dd3e2ee1-aeaf-4c54-a2b5-b626c70acba3" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f20d41fe-68c3-4e84-ad5b-3822fd799685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_39345fab-9a50-40a5-a290-955079fe9656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f20d41fe-68c3-4e84-ad5b-3822fd799685" xlink:to="loc_us-gaap_RestructuringPlanAxis_39345fab-9a50-40a5-a290-955079fe9656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b8520b69-e653-431d-a9f0-6806aa06903e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_39345fab-9a50-40a5-a290-955079fe9656" xlink:to="loc_us-gaap_RestructuringPlanDomain_b8520b69-e653-431d-a9f0-6806aa06903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_dcb0330c-940f-4d42-9703-9fe04f0972c7" xlink:href="jnj-20220403.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_b8520b69-e653-431d-a9f0-6806aa06903e" xlink:to="loc_jnj_MedicalDevicesMember_dcb0330c-940f-4d42-9703-9fe04f0972c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_dd0bb7ee-b3ae-4b78-9994-52cc54b4faca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f20d41fe-68c3-4e84-ad5b-3822fd799685" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_dd0bb7ee-b3ae-4b78-9994-52cc54b4faca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_dd0bb7ee-b3ae-4b78-9994-52cc54b4faca" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_688e18a5-8641-492d-8e7b-c613bae6fee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:to="loc_us-gaap_EmployeeSeveranceMember_688e18a5-8641-492d-8e7b-c613bae6fee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_b7338122-800f-4f9d-a20e-90b162f439e4" xlink:href="jnj-20220403.xsd#jnj_AssetWriteoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:to="loc_jnj_AssetWriteoffMember_b7338122-800f-4f9d-a20e-90b162f439e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_b4dafa15-c1c5-462b-b9d9-64f2a9dddebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_2dfcaea8-c313-42c6-921d-edb741ff8754" xlink:to="loc_us-gaap_OtherRestructuringMember_b4dafa15-c1c5-462b-b9d9-64f2a9dddebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9a23b56c-2ef9-4d68-af83-68e8e01cc6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f20d41fe-68c3-4e84-ad5b-3822fd799685" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9a23b56c-2ef9-4d68-af83-68e8e01cc6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9a23b56c-2ef9-4d68-af83-68e8e01cc6cd" xlink:to="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4693373b-4c2e-43ef-af4c-9e245238b565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:to="loc_us-gaap_RestructuringReserve_4693373b-4c2e-43ef-af4c-9e245238b565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_54b49c7c-af2a-4ef6-a258-c49d57a6d4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:to="loc_us-gaap_RestructuringCharges_54b49c7c-af2a-4ef6-a258-c49d57a6d4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsForRestructuringNet_43fc73c3-5c00-4102-82d9-e238254d6509" xlink:href="jnj-20220403.xsd#jnj_PaymentsForRestructuringNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:to="loc_jnj_PaymentsForRestructuringNet_43fc73c3-5c00-4102-82d9-e238254d6509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5d3eba74-711a-4c31-8eae-14300b54bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5d3eba74-711a-4c31-8eae-14300b54bc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6f691169-5a23-4593-8074-66da3253d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88fbcf46-28f6-41a3-a10b-f037e6dcc843" xlink:to="loc_us-gaap_RestructuringReserve_6f691169-5a23-4593-8074-66da3253d9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>jnj-20220403_g1.jpg
<TEXT>
begin 644 jnj-20220403_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOBI\;OV5?%OP$M?!?Q?^!FMWFEZWHT/BE[[1M5D@NI[,RP7OV5)8T%Q 5;=
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M\]UAQN_UAV?>XK]S?V=T_:J7PG*?VLI_A\^N;D$(^'<5\MI@ [RWVQB^2<$
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M6N>$[OQ)>I:CQ3ID UW%W9-*1]J\S[9:X6/<V^;80'4J.0_8R_9R^(O['/\
MP:A?M'^+?VD86\)2_%J^EU'P=HNON+6>XMWCL;>W81R8;S+AH961,9:)$<95
M@:_H7UGPOX9\1RVT_B'P[87[V4OFV;WMHDI@?^\A8':>!R,'BKU '\NO[37Q
M/^&][_P9]_LZ?#FS\>Z/+X@@^.>II/H<6HQM=QM'?>(9Y-T(;>-L5W:NQ(X6
MYA)_UBY_H@_X)N^*O#/C7_@GS\$?$?A#Q#9:I82_"C0(X[W3[I9HF>/3X8Y$
MW*2-R2(Z,.JLC*<$$5[510 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#$WPUIJ7^N^"K;45:_L[=A&0[Q^PEB) R5$J%@ PS^07QV55_X/8?A*54
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,KY67]>:J:MH.A:];2V>N:+:7L,\)AGBN[99%DC)!*,&!!4D X/'% 'YF?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML_L2>(->\/\ P=U.XN]8U6\\:>&[%=1+:A:3 6T<^IK(04M"<R)&?WJ@@$,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4IJTHMI^JT9_<="M3Q%&-6F[QDDUZ-704445F:A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %</^TY\2_%7P6_9L^(7QC\">$CK^N>$_ ^K
M:SHVA*K$ZE=VMG+/#; +\Q\QT5..?FXKN*POBC\1/#WPA^&?B+XL>+1/_97A
M?0KO5]3^RQ;Y?L]M"\TFQ21N;8C8&1DXYH _#3_@E5^U'X-_X+!_%/X4Z7\0
M_P!M?XO67QRE\ _$6X^(EWH'Q U'1FT2].HZ&VE/I=I!(EB+46OG?N!"ZRM
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MGA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_+WBQ44^+I)?9A!?F_U/ZI\(J;AP?&3^U.;_ "7Z!1117YH?IX4444 %%%%
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M)^Z;XEN8-DWC'Q)J&KG<N&V*ZVB?@1:[A[/GO7VC7\A<>XQ8[B_%U%LI<O\
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M!\64,9@LWG0JR;AO'MRO;3;3:_D%%%%?3GRX4444 %%%*JL[!$4DDX  Y)H
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M(!_MEC7FE%%??X/ X++J"HX6G&$%TBDE^'7S/SW&X_&YE7=?%5)5)OK)MO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF'L]&!#*W/0W#A9/=$A/<BOT$J.TM+6PM8K&QMHX8(8UCAAB0*D: 8"J!P
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M<8>4>\N\ODM+ME%%%?F9^H!1110 4444 %%%% !1110 4444 %%%% !1110
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MX914EW:7=A<R65];20S1,5EBE0JR,.H(/(-1U]RFFKH^#::=F%%%%,04444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXUUWP8/C?/I5];_LBZ59>3X:\6+:7+WB>)]1D>T;8VYG6.5)#%]X!E8C!!H
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MO\2'U*?0+>XL)[VWDNHFL(8Y581)"6AF<++,%&]!YA[?X\_M8? #X=Z5\2O
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MIJ^OQ_$#]B5[_3[/X5W7BO1;GP1XMCO6N=7@;'_"-.MQ% WVN161HIU!A?\
M> [-@+X_[+/[?.L_&[]J;Q'^R?XV\(^&(-9T3X<:3XO&J>#O%9U2UB%U=W5G
M<:9.3#'LN;:>V(+*6619 2L3 I0!],4444 %%%% !1110 4444 %%%% !111
M0 5X!_P4M_:'\+_LO_LO7?Q6\8?"C_A,[*'6;.V;1/[=?3MS2,0'\Y(Y"-N,
MXV\^U>_U\6?\%\_^4>FI?]C5I?\ Z,:O>X6H4\5Q'A*-2_+*I%.S:=F^C337
MJFF?/\68BKA.&L76IVYHTY-72:NEU333]&FCXZ_X?8_L_?\ 2.G_ ,R[=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>jnj-20220403_g2.jpg
<TEXT>
begin 644 jnj-20220403_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%=0\<>-=:ATW2-*M7N=1U"Y)$=O"HRTC'LH')/8<UQ_[.O[6O[,G[7/AZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[#H'AZUS';1$&YU.[;(@LK9"1YDTK_*HX &68JBLP]9HH _G1_9)_P"#FO\
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MH^E6'CWXA:Q'J7B'3=&OVO+;28(;>.VL].BN'CC:98H8@[OL56GGN'4!7 H
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MR]\,M!J,;#5K8>(KN4RVV&_?)Y<B/N3(VL&Z<U^\-% 'X0?\&U7CS1/V7_\
M@J'^V3^S?\;+74M&\=>*_']BGA_PO)I,[75Y'#J6KF:X550@01QW4$S3,0GE
M.'!((S^[],%O;K.;I8$$K*%:0*-Q49(&?3D_G3Z "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<O&\OA'4-?O)"]QJFF!YH[*>=CRTH-K<PECDLL",Q9F8U^D% !1110 4444
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M[F]G=B\UW<2 #S)I9&9V; &6PH50JCU"@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX_\ [0/Q5_:;^)^H?%SXP^)I=3U>_? SD0VL0)V00IG$<2Y.%'J226))_3^
M?#ROQ/46,QEX85/T<VND>R[R^2UNU^6>(/B-A^%J;P>#M/%27JJ:?67=]H_-
MZ63[+]L_]NCXX?MO>/CXJ^)^K?9M*M)&_L'PQ92,+/38S_=!_P!9*1]Z5OF;
MH-JA5'C-%%?U'@L%A,NPL<-AH*$(JR2V7]=7NWJS^5,=CL9F6*GB<5-SJ2=V
MWJW_ %T6R6B"BBBNHY0HHHH **** "BBB@ HHHH **** "BBB@#T7]F/P%_P
MF/Q(BU>^M]UAH8%Y<;ERKR@_N8^05.7^8J?O)&XKZ?)).2:XK]GWP&O@+X9V
M<=Q"%O\ 50M]?G R-Z_NHR1V6/!P>5>205VM<$I<\W+^K'H1CR04?ZN_ZL%%
M%%(!]O<7%I<)=VD[Q2Q.'BEC8JR,#D$$<@@]Z^T?V.?^"BQD:U^&/[1&K\DB
M+3?%,YZ]@ET?T\W_ +[[O7Q717@\0<.97Q+@GA\9'_#)?%%]T_S6SZH^@X=X
MES7AC'+$X.?^*+^&2[-?D]UT9^T<<B2HLL3AE8 JRG((]12U\"_L-_MVW?PY
MN+/X0?&+5&F\.R,(M+U>=\MIA/ 1R>L';/\ !_N\+]\12Q3Q+/!(KHZAD=#D
M,#T(/<5_*O$_#&8\+9@\/B5>+UC);27Z-=5T\TTW_6?"W%.7<5Y>L3AG:2TG
M![Q?ZI]'U\FFDZBBBOFSZ4**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *\N_;!_:O^'/[&OP1U+XR?$*82F$>1
MHVDQRA9=3O6!,=NF<XS@EFP=J*S8.,'T'Q9XK\.>!?"^H^-/&&L0:?I6DV4M
MWJ-]<OMCMX(U+.['T"@FOP%_X**?MR^+?VX_CG<>+II9[7PIH[R6O@_1G.!;
MVV[F9UZ>=+@,Y[85,D(#7WG /!U7BS-/WEUAZ=G-]^T5YOKV5WO:_P !X@\:
M4N$<J_=6>(J74%V[S?E'IW=EM>WG?[1W[1/Q._:F^+FJ?&7XLZT;O4]2DQ'"
MF1#90 GR[>%23LC0' '4DEB2S,3PM%%?UUA\/1PM"-&C%1A%))+1)+9(_CS$
M8BOBZ\JU:3E.3;;>K;>[84445L8A1110 4444 %%%% !1110 4444 %%%% !
M79? 7X?I\1?B19Z9?6XDT^S!O-44]&A0CY#@@X=RD>1R/,SVKC:^GOV8O 1\
M'_#A=:OH"E[KSK=.'4@I;J"(%P1QD,\F0<,LJ?W:QKS<866[_I_UWL;T(<T[
MO9:_U_6USTB662>5IIG+.[%F8GDD]33:**Y=CIW"BBB@ HHHH *^P_\ @GC^
MV;)H]U:? #XJZN39S,(O#.IW+_\ 'NYX%J['^ ]$)^Z?EZ%=OQY0"5(93@CH
M17B<0Y!@>(\LG@\2M'JGUC+I)?KW5T>[P[Q!C^&LTAC<*]5I)=)1ZQ?Z=G9]
M#]I**^<_^"?O[5__  NWP9_PKGQMJ.[Q3H-L/WTK?-J%J,*LV>[KD*_KE6YW
M''T97\A9SE&,R+,JF"Q*M*#^371KR:U_X)_8V2YQ@L^RRGCL*[PFOFGU3\T]
M'^&@4445Y9ZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%>6_MG_M+Z%^R/^S?XE^..L+%-<:;9^7HUC*V!>7\AV01<<D%
MR"V.0BN>U=&$PM?'8J&'H1O.;44N[;LCGQ>+P^!PL\37ERP@G)OLDKL^!?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_'[_@OW^U5/\0/C?I?[+OA
MO4,Z1X)A6\UI8W^6;5)XP5!['RH&4 ]0T\@/2OU=^,/Q.\/_  5^%/B/XN>*
MF/\ 9_AO1;G4;I5;#2+%&S[%_P!IB H'<L*_FW^)OQ"\2?%KXBZ[\4/&-WY^
MJ^(=6N-0U"0=#+-(78#T4%L =@ .U?LO@WD*QN;U,SJJ\:*M'_'+K\HW^<DS
M\5\:<_>"R>GEE)VE7=Y?X(]/^WI6^46C#HHHK^ES^80HHHH **** "BBB@ H
MHHH **EL+"^U6^ATO2[*:YN;F58K>WMXR\DKL<*JJ.6))  '))K] ?V,_P#@
M@Q\5_BI:VGCK]JC7;CP3HTNV2/P[9HKZM<(>?WA;*6F1CA@[CD,BFO%SOB')
M^'<-[?'U5!/9;REZ16K_ "76Q[>1\.9SQ'BO89?1<VMWM&/G*3T7YOHF?GR
M2< 9)Z"O4/AS^Q/^UW\6H([WX>_LW>,M1M9AF*^70)H[9Q[32*L9_P"^J_=G
M]GW]@O\ 9*_9AMH#\(_@IH]KJ$ '_$]OH/M>H,W=OM$VYTSUVH57T KU^OQW
M,_&V*FXY?A+K^:H__;8__)'[1E?@:W!2S'%V?\M./_MTO_D3\$=/_P"".?\
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M^&.H>+/$WB;4XO%C>&]:/P^\!ZKX@@T74EL;F^>VNIK"WE19T@M97>VC+W"
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MG8G 4 6^22>,5^C%M,+FWCN!$Z>8@;9(NUER,X(['VK\H_VVO^">?[!^L_\
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M%\/?A7-)#\'['Q;X"UNVMUU$[DG\1/;I;_/<NG[NV\SFWB+,%665RH!^D/\
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MH_ 5][U\4?\ !7I4%]X <,-QBU,$>V;7'\S7Z#X7U94^,Z$5]I33_P# )/\
M-(_._%2E&IP3B)/[+@U_X'%?DV?&5%%%?U6?R6%%%% !1110 4444 %?5O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ6SU*RG7#P3QN4=#[A@16=7]FQE&<5*+NGLS^*)1E"3C)6:W044451(4444
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MTXNSW"BBBF(*L:1I.I:]JUKH>CV;W%W>W"06MO&,M+([!54>Y) _&J]?5/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP* ):*9;7-M>VT=Y9W"2PRH'BEB<,KJ1D,"."".<T^@ HHHH **** "BBB@
MHHJM;:SH][J-UH]GJMM+=V00WMK%.K26X<$IO4'*;@"1G&0.* +-%%-GGAMH
M7N;F98XXU+22.P"JH&223T% #J*AL+^PU6P@U32[V&YM;F%9;:YMY \<L; %
M75APRD$$$<$&IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH SO&/\ R*.J_P#8-G_]%M7@E>_^)+2XU#P[J%A:1[Y9[*6.
M),@;F*$ 9/ Y->1_\*E^(/\ T+__ )-Q?_%U]/D&(H4:,U4FEKU:1\MQ!A\1
M6K0=.#EH]DW^1SE>]^#O^11TK_L&P?\ HM:\G_X5+\0?^A?_ /)N+_XNO7/#
M=I<:?X=L+"[CV2P644<J9!VL$ (R.#R*,_Q%"M1@J<T]>C3%P_A\11K3=2#C
MIU377S+M%%%?,'U04444 ?"?Q9\1/^UM_P %L;7]A[XLVZWWPN^&?P(7QU<^
M#+Q=UEXDUV\U,6<,U["<I=V]K K&.*0%!/)YA!:-"/9OBW\*/V3OV(]1U_\
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M7[/WP^O_  5J-W+X =X/$>EW=MIT#O'"=0S8W*_V9 RNSW"9=\QL,+7)S_\
M!)GXNW'[/&H_ E_VL/#HEU#]I(_%TZP/A=/A)SX@773IWD_VORGVA?+\W?GR
M_P"'=\U 'V]1381,L*+<.K2!1O9$V@GN0"3@>V3]:=0 4444 %%%% !1110
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M1<Q$D+(Y13-\IQDM@Y /#/V8_P!M3XQ>'/B5X)_93^*O[.]C9V^L_L^'QIX
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MTMT@27R&FF,198U)7S&YS@XX'=4 %%%% !1110 4444 %%%% !1110 4444
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MT31H%V[1^M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+Q+X=T?
MQ?X=O_"?B*S^T:?JEE+:7UOYC)YL,B%'7<I#+E6(R"",\$5Y'_P[R_8]_P"B
M0?\ EP:A_P#)%>TT5Z."S?-LMBXX3$3IIZM0G*-_6S5SSL=D^49G-2QF'A5:
MT3G",FEY73L>+?\ #O+]CW_HD'_EP:A_\D5ZYX;\.Z/X0\.V'A/P[9_9]/TN
MRBM+&W\QG\J&- B+N8EFPJ@9))..2:NT48W-\VS**CB\1.HEJE.<I6]+MV#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>jnj-20220403_g3.jpg
<TEXT>
begin 644 jnj-20220403_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#)!_KKQ-_S_P#_ "6'_P B?1G_  W]_P!4F_\ *]_]HH_X;^_ZI-_Y7O\
M[17SG11_J;PW_P ^/_)I_P#R0?ZZ\3?\_P#_ ,EA_P#(GT9_PW]_U2;_ ,KW
M_P!HH_X;^_ZI-_Y7O_M%?.=%'^IO#?\ SX_\FG_\D'^NO$W_ #__ /)8?_(G
MT9_PW]_U2;_RO?\ VBO1O@!\?_\ A>?]K?\ %)?V7_9?D?\ +_Y_F^;YG_3-
M-N/+]\Y[8KXMKZ,_8!_YFW_MP_\ ;BO"XFX9R3+\DJXC#TN6<>6SYI/>44]&
MVMF>_P ,<3YYF.>4</B*W-"7-=<L5M&36JBGNCZ,HHHK\G/UP**** "BBB@
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M_P B7#?]>X?^DH_F_//^1WBO^OD__2F%%%%>F>6%%%% !1110 4444 %%%%
M!1110 4444 %?1G[ /\ S-O_ &X?^W%?.=?1G[ /_,V_]N'_ +<5\QQE_P D
MW7_[=_\ 2XGU/!7_ "4U#_M[_P!(D?1E%%%?A1^]A1110 4444 %%%% !111
M0 5^<]?HQ7YSU^G>''_,5_VY_P"WGY;XE?\ ,+_W$_\ ; HHHK]./RT****
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M^W'!$:'G%>^Z?I&F:/H\&@:)8PV-G:VRV]I;6<2QQV\2J%1$51A54   #
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M1J_G?._^1UB?^OD__2F?T?D?_(DPO_7N'_I*"BBBO+/5"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#XM_:T_Y.!\0?\ ;I_Z20UYS7HW[6G_ "<#X@_[
M=/\ TDAKSFOZ)R3_ )$N&_Z]P_\ 24?S?GG_ ".\5_U\G_Z4PHHHKTSRPHHH
MH **** "BBB@ HHHH **** "BBB@ KZ,_8!_YFW_ +</_;BOG.OHS]@'_F;?
M^W#_ -N*^8XR_P"2;K_]N_\ I<3ZG@K_ )*:A_V]_P"D2/HRBBBOPH_>PHHH
MH **** "BBB@ HHHH *_.>OT8K\YZ_3O#C_F*_[<_P#;S\M\2O\ F%_[B?\
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M[B?^V!1117Z<?EH4444 %%%% !1110 4444 %%%% !1110 4444 ?:7[)?\
MR;]X?_[>_P#TKFKT:O.?V2_^3?O#_P#V]_\ I7-7HU?SOG?_ ".L3_U\G_Z4
MS^C\C_Y$F%_Z]P_])04445Y9ZH4444 %%%% !1110 4444 %%%% !1110 44
M44 ?%O[6G_)P/B#_ +=/_22&O.:]&_:T_P"3@?$'_;I_Z20UYS7]$Y)_R)<-
M_P!>X?\ I*/YOSS_ )'>*_Z^3_\ 2F%%%%>F>6%%%% !1110 45S_CSXJ_#C
MX7_V;_PL/QII^C_VQJ"6.F?;[@)]HG;HBY_4G@9&2,BN@H **** "BBB@ HH
MHH *^C/V ?\ F;?^W#_VXKYSKZ,_8!_YFW_MP_\ ;BOF.,O^2;K_ /;O_I<3
MZG@K_DIJ'_;W_I$CZ,HHHK\*/WL**** "BBB@ HHHH **** "OSGK]&*_.>O
MT[PX_P"8K_MS_P!O/RWQ*_YA?^XG_M@4445^G'Y:%%%% !1110 4444 %%%%
M !1110 4444 %%%% 'VE^R7_ ,F_>'_^WO\ ]*YJ]&KSG]DO_DW[P_\ ]O?_
M *5S5Z-7\[YW_P CK$_]?)_^E,_H_(_^1)A?^O</_24%%%%>6>J%%%% !111
M0 4444 %%%% !1110 4444 %%%% 'Q;^UI_R<#X@_P"W3_TDAKSFO1OVM/\
MDX'Q!_VZ?^DD-><U_1.2?\B7#?\ 7N'_ *2C^;\\_P"1WBO^OD__ $IA1117
MIGEA1110 5Y_^TE^TE\./V7OAQ<?$/XAW_K'IFF0L//U"?&1%&#^;,>%')[
M^@5Y_P#M)?LV_#C]J'X<7'P\^(=AZR:9J<*CS]/GQ@2QD_DRGAAP>Q !^/\
M^TE^TE\1_P!J'XCW'Q#^(=_ZQZ9ID+'R-/@SD11@_FS'ECR>P'UY_P $Y?\
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MW2O"/BSP!IGA73[?0Q:65J-'AM$6V$#"Y#1>6!MV$$@KC')KYGC&W^KE>_\
M=_\ 2XGU'!=_]9:%O[__ *1(^B]!\=>"/%7A&'X@>&/&.E:EH-Q:FYM];L-0
MBFLY8 "3*LR,49!@_,#C@\T[1_&G@[Q#X6C\<Z!XLTR^T2:V-S%K%G?QRVKP
M@$F02J2A0 '+ XX-5?#WPQ^'7A'X?Q?"CPKX'TK3?#$%@UE!H%A8I#9QVS A
MH5B4!50AB-H&.33?#'PL^''@KX=0?"+PEX(TS3O"]MI[6-OH%G:*EK';,"&A
M$8& A#,".G)K\.?L=;7WTVV_SV\C]W7M]+VVUWW\O+?S+NB^,?"/B3PQ%XV\
M.^*M-O\ 19[<W$&KV5]'+:R1#.9%E4E"HP?F!QP:?I?BOPOKGAV/QAHOB2PO
M-)EMS/%JEK>));/$,DR"125*C!^;..#6=X:^%7PW\&_#B'X0>$_!.FZ;X7M]
M/>PM]!LK58[6.V8$-$L:\!2&88'J:;X4^$OPT\#?#.W^#7@_P58:=X5M=.>P
MM]!M8 MM';,"&B"]E(9ACW-#]CK9O?3;;_/;R!>WTNEMKOOY>6_F:>D^*?#.
MO>'X_%NA>(K"]TJ: S0ZG:7B26[Q#.7$BDJ5X/(..*?I_B+P_JVAIXFTK7;.
MYTV2$S1ZA;W2/ T8SEQ(#M*\'G..*R/"WPC^&G@CX8P?!CPCX*L-.\*VVFOI
M]OH5I%LMX[5@P:(*.BD,PQ[TWPA\'?ACX!^%EO\ !+P;X,L]/\)VFF/I]MH5
MNI$$=JP8-$ 3G:0S#KWH:H:V;WTT6WW[^6WF"=?2Z6VNKW\M-M]=_(V=-\0:
M#K.BQ^)-'UNSN].EB,L5_;7*20O&.KAU)4KP><XXI]GK6CZAI2Z[I^K6T]B\
M1D2\AG5HF0=6#@X(X/.<5A>$O@Y\,/ GPJ@^"'@[P99Z=X3M=+?3K?0[8,L,
M=JX96B'.0I#,.N>:;X,^"WPN^'GPEMO@5X+\&VVG^$K/2WTVVT.%G,4=JX8-
M$"6+8(9AUSS0U1ULWOIHMOOWVTV\P3KZ72VUU>_EIMOKOY'16^I:==V*ZI:7
M\,MLR;UN(Y0T97^\&!QCWI;6_L;ZS74+*]BFMW7<D\4@9&7U##@BN9\$? _X
M5_#CX/VOP"\$^#X;#PA9:2^F6NB1S2-'':.&5H@S,7P0S<EL\]:3P5\#?A5\
M.O@Y;?L_^"O!\6G^#[/2'TNVT6*>4I':.K*T0=F+X(9N=V>>M#5'6S>^FBV[
M[[[:;>8)U]+I;:ZO?LM-M]=_(ZF.YMYH!=13HT17(D5@5(]<U^=,<D<R"2*1
M64CAE.0:^Z_ GP'^$_PS^"]K^SUX'\(I8>#K+2'TNUT5;N9UCM'5E:+S'<R'
M(=N2V[GK7Y[^&OAAX%\'_#N'X3^&]!6U\/V^GM90Z<MQ(P6!@0R;V8OT8\[L
M\]:_3/#M04L7RMM7ANK:>_;J]?+\6?E_B.YN.$YTD[3V=]?<OT6GG^"-ZBN?
M\+?"WP)X+^'$'PC\,Z%]F\/6VGM8P:?]JE?; P(*>8[%SPQY+9YZT>%OA=X&
M\%?#>#X2>%]%-IX?M=/:QM[%;J5RD# @KYCL7/#'DMGGK7Z6?F!T%%<_X6^&
M'@OP;\.(/A-X>TV2'0K;3VLH;5[N1V$# @KYC,7)PQY)S[T>%_AAX-\&?#>#
MX3^&]/EM]#MM/:R@MC=R.Z0L""/,9BY/S'DG/O0!T%%<_P"%_AEX3\'?#>#X
M4Z%;W":-;:>UE%'+>222B%@009&)<GYC\V<T>%_AIX:\(?#B#X6:0UX=+M]/
M:RC-Q>O)/Y3 @YE8[BWS'YLYH Y_]I+]I+X<?LO?#BX^(?Q#O_6/3-,A8>?J
M$^,B*,'\V8\*.3V!_+__ (>2?M'_ /#1_P#PT-_;_P#T[_\ ",^:WV#[!NS]
MEV?KYGWMWS>U?1'_  4A_P""?/BR?P;I?Q+^#&KZSK-CX3T<6=SX:OKU[J6W
MM4)8SVY;+,>29%Y8XW#.,5^>] '[@?LV_M)?#C]J'X<6_P 0_AY?^D>IZ9,P
M\_3Y\9,4@'YAAPPY'<#T"OA__@D_^QC\1_A?O_:&^(>K:AH_]L:?Y.F>&4<I
M]H@;D3W2'\XT/(SN.,@5]P4 %%%% !1110 4444 ?:7[)?\ R;]X?_[>_P#T
MKFKT:O.?V2_^3?O#_P#V]_\ I7-7HU?SOG?_ ".L3_U\G_Z4S^C\C_Y$F%_Z
M]P_])04445Y9ZH4444 %%%% !1110 4444 %%%% !1110 4444 ?%O[6G_)P
M/B#_ +=/_22&O.:]&_:T_P"3@?$'_;I_Z20UYS7]$Y)_R)<-_P!>X?\ I*/Y
MOSS_ )'>*_Z^3_\ 2F%%%%>F>6%%%% !1110!S_CSX5?#CXH?V;_ ,+#\%Z?
MK']CZ@E]IGV^W#_9YUZ.N?U!X.!D' KH*** "BBB@ HHHH **** "OHS]@'_
M )FW_MP_]N*^<Z^C/V ?^9M_[</_ &XKYCC+_DFZ_P#V[_Z7$^IX*_Y*:A_V
M]_Z1(^C****_"C]["BBB@ HHHH **** "BBB@ K\YZ_1BOSGK].\./\ F*_[
M<_\ ;S\M\2O^87_N)_[8%%%%?IQ^6A1110 4444 %?/_ /P[;_9P_P"&C_\
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M  ;X^T[1OBGX=%M>Q7NCB71M56+YFL[I8IOD)&0L@CA8COL7/2OG=OAK;?M
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MZ?K&I_"OQ/8ZP=,CU",)J5HUKY%W;I)G8EP$<.F\A2R;6*AMRX'P[\&_%/\
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M5!T9*T6HO9OKHM?G=.W1->K****Z3E"OHS]@'_F;?^W#_P!N*^<Z^C/V ?\
MF;?^W#_VXKYCC+_DFZ__ &[_ .EQ/J>"O^2FH?\ ;W_I$CZ,HHHK\*/WL***
M* "BBB@ HHHH **** "OSGK]&*_.>OT[PX_YBO\ MS_V\_+?$K_F%_[B?^V!
M1117Z<?EH54UW7M#\+Z+=^)/$VLVNG:=86[W%]?WUPL4-O$@+/)([$*BJ 26
M)  %6ZQ?'?P^\&_$S1H_#GCW0H=4TV.\ANI-/NP6@GDB;?'YL?W955PKA6!7
M<BG&5%3/FY7R[E0Y.9<VW6QQWP._;)_97_:6UF_\._ ;X\^&O%.H:9'YE[8Z
M5J*O-''N"^8$.&:/) WJ"N2!GD5V7C_XB> ?A5X4NO'7Q-\::7X?T:Q3==ZK
MK-]';01#_:>0@ GL,Y/:OBS2O%_[&WQO_P""QWA/5O@_\2= TOQ1\/?!&IP:
MQ:V%JUN_BJ>YC*16L;;%CN5M8?.G9@S']Y%MW".0Q^J_\%?/!WA/Q/\ \$[O
MBGJ7B+PS87USI?A.>?3;F[LTDDM) \;;XV8$H<HO*X^Z/2O(IYC7E@*];W9.
MFY6<7[KY5?NVM;IJ_2^S/9JY;0CF&'H^]%5%&ZDO>7,[=DGI9IVZVW1]%^'M
M?T;Q9H%CXI\.WZ7>GZG9Q75C=1YVS0R('1QGG!4@_C4?BSQ9X9\!^&-0\:^-
M-?M-*TC2;.2[U/4K^=8H;6"-2SR.[<*JJ"23Z5R?[*__ ";#\./^Q"T?_P!(
MH:U_BU\)/!'QP\%3?#CXE:8=0T&\N()-3TIVQ%?I%(LJPS#&7B+HA9,@.%VM
ME&96]*,ZD\,IQ2YFKKM>WY'EN%*&)<)M\J=GWM?\SS'_ (>;_P#!/3_H\WX<
M_P#A4V__ ,57>_$G]H_X&_"&*SE^(WQ+TW3/MUA)?VR2.SN;.,*9;ME0,4MT
MWKOF8"--PW,,BOFO]M?]D?\ 93U/6OA=^S9\/OV9/A[I.J_$+Q[;MJ-[I/@N
MQMKBWT/3!_:&H,DL<0:/>L4-MD$9^UX[X,/QLAN?A#^W;\5/BK\8+*XD\+>+
MO@ FE^$+LVKRQ3W%O-,;C28\ YN96E61(!\TH<[0Q5L>1+'YA1<E54='%72=
ME=-N]WVY>VLCV8Y?EU=0E2<]5)\K:NTFHJUEWYGUTB?96GZA8:O80:KI5]#=
M6MU"LMM<V\H>.6-@"KJPR&4@@@C@@U0\+^-_"GC5]33PKK45\-'U673=1> $
MI%=QA3)%NQAF0L%;:2%8,IPRL!\M_LQCXZ?!/]A+X-_LH/)+9?%G7O"JVJ"[
MC$C^&K!#NGOIT/'^B0RPPI&>'N&@B/REF7Z/^$&@?#'X?^$;?X2_##5+26V\
M,1+:W%M%?K<7$4A)9GN#DL9I'+R.[_,[LS'))->CAL5/$*#Y>6Z3:>Z;2?+Z
MKK\N^GFXK"0PSFE+FM)I-;-)M<WHWM\^VO54445VG"%%%% 'VE^R7_R;]X?_
M .WO_P!*YJ]&KSG]DO\ Y-^\/_\ ;W_Z5S5Z-7\[YW_R.L3_ -?)_P#I3/Z/
MR/\ Y$F%_P"O</\ TE!1117EGJA1110 4444 %%%% !1110 4444 %%%% !1
M110!\6_M:?\ )P/B#_MT_P#22&O.:]&_:T_Y.!\0?]NG_I)#7G-?T3DG_(EP
MW_7N'_I*/YOSS_D=XK_KY/\ ]*84445Z9Y90\5ZAKND^%]2U7POX>&KZG;6$
MTNG:2;Q;<7LZH3'!YK K%O8!=Y!"[LGI7S;X\\4_M)_MH?LW^(/V?_$/['7B
M'X;ZIXRT>;1M>U7Q5K6EW>F:3;SJ8YIX'MKEI[N58RQB7R(U,@7>\:_,?J&B
MN;$8=XA<KFU%III6UOYM-_<T=6'Q*PWO*"<DTTW>ZMY)I/YIGSK^U)<_M2?
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M7]$Y)_R)<-_U[A_Z2C^;\\_Y'>*_Z^3_ /2F%%%%>F>6%%%% !1110 4444
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M'_$0<Z_Y]T_NE_\ )G/_ ,0ZR3_GY4^^/_R!^;7_  TK^SU_T6WPK_X/8/\
MXJC_ (:5_9Z_Z+;X5_\ ![!_\57Z2_\ "C/@E_T1WPK_ .$];?\ Q%'_  HS
MX)?]$=\*_P#A/6W_ ,11_P 1!SK_ )]T_NE_\F'_ !#K)/\ GY4^^/\ \@?F
MU_PTK^SU_P!%M\*_^#V#_P"*H_X:5_9Z_P"BV^%?_![!_P#%5^DO_"C/@E_T
M1WPK_P"$];?_ !%'_"C/@E_T1WPK_P"$];?_ !%'_$0<Z_Y]T_NE_P#)A_Q#
MK)/^?E3[X_\ R!^;7_#2O[/7_1;?"O\ X/8/_BJ/^&E?V>O^BV^%?_![!_\
M%5^DO_"C/@E_T1WPK_X3UM_\11_PHSX)?]$=\*_^$];?_$4?\1!SK_GW3^Z7
M_P F'_$.LD_Y^5/OC_\ ('YM?\-*_L]?]%M\*_\ @]@_^*H_X:5_9Z_Z+;X5
M_P#![!_\57Z2_P#"C/@E_P!$=\*_^$];?_$4?\*,^"7_ $1WPK_X3UM_\11_
MQ$'.O^?=/[I?_)A_Q#K)/^?E3[X__('YM?\ #2O[/7_1;?"O_@]@_P#BJ/\
MAI7]GK_HMOA7_P 'L'_Q5?I+_P *,^"7_1'?"O\ X3UM_P#$4?\ "C/@E_T1
MWPK_ .$];?\ Q%'_ !$'.O\ GW3^Z7_R8?\ $.LD_P"?E3[X_P#R!^;7_#2O
M[/7_ $6WPK_X/8/_ (JC_AI7]GK_ *+;X5_\'L'_ ,57Z2_\*,^"7_1'?"O_
M (3UM_\ $4?\*,^"7_1'?"O_ (3UM_\ $4?\1!SK_GW3^Z7_ ,F'_$.LD_Y^
M5/OC_P#('YM?\-*_L]?]%M\*_P#@]@_^*KVG]D']N[]CKX7?\)#_ ,)W^T;X
M5L?MWV3[+_Q,EEW[/.W?ZO=C&]>N.M?7G_"C/@E_T1WPK_X3UM_\11_PHSX)
M?]$=\*_^$];?_$5P9GQCF>:X&>%JP@HRM>RE?1I]9/MV/0RO@O*\IQT,71G-
MRC>UW&VJ:Z13V?<\L_X>D?\ !/G_ *.L\*_^!$G_ ,11_P /2/\ @GS_ -'6
M>%?_  (D_P#B*]3_ .%&?!+_ *([X5_\)ZV_^(H_X49\$O\ HCOA7_PGK;_X
MBODSZX\L_P"'I'_!/G_HZSPK_P"!$G_Q%'_#TC_@GS_T=9X5_P# B3_XBO4_
M^%&?!+_HCOA7_P )ZV_^(H_X49\$O^B.^%?_  GK;_XB@#RS_AZ1_P $^?\
MHZSPK_X$2?\ Q%'_  ](_P""?/\ T=9X5_\  B3_ .(KU/\ X49\$O\ HCOA
M7_PGK;_XBC_A1GP2_P"B.^%?_">MO_B* /+/^'I'_!/G_HZSPK_X$2?_ !%'
M_#TC_@GS_P!'6>%?_ B3_P"(KU/_ (49\$O^B.^%?_">MO\ XBC_ (49\$O^
MB.^%?_">MO\ XB@#RS_AZ1_P3Y_Z.L\*_P#@1)_\11_P](_X)\_]'6>%?_ B
M3_XBO4_^%&?!+_HCOA7_ ,)ZV_\ B*/^%&?!+_HCOA7_ ,)ZV_\ B* /+/\
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M  >P?_%4?\-*_L]?]%M\*_\ @]@_^*K])?\ A1GP2_Z([X5_\)ZV_P#B*/\
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M[X5_\)ZV_P#B*/\ B(.=?\^Z?W2_^3#_ (AUDG_/RI]\?_D#\VO^&E?V>O\
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MWI%VD]I>6Z3VL\?W9(W4,K#V((/XU8ID$$%K EK:PI'%&@6..-0%50,  #H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>jnj-20220403_g4.jpg
<TEXT>
begin 644 jnj-20220403_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***\D_;5_Y(HW_85M__ &:NW+L)]?QU/#<W+SM*
M]KVOY:?F<.98S^S\!4Q/+S<B;M>U[>>OY'K=%?G/17Z#_P 0X_ZBO_)/_MS\
M[_XB5_U"_P#D_P#]H?HQ17YST4?\0X_ZBO\ R3_[</\ B)7_ %"_^3__ &A^
MC%%?G/11_P 0X_ZBO_)/_MP_XB5_U"_^3_\ VA^C%%?G/11_Q#C_ *BO_)/_
M +</^(E?]0O_ )/_ /:'Z,45^<]%'_$./^HK_P D_P#MP_XB5_U"_P#D_P#]
MH?HQ17YST4?\0X_ZBO\ R3_[</\ B)7_ %"_^3__ &A^C%%?G/11_P 0X_ZB
MO_)/_MP_XB5_U"_^3_\ VA^C%%?G/11_Q#C_ *BO_)/_ +</^(E?]0O_ )/_
M /:'Z,45^<]%'_$./^HK_P D_P#MP_XB5_U"_P#D_P#]H?HQ165X%_Y$C1O^
MP5;_ /HI:U:_-*D.2HX]G8_3Z4_:4XS[I,****@L**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KR3]M7_DBC?\ 85M__9J];KR3]M7_ )(H
MW_85M_\ V:O9X=_Y'N&_QQ_,\3B3_D0XG_ _R/D*BBBOZ#/YV"BBB@ HHHH
M**^-_'?[6'QB^.GQA\>_#+X-?$:P\%Z;\,OB;X7\,W972Q=ZEJ=Q>WL"S3OO
MD5(K0;FC6,(S3;')=!\M?0?P \3_ !LN])\4Z+^T-'H8U+PSXGDL+36]#LI;
M2TU;3_LEK<Q7GE322&)OW[QR*'95>%\'%<-#'TL15<8)VU5^ETVGUONGNNGH
M=]?+ZV'I*<VKZ.VM[-)KI;:2V;W]3T6BOB[0/BW_ ,%2/VH=<E^+O[)/C_X
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M110 4444 %%%% 'R]^WE_P COH?_ &"G_P#1IKPBO=_V\O\ D=]#_P"P4_\
MZ-->$5^]\*?\D]A_1_FS^?N+O^2CQ'JO_24%%%%?0GS@4444 %%%% !1110
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M?^1[AO\ ''\SQ.)/^1#B?\#_ "/D*BBBOZ#/YV"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _0/P+_R)&C?]@JW_P#12UJUE>!?^1(T;_L%6_\
MZ*6M6OYIQ'\>?J_S/Z=PW^[0]%^04445B;A1110 4444 %%%% 'R]^WE_P C
MOH?_ &"G_P#1IKPBO=_V\O\ D=]#_P"P4_\ Z-->$5^]\*?\D]A_1_FS^?N+
MO^2CQ'JO_24%%%%?0GS@4444 %%%% !1110 4444 %%%% !1110 4444 =C^
MS[_R6OPU_P!A6.ON>OAC]GW_ )+7X:_["L=?<]?DGB'_ ,C*C_@_5G[!X<_\
MBRM_C_\ ;4%%%%?GQ^B!1110 4444 %%%% !1110 4444 %%%% !7DG[:O\
MR11O^PK;_P#LU>MUY)^VK_R11O\ L*V__LU>SP[_ ,CW#?XX_F>)Q)_R(<3_
M ('^1\A4445_09_.P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MZ!^!?^1(T;_L%6__ **6M6LKP+_R)&C?]@JW_P#12UJU_-.(_CS]7^9_3N&_
MW:'HOR"BBBL3<**** "BBB@ HHHH ^7OV\O^1WT/_L%/_P"C37A%>[_MY?\
M([Z'_P!@I_\ T::\(K][X4_Y)[#^C_-G\_<7?\E'B/5?^DH****^A/G HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH [']GW_DM?AK_L*QU]SU\,?L^_\
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M$G_(AQ/^!_D?(5%%%?T&?SL%%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^2*-_V%;?\ ]FKV>'?^1[AO\<?S/$XD_P"1#B?\#_(^0J***_H,_G8****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#] _ O_ ")&C?\ 8*M__12U
MJUE>!?\ D2-&_P"P5;_^BEK5K^:<1_'GZO\ ,_IW#?[M#T7Y!1116)N%%%%
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MB'_R,J/^#]6?L'AS_P BRM_C_P#;4%%%%?GQ^B!1110 4444 %%%% !1110
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MJU_-.(_CS]7^9_3N&_W:'HOR"BBBL3<**** "BBB@ HHHH ^7OV\O^1WT/\
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M@HHHKZ$^<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#L?V??^2U^&O\
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M]1M1FFG;?7MO^1^;7_#2O[/7_1;?"O\ X/8/_BJ/^&E?V>O^BV^%?_![!_\
M%5^DO_"C/@E_T1WPK_X3UM_\11_PHSX)?]$=\*_^$];?_$5]E_Q$'.O^?=/[
MI?\ R9\7_P 0ZR3_ )^5/OC_ /('YM?\-*_L]?\ 1;?"O_@]@_\ BJ/^&E?V
M>O\ HMOA7_P>P?\ Q5?I+_PHSX)?]$=\*_\ A/6W_P 11_PHSX)?]$=\*_\
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M?\*,^"7_ $1WPK_X3UM_\11_Q$'.O^?=/[I?_)A_Q#K)/^?E3[X__('YM?\
M#2O[/7_1;?"O_@]@_P#BJ/\ AI7]GK_HMOA7_P 'L'_Q5?I+_P *,^"7_1'?
M"O\ X3UM_P#$4?\ "C/@E_T1WPK_ .$];?\ Q%'_ !$'.O\ GW3^Z7_R8?\
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M-*94ANA!H ]YHJ*RO;/4K.'4=.NXKBWN(ED@G@D#I(C#*LK#@@@@@C@@U+0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>jnj-20220403_g5.jpg
<TEXT>
begin 644 jnj-20220403_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M: 'T P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3?\ E>_^T4?\-_?]4F_\KW_VBOG.BC_4WAO_ )\?^33_ /D@_P!=>)O^?_\
MY+#_ .1/HS_AO[_JDW_E>_\ M%'_  W]_P!4F_\ *]_]HKYSHH_U-X;_ .?'
M_DT__D@_UUXF_P"?_P#Y+#_Y$_0[0]2_MG1;/6/)\O[7:QS>7NSLW*&QG SC
M/6K59?@?_D2]'_[!=O\ ^BUK4K\.K14:LHK9-G[M1DYT8R>[2"BBBLS4****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS]_T/_\ Y2KO_P"-4?\ #6?[/W_0_P#_ )2KO_XU7Q;11_Q#[)?^?E3[X_\
MR ?\1%SO_GW3^Z7_ ,F?:7_#6?[/W_0__P#E*N__ (U1_P -9_L_?]#_ /\
ME*N__C5?%M%'_$/LE_Y^5/OC_P#(!_Q$7._^?=/[I?\ R9]I?\-9_L_?]#__
M .4J[_\ C5'_  UG^S]_T/\ _P"4J[_^-5\6T4?\0^R7_GY4^^/_ ,@'_$1<
M[_Y]T_NE_P#)GVE_PUG^S]_T/_\ Y2KO_P"-4?\ #6?[/W_0_P#_ )2KO_XU
M7Q;11_Q#[)?^?E3[X_\ R ?\1%SO_GW3^Z7_ ,F?:7_#6?[/W_0__P#E*N__
M (U78>"O'7A7XB:(/$?@[5/MEF96C$WD/'\R]1AU![^E?G[7U]^Q9_R1./\
M["EQ_P"RU\]Q-PIEV39;]8H3FY<R7O-6UOVBCZ/A?BW,L[S/ZO7A!1Y6_=33
MTMWD^_8]:HHHK\^/T0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KX9_:$_Y+9XE_["C_TK[FKX9_:$_P"2V>)?^PH_]*_0/#S_ )&5;_!_[<C\
M[\1O^191_P ?_MK.-HHHK]</Q\**** ,3XE>*;[P-\.=?\:Z7HS:C<Z/HEU?
M6^GH2&NI(H6D6(8!.6*A> 3ST-?"_P"VY\1/^"?W[;GAFP\0^/?'>@:OI,GP
MAU^XT'[/>H=6TW6FN=+^SP0PJ?.2^WY3[/MW.0R%2"PK] ZPI?AEX"F^(5O\
M5I/"UK_PD-KILUA!JH4B1;>5XGD0X.#EH8_F(+  @$!F!\_,,)5QE)TDURO=
M25^M[[K[OQ1Z678RE@:JJM2YE>SB[=+6V?W]-=&?/OP _:8T#]D7]D/X+>&/
M^"@WQ9B\+^,_$6@QV1N?$QE&^XC16\NZN-I2&5(GB#M,ZY<-R3FL.'X>_#C]
MH+_@IUX&_:N_9WO=.U'2_"'@C5K3QYXRT&1);#5YK@)%86*W$64NIHPUQ*^T
MMY2I$KE246OK/4M)TO6;;['J^FV]W#N#>5<PK(N1T.&!&:FAAAMH4M[>%8XX
MU"HB* % Z  =!4?4)SA"E.2<(.+6GO7C:UY7MJUKHM+KS*680A.I5IQ:G-33
MU7+:=[I1M?1/35ZV?D>>^%/VIO@SXU^/?C']FCP]K]U-XN\":=:7OB.P.F3A
M(8;B-9(RDFW;(=KH2%)/S@#)#8\LN/\ @H3^Q+^TY\%O$'AWX9^/[+QQ?ZUI
M=YI:_#JWM9%UG49'1XC;M82JLR(Q.UIG58D4EG=5!8?24=E9PW4E]%:1+/,J
MK-,L8#R!<[03U(&3C/3)]:9::1I5A<S7ECIEO#-<MNN)8H55I3ZL0,L?K6\Z
M6,FN7GC9\U_=>SV^UNEH[II[V6QA3JX*#YN25URV]Y;K>_N[-ZJS36UWN>=_
ML9_!36?V<?V4_A_\#/$>I)=ZEX8\*VECJ,\3%D-PL8,H0GDH'+*I_N@<"O3*
M**Z*-*%"E&G#:*27HM#FK59UZTJD]Y-M^KU"BBBM#,**** /T$\#_P#(EZ/_
M -@NW_\ 1:UJ5E^!_P#D2]'_ .P7;_\ HM:U*_FG$?QY^K_,_I[#_P"[P]%^
M04445B;!1110 4444 %%%% 'R_\ MY_\CIH7_8+?_P!&&O!Z]X_;S_Y'30O^
MP6__ *,->#U^]\*?\D]A_1_FS^?N+O\ DH\1ZK_TE!1117T)\X%%%% $-[J%
MAIL:3:C?0VZ23)$C32A TCL%1 3U9F( '4D@"IJ_.#XC_&#PS\8/VY?B%^S=
M^U+KNI6VO:;\3?!T/PM\*76J7%K8W.@O?6IGN+6.-U2>X?<[R2-ND5>$*K$X
M7[)^%WP,^(OPR\!^-?AOH?Q?UIK;4/$,LO@C5]=OY-6O-#T^6TM5,*O<LS2>
M5.+LPB4N #'NW@$'R\+F+Q=22A"\8MK?6Z;5FNE[::]5?<]7%98L)2@ZD[2D
MD]M&FD[IZWM?73H[;'JU%?"_Q3_9%\4_LX?M@_!/Q;^R9\7_ (@7FM^(_%[Q
M?$K1?$?C.[U2WU3P_''OOM0N%N'8(R$QQJ0%3S;B$*%;;G[HKHPF)JUY3A4A
MRN+MO=.Z3T=EWU5M#GQ>%I4(TYTY\RFK[6:LVM5=]M'?4**^=_CS^P6G[67C
M+6/$/QT^-_CJPTN-A;^#O#O@KQ1)IMMID*QJ#=RB-?\ 2+MY3(^Z3<B)Y:!>
M&9N4_P""1OC3XZ:C\,/B/\'_ (W>/;SQ>WPM^+&K>$="\7ZDQ:YU.TM?+QYK
ML29'5F(+$DC<$).S-9K&U5C8T9T[*5^5W3V[KI?=;^=GH:/ TI8*5>G53E&W
M-&S5N;L^MGH]%Y76I]9T445Z!YP4444 %?7W[%G_ "1./_L*7'_LM?(-?7W[
M%G_)$X_^PI<?^RU\7Q[_ ,B+_M^/Y,^W\/\ _D?/_!+\T>M4445^+G[:%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5\,_M"?\ );/$O_84?^E?
M<U?#/[0G_);/$O\ V%'_ *5^@>'G_(RK?X/_ &Y'YWXC?\BRC_C_ /;6<;11
M17ZX?CX4444 %%%% !1110 4444 %%%% !1110 4444 ?H)X'_Y$O1_^P7;_
M /HM:U*R_ __ ")>C_\ 8+M__1:UJ5_-.(_CS]7^9_3V'_W>'HOR"BBBL38*
M*** "BBB@ HHHH ^7_V\_P#D=-"_[!;_ /HPUX/7O'[>?_(Z:%_V"W_]&&O!
MZ_>^%/\ DGL/Z/\ -G\_<7?\E'B/5?\ I*"BBBOH3YP**** /D[_ (*'_L\?
MLZ?MN_"'3)]5M5&M:5\2=-\.V'B_2U$.J:'.=9AL[E8I",C!+$*P*'Y' SM:
MI_\ @EY\4_V@-7L/B;^S=^T/XQ7Q?JGP>\:#P_8^.A&5?6K4PB6/S^3FXC4J
M'.2WSJ&+,"[=M\3/V OA!XUUR_\ %7@[7?$OA#4=<\5V&N^)'\/^)[^&WU.X
MM[F*9I&MEN%BCG=8@HN$59%.ULMM KI[[]CK]G._^ .K_LQR?#I$\':\TDFL
MV$6H7"SWL[RK*]Q-=>9Y\L[2*KM,\A=BHRQZ5X<<#BEF+Q2BHNUG9NT]'9/3
M3H[V;6RNCWI8[!O+5A)2E)7NKQ5X:J[3OKU5DTGN[.Q\N_\ !5;]DC1O!MWX
M;_;J_9WU36='^,FD>.]%L=,F@UVYF_MY+R_CMSIYADD9=G[YFV(%7RUD4J5Q
MM^Z+G5-,LKNWL+S48(I[MV6TAEF57F95+,$!.6(4$D#H!FO-/A/^QY\%?@_=
M:7?Z-%XCUFYT)6709O&'C'4=9_LH%#&3:I>SR);-L)3?&JML8KG:<5I_%+]F
M+X,?&;XH>!OC'\0_"TE[X@^'%]<7?A*\6_FB6UEG5%D+(C!90?+C(#@X*#U(
M/1A\)5P]2I6A"*<^6\4W;3XI7MNT^VO*KO73GQ.,I8FG3HU)R:AS6DTKV:]V
M-N;X4UWTYG9:6<7QI^)_B.QO(O@[\&S;W'CS6K0R6KSQ^9;Z%:$E&U.[ /\
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M^VA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?#/[0G_);/$O\
MV%'_ *5]S5\,_M"?\EL\2_\ 84?^E?H'AY_R,JW^#_VY'YWXC?\ (LH_X_\
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M444 ?+_[>?\ R.FA?]@M_P#T8:\'KWC]O/\ Y'30O^P6_P#Z,->#U^]\*?\
M)/8?T?YL_G[B[_DH\1ZK_P!)04445]"?.!1110 4444 %%%% !1110 4444
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M$_B/7]+M[36;34DN/#FKO93M);R;UC9TY,;$89.C#@T?'#X*:!\>?"5KX/\
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MO;7Y(Z6BBN;M_B_\,KOXL7'P+M?&EE+XNM=#76+K08Y"T\-BTOE+.X PJER
M 3DYSC'-$IPA;F=KZ?,(PG._*KVU^1TE%%>2>*?V]/V,/!'Q4/P2\7?M-^#=
M.\4K<BWET>ZUN)'AG)P(I&)V1R9P-C$-DCCD5%6O1H).I)1OIJTM?F72H5Z[
M:I1<K:Z)O3Y'K=%8OC_XC>!?A9X:?Q?\0_%%II.G)-'"+F[DP))I'"1Q(!\T
MDCN0JHH+,Q 4$G%1_#GXG^ /BYX</BSX;^*K75K!;N6UFEMF.Z"XB8I+!*C
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M_P#2ON:OAG]H3_DMGB7_ +"C_P!*_0/#S_D95O\ !_[<C\[\1O\ D64?\?\
M[:SC:***_7#\?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]!/ __(EZ
M/_V"[?\ ]%K6I67X'_Y$O1_^P7;_ /HM:U*_FG$?QY^K_,_I[#_[O#T7Y!11
M16)L%%%% !1110 4444 ?+_[>?\ R.FA?]@M_P#T8:\'KWC]O/\ Y'30O^P6
M_P#Z,->#U^]\*?\ )/8?T?YL_G[B[_DH\1ZK_P!)04445]"?.!1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\!O#EQKU_JLOEI80QZ3 Q\TM]W8@ (ZY7% 'D/\ P3<_;P_;?O\ ]N7XC_\
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MOBI^WWXB_:C\+:XOQ;TG1].UWPA9_"ZXLA:0Z; L-N;>Z;6)B'*ABY>)P2W
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M/5(=+MH=<O+>XO4MT%Y<6ELT,4LH4;V2-G<QJ6R0I=R 0"S8R;%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jnj-20220403_g6.jpg
<TEXT>
begin 644 jnj-20220403_g6.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MRK'J%JJG&T1731R[>I-[*>BU^O7[;'[9OP+_ & ?V;/$?[4_[1.ORV7AOPY
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M+#&&C;B5G\K DY/_ (-=?V@_VN?B9^P-X)TKXE?L[W=[X1U/4?%.JW/QJO\
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MHHH _?[_ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H
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M  R_;E_9:\;?LG_&"!SH/C717L;BXA4&6SF#+);W48/'F0SI%,N>-T8SD9%
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M:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0 4444 %%%% !1110
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MEKK\&D:OJT$-[X7U>Z5C%9ZI:RK-;F3:"1$Y4Q.0"0DKD D 5^=W_!%[3O\
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MI31P688?\M5N;N=R/^G&0'MD _:2BBB@ HHHH **** "BBB@ HHHH *^0/\
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MM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\@?\%^/^4-G[0G_ &3^;_T=%7U_7R!_P7X_Y0V?
MM"?]D_F_]'14 ?QA4444 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE
M,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]H3_ +)_-_Z.BH _C"HHHH _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
ME*9^UW_V\?\ I\GK]_J "O&/VV]._;KU3P#H%G^P'XK\!Z/XFE\40IK][\0M
M'GO;*+23!-YDB)!-$YE6408 )RI88[CV>OG7_@HU\&OA#\?/!W@'X6_%C]L+
MQ5\'3JGQ&M(=#O?!?Q!D\.ZCXCO&M[E%TB*:.13*90Q<1 ,28%P,\T >5?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'N]0W6FZ=?3VUU>V$,TMG,9K.26(,T$A1XRZ$CY6V2.N1SM=AT)H _,'4/\
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M  _W_;Y_Z#?AG_PFX_\ XJC_ (?[_M\_]!OPS_X3<?\ \57W]_PX>_X)^?\
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M'_!?C_E#9^T)_P!D_F_]'14 ?QA4444 ?O\ ?\&FW_*4S]KO_MX_]/D]?O\
M5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7R!_P7X_Y0V?M"?]D_F_\ 1T5?7]?(
M'_!?C_E#9^T)_P!D_F_]'14 ?QA4444 ?O\ ?\&FW_*4S]KO_MX_]/D]?O\
M5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7R!_P7X_Y0V?M"?]D_F_\ 1T5?7]?(
M'_!?C_E#9^T)_P!D_F_]'14 ?QA4444 ?O\ ?\&FW_*4S]KO_MX_]/D]?O\
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M5=/U_P /:C'=6MP8I&BD"R1D@E9$92.Q4BN9_;?MX+K]BWXO6MS"LD<GPO\
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M^*.C6'Q6\.S75Q^S+IFD00Q:S S2ZC%JT<DEFN&^:X5&#&(?.!DD8!K]-**
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MOC6W[05IH,4'BB?PTV@W]_!$BM>V7GI/&DQV[G\IU?R^<*)Y>#N& #QO1?\
M@L'_ ,$L/$,<MQI'_!0;X1R06X!N;IO'-FD,(/3?(SA$_$BO<?AM\5/AA\9?
M"<'CWX0?$?0?%>A71(MM:\-:Q!?6DQ&,A9H&9&QD=#WK\XO^#2RSM&_X)'_8
MFM8S"WQ0\1(T10;2OFQC!'0C'&/2O.?VJ_#6D_\ !'?_ (+R?L\_$3]EJR3P
MU\._VMM6G\*?$KX>:2GDZ7/JR7%K;Q:E';KB."7S-1M7RBC_ %4__/=\@'[
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M9X)^'.OM<^ O!DGA#6KE]7U2W+*FOW@@LG1EC.XV5L"Q0G[3*/.,,=K^L%%
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M*OK^OD#_ (+\?\H;/VA/^R?S?^CHJ /XPJ*** /W^_X--O\ E*9^UW_V\?\
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M_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q&\_LL_\
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,T'K0!^%M%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20220403_g7.jpg
<TEXT>
begin 644 jnj-20220403_g7.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M5^(/_![S_P FL_ __LH&H_\ I"* //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\
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MQ>%5F$4N#'"9EED2.0QBXCRIRHKZR_9Z_P"#K3P9\?;'XGZ)I'[ 7CNY\;>
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M&$&OZ9>PSQ:>&BCNXXH66YA9,2PM$ HDC9))0Q*_KM^V[_P5;\ ?\$VOA)\
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M/BSX6UWQ59M!X>TZ?Q/:_:IG:52NH+;,%C$4(5GP&3:%%?H?X[_X+E_L^?\
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M7]I_]F#XYWW@WQ;\/[*VO;;[-H^FW]O>B6\MH&BN8KVVF(7RY7*F,QL&()+
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MXS\4>++7PQX9N=4@\VWTV::WN;A[MX\@2E(K60*A.WS'0L&4,IX+_@G;X?\
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MWB/PW8G3(?&&I>-=,:WU?3O[62[AM[***=O,N<L8R[NEND,)D,A<K$P!J?\
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M\1FRNX?M8NWNYI))_M,%TJOO8X=!*NV3YZ]K_P""^O[8WQ"_:!_X+!?LV?\
M!(W3O$^H6/PH\0^)O"UW\3-+TZ\DM_\ A)DU'5!&UI<,A#/;I:)D)G:7N&9@
M3'&5U?\ @I+_ ,$]OV]_^"Z7_!1'X.67Q3_8TU[X-_!WX7V;)XUUKQEXCTNY
MDOGFNHY;V&Q%A<S>>)([>***3  )9Y!'PA]@_P""T_\ P21^/7Q6_;W^!/\
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M5\3?"'3OA_$MQ\9/&GC?4=+:UL;A;6WM7CTU+2[FDU D1W+(P5$.^'<R9?8
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M !1110 5^(/_  >\_P#)K/P/_P"R@:C_ .D(K]OJ_$'_ (/>?^36?@?_ -E
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M05[#'X;\;^"OBNNOVFC+-IMS?10:@IT^V:*Y80>4%B\V'=O!F#*$?I/VA?\
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M=(.IZMX;U'71I-_9PQ2F&[A)$-PAN8)1@QG:CJ&=)&&P2>3?#W_@X ?XI_\
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MLCWGB73/&MC:WVB>*= \8$RBWDN#;2^99?8F?SHY%<B.-Y/,79A@S%%^"_\
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MA\-^'U3Q5HD@2?2[6'6+U;^2W9T=?.A2<3$;6XDCXY% 'ZQ_LR?\%38/B/\
MMV^,?^"9W[2WPBL_A[\8/"^C0ZUI5OHWBEM9T?Q)IDD4<AFL[N2UM)?,02#?
M#) I&QRI<(Q'D?PA_P""Z_Q _:M\/_&/XS_L5?L66GQ)^''P9UJYTW5)8/B?
M'9^*-:$,)E-[8Z.;%T>V958QF2ZCDE"L(XVD1HJ[+P3_ ,$T_P!@_P '_M^?
M#/\ ;^U/]I+QYXU^+NKZ=<VW@/5M7\7P7\6L6/\ 9=RLC>7:VRH]LEK,Y\XD
M1AY(1OWR1JWXZ?MM_P#!.[]HW_@E;K<?_!;G_@C!\?KNY^#6L77]HW,-C*%N
MO#45Q=B.33KZV?*7UBMR1 58%XG4+(F8O.(!^R'[9/\ P6G\ _LI?#;]GJ6Q
M^&UEK?C_ /:3;34\$^&]5\6)I6F6"W,=HTES?:BT$ODV\37D*[EA9I"3M48.
M/5/V9/VQ?CK\4/VFO&'[*?[1/[*(^'>O^$O".FZ[#J^G>,!K.E:]#=7-S 7L
M9_LMN[1QFW ;S8HI SX,8&UW^!_V^OV-?A+_ ,' ?[!G[,MU<^(-,^%'QZ\1
M?">\\7_##29K9TTFZMXX=,74M.( ++;[KBRDA90TD<?SA'42 ^0_\$'OVEO^
M"F.D?$O]H+_@B_\ M<Z=?ZCXU^&OP>U67P7K6K3K<:CH,P%M#!8"]!)GM)A>
MVT\!+':L8VG85" 'VQ>_\%TM3^*^D_'7XI_L._LL6WQ/^&O[.D,K^//&FI^/
M?['.L/!'+-=QZ+ MC<B]\F&)Y2\TENL@"B/<)%>MO]HG_@O]^R%\&/\ @F1X
M1_X*8^#=+U'Q3H_Q U&'2/!OA5KJ*QNIM68S"6TNY6WI:" V\_FRX=1Y8*[P
MZ%ORJ_X-2_!7PI_:4^%OQQ_8%^*G[2'Q \$:QJ5R;JY\#>'M=MK!=?TVXM&L
MK]6CFMI)'DB$:)(%92JS)QP2/N/]H3_@C?\ \$NO''_!-[2/^"9?P@^.^M:)
MIVL?'"]@^&'C#5KLZC'9^-HM-NI9K/S2D4<\!AM+R%XT;'GJ\883)L4 ^NO@
MS^W+^TGK/[4?@_\ 9B_:)_9"TGPNOC7P7J7B+0O'W@SXCCQ#H-\EJ;3_ $6*
M9K&TE\XK=!R'C5-JAHWF!8I]25^ '_!#3XD?\%*?^"7_ /P5ET#_ ((F_ME0
M?\)%X3UG2-1O_"!EN#?0:+#'97=S%J6E7# /'9S_ &6:!X"%"NY^1'5U?]6_
MV1_^"S'_  3T_;B_:/\ %7[*?[.?QO\ [8\9>$Q</<6<^E3V\.HQ02B*>6SF
MD4)<(CD [3D@[U#)EJ /IS6)=6@TFZFT"RMKF_2V=K*VO+IH(99@IV(\BI(T
M:EL N$<J"2%;&#^6_P"S#_P<J>-?VK_VB?B%^R'\)O\ @F3XOUKXE^"+;4%M
MO#^B>/+*6WO;NSO%MIUGO+B""&RME)8_:)"23L1(W>15K]4*_GT_X-EB#_P7
MZ_:[P1S9>*L?^%5;4 ?HY_P19_X+C>#?^"NH\?>"]3^ U]\,_'?PZNH1K7AF
MZUP:E%+;2O+&LL<XAA.Y)(722-HQM)0AFW';?UG_ (+#:]\6_P!H[XO_ +-_
M_!/W]FRR^+-Y\!M&>Z^)>O:UXY.A6"WRF4#2+!H[*\:ZO&:"X3,BP0J\#@R<
M G\U/^#1QO\ C9U^U:H;@V4QQGK_ ,3J6O-_^#92QAA_;L_:(_8J^/W[2GCS
MX:^/_$%\K+9>'-;MK"36]0TZ[OHK^VE^TV\IEF7[29$1<-M6=L$ D 'ZC?$K
M_@N?#\3O^"-/B+_@J!^P;\&9/%%]I%K<6VM:%XCU.WME\(WL*#SWO1Y@:Y6+
MS(9%B@RTRS1',89BGB'_  :Q_M6_MK?&_P#9MO-4^)?P"NO%'AWQC\5?$>L>
M+?C9>^.[-)$U&2&.5HCIFSSG!D6.,%"$42C "IBMO]IC]@7]BS_@GK_P1'_;
M%^ O[$7B?7]3L8=(N)O&%OK&KF_%CJJVML6A641(@D%OY#2("S+E-VW(%3?\
M&?FNZ'8?\$C+/3K_ %FU@N+[XMZY;64$UPJO<3"VMYC&BDY=Q$CR;1D[49N@
M)H _5NBBB@ HHHH **** "OQ!_X/>?\ DUGX'_\ 90-1_P#2$5^WU?B#_P '
MO/\ R:S\#_\ LH&H_P#I"* //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2
MF?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@#YU_;?_P""3_[ 7_!1O7_#?BG]
ML7]GVU\6ZEX45X]&OUUB]L9D@=@[02/:31&:(L-VQRP4EBN-S9Y/X@?\$)_^
M"37Q,^)?@WXK>)OV+?#":GX#TZWL/#MMI4US8V"V\#M)#'-9VTJ6]R%9V)\U
M'+[B'W#BOK:B@#YX^*O_  2^_95^*OQKUO\ :4,7C;PM\0?$-C;V&J^,/ /Q
M&U;0KN>QAA2&.T86=Q'&\(5 0K(Q#?,"#@B>U_X);_L)Z?\ L7R_\$^--^ E
MC;?"2ZN[:YU+PM#?7(.H307L%Z)+BX\SSYG:>WB+N\A9@NTG;@5] 44 ?.?P
MK_X)7?L@_"GXV>'OV@XM&\7>*/$_@O3I;#P#>?$#X@ZMX@3PK;2KMDCT]+^X
ME6 LH"&3F3:H4.!Q6=^WU_P1W_X)\?\ !2_4]+\3?M9_ N/5]?T:V^RZ=XET
MK5+C3]0CM]Q;R'EMW7SH@S,520.$+L5VEF)^G:* /)OV.?V'/V7/V!?A5_PI
MO]E/X4VGA?19;G[5?E;B6YNM0N-H7SKFYG=Y9WVJJ@NQ"J JA5  \V^#7_!%
M_P#X)H?L^_M*:A^UI\'_ -E_3M$\::C?M?2SV^KWS6$5TS,WGQ6#SFTB<,Q9
M"D0\LG,>PU]144 ?)_C#_@BQ^PCXQF\;H= \=:18_$_Q#?ZS\3M$\.?%/7-/
MT[Q;<WEU)<W'VZU@NUBD5FE9/E5#Y>(\E0 /3-!_8+_9G\*_&WX??'3PKX'.
MF7_PK\"W7A+X?Z/83>5IFB:?<&/S?)ME&U962%(_,SG8,=\U[)10!YS^U1^R
M?\!OVU/A%-\!_P!I/P0OB/PE=:I97][HLMW+#'<R6MPEQ$LAB969/,C7<F<,
M,J<@D5X=XA_X(@?\$[_$NB/\.KWX:>(8/AW+X@&N2_"+3_'FJVWA%K\/YGFC
M28KA;=$\S#^0BK#N&?+R3GZWHH P]0^&/PYU7X:S_!J_\"Z3)X2N-#;1IO#7
M]GQBQ;3FA\@VGD ;!#Y1\ORP-NWC&*^-?A[_ ,&WW_!'?X<>'_%/A+3?V5)+
M[2O%JLE]I^K>,=6G2S1F4D6A-R&M7(4(9HR)BA:,R%&93]S44 ?-?PU_X)%?
ML _!_P#97\3_ +$WPY^#%_8?"WQC<I/X@\'77C?6+ZVF994E81_;+N5K8.T:
M[Q"4WXYR0"&_#K_@DI^Q=\.?BOX/^,"^&_%GB/4?AS'(GPTL?''Q#U?7;#PB
M'"JQT^WOKF5(&VI&%8AF01H$*A%Q]+44 ?*OQN_X(I?\$W/VC?VD8?VO?C+\
M$M>UGXDVE_;7NG>+/^%J>);>XT^:VD\VW-JL&HHEJL4@WHD*HJ-RH%2?M1_\
M$6O^"<'[:GQ9T_XY_M/?!'6_%GBO2;&WL](U>Z^*'B2!K"& [HU@2#4$2$A\
MN610S2,SL2[%C]344 ?*?Q__ .")O_!-K]J;XU:9^T9\?O@IXA\2^.-$M+&V
MT;Q+=_%?Q/'<V$=F=UN(3%J2B(HY:3<H#&1WD8EW9CWO[9O_  3F_8Z_X*!_
M"/3_ (*_M:?!^'Q;I&CN)-$NKK4KF/4-/EV!#)%>)()PS!5WY<B3:/,#XKV^
MB@#YR_8)_P""3_["G_!-.TU+_ADOX,+HVHZS"(-4U_4]3N-0U"> -O$ FN'8
MQ0[L,8H]B,RAF!8 UQUU_P $,?\ @GE<^$+OX81>"_&MOX)UC55U/Q/X M?B
MEKD>@Z_>K,LWVB\L%N_)D8RHCL%55<HNX,% 'U]10!XA^T-_P3L_9._:=U#P
M%J_Q+\ WUM>_"VSNK?X<7WA/Q)?:'/X;^T"U5GM)-/FA:)E2S@1<'"H&7&UF
M!M?LL_L%?LV_L?\ B'Q9X]^$WAO5+KQ=X\NXKCQKXX\5^(;O6-:UIXEV0K/=
MW<CR>7&GRI&I5% X7/->RT4 ?$G[1'_!N[_P24_:>^/=W^TE\3?V9FB\3ZI?
MF]UV7P]XFO\ 3+?5+@G+RS0VTR('<Y+O&$9RQ9B6)->V_&G_ ()S_L:_'WX&
M^#?V:OB'\%K5? OP_P!6MM3\'^'-!O[G2HM+NK:UN+:WDA>RDBDC:-+F5E*L
M"'VOG<H->W44 >$?L_\ _!./]F+]G7XU:G^TIX>TWQ+XD^(NJ:,FC2>.?B#X
MSU#7]4M],1MRV,$U]-(8(=V6(3!<DERQKY:_95_X)$_LR?#/_@K,_P"VQ^RG
M^S;?_#;PIX4T/78-7U*_EOX?^$N\1:E(D<GV.RO)#Y&GVD*3D2QQQ1327@\D
M21Q!A^CE% %?5=-M]9TNYT>\DN$BN[=X97M+N2"5592I*2Q,KQM@\.C!E.""
M" :^6_V>/^")G_!-K]D_XN:O\>?V>/@IXA\+>,=?TZ]L=;\0V/Q8\3O<W\%V
M=UP)6DU)O,9G"RAR"Z2HDJE9$5A]644 ?+_[(?\ P1J_X)S_ +!OQ;N_CG^R
M?\#=4\)>)]0M);74[^/XC>(+Q+^*0[F6X@N[^6&X^;YP9$8JX#+A@#7+_MB_
M\$#?^"6W[='QG;]H7X\?L[L?&-R\;:KK7AWQ!>:6^IF, *;A;:54D<  >;@2
MD  OA5Q]D44 >?\ P\_94_9R^%/[/4?[)_@#X-Z%IWPX31I]*?P@MF)+.>TG
M#B>.99-QF\WS)#(TA9I"[,Y8L2?+_P!BS_@DC_P3\_X)Z^)M4\8_LE_ &/PU
MJ6K&437-QK^H:B;=)-GF);B\GE%N&\N,-Y84N(T#%@B@?2%% !1110 4444
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M0-1_](10!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "OQ!_P"#WG_DUGX'_P#90-1_](17[?5^(/\ P>\_\FL_ _\
M[*!J/_I"* //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\
MI\GK]_J "O&/VV_BU^U[\(? .@:K^QG^S5H_Q0\1ZIXHAT[4=&UKQ2VD0V-D
M\$SM>M.(91M22.-""!_K<@\8/L]>*?MP_![]IKXU> _#GA7]EK]L"Z^"^LIX
MLAEU?Q':>'[#4Y+S3O(G$EHD%[&Z&0N8G!&T@1-R02" >!P?M!_\%T;;4;C5
M[;_@E/\ !>.[NDC2ZND^/F))E3=L#L-.RP7<V >FXXZFO4_V'_B1_P %!?B)
M\6_B#-^W)^RQX2^&MK:>'_#Z^$'\*>)UUE-29IM6^V"2[\F)LQXM<0E<()MP
M.937E%U^P/\ \%*+*=K6]_X.!/&D,J?>CE^#WA-6'?D&#BO2/V#/@%\>O@?\
M;/B3+\>_^"B=[\>;W5_#/AHV,&J:#8Z;<:!%%/K()\BQ58?+N"_ROC>6M9 W
M"K0!]1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^
M(/\ P>\_\FL_ _\ [*!J/_I"*_;ZOQ!_X/>?^36?@?\ ]E U'_TA% 'G_P#P
M:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !7DW[7O@
M[]DB7P-I/Q\_;$@T>WT#X.Z_%XUTKQ!KE]+!#H6H6J2)%>9C==[*)658V#AF
M=0$9MM>LU\G?\%A?B7^S+\*OV?\ P3XH_;0U.UMOA1'\7=$D\;C4-.EO+66&
M 7%U;)/;Q1R-/%]MM[0M'L8$+\P(S0!\.?M*_&'_ (-4_P!JJQ^(/_!3WXPM
MIWQ3O[[6-'T'5[*TM-9MM6GU(6TD5I%!IY:U=C+;VS$2LNPBU;]YE2H^J/\
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M<?#S6%TOXA_#?QQIXM=6T&Z;>$\Q 2&C<Q2A6X.8G#*I&* /I>BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IES<V]G;R7EY<)%%$A>661PJHH&2Q)X
MYS3Z_/#_ (.:OC/XV^'G_!.S2/@UX$URYTVY^-WQ8T'X>7]]9RE)8["],\]R
MJL.@DBM&A;U29AWH ^P/A%^VE^RG\>O%G_"#?!WX\^'?$&JO9RWEE:Z?? _V
MA:QN(Y+FT8@+>0(Y56F@,B*64%AN&?3Z_-O_ (.,-8M/V.?V&/A5^UA\&--A
MT35_@!\7_#=]X373D$7DZ>5DL;C35QC_ $::WD$3Q?=944'H*_2..1)HUEC8
M%64%2.X- &/\0/B+\/\ X3>#K_XA_%/QSH_AK0-+A\W4]<U_4HK.TM(\@;I)
MI65$&2!DD<FJOPP^+'@;XQ^'3XM^'>HW5[IAF\N&^GTFYM8KGY0WF0M/&@GB
M(88ECW(3D!B00/RMT+]L67]N;_@I_P#%_P",WQ ^ 'Q,^*7PG_92\0'P]\,?
MAYX!\*C4+6\\30&1=1U^X\^6&VN;JW*>7:P^8\JI.LL40<%S^CO[%O[:_P"S
MQ^W]\";']HC]F?QB^KZ!=74MG=175JUO=Z;>Q8\ZSNH'^:&9-RDJ>"K*REE9
M6(!ZQ1110 4444 %%%% !1110 5^(/\ P>\_\FL_ _\ [*!J/_I"*_;ZOQ!_
MX/>?^36?@?\ ]E U'_TA% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_
MRE,_:[_[>/\ T^3U^_U !6#XZ^&7@3XF'2%\>>&;358]#U8:EI]O?0++$ER(
M9H5D*,"&*K/)C(X;##D UO44 <__ ,*F^%?_ $33P_\ ^":#_P"(J/PM\(OA
MKX(\9:KX^\'^#-.TS5-;TVRL-4N+"S2'[1!:27,D"L$ SL:\N""?^>AKX@^/
M%I^V-\=_VX?BA\.;G_@K#%^S[X/\'KH__""^$_#GAW0Y[K6+.XT^.2XU&XNM
M0#N7%Y]I@\A0!&D,3D8F1W]0_P""=_PJ\??"_P".'Q/A^('_  4KO/VAI[SP
MOX8:WCU*UL(9_#J+<:WU73U6'9<%C@X\S-LP;Y0E 'UG1110 4444 %%%% !
M1110 5XS_P %&_'7BGX8?\$]OCM\2O ]S+!K7A[X-^)]2TB> D/%<P:5<RQ.
MI'.0ZJ>.>*]FK*\=^"O#7Q*\$:S\.O&>F)>Z/K^E7&FZM9R'Y9[:>)HI8S[,
MC,/QH ^!O^"5/@3PK;?\&V/@WP;<VL3:7J?P'UR34(BHVN+M+Z:?/U::3/U-
M=+_P;3>-?%'C[_@B'\"-:\77,LUU;:3JVFP2S$DFUL]:O[6V49_A6"&)![*,
M<8KAOA#^S;^W=^RU_P $T/%7_!)/P+\$M0\3:U#8ZYX3^&?Q>;6-/AT+^P-2
MEN#!J6H;K@75O<6<5TZ/;1VTA=X(_+,B.SI[C;?#?X[?\$P/V'_@M^S/^P=^
MS0OQ?;PSJ^C>&?$,-UXB@TAK;37$C7^M,9<JSF?+F)<X-P6Y5"* /J*'1?#>
MAZAJ/BF'3;2UNKY(VU34/+5'F6)2$\Q^I5%SC)P,GU-?&G_!,WX(P^-_VQOV
MD?\ @J-9::;+0/CAK.C:7\.XS%L.I:'HUDMF-9QP3'?3AY820"UO'#(,B4&J
M?_!33XA?\%)_$WQ1T[X'?L]?\$Q=8^*_P>2U6?QS?0_%_P /^'?^$JD8*RZ8
M!=3M.E@,D7*M$C7)'E9$'F?:/0OV+_C_ /\ !2KXV?%BZTG]J3_@G)IO[/\
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M&H_^D(K]OJ_$'_@]Y_Y-9^!__90-1_\ 2$4 >?\ _!IM_P I3/VN_P#MX_\
M3Y/7[_5^ /\ P:;?\I3/VN_^WC_T^3U^_P!0 5XG^WC^W=\&?^"=WPCTOX^?
MM!2WT'A&X\46VCZK?Z=8274UF;B&<Q2"&(%Y098XT(4$@2%L';@^V5G:[X2\
M.>)K[2=2U[28[J?0]1-_I3R9_P!'N?(E@\P '!/E3RKSD#?GJ 0 ?C;\8O\
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M_P"*H_X?T?\ !0;_ *"?AO\ \)J/_P"*H_U;S;M#_P &TO\ Y,/]9LH[S_\
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M?"__ ((+;_XBNHHH Y?_ (4A\%O^B0^%_P#P06W_ ,11_P *0^"W_1(?"_\
MX(+;_P"(KJ** .7_ .%(?!;_ *)#X7_\$%M_\11_PI#X+?\ 1(?"_P#X(+;_
M .(KJ** .7_X4A\%O^B0^%__  06W_Q%'_"D/@M_T2'PO_X(+;_XBNHHH Y?
M_A2'P6_Z)#X7_P#!!;?_ !%6-+^$OPJT34(M6T7X9^'K.Z@?=!<VNBP1R1MZ
MJRH"#]*Z"B@ HHHH *_$'_@]Y_Y-9^!__90-1_\ 2$5^WU?B#_P>\_\ )K/P
M/_[*!J/_ *0B@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\
M;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR?A]JWC]+N2T7PS8^(X7GEN8\[X(R#LEE7#9C1F<;6R/E./=Z_*?_@K[?_\
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MUQXU^">DI>WJ:H/&HLO$FKZ19RR1W.JV&DO9M%+!B*66-)KR":6--WEJ616
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MOQ!_X/>?^36?@?\ ]E U'_TA% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\
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MA_X0OPU:IJ$"*Y+^1>V<NUQE1+:$$Y4BO._^"$7A+]INV^'P^(W_  4?FL=
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MCQ%^RI^TUH'B#2K:^L+W]K[QI!>V5Y LL-Q$]EI2O&Z,"KJP)!4@@@X-8?\
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M+/%/BCQ?K5_^\N=1U?47O+L7\KGEYT8P%7/(,$>/NBN]_P""1MMX4_X*@?\
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MQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\
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MQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PH _;ZBOQ!_XC>?V6?\ HQ[X@?\
MA16/^%'_ !&\_LL_]&/?$#_PHK'_  H _;ZOQ!_X/>?^36?@?_V4#4?_ $A%
M'_$;S^RS_P!&/?$#_P **Q_PKX#_ ."^G_!?3X1?\%A/A%X ^&_PW^ /B3P=
</X.\276I7-SKFIV\Z7"2VXB"*(AD$$9R: /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20220403_g8.jpg
<TEXT>
begin 644 jnj-20220403_g8.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MKBVM+6XMUT^1XIYKFUG"A6=?)ADEW%E\H@"_LX_\%2OV&/VL_P!ICQU^R%\
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MQ,^)'A#PQ+KOQ O_ !!XQ;0M"\/1+Y02U>ZBL[R2:[=IX5\I(=J>:-S@I($
M/L.BOB_]E?\ X+'>#_VR_P!A;XC?M5_!/X,S)XT^$HOH?'WPH\1>(EM+C3[R
MSC:6>!;R."59%>))3#+Y861T*-Y6'*?,GP(_X.@_&_[57[*WQ/\ VBOV;_\
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MW>XO;V[F6.*WB12SR.[$!%5026)  !)J6WGBNK=+JW<-'(@9&'<$9!K\/?\
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ME,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444
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M%GQ/->7-Q,")C,9=299U<,RM'(&1E.TJ1Q0!^:7_  =O_LQ>._V>?C/\%_\
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M#^'_ ,5[6YM_$.D_"70K;4[.\!$UHZV46+=P>0\:[8R.Q0CM7T%110 4444
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M]AW74F^(/@JP7PFNC>./#-R+N\LUOU^R,1J@\II/MJ%7?$8$;[F4[0P!D_\
M!G_^U[XZ\(_L&?M(V?Q&\1ZCK'A3X._9O$6AZ7/=%_L<,EC?3W4$!;/EHQL5
M8(/E#N[8R[$X/_!"KP/X=_X+8>%/VM_VNO\ @HOX<L/B+XLOQ!I?A*ZUZ#[0
MG@R"2UO)RNCJ^?[/*,;?9)%MD7R%.[+.6]G_ .#8[_@EK^VY^PGX7^//P/\
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M JAP027. #Z;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MD#_@OQ_RAL_:$_[)_-_Z.BKZ_KY _P""_'_*&S]H3_LG\W_HZ*@#^,*BBB@#
M]_O^#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H *\2
M_;I^#'Q^^.'P^\/^&?V>?VQ=1^"FHVWBJ&YUKQ+I>G6=W+=Z<()UEM%CNXWC
MW%VA<-QCRCS@D'VVOF7_ (*;?"#]@CX^^&?A;\&OV_/!\NNZ1XA^+-A9^"]*
M33+R>.ZUU[6[6&*9[1"T,+1-/N=V2/@;FP* /*O^'>O[<G_2?WXH?^$5X7_^
M1J](_8(_9^^*WP)^.OQ.C^+G_!1'6/CQJ&I^&/#/DVVOV-E;77AZ..?6>?*L
MD2$1W!D.UL;R;9]W 2OB']I;X2_\&H'[(OQSUS]G#X[?LJV6F^+_  ZEJ^K:
M=8^ /%5^D2W$"3PLLUK')$X:-U.58@$,IY4@?1'_  19US_@D!J_Q-^+\?\
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M1IJ\I-)+NV[)?>95Z]+#4)5JKM&*;;[)*[?W'V+17X;?\/\ ?]OG_H-^&?\
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M  _W_;Y_Z#?AG_PFX_\ XJC_ (AYQG_T"/\ \"A_\D'_ !$;@K_H,C_X#/\
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M-G[0G_9/YO\ T=%0!_&%1110!^_W_!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\
MP:;?\I3/VN_^WC_T^3U^_P!0 5\K_P#!6;P[JNI_!;PEXHU^RTS4/AUX7\>V
M>L?%#2-3^'MYXG2;3H8IC;W$FGVES#+=6]M?&TN98E#G;#YN"L+1R?5%% 'X
M^Z3X9_:(_P""^7QMTWP=8:YH-E^R+\'=2AO[>^O_ (0:IHVD_%#7$ \FT.F3
MZFD\NGVF&8DRQHSD*T39!3Z>_P""=WA+P3X&_;8^+'@;]F'QE\(SX(TGPWH3
M>/='^$OP\DTC1X_$#R:BB+ (]3GMHKU;>*+[440ED%JCA74&ON2B@ HHHH *
M_-__ (.0?^2%?#S_ +&:[_\ 285^D%?F_P#\'(/_ "0KX>?]C-=_^DPKU\@_
MY'N$_P"OM/\ ]*1Y'$'_ "(<7_UZJ?\ I#/Q[HHHK^U3^'@HHHH **** "BB
MB@ HHHH **** "BBB@ K]V?^"#W_ "C[TS_L9M2_]#6OPFK]V?\ @@]_RC[T
MS_L9M2_]#6OQ#QI_W;!>L_RB?NG@C_O>-_PP_.1]ET445^!']"'Y%_\ !R3_
M ,E=^'/_ &+%U_Z4BOS/K],/^#DG_DKOPY_[%BZ_]*17YGU_3?A%_P DI+_K
MY+\HG\N>,7_)6Q_Z]1_.04445^HGY4%%%% !1110 4444 %%%% !1110 4Z'
M_6K_ +PIM.A_UJ_[PK#%?[K4_P +_(Z,)_O=/_$OS/Z*O^"8/_)@/PK_ .Q6
MC_\ 1CU[Q7@__!,'_DP'X5_]BM'_ .C'KWBOX:/[P"OD#_@OQ_RAL_:$_P"R
M?S?^CHJ^OZ^0/^"_'_*&S]H3_LG\W_HZ*@#^,*BBB@#]_O\ @TV_Y2F?M=_]
MO'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ KR?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KY _X+\?\H;/VA/^R?S?^CHJ^OZ^
M0/\ @OQ_RAL_:$_[)_-_Z.BH _C"HHHH _?[_@TV_P"4IG[7?_;Q_P"GR>OW
M^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@ KA/VB?VG
M_P!GC]DCX=O\6/VF?C+X>\#^'4N5MUU7Q%J26\<L[ E88PQW2R$*Q"("Q"L<
M8!([NO._C1X4_9R\.7P_:7^/6F:,/^$/T>:"UUSQ @FBTF"9T,Q@1]RQR2LL
M2,R+YDFR-,GA: +/[.W[3_[//[6_PZC^+7[,WQD\/^-_#CW+VQU7P[J*7$<4
MZ@%H9 IS%( RDHX# ,IQ@@GI?''CGPG\-O"MYXX\<ZW%INDZ=&)+Z^G!V0)D
M#<V 2!DC)Z#J>*_._P#X(#ZA^QE\4/C%^U=^U)^Q9\4-%D\-?$3XHV36WPXT
MBSDLV\.065M+"+Z6TD2,P-J$[W=RH5=GEK$I(D22./\ 2:@#@?V>?VIOV;_V
MM/"-WX^_9D^.'ACQYHMAJ+6%[J?A;6(KR&"Z5$D,+M&2%?9(C8/.'![UU/CG
MQSX-^&/@O5OB-\1/%%CHF@:%ITU_K.L:I<K#;65K$A>6:61B%1%52Q8G  K\
M0?\ @D;J5]_P2S_;]^'&FZE=R6_P@_;8\,W*V+2N?L^E^-].O;B)(ESG:)T9
M5 &-\E]&H^6$8^VO^"[&JZI\<?@/XA_8>\)ZC-#;7'PO\1?$'XG7-K(5:WT#
M2+222SM2PP5-[JHM4QGY[>TOA@@&@#Z]^ ?[4'[/?[4WAF3QK^SG\7M$\::-
M$^QM7\/7@N;5FW,I595^1B&1@0"<$8.*[ROSP_X(W?M%?"#]C[_@W:^%7[2?
MQPU]=(\)>#_A_>:CK%VD6]\?VE<A8XT'WY9)'6-%ZL\BCO7I'QW_ ."I/Q/_
M &/O OA']HC]L7]CZ3P=\(_%&J65CJGBK2_&XU/5/!S7A MI-:TX6<201[F5
M)&MKFZ\MSM^<E=P!]CT5\B?M,?\ !5J?]GC]N;X:_L3:?^R-XT\67'Q/T/5-
M1\->)=#U2P:+4C9V;3^5:1"5BV7\J-Y;IK2*)9#*7,:%B_\ 9/\ ^"F/Q,^/
M/[0_Q5_8T^,?[']U\-?BY\./#EMX@TWPQ<^-[;5++Q!IER"()X[Z"%5A/F>7
M'(I1MADX+E6  /J#Q_\ $#P/\*O!NH_$3XE>+=/T+0M)MS/J>KZK=K!;VT8(
M&YW<@#D@#U) &20*YK]FC]IWX%?MB?!S3?V@?V;?B!#XH\':Q<7<&F:Y;V<\
M$=R]M<RVLVU9T1RJS0R*&V[6"[E+*03\;_\ !$C]KK]L?]KRQ^-_BK]HWX9Z
M"+./X^^)-'O;_3O%KS1:,UA:6%I'IEM:O; RP*L0)GWIYCR22&,%B#\H?\$<
M?^"AGQL_8@_X-^_A[\6OA[^PKXC^)7@_P(/$=_\ $/Q&GBJTT:/3[/\ M^_D
ME>RBG5Y=2>*)A))L5(AR@F+I*D8!^VE%?._Q%_X*$^#+.V^!NC_!/P_9>)?$
M/[1%E)J'PUL?$&NG1[.6PBTU=2FN+BX6"X>,B"2(+''#*[/*HP%#NG8_LS?'
MOXJ?&#7O'W@OXQ_ B/P+K7@/Q-#I3):>)/[5L]7BEL;>[2]M9S;P,82+CRP'
MC5PT3AE4@@ 'J]%%% !1110 4444 >5_M1_MO_LC?L4:%IWB/]J_]H;POX#M
MM7G:+21X@U-8I;UDP7\F(9DD"[EW%5(7<N2,C/8_"3XO_"OX]_#O2_BW\%/B
M'H_BOPQK4!FTK7M!U".ZM;I Q4[)(R02&#*PZJRE2 017FW[4%W^Q/\ LV^'
M_%?[7?[5.F^'[:VDT-=.UK7O$&FG4)7L(DE<6$$121S&<SR&")<.S2.RGDCY
MM_X-O?#/[/VD_L!ZWXT_9J^)^F:WX9\<_%SQ#XGM/#NE2/L\%1W<L?V?071P
M&BEM[:.W+KM"F29V0O&R2. ?:GQC^-WPE_9[\#W'Q,^-OC[3O#'AZS/^F:UJ
M\WE6UN-K-NDD/RQKA2=S8 QUH^"WQQ^#O[1OPYL/B]\!?B;HGC#POJ;2KI^O
M^'M1CNK6X,4C12!9(R02LB,I'8J17,_MOV\%U^Q;\7K6YA62.3X7^($DC=<A
ME.G3@@CN,5^9G_!!W6M5_P""<'[:/B7_ ()1>-]1G7P7\5O!&F_%GX#W%Y*2
M#]ILHSJFG(6R24:-RJYX6QED;F7D _5KXS_&[X/_ +.GPYO_ (O_ !X^)>B^
M$/"VE&(:CK_B'4([6TMS+*L48>20A06D=$ [E@.]+\(/C5\*?C_X)M_B3\%_
M'>G^)= O #9:SI4OF6URI56#1R8Q(I5@0RY!SUK\K_\ @Z!U75/VCOV7?BM\
M*="U&9/"?P$\':9XK\8O;R%4O/$FIZA!::5I[D8W""QDO[R1.0&N+!B.E?9_
MA7]K;X8?L4?\$Q?@K\2_'^GWVH2ZGX*\'^'/"'AC1(HVOM?UF]LK:&STZU5V
M1/,D<]6951$=V("F@#ZIHKY.\?\ _!2?QK^S!\?OAO\ !S]N;]G;3_ FB_%S
M5QHG@CQ]X6\<MKNF1:VP!BTS4?-L;-[.:7D1NBS1,0?G 5F7$\6_\%9?'&G?
M\% /%W_!/#P/^PAXWUWQ=H'P\'B?1+C_ (2'388M:1KR*VC;>)'AL[,AI7:X
MN)4E'E"-;=Y9$0@'V97&_'K]H7X)?LN_#+4/C+^T)\3=)\)>&-+3-YJ^L7(C
MC4X)"*.6D<A6(1 6.#@'%?-7[,__  5!^*?[4GP3^.":%^R>GA/XV? W6Y]&
M\3?##Q)XTCFL1="'S8)UU.W@(DMY$#L&6'<?+( PRN?F;]G;]I3]IG]K7_@V
MD^,'QI_:*\(:?*?$_P !?B5K"^*HO$)GEU&ZEDUJ1H_L9A'V2*(G9&HE<!(D
M  &  #]/OA#\6/A_\>?A5X;^-WPG\0?VMX7\7:':ZQX=U06LL'VNRN8EFAE\
MN94D3<CJVUU5AG! /%=%7Y5?LW?\%6O'_P"PE_P2Y_9?^(WC?]B#Q/??!2W^
M'/@KP_XM^*\OB:TLY-+EGLK6V%U#I3JUQ<VBRD)YS&'>?FC$D;1R/]Q?&']L
M+6?#?[4^C_L6_!+P#H7B3X@ZAX%N/&-Y:^*?%[Z)96ND1W:6:NLL5G>2S3/.
MS 1I#M58G9Y$RBN >YT5YI^RC\=/&G[0?PMN?&GQ%^#ESX"UO3_%&KZ)J7AJ
MZU9+XPR6-[+:^:LZ(BR1RB(2HP7E)%/>O2Z "BBB@ KY _X+\?\ *&S]H3_L
MG\W_ *.BKZ_KY _X+\?\H;/VA/\ LG\W_HZ*@#^,*BBB@#]_O^#3;_E*9^UW
M_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH *
M*** "O%?CS_P47_8@_9;^-6@_L^?M(?M)^&_ OBGQ/H[ZIH=MXJG>QM;FV61
MHRWVV55M4;>I C:4.>,*<C/M54=:\,^&_$8B'B'P_8WX@8M +VT27RV]5W X
M/ Z>E 'PQ^Q;^S_X \7_ /!83XR_\%#_ -FBQM8?AAXG^%>D^&[S7=*B":=X
MQ\3"]>XNM1LV0;+J*&VBM(6NDS')-+,%=V27'W%XR\:^#?AUX:NO&?Q!\6Z9
MH6CV*!KW5M9OX[6VMU+!07ED950$D#)(Y(%:8  P!10!^0GB7]G_ ,#?\%0O
M^#>/1=)_9?\ B%IFL_$SX6>?XR\ 7/AW4HY;[3M;L=0O98X,1DO%)/"L\48;
M;EWC?G8*[_P/\0M?OO\ @C7\;O\ @HS^W1K.A>$/B%^T)\%[ZX2PO[]+:.ST
MR'0+B#2-+MA*5+&8O<7PA +^=JDB@' K]/** /PQ\+?"KQ-^W=_P:'^'/@?^
MR=XBLO%'CGP?HMKJFJ>#]%O([B]D-EKD]Q)9R0(2ZRF.-Y8XRNZ5HD"@[A7T
MI_P4F_;2^ '_  5 _P"",^K?"G]F7Q9I'BOXE?&O3M&TGPW\+K"_CEUJTUAM
M0M)+B"YM<^9:BR,4LDTLJK'&MN7+8*EOTZJC8^%_#.F:O=:_IOAVQM[^] %[
M>P6B)-< =-[@;GQ[DT ?E?\ M">*/A#^SM_P6W_8 ^!OB[XV^'OMOP[^$OBG
M0]>NK_688FAE;08X+5I][@Q-<-$3&'P7) &21GJO@Y\;_@UJ'_!T5\4=&L/B
MMX=FNKC]F73-(@ABUF!FEU&+5HY)+-<-\UPJ,&,0^<#)(P#7Z:44 ?EI_P $
M,OVH/@5\![7]J?\ 9Z^,?Q!M?#7BW0/VIO'.OZ_I>LQO;C2](E:W,6H7,KJ(
MX+:1D*)*[!7=E5<EESX-_P $^?C?\&-)_P"#//QQX5U;XL>&[;4[+X:^/=)N
M]-N-;@2>&_O+O5WM+5HR^Y9IE8-'&1N<'*@BOW!2WMXI7GC@17EQYCJH!? P
M,GOBGT ?DFUO_P $QOVPO^":7[$/[+/[8/Q(M-&;Q#\&M/;X?_%+0O&$>GW7
MA7Q1I.D:/%+9QW7*07+_ &F0>7-\OF6JH4,ABV^Z_P#!$OQO^UY8>+/CO^RU
M\?/VBV^-_@;X3>*=*T[X8?&V9%>;7H[BS>>\L)KA&9;J:R;[/'))O=Q+*ZLY
MVA4^[]3TG2M:LY-.UC3+>[MYD*2P7,*R(ZG&5*L"".!Q[4NEZ5IFB:?#I&BZ
M=!9VEN@2WM;6%8XXE'1550 H]A0!/1110 4444 %%%% '@_C_P#X*=_\$^OA
M3^T'J_[*GQ@_:R\&^#_'6BZ;;WVHZ+XRU'^R8_L\\8DC:.YNQ';SDH02D4CL
MO.X#!KQ'_@D%^RWHOPD^._[47[2?PG\)2^'/A9\8?B787_PVT1[!K..>"UL
ME[JD%NRKY5O=7TUPT)VKOBACD4>6\9/VQ?\ ACPWJNI0:SJ?AZQN;RUQ]FNI
M[1'DAP<C:Q&5YYXJ]0!XK_P47^)OPZ^%'[#7Q8\1_$SQUI&@6,WP[URVM[G6
M-1CMDFG?3KC9"AD8;Y&P=J+EFQP#7Y\?\%-/ DWQ:_X)A_L]_P#!4_\ 8:\1
MZ9XF^(G[+=GH7B33[CP]>I="^TK[':#5=-E,))P(Q%+)&W*Q1S+MS)S^N-%
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MO !%CK/A/]I'3/"=R;8!/M'A_6+.Y34;(XX,;QV<6%/"LJL!E10!];_M1_\
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M\'4-LG@+P7I6B+JW[$D]_J::3I\=NMW=MXL9&GD$:@/(RH@+G)(1<GBOTDH
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<VFK:AKEI)#:NSHV]U0;B/EZ#UH _"VBBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262251016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  03,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Johnson & Johnson<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,631,401,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636260378824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,463<span></span>
</td>
<td class="nump">$ 14,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">19,925<span></span>
</td>
<td class="nump">17,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, trade, less allowances for doubtful accounts and credit losses $234 (2021, $230)</a></td>
<td class="nump">15,594<span></span>
</td>
<td class="nump">15,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 2)</a></td>
<td class="nump">10,990<span></span>
</td>
<td class="nump">10,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">3,452<span></span>
</td>
<td class="nump">3,701<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,424<span></span>
</td>
<td class="nump">60,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment at cost</a></td>
<td class="nump">47,702<span></span>
</td>
<td class="nump">47,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(29,001)<span></span>
</td>
<td class="num">(28,717)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">18,701<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (Note 3)</a></td>
<td class="nump">44,420<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="nump">34,935<span></span>
</td>
<td class="nump">35,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">9,936<span></span>
</td>
<td class="nump">10,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">9,939<span></span>
</td>
<td class="nump">10,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">178,355<span></span>
</td>
<td class="nump">182,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">4,297<span></span>
</td>
<td class="nump">3,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,309<span></span>
</td>
<td class="nump">11,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">13,006<span></span>
</td>
<td class="nump">13,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">12,972<span></span>
</td>
<td class="nump">12,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">2,098<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income (Note 5)</a></td>
<td class="nump">1,708<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">43,390<span></span>
</td>
<td class="nump">45,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 4)</a></td>
<td class="nump">28,851<span></span>
</td>
<td class="nump">29,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">6,424<span></span>
</td>
<td class="nump">7,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employee related obligations (Note 6)</a></td>
<td class="nump">8,739<span></span>
</td>
<td class="nump">8,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable (Note 5)</a></td>
<td class="nump">5,745<span></span>
</td>
<td class="nump">5,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">10,497<span></span>
</td>
<td class="nump">10,686<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">103,646<span></span>
</td>
<td class="nump">107,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss) (Note 7)</a></td>
<td class="num">(13,757)<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">124,380<span></span>
</td>
<td class="nump">123,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost (490,459,000 and 490,878,000 shares)</a></td>
<td class="nump">39,034<span></span>
</td>
<td class="nump">39,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">74,709<span></span>
</td>
<td class="nump">74,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 178,355<span></span>
</td>
<td class="nump">$ 182,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262173976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">490,459,000<span></span>
</td>
<td class="nump">490,878,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262545464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 23,426<span></span>
</td>
<td class="nump">$ 22,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesRevenueGoodsNetPercentToSales', window );">Sales to customers percent to sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 7,598<span></span>
</td>
<td class="nump">$ 7,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CostOfGoodsSoldPercentToSales', window );">Cost of products sold percent to sales</a></td>
<td class="nump">32.40%<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 15,828<span></span>
</td>
<td class="nump">$ 15,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_GrossProfitPercentToSales', window );">Gross Profit Percent To Sales</a></td>
<td class="nump">67.60%<span></span>
</td>
<td class="nump">68.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">$ 5,938<span></span>
</td>
<td class="nump">$ 5,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales', window );">Selling marketing and administrative expenses percent to sales</a></td>
<td class="nump">25.40%<span></span>
</td>
<td class="nump">24.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">$ 3,462<span></span>
</td>
<td class="nump">$ 3,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales', window );">Research and development expense percent to sales</a></td>
<td class="nump">14.80%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">$ 610<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentInProcessPercentToSales', window );">In-process research and development percent to sales</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InvestmentIncomeInterestPercentToSales', window );">Interest income percent to sales</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net of portion capitalized</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_InterestExpensePercentToSales', window );">Interest expense, net of portion capitalized percent to sales</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">$ (102)<span></span>
</td>
<td class="num">$ (882)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherNonOperatingIncomeExpensePercentToSales', window );">Other (income) expense, net percent to sales</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (Note 12)</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Restructuringchargepercenttosales', window );">Restructuring charge percent to sales</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 5,862<span></span>
</td>
<td class="nump">$ 7,429<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales', window );">Earnings before provision for taxes on income percent to sales</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income (Note 5)</a></td>
<td class="nump">$ 713<span></span>
</td>
<td class="nump">$ 1,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_IncomeTaxExpenseBenefitPercentToSales', window );">Provision for taxes on income percent to sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 5,149<span></span>
</td>
<td class="nump">$ 6,197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_NetIncomeAttributableToParentPercentToSales', window );">Net earnings percent to sales</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">27.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (per share)</a></td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (per share)</a></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>AVG. SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">2,629.2<span></span>
</td>
<td class="nump">2,631.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">2,666.5<span></span>
</td>
<td class="nump">2,672.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CostOfGoodsSoldPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CostOfGoodsSoldPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_GrossProfitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross profit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_GrossProfitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeTaxExpenseBenefitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax expense benefit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeTaxExpenseBenefitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InterestExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InterestExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InvestmentIncomeInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment income interest percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InvestmentIncomeInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NetIncomeAttributableToParentPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income Attributable to Parent Percent to Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NetIncomeAttributableToParentPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonOperatingIncomeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other non operating income expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonOperatingIncomeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense excluding acquired in process cost percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentInProcessPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>research and development in process percent to sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentInProcessPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Restructuringchargepercenttosales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring charge percent to sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Restructuringchargepercenttosales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesRevenueGoodsNetPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales revenue goods net percentage to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesRevenueGoodsNetPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling general and administrative expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SellingGeneralAndAdministrativeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262102264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 5,149<span></span>
</td>
<td class="nump">$ 6,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="num">(554)<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service cost amortization during period</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss) amortization during period</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to earnings</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(296)<span></span>
</td>
<td class="num">(595)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(699)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 4,450<span></span>
</td>
<td class="nump">$ 6,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262221000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign Currency Translation</a></td>
<td class="num">$ (145)<span></span>
</td>
<td class="num">$ (319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee Benefit Plans</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives &amp; Hedges</a></td>
<td class="num">$ (78)<span></span>
</td>
<td class="num">$ (157)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262571800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jan. 03, 2021</a></td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="nump">$ 113,890<span></span>
</td>
<td class="num">$ (15,242)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (38,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">6,197<span></span>
</td>
<td class="nump">6,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,659)<span></span>
</td>
<td class="num">(2,659)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">542<span></span>
</td>
<td class="num">(920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Apr. 04, 2021</a></td>
<td class="nump">65,834<span></span>
</td>
<td class="nump">116,508<span></span>
</td>
<td class="num">(15,328)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,466)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jan. 02, 2022</a></td>
<td class="nump">74,023<span></span>
</td>
<td class="nump">123,060<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(39,099)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">5,149<span></span>
</td>
<td class="nump">5,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,787)<span></span>
</td>
<td class="num">(2,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">600<span></span>
</td>
<td class="num">(1,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Apr. 03, 2022</a></td>
<td class="nump">$ 74,709<span></span>
</td>
<td class="nump">$ 124,380<span></span>
</td>
<td class="num">$ (13,757)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (39,034)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636266521384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636260456216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 5,149<span></span>
</td>
<td class="nump">$ 6,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="num">(168)<span></span>
</td>
<td class="num">(580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="num">(926)<span></span>
</td>
<td class="num">(730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(427)<span></span>
</td>
<td class="num">(1,604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(600)<span></span>
</td>
<td class="num">(695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accrued liabilities</a></td>
<td class="num">(2,817)<span></span>
</td>
<td class="num">(2,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other current and non-current assets</a></td>
<td class="nump">995<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Increase/(Decrease) in other current and non-current liabilities</a></td>
<td class="nump">110<span></span>
</td>
<td class="num">(902)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH FLOWS FROM OPERATING ACTIVITIES</a></td>
<td class="nump">3,979<span></span>
</td>
<td class="nump">4,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(607)<span></span>
</td>
<td class="num">(677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net (Note 10)</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note 10)</a></td>
<td class="num">(252)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(9,018)<span></span>
</td>
<td class="num">(5,994)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">6,303<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="num">(249)<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (primarily licenses and milestones)</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED BY INVESTING ACTIVITIES</a></td>
<td class="num">(3,634)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="num">(2,787)<span></span>
</td>
<td class="num">(2,659)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(1,577)<span></span>
</td>
<td class="num">(1,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="nump">3,019<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="num">(856)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(2,132)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="num">(235)<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED BY FINANCING ACTIVITIES</a></td>
<td class="num">(4,385)<span></span>
</td>
<td class="num">(5,125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash and cash equivalents</a></td>
<td class="num">(4,024)<span></span>
</td>
<td class="num">(1,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash equivalents, beginning of period</a></td>
<td class="nump">14,487<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">10,463<span></span>
</td>
<td class="nump">12,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed and noncontrolling interests</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263849112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended April&#160;3, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal first quarter of 2022 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal first quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636264959096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">INVENTORIES <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263828968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,960&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,147)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of April&#160;3, 2022 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at April 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $1.2&#160;billion for the fiscal first quarters ended April&#160;3, 2022 and April&#160;4, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263690232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April&#160;3, 2022, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $1.1 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April&#160;3, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $42.5&#160;billion, $37.4&#160;billion and $10.0&#160;billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion,  $37.4 billion and $10.0 billion respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;3, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $632&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2022 and 2021, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  April&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2022 and 2021: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"><tr><td style="width:1.0%"/><td style="width:32.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.127%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal first quarters ended in 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:24.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair  </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:25.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.464%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, there was a decrease of $5 million in the fair value reflected in net income as a result of impairments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of April&#160;3, 2022 and January&#160;2, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $469 million and $520 million, classified as non-current other liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $17 million and $13 million classified as current liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of April&#160;3, 2022 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:25.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.373%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/( Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;2, 2022 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of April&#160;3, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;3, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.1311)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500 MM GBP 1.3485)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.1311)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.1311)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is 3.04%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $3.2 billion at January 2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of April&#160;3, 2022 includes $3.8&#160;billion of commercial paper which has a weighted average interest rate of 0.37% and a weighted average maturity of approximately three months.</span></div>Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263690232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal first quarters of 2022 and 2021 were 12.2% and 16.6%, respectively. This decrease in the consolidated tax rate is primarily due to lower income in higher tax jurisdictions, primarily in the U.S., compared to the same period in the prior year. This lower income in the first fiscal quarter of 2022 was caused by a mark to market adjustment to the Company&#8217;s investment portfolio and the impairment of the bermekimab AD IPR&amp;D (for further information see Note 3 of the Consolidated Financial Statements), both at the U.S. statutory rate. The impact of the income mix was partially offset by incremental tax costs directly related to the planned separation of the Company&#8217;s Consumer Health business.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also had tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal first quarters. Additionally, the Company&#8217;s effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal year 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of April&#160;3, 2022, the Company had approximately $3.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.  In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263747176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and Other Benefit Plans</a></td>
<td class="text">PENSIONS AND OTHER BENEFIT PLANS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"><tr><td style="width:1.0%"/><td style="width:45.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal three months ended April&#160;3, 2022, the Company contributed $29 million and $5 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263847432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,538)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263735624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.011%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.335%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,666.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. </span></div>The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;4, 2021 excluded 9&#160;million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263721928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business and Geographic Areas</a></td>
<td class="text">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA / INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1,2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In the fiscal first quarter of 2021, approximately $0.1&#160;billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Previously referred to as Medical Devices</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.251%"><tr><td style="width:1.0%"/><td style="width:53.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.1)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*Fiscal first quarter 2021 earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2022 and 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.8&#160;billion and $0.9&#160;billion in the fiscal first quarter of 2022 and 2021, respectively</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A loss of $0.4&#160;billion related to the change in the fair value of securities in the fiscal first quarter of 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2022 and 2021 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.3&#160;billion in both the fiscal first quarter of 2022 and 2021 </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest income/expense and general corporate income/expense. </span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.190%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,024&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263922072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">ACQUISITIONS AND DIVESTITURESThere were no material acquisitions in the fiscal first quarter of 2022. During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263828968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">LEGAL PROCEEDINGS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of  April&#160;3, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON&#8217;S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of April&#160;3, 2022, in the United States there were approximately 230 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 3,900 with respect to the PINNACLE Acetabular Cup System; 9,800 with respect to pelvic meshes; 8,600 with respect to RISPERDAL; 4,300 with respect to XARELTO; 40,400 with respect to body powders containing talc; 80 with respect to INVOKANA;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and 4,800 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. In March 2022, the Court appointed a barrister to prepare a written report and recommendation on the form and mechanism of the individual case assessment process, due by August 2022, with a court hearing on those findings later that month. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement is expected to be filed with the Court by May 2022. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The deadline for issuance of Individual Allocation amounts by the Special Master was March 2022. Plaintiffs requested an extension of the deadline. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of April 2022, there are approximately 105 active cases subject to these orders which are being reviewed and evaluated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Discovery is underway in the MCL proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp; Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No. ED 207476 (Mo. App.), reducing the overall award to  $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay, and also asked the New Jersey Bankruptcy Court for leave to pursue direct appeals to the Third Circuit Court of Appeals, which was granted. In April 2022, claimants filed a request with Third Circuit Court of Appeals to hear the case, and LTL filed its opposition to the request. While the New Jersey Bankruptcy Court&#8217;s order effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn as improperly voted. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#8217;s insurers (the Mediation Parties) have since agreed to engage in mediation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding). The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus adversary proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the stay applied to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs&#8217; motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. In February 2022, the Court granted Johnson &amp; Johnson&#8217;s cross motion to dismiss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In November 2021, at the Court&#8217;s request, the parties submitted supplemental briefing on Plaintiff&#8217;s motion for discovery. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MedTech</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#8217;200); 6,491,701 (&#8217;701); 6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); 8,620,473 (&#8217;473); 8,801,601 (&#8217;601); and 9,452,276 (&#8217;276) based on Auris&#8217; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;200, &#8217;056, &#8217;601 &#8217;701, &#8217;447, &#8217;276 and &#8217;906 patents. Intuitive subsequently dropped the &#8217;200, &#8217;473 and &#8217;701 patents from the suit. In December 2019, the USPTO instituted review of the &#8217;601 patent and denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;200, &#8217;447, &#8217;701 and &#8217;906 patents and denied review of the &#8217;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#8217;601 patent to be invalid. In March 2022, the U.S. Court of Appeals for the Federal Circuit affirmed the finding of invalidity of the &#8217;601 patent. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris has appealed that decision. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in January 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. Trial is scheduled to begin in December 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 and 10,517,583 (&#8217;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#8217;180 patent, and awarding damages in the amount of $20 million. DePuy is challenging the verdict in its post-trial motions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc. and Janssen Oncology, Inc. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#8217;310). The following generic drug companies are named defendants:  Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. No trial date has been set in this lawsuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Micro Labs Ltd. and Micro Labs USA Inc. (collectively, Micro) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In March 2022, the case against Micro was consolidated for all purposes, including trial, with the consolidated Delaware lawsuits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Parties Review with the United States Patent and Trademark Office, seeking to invalidate the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, Janssen Pharmaceuticals, Inc. (JPI), Bayer Intellectual Property GmbH and Bayer AG filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Changzhou Pharmaceutical Factory, which filed an ANDA seeking approval to market generic a version of XARELTO (10 mg, 15 mg, and 20 mg) before expiration of U.S. Patent No. 9,539,218 (&#8217;218). In this lawsuit, JPI, Bayer Intellectual Property GmbH and Bayer AG are seeking an order enjoining Changzhou from marketing its generic version of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVOKANA/INVOKAMET/INVOKAMET XR</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Janssen Pharmaceuticals, Inc., Janssen Research &amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET before expiration of MTPC&#8217;s United States Patent No. 7,943,788 (&#8217;788) relating to INVOKAMET. In this lawsuit, Janssen and MTPC are seeking an order enjoining DRL from marketing its generic version of INVOKAMET before the expiration of the &#8217;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR before expiration of MTPC&#8217;s United States Patent </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nos. 7,943,582 (&#8217;582) and/or 8,513,202 (&#8217;202) relating to INVOKAMET XR. In February 2022, the case was dismissed by stipulation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of INVOKANA before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA before the expiration of the relevant patents. The trial is scheduled to begin in August 2022. In February 2022, the case was discontinued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Trial against Sandoz concluded in February 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Trial against Apotex concluded in March 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg before the expiration of the &#8217;770 patent and Canadian Patent No. 2,621,273 (&#8217;273). In April 2022, the parties entered a confidential settlement agreement, and the case was discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of United States Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. A trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. The action has been consolidated with the November 2020 action for trial, which is scheduled to begin in July 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Trial is scheduled to begin in October 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. The trial is scheduled to begin in July 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SYMTUZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of United States Patent Nos. 10,039,718 (the &#8217;718 patent) and 10,786,518 (the &#8217;518 patent). Janssen is seeking an order enjoining Lupin from marketing its generic version of SYMTUZA before the expiration of the &#8217;718 and &#8217;518 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Other Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#8217; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#8217; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in responses to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment and directed entry of judgment for Defendants. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#8217; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of  $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and up to one-third of the all-in settlement is expected to be paid within the next 12 months, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022 and initial payments are set for July 2022. In April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are approximately 100 cases remaining post-settlement in various state courts. There are approximately 1,000 remaining federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.  By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted Johnson &amp; Johnson&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The Relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit, and the Relators&#8217; brief is due in May 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. Janssen&#8217;s motion to dismiss was denied in December 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for May 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. The Company is pursuing an appeal to the Supreme Court of California.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting and in January 2022, the Court granted plaintiff&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to enter into negotiations to determine if they would resolve their claims through the LTL Bankruptcy Case.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products, LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. This case was settled in March 2022, subject to Court approval. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022, subject to Court approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. This case was settled in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2022, defendants petitioned for rehearing en banc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. Discovery is ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for February 2023.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In March 2022, the Court granted preliminary approval of the settlement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263887592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">RESTRUCTURING<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal first quarter of 2022, the Company recorded a net pre-tax charge of $72 million, which is included on the following lines of the Consolidated Statement of Earnings, $70 million in restructuring, $16 million in cost of products sold and income of $14 million (from property sales) in other (income) expense, net. Total project costs of approximately $1.8 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.1 billion to $2.3 billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:32.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, April 3, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636265235352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#8217;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended April&#160;3, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New and Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal first quarter of 2022 that impacted the Company.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal first quarter of 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263834056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262564536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,960&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,468&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,147)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of April&#160;3, 2022 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at April 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262124120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2022 and 2021, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal first quarters ended in 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  April&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2022 and 2021: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"><tr><td style="width:1.0%"/><td style="width:32.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.454%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.127%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:25.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.464%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.667%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of April&#160;3, 2022 and January&#160;2, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $469 million and $520 million, classified as non-current other liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $17 million and $13 million classified as current liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.</span></div>           (6)    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of April&#160;3, 2022 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:25.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.373%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.016%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/( Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other sovereign securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available for Sale Securities Maturities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of April&#160;3, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial Liabilities not Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;3, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.1311)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500 MM GBP 1.3485)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.1311)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.1311)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263934248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"><tr><td style="width:1.0%"/><td style="width:45.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263896040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,538)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263900984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.011%"><tr><td style="width:1.0%"/><td style="width:69.982%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.335%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,666.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636350047048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Sales By Segment Of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA / INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1,2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In the fiscal first quarter of 2021, approximately $0.1&#160;billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Previously referred to as Medical Devices</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating Profit by Segment of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.251%"><tr><td style="width:1.0%"/><td style="width:53.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.891%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.1)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*Fiscal first quarter 2021 earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2022 and 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.8&#160;billion and $0.9&#160;billion in the fiscal first quarter of 2022 and 2021, respectively</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A loss of $0.4&#160;billion related to the change in the fair value of securities in the fiscal first quarter of 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2022 and 2021 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.3&#160;billion in both the fiscal first quarter of 2022 and 2021 </span></div>(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.190%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,024&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263904552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 03, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:32.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, April 3, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262454424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">2,629<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">6,682<span></span>
</td>
<td class="nump">6,508<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 10,990<span></span>
</td>
<td class="nump">$ 10,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636257547656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">$ 16,189<span></span>
</td>
<td class="nump">$ 16,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets - net</a></td>
<td class="nump">44,420<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">6,947<span></span>
</td>
<td class="nump">6,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased In-Process Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="nump">9,242<span></span>
</td>
<td class="nump">9,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">37,960<span></span>
</td>
<td class="nump">38,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(20,492)<span></span>
</td>
<td class="num">(20,088)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">17,468<span></span>
</td>
<td class="nump">18,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">22,910<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(12,147)<span></span>
</td>
<td class="num">(11,925)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">10,763<span></span>
</td>
<td class="nump">$ 11,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636264041896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill By Segment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 03, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">$ 35,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">34,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">9,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">9,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">10,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">10,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">14,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">$ 14,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262488744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636264920440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 03, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263981992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Accumulated other comprehensive income on derivatives, after tax</a></td>
<td class="num">$ (632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss', window );">Reclassification of foreign exchange contracts into earnings, period</a></td>
<td class="text">next 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Maximum length of time for hedge exposure</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate on non-current debt</a></td>
<td class="nump">3.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt', window );">Excess of the estimated fair value over the carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 4,297<span></span>
</td>
<td class="nump">3,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">0.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral already posted, aggregate fair value</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">42,500<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">37,400<span></span>
</td>
<td class="nump">37,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember', window );">Equity Investments without readily determinable value | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentImpairmentLoss', window );">Equity, fair value adjustment, impairment loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of fair value over carrying value of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfFairValueOverCarryingValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636256911688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="num">(531)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">33<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(307)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262198968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="nump">$ 1,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term Debt | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">9,313<span></span>
</td>
<td class="nump">9,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability</a></td>
<td class="num">$ (694)<span></span>
</td>
<td class="num">$ (142)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636368991464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636260390024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract | Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636262026776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 9,939<span></span>
</td>
<td class="nump">$ 10,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments with readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, beginning of period</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, end of period</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, beginning of period</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, end of period</a></td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636256173496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">$ 1,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">2,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">19,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">1,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(1,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,285)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total Net Asset</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total Gross Liabilities</a></td>
<td class="nump">2,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(2,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,855)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total Net Liabilities</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value (6)</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">2,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">19,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636256347608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">$ 19,583<span></span>
</td>
<td class="nump">$ 19,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">10,463<span></span>
</td>
<td class="nump">14,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">19,925<span></span>
</td>
<td class="nump">$ 17,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and current marketable securities, Carrying Amount</a></td>
<td class="nump">30,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss', window );">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue', window );">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</a></td>
<td class="nump">30,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">10,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">10,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">7,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">3,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Non-U.S. sovereign securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">3,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">1,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">1,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">19,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">19,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">3,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">16,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Non-U.S. sovereign securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">19,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">19,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 16,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636265551000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 03, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 19,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">19,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">19,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 19,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636253195752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 4,297<span></span>
</td>
<td class="nump">$ 3,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">28,851<span></span>
</td>
<td class="nump">$ 29,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">4,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">28,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">4,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 29,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1311)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1311) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.1311) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500 MM GBP 1.3485)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500 MM GBP 1.3485) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500 MM GBP 1.3485) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1311)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1311) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.1311) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1311)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1311) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.1311) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 2,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636350025336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Worldwide effective income tax rate (as a percent)</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="nump">16.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636260557800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(699)<span></span>
</td>
<td class="num">(680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636260492856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 03, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International retirement plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636260591992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 74,023<span></span>
</td>
<td class="nump">$ 63,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(699)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">74,709<span></span>
</td>
<td class="nump">65,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Foreign Currency Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(10,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(10,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Investment Gain (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(2,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(2,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(13,058)<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(699)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (13,757)<span></span>
</td>
<td class="num">$ (15,328)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636265272776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings per share</a></td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding &#8212; basic</a></td>
<td class="nump">2,629.2<span></span>
</td>
<td class="nump">2,631.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Potential shares exercisable under stock option plans</a></td>
<td class="nump">140.1<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares which could be repurchased under treasury stock method</a></td>
<td class="num">(102.8)<span></span>
</td>
<td class="num">(87.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding &#8212; diluted</a></td>
<td class="nump">2,666.5<span></span>
</td>
<td class="nump">2,672.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share</a></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636244069096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 23,426<span></span>
</td>
<td class="nump">$ 22,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 11,414<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 12,012<span></span>
</td>
<td class="nump">11,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,586<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,557<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,029<span></span>
</td>
<td class="nump">2,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | OTC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,461<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | OTC [Member] | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 670<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | OTC [Member] | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 791<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Skin Health/Beauty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Skin Health/Beauty | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Skin Health/Beauty | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Oral Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Oral Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Oral Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Baby Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Baby Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Baby Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Women's Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Women's Health | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Women's Health | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Wound Care/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Wound Care/Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Wound Care/Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 12,869<span></span>
</td>
<td class="nump">12,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,632<span></span>
</td>
<td class="nump">6,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,237<span></span>
</td>
<td class="nump">5,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 4,119<span></span>
</td>
<td class="nump">3,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,501<span></span>
</td>
<td class="nump">2,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,617<span></span>
</td>
<td class="nump">1,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(26.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE | U.S. Exports</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">40.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,288<span></span>
</td>
<td class="nump">2,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,379<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 909<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">41.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">42.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">38.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(22.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,297<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 461<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">72.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 457<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(24.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19 | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 382<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 501<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(20.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES(</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(62.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,741<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 898<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(26.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 661<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 387<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(17.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(26.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">25.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,950<span></span>
</td>
<td class="nump">3,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,582<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,369<span></span>
</td>
<td class="nump">2,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,856<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 953<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">37.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 903<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,038<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(16.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 668<span></span>
</td>
<td class="nump">680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 539<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(62.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(35.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">63.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(47.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 572<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 269<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(20.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(29.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 910<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 672<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(13.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(13.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(30.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,971<span></span>
</td>
<td class="nump">6,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,225<span></span>
</td>
<td class="nump">3,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,746<span></span>
</td>
<td class="nump">3,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">15.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Interventional Solutions | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Interventional Solutions | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">16.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,188<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 899<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | HIPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | HIPS | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | HIPS | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | KNEES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | KNEES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | KNEES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | TRAUMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | TRAUMA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | TRAUMA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | SPINE, SPORTS &amp; OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | SPINE, SPORTS &amp; OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 387<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | SPINE, SPORTS &amp; OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,434<span></span>
</td>
<td class="nump">2,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,513<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | ADVANCED</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,146<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | ADVANCED | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | ADVANCED | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | GENERAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | GENERAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 504<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | GENERAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 784<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,257<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 521<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 736<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | CONTACT LENSES / OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 910<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | CONTACT LENSES / OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | CONTACT LENSES / OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 511<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | SURGICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | SURGICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | SURGICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember', window );">CONSUMER HEALTH and PHARMACEUTICAL [Member] | OTC [Member] | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ERLEADAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ERLEADAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINEOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINEOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636256110024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Worldwide income before tax</a></td>
<td class="nump">$ 5,862<span></span>
</td>
<td class="nump">$ 7,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(21.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_AmountPrepaidAndDueToManufacturers', window );">Amount prepaid and due to manufacturers</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">In-process research and development expense</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 6,087<span></span>
</td>
<td class="nump">7,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(20.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CONSUMER HEALTH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(18.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 3,924<span></span>
</td>
<td class="nump">5,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(24.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on disposition of assets</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Unrealized gain (loss) on securities</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">1,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(9.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AmountPrepaidAndDueToManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Prepaid and Due to Manufacturers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AmountPrepaidAndDueToManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in operating income loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636256146424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 23,426<span></span>
</td>
<td class="nump">$ 22,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 11,414<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 6,024<span></span>
</td>
<td class="nump">5,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">11.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember', window );">Western Hemisphere, excluding U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 1,482<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember', window );">Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="nump">$ 4,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesByGeographicArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by geographic area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesByGeographicArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636263924312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_EvraAndDoxilMember', window );">Evra and Doxil</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on disposition of assets</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_EvraAndDoxilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_EvraAndDoxilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636253524808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 03, 2022 </div>
<div>claimant </div>
<div>claim </div>
<div>patient </div>
<div>cases</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>cases</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>cases </div>
<div>claimant</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">XARELTO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_InvokanaMember', window );">Invokana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpioidMember', window );">Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember', window );">Contact Lenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss', window );">Loss contingency, estimate of additional possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement', window );">Number of claims within settlement agreement | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LossContingencyReserveEstablishedWithinTrust', window );">Reserve established | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Judicial Ruling | Damages from Product Defects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Litigation contingency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember', window );">Surgical Mesh Products Marketing | Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember', window );">Surgical Mesh Products Marketing | Judicial Ruling | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="nump">$ 302.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalProceedingTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal Proceeding Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalProceedingTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Additional Possible Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyEstimateOfAdditionalPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Claims within Settlement Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyReserveEstablishedWithinTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reserve Established within Trust</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyReserveEstablishedWithinTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_InvokanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_InvokanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpioidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpioidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ContactLensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636257524248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring charges recorded to date</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostExpectedFutureSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Future Savings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostExpectedFutureSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140636256748200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Reserve (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Apr. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech | Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech | Asset Write-offs/Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PaymentsForRestructuringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Restructuring, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PaymentsForRestructuringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>jnj-20220403_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20220403"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20220403.xsd" xlink:type="simple"/>
    <context id="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie1bfbdd2721a47c78e496b6496fc1e14_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ied996a6da7cf4f25bd1d614be305c4fc_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i902d46a64ed041188ea441b2e02dd66d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2fc9d571951142629fdd9f5cbbd77efa_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i58cd890282c34ce19a979c568d6b2d2e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibc6c7e3c97b04a4c81417695c15b5102_I20220422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-04-22</instant>
        </period>
    </context>
    <context id="i2e490e1b4676470caee65dbdb296781b_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="if6d5ec7bb88b49bb9225ff6447a06091_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i92abad263bf8419daa6c3d10a1e69673_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2336cd90b8e74beeb66f460bec6b6238_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic266b1b5dc484c669aed5ae886e3f910_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i39899651e6354f279c457a156b59b4a6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ifb5ba76506ab44498ae6e4962d624eae_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8f1bd088462748abb8bf782cfcc07129_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifbe0f983eea14da3b437dcf18bfa144b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i225ea33e8dbf48579d422823c0350b4f_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i795ff92791494382a1d26a7b84fee3e5_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ib230b0f5235943ff892ee51f02112200_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="if7dd50adc00246e78b4d70267adf860f_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iccce36176b41451cb72ade5fd7acd620_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="idab9077c64f34317815b7b3af8096958_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="idc5b2d28a80e44d9bdcda5d265440506_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i73bff5df510141c6acab233c801c6f0b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i333b166f4d2f445f9cd585f8eb2f1c02_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ifeeeea464c1645cf8c4b046709808f46_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6e4b855ab6e9400da78a4a7e4118d0c0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ifcd4bbc39e1a4259935490333ab02382_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib4ebcce5ed4d4fa88b1380565ad0cd2f_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i613a24ca8cd34aaf87209b0ce754c9a4_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i8f965bb993c84e458df2a90932f7f838_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i5d6448f96ad7486da2e84f5da3d3c578_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="id4dc0429231c4601861ff53b097feae5_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i7c14471cebb545af9f344092e43e244d_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i751430dc512846d6bd038f8d3e545317_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8427fded54d64f59a314115c202ccb4b_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i2ca6e4c72b3b411e8e7e9c40313e1011_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i631a68382dbe4356a80463ddeb81e9e7_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ifbab423fd5014e1482bba4a9327c8dc4_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i97cbf7df6c0c4273a06533b0d3e5c206_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic60ed3f5f8b143f28c600b4ef6f83731_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i754795b41ad945a7ac5ecd6f2ea1cbe2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i273a2ba53146449c8a18b08bc38532ee_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i706befc122c24b74b7c46cad04eefa00_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6ac3910bc9284705b8c0311e059b8e26_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id6fe7c6e2f574a619178fc635b10b3b2_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic00ca16d24bf44179d8fcf374cbf27d7_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i681532a4eb3648508653f9fb60ec8408_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i9b8fe868a0e94657aceaf9efda5d051e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4bcace6a0596406b8dd0416cfb063a83_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2d4870c963ef433abc7a4fea5eba6e84_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i0a8ab9973a5e462d9e057abf51bcf297_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i5eadcdc996d94731b0bc1014ca9e7fd0_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic315dcf608444a39b1cabd079a7d46cb_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7bdcc356986e4b3e80fe4abf6ec3b52c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i07dd6b6cd781421abf5b7b35627e6b59_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i75b7f48faa4c44dd8729fef7add9958e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i19d4778b3c184c5b9a1268b12772f834_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifab697ff2c9043c0af2d3551559c5cc6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if7ca621269f74333bfcea41317eb612d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic2ef606fc8d54064ac6785b084df413c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibc4d7ef218294617ab67cdd7ff8ae201_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i285862bf68fe4a1e9a5f16fb54ec99bb_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i50372bc3c1fc4262a02f85583b8add01_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ide7dc652d8a14e07b4a76aeb7b9c4d21_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib13b350d42d74d879d6f63915693746c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6fbe2ddfa5bd4c3c81d6b1a89bd6a3c6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if6710a293c7049a89bd678b9ebf357ee_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic8c65dce193b4085ac9029e9479cc836_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4612c0bb5e5643f0995c9a09afdf8c41_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ica35e7e4a05a4bf1ae3566e17b66227a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id3a21486e41041aea8b93609d24e888e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id5125127475344a8bec0db5ebc5cba0d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i24069a0bb5314816b75b91710ef6fb4f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1fb4260113ae447a8ac220acba4cae35_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1dd707f3f168499dbac4bc8fb516087e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i35c1225f1fc642b89ce27325e2764fe6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1ca0c41746e24c10a5010f5e3b375875_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i906bc2f6d0734e46a265b998dfb78e1f_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic3a7b113cd604b97b6359f1ca89f88e9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iac181bd434134d0f99d2723052ebb78c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i98498dc117454edda8260632bcf14b3e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icc1a147f22b444088512ccac59a70251_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i629d4c6fdf6e40a39dfb7d01c00f6bbc_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icc4edbfa092a4db08c3097d31dfde751_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5358dcc8f8d448188a6577bca61d7df2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i25e8ee39318f4e8b8637328665ee6121_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9976c768bbec41ceb31dd3e5aeee895b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifa0acd8032704810ac6c33c652bb3f4a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i86deefadb42a48e9bb9ba37613cdc416_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i096bbfc984b74afe83163ab74df3e9c9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iae4da99d4bba480d99292b2891dc32d9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i200c16a786fd4d0d8795c1fc3f58843c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5d4939c05de24312b1d31bf71b02fe56_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i65442762e5c14bc1abd1248fe23d8341_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2c04b36d74874be78fc77e16c8fb290e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i92ed1d2317744e2fbc2c3b45e1b4d2e2_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic66d9ac41ee14e4f935d98d0f8036683_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0dc14e7b1e2e4a29877dd2b95650a3ac_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ice21f8d2655e4d0f8095be5911f1fd8b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2a4f1c2e35354c268ad4b4f0c299f46c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibe06a04b32f541198cc74c4294d74b7e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i58ce73a23c814452a90b72fe868271de_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i977c041569204263b24ecc0054d30d6f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i581046ca0e0f48929501b5a10dbaba2f_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i645a971a555b4c089758583b67f9d08c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6f4dbad0006c47f48dad1e81741750fc_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic3823718f66a4b499cedb42d987cd246_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if80323310c7943d89e72028b427412c1_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iaf02920ebc8f4f46a0a1307481df3c99_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i195975cd0e7f446da43714458700190f_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i33f60cf5f7ad40df935bf2a4865220fc_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic8a3783f757347e6a884c99fba04723c_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i05510e5c3ec344fca7b25f4799ad39c6_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7ee07eab57304c94a3dfcb3ae7fbee1e_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i40143a9bc0fb45f6989738a947b0838e_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ia2b3a8c85a4a4df28a3c6f3b7f5df006_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iad75e5d7a8d640fc9b410ca0e00b1a1a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i423527772d4f4352be8af130cdc45743_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5e32e93333a24edd846ce09ab84c19ef_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i40bc079e1bf040d6a6c8095e02268b3f_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="id2153712ae1a485ab5669a52af66f1b4_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i144bd07273654fd298013a92e5d0b27f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i37485b7a6e8c4c1689bb2f8982088f64_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i59607f6cdca645209d4015cb4e2f5619_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="idc5cdf7b3948454394fae9e0a5c60184_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib5aed6e544644ac091fcfd4f67609c7d_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i68a4afb3d1574ea6841481a8c54e0b66_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i32a07094db884448a992148a352debab_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="id4d06754ef7e4c02b339a96da42f23d6_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i58c2d2898cff43b78e1d5e6035922a00_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="idefc9360cf7d4a84871e4e4fd6c66079_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i612d93e077824654b25097d940711e0c_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="if17e9a78d65144cabf6d0224cea88596_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic0abb325296848eab35197c32673d301_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i40df713ca2794a8f8f08885f6d2c8143_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i98b0e360214949eebb51638497d0ec18_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i80cc25f225c142c9b2e51f9cc136f5e5_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i574a41416f664b5a90a57869a7b69d04_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i10a6f23182d14a35bc979be835d03213_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic03f9d9c139545c6bf756b9af8dd04ce_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic97fa957218749a5b2bbde6c2237328b_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i88fb397aabc74f9d9919879a38532a66_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ibb107f40561b447d8a9bf98e62f3c54e_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i3d1cab1bb8af45f486a55147f5bdbe07_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iafb5c763b5bb45f899c132bc31626b95_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i11c666c963c647308254b695cefee498_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i4ced426dcbd04d1f98029e772acf4b64_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i53b54bd64a574cf0ae8d1e57ec0bc8c6_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i8afc02d95284431197455ed2c01e0b02_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i1774beb33cd94056b250899436621d79_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ia9905446b33e44249abeae66f95c5b42_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic8f3e5d7909e4521b088bd43ea9303f3_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="idb2b18369ff14783885a3ab5d402b053_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i410644799f39419bbcdf5b89613bbc9b_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i4cf0299af0124017b184f3378b2e8260_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i6d410447a42f4d80ad241f38be44e316_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i02c9f5cae6f44540a89c680000306ed9_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic108a9e12f3341939ea27c4f85b55d98_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i14b3ec03d9234219b5bd925a86a41790_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic66945fc64dc4dd2b97e6ae77585e006_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i22df2c32fde24c49ad70d6267b39461c_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i73b4ecb878554ed895e6731af84a2410_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iec5b6d69f26346649c425f8e2933241b_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ib3ae7da6e5e348d3bfd658d212535274_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ia4fd353404164731a511e7927bec85a8_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i92d34c20152a4de3a3f77d8cb010b8de_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i9b80c19de72d40139ee47e1d21a6e42a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i56414cfcd9cc49dd995d25343ea06a1c_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iafde104933164c4cad0deb69abac440e_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="idf01842c5cf54c898543482c4a444521_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i3bbe50e67f15448d8798dfde818d59e8_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic4d10d54d1af41b08272b793afbde882_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i1ed4cca79f874285afd96939684875d4_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i253bb8f802eb4367b1f601f0eb271aa8_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="id79227d6ca8e47c096d1f5db54292e11_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i26657c8981ae46e79d22c832389a2403_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ie9b9d5f07bc14a4ea1751fd21547dfb0_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i050bb5d8583f4db5b7cab1781f41402a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i98f5927fb8dc474187a16c8bb7a8f633_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ia0640760a4d046fdb9b6672981624f0a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic7815fcc60b846c4bd4ae4cf64f6a1f5_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i6ee6a13418e74e9f97b7fce4de45eee6_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i4a7cb32255274ae599a981a6313a0d95_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i56cae7f5eeee4fc995a14d122519fdf4_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ice21280ebab242638498d336fcf84a9c_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i25f1dd3b92e340df9e2c6814f388f614_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ifc07bbbd134548d4bab1577bebc273ed_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ic9c6f72bf20e4383ba64ecbe3c4bd15b_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i3a714f2428ce4aba8dc71a3ce15cc543_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i2c824e2faeb34de8b822a2f57f817f25_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i2f54a6d9c9f2407397bc4616bc6e7af9_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i7ca5c18e09944b9b8a34ad2546775220_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ifdd4fbd384b84fd3a0d6693ec4c9c252_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i89b2afac7f2047619163d4ced5060322_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="idb79658f5f2d475486e1d306a4118a47_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="idb22c0fec5c4490384df777e042c7c81_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i52075d97746b4d90bea9272a17635cd9_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ia51b7240c69e498bbd44aa9775d04606_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ice9f99b199274666b12ae2df91d2c820_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i67077af31f114a30bffdc32fea20dfff_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i188f32b459e74d5cb0f963e4e0a3f7ed_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ie3ca814e494941cc9558570cc4279cea_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i44982952c49f4e749aabaf9dcdbec1dc_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i07b685ecce1643ff89bfb3895523a51e_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ibea8fdb3616f451c90baf65707bdf669_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i08457c1d48c94eff8dc2ac47bdf0c7b5_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i5fe81741fd58415cb3509d83ffdc5e73_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i6c1d9e65495e4ece85762fec2639f5dd_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i12629c9f73b74eff9c5a235f547f2241_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i3970f29929a24eacb55a58c7e37c52c1_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i3a3af18d0134471c93564e5fd5f3fe0e_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i5a1c7715113b48dcbff2dfe6536eb602_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i3ec5bcf102a34a1b87cf004f535337de_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i6885bfb3e4984c65abbb4580fc179cba_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="if4d3a223ac884f86b9a206b4617aa103_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="id914def5ea98451bbfd52ec51a11e6d4_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iededfd7a59eb43208e3672b72a308066_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ia4f9a83e7716457aa17dcab50434530a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i3a3f9d6c591e4c379b03f6a63223ff4c_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iffc2dad290bf4b1f84e0014e807f7d22_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="idfe07c4d0ab547cf987486709e3723ea_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i9a3fd14bab994cb2b98c874567c9124a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="idb0087669f7d433a94c2175b61948c30_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ia7ae03e86ec34f059e03de3ba7a0fa16_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i7525d9cf9c7a4c2eb64364d6f1fe110a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ife167dfbe51e4f7bba2d6c116e0acbe8_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i6724f9eb2f284a7897adfe49ccf0a1bc_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i7e6d608431ea4c5398a0d5693ec02ce7_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ia1fb99008d5c46f782ebe421c09b6c86_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i809a6e12d5804dfb8ab4ace60751a5d4_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ia20a226df1534401beb4ebac52ca168e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i64bc3e5d158d4182ad9506d5f1a6e623_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i02143dea06fb4fbbba003f6bb1395472_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i371566e0803142cea79b2a73e447ad55_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ieb12711ae25c499293d55bef830a1392_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ifd9afdfa4aab43f5aec11564a7a210ec_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9d981e7841b2446e99bdfd3c1765f8fd_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i655ff821171a4447a9788502f3181ca5_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i79fbbc6f7a9f4234af3a15aaeeaba82e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ieb1f6b66a0df4ab5a5db2bb2552e5b52_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3b3c368d3ea94156894bb15d205cbe39_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id04f969ee3dd48eb9bd1be04f519efba_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie1fcea51f4fa46ea9140cbab41a14eb8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia9ab2638f2434165b9cb7a98bca9725c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i036b309881ec46189aa9470289afa49d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i68eb55b964054c96a96b26b18621d7fd_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i326f78b1620b461cb2172429271e8699_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i49a97e3323484686a9262c40ba0b98ce_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i579a8661a8a943369207a48d2742c946_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ie58211c7e72c4650b6392f3161a3bffe_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="idc118b408a9a4fa0a2216582ec2c57d3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iea43f39e6f7e4722a355ac665f3270c0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i59a68fc6f7f84ab9bd6670bd40be776f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i822f34b9534c4b36800cd53b915bfd96_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i04e49973bd224b328cb521a49bd33c14_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7cc09b5880e446b6b7704ca8b8c71bf9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="icebf6d8f73bf4c99a24334b6c6b70834_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0d1e565782ba4f77b615f220541630b5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8572638eba1747738bf792b8ccc0d65b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i106a09af4412484ab101b4dff6f6060a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i30c0af8ca15849f8888a804c0a76e8f5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1cfa95d8a78b40e4a7dfc45c287e5d8a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i08c6944ea87e4a3dafff3f45a308061f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i46c50a0f6783436cb25640408523922e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2e793e0192504c92a6fb0cb90815740a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i908ec40014fe4b879088ba1b344b5a37_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie3aa331b4f344986bd6aefd2d877917a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4c161740da694af9a2557994290040f0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8b056bd57be1420eb472b82a9ad65490_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9cd2d0c278fd4ccb9e5f826f44c15a6b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifdd5fd3ed29041aeba59bb41d9957e8e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i43ceb1cef02743f1b6c9be2aa05040b3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4acd3aa5bee74304878a6f9cbf1956ec_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie77366e1975a48bd8912cb5972f077ca_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i45ceadbf51b24faa9f04ba01b0a27b54_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4d4e3ae4eef749e986b5c6bd8d739748_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i84d71c2b7b4544b1a58237715b2b3c42_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i678bfbf7014e416f8aa38a66f366d4be_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib688bd3f296d41f0b14572e3064b458d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia4627a516050411dbd08c0de6091128b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9d275cd215484120b60ac1c7626e17a7_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i932bcfc6315d438f826521020670f715_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7411eebec7264351bf377981afe68c71_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i41f0f05017af45e3863ccf8b056567cb_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2c3d886ec05249aab4e1f0ce7760f1c8_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7a5159ea7ea34a9486f467d8b275261c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1b965aef16c049ca90d08a094faafdcd_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6cbacfe0de454d4fa786ace56cada354_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3dd509ce95fe400781462e4ad6cfa01f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1d4fd750dd7840a1bd8f81d424809f1a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iac6c831f375741cd86628f708528bbc4_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i378ba8c96ec94703a6594ef190bcf501_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i770e070317374dd9bbc2d03a76164315_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id00933be305c4a70bc5ab93fcafbfa34_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i30ecdf550ad642faad28a0a3da3a0c49_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic914d835318f4ac59e6afec0dc209943_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9ea83d16b7bb4bb4852dde662d6d8a03_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i355c4b8323c94982a0e7d8ad5ef02138_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id5fe9781715b43f6b43d02d8a29fdd61_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib1de5e9029e04a3088baa1a08b8ee842_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i919b94882de1475288644c1f41c738db_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id74ae7d88be64d3c866359475a6b9e4d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i64b27662b65c465dbfc102823591a764_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i275f4a59164a4f3cb58fd6b37c979201_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9d196ab07bb74237905594d14817fae6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iea6e2e05dd264470bda927b1746471f2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5baa35e48631478bb99da941854cbc28_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i5218805bf34a4f8f9bca9cd6f32c57b2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3f43191ea7584ff5a4538caed79690b3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i80675b68ae0443c09f1f157dcafd38b5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9d5eb90c90324a6c99251bc1ef4cd0b0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8a3a53a0ad9046aca93e6a7542cd2283_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3bae0a6534fb41dfa209ab28eb17aac8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifbb41835a7214d6cbbc92d58157fea67_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7211490fa1584a8e8f0474626afbda8b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if075bf0d83ea40f880b89b7f1b810a39_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6904e2c80904427fb7a581c5096e57a2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="icb39ed1f03bf4875b56192f82a2d67c8_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8f8d1cf7d44f47e6b575833e5e6f0d05_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iff32341c0bbe4b5ea9b566ba153fbf51_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i11ac62a4e6cb4f948252748f571a1ff6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iab0aa5e7ee2b48aba645333335c83702_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9efb7452eea34bc9898890c0842597d0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1665d864d98a4d47962732594b5b38f9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ifc4d03da8ff94f98aab51935db754a84_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ieb131415d3694db89b4c3cc631aebfad_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i04b92c4c34a94ef0a8c83ea08eee3b04_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i05d97f7b5e9e411796b79b2aed308f49_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ifd4c0bdbeb7e481486ce84464add9cec_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if8f65547983b48f38c56effa03744e71_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i42a180a67aa34f04985a9c36da5181f4_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i726bc4433398439cae78ea7e13f10dd7_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic26e429353e64268acab78bb090eb6ee_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i41cfcf4ec4d349ac965bd4f72a911528_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8d87460fbbce401e9e230c449de32a04_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7518353c94d148b98920a57e3c13f558_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i72f3a3fff4b64c42b7391f6783fc86d0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i283ab968a33a4019bbca8dd07bb73fb5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icbe04729f6a041dcbcc8950cffbd70ad_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1d850d220f25461faec903dbc0514f8c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0520f0e2ba8d45dbbb23db3edcb3b1ec_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id9fba2a4e93645948a9ff0513bb728e3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i78f85b561077441a8f29c95efc82e1ff_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="idb33e483487440ffb0cfd196244dae1e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic2104212889d4866a172b2ffa3412b5b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i69d54355525c45a48dcc9d5a2c07b492_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic73699a20bfe4592ab11597b967e3e81_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i43632776d7d241d6acebca744803b602_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie8041af648d74844acd07d971cac9b88_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3003caab41114b89887d780481856b8f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ieefaab0fe06d4a1d8825a8a2912d415d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1c1c0146fd1e40afb97e83e53dac0b3c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i113143b999484cd6b7094f5ffb7f6934_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if6df7baa0a5740ee8592ff53dd67a1be_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4dc562abb9fc439a87f2465b603dc878_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie870e747ed874ff9a84adcffcef46376_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i23204760220240d9910ea175d94d29aa_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i337ee039b35a4dd29e3fda93f8888073_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i060264da9f6d465d94d5b31aa47981f0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i5e6a826272dc41a88d80ad0ce8b56bc4_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i26d3e119c5794d36acde2361b37d9315_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i371b019e1643431bbc3c4121387c7e9f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3d4ebc5182ee44909c1d020a6781ee9b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ide5e99b0b04b4efeaf8272a60bfe9724_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1470034f0eb141a98c1afe534e4076cd_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i37a067e9da7f41b8a982801bb0a850bf_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0dcdb3a4cc9d45ba8da97ec07cd15b51_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibf27b40739cc4a25b5ec694c5b8c000a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4b61e2b815e447c49c894f30ace4c7a6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifaa838e3db72457496cc39435fbf78f1_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic91a06bb3ee246aa9b6beeac53b5b676_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie69adf3622ff4db8a081d1405d03154b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib8b076947d8349c4991ca5f8d983bb95_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic57498e999f848169b4085103b58e794_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie49109641ba840d7ab935c9251557fcc_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie4d7ac479b54426c9c4da3f1551137ba_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i80e016b979bf4274a83e021809fededc_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i04a88fda6b614cf0bc0a0b4fcc001282_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2982a107598a4da5a6e1a03aedec047e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib1e34ced22b4405fbd24f5ec2c767132_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ide41d96049794347b667732daaad5f29_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ice792ebb5db345a282d8d06424353702_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i46ba5f0fbf984535b145a1eb04807f5a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2d2ba44f06524718a59342b7ecc0be0a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ibd97dd4e710848aa948f66ce61e79d4e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i756b031800b74f1088dc4e2c1b95636e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i002baa7993ed4772b35c50223b4dcc36_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic38731cd692a4b1c87ff4416775e7a6d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2b7974a50c1c4182af2999542e8fdf1d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8e49e3349adb4e589300bc5c59272da4_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9457829763fe4b90be78ca6d38abd305_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9eaa50ccd6ea42d1be79c5484c2037fa_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie4a95b9177eb4a48b5fd6f019f635f7c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifd9a1c9e24cc4521a4e8fd258ab91323_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7caf84ee3bdf4518b4c9c4166e4f8887_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib49af7ebdc1b4c46b17b462113ef14c1_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i602a6924da2441d3ab9cf85ee12fbb06_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3dc426c53b2a430092d248e6084cd03e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iaf7d6e57e38d42b4b47bd10b91df04e7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7798838f313f4f9e83d9c4854b30c499_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idff12de1146540caa7c4f80581344a74_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia86c98d81e2a4e789e3c6e3880743868_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1acbda17e2e04d3f9f18cad52f4e5d80_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if25efb856b06413aacf054618e7f99bd_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6b5a6d2f7e6f47649ada40e475d62200_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia56ec1f9700b4dec9314c88e00ec7a74_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i03297ccd7c91439abd458f48a7b57605_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i33e589a7b70e4b8c9ec8c56de960196c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i92068e5088f447999d216d73ce8cdb46_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9791432463c54215891a18b29d7d056c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1074a5e410494804aa84259fe458782f_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1fadc8348894481296db094bdc2eda3c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8d635d3f096e49c9b21f9616e12851e5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic28be830ce4b48dcb3d8a7b426fae4d6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i379186cc31f04dbb9749d2943a0e1ed9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ida711057f67c47f1b72ad683127c4a91_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="if5cb6c1da36a4a4d8766dfa0e1727ff5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6c47976576a747deb5a1820cec87eb07_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i802b2a8cc9be4de697db22398b60df0e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i5df3d2e7456f46cd95f6b08a1c33601d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ibc87f78159374d8bbc9c762e4102e794_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if926194c123b420385c4516a85ca9777_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7d59f0918fbc414a8a87e6ccf2473d9b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id48f03c674f5473cb05d01f5147b5df3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3fb5e19b994341e19c1180af2eb7b115_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2bea0dc705a44771a477c405cdd10da9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="iadbad500e92547ec9a836181ccd9e6c3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9e6d7f1b310549b0a446ef5d8d0aaea2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6498d554bec346f290453c23da02bd60_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibb99ff4ae20743c7b4a1bc974a427a75_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie79b08d56cce40828e2c38bf848ff8fd_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i52cdeb0271e2486999508f7150d31fe2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="if7068d970c8e44a1ab1a0f2f2c4db613_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i5887b0c29a144ebaa712e90100c41c32_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i08831d99e88b4248b1d03a755ae3c76b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6b566c9ea6ee4374bb5e2d126e55db93_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i55dd11d66bb94525afadc67611182a00_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i62a96b70190a426784c40cbc850a392d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i26fe8d48a8184400b9c1e5dce618bf41_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8ca7c88cc02d4eaf88560c8548ee94ef_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0812afd8e2b348de81fda97685ddef59_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7bf731f09e014c3d94757d58a2be8657_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6c940a55fb57493188d86966342836e0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3b96b154e0074943b4b122886b03054d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i787149c50a1840428285fe2906bb98f1_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if3a0ca8ea65246758d0aea04a19962b9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ife5cdc6b13e543ce8b0e1c2f9ffa25d3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8a5a3f74e1d54099823fc731564879ce_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5c342b6c1941447a8365ead0b83ea272_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="idc76581373f04f5aa51d38fcdda40da3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie045af3f8e52486eb07c7ba39e98e056_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i0e8eea6eeee44e8a8748c5f8411ca6a8_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i658cc2fee1f04efda949f70dfc908648_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1105c10c9a2445a198e98e2af0ac9d83_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i3dadb8ca74864bdda389d9aa76f05723_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3d7e2f6cd3d9401f9fda49c75afe417f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i21f9118b127a41df8281a7b4b70328ed_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6b44f394b70346ee9c246aae215158bd_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic62dc76763e348cbba7e08433976fac4_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9c091791d85f44618179b9d279f48c9f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ibd9e9d0ec3a546c8a723d87323ac7ab7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i68a1e608de7843568d26a9b8fe5ffb43_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="id3fe1671e59d4c6a8a3250a87dd2e2cb_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7f402cf66c9c43bf9d8b0155d69da95c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i29def461faf7492f917e166e064b38d4_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia0686bf4a5394db3864d38ab25d077e9_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i153a273ca54c4800aa20e3895cc837ed_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1154bb4afd9247c784b55466aae7d770_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icf0009ecb1334c43a265b7735989172d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i857d98c87ac0445e9582504c037c4449_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8de874f946f841458bbfbdc60ac530c4_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i62ddb318fec741089c74f936f4d258c0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i74673f6468f34983ba990177525051f9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4f7260c372bc4cd69cc06c643d11c56c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i2ea854374a484fe38540c4f8a7470fe9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2ebe25dea81647f0a7c2f6f7eaaa9f12_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0f54f96121d4454b850945a4950be020_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1dd9e58933a04c87b85bedb0a3a11e3a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia5388243b1444a0197156f13c035f594_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ibf14c9d52f00401b9b7af8c1eaaf40a2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2555b2153a3248ee8fd4e5f32f461af3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic5167453e1314559964afd83c4a97121_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i94504e48d701461ab9ef57de03631801_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icd9d91209813438cb5425bacbb2957d7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i49cc1963139e40a48ba54590e9d558c2_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic37a5f0e1b4645c18d5404587f248c4e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i71825d51651b4f4c94dc7432c265826b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i26c03d0211654555ae2faaa6bfbef7f0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib8b09f0f2d404dcb90ab77349fb4e6d6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i94c393b101be4a43a6732a4be31c57aa_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i41cc552be0964064ae3332e0d4c7ef8d_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="if4de0d5ad9f549948fe05ce4c2e25b4a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i83221080ad384b21800f5cd10f1c9fbc_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9a9d112bcae04f66b84e47128a5cc21f_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i52f9480fa6a64211bbaffb8bf7069aa5_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8ec92e1bd5064846ace07af1534211f5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i761be9058b0d43bf94db251536405133_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i6eddee4e37b042bc9c060f40341f10dd_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i5cd8fd20f19644798d62ca131883fb7b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4b87a33ea414436bb9dad4941879ae83_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie8bb59b5b9cf4f78a4e291ae63400ced_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icd947e6c419b48a4bda0b804eeafe4d6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="icd983febe9574fdfabf56cea42386e21_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ifc8fed7991104862922245840fbbb6d8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ieaa59186f7b14958a9b1c02f519eb369_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ie4bf77c080c34fcb8c7da93917014ef3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia86e1d075b324aada06b3181f83ab15c_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i372a0801e4354df09390de4a1bc1fe8a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2b4bbabb621c4b65a1340f25f3b79d25_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i505f40abf9134ef195fcf3699c50574e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i99e6f27a9bec4c019c8c57696e6bf1e8_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ifa62410b761147768b8c6e1d72541097_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia8060def9fa5447d9f08d7bf2126beb6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4b9dff4050ad4ec1ad3383f53e178b09_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i402913e98e314dc99d1428cd761b3db0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="icd2bfa4745e2435c84b3ff4622725d92_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i34166c04357b40ca861f436c846dbdc3_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ib41d736c9cbf4af88635765f2162af86_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ica1e5574642c4970ac6c5731d2f54fcb_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i736971e06954421791a102526ef927cc_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i462f6596d7e54be4b09bd4bcb7c18bad_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i73eef6d7fd9b4dd2b5426cfa7104e199_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i865bbce87767495d83951aa8eb044329_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia9ef4bc104ab4018b38aa4cdf80cf5a7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i479f5df29cba41dd8ba610461abe4e2e_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5794644b54414f8eaa877a9f828a6f9c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i24a4d5dee1ac4cf28da4e534b4453f02_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic3342c6f86e341f5ab416482e21b984c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie4b1e669d8404534b72479a0f4e7a968_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4b56dc097e104e6a9d6bf065e10288ee_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibb28ec2e8cc243329eac4eaf64db5f0f_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5082af2c38dc4e9b94951ce99a46799d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6d44704539114f25b07e12eb55564a99_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i8f23f5841b48406ab8cda610d6c44c21_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if956dbb8930a4658bd499404ec02618a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9a91d5d2384349c3b9f8ba37ce939f63_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i976cfa9383c14f68936e4add9e92c113_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i45d224b06bb144ad871048ad6fc1df0b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="icd7a59ebb6304063a306b51e19b294ca_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic0b42f4cd0274c2cadf3f13f4563f625_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i281dec684941496ba9be125acb8ea3a6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9207f2f3c7994a8a8ecfaf008603423f_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib7bcbf2c88c141309a3b412412019b86_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="idf66e290093647d2ac7eef16e4827efc_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id8cbe17fae384b13888b74cd6b1ec015_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i769786328e84403f83835f16dd6077be_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ied814a23dede4859b4dd10f99d05cfb6_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia8addd19a2534d7298a26e3173b6a863_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i25e78ffd9d9242b9b0cd697326116473_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1d97d2295755409ca589230c611d4a1c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib19f1a5dbe744c66ae815743a7372c8b_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic394e1061f43492797075bd9f149992c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iddf6412609614f56bce482cc6a3e294a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i307797df24904531853ec0fc2169f7e0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i045574b786544774882db0b6a4f87c00_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0dd0ee7f3ac94e1093e3d7ad447b4526_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie83976fce48a46b3b8d46aa9df8aa8b1_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i53a2d3e56a004f59a45bdb87953ecc0a_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7ef3242829b546d9957de36a60faad96_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7cf2d6ac264147d5bc7eea61f5da1000_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i4649418b20f44a60bfb39416a9fe963b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7614bac3435145d3a723efd9bb087597_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i0d9f1ecfd5c34f7a9fd27206d4b69544_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i01abbe2b4f24422780127bb041f28468_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i9aa048d8675b4238a8d76e97c5690aef_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7843d84472f449c3bef37bc9121ca5f0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i1a3ed337e07c472b931ca6aecf7946c3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i447684ff42fa4bd582534e7299148f49_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i431d8a724aa54139ab3b857d81e71735_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ic04865d6630d448b86af337d00e81758_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic6511d5e0bf74508adf0aa6bdedfe8bc_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i09018b2d45d249cd8716cb425feef71d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i13abd60e97db49d09d10b6d9a10a6b80_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="if894d62118864420a5c2c56cb58ec015_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="if8404f4966e9457699f55005e32abc65_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iefcbb252e7bb4f458a41283b135a86ec_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ib22b3a738c7e4ab29b10ad29e3acd8a9_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ice23be6cbe2746dd8d736fa8da0659cc_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i37533ea8707341c89db72e8585de3a87_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="if5e5fa8d553d4bdfac44b45081a72bad_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i4f89bd9fe89d4fdc8e39741b72fb0768_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ifeab3c5384914043b5f61dde75cfbcfc_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="if160682b2ae54bd29b1935327968059a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="iaecd09df5a17466f94617abfae776151_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i1b15385aca15402cb972e9d0c02e804f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0487ffe3bd6846938c1d7cb60790531d_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i812c90cdefa246e3bcebf7398bdb44f4_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i5421e9f4d1234869a6e154317b70cd16_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i339e763d52094be9ae4c3c2454a17c00_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i14361e93fcc9401dad202a5affb4254d_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if0ab2dba81b64612b4248a3cd41c97e2_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1508c05368864604ae6acac4ed5e0fe4_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i876621f6fe4046ebafa49eee939aae65_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i1ba7f11cf3c6444fb13f272778b14648_D20181231-20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2019-12-29</endDate>
        </period>
    </context>
    <context id="ibc133ce8aefa43cbbac33e0c79222c18_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="ic211f008f0c343b9b6dbe0257a30891d_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i8843c5f5a5344884a0b6d6b1eabc68b6_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="idb0be9010ee64ef5a74536a9b8bf4b5e_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i7bf5bf7a3b0c4bcdba8ba036de5060bd_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="iab1eb6318e4a48a59682988b2dc916e0_I20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="ic71f1704f9cc4887aecf9df02c808339_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i429a51537c514c5d901ca9e7b22c4175_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i77698652b7224cc1aa4d7e90f3dc8d52_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3c5ffba5806541d5ba6376f4fc012752_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9829b5b0fbb446f5a0b0c27c4eb65328_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i8c4ee00cbdf34df08cf085ad78a22765_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ide55be3475194704afb071efa17c609a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i5135a58860bc4428aa25ef065e2d9395_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id8c4ef8d93674a29b417806bb3af7d59_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i964e0dcb3290414a948e1f7f5b6a98f0_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1e4afcfd6d8e427c8043eca9ef363498_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i55870fa5009d42c29ee665e83387efd6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i84f8b7c83d8e4a408decca1a1e440fef_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i947a2e9e4d9745a88afc0f03c30a4835_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifad79f71187349d286755258d2aaae39_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3dd52c3fe3994d508717b89e90774fc7_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i7d132ccbcb6c479395ae1351d7e61a30_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ib2eb914c66f44b7eacd607705a3c6eff_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="icd1e6b53d4a34fa48ef408b420626ba5_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="patient">
        <measure>jnj:patient</measure>
    </unit>
    <unit id="cases">
        <measure>jnj:cases</measure>
    </unit>
    <unit id="claim">
        <measure>jnj:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV80LTEtMS0xLTU5NzQw_86b9e38f-824d-4bc7-b3df-a7e96dd7c2a3">0000200406</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV81LTEtMS0xLTU5NzQw_c3910bc9-ea60-478b-a857-8ecc4808d8dc">--01-01</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV85LTEtMS0xLTU5NzQw_84cb03bb-afae-43ca-a6b5-82e6bebd537a">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV8xMC0xLTEtMS01OTc0MA_c3da6c71-7756-4b03-9e82-d41641030966">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83L2ZyYWc6YzViOTRjZmRkYzBkNGM3OGIxYWJlZDNlOWM0N2RiNGEvdGFibGU6ZTRkODBiYzY1NGYyNGUwNWE5ZjczOTMxZTI3MDI3MGUvdGFibGVyYW5nZTplNGQ4MGJjNjU0ZjI0ZTA1YTlmNzM5MzFlMjcwMjcwZV8xMS0xLTEtMS01OTc0MA_b15850b3-2e81-440c-8a2c-34efd318d66c">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY2_9691e6df-36ee-412f-b8e9-3f77d5d4598c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTYwOWNmNjU0ZDQ3NDJhZjhkYWZiMjEyNDBmZWNjNTcvdGFibGVyYW5nZTo1NjA5Y2Y2NTRkNDc0MmFmOGRhZmIyMTI0MGZlY2M1N18xLTAtMS0xLTU5NzQw_c20a6f87-a78f-4c60-8b5a-bf0408f36eac">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18xMjI_daf52676-b495-4ac7-9097-0a9784867270">2022-04-03</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NmVlMzMzZDA4Y2M1NDFiNDhhOWU1ODM0N2E0NjlkOTQvdGFibGVyYW5nZTo2ZWUzMzNkMDhjYzU0MWI0OGE5ZTU4MzQ3YTQ2OWQ5NF8xLTAtMS0xLTU5NzQw_15b2c04b-0a0b-47f8-9bb6-032c07b41a8f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY3_07527ef2-df53-405d-b6fe-69f9478b6c99">1-3215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDYw_bd9107b9-fee6-4aa9-a331-27bb6b21ae19">Johnson &amp; Johnson</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NGUwYjAzYzEyNjlhNDRmYTg1ZWFmNzZmZjE2MDU3NjAvdGFibGVyYW5nZTo0ZTBiMDNjMTI2OWE0NGZhODVlYWY3NmZmMTYwNTc2MF8wLTAtMS0xLTU5NzQw_69140ed8-bbbd-40d7-869b-9f27a86d05cd">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NGUwYjAzYzEyNjlhNDRmYTg1ZWFmNzZmZjE2MDU3NjAvdGFibGVyYW5nZTo0ZTBiMDNjMTI2OWE0NGZhODVlYWY3NmZmMTYwNTc2MF8wLTItMS0xLTU5NzQw_d61d1fa3-5b08-4057-bf89-06bf99f7f25f">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDYx_54d3b06f-1d4b-4b51-abe0-4704a4ba786b">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDYy_c2f71238-b2ef-4475-b650-18518bda3329">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDYz_701958a7-57b0-44d6-ac51-842612473c92">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY4_da471979-84b1-4731-9c59-d481365cdba1">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY5_9cecba3b-f955-4c3a-b512-0faf819b146a">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY0_c0eb8ba3-1e59-440d-b481-9c5313cf3e66">524-0400</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDcw_a42e3d55-b31d-4545-9e61-8df3cd8927a7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDY1_1ff70b72-18f1-47bc-84fd-e6ada0c8f4d1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6ZmFlMWZmMjc0ODFkNDk0ZmI3ZjQxMjRkM2M3NDc4MmMvdGFibGVyYW5nZTpmYWUxZmYyNzQ4MWQ0OTRmYjdmNDEyNGQzYzc0NzgyY18wLTEtMS0xLTU5NzQw_012763e0-e7ec-47b7-91eb-b51088ff16ed">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6ZmFlMWZmMjc0ODFkNDk0ZmI3ZjQxMjRkM2M3NDc4MmMvdGFibGVyYW5nZTpmYWUxZmYyNzQ4MWQ0OTRmYjdmNDEyNGQzYzc0NzgyY18xLTQtMS0xLTU5NzQw_24549999-7148-4368-a6ab-ee63769392b0">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6ZmFlMWZmMjc0ODFkNDk0ZmI3ZjQxMjRkM2M3NDc4MmMvdGFibGVyYW5nZTpmYWUxZmYyNzQ4MWQ0OTRmYjdmNDEyNGQzYzc0NzgyY18yLTItMS0xLTU5NzQw_182d68fb-e33f-4421-8c5e-e1a32508cc45">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18yMDcx_a4d10d54-6126-460b-b778-5e55b5f5dd4d">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="ie1bfbdd2721a47c78e496b6496fc1e14_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18xLTAtMS0xLTU5NzQw_c8beb0cc-4bc0-4ce5-9a06-f94856ae625a">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie1bfbdd2721a47c78e496b6496fc1e14_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18xLTEtMS0xLTU5NzQw_3169da35-8e0e-470c-9b24-703a25baf84e">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie1bfbdd2721a47c78e496b6496fc1e14_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18xLTItMS0xLTU5NzQw_799fd5a3-ea23-4f9d-a02c-3d924b918eb7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ied996a6da7cf4f25bd1d614be305c4fc_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18zLTAtMS0xLTU5NzQw_aa4e8506-d7c3-458d-bbd4-8332827d4de4">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ied996a6da7cf4f25bd1d614be305c4fc_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18zLTEtMS0xLTU5NzQw_207f9904-cd71-46cd-a3f6-82b156d453c4">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ied996a6da7cf4f25bd1d614be305c4fc_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM18zLTItMS0xLTU5NzQw_9290d8c2-c243-4d65-bed2-2de55c603a83">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i902d46a64ed041188ea441b2e02dd66d_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM180LTAtMS0xLTU5NzQw_429235b0-1aea-4c00-b89d-0a67626547db">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i902d46a64ed041188ea441b2e02dd66d_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM180LTEtMS0xLTU5NzQw_dbe5d544-7089-41f5-8517-a5e83c3349a5">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i902d46a64ed041188ea441b2e02dd66d_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM180LTItMS0xLTU5NzQw_d7023c27-61ac-4b79-bb14-3f53bcb89f94">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i2fc9d571951142629fdd9f5cbbd77efa_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM181LTAtMS0xLTU5NzQw_8d63f689-1347-4629-8f8a-b601af99511c">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2fc9d571951142629fdd9f5cbbd77efa_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM181LTEtMS0xLTU5NzQw_8b619e2e-da5b-4189-a990-75210a4c20c5">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2fc9d571951142629fdd9f5cbbd77efa_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM181LTItMS0xLTU5NzQw_4d07038c-7b00-4cf6-a39b-aacce92bb9f0">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i58cd890282c34ce19a979c568d6b2d2e_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM182LTAtMS0xLTU5NzQw_29c837be-e9e6-4698-b83b-af38a00446c4">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i58cd890282c34ce19a979c568d6b2d2e_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM182LTEtMS0xLTU5NzQw_c8223a68-9985-4026-973a-b00fa2962c1c">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i58cd890282c34ce19a979c568d6b2d2e_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGFibGU6NTMxOGFhOTk4YWZmNGM4NGI3ODU4OGFjOWExNTVhMzMvdGFibGVyYW5nZTo1MzE4YWE5OThhZmY0Yzg0Yjc4NTg4YWM5YTE1NWEzM182LTItMS0xLTU5NzQw_c8593086-fb35-4c69-953d-9c0f7d05a01c">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ibc6c7e3c97b04a4c81417695c15b5102_I20220422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8xL2ZyYWc6Y2M0N2NjNjEwMTNhNGIxMzhmYWIxY2M4NTBhMTcxYTMvdGV4dHJlZ2lvbjpjYzQ3Y2M2MTAxM2E0YjEzOGZhYjFjYzg1MGExNzFhM18xOTk5_b6f60c34-05f8-4501-b0a5-fe29cfa2178e"
      unitRef="shares">2631401804</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMy0yLTEtMS01OTc0MA_a0e65207-a29d-40f0-a347-5821c5c2e6fe"
      unitRef="usd">10463000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMy00LTEtMS01OTc0MA_ce74d432-2c1a-49b6-a039-1fdcc360aa0a"
      unitRef="usd">14487000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNC0yLTEtMS01OTc0MA_504c3a87-b0ea-4e43-aa9d-7d4e60a3b864"
      unitRef="usd">19925000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNC00LTEtMS01OTc0MA_02cae481-6c6b-43a9-8016-64191e58df96"
      unitRef="usd">17121000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNS0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjYzMTBlOWZkNzU2ZTQ2YTJhMTk2NGFlNjIxYzNmNGQyXzg4_d819f08c-7a58-4316-9ed9-9fbb0bc5f8a6"
      unitRef="usd">234000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNS0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjYzMTBlOWZkNzU2ZTQ2YTJhMTk2NGFlNjIxYzNmNGQyXzk4_4e7d0439-4fe6-4d10-b824-53bfce217694"
      unitRef="usd">230000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNS0yLTEtMS01OTc0MA_82bf7e75-70dd-4ba6-92e7-cb815f44b4fb"
      unitRef="usd">15594000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNS00LTEtMS01OTc0MA_89ae2a72-7fcf-4ef7-9e89-8e6060ee4022"
      unitRef="usd">15283000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNi0yLTEtMS01OTc0MA_6e0e38ab-9ea6-47ce-bb00-4f290a7b60c9"
      unitRef="usd">10990000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNi00LTEtMS01OTc0MA_cbc2ae35-36ff-4599-a035-94167daea3b0"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNy0yLTEtMS01OTc0MA_9b0b78c4-0a98-4a0f-bbc2-eff8c1607dfd"
      unitRef="usd">3452000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNy00LTEtMS01OTc0MA_d73284cc-7c91-4fd9-89c4-217008f4e4f4"
      unitRef="usd">3701000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfOS0yLTEtMS01OTc0MA_6e03d5aa-a1c3-4d63-9227-b2b3cbbcebdc"
      unitRef="usd">60424000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfOS00LTEtMS01OTc0MA_344ddfcb-f56d-4af2-a2ee-8045af17c18e"
      unitRef="usd">60979000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTAtMi0xLTEtNTk3NDA_52e07741-58d7-448f-9a98-f6b3ec5534db"
      unitRef="usd">47702000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTAtNC0xLTEtNTk3NDA_7a146acb-cd73-4f22-8637-9d9ca4529ea6"
      unitRef="usd">47679000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTEtMi0xLTEtNTk3NDA_15c47057-d727-434e-be7d-c6ec50d3db76"
      unitRef="usd">29001000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTEtNC0xLTEtNTk3NDA_a9ae2994-6a30-4856-9422-0aa68333a669"
      unitRef="usd">28717000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTItMi0xLTEtNTk3NDA_598c2e04-1a96-480b-a31d-6ea2b626a5d4"
      unitRef="usd">18701000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTItNC0xLTEtNTk3NDA_45040070-17fd-49f4-b160-ef86983bf4ad"
      unitRef="usd">18962000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTMtMi0xLTEtNTk3NDA_c5cb464a-1d47-467d-9414-7892c0d94a37"
      unitRef="usd">44420000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTMtNC0xLTEtNTk3NDA_6a6c0d13-3b14-4396-999f-b50a4ea2f7ff"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTQtMi0xLTEtNTk3NDA_54cc0d8d-76a7-4d68-8070-c54ec17f8dc3"
      unitRef="usd">34935000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTQtNC0xLTEtNTk3NDA_9ee69782-e3db-4124-bc5b-f9f803cc4120"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTUtMi0xLTEtNTk3NDA_aa001982-d366-48ed-90b8-0589c31a242e"
      unitRef="usd">9936000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTUtNC0xLTEtNTk3NDA_9a33dd48-aa6a-4ea9-89c3-1cc3a64d66f3"
      unitRef="usd">10223000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTYtMi0xLTEtNTk3NDA_664eb702-43f9-4ab0-ae89-414469a1f7dc"
      unitRef="usd">9939000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTYtNC0xLTEtNTk3NDA_29caf809-750e-48c5-95bc-904fb381f23e"
      unitRef="usd">10216000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTctMi0xLTEtNTk3NDA_5bebc13c-b72d-408b-a924-a99ae18afd80"
      unitRef="usd">178355000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMTctNC0xLTEtNTk3NDA_39e0be50-11db-491a-8c3e-65ffb34a0fcf"
      unitRef="usd">182018000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjAtMi0xLTEtNTk3NDA_a4e815be-4b85-415e-9fcb-0d17e12e62c6"
      unitRef="usd">4297000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjAtNC0xLTEtNTk3NDA_d6262d88-4d63-4fb6-964a-56c452cc7eb5"
      unitRef="usd">3766000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjEtMi0xLTEtNTk3NDA_39de1606-4512-4e91-8dc5-41297127d3c2"
      unitRef="usd">9309000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjEtNC0xLTEtNTk3NDA_9fd9aa73-72f3-4fb5-b3b2-ad5b2d393257"
      unitRef="usd">11055000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjItMi0xLTEtNTk3NDA_935cd373-228b-438a-a056-f4a1b3df67df"
      unitRef="usd">13006000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjItNC0xLTEtNTk3NDA_05462d16-d52d-4d73-ab86-7cd8c4c03cc8"
      unitRef="usd">13612000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjMtMi0xLTEtNTk3NDA_05423523-8336-4bb9-b799-c1f28e69d6ad"
      unitRef="usd">12972000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjMtNC0xLTEtNTk3NDA_e07dae86-0a0e-47a6-98a2-c2523d9a6ae1"
      unitRef="usd">12095000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjQtMi0xLTEtNTk3NDA_47631aa9-106e-40a9-95ee-8d7b0eebe09a"
      unitRef="usd">2098000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjQtNC0xLTEtNTk3NDA_06a13098-6248-40d0-afbd-41232b4d7518"
      unitRef="usd">3586000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjUtMi0xLTEtNTk3NDA_23e76bb1-5359-44d4-8281-a85c1a5699f3"
      unitRef="usd">1708000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjUtNC0xLTEtNTk3NDA_1f644c68-cccc-4d9d-8ac3-8288de2075cc"
      unitRef="usd">1112000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjYtMi0xLTEtNTk3NDA_f8e559c1-3e95-4fce-b233-89f5588e7642"
      unitRef="usd">43390000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjYtNC0xLTEtNTk3NDA_9e667775-a7fb-40b4-b01b-ad4d797e5326"
      unitRef="usd">45226000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjctMi0xLTEtNTk3NDA_30fa12d9-b1e4-4279-bcce-ad938266c392"
      unitRef="usd">28851000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjctNC0xLTEtNTk3NDA_f5a62684-8246-4551-8d77-40edbf29a83b"
      unitRef="usd">29985000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjgtMi0xLTEtNTk3NDA_8ccad7ad-6a21-4c20-9e1c-31a947d5f2d6"
      unitRef="usd">6424000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjgtNC0xLTEtNTk3NDA_ed44dc8c-e369-4321-bbc2-f345768072d2"
      unitRef="usd">7487000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjktMi0xLTEtNTk3NDA_d72d725e-f38d-4fbc-be87-5e04b6c0e9bb"
      unitRef="usd">8739000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMjktNC0xLTEtNTk3NDA_8647a0e2-3508-4421-aff5-23f25b59086e"
      unitRef="usd">8898000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzAtMi0xLTEtNTk3NDA_88ae2d69-dd19-49bc-8103-021b3b1a0237"
      unitRef="usd">5745000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzAtNC0xLTEtNTk3NDA_20bd0cbc-e45a-4400-a3db-d664b0c1f18a"
      unitRef="usd">5713000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzEtMi0xLTEtNTk3NDA_1e3a6f19-1ec9-4242-8326-d41ea7567fb6"
      unitRef="usd">10497000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzEtNC0xLTEtNTk3NDA_2609abc3-9a40-4a48-92a9-ce9373766364"
      unitRef="usd">10686000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzItMi0xLTEtNTk3NDA_42091e96-1427-49f8-a114-f1f99fa97aba"
      unitRef="usd">103646000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzItNC0xLTEtNTk3NDA_8f38a962-1672-4841-84ef-df9fa29b7381"
      unitRef="usd">107995000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzMtMi0xLTEtNTk3NDA_9782106c-a32b-4711-b128-e4255617de01"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzMtNC0xLTEtNTk3NDA_4d4751c4-bb97-4533-94e6-59981faf3326"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY18yOQ_3b62be13-d30b-49a9-b565-b2b4a8a739ab"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY18yOQ_638cba20-27f2-45ab-9a31-cc83bee0ac71"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY181NA_347527d0-0341-4061-9df2-3a7bfed0e9f9"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY181NA_3ae0a780-4bd6-4aaf-8b71-8901a142ed04"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY183Mg_8a0bf196-707e-489c-bfbb-1c4f872bffa8"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4MWQzYzg5M2ZjMDk0YmJhYmNkZTI3OWJhNWUxODkwY183Mg_d2c30d29-8607-4b75-8206-f444dd948e71"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtMi0xLTEtNTk3NDA_8f4d3f84-5055-4e28-89b1-b910945f2114"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzUtNC0xLTEtNTk3NDA_13b990a6-cf62-4cf4-b348-3ea93b46363e"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzYtMi0xLTEtNTk3NDA_cd6c1403-7304-437b-8d3e-5a709a51081f"
      unitRef="usd">-13757000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzYtNC0xLTEtNTk3NDA_bbf171e9-fead-4b18-ac6a-5ff5de3dbae5"
      unitRef="usd">-13058000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzctMi0xLTEtNTk3NDA_1578defe-0231-4bd6-a032-4d41960fb62d"
      unitRef="usd">124380000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzctNC0xLTEtNTk3NDA_73b12e20-cef2-467d-aeac-6015b3b71d5e"
      unitRef="usd">123060000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiNDhkNjM5OTcyODM0NTlkYjZkNmQ3MzkyMzYyMWFkZV81MA_c07fdcdd-b2bf-4ca4-a09d-668ec49cb058"
      unitRef="shares">490459000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiNDhkNjM5OTcyODM0NTlkYjZkNmQ3MzkyMzYyMWFkZV81Nw_31aafcc8-6c46-4ae3-a1c1-2515d344447d"
      unitRef="shares">490878000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzgtMi0xLTEtNTk3NDA_88c1518b-b645-4133-8516-3f5b6d72bd4d"
      unitRef="usd">39034000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzgtNC0xLTEtNTk3NDA_e750b035-6238-4786-9146-0f703c2858ed"
      unitRef="usd">39099000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzktMi0xLTEtNTk3NDA_a87fa160-78df-4b24-9b2a-85ecafd686cb"
      unitRef="usd">74709000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfMzktNC0xLTEtNTk3NDA_c6efaa1e-ca00-4248-9c73-6932353a5ac5"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNDAtMi0xLTEtNTk3NDA_148c85ab-8efe-46cb-a6b1-1176aceebd35"
      unitRef="usd">178355000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yMi9mcmFnOjhiZTY0MDQ5NjgwNTQ3ZGQ4YTczM2VkN2IyZDRlNWNlL3RhYmxlOjJlMmY0ZWNlNTlmYzQ0ZGI5YThhZTdmMzBlNmNiMmVkL3RhYmxlcmFuZ2U6MmUyZjRlY2U1OWZjNDRkYjlhOGFlN2YzMGU2Y2IyZWRfNDAtNC0xLTEtNTk3NDA_d8aa5874-4447-497c-8685-cdb1f09c8c9a"
      unitRef="usd">182018000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMi0yLTEtMS01OTc0MA_ca056112-3b1e-4c4d-94da-7d08a70ef8d0"
      unitRef="usd">23426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMi00LTEtMS01OTc0MA_b14f7401-cd26-4685-99da-c1ca6293b9a6"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMi02LTEtMS01OTc0MA_0b381f1a-4649-4e87-9a34-8dcd001ac0d0"
      unitRef="usd">22321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMi04LTEtMS01OTc0MA_138fe261-ced1-429e-ad36-4d9e2f90afa9"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMy0yLTEtMS01OTc0MA_ddd9ee88-184f-4ca5-af1b-9436c1ed0c90"
      unitRef="usd">7598000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMy00LTEtMS01OTc0MA_7cc23445-6c8e-4e5d-8c3b-ce6a39061ab9"
      unitRef="number">0.324</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMy02LTEtMS01OTc0MA_ba5596fb-1d7e-4edc-82e5-7ad2c7f7edba"
      unitRef="usd">7063000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMy04LTEtMS01OTc0MA_ec64163b-5334-4600-95a2-a16eb92eca10"
      unitRef="number">0.317</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNC0yLTEtMS01OTc0MA_8bc8236b-84d5-48aa-b10e-12261f03b414"
      unitRef="usd">15828000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNC00LTEtMS01OTc0MA_977cd2c9-eaee-4211-9332-0fa704a30408"
      unitRef="number">0.676</jnj:GrossProfitPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNC02LTEtMS01OTc0MA_8aec9c9a-de31-48bd-8807-3b3f681dad73"
      unitRef="usd">15258000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNC04LTEtMS01OTc0MA_117f2aa4-9be2-483e-844e-9fbc3f75b93e"
      unitRef="number">0.683</jnj:GrossProfitPercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNS0yLTEtMS01OTc0MA_d0c3217e-2ca9-493e-9ee5-9be7a8249bb8"
      unitRef="usd">5938000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNS00LTEtMS01OTc0MA_139af531-44d3-472b-8cb3-b26da7cd945e"
      unitRef="number">0.254</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNS02LTEtMS01OTc0MA_2b224cf6-fad5-46dd-8713-bf94b6364b1d"
      unitRef="usd">5432000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNS04LTEtMS01OTc0MA_85db8233-47cf-4eeb-81be-7606e30e84f1"
      unitRef="number">0.243</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNi0yLTEtMS01OTc0MA_2a44df57-503c-409d-b3cb-439755801587"
      unitRef="usd">3462000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNi00LTEtMS01OTc0MA_bfa342a9-5b80-4b9b-a8e7-42d48a42eae5"
      unitRef="number">0.148</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNi02LTEtMS01OTc0MA_cb334b49-f84b-4521-9a50-c37a5877afca"
      unitRef="usd">3178000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNi04LTEtMS01OTc0MA_8deef34a-2394-470d-b7d4-3128e0005387"
      unitRef="number">0.142</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNy0yLTEtMS01OTc0MA_2989edbd-615d-41e8-b725-9e31cec18985"
      unitRef="usd">610000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNy00LTEtMS01OTc0MA_ddcc954b-d819-4e62-94fa-c5a36eede252"
      unitRef="number">0.026</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNy02LTEtMS01OTc0MA_a9ef2754-5c5c-4179-941a-7c836676c5c3"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfNy04LTEtMS01OTc0MA_6db21a1d-9218-4a25-9954-52b93df188bf"
      unitRef="number">0</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOC0yLTEtMS01OTc0MA_7d244ff0-72cc-4e75-a607-47058aff6011"
      unitRef="usd">22000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOC00LTEtMS01OTc0MA_3ba015ea-4c60-4a60-a994-975a3a54f9b6"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOC02LTEtMS01OTc0MA_b37a4327-6410-45cc-a1bb-70321c236bd8"
      unitRef="usd">15000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOC04LTEtMS01OTc0MA_5210c66b-7024-4077-997e-f2a8f356f626"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InterestExpense
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOS0yLTEtMS01OTc0MA_239683a1-9e9f-492a-8d40-9e1f66d27c5c"
      unitRef="usd">10000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOS00LTEtMS01OTc0MA_3b4f9575-3d7e-42b0-b2f7-2462bf56f677"
      unitRef="number">0.000</jnj:InterestExpensePercentToSales>
    <us-gaap:InterestExpense
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOS02LTEtMS01OTc0MA_917539a9-9cbb-4645-b84f-c5bce342a076"
      unitRef="usd">63000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfOS04LTEtMS01OTc0MA_b0da9c4b-20b0-483e-8bdc-f51af706632a"
      unitRef="number">0.003</jnj:InterestExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTAtMi0xLTEtNTk3NDA_945cd14c-3402-49e0-aca9-8f6340153f2f"
      unitRef="usd">102000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTAtNC0xLTEtNTk3NDA_fb04b973-b005-4131-870a-f633d19fdf9b"
      unitRef="number">-0.004</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTAtNi0xLTEtNTk3NDA_57b1ff55-8ea3-48a5-a6cb-84184b68cb51"
      unitRef="usd">882000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTAtOC0xLTEtNTk3NDA_5806fda2-fea7-4dbd-a2b3-91d7a2994b45"
      unitRef="number">-0.039</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:RestructuringCharges
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTEtMi0xLTEtNTk3NDA_dea4dea9-bde6-43c7-ab60-aa42e2fce89b"
      unitRef="usd">70000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTEtNC0xLTEtNTk3NDA_3d34a6a0-a526-4cf0-b166-19f9dcdd178e"
      unitRef="number">0.003</jnj:Restructuringchargepercenttosales>
    <us-gaap:RestructuringCharges
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTEtNi0xLTEtNTk3NDA_4955d2a7-2578-4769-b925-24fe79adc5f8"
      unitRef="usd">53000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTEtOC0xLTEtNTk3NDA_5c9a951f-c0cd-4f7f-a29d-6be84724a799"
      unitRef="number">0.002</jnj:Restructuringchargepercenttosales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTItMi0xLTEtNTk3NDA_9a2db576-dc94-4e02-8298-f880f0fc1e38"
      unitRef="usd">5862000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTItNC0xLTEtNTk3NDA_8775d680-c7a9-4565-8b9e-48303151ba30"
      unitRef="number">0.250</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTItNi0xLTEtNTk3NDA_afe92bf3-42d2-4b8b-93aa-ea6b0717470c"
      unitRef="usd">7429000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTItOC0xLTEtNTk3NDA_dd212148-9e08-4495-b417-d2b2b14564fa"
      unitRef="number">0.333</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTMtMi0xLTEtNTk3NDA_b08bafa1-e4eb-4bf4-b9be-a2591a4b727a"
      unitRef="usd">713000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTMtNC0xLTEtNTk3NDA_5e1d7e4f-7817-4981-99ce-78a0439250f3"
      unitRef="number">0.030</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTMtNi0xLTEtNTk3NDA_ae4787cb-ebdb-468f-a1d9-7587dc755ab9"
      unitRef="usd">1232000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTMtOC0xLTEtNTk3NDA_23c55f69-2e86-45d9-baea-f88a42237ee6"
      unitRef="number">0.055</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTQtMi0xLTEtNTk3NDA_a7981d53-cbc8-45b6-ac56-a80c7bd3af92"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTQtNC0xLTEtNTk3NDA_b2b221c8-0951-460d-8817-3cadc199c9dd"
      unitRef="number">0.220</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTQtNi0xLTEtNTk3NDA_eabbe06a-a729-44b8-99c8-98f76c03cc95"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTQtOC0xLTEtNTk3NDA_b1ad62a9-d248-4e26-8381-8b11070514b4"
      unitRef="number">0.278</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTctMi0xLTEtNTk3NDA_71476954-faa1-41ac-8401-6d41d626e374"
      unitRef="usdPerShare">1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTctNi0xLTEtNTk3NDA_470fc064-b8f8-4253-89c5-2ca6ed3f6a46"
      unitRef="usdPerShare">2.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTgtMi0xLTEtNTk3NDA_19c0ad84-967e-48bb-b026-9cce676c3045"
      unitRef="usdPerShare">1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMTgtNi0xLTEtNTk3NDA_b9190d2a-7717-4d28-a66b-6d2fa4c0550c"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMjEtMi0xLTEtNTk3NDA_0d21dcc1-159e-4e3b-9c43-976b9607a1a3"
      unitRef="shares">2629200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMjEtNi0xLTEtNTk3NDA_004aad0b-80fc-4961-a46b-94b75762a7e3"
      unitRef="shares">2631600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMjItMi0xLTEtNTk3NDA_529b1803-5b32-4247-b2ee-aa73a100eb1b"
      unitRef="shares">2666500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8yOC9mcmFnOjcxZDIzNDVmMTA1MzQ5NWU5ZDYwOTEwMTY1YmVlYzk1L3RhYmxlOjg1ZGIwOGVkN2NlNzQwMzI4ODU5MTE3YTZlNGY3ZWI3L3RhYmxlcmFuZ2U6ODVkYjA4ZWQ3Y2U3NDAzMjg4NTkxMTdhNmU0ZjdlYjdfMjItNi0xLTEtNTk3NDA_35132c18-cb5d-4cfb-bb52-c0d1ee5d1420"
      unitRef="shares">2672700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMy0xLTEtMS01OTc0MA_a511aad7-87a7-4206-98b6-4d9e9f43a068"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMy0zLTEtMS01OTc0MA_0be685a4-c5ab-4aa2-8065-bd62d6456d2b"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfNi0xLTEtMS01OTc0MA_381c99dd-615f-47ef-bf4a-1945fa3389bf"
      unitRef="usd">-554000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfNi0zLTEtMS01OTc0MA_53a01bf6-5097-477a-a035-74137fed3f0d"
      unitRef="usd">276000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfOS0xLTEtMS01OTc0MA_a117cfef-dea6-475c-acac-d6df76505ba9"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfOS0zLTEtMS01OTc0MA_dc9be0e0-383c-4a89-a0ed-296aa714a886"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTAtMS0xLTEtNTk3NDA_947a63f6-c941-4987-b71b-e5e488e96f9f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTAtMy0xLTEtNTk3NDA_3e2de1d8-4890-46db-bf9b-9b95bf4e1b8a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTItMS0xLTEtNTk3NDA_5574e616-a811-43f0-bdc5-665ad9b1dd85"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTItMy0xLTEtNTk3NDA_2810c6fd-3b89-4800-9084-e3f5e7b47e4e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTUtMS0xLTEtNTk3NDA_602ec9ee-88f1-4b5d-a2c6-d35a1216d320"
      unitRef="usd">53000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTUtMy0xLTEtNTk3NDA_bff4bbe0-20f7-441a-a19d-68aae7f56ee4"
      unitRef="usd">41000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTYtMS0xLTEtNTk3NDA_d9516412-b430-4d09-9ab4-0e519cca012a"
      unitRef="usd">-217000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTYtMy0xLTEtNTk3NDA_be22c2e4-fca9-4290-9629-556e38c8dc8d"
      unitRef="usd">-274000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTgtMS0xLTEtNTk3NDA_b610f611-accb-49d4-bf55-f71a52f78f71"
      unitRef="usd">-164000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMTgtMy0xLTEtNTk3NDA_9ff68290-2c37-4a3f-a727-771488271ee1"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjEtMS0xLTEtNTk3NDA_b1b4337f-3488-4561-bab4-e8d8a7fcbc0f"
      unitRef="usd">-195000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjEtMy0xLTEtNTk3NDA_0fb32db8-1df7-485e-97cc-3f304328a2e7"
      unitRef="usd">-522000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjItMS0xLTEtNTk3NDA_11def983-98dd-43d6-b676-0d7ccc10b655"
      unitRef="usd">101000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjItMy0xLTEtNTk3NDA_60498241-2c62-4792-8c0a-3a603f0de9f9"
      unitRef="usd">73000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjMtMS0xLTEtNTk3NDA_c78a97ba-ca01-449b-8329-d6bfa3e2deec"
      unitRef="usd">-296000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjMtMy0xLTEtNTk3NDA_b0b28ecb-009c-41ab-ae89-06fb05d0dbb0"
      unitRef="usd">-595000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjUtMS0xLTEtNTk3NDA_0539c017-a6ad-4bc7-a2e0-291323f6f8da"
      unitRef="usd">-699000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjUtMy0xLTEtNTk3NDA_aaf81e2e-e829-44ea-bc39-9f8be9dddcde"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjctMS0xLTEtNTk3NDA_2c97fe46-d3df-4177-a635-67ef179eddd7"
      unitRef="usd">4450000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjJjN2NmMzljZDljMDRiNjQ5YWM1MmZhODExNmFjNWNhL3RhYmxlcmFuZ2U6MmM3Y2YzOWNkOWMwNGI2NDlhYzUyZmE4MTE2YWM1Y2FfMjctMy0xLTEtNTk3NDA_5fbd4a6e-a554-46e0-bbcc-baff9f4b0a01"
      unitRef="usd">6111000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzE1OQ_775d2d95-b731-4fd7-af29-f0ef45d9444b"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzE3NQ_a5a1bca3-31e0-42eb-899c-ba7aeb649801"
      unitRef="usd">-319000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzIxOTkwMjMyNTU4ODE_9027d67e-f6f5-42d7-88a0-133f35f23a20"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzIxMg_e48fc63c-5ba2-4042-a646-e7bb290ecd34"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzIyOA_2a2da1c0-d5cc-4854-88cf-903a47fdfc38"
      unitRef="usd">66000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzI2Mw_f2b17f06-f458-4d11-88f0-31585845e7ae"
      unitRef="usd">-78000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF8zNC9mcmFnOmNkZjJkZjY2ZjA2MjQ0MWNhOTMxMDgwZDgyNGUzYTRlL3RhYmxlOjBkMDYxODllMjU1ZDQzNGVhMWFlNmQ1MTQzZWY0MDZmL3RhYmxlcmFuZ2U6MGQwNjE4OWUyNTVkNDM0ZWExYWU2ZDUxNDNlZjQwNmZfMC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjIyYWJhMTQ0MGE2OTRmYWNiY2NjODI2ZmI5Y2FkOWI4XzI3OQ_99cc1dab-6141-4eb0-ab99-afdb8ad42a0f"
      unitRef="usd">-157000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS0xLTEtMS01OTc0MA_515f5b8c-e9de-4290-b708-fdb6ed836a3a"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i92abad263bf8419daa6c3d10a1e69673_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS0zLTEtMS01OTc0MA_4d1bfcd6-abfb-43c3-9b79-208407a08fcf"
      unitRef="usd">123060000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2336cd90b8e74beeb66f460bec6b6238_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS01LTEtMS01OTc0MA_fc4c4610-0e43-4891-afcd-29e19e1b58bb"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic266b1b5dc484c669aed5ae886e3f910_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS03LTEtMS01OTc0MA_ee2e0ec4-ab9e-4ade-95e4-0310a34abfb1"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39899651e6354f279c457a156b59b4a6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMS05LTEtMS01OTc0MA_d4c82cb1-ab0d-4944-b7d3-f21979ce0ef9"
      unitRef="usd">-39099000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMi0xLTEtMS01OTc0MA_9beb7116-bce2-4b26-9e66-f2049ff45937"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifb5ba76506ab44498ae6e4962d624eae_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMi0zLTEtMS01OTc0MA_c1966a2b-14d6-4f39-b5a2-c5bd7cbaf9b2"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMy0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjE3YjYxMDVkY2IzYTQ2MzNhMmJiZTFiNWQ1MjVmZTE0XzI2_14ef7ab3-b493-44ae-853a-ed50f9794de0"
      unitRef="usdPerShare">1.06</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMy0xLTEtMS01OTc0MA_7a9074c4-1ac1-4cd9-88ac-f1d016b52a76"
      unitRef="usd">2787000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ifb5ba76506ab44498ae6e4962d624eae_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfMy0zLTEtMS01OTc0MA_f1248809-890d-475a-8f38-069e65d2457b"
      unitRef="usd">2787000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNC0xLTEtMS01OTc0MA_bf1e6ce0-a5c9-4fa2-b49c-ac6daed96aad"
      unitRef="usd">600000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ifb5ba76506ab44498ae6e4962d624eae_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNC0zLTEtMS01OTc0MA_9ab120ea-016d-4251-a913-0bf5290a2d0b"
      unitRef="usd">-1042000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i8f1bd088462748abb8bf782cfcc07129_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNC05LTEtMS01OTc0MA_9ee47664-b9c7-4140-80db-4733ef81c271"
      unitRef="usd">1642000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNS0xLTEtMS01OTc0MA_5c543506-c557-47ce-b422-c1a55b2084d9"
      unitRef="usd">1577000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8f1bd088462748abb8bf782cfcc07129_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNS05LTEtMS01OTc0MA_dab4690a-d113-4203-8f94-35384299b4ae"
      unitRef="usd">1577000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNy0xLTEtMS01OTc0MA_dfc7b452-bb0b-495d-b20b-7d15633b2028"
      unitRef="usd">-699000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifbe0f983eea14da3b437dcf18bfa144b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfNy01LTEtMS01OTc0MA_84610cff-8210-4ab1-a9ec-d36eda601790"
      unitRef="usd">-699000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC0xLTEtMS01OTc0MA_8ea9676f-45e0-4dd5-8758-996cb82d9f99"
      unitRef="usd">74709000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i225ea33e8dbf48579d422823c0350b4f_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC0zLTEtMS01OTc0MA_2b56da35-1535-40bd-a716-e43a0b9fef53"
      unitRef="usd">124380000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i795ff92791494382a1d26a7b84fee3e5_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC01LTEtMS01OTc0MA_2f450214-3141-4058-a487-85e9dffe3626"
      unitRef="usd">-13757000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib230b0f5235943ff892ee51f02112200_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC03LTEtMS01OTc0MA_dbf6009d-cb88-4159-a3b3-6bc678a18f1d"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7dd50adc00246e78b4d70267adf860f_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjY1OGY4ZDgxZTEwNDQ5MTVhMTVhNTRkYzliZmRmNjNlL3RhYmxlcmFuZ2U6NjU4ZjhkODFlMTA0NDkxNWExNWE1NGRjOWJmZGY2M2VfOC05LTEtMS01OTc0MA_b2dc4fed-65e6-4426-b1fc-292e58cad275"
      unitRef="usd">-39034000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccce36176b41451cb72ade5fd7acd620_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS0xLTEtMS01OTc0MA_8f43bbc2-d90f-40dd-ba3c-2bae92f6a323"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idab9077c64f34317815b7b3af8096958_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS0zLTEtMS01OTc0MA_f4e40846-994d-48b3-a12a-0fefe613a825"
      unitRef="usd">113890000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc5b2d28a80e44d9bdcda5d265440506_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS01LTEtMS01OTc0MA_6c9ce107-08f6-4f14-be04-84e8f766a3e1"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i73bff5df510141c6acab233c801c6f0b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS03LTEtMS01OTc0MA_b1289b98-3a0f-4851-b446-99881460d6e3"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i333b166f4d2f445f9cd585f8eb2f1c02_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMS05LTEtMS01OTc0MA_1ee432b9-83d8-4d21-a987-c17e4150a4c4"
      unitRef="usd">-38490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMy0xLTEtMS01OTc0MA_02043b80-e64f-4093-b13e-6531fa7a99c7"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifeeeea464c1645cf8c4b046709808f46_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfMy0zLTEtMS01OTc0MA_0e8e9367-2a3e-47f6-92ea-95e707c25475"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOmY2MmJlOTA2NTUzNTQxN2E4MjIzOTFlMjBmM2E1YmJmXzI2_7f6699c7-88e9-43e8-8810-53cbaf037865"
      unitRef="usdPerShare">1.01</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNC0xLTEtMS01OTc0MA_2597d257-6272-4a90-a67f-624429c35ce2"
      unitRef="usd">2659000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ifeeeea464c1645cf8c4b046709808f46_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNC0zLTEtMS01OTc0MA_44e40065-48ae-4fef-9bd0-45c2440f59b5"
      unitRef="usd">2659000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNS0xLTEtMS01OTc0MA_1249bbeb-d607-4caf-8d3d-65e3187031d5"
      unitRef="usd">542000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ifeeeea464c1645cf8c4b046709808f46_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNS0zLTEtMS01OTc0MA_9174af65-b697-44db-9fa2-7530b8657868"
      unitRef="usd">-920000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i6e4b855ab6e9400da78a4a7e4118d0c0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNS05LTEtMS01OTc0MA_6ecc2a48-d0a4-4ed0-869a-c96e703d8ff7"
      unitRef="usd">1462000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNi0xLTEtMS01OTc0MA_6f936f7a-9424-4638-a951-253ac7e16e1c"
      unitRef="usd">1438000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6e4b855ab6e9400da78a4a7e4118d0c0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfNi05LTEtMS01OTc0MA_3f775879-8d81-499e-8177-40c9e23241a8"
      unitRef="usd">1438000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOC0xLTEtMS01OTc0MA_03ddae73-ebcf-41ee-9479-0994282d7feb"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifcd4bbc39e1a4259935490333ab02382_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOC01LTEtMS01OTc0MA_ed3107c0-3e29-4a8d-af1f-189ab3cd61c9"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4ebcce5ed4d4fa88b1380565ad0cd2f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS0xLTEtMS01OTc0MA_9fa8dcc0-7558-479d-a1c8-7d5f9229264a"
      unitRef="usd">65834000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i613a24ca8cd34aaf87209b0ce754c9a4_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS0zLTEtMS01OTc0MA_f131cafe-b39c-4d16-b8c8-c171cb76693c"
      unitRef="usd">116508000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f965bb993c84e458df2a90932f7f838_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS01LTEtMS01OTc0MA_603a4dd9-7789-40db-9f66-f940965bb6da"
      unitRef="usd">-15328000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d6448f96ad7486da2e84f5da3d3c578_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS03LTEtMS01OTc0MA_3d2f71a9-b89c-4d4a-a5ec-367884be89e9"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4dc0429231c4601861ff53b097feae5_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80MC9mcmFnOmI1YTZmNWNhY2QxMzRiNjdiMmZkMjVhNWVkNWM5ZmIxL3RhYmxlOjM5YWQ3MGM3YmI2YTQ2MDVhNGJlMTE5NDQ1YmUxNDE4L3RhYmxlcmFuZ2U6MzlhZDcwYzdiYjZhNDYwNWE0YmUxMTk0NDViZTE0MThfOS05LTEtMS01OTc0MA_be676b3c-d05a-4fb6-a38a-782d1da93b5f"
      unitRef="usd">-38466000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMy0yLTEtMS01OTc0MA_6d71aa27-3c12-49f3-8130-0a8e78b0df44"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMy00LTEtMS01OTc0MA_6f77a5fa-07e1-467f-9cc6-fb37c94b04b1"
      unitRef="usd">6197000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNS0yLTEtMS01OTc0MA_d343e7b1-6f5b-47c8-a749-fa75ac892ef3"
      unitRef="usd">1769000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNS00LTEtMS01OTc0MA_131e8c19-502f-4ceb-b66d-7b8369ff874a"
      unitRef="usd">1894000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNi0yLTEtMS01OTc0MA_91357beb-20bb-4a36-b862-13dfeb6219ed"
      unitRef="usd">278000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNi00LTEtMS01OTc0MA_0eec2ec6-5af9-4c89-8b52-d5bee207e6c9"
      unitRef="usd">307000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfOS0yLTEtMS01OTc0MA_360e8107-5b19-488a-8cdf-b8825646a5d4"
      unitRef="usd">610000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfOS00LTEtMS01OTc0MA_51457d5b-6ce5-48db-a3b8-bf51b2840906"
      unitRef="usd">14000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTEtMi0xLTEtNTk3NDA_2b234f9e-1d9e-49b1-b1f2-39436c735c81"
      unitRef="usd">168000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTEtNC0xLTEtNTk3NDA_bc11d246-1c26-4fe6-8e39-8a353b13e659"
      unitRef="usd">580000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTMtMi0xLTEtNTk3NDA_8c4b80f9-84d2-403b-b0fe-d174802a1ab3"
      unitRef="usd">-926000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTMtNC0xLTEtNTk3NDA_2ff8c8a7-9d39-452b-846d-db75e97a90f3"
      unitRef="usd">-730000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTQtMi0xLTEtNTk3NDA_99c2d5eb-1a17-45ac-b596-19673d0775fd"
      unitRef="usd">6000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTQtNC0xLTEtNTk3NDA_447db48a-9c54-4184-a926-1242a99ac9bd"
      unitRef="usd">-13000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTYtMi0xLTEtNTk3NDA_538981af-fd77-4cbb-b2bc-b9d1ef04b229"
      unitRef="usd">427000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTYtNC0xLTEtNTk3NDA_35ea0a96-321b-4f17-bcb8-57d951295357"
      unitRef="usd">1604000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTctMi0xLTEtNTk3NDA_7d8e0338-ccac-419c-9265-256417a81f45"
      unitRef="usd">600000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTctNC0xLTEtNTk3NDA_7a357294-a9f7-4a84-b450-a6a1fc2e400a"
      unitRef="usd">695000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTgtMi0xLTEtNTk3NDA_d1de115e-d84e-4f40-ab11-fb83d5543cff"
      unitRef="usd">-2817000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTgtNC0xLTEtNTk3NDA_5767fe08-e6b0-4c3d-81db-bc977594c7ec"
      unitRef="usd">-2336000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTktMi0xLTEtNTk3NDA_6c600a3e-19b8-4035-8c6a-002f63dca37e"
      unitRef="usd">-995000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMTktNC0xLTEtNTk3NDA_6745b34e-e3e6-4f73-9aea-8a092fd3eb30"
      unitRef="usd">-2522000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjAtMi0xLTEtNTk3NDA_d5f4ad5b-f4cc-4b6f-a82b-73d06ac166ab"
      unitRef="usd">110000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjAtNC0xLTEtNTk3NDA_56417a86-db9b-4abd-aec4-7314460d664d"
      unitRef="usd">-902000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjItMi0xLTEtNTk3NDA_328f33e7-e42d-4fc4-96f4-ef7a1a86f726"
      unitRef="usd">3979000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjItNC0xLTEtNTk3NDA_3469b0f7-9f49-4038-a9c2-c31d42b28495"
      unitRef="usd">4074000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjUtMi0xLTEtNTk3NDA_fe2d3745-1b36-4aca-8ae9-983b91840396"
      unitRef="usd">607000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjUtNC0xLTEtNTk3NDA_5674293c-301f-4b7e-bfea-e2447c801eb5"
      unitRef="usd">677000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjYtMi0xLTEtNTk3NDA_deaac64c-7c46-4cd9-9d03-ce341cb3f032"
      unitRef="usd">248000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjYtNC0xLTEtNTk3NDA_f25114e4-f1b0-4674-bb53-d2a665b96817"
      unitRef="usd">603000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjctMi0xLTEtNTk3NDA_db3f16c5-46c3-475d-8dad-738cce06b32b"
      unitRef="usd">252000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjctNC0xLTEtNTk3NDA_163ed107-0dc6-4bff-9a31-ff2758493090"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjgtMi0xLTEtNTk3NDA_70285326-aa93-4df1-ad3e-11e9b4b9fec8"
      unitRef="usd">9018000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjgtNC0xLTEtNTk3NDA_2d32f9c8-ef8e-46b9-b4ec-307f23ce9fab"
      unitRef="usd">5994000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjktMi0xLTEtNTk3NDA_775809ec-2b46-4376-9a14-406e3eb9ce50"
      unitRef="usd">6303000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMjktNC0xLTEtNTk3NDA_9618bc51-aaa7-42a4-a75a-96ceaeab49fa"
      unitRef="usd">5233000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzAtMi0xLTEtNTk3NDA_b1a21014-fc96-4def-9c79-e2249e06474d"
      unitRef="usd">-249000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzAtNC0xLTEtNTk3NDA_118f9f87-0d6e-4f93-b8aa-39a0945466d2"
      unitRef="usd">751000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzEtMi0xLTEtNTk3NDA_99ea7ae8-baad-4583-91a9-e3e7b1d60da0"
      unitRef="usd">59000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzEtNC0xLTEtNTk3NDA_2f514b6d-b0a1-4080-a062-378288ea2b53"
      unitRef="usd">101000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzMtMi0xLTEtNTk3NDA_c2df8467-51ea-4e3c-9d5b-17b717dc41b9"
      unitRef="usd">-3634000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzMtNC0xLTEtNTk3NDA_1d2abda6-aa15-4378-b6fa-d7570b38de79"
      unitRef="usd">-185000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzYtMi0xLTEtNTk3NDA_f7de559c-3ff4-4654-bb41-98404e8966f6"
      unitRef="usd">2787000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzYtNC0xLTEtNTk3NDA_ea173096-015b-4895-b50a-402c1e6df203"
      unitRef="usd">2659000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzctMi0xLTEtNTk3NDA_5dc493fa-4e12-49b0-9b2e-821b4f49ad0a"
      unitRef="usd">1577000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzctNC0xLTEtNTk3NDA_32f3ab13-4243-43d0-afbc-6d0690a84a13"
      unitRef="usd">1438000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzgtMi0xLTEtNTk3NDA_0c6b6703-6bb8-47ea-8271-e34f1e69cea8"
      unitRef="usd">3019000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzgtNC0xLTEtNTk3NDA_92e8ee9e-c370-4f1c-9653-bf0c8cc6471c"
      unitRef="usd">23000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzktMi0xLTEtNTk3NDA_6c2e9f79-dc4f-401a-bd9a-cac099a69b1e"
      unitRef="usd">856000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfMzktNC0xLTEtNTk3NDA_9a6fd6b3-53be-4283-ac1c-0c32199b83bb"
      unitRef="usd">475000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDAtMi0xLTEtNTk3NDA_f7ea3b66-f85d-4978-b1b3-6d6675232f9e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDAtNC0xLTEtNTk3NDA_f7a3beb4-a6cc-461a-ba9f-981bc67c4019"
      unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDEtMi0xLTEtNTk3NDA_0d9ce7d2-78f4-4a61-8ade-06159e240557"
      unitRef="usd">2132000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDEtNC0xLTEtNTk3NDA_a2ff9355-cd20-4880-81b6-9c0633204445"
      unitRef="usd">1001000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDItMi0xLTEtNTk3NDA_bfe3e661-d04d-4d36-9776-8550d7137bd3"
      unitRef="usd">321000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDItNC0xLTEtNTk3NDA_b4c574fa-6b14-4f99-975f-eeff238ae95f"
      unitRef="usd">236000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDMtMi0xLTEtNTk3NDA_7c495eac-8a48-48f9-ab6f-cd9fc4fa4550"
      unitRef="usd">-235000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDMtNC0xLTEtNTk3NDA_bb90f902-48e8-408e-aac1-5c908bde34de"
      unitRef="usd">212000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDQtMi0xLTEtNTk3NDA_359b421a-6547-4fee-8459-484cc49fd95a"
      unitRef="usd">-138000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDQtNC0xLTEtNTk3NDA_7a63709b-1a9e-4ee9-83a8-d89378e8b816"
      unitRef="usd">-24000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDYtMi0xLTEtNTk3NDA_58cb41ec-1195-4e04-af9e-ef8a1f5ee492"
      unitRef="usd">-4385000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDYtNC0xLTEtNTk3NDA_932985b7-af2d-416e-a6a8-2d6b669fee48"
      unitRef="usd">-5125000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDgtMi0xLTEtNTk3NDA_f55daaac-8d33-46d6-b60d-2dba733d0fac"
      unitRef="usd">16000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDgtNC0xLTEtNTk3NDA_6631cf3d-e65b-4c48-a1f2-05b71f31611f"
      unitRef="usd">-78000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDktMi0xLTEtNTk3NDA_9edcf010-3b69-4a36-8dda-5a9ea9c6fd39"
      unitRef="usd">-4024000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNDktNC0xLTEtNTk3NDA_e5a3f9a1-305d-4487-98a1-7279e08c6583"
      unitRef="usd">-1314000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTAtMi0xLTEtNTk3NDA_0c98dc73-60f1-457b-94c4-49a5026b35ea"
      unitRef="usd">14487000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iccce36176b41451cb72ade5fd7acd620_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTAtNC0xLTEtNTk3NDA_f67ca8d0-c2a0-4ded-a3f5-71723a93befc"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTEtMi0xLTEtNTk3NDA_cc2173e1-80d4-449a-b91b-2eec0d43e191"
      unitRef="usd">10463000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib4ebcce5ed4d4fa88b1380565ad0cd2f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTEtNC0xLTEtNTk3NDA_9424d317-782c-4b24-b7be-55f991a97633"
      unitRef="usd">12671000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTgtMi0xLTEtNTk3NDA_db72b387-7cc2-43e2-9f89-232b9e53bb91"
      unitRef="usd">255000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTgtNC0xLTEtNTk3NDA_6e94005d-9a96-4c4b-b8e8-894cf57b0e9a"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTktMi0xLTEtNTk3NDA_8fc6216e-ab31-4e18-b278-edcd06926258"
      unitRef="usd">3000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNTktNC0xLTEtNTk3NDA_43800075-be8e-42d8-8769-a3af023da82d"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNjAtMi0xLTEtNTk3NDA_b440bd49-48ec-419d-b991-b6cd7dee97ea"
      unitRef="usd">252000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF80Ni9mcmFnOmY3MzI2MzM5MjUyMDQyNTlhY2Y3YmIyMDAxZWZhZjRiL3RhYmxlOjk1NGMyZmQ0NzY1ZDQyNTI4Y2U5MmYxNjM0NjUzMjcxL3RhYmxlcmFuZ2U6OTU0YzJmZDQ3NjVkNDI1MjhjZTkyZjE2MzQ2NTMyNzFfNjAtNC0xLTEtNTk3NDA_5f80250c-e905-42d4-b3f3-11eb7a3224b1"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81Mi9mcmFnOjI1MGI1NDA1MmZhZjQ4YWViMmRiOWJmYTVmMzZjZmM2L3RleHRyZWdpb246MjUwYjU0MDUyZmFmNDhhZWIyZGI5YmZhNWYzNmNmYzZfMjgyNQ_eccf885b-3fcb-492a-9af4-dba68ad8d1c0">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp;amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#x2019;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended April&#160;3, 2022, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal first quarter of 2022 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal first quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81Mi9mcmFnOjI1MGI1NDA1MmZhZjQ4YWViMmRiOWJmYTVmMzZjZmM2L3RleHRyZWdpb246MjUwYjU0MDUyZmFmNDhhZWIyZGI5YmZhNWYzNmNmYzZfMjgyOA_2649cec5-b437-4ca1-89f5-28387e3c49a1">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of April&#160;3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets along with the Company&#x2019;s on-going vaccine development and distribution efforts. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended April&#160;3, 2022, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81Mi9mcmFnOjI1MGI1NDA1MmZhZjQ4YWViMmRiOWJmYTVmMzZjZmM2L3RleHRyZWdpb246MjUwYjU0MDUyZmFmNDhhZWIyZGI5YmZhNWYzNmNmYzZfMjgyOQ_32e1fa53-dfb4-453b-bc8e-090e20dc4487">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. There were no new material accounting standards issued in the fiscal first quarter of 2022 that impacted the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal first quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81Mi9mcmFnOjI1MGI1NDA1MmZhZjQ4YWViMmRiOWJmYTVmMzZjZmM2L3RleHRyZWdpb246MjUwYjU0MDUyZmFmNDhhZWIyZGI5YmZhNWYzNmNmYzZfMjgzNQ_e554cf5b-4e93-4a63-bbed-e11064e728d0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RleHRyZWdpb246ODk1NDI2NjJiZTlkNGMyNzgzODVkYWRlNDdiY2IzYThfMzc_5a222967-57c0-489f-a3fe-a3a59f90d25c">INVENTORIES &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RleHRyZWdpb246ODk1NDI2NjJiZTlkNGMyNzgzODVkYWRlNDdiY2IzYThfMzM_fac69bb2-c6e6-4734-bde4-3229c297bee3">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMS0yLTEtMS01OTc0MA_bc13bbb4-6e37-476c-8a4e-4fd360792f1d"
      unitRef="usd">1679000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMS00LTEtMS01OTc0MA_6ab1658b-44cd-4249-b587-9d4b24bf883b"
      unitRef="usd">1592000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMi0yLTEtMS01OTc0MA_c69989ec-4e70-405b-bfba-29f1be1ba2ab"
      unitRef="usd">2629000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMi00LTEtMS01OTc0MA_6e81bef7-6194-4604-aa6c-75acb8ed0da6"
      unitRef="usd">2287000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMy0yLTEtMS01OTc0MA_24e73555-17a2-41b6-897c-ce40e8c7ab73"
      unitRef="usd">6682000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfMy00LTEtMS01OTc0MA_36299751-1f99-4bf3-ad3c-b522d3972ada"
      unitRef="usd">6508000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfNC0yLTEtMS01OTc0MA_7de38ef8-73aa-4d5b-9f65-490967ab37e5"
      unitRef="usd">10990000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81NS9mcmFnOjg5NTQyNjYyYmU5ZDRjMjc4Mzg1ZGFkZTQ3YmNiM2E4L3RhYmxlOmFiMzNiZDc2YTM3YTRhMzhhNmE0MDdlYTJkNDZiMDkzL3RhYmxlcmFuZ2U6YWIzM2JkNzZhMzdhNGEzOGE2YTQwN2VhMmQ0NmIwOTNfNC00LTEtMS01OTc0MA_b454f8e7-6b8b-4a31-a869-0e556ded7492"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMjAxMA_fe248bec-b51a-44e2-86f3-5cd382d59bfa">INTANGIBLE ASSETS AND GOODWILL&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of April&#160;3, 2022 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $1.2&#160;billion for the fiscal first quarters ended April&#160;3, 2022 and April&#160;4, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMjAwNw_0207071f-d589-42aa-9b2a-a897d23471e8">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020.&lt;/span&gt;&lt;/div&gt;</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7c14471cebb545af9f344092e43e244d_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMi0yLTEtMS01OTc0MA_8d2a3dc8-e6a7-48ef-8ab8-637b2ef7a6dc"
      unitRef="usd">37960000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i751430dc512846d6bd038f8d3e545317_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMi00LTEtMS01OTc0MA_bc123373-86bb-44c0-8111-128cc1da60e4"
      unitRef="usd">38572000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7c14471cebb545af9f344092e43e244d_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMy0yLTEtMS01OTc0MA_232b9087-4e03-4911-aa19-4f76a3e7aca5"
      unitRef="usd">20492000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i751430dc512846d6bd038f8d3e545317_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMy00LTEtMS01OTc0MA_61bdbbb9-f00b-4adb-99ef-18fba65e3696"
      unitRef="usd">20088000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7c14471cebb545af9f344092e43e244d_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNC0yLTEtMS01OTc0MA_5843e47b-cf8b-4965-8431-64f0098a8f83"
      unitRef="usd">17468000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i751430dc512846d6bd038f8d3e545317_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNC00LTEtMS01OTc0MA_6875e875-d985-43f2-8e6d-3579c9eefd9b"
      unitRef="usd">18484000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8427fded54d64f59a314115c202ccb4b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNS0yLTEtMS01OTc0MA_4824c378-9cb3-49c3-914a-4544b76cfc57"
      unitRef="usd">22910000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2ca6e4c72b3b411e8e7e9c40313e1011_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNS00LTEtMS01OTc0MA_9abd355c-b220-484d-ac0b-020201848ea3"
      unitRef="usd">23011000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8427fded54d64f59a314115c202ccb4b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNi0yLTEtMS01OTc0MA_f2678ef0-7473-4cab-bcbe-30f0c8669cdc"
      unitRef="usd">12147000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2ca6e4c72b3b411e8e7e9c40313e1011_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNi00LTEtMS01OTc0MA_0218dfeb-7264-4e86-974e-894c404124fd"
      unitRef="usd">11925000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8427fded54d64f59a314115c202ccb4b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNy0yLTEtMS01OTc0MA_25b1b09f-8a8e-4bd0-8525-3b1a0ce73613"
      unitRef="usd">10763000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2ca6e4c72b3b411e8e7e9c40313e1011_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfNy00LTEtMS01OTc0MA_c3314831-937e-4faf-91db-ca52371378d8"
      unitRef="usd">11086000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i631a68382dbe4356a80463ddeb81e9e7_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfOS0yLTEtMS01OTc0MA_8bf96e8f-9d17-4e31-b741-b9758f093bec"
      unitRef="usd">6947000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ifbab423fd5014e1482bba4a9327c8dc4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfOS00LTEtMS01OTc0MA_8c6d68ab-bddf-4f34-8d4c-b7b88239ec4e"
      unitRef="usd">6985000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i97cbf7df6c0c4273a06533b0d3e5c206_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTAtMi0xLTEtNTk3NDA_13b8fcb7-b0ff-466f-9753-8a091e7a7e93"
      unitRef="usd">9242000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic60ed3f5f8b143f28c600b4ef6f83731_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTAtNC0xLTEtNTk3NDA_5068fe9a-422f-4e5f-ba4c-fe3b2dd6a5f5"
      unitRef="usd">9837000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTEtMi0xLTEtNTk3NDA_23f79018-30a7-45ef-88a9-ae2f8354c51c"
      unitRef="usd">16189000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTEtNC0xLTEtNTk3NDA_cfcff3cf-5785-4779-b6a4-61691c90a437"
      unitRef="usd">16822000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTItMi0xLTEtNTk3NDA_6a5b48b4-9e8f-4580-a3b4-1aa6e0b7c468"
      unitRef="usd">44420000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjliYjA0YTRjNjQ1NjQyZWJhOTRiNTg3NWJlYzM3ZGJlL3RhYmxlcmFuZ2U6OWJiMDRhNGM2NDU2NDJlYmE5NGI1ODc1YmVjMzdkYmVfMTItNC0xLTEtNTk3NDA_fbce53b6-e123-4762-a96f-fafb47b4c00a"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i754795b41ad945a7ac5ecd6f2ea1cbe2_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfNTk1_615d2341-311b-4f3c-89cc-a6741c6ff29e"
      unitRef="usd">600000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMjAwOA_98eb7cd9-b715-4265-8f98-8dc6e3b82fcf">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of April&#160;3, 2022 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i273a2ba53146449c8a18b08bc38532ee_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMS0yLTEtMS01OTc0MA_e0f4f41f-77c5-401e-a7e4-b880eb539f1c"
      unitRef="usd">9810000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i706befc122c24b74b7c46cad04eefa00_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMS00LTEtMS01OTc0MA_843cbffd-f5cc-461e-a816-27476a64637a"
      unitRef="usd">10580000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6ac3910bc9284705b8c0311e059b8e26_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMS02LTEtMS01OTc0MA_f6db6569-5d85-4b76-885a-827c3fba9c06"
      unitRef="usd">14856000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMS04LTEtMS01OTc0MA_d54249ed-9015-430c-9331-692ba9d0141f"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMi0yLTEtMS01OTc0MA_4993ae68-f6ed-4419-a9b0-6b66e43cf7e0"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMi00LTEtMS01OTc0MA_23aab6b9-9979-4b46-8fb8-5e0306688e16"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMi02LTEtMS01OTc0MA_00c45908-00ba-4778-a0a0-e23ec997de7a"
      unitRef="usd">73000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfMi04LTEtMS01OTc0MA_7ee37592-6521-43f2-8106-cad22aeb5314"
      unitRef="usd">73000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNC0yLTEtMS01OTc0MA_f5bc22eb-90fa-46b7-9e33-84f5b126461c"
      unitRef="usd">-195000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNC00LTEtMS01OTc0MA_45c11642-b57b-42be-bc1c-e2204cf68436"
      unitRef="usd">-170000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNC02LTEtMS01OTc0MA_f984e05f-cdf2-4c58-824e-1d8a58a9af1f"
      unitRef="usd">-19000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNC04LTEtMS01OTc0MA_cf95fbc0-b4e9-4f9d-96fa-c8305bf70aa3"
      unitRef="usd">-384000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="id6fe7c6e2f574a619178fc635b10b3b2_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNS0yLTEtMS01OTc0MA_0006f9c5-82aa-423e-8fad-3ba93c9640a8"
      unitRef="usd">9615000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic00ca16d24bf44179d8fcf374cbf27d7_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNS00LTEtMS01OTc0MA_c044bba4-6920-4cd2-966e-b5e9c4a1d8b4"
      unitRef="usd">10410000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i681532a4eb3648508653f9fb60ec8408_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNS02LTEtMS01OTc0MA_b7c014b0-d911-4f45-a022-20a7e2530d8c"
      unitRef="usd">14910000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjA1MjQyZGE3Nzg3NjQ3MTY4OWUzZGUxNDNlZWY2OWRiL3RhYmxlcmFuZ2U6MDUyNDJkYTc3ODc2NDcxNjg5ZTNkZTE0M2VlZjY5ZGJfNS04LTEtMS01OTc0MA_88f1a95b-ce3b-4b9b-8b41-d9517d8504a8"
      unitRef="usd">34935000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9b8fe868a0e94657aceaf9efda5d051e_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMTI3NQ_ec474807-d58a-4fb2-99d4-aef5670e6fea">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4bcace6a0596406b8dd0416cfb063a83_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMTM4NA_ec36233a-fe05-4225-a2b5-253914308946">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMTQ5MA_8369af1a-2c4f-4f5a-ab84-46829fcf7a9b"
      unitRef="usd">1100000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMTQ5Nw_bf1e0778-94f6-4046-8d05-38d754240e9b"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RleHRyZWdpb246NjU2NDQyZGE4MTNiNDQ3NTg0M2UyN2Q0N2E4YWUxZWVfMjAxNw_12b7ac2a-ff98-4d14-be90-22203faab260">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi0wLTEtMS01OTc0MA_c6de0ba4-d2c6-4ca0-832f-41e570c9fc7c"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi0yLTEtMS01OTc0MA_2d5cfddf-31d2-4cbc-8d52-42aa86570ba6"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi00LTEtMS01OTc0MA_d5d22afb-de78-44de-9e7b-fcccbb657ec1"
      unitRef="usd">4400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi02LTEtMS01OTc0MA_d89d100e-4d4a-4f9c-bcb2-24f7dd9a8d19"
      unitRef="usd">3600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF81OC9mcmFnOjY1NjQ0MmRhODEzYjQ0NzU4NDNlMjdkNDdhOGFlMWVlL3RhYmxlOjVhMGU3ZjQxMjg4OTQ2YTU5NDBiZjA4YjZiYzg0M2ZiL3RhYmxlcmFuZ2U6NWEwZTdmNDEyODg5NDZhNTk0MGJmMDhiNmJjODQzZmJfMi04LTEtMS01OTc0MA_4813cf7d-8706-4067-9da1-0de2a748e1ae"
      unitRef="usd">3000000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwOTg_01889c12-2c23-4364-a7cb-2308a58efd14">FAIR VALUE MEASUREMENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April&#160;3, 2022, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $1.1 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April&#160;3, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $42.5&#160;billion, $37.4&#160;billion and $10.0&#160;billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion,  $37.4 billion and $10.0 billion respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April&#160;3, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $632&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net investment hedge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  April&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal first quarters ended in 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="33" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity investments without readily determinable market values, there was a decrease of $5 million in the fair value reflected in net income as a result of impairments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of April&#160;3, 2022 and January&#160;2, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $469 million and $520 million, classified as non-current other liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $17 million and $13 million classified as current liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of April&#160;3, 2022 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain/( Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other sovereign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the fiscal year ended January&#160;2, 2022 the carrying amount was approximately the same as the estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of April&#160;3, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;3, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.1311)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500 MM GBP 1.3485)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.1311)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.1311)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average effective interest rate on non-current debt is 3.04%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the estimated fair value over the carrying value of debt was $3.2 billion at January 2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The current debt balance as of April&#160;3, 2022 includes $3.8&#160;billion of commercial paper which has a weighted average interest rate of 0.37% and a weighted average maturity of approximately three months.&lt;/span&gt;&lt;/div&gt;Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTY0Nw_d77ead34-59d5-4d5d-bfda-12c1eda53ecf"
      unitRef="usd">1100000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjMxMg_e4900dc1-553e-489d-b13a-f9424b756744"
      unitRef="usd">42500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0a8ab9973a5e462d9e057abf51bcf297_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjMxNg_ee62e863-6bda-4424-8621-89ce3f81c93a"
      unitRef="usd">37400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5eadcdc996d94731b0bc1014ca9e7fd0_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjMyMw_00c00f59-4630-4e0a-8244-0e9c5c1d5cf2"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic315dcf608444a39b1cabd079a7d46cb_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjQ3Nw_0874b30e-88c7-4b9c-9e06-c35031d876e0"
      unitRef="usd">45800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7bdcc356986e4b3e80fe4abf6ec3b52c_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjQ4NA_f4d4bde0-414c-4ac2-a330-b0d8712d2732"
      unitRef="usd">37400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i07dd6b6cd781421abf5b7b35627e6b59_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMjE5OTAyMzI2NzkxMQ_f17a2e39-d492-4aec-bb97-3b146f4806bf"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfNDYxNQ_c2c5d94f-2857-42b5-96d3-d1acd5447797"
      unitRef="usd">632000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfNDg3Mw_684c0c05-ea14-42c8-b18a-d13d49bf4e6c">next 12 months</us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfNTAzNA_7c819589-48a6-46fa-8f8d-3a2f6e58978a">P18M</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwNTE_b535d7b5-c8c6-4b9f-a38e-fad8566d33fb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal first quarters ended in 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i75b7f48faa4c44dd8729fef7add9958e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC0xLTEtMS01OTc0MA_1d256fad-fdc8-488b-a833-89058369796b"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i19d4778b3c184c5b9a1268b12772f834_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC0yLTEtMS01OTc0MA_4b816321-d7dd-44f3-88fd-62a8bb4dc7f4"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ifab697ff2c9043c0af2d3551559c5cc6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC0zLTEtMS01OTc0MA_93670d3d-fa4c-4fc4-9ec0-63d710eec208"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if7ca621269f74333bfcea41317eb612d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC00LTEtMS01OTc0MA_ad864f4b-a68c-43f3-85e3-77c7b98e87aa"
      unitRef="usd">-531000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ic2ef606fc8d54064ac6785b084df413c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC01LTEtMS01OTc0MA_72032d3e-1fb7-4623-a02e-1928e2180b94"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ibc4d7ef218294617ab67cdd7ff8ae201_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC02LTEtMS01OTc0MA_15b5e446-ffe3-49a0-9a19-2e430c259254"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i285862bf68fe4a1e9a5f16fb54ec99bb_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC03LTEtMS01OTc0MA_33ce210b-7c0b-47f1-94e0-53d381269f27"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i50372bc3c1fc4262a02f85583b8add01_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC04LTEtMS01OTc0MA_5d7d2ccb-e555-459d-a96d-ed2763872740"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ide7dc652d8a14e07b4a76aeb7b9c4d21_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC05LTEtMS01OTc0MA_5550451e-8a74-4971-8335-a3f7ddacb66a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ib13b350d42d74d879d6f63915693746c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOC0xMC0xLTEtNTk3NDA_115fff2f-f0e5-4b97-812b-b1e3ec3ea2d8"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i75b7f48faa4c44dd8729fef7add9958e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS0xLTEtMS01OTc0MA_daed4cc5-5fcd-4f8e-a709-70c0672659a0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i19d4778b3c184c5b9a1268b12772f834_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS0yLTEtMS01OTc0MA_e34392b3-151e-46f1-b6a3-9772ffae4955"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ifab697ff2c9043c0af2d3551559c5cc6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS0zLTEtMS01OTc0MA_e5ff2791-3aac-4151-a0ca-faafb245a933"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if7ca621269f74333bfcea41317eb612d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS00LTEtMS01OTc0MA_15ce752d-9b2f-4e26-b42e-18ebd454399e"
      unitRef="usd">531000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic2ef606fc8d54064ac6785b084df413c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS01LTEtMS01OTc0MA_f2b7154c-cc0a-4c6b-bea2-dd688df010db"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibc4d7ef218294617ab67cdd7ff8ae201_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS02LTEtMS01OTc0MA_38068b05-de60-4c1a-a71c-ec11eaae70c6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i285862bf68fe4a1e9a5f16fb54ec99bb_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS03LTEtMS01OTc0MA_13330c78-814d-45b5-98b6-1936365abc1b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i50372bc3c1fc4262a02f85583b8add01_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS04LTEtMS01OTc0MA_42cf86cd-8e19-4c2b-bac4-a6d941111f28"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ide7dc652d8a14e07b4a76aeb7b9c4d21_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS05LTEtMS01OTc0MA_0c524d25-1d49-4ee2-9728-15a04894c054"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib13b350d42d74d879d6f63915693746c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfOS0xMC0xLTEtNTk3NDA_bcfe5200-d455-4e74-ae2a-c61e0575b75f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i6fbe2ddfa5bd4c3c81d6b1a89bd6a3c6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtMS0xLTEtNTk3NDA_4d09bdc3-23a9-41c3-9f0d-235d8522140a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if6710a293c7049a89bd678b9ebf357ee_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtMi0xLTEtNTk3NDA_1d8ba734-0363-433e-a7f2-b8d4ee802ee7"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ic8c65dce193b4085ac9029e9479cc836_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtMy0xLTEtNTk3NDA_c1ffbe85-bf7d-4e0f-877b-30ccbc90b485"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i4612c0bb5e5643f0995c9a09afdf8c41_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtNC0xLTEtNTk3NDA_3e0ab571-185a-4769-b01a-c8435d58f482"
      unitRef="usd">45000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ica35e7e4a05a4bf1ae3566e17b66227a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtNS0xLTEtNTk3NDA_701110bf-ec5d-4b45-a350-13ef0201cf05"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id3a21486e41041aea8b93609d24e888e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtNi0xLTEtNTk3NDA_498d4bda-f2ad-4490-8813-bafcf785ee6c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id5125127475344a8bec0db5ebc5cba0d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtNy0xLTEtNTk3NDA_cb117bc0-0f74-4215-bf32-4a6fb5bbe4fe"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i24069a0bb5314816b75b91710ef6fb4f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtOC0xLTEtNTk3NDA_16687cee-0350-41ff-9b4c-a3c5c2cc97e7"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i1fb4260113ae447a8ac220acba4cae35_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtOS0xLTEtNTk3NDA_fa0a0d8f-40d7-4a10-934e-6ce2efad4d4a"
      unitRef="usd">40000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i1dd707f3f168499dbac4bc8fb516087e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTMtMTAtMS0xLTU5NzQw_cae4c226-cf9f-4503-952d-d584a8825c09"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6fbe2ddfa5bd4c3c81d6b1a89bd6a3c6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtMS0xLTEtNTk3NDA_760247ac-7fa8-4a85-b2f1-7eb3ab3ce197"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if6710a293c7049a89bd678b9ebf357ee_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtMi0xLTEtNTk3NDA_2e7dad8f-3de1-4fee-9c85-66df1cedccc7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic8c65dce193b4085ac9029e9479cc836_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtMy0xLTEtNTk3NDA_a39b244d-5d10-4dda-a027-74273dcc8e95"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4612c0bb5e5643f0995c9a09afdf8c41_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtNC0xLTEtNTk3NDA_b352e780-1f6f-44cf-9ae1-e54f2e1549b2"
      unitRef="usd">45000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ica35e7e4a05a4bf1ae3566e17b66227a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtNS0xLTEtNTk3NDA_9ed0029e-4766-4ba6-a2ef-ab422b4c3aa4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id3a21486e41041aea8b93609d24e888e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtNi0xLTEtNTk3NDA_c0b8950f-f795-4fea-a727-bc4b6bad34b5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id5125127475344a8bec0db5ebc5cba0d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtNy0xLTEtNTk3NDA_040cff8e-93f5-4687-9348-fb0af9a31eba"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i24069a0bb5314816b75b91710ef6fb4f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtOC0xLTEtNTk3NDA_fb7260ab-aa4d-4753-9963-d90a24be08c0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1fb4260113ae447a8ac220acba4cae35_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtOS0xLTEtNTk3NDA_73cc248a-fc96-4045-86c9-5ecd8938dd86"
      unitRef="usd">40000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1dd707f3f168499dbac4bc8fb516087e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTQtMTAtMS0xLTU5NzQw_01f57874-714f-4488-bc4d-a5ce47e95a93"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i35c1225f1fc642b89ce27325e2764fe6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtMS0xLTEtNTk3NDA_5f7b6779-20e2-4401-aea5-dd74649ee9c8"
      unitRef="usd">-17000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i1ca0c41746e24c10a5010f5e3b375875_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtMi0xLTEtNTk3NDA_0ed11395-bd04-4f6e-b695-914efd33208b"
      unitRef="usd">-52000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i906bc2f6d0734e46a265b998dfb78e1f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtMy0xLTEtNTk3NDA_93a91df4-7a3d-4e19-8bb9-0ac3c8a194e6"
      unitRef="usd">23000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ic3a7b113cd604b97b6359f1ca89f88e9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtNC0xLTEtNTk3NDA_098a36b7-6e17-43d8-b68d-5555216db886"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iac181bd434134d0f99d2723052ebb78c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtNS0xLTEtNTk3NDA_1fc1c059-fd9e-4a43-8919-ca52cabc39be"
      unitRef="usd">-18000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i98498dc117454edda8260632bcf14b3e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtNi0xLTEtNTk3NDA_9224da70-e9e7-421f-bcd3-89b836cc0300"
      unitRef="usd">17000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="icc1a147f22b444088512ccac59a70251_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtNy0xLTEtNTk3NDA_3f705401-144a-4191-8cfb-397827d7c859"
      unitRef="usd">34000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i629d4c6fdf6e40a39dfb7d01c00f6bbc_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtOC0xLTEtNTk3NDA_e8d6ce76-1b4b-4a63-b444-1c255e35c85f"
      unitRef="usd">-113000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="icc4edbfa092a4db08c3097d31dfde751_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtOS0xLTEtNTk3NDA_d064f1ea-d77a-4364-bdb3-5a1d240454fe"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i5358dcc8f8d448188a6577bca61d7df2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMTgtMTAtMS0xLTU5NzQw_60b76d4d-1219-4ed2-82d3-df7523e4a456"
      unitRef="usd">3000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i35c1225f1fc642b89ce27325e2764fe6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItMS0xLTEtNTk3NDA_3e3f1f55-1d55-45eb-b3c3-47aa9702273a"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1ca0c41746e24c10a5010f5e3b375875_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItMi0xLTEtNTk3NDA_8b8f4e07-171f-480f-b720-def2b09dd24b"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i906bc2f6d0734e46a265b998dfb78e1f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItMy0xLTEtNTk3NDA_3ab18a16-fd50-4168-a8ab-bc26b5b2e041"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic3a7b113cd604b97b6359f1ca89f88e9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItNC0xLTEtNTk3NDA_eb62e0e9-855d-46ef-ac60-d291e0fc7603"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iac181bd434134d0f99d2723052ebb78c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItNS0xLTEtNTk3NDA_98f62c2f-9718-493e-a940-1a91ac8f92b4"
      unitRef="usd">-73000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i98498dc117454edda8260632bcf14b3e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItNi0xLTEtNTk3NDA_1739e50f-de99-4ae1-bdc1-0d5787918639"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="icc1a147f22b444088512ccac59a70251_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItNy0xLTEtNTk3NDA_27ce767d-031d-4974-a4c7-12b90d0bda94"
      unitRef="usd">-193000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i629d4c6fdf6e40a39dfb7d01c00f6bbc_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItOC0xLTEtNTk3NDA_c0c8ee21-92f7-4a4f-8ba1-c41aed9bdced"
      unitRef="usd">-76000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="icc4edbfa092a4db08c3097d31dfde751_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItOS0xLTEtNTk3NDA_c236f2d7-cef4-4576-8f93-192a774ad570"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5358dcc8f8d448188a6577bca61d7df2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjItMTAtMS0xLTU5NzQw_f8f22104-71a7-49db-b820-e24f586705d1"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i25e8ee39318f4e8b8637328665ee6121_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtMS0xLTEtNTk3NDA_74eef1bf-d1d8-4055-8852-57f79f287186"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i9976c768bbec41ceb31dd3e5aeee895b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtMi0xLTEtNTk3NDA_55cadf4d-95b6-4cec-b1e4-40477dd79d9e"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ifa0acd8032704810ac6c33c652bb3f4a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtMy0xLTEtNTk3NDA_81292113-871c-4cd3-aa8b-50bb2fe4ac4b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i86deefadb42a48e9bb9ba37613cdc416_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtNC0xLTEtNTk3NDA_6830ab75-2388-49f5-93ad-1f82cf55600c"
      unitRef="usd">120000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i096bbfc984b74afe83163ab74df3e9c9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtNS0xLTEtNTk3NDA_f8d92983-74f8-4c79-974d-e8a4899fb6bf"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iae4da99d4bba480d99292b2891dc32d9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtNi0xLTEtNTk3NDA_1d83900d-fa00-4c55-81f8-8765735f80cd"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i200c16a786fd4d0d8795c1fc3f58843c_D20210104-20210404"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtNy0xLTEtNTk3NDA_901365cb-f17a-4b40-9867-b251be5374e4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i5d4939c05de24312b1d31bf71b02fe56_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtOC0xLTEtNTk3NDA_f019b33c-b15c-40c5-baa2-e0f1ddeedd91"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i65442762e5c14bc1abd1248fe23d8341_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtOS0xLTEtNTk3NDA_73305724-5c97-450f-b03f-1152623fce71"
      unitRef="usd">92000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i2c04b36d74874be78fc77e16c8fb290e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjUtMTAtMS0xLTU5NzQw_69ba8e87-35ae-4789-86ef-74fcc5b3290a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i25e8ee39318f4e8b8637328665ee6121_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctMS0xLTEtNTk3NDA_b3b7acce-71ca-498e-bc57-11e6dabb0fc4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9976c768bbec41ceb31dd3e5aeee895b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctMi0xLTEtNTk3NDA_0e27b1de-d118-48fa-9393-fe3b47a64818"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ifa0acd8032704810ac6c33c652bb3f4a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctMy0xLTEtNTk3NDA_70de4a4f-a753-4fc3-9a35-24dd98a8b293"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i86deefadb42a48e9bb9ba37613cdc416_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctNC0xLTEtNTk3NDA_5d4cd0e7-94cb-465b-b8c0-9a1c78944a73"
      unitRef="usd">-128000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i096bbfc984b74afe83163ab74df3e9c9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctNS0xLTEtNTk3NDA_8fd40847-3cbc-44bc-8666-33a7d5ec787e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iae4da99d4bba480d99292b2891dc32d9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctNi0xLTEtNTk3NDA_5b3445b7-6aab-4c40-b458-096d1667c1e9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i200c16a786fd4d0d8795c1fc3f58843c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctNy0xLTEtNTk3NDA_e7f09b6a-0b8c-46f7-be95-566a7ff672d0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5d4939c05de24312b1d31bf71b02fe56_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctOC0xLTEtNTk3NDA_3dd85412-a8cb-4079-b68f-7525dc0c644a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i65442762e5c14bc1abd1248fe23d8341_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctOS0xLTEtNTk3NDA_27b9da74-c7c5-44f5-9d25-f2466269a7ed"
      unitRef="usd">-307000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2c04b36d74874be78fc77e16c8fb290e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjM2MGUwZWNmNzM0NjRkNDRhYTFiYzkzZTZiNTM5YjQyL3RhYmxlcmFuZ2U6MzYwZTBlY2Y3MzQ2NGQ0NGFhMWJjOTNlNmI1MzliNDJfMjctMTAtMS0xLTU5NzQw_1a0eb1f5-8928-4c1e-9274-5c145ea3ade9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwODk_1b11ef31-2071-4032-994e-395f649c1e98">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  April&#160;3, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i92ed1d2317744e2fbc2c3b45e1b4d2e2_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjJhYzY3Njg5MmNiODQ4ODg4NmI2ZTEyYmZhMmRjZGE4L3RhYmxlcmFuZ2U6MmFjNjc2ODkyY2I4NDg4ODg2YjZlMTJiZmEyZGNkYThfNC0yLTEtMS01OTc0MA_2703dd17-6518-4f25-8937-ce2f3c62e8f1"
      unitRef="usd">9313000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ic66d9ac41ee14e4f935d98d0f8036683_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjJhYzY3Njg5MmNiODQ4ODg4NmI2ZTEyYmZhMmRjZGE4L3RhYmxlcmFuZ2U6MmFjNjc2ODkyY2I4NDg4ODg2YjZlMTJiZmEyZGNkYThfNC00LTEtMS01OTc0MA_d1b74669-9f58-40bc-b8eb-8875a2b643a4"
      unitRef="usd">9793000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i92ed1d2317744e2fbc2c3b45e1b4d2e2_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjJhYzY3Njg5MmNiODQ4ODg4NmI2ZTEyYmZhMmRjZGE4L3RhYmxlcmFuZ2U6MmFjNjc2ODkyY2I4NDg4ODg2YjZlMTJiZmEyZGNkYThfNC02LTEtMS01OTc0MA_b95e5d30-593e-4f52-bea8-036726266a5f"
      unitRef="usd">-694000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ic66d9ac41ee14e4f935d98d0f8036683_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjJhYzY3Njg5MmNiODQ4ODg4NmI2ZTEyYmZhMmRjZGE4L3RhYmxlcmFuZ2U6MmFjNjc2ODkyY2I4NDg4ODg2YjZlMTJiZmEyZGNkYThfNC04LTEtMS01OTc0MA_faa95730-3b15-471d-bf03-daf79d419350"
      unitRef="usd">-142000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwNzM_2f82a726-3e8c-4c9e-9ca8-05dc1df3c43c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i0dc14e7b1e2e4a29877dd2b95650a3ac_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjgyYTZjNzZmOTBjMjQ5ODA4YzUwN2E3N2MxNGY5Y2RjL3RhYmxlcmFuZ2U6ODJhNmM3NmY5MGMyNDk4MDhjNTA3YTc3YzE0ZjljZGNfNC00LTEtMS01OTc0MA_2a6ede29-3663-478a-a2e3-43c25739de04"
      unitRef="usd">29000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ice21f8d2655e4d0f8095be5911f1fd8b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjgyYTZjNzZmOTBjMjQ5ODA4YzUwN2E3N2MxNGY5Y2RjL3RhYmxlcmFuZ2U6ODJhNmM3NmY5MGMyNDk4MDhjNTA3YTc3YzE0ZjljZGNfNC02LTEtMS01OTc0MA_99ebd2b9-f83a-4492-ba2d-2548eeda50af"
      unitRef="usd">-16000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfMy0yLTEtMS01OTc0MA_38efe80d-8ec1-4487-8c65-7fa549780c59"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfMy00LTEtMS01OTc0MA_549a0f6b-abb5-4f0e-bdf0-833e3eb245e9"
      unitRef="usd">209000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i2a4f1c2e35354c268ad4b4f0c299f46c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfMy04LTEtMS01OTc0MA_32e6757d-e3b2-46a4-8d4d-2ec29d228700"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ibe06a04b32f541198cc74c4294d74b7e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfMy0xMC0xLTEtNTk3NDA_f71e1243-0995-40ac-8b01-a06301c098df"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i58ce73a23c814452a90b72fe868271de_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfNC0yLTEtMS01OTc0MA_7840d9a7-570c-4123-991f-6b5ec8bf3e79"
      unitRef="usd">560000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i977c041569204263b24ecc0054d30d6f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfNC00LTEtMS01OTc0MA_7ca7bbc9-a0db-4cfd-9245-c48bcb68c969"
      unitRef="usd">361000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i581046ca0e0f48929501b5a10dbaba2f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfNC04LTEtMS01OTc0MA_a4f587af-b56f-4590-81d2-71f7f8cee9e1"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i645a971a555b4c089758583b67f9d08c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjRhYTI1NTU4NDk1MzQ1MWJiNzUzYzViMzAxMWZjMjc0L3RhYmxlcmFuZ2U6NGFhMjU1NTg0OTUzNDUxYmI3NTNjNWIzMDExZmMyNzRfNC0xMC0xLTEtNTk3NDA_ec62a82f-a6bb-43aa-8b74-94a13ac39f0c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwMzc_42966425-cd61-4525-adbe-4468ba8b40f6">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.464%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i6f4dbad0006c47f48dad1e81741750fc_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi0yLTEtMS01OTc0MA_c5399613-1901-47b2-baa3-ae8f49657cb0"
      unitRef="usd">1884000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="ic3823718f66a4b499cedb42d987cd246_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi00LTEtMS01OTc0MA_3934f03f-543a-4e99-9092-5af48178f688"
      unitRef="usd">-402000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="ic3823718f66a4b499cedb42d987cd246_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi02LTEtMS01OTc0MA_b180733b-7f63-4014-a54d-9297a54b09e0"
      unitRef="usd">-30000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="if80323310c7943d89e72028b427412c1_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi04LTEtMS01OTc0MA_59aa7ab2-29a1-4cb3-87b8-c0d4b9042d60"
      unitRef="usd">1452000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if80323310c7943d89e72028b427412c1_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfMi0xMC0xLTEtNTk3NDA_d1732cf1-f295-4634-9a24-81049b15bdd8"
      unitRef="usd">1452000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="iaf02920ebc8f4f46a0a1307481df3c99_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC0yLTEtMS01OTc0MA_565629b3-065f-4116-86ea-18d0a8920d9e"
      unitRef="usd">500000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i195975cd0e7f446da43714458700190f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC00LTEtMS01OTc0MA_3c57d007-2737-4b88-a7df-ca7701f86939"
      unitRef="usd">-5000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i195975cd0e7f446da43714458700190f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC02LTEtMS01OTc0MA_e2824550-099d-460a-8c2a-f48d19a6b663"
      unitRef="usd">10000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i33f60cf5f7ad40df935bf2a4865220fc_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC04LTEtMS01OTc0MA_8f4e19f3-d276-42ae-81ca-503049c776fb"
      unitRef="usd">505000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i33f60cf5f7ad40df935bf2a4865220fc_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjAzNWM2MDcwYTk2ZjQyMzViODIwYzM2NDY1MzNiZDg2L3RhYmxlcmFuZ2U6MDM1YzYwNzBhOTZmNDIzNWI4MjBjMzY0NjUzM2JkODZfNC0xMC0xLTEtNTk3NDA_dd22036c-c06c-4ab1-b8f5-8c7e588ef262"
      unitRef="usd">505000000</us-gaap:OtherAssetsNoncurrent>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="i195975cd0e7f446da43714458700190f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfNjc0OA_9ec5b120-91c3-4738-8fa9-cfe1903dcd3d"
      unitRef="usd">-5000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwNjM_5c7eae83-400f-477c-b468-28aedd349883">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of April&#160;3, 2022 and January&#160;2, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $469 million and $520 million, classified as non-current other liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.  Includes $17 million and $13 million classified as current liabilities as of April&#160;3, 2022 and January&#160;2, 2022, respectively.&lt;/span&gt;&lt;/div&gt;           (6)    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ic8a3783f757347e6a884c99fba04723c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC0yLTEtMS01OTc0MA_5e3374c9-5519-4b19-9866-f2be8ca1cabd"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC00LTEtMS01OTc0MA_3958cbf8-5999-4cb4-908a-411bd8605031"
      unitRef="usd">742000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i05510e5c3ec344fca7b25f4799ad39c6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC02LTEtMS01OTc0MA_f983db70-eee4-41c0-a815-eb448462899f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC04LTEtMS01OTc0MA_ed432170-4aab-4209-98fa-853ca3f2d58e"
      unitRef="usd">742000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNC0xMC0xLTEtNTk3NDA_a085621a-e2be-4623-a3dd-0f4b49d32b3d"
      unitRef="usd">540000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7ee07eab57304c94a3dfcb3ae7fbee1e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS0yLTEtMS01OTc0MA_a65dacae-e649-45ec-bf4d-783141e0d5e5"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i40143a9bc0fb45f6989738a947b0838e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS00LTEtMS01OTc0MA_fafc67e1-6e50-4fba-beba-0f0f2a1b3be1"
      unitRef="usd">975000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ia2b3a8c85a4a4df28a3c6f3b7f5df006_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS02LTEtMS01OTc0MA_7a36cffa-9d9e-4720-ae22-6868a7f4d1d5"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="iad75e5d7a8d640fc9b410ca0e00b1a1a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS04LTEtMS01OTc0MA_b90a142b-13f9-40ed-9750-7e6d7357035d"
      unitRef="usd">975000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i423527772d4f4352be8af130cdc45743_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNS0xMC0xLTEtNTk3NDA_ede9cf42-0c09-424b-bdd1-6e47b0510845"
      unitRef="usd">796000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy0yLTEtMS01OTc0MA_dc804fac-2524-436e-bb9d-e7a70353c5db"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy00LTEtMS01OTc0MA_bc8747b1-dac5-4360-b883-ac2c92410bd3"
      unitRef="usd">1717000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy02LTEtMS01OTc0MA_43a6415e-e16e-497a-a7ba-dea0d9fa0c56"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy04LTEtMS01OTc0MA_11df5d80-2af2-46ee-a5e6-84cf13d50d9e"
      unitRef="usd">1717000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="id2153712ae1a485ab5669a52af66f1b4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfNy0xMC0xLTEtNTk3NDA_89f77a1d-4082-405f-ac8e-d1bf4dcb87c3"
      unitRef="usd">1336000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ic8a3783f757347e6a884c99fba04723c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS0yLTEtMS01OTc0MA_4126ecc5-5daf-4512-803d-3a2f01c87163"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS00LTEtMS01OTc0MA_d7db2732-560b-4002-a9c5-b11ca84dea47"
      unitRef="usd">1058000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i05510e5c3ec344fca7b25f4799ad39c6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS02LTEtMS01OTc0MA_e7f422a1-ae3b-4151-924b-278b7ec752f4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS04LTEtMS01OTc0MA_b0d4047d-6043-4c0e-af34-a8489fe41b0f"
      unitRef="usd">1058000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfOS0xMC0xLTEtNTk3NDA_0c6ac260-2399-44c6-abb1-818feccc99ed"
      unitRef="usd">881000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7ee07eab57304c94a3dfcb3ae7fbee1e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtMi0xLTEtNTk3NDA_068d7815-5571-4052-b41f-7f987cf20160"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i40143a9bc0fb45f6989738a947b0838e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtNC0xLTEtNTk3NDA_eb4c1bd0-f5aa-4565-aa41-b4bfd80475b0"
      unitRef="usd">1652000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ia2b3a8c85a4a4df28a3c6f3b7f5df006_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtNi0xLTEtNTk3NDA_fb8fe7d0-2c0c-4ffc-8d23-a5d799dc9d58"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="iad75e5d7a8d640fc9b410ca0e00b1a1a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtOC0xLTEtNTk3NDA_dad032b9-b60c-4605-88d3-232572ae7bf2"
      unitRef="usd">1652000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i423527772d4f4352be8af130cdc45743_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTAtMTAtMS0xLTU5NzQw_797d49a8-ca38-4574-a6f7-2d28d6de7039"
      unitRef="usd">979000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItMi0xLTEtNTk3NDA_e364b3bd-05d2-469f-b82a-db63f041ff6b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItNC0xLTEtNTk3NDA_664ec61b-e9ee-443c-b7d2-0ffae75e3ac6"
      unitRef="usd">2710000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItNi0xLTEtNTk3NDA_a6aa9f2d-fa51-40ba-a26a-aaf522cdf526"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItOC0xLTEtNTk3NDA_7d82685b-52ef-4cf9-985b-80504ca05d01"
      unitRef="usd">2710000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="id2153712ae1a485ab5669a52af66f1b4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTItMTAtMS0xLTU5NzQw_e53877f3-e9df-4e83-b1b9-afc7c5baf484"
      unitRef="usd">1860000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ic8a3783f757347e6a884c99fba04723c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtMi0xLTEtNTk3NDA_1e3ae94f-d387-4f29-94f7-bceb3e9d8f52"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtNC0xLTEtNTk3NDA_c83fd755-9c72-44e8-9862-8c9d63f219b9"
      unitRef="usd">36000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i05510e5c3ec344fca7b25f4799ad39c6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtNi0xLTEtNTk3NDA_df29ee44-3a89-4abe-97d4-213a7572efd7"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtOC0xLTEtNTk3NDA_09d34dc9-6256-47be-888a-6d956cceadbb"
      unitRef="usd">36000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTUtMTAtMS0xLTU5NzQw_5e9fe0e8-61d8-499a-b94f-141a4ef85613"
      unitRef="usd">24000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ic8a3783f757347e6a884c99fba04723c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctMi0xLTEtNTk3NDA_655b2ce0-b2d5-42a6-83ab-cf71a7b1ebbe"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ibcd26aa540cf4665b2fb7507191ad2d1_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctNC0xLTEtNTk3NDA_5c95fe92-309a-4d0a-a938-1259b5635caf"
      unitRef="usd">68000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i05510e5c3ec344fca7b25f4799ad39c6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctNi0xLTEtNTk3NDA_e6e56267-7718-47e3-a465-828901674db0"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i2d4870c963ef433abc7a4fea5eba6e84_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctOC0xLTEtNTk3NDA_8f2c1990-07c4-4666-9596-8965c38aab5f"
      unitRef="usd">68000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i9a84fa7c6c0b4717911dd53780a1feb5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTctMTAtMS0xLTU5NzQw_122247d4-cd7b-414f-9a2f-a255654131c4"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktMi0xLTEtNTk3NDA_6ae4d426-f723-4301-a1b4-b2ec7c4f2be0"
      unitRef="usd">1452000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktNC0xLTEtNTk3NDA_c24e0cfd-185d-43f1-96cc-35b73032eccd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktNi0xLTEtNTk3NDA_76695ba3-8c4f-47cc-a408-b9578bb09994"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktOC0xLTEtNTk3NDA_48019f63-a95a-41df-bd35-fba0c0a783c3"
      unitRef="usd">1452000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMTktMTAtMS0xLTU5NzQw_04a72a7b-1687-4139-95e0-24377e042e46"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtMi0xLTEtNTk3NDA_60477627-ca77-4c87-bd1d-2c603f10cc5d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtNC0xLTEtNTk3NDA_1274de58-01b3-40fb-8ccb-10a898d15310"
      unitRef="usd">19583000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtNi0xLTEtNTk3NDA_c23a8f13-d14b-4f21-8949-3db104bd01cc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtOC0xLTEtNTk3NDA_f3744ef7-fdb8-49a1-8237-440e8a0d301f"
      unitRef="usd">19583000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjAtMTAtMS0xLTU5NzQw_98aa6d4e-edff-4445-9063-63281bb9b875"
      unitRef="usd">19727000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5e32e93333a24edd846ce09ab84c19ef_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItMi0xLTEtNTk3NDA_4c7394d3-0c1b-4a47-b9c6-b25ceabf085c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6d3024ae4e584d51ad202e09fa7e35c7_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItNC0xLTEtNTk3NDA_54e676de-683d-4d63-b360-5ffec60ed340"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i40bc079e1bf040d6a6c8095e02268b3f_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItNi0xLTEtNTk3NDA_5291a263-11cd-43d6-ba1f-1bb9107c2cb8"
      unitRef="usd">486000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItOC0xLTEtNTk3NDA_498b152d-d3e8-4fa4-a2ea-ab1e3fbe2f19"
      unitRef="usd">486000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjFlY2YzNWFlN2RhOTRkM2M5ZThiOTQ5YzM5Y2YwZDc0L3RhYmxlcmFuZ2U6MWVjZjM1YWU3ZGE5NGQzYzllOGI5NDljMzljZjBkNzRfMjItMTAtMS0xLTU5NzQw_c139fa65-682c-451a-98a2-bde7630f42a6"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfMi0yLTEtMS01OTc0MA_fd5f8549-d68d-457f-a956-f7d834c50f32"
      unitRef="usd">1753000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfMi00LTEtMS01OTc0MA_8a3f2b38-36d6-4619-96df-2305338952e3"
      unitRef="usd">1360000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfMy0yLTEtMS01OTc0MA_ddeacc13-d99b-4240-a8d7-ac1d310db345"
      unitRef="usd">1655000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfMy00LTEtMS01OTc0MA_35f26742-bf41-4a8f-86aa-14d3740804e4"
      unitRef="usd">1285000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNC0yLTEtMS01OTc0MA_0e7a9483-62d8-41c4-8ca6-38d162fa1781"
      unitRef="usd">98000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNC00LTEtMS01OTc0MA_23d7cb13-7ee7-4c13-b298-2dd08b381ace"
      unitRef="usd">75000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNi0yLTEtMS01OTc0MA_413b5e88-70dd-4c7b-abd7-cfa7a4d80b19"
      unitRef="usd">2778000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNi00LTEtMS01OTc0MA_a9b3bab2-4b50-41e6-ad83-83d32022ae3a"
      unitRef="usd">1888000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNy0yLTEtMS01OTc0MA_cde4493d-ca8b-4f1a-aa4f-93e46e669b0d"
      unitRef="usd">2709000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfNy00LTEtMS01OTc0MA_28234090-07fb-408b-b8c4-72f9e471df2c"
      unitRef="usd">1855000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfOC0yLTEtMS01OTc0MA_e94191b2-39a4-4cdb-9684-18be7c58263d"
      unitRef="usd">69000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmQ1NDk0MjZkYTUwOTQwYWM5YzQxODdhMTBjMDVjODk0L3RhYmxlcmFuZ2U6ZDU0OTQyNmRhNTA5NDBhYzljNDE4N2ExMGMwNWM4OTRfOC00LTEtMS01OTc0MA_331c2273-cbd6-4545-aad9-cc5e95881624"
      unitRef="usd">33000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if6d5ec7bb88b49bb9225ff6447a06091_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfMy0yLTEtMS01OTc0MA_85c69c74-ba56-4e01-be57-fbacbb3d4cdd"
      unitRef="usd">533000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iccce36176b41451cb72ade5fd7acd620_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfMy00LTEtMS01OTc0MA_adffd16b-ab1f-469b-bb47-4d75ce2e1c92"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNC0yLTEtMS01OTc0MA_37382722-12a2-4eee-8af0-63d89a8569c9"
      unitRef="usd">-47000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNC00LTEtMS01OTc0MA_15a40211-7e93-4df4-8aa2-0a6df50c67f2"
      unitRef="usd">15000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNS0yLTEtMS01OTc0MA_79184f9d-5c91-40a4-a3c3-1dd0bf51a30a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNS00LTEtMS01OTc0MA_9b83de0b-93cf-4818-8886-9ab92334211b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNi0yLTEtMS01OTc0MA_3b707a8f-ab0d-458b-b69b-2c9198dd65b4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNi00LTEtMS01OTc0MA_4429a2bc-a703-4f45-9172-d428e0af9454"
      unitRef="usd">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNy0yLTEtMS01OTc0MA_54ce10b3-8aef-40ea-a532-a285bce6a4a0"
      unitRef="usd">486000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib4ebcce5ed4d4fa88b1380565ad0cd2f_I20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOmRkMTFjY2ExNjVkNjRlMDY4NDMxM2FkMTJkOGFlZGUwL3RhYmxlcmFuZ2U6ZGQxMWNjYTE2NWQ2NGUwNjg0MzEzYWQxMmQ4YWVkZTBfNy00LTEtMS01OTc0MA_288c693e-b9ed-451e-9ad1-a47b7a6caee7"
      unitRef="usd">600000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i144bd07273654fd298013a92e5d0b27f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTE1Mg_55a47ec7-d826-4423-93dd-e94a3cedd946"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i37485b7a6e8c4c1689bb2f8982088f64_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTIyMA_b26a9993-5b3c-43d8-a713-5f4d6b1b57fd"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i59607f6cdca645209d4015cb4e2f5619_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTUzOQ_6e297af4-613d-40db-b862-49f86dc36342"
      unitRef="usd">469000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idc5cdf7b3948454394fae9e0a5c60184_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTU1NA_8bb0a4f6-aa60-4d7f-ba9e-2bf722b0d5c4"
      unitRef="usd">520000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib5aed6e544644ac091fcfd4f67609c7d_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTY1MQ_508f82ca-8f93-4aad-bcb0-e5d8fe8f65c6"
      unitRef="usd">17000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i68a4afb3d1574ea6841481a8c54e0b66_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfOTY2Ng_bfd29a19-801c-41a3-a05e-b1fe45a49606"
      unitRef="usd">13000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwNjk_e21c0db3-0438-493d-bde8-8f982e78678c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of April&#160;3, 2022 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain/( Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other sovereign securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i32a07094db884448a992148a352debab_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS0xLTEtMS01OTc0MA_19692daf-a719-4290-80a7-a7c890fc596b"
      unitRef="usd">3128000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i32a07094db884448a992148a352debab_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS01LTEtMS01OTc0MA_8b93085b-2864-4e41-b3f4-cb93feba4c9d"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i32a07094db884448a992148a352debab_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS03LTEtMS01OTc0MA_5e58849e-83db-4c53-94cb-0c64b33cfa96"
      unitRef="usd">3128000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i32a07094db884448a992148a352debab_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS05LTEtMS01OTc0MA_ec81a505-a2e6-4ab7-b417-4b22e2c166c8"
      unitRef="usd">3128000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i32a07094db884448a992148a352debab_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMS0xMS0xLTEtNTk3NDA_c725d156-836f-4478-b671-599b08485764"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy0xLTEtMS01OTc0MA_cda1f6db-2d39-4866-9070-768bb612ed18"
      unitRef="usd">329000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy01LTEtMS01OTc0MA_e49cb3b8-fa21-4a2c-9811-9eace9db8c90"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy03LTEtMS01OTc0MA_dd8f6e80-74dd-41cf-a8cc-6859e8db1c0b"
      unitRef="usd">329000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy05LTEtMS01OTc0MA_c3771875-57c2-4777-90a7-37927ce0596d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id4d06754ef7e4c02b339a96da42f23d6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMy0xMS0xLTEtNTk3NDA_a741e7e8-25bc-4cde-bd6f-9ddbd31379e2"
      unitRef="usd">329000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC0xLTEtMS01OTc0MA_f05e8802-599b-43ec-bef1-941cad413acf"
      unitRef="usd">1449000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC01LTEtMS01OTc0MA_25651ed5-efbf-40c0-9145-c381f07b6743"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC03LTEtMS01OTc0MA_696bc987-c82f-4771-85eb-2e0637184779"
      unitRef="usd">1449000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC05LTEtMS01OTc0MA_6786e93a-77bf-4b39-98a8-f0918d99e323"
      unitRef="usd">1449000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i59da01083b2a45a3823b3b6d2c7f19e0_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNC0xMS0xLTEtNTk3NDA_32d36a96-322b-4f6a-82c1-98f403c32a2f"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi0xLTEtMS01OTc0MA_fb8da110-c6f8-4f4d-9dfb-95bfec6e9780"
      unitRef="usd">3557000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi01LTEtMS01OTc0MA_ead89a2a-f1db-4ab6-80d7-021a7d79210b"
      unitRef="usd">6000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi03LTEtMS01OTc0MA_770c3cc4-e258-4bc9-abf9-f27c95212431"
      unitRef="usd">3551000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi05LTEtMS01OTc0MA_9d823757-f86a-42d4-afab-7e3b4eb65a24"
      unitRef="usd">540000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i58c2d2898cff43b78e1d5e6035922a00_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNi0xMS0xLTEtNTk3NDA_b8b827a0-4a36-48f0-a67e-0c8b4f59c43d"
      unitRef="usd">3017000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy0xLTEtMS01OTc0MA_7397bcf3-f275-4494-9ce0-f22d308e0cae"
      unitRef="usd">1579000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy01LTEtMS01OTc0MA_9ae9f276-7e86-40a6-9c09-4c105cc1a519"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy03LTEtMS01OTc0MA_c108f2fb-2dfd-4380-a2ae-dcfc9e604ad8"
      unitRef="usd">1579000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy05LTEtMS01OTc0MA_40e18094-e020-42db-ba2a-757907545e2b"
      unitRef="usd">1579000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="idefc9360cf7d4a84871e4e4fd6c66079_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfNy0xMS0xLTEtNTk3NDA_59a4bbbb-80b1-4287-8b28-161ef540e876"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i612d93e077824654b25097d940711e0c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC0xLTEtMS01OTc0MA_d6c27ed6-9ea2-4567-9ec5-29fbb2533c34"
      unitRef="usd">763000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i612d93e077824654b25097d940711e0c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC01LTEtMS01OTc0MA_a0865e9e-2ee6-4f54-b4f7-2ed8e1884333"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i612d93e077824654b25097d940711e0c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC03LTEtMS01OTc0MA_368146e4-b873-48bd-b405-f57d762fe31e"
      unitRef="usd">763000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i612d93e077824654b25097d940711e0c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC05LTEtMS01OTc0MA_eb2d7b75-833e-4a83-ba9d-cb7aaedb43fc"
      unitRef="usd">763000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i612d93e077824654b25097d940711e0c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOC0xMS0xLTEtNTk3NDA_a803bca0-eac4-4ad5-a915-746847ec4cb0"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS0xLTEtMS01OTc0MA_6976a90f-4979-4439-ad9e-908b6a2ba686"
      unitRef="usd">10805000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS01LTEtMS01OTc0MA_68de31ce-78a2-4ab4-b91d-d52ec2e986f8"
      unitRef="usd">6000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS03LTEtMS01OTc0MA_2e4b2021-2147-4acb-aa80-fe9fce73bfdc"
      unitRef="usd">10799000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS05LTEtMS01OTc0MA_46e25075-981b-4eff-af64-a577edf1417d"
      unitRef="usd">7459000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if17e9a78d65144cabf6d0224cea88596_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfOS0xMS0xLTEtNTk3NDA_200c4ed1-c3df-4d4e-b84d-a3771078c909"
      unitRef="usd">3346000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic0abb325296848eab35197c32673d301_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItMS0xLTEtNTk3NDA_e0c2460c-d627-4fdd-a6dd-beb36ef86bb3"
      unitRef="usd">19354000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic0abb325296848eab35197c32673d301_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItNS0xLTEtNTk3NDA_887d0818-828d-4769-b490-4ae2dea40a99"
      unitRef="usd">19000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0abb325296848eab35197c32673d301_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItNy0xLTEtNTk3NDA_b96dcfbe-eb59-41fd-8685-9b335fa7ebb5"
      unitRef="usd">19335000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic0abb325296848eab35197c32673d301_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItOS0xLTEtNTk3NDA_ff2488c3-f049-4643-b11f-ee0f9f943141"
      unitRef="usd">2968000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic0abb325296848eab35197c32673d301_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTItMTEtMS0xLTU5NzQw_023c19ed-a919-44cb-bf3f-a3cc39b0d32e"
      unitRef="usd">16367000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtMS0xLTEtNTk3NDA_579dc931-d6eb-4d0e-a346-38e5ad3e525f"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtNS0xLTEtNTk3NDA_a975be18-c0d2-4deb-bf98-405700ecb057"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtNy0xLTEtNTk3NDA_beb9f410-a226-45a3-95e1-b29b7085c587"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtOS0xLTEtNTk3NDA_b55d0ced-7bf2-45d7-a634-c2878429fc62"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtMTEtMS0xLTU5NzQw_00741378-ff91-42fa-af4b-9ab91c8eba23"
      unitRef="usd">3000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i40df713ca2794a8f8f08885f6d2c8143_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTMtMTEtMS0xLTU5NzQw_7ca89b32-d7e8-4021-a600-fd19557e3d29"
      unitRef="usd">3000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i98b0e360214949eebb51638497d0ec18_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtMS0xLTEtNTk3NDA_38627eca-09fa-4cd1-9e84-b4e6dfb51f1a"
      unitRef="usd">246000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i98b0e360214949eebb51638497d0ec18_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtNS0xLTEtNTk3NDA_791d6959-9130-4272-95f3-97c24b818f77"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98b0e360214949eebb51638497d0ec18_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtNy0xLTEtNTk3NDA_aa37c8e9-76da-446e-a985-9a9cb54ff353"
      unitRef="usd">245000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i98b0e360214949eebb51638497d0ec18_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtOS0xLTEtNTk3NDA_bda58d60-3bad-465a-8962-f6b4a717b27a"
      unitRef="usd">36000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i98b0e360214949eebb51638497d0ec18_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTQtMTEtMS0xLTU5NzQw_9f3d9577-3d82-45ee-8fdb-ef8353b7ac31"
      unitRef="usd">209000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtMS0xLTEtNTk3NDA_04258481-b39b-4a01-9fcf-dca93197f0c6"
      unitRef="usd">19603000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtNS0xLTEtNTk3NDA_12cf701b-6484-415c-a09c-d69c96c25710"
      unitRef="usd">20000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtNy0xLTEtNTk3NDA_892934d9-3ba4-4058-bbad-288eb034e63f"
      unitRef="usd">19583000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtOS0xLTEtNTk3NDA_6a91748d-a37c-4678-ae73-46a2243c0f08"
      unitRef="usd">3004000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id88ae0750e7345518a0d67c7fc3a2d2e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTUtMTEtMS0xLTU5NzQw_a8fdc871-d960-412f-b7ad-45e4596a43c1"
      unitRef="usd">16579000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtMS0xLTEtNTk3NDA_8ade641e-529c-47b6-a0e3-8ec6fbe733d1"
      unitRef="usd">30408000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtNS0xLTEtNTk3NDA_cb5ced81-42e8-4dd0-af82-08da6e621563"
      unitRef="usd">26000000</jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtNy0xLTEtNTk3NDA_4c134c60-4118-481a-924e-5677a6463b00"
      unitRef="usd">30382000000</jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtOS0xLTEtNTk3NDA_dea5ba02-12b2-4b10-aad0-baf80e0cdcaf"
      unitRef="usd">10463000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjlmY2UyYzEyODExODQ0ZDE4YTU0YTlkYTI0NTIyNGQ2L3RhYmxlcmFuZ2U6OWZjZTJjMTI4MTE4NDRkMThhNTRhOWRhMjQ1MjI0ZDZfMTYtMTEtMS0xLTU5NzQw_7c0e2a35-c56a-4ebc-ae27-55661523505b"
      unitRef="usd">19925000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwODU_135c222f-e8cf-4bf1-a5a9-839d4ad55b48">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIwMjg_7c8b2f3b-3f08-4cb8-a247-75bf4ea69037">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of April&#160;3, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMS0yLTEtMS01OTc0MA_c14e90ba-7308-4185-9bab-0641b5ef5cfa"
      unitRef="usd">19585000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMS00LTEtMS01OTc0MA_7b019d63-3df8-488c-9d04-4a13629fad93"
      unitRef="usd">19564000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMi0yLTEtMS01OTc0MA_35b6ff56-6724-418d-90ec-2b9c1abcb130"
      unitRef="usd">19000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMi00LTEtMS01OTc0MA_f1de03fc-593a-4466-ba10-112533710f10"
      unitRef="usd">19000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMy0yLTEtMS01OTc0MA_a479a1cc-04a0-424b-9df5-01f6784ad845"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfMy00LTEtMS01OTc0MA_6621898a-c850-4876-8ea9-86417aeaa7a4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfNC0yLTEtMS01OTc0MA_60972d80-dfd2-45f7-97f4-36e57ca9d102"
      unitRef="usd">19604000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjIzOWZiZTE2ODY3ZTQyNmM4OTg0ODNkOTE1MDQwY2I3L3RhYmxlcmFuZ2U6MjM5ZmJlMTY4NjdlNDI2Yzg5ODQ4M2Q5MTUwNDBjYjdfNC00LTEtMS01OTc0MA_09ffc8f3-832c-4a14-9161-7fc06f748b0f"
      unitRef="usd">19583000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTIxMDQ_00b18075-34a5-43ff-b5ed-a84809a2232c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;3, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.1311)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500 MM GBP 1.3485)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.1311)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.1311)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="i80cc25f225c142c9b2e51f9cc136f5e5_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNC0yLTEtMS01OTc0MA_c7a73e62-0bb3-4a9c-91f1-0d9e18ef4577"
      unitRef="usd">4297000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i574a41416f664b5a90a57869a7b69d04_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNC00LTEtMS01OTc0MA_21a1f75b-8f41-4af7-b624-49a0820ed9f5"
      unitRef="usd">4298000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i10a6f23182d14a35bc979be835d03213_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNy0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjhiNDU4MWQxYTFkMzQyYWQ4ODU5YjBmNTcyNWRiNDI2XzQ_cd1d130f-ed3c-4523-bc72-ce1f582102e0"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic03f9d9c139545c6bf756b9af8dd04ce_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNy0yLTEtMS01OTc0MA_dccb2c31-4eee-4375-8e63-e36e7569c833"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic97fa957218749a5b2bbde6c2237328b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNy00LTEtMS01OTc0MA_bec5eadc-f42a-4467-8b08-c14dbcadffec"
      unitRef="usd">266000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88fb397aabc74f9d9919879a38532a66_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfOC0wLTEtMS01OTc0MC90ZXh0cmVnaW9uOjg5YTY0MmQzMzhjYzQzMDFhY2UxYzkyMGRjNTBiZjMzXzQ_b83794b5-5031-4bdf-9ddd-055ff1f278ef"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibb107f40561b447d8a9bf98e62f3c54e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfOC0yLTEtMS01OTc0MA_051250ee-363b-4c53-9a35-a230a36d23da"
      unitRef="usd">802000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3d1cab1bb8af45f486a55147f5bdbe07_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfOC00LTEtMS01OTc0MA_46d2012a-c288-4ba1-8fd7-d294be56f8b7"
      unitRef="usd">820000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iafb5c763b5bb45f899c132bc31626b95_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTAtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjowNTBjNWIwNTY5ZjA0MGI1YWM2ZDA2NDk1NTkyNjhhZF80_db23e159-cb54-403e-b35a-5fdf8151ba62"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i11c666c963c647308254b695cefee498_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTAtMi0xLTEtNTk3NDA_78087391-3520-466b-a4ae-dfceffa8bb50"
      unitRef="usd">824000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4ced426dcbd04d1f98029e772acf4b64_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTAtNC0xLTEtNTk3NDA_1e12e997-a82c-4f2b-ae82-a6bc42351aba"
      unitRef="usd">829000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53b54bd64a574cf0ae8d1e57ec0bc8c6_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTEtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo2MGMwZDhiNzY1YTk0MWM4YTg1ZjdiYzcyYjdmYzM3NV80_5e9cb233-0ac5-481b-9319-a4d928fbd40d"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8afc02d95284431197455ed2c01e0b02_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTEtMi0xLTEtNTk3NDA_d52f3237-fbf3-4a2d-be09-467356ae1e7c"
      unitRef="usd">654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1774beb33cd94056b250899436621d79_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTEtNC0xLTEtNTk3NDA_d614e260-f2be-42be-9978-983b289cd1be"
      unitRef="usd">713000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia9905446b33e44249abeae66f95c5b42_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTItMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo1MjE2MDI0ZTcwNzM0NzhiOTJkNmM3NjgwNDJjZmMwOV80_a0f68679-92c6-41c7-ab27-85b0826dc25e"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic8f3e5d7909e4521b088bd43ea9303f3_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTItMi0xLTEtNTk3NDA_526edded-4da6-4fe3-baf8-097a4304f54e"
      unitRef="usd">749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idb2b18369ff14783885a3ab5d402b053_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTItNC0xLTEtNTk3NDA_40afbd06-8217-46f8-ab77-80ea7a92c8cd"
      unitRef="usd">762000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i410644799f39419bbcdf5b89613bbc9b_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTQtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozOWI5NWFkY2FmN2U0OGEwYTg4N2M1ODIzMDM4MDEwY180_ed49b6e8-012b-40a5-959a-d6acbee8b3ac"
      unitRef="number">0.0055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4cf0299af0124017b184f3378b2e8260_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTQtMi0xLTEtNTk3NDA_22dc5104-874f-4f41-9f97-624b92ebcabc"
      unitRef="usd">950000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6d410447a42f4d80ad241f38be44e316_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTQtNC0xLTEtNTk3NDA_e3019ecb-c1de-4596-9633-db4cbbed1763"
      unitRef="usd">886000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i02c9f5cae6f44540a89c680000306ed9_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiMjIwNzgyMWNiMjY0YWJiOWFhYzRiYWViYmZlNTg4M180_a4076bc3-2bfe-4843-9e45-b349408b4855"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic108a9e12f3341939ea27c4f85b55d98_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTUtMi0xLTEtNTk3NDA_b59b53db-70b1-4695-a630-848ec1f2ee4b"
      unitRef="usd">1995000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i14b3ec03d9234219b5bd925a86a41790_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTUtNC0xLTEtNTk3NDA_1fc2921f-748c-4a4e-b446-8e2881143c32"
      unitRef="usd">1981000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic66945fc64dc4dd2b97e6ae77585e006_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTYtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozZTc1NDRkYTM0YTI0ZTlmODZiYWU4NmJjZDhlYzM3MV80_4e04ef28-cbda-4694-b5ca-6cd3afe06879"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i22df2c32fde24c49ad70d6267b39461c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTYtMi0xLTEtNTk3NDA_601d99a1-e8ce-4d2d-9779-1145d2d59f81"
      unitRef="usd">930000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i73b4ecb878554ed895e6731af84a2410_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTYtNC0xLTEtNTk3NDA_cd6cd845-89ee-47d1-8bba-e6794a6e0acc"
      unitRef="usd">934000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iec5b6d69f26346649c425f8e2933241b_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo3MjhmOTEzYjIzZmM0NDZkOTA5NGRkN2NkOWE2MWYyNV80_e6c71da5-ccd2-403b-8406-d5aed4045c25"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib3ae7da6e5e348d3bfd658d212535274_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTgtMi0xLTEtNTk3NDA_729a104a-a11d-473c-b184-08890f987f7e"
      unitRef="usd">1436000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia4fd353404164731a511e7927bec85a8_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTgtNC0xLTEtNTk3NDA_0c6624f7-3f22-4c3b-9c1f-6568ff55a866"
      unitRef="usd">1307000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i92d34c20152a4de3a3f77d8cb010b8de_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTktMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4YzQwZjkzNzU1NDc0OGZhOThiNTQ2ZDA3YmEwN2JiM180_67bb8188-144d-4f99-9166-7d753805a790"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9b80c19de72d40139ee47e1d21a6e42a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTktMi0xLTEtNTk3NDA_c344f19a-5f05-4676-9133-d317e35da90e"
      unitRef="usd">1496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i56414cfcd9cc49dd995d25343ea06a1c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMTktNC0xLTEtNTk3NDA_498d3eb4-078d-480e-b7df-628c0e7a9f0b"
      unitRef="usd">1489000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iafde104933164c4cad0deb69abac440e_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjAtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo5MGRkM2YzZDUxMjQ0NTMwOTQyNmMwNzJlYzg5ZDhmOV80_0b748bde-f446-4480-8f85-3f5e66fe652e"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idf01842c5cf54c898543482c4a444521_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjAtMi0xLTEtNTk3NDA_a176156a-6a71-4c27-90f7-108529ee8738"
      unitRef="usd">826000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3bbe50e67f15448d8798dfde818d59e8_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjAtNC0xLTEtNTk3NDA_18b4ebee-0817-47e1-9772-f2233e4d13d8"
      unitRef="usd">829000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic4d10d54d1af41b08272b793afbde882_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjEtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiZTU4MDU5NWM0N2I0YzczODk5ZGM3ZmNhNzMxNmYwOV80_39186a1a-15f7-4069-aada-a6fdcf3b4ac7"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1ed4cca79f874285afd96939684875d4_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjEtMi0xLTEtNTk3NDA_7c882419-2201-4fbd-96f2-2ac013e6eb96"
      unitRef="usd">298000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i253bb8f802eb4367b1f601f0eb271aa8_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjEtNC0xLTEtNTk3NDA_64d4127c-a7d7-4e40-ab06-6a8c50421530"
      unitRef="usd">379000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id79227d6ca8e47c096d1f5db54292e11_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjMtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpkZWNmNWVhNzc1OTY0NTM4ODRjMzk4Zjc1YjNjZTU3OV80_7a9c03fa-f0c9-43dc-bd90-701dcda83454"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i26657c8981ae46e79d22c832389a2403_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjMtMi0xLTEtNTk3NDA_0c37c9ea-0439-4f24-8213-e31eb255a1ff"
      unitRef="usd">1672000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie9b9d5f07bc14a4ea1751fd21547dfb0_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjMtNC0xLTEtNTk3NDA_c6f6ae48-fcc1-4ac3-90e5-da747c015eb2"
      unitRef="usd">1486000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i050bb5d8583f4db5b7cab1781f41402a_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjQtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozMTNhNTRiOTVjNDg0OTU3OWJlNDcxZTJkM2Q5MTUzMl80_03a66410-3472-4858-9520-5046cdd61384"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i98f5927fb8dc474187a16c8bb7a8f633_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjQtMi0xLTEtNTk3NDA_e300f689-f9ad-40bb-ab3b-bb065a58a0af"
      unitRef="usd">498000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia0640760a4d046fdb9b6672981624f0a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjQtNC0xLTEtNTk3NDA_82e7c550-6067-4c54-a8b5-82be7e6fd175"
      unitRef="usd">590000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic7815fcc60b846c4bd4ae4cf64f6a1f5_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozNTBiOGU2YzY5MTY0ODMzOTAxZjA4MmY3ZmI5N2FiZl80_897f19ac-9173-446c-9fec-391675702135"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6ee6a13418e74e9f97b7fce4de45eee6_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjUtMi0xLTEtNTk3NDA_18d3ccb1-6217-4127-8911-0dd92ce33ce1"
      unitRef="usd">855000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4a7cb32255274ae599a981a6313a0d95_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjUtNC0xLTEtNTk3NDA_1740139d-b66f-44a9-a57f-a8df5977756d"
      unitRef="usd">959000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i56cae7f5eeee4fc995a14d122519fdf4_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjYtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo0MzY4OTcyZDY0YTE0MzZmODdlNTk3MjAwMGNkYjgzOF80_4e9e5aa2-5b3e-46dd-967f-44de4038ca50"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ice21280ebab242638498d336fcf84a9c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjYtMi0xLTEtNTk3NDA_d846644e-07d5-4a3b-8ef7-5fcbf1856ad8"
      unitRef="usd">1654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i25f1dd3b92e340df9e2c6814f388f614_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjYtNC0xLTEtNTk3NDA_71ff2848-64ad-4495-bdf2-4bb310e4b924"
      unitRef="usd">1687000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifc07bbbd134548d4bab1577bebc273ed_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjctMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpkZGRmNDk4NWM5ZDg0ZmJjOThkZjNkZWZhMjdkNTBmMF80_f9c50d6c-78c0-42ec-b453-7fd8fff257e0"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic9c6f72bf20e4383ba64ecbe3c4bd15b_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjctMi0xLTEtNTk3NDA_4a1e641f-8cfd-4013-b64e-4f719d9ef69c"
      unitRef="usd">917000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3a714f2428ce4aba8dc71a3ce15cc543_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjctNC0xLTEtNTk3NDA_bb61071c-e1b2-4338-806a-4ccdf5c231c3"
      unitRef="usd">947000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2c824e2faeb34de8b822a2f57f817f25_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpmOWJjNTY5ZWY5MjU0ZmFkYWM2OGU5ODk4ZjkyOWFjZV80_b25b2a27-613a-42bd-8b90-4d6182b611ea"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2f54a6d9c9f2407397bc4616bc6e7af9_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjgtMi0xLTEtNTk3NDA_8daf794c-2d1c-4443-b889-04000cb64673"
      unitRef="usd">993000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7ca5c18e09944b9b8a34ad2546775220_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjgtNC0xLTEtNTk3NDA_b107d125-a13a-4ac5-b1d8-7c839ef4897c"
      unitRef="usd">1288000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifdd4fbd384b84fd3a0d6693ec4c9c252_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjktMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo5MjM2YzM1MjcyNzk0OTE2ODMzMjM1ODU0NmE1YjM5Y180_4e26baef-ccf2-4418-9df9-bb8529b27ff2"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i89b2afac7f2047619163d4ced5060322_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjktMi0xLTEtNTk3NDA_7300d8ff-7bdd-497e-be89-8bdac7c3e8ff"
      unitRef="usd">1416000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idb79658f5f2d475486e1d306a4118a47_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMjktNC0xLTEtNTk3NDA_a220541c-696c-4f25-81ad-14d3c9473ceb"
      unitRef="usd">1463000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idb22c0fec5c4490384df777e042c7c81_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzAtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjozZTcyM2IwODlkZDg0N2JkOWVlMGUyZmQ1ODJkZWZjNl80_cc2de636-4d4a-4d4a-a922-53a1e4dae326"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i52075d97746b4d90bea9272a17635cd9_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzAtMi0xLTEtNTk3NDA_f8009b0c-3de4-4162-9d59-dcffcadc3369"
      unitRef="usd">992000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia51b7240c69e498bbd44aa9775d04606_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzAtNC0xLTEtNTk3NDA_85cb8e00-2593-45e9-acc9-ad412348f9d9"
      unitRef="usd">999000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ice9f99b199274666b12ae2df91d2c820_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzEtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo5NWY1YTFiZTJkNWM0ZmIzYTNkZDZkNjZiZjFhMjNjZF80_e166317e-3e1d-4d79-ab51-0ca66818f163"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i67077af31f114a30bffdc32fea20dfff_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzEtMi0xLTEtNTk3NDA_3a66ecd0-bd0b-4b84-a041-ab63ab28322a"
      unitRef="usd">697000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i188f32b459e74d5cb0f963e4e0a3f7ed_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzEtNC0xLTEtNTk3NDA_43343dbc-693b-4d69-ace1-2f706b517ed8"
      unitRef="usd">901000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie3ca814e494941cc9558570cc4279cea_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzItMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjoxZGNhNmRiYTE4MDY0OTA1YTcyM2U4OTUxNjk2NWVkYl80_52c16c0a-96b3-4cf9-be50-fcd7346be452"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i44982952c49f4e749aabaf9dcdbec1dc_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzItMi0xLTEtNTk3NDA_e1355641-ecbe-493f-be9c-143e59232468"
      unitRef="usd">540000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i07b685ecce1643ff89bfb3895523a51e_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzItNC0xLTEtNTk3NDA_95b5e23c-426b-4051-9765-c93c2ca90647"
      unitRef="usd">617000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibea8fdb3616f451c90baf65707bdf669_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzQtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiMWQ5MTVmNjY2Njk0NTJhODIwMDBiYjQwOWM1YWNjOV80_02176a37-423a-49fd-a5e2-d881dfd3cd01"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i08457c1d48c94eff8dc2ac47bdf0c7b5_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzQtMi0xLTEtNTk3NDA_04ffcb4f-8c25-4be1-b726-65929a73bee7"
      unitRef="usd">914000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5fe81741fd58415cb3509d83ffdc5e73_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzQtNC0xLTEtNTk3NDA_faf729dd-9287-4285-b300-11c7e69c2f98"
      unitRef="usd">777000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6c1d9e65495e4ece85762fec2639f5dd_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzUtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo4YzZkMzNjN2FlNGQ0NGJkYTZiOWEzMzgwMTczNjU4MV80_26e5cb05-865f-4baa-b202-cd16daf8e6f2"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i12629c9f73b74eff9c5a235f547f2241_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzUtMi0xLTEtNTk3NDA_fb79fb94-caad-46a8-9079-f0db8b692d90"
      unitRef="usd">297000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3970f29929a24eacb55a58c7e37c52c1_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzUtNC0xLTEtNTk3NDA_72e9a331-c91b-4889-94e6-f1c4774b580b"
      unitRef="usd">342000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3a3af18d0134471c93564e5fd5f3fe0e_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzYtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo3OGFmNGY3OGZlNDI0Yzc2OTkwMzkyZDllNTI2MGNjZF80_8f831ffa-314f-42b9-98f3-edf7e1bc9967"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5a1c7715113b48dcbff2dfe6536eb602_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzYtMi0xLTEtNTk3NDA_6cd3bbaf-2ce5-446d-88e1-8e6ce0e145ff"
      unitRef="usd">496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3ec5bcf102a34a1b87cf004f535337de_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzYtNC0xLTEtNTk3NDA_2a73c304-5695-4c95-9c55-e5b8ef17ec8d"
      unitRef="usd">565000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6885bfb3e4984c65abbb4580fc179cba_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzctMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo2ZDE0ZjY2NGUyYTQ0Y2ZjODExMGE2ODIzYmMyMDc0OV80_f30642d9-6055-4257-baff-51269446167d"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if4d3a223ac884f86b9a206b4617aa103_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzctMi0xLTEtNTk3NDA_623afbb8-e92b-4c65-80b6-c42349af4c4b"
      unitRef="usd">1975000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id914def5ea98451bbfd52ec51a11e6d4_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzctNC0xLTEtNTk3NDA_5cad65c0-b82c-4beb-86d9-99c9813a4cf4"
      unitRef="usd">2097000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iededfd7a59eb43208e3672b72a308066_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzgtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjpiODFjNzhmODgyOGQ0YTQ0OGM0ZGExNGI0MTU1NWY5Ml80_1dd96832-e6ab-4356-a694-a24871c3f10a"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia4f9a83e7716457aa17dcab50434530a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzgtMi0xLTEtNTk3NDA_b7e97d73-40a2-4fa8-93cc-e8ca721e5609"
      unitRef="usd">906000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3a3f9d6c591e4c379b03f6a63223ff4c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzgtNC0xLTEtNTk3NDA_88caf3ae-f3f7-49f4-bc31-7ad2fb3f7264"
      unitRef="usd">969000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iffc2dad290bf4b1f84e0014e807f7d22_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzktMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjoyZDczODA0YjA5MDg0MjAwYWYwMjliM2U2NDQ4NDg1ZF80_56d6f0a9-c61a-4df1-b233-538a91f3cf81"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idfe07c4d0ab547cf987486709e3723ea_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzktMi0xLTEtNTk3NDA_6e87d001-3d3d-475f-af42-02e03563de26"
      unitRef="usd">743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9a3fd14bab994cb2b98c874567c9124a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfMzktNC0xLTEtNTk3NDA_337eff8b-b5a1-4895-a357-5218b89e2a58"
      unitRef="usd">766000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idb0087669f7d433a94c2175b61948c30_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDAtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo2ZDUxZmQ2ZDIzOTM0YjUwOWM2MGFhNTc5NTA1ODlkZV80_ef2f6031-a6c8-4c98-880f-f7a89524ac3b"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia7ae03e86ec34f059e03de3ba7a0fa16_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDAtMi0xLTEtNTk3NDA_ef132c54-f44b-4a27-b333-c3182ef01afa"
      unitRef="usd">914000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7525d9cf9c7a4c2eb64364d6f1fe110a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDAtNC0xLTEtNTk3NDA_067375d4-7c10-4640-83f0-bd8658edbb31"
      unitRef="usd">759000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ife167dfbe51e4f7bba2d6c116e0acbe8_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDEtMC0xLTEtNTk3NDAvdGV4dHJlZ2lvbjo5NTQzY2ZiMmY3ZjU0ZjI4YTU4ZjI2MDU4ZTM0NWM5ZF80_14b9a2e4-4465-436e-8dc1-58636321ef8e"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6724f9eb2f284a7897adfe49ccf0a1bc_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDEtMi0xLTEtNTk3NDA_5be761f7-dfc6-484a-b835-750f6fd669b2"
      unitRef="usd">1155000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7e6d608431ea4c5398a0d5693ec02ce7_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDEtNC0xLTEtNTk3NDA_60d598f2-85a4-4c73-a542-bf5bf0b55b03"
      unitRef="usd">942000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia1fb99008d5c46f782ebe421c09b6c86_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDItMi0xLTEtNTk3NDA_15f64e30-4035-4c11-bce7-b4ab090c1919"
      unitRef="usd">7000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i809a6e12d5804dfb8ab4ace60751a5d4_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDItNC0xLTEtNTk3NDA_244fbe29-d860-4419-a956-6a0bcd15f3c6"
      unitRef="usd">7000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i80cc25f225c142c9b2e51f9cc136f5e5_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDMtMi0xLTEtNTk3NDA_91df9965-0f20-48cc-a1d6-b3f4e626cab9"
      unitRef="usd">28851000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i574a41416f664b5a90a57869a7b69d04_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RhYmxlOjY5Zjg1Y2UwNGY2ZjRlNDNiMTY2NWRkZjg2MjVhOTYwL3RhYmxlcmFuZ2U6NjlmODVjZTA0ZjZmNGU0M2IxNjY1ZGRmODYyNWE5NjBfNDMtNC0xLTEtNTk3NDA_cdb4b00b-ef5a-490b-904b-59e9a848254c"
      unitRef="usd">29356000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE1ODg_6dd65f77-9e9e-478f-83f7-c34f6525fbe9"
      unitRef="number">0.0304</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="ia20a226df1534401beb4ebac52ca168e_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE2Njg_8803a906-5642-49b7-98ce-21d593082401"
      unitRef="usd">3200000000</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="i64bc3e5d158d4182ad9506d5f1a6e623_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE3MzU_eb5403e7-f2d7-4871-82a9-8e942a764253"
      unitRef="usd">3800000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i64bc3e5d158d4182ad9506d5f1a6e623_I20220403"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE4MDQ_e35f6c6a-a8f0-4894-9da6-270ac6572c72"
      unitRef="number">0.0037</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm
      contextRef="i02143dea06fb4fbbba003f6bb1395472_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF82NC9mcmFnOjkyYzFjNzkxY2FiMjRmYTFiZTg4ZTc2NTdkNTZiMGYxL3RleHRyZWdpb246OTJjMWM3OTFjYWIyNGZhMWJlODhlNzY1N2Q1NmIwZjFfMTE4NTY_4dff14b9-b416-43e6-a270-ac9a738aea90">P3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83MC9mcmFnOjRiNTJhZjFkOWQwNDRiOTk5Mzc5NzRhOTU4MjlmZjY5L3RleHRyZWdpb246NGI1MmFmMWQ5ZDA0NGI5OTkzNzk3NGE5NTgyOWZmNjlfNDU4MA_ef86c3ca-4af6-49e5-91c3-30067edb1949">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The worldwide effective income tax rates for the fiscal first quarters of 2022 and 2021 were 12.2% and 16.6%, respectively. This decrease in the consolidated tax rate is primarily due to lower income in higher tax jurisdictions, primarily in the U.S., compared to the same period in the prior year. This lower income in the first fiscal quarter of 2022 was caused by a mark to market adjustment to the Company&#x2019;s investment portfolio and the impairment of the bermekimab AD IPR&amp;amp;D (for further information see Note 3 of the Consolidated Financial Statements), both at the U.S. statutory rate. The impact of the income mix was partially offset by incremental tax costs directly related to the planned separation of the Company&#x2019;s Consumer Health business.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company also had tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal first quarters. Additionally, the Company&#x2019;s effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal year 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of April&#160;3, 2022, the Company had approximately $3.3 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.  In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83MC9mcmFnOjRiNTJhZjFkOWQwNDRiOTk5Mzc5NzRhOTU4MjlmZjY5L3RleHRyZWdpb246NGI1MmFmMWQ5ZDA0NGI5OTkzNzk3NGE5NTgyOWZmNjlfMTE1_4bfbca15-3b98-4346-ad22-8cbd39bcdca2"
      unitRef="number">0.122</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83MC9mcmFnOjRiNTJhZjFkOWQwNDRiOTk5Mzc5NzRhOTU4MjlmZjY5L3RleHRyZWdpb246NGI1MmFmMWQ5ZDA0NGI5OTkzNzk3NGE5NTgyOWZmNjlfMTIy_f6f00f7a-84d2-4c77-ab7f-455ce6cef073"
      unitRef="number">0.166</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83MC9mcmFnOjRiNTJhZjFkOWQwNDRiOTk5Mzc5NzRhOTU4MjlmZjY5L3RleHRyZWdpb246NGI1MmFmMWQ5ZDA0NGI5OTkzNzk3NGE5NTgyOWZmNjlfMzc0Mg_c63f48b4-4ac4-4bcc-8d2d-6cabb850d825"
      unitRef="usd">3300000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RleHRyZWdpb246MTBjNTkzNTUwYzc4NDUxMTk1MmJhZTI4ZWQ0MjhhNTdfODk5_cd288301-308b-4449-a7a2-362d00f9af6d">PENSIONS AND OTHER BENEFIT PLANS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Company Contributions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal three months ended April&#160;3, 2022, the Company contributed $29 million and $5 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RleHRyZWdpb246MTBjNTkzNTUwYzc4NDUxMTk1MmJhZTI4ZWQ0MjhhNTdfODg3_f97a55b4-58d2-4db2-a401-7079022fa0a8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMy0yLTEtMS01OTc0MA_6e705d13-a5ff-40d7-a4e9-1ea8a69ea2ff"
      unitRef="usd">321000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMy00LTEtMS01OTc0MA_ba1876d2-52a8-4ef4-999a-a98b734612b0"
      unitRef="usd">353000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMy02LTEtMS01OTc0MA_4cd9058c-10b6-4b17-9cae-684f022a121a"
      unitRef="usd">80000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMy04LTEtMS01OTc0MA_8ed28a55-4948-4a76-b33a-508ea90b103e"
      unitRef="usd">77000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNC0yLTEtMS01OTc0MA_cc02ba82-59ae-4058-8f8c-a687a796d984"
      unitRef="usd">230000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNC00LTEtMS01OTc0MA_c7463490-cbad-452a-90f9-83fd6174e643"
      unitRef="usd">193000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNC02LTEtMS01OTc0MA_26763d2d-3fde-4e05-aca3-af2682377f68"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNC04LTEtMS01OTc0MA_dab70431-61a5-4318-8734-0e0477216cc2"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNS0yLTEtMS01OTc0MA_7e06e7eb-6486-4ea7-a382-6fafdad143a9"
      unitRef="usd">699000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNS00LTEtMS01OTc0MA_c29e8746-a7a1-4a6c-90b0-e95510489eda"
      unitRef="usd">680000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNS02LTEtMS01OTc0MA_4132e31e-d183-483a-89d4-6af85a2d277a"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNS04LTEtMS01OTc0MA_6af45dc4-05c4-4ebd-be87-58321e5cd94c"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNi0yLTEtMS01OTc0MA_cbd3c129-9bde-45a4-93d8-4d051a427358"
      unitRef="usd">-46000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNi00LTEtMS01OTc0MA_1bd1d53f-0347-438f-a33c-dc6741151ab5"
      unitRef="usd">-45000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNi02LTEtMS01OTc0MA_a329dcca-25dc-4b2e-b074-a05903cf5373"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfNi04LTEtMS01OTc0MA_fdce7869-d81e-4632-8a99-a63571401cba"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOC0yLTEtMS01OTc0MA_d7300a9e-00c0-4148-a999-1f6294695036"
      unitRef="usd">-162000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOC00LTEtMS01OTc0MA_c958a94f-d555-4dcb-8f57-d2e85e4a4ff0"
      unitRef="usd">-314000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOC02LTEtMS01OTc0MA_27ef7a17-3b16-4bf9-bf0e-63675b023e8c"
      unitRef="usd">-30000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOC04LTEtMS01OTc0MA_3c1ba08b-f030-47df-bfcf-6c2114ba1002"
      unitRef="usd">-38000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOS0yLTEtMS01OTc0MA_47a29318-edfb-4ebf-a7af-f646a789c1df"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOS00LTEtMS01OTc0MA_6d23c5f1-8358-47e5-a840-98e90f7e92de"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOS02LTEtMS01OTc0MA_face1e08-1b0b-4676-93a0-92f5beef034c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfOS04LTEtMS01OTc0MA_3b62c454-556d-4fea-870a-3dd918c8cfb3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMTAtMi0xLTEtNTk3NDA_31c6fdbb-0212-4fc5-8c26-abb18e167fdd"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6edefee7cf344fa68044d87c2f8d3a88_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMTAtNC0xLTEtNTk3NDA_cbcadc8e-a80f-4434-b11b-9b4dd0ae2125"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i371566e0803142cea79b2a73e447ad55_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMTAtNi0xLTEtNTk3NDA_c6e60789-2b56-4be3-b8ab-c8a0bf2f4dfd"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ieb12711ae25c499293d55bef830a1392_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RhYmxlOjc5ZThiN2RiOGNjODRlZTk5YmZkMDliZDExZDBkZTcxL3RhYmxlcmFuZ2U6NzllOGI3ZGI4Y2M4NGVlOTliZmQwOWJkMTFkMGRlNzFfMTAtOC0xLTEtNTk3NDA_78d9e077-3e63-48fb-ae0a-234a647cf40b"
      unitRef="usd">125000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:PensionContributions
      contextRef="ifd9afdfa4aab43f5aec11564a7a210ec_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RleHRyZWdpb246MTBjNTkzNTUwYzc4NDUxMTk1MmJhZTI4ZWQ0MjhhNTdfNjIz_6050e08f-1d8a-48e1-af69-6e2dc5e8cbb6"
      unitRef="usd">29000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="i9d981e7841b2446e99bdfd3c1765f8fd_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83My9mcmFnOjEwYzU5MzU1MGM3ODQ1MTE5NTJiYWUyOGVkNDI4YTU3L3RleHRyZWdpb246MTBjNTkzNTUwYzc4NDUxMTk1MmJhZTI4ZWQ0MjhhNTdfNjMw_ccf2e3f8-7498-48c4-b3cf-c917ebad4a15"
      unitRef="usd">5000000</us-gaap:PensionContributions>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RleHRyZWdpb246N2U0MDU0Y2M1ZDI1NDM0ODhhNzFkOWRlNzA4MDdjY2RfOTI1_7fd33335-cac1-4edd-9ca3-dedac86d1212">ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RleHRyZWdpb246N2U0MDU0Y2M1ZDI1NDM0ODhhNzFkOWRlNzA4MDdjY2RfOTM3_c6b03e5a-1112-4495-b302-36154a5695aa">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i655ff821171a4447a9788502f3181ca5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC0yLTEtMS01OTc0MA_0ca29a67-6e3d-45d4-a66c-aa673f086064"
      unitRef="usd">-10017000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79fbbc6f7a9f4234af3a15aaeeaba82e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC00LTEtMS01OTc0MA_cff46b52-3663-4a7b-9ee5-a87f36c6afa3"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb1f6b66a0df4ab5a5db2bb2552e5b52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC02LTEtMS01OTc0MA_1a0e309b-c87c-40ce-91ac-47eb259b1499"
      unitRef="usd">-2702000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b3c368d3ea94156894bb15d205cbe39_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC04LTEtMS01OTc0MA_205ad5eb-ad1c-49f9-a419-33525ff023af"
      unitRef="usd">-336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2336cd90b8e74beeb66f460bec6b6238_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNC0xMC0xLTEtNTk3NDA_12899e42-0d26-4d5f-b336-d39dbca36c4b"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id04f969ee3dd48eb9bd1be04f519efba_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS0yLTEtMS01OTc0MA_cb8be334-1054-452a-acee-4e4f25cf3fd2"
      unitRef="usd">-554000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie1fcea51f4fa46ea9140cbab41a14eb8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS00LTEtMS01OTc0MA_374573cd-4e49-4c5c-b71a-b07bff872d0e"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia9ab2638f2434165b9cb7a98bca9725c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS02LTEtMS01OTc0MA_5b535199-4b40-473a-ba90-72e07e69041a"
      unitRef="usd">164000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i036b309881ec46189aa9470289afa49d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS04LTEtMS01OTc0MA_ea1cce0c-db5a-4542-867e-75ab012127a3"
      unitRef="usd">-296000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifbe0f983eea14da3b437dcf18bfa144b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNS0xMC0xLTEtNTk3NDA_ce80ad71-3b45-41d5-9a40-e10a2c01b350"
      unitRef="usd">-699000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68eb55b964054c96a96b26b18621d7fd_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy0yLTEtMS01OTc0MA_b46bf5d2-301e-49d0-adc6-cd2e8d466dea"
      unitRef="usd">-10571000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i326f78b1620b461cb2172429271e8699_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy00LTEtMS01OTc0MA_ce7eb60f-8236-4fad-a908-a2077e1408b4"
      unitRef="usd">-16000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49a97e3323484686a9262c40ba0b98ce_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy02LTEtMS01OTc0MA_d2961795-3320-42b2-9850-15f8993796d7"
      unitRef="usd">-2538000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i579a8661a8a943369207a48d2742c946_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy04LTEtMS01OTc0MA_63759510-38a6-4623-98bc-233246fad092"
      unitRef="usd">-632000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i795ff92791494382a1d26a7b84fee3e5_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83Ni9mcmFnOjdlNDA1NGNjNWQyNTQzNDg4YTcxZDlkZTcwODA3Y2NkL3RhYmxlOmMzMzEwY2EyNmM5NjQ5OWI4MTVmYjZlNzJiNTliNmVlL3RhYmxlcmFuZ2U6YzMzMTBjYTI2Yzk2NDk5YjgxNWZiNmU3MmI1OWI2ZWVfNy0xMC0xLTEtNTk3NDA_778ce9f7-13f6-4e84-9c25-5d4f374ad033"
      unitRef="usd">-13757000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RleHRyZWdpb246NzE1YWY5MGNkYWViNGY2NGIyNDkwM2EyNmJiZmJhMTlfOTkz_f34541d4-4d37-49d9-9556-22f5047b093d">EARNINGS PER SHARE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.011%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,666.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#x2019;s stock. &lt;/span&gt;&lt;/div&gt;The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;4, 2021 excluded 9&#160;million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RleHRyZWdpb246NzE1YWY5MGNkYWViNGY2NGIyNDkwM2EyNmJiZmJhMTlfMTAwMQ_a77c00a6-ff68-4a32-87d2-d66697d6aee6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.011%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,666.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfMi0yLTEtMS01OTc0MA_ac8d6b56-b77c-4f9d-9ac4-464f87c51089"
      unitRef="usdPerShare">1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfMi00LTEtMS01OTc0MA_21658fe7-6828-4700-8a78-182930066711"
      unitRef="usdPerShare">2.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfMy0yLTEtMS01OTc0MA_cd876ad2-1d1d-4a5e-95f5-667712632925"
      unitRef="shares">2629200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfMy00LTEtMS01OTc0MA_6995128d-dff2-4f4f-b824-8226174eb768"
      unitRef="shares">2631600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNC0yLTEtMS01OTc0MA_1fbd7950-ee3e-4b1c-b772-23823a98da19"
      unitRef="shares">140100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNC00LTEtMS01OTc0MA_b590dba2-be9b-48b8-8b51-0c3e851c5d99"
      unitRef="shares">128400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNS0yLTEtMS01OTc0MA_ea0870c4-cf3d-4244-a65e-c8e7cb3c7b1d"
      unitRef="shares">102800000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNS00LTEtMS01OTc0MA_4f3b1961-bb87-4cd5-811e-98218a27f25a"
      unitRef="shares">87300000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNy0yLTEtMS01OTc0MA_a1b38437-f40e-4376-8750-df09d85a68c2"
      unitRef="shares">2666500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfNy00LTEtMS01OTc0MA_2f3f67cb-bc24-4623-8aef-c44c5a133d7d"
      unitRef="shares">2672700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfOC0yLTEtMS01OTc0MA_69e164be-68e0-41da-8c31-20e9b2070e96"
      unitRef="usdPerShare">1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RhYmxlOmU4MDFmNzYxNTA1ZTQ5MTQ5NTBkODQzOWM4YWViOGZlL3RhYmxlcmFuZ2U6ZTgwMWY3NjE1MDVlNDkxNDk1MGQ4NDM5YzhhZWI4ZmVfOC00LTEtMS01OTc0MA_11dc7c24-05a5-468a-92f4-800cf9052e5e"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF83OS9mcmFnOjcxNWFmOTBjZGFlYjRmNjRiMjQ5MDNhMjZiYmZiYTE5L3RleHRyZWdpb246NzE1YWY5MGNkYWViNGY2NGIyNDkwM2EyNmJiZmJhMTlfNDYw_df378649-d1fd-4503-9219-bda8ab8dd134"
      unitRef="shares">9000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzczOA_55c3c6d2-2e29-4b29-8d14-14e957fef0e2">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA / INVOKAMET&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1,2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDTECH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; In the fiscal first quarter of 2021, approximately $0.1&#160;billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of  PROCRIT / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Previously referred to as Medical Devices&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.5)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.1)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*Fiscal first quarter 2021 earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2022 and 2021&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Divestiture gains of $0.6&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.8&#160;billion and $0.9&#160;billion in the fiscal first quarter of 2022 and 2021, respectively&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A loss of $0.4&#160;billion related to the change in the fair value of securities in the fiscal first quarter of 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2022 and 2021 &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.3&#160;billion in both the fiscal first quarter of 2022 and 2021 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Amounts not allocated to segments include interest income/expense and general corporate income/expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <jnj:SalesBySegmentOfBusinessTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzc0Ng_a5603c06-0eee-4b51-b43a-9e51e3cc2247">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA / INVOKAMET&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1,2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDTECH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; In the fiscal first quarter of 2021, approximately $0.1&#160;billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of  PROCRIT / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Previously referred to as Medical Devices&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie58211c7e72c4650b6392f3161a3bffe_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNS0yLTEtMS01OTc0MA_5f3c4578-5c16-4710-9dc2-077d0d92e926"
      unitRef="usd">670000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc118b408a9a4fa0a2216582ec2c57d3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNS00LTEtMS01OTc0MA_2e79e29e-8007-4a7b-85d7-63cba963ac03"
      unitRef="usd">599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie58211c7e72c4650b6392f3161a3bffe_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNS02LTEtMS01OTc0MA_13fd33be-d047-48cf-8fa8-54d85f4ad14f"
      unitRef="number">0.118</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea43f39e6f7e4722a355ac665f3270c0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNi0yLTEtMS01OTc0MA_0e1c51f6-5dee-4331-91ea-974e59de20f3"
      unitRef="usd">791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59a68fc6f7f84ab9bd6670bd40be776f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNi00LTEtMS01OTc0MA_ef72179b-2079-4379-a036-0bac5f0dc6af"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iea43f39e6f7e4722a355ac665f3270c0_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNi02LTEtMS01OTc0MA_cfeada2c-be27-4392-92d5-6ef9a608651f"
      unitRef="number">0.175</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i822f34b9534c4b36800cd53b915bfd96_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNy0yLTEtMS01OTc0MA_0910f3f8-13f7-4a5c-a903-71b840804a39"
      unitRef="usd">1461000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04e49973bd224b328cb521a49bd33c14_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNy00LTEtMS01OTc0MA_7332e281-df07-4a71-801e-a2311b9cbba2"
      unitRef="usd">1273000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i822f34b9534c4b36800cd53b915bfd96_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNy02LTEtMS01OTc0MA_4f98e118-e837-48a8-b2e0-fbfc9ca67928"
      unitRef="number">0.148</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cc09b5880e446b6b7704ca8b8c71bf9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOS0yLTEtMS01OTc0MA_831b4d79-ab3d-4c6f-ac9e-c75c5b0b6329"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icebf6d8f73bf4c99a24334b6c6b70834_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOS00LTEtMS01OTc0MA_89eb3555-ea1d-4f99-bf40-28b965cdea46"
      unitRef="usd">634000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7cc09b5880e446b6b7704ca8b8c71bf9_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOS02LTEtMS01OTc0MA_946ce16f-9997-4fa0-b3d2-631d6da2585f"
      unitRef="number">-0.142</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d1e565782ba4f77b615f220541630b5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAtMi0xLTEtNTk3NDA_b2b0e5a7-4f06-42a9-b2b1-f60f1f406fb9"
      unitRef="usd">468000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8572638eba1747738bf792b8ccc0d65b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAtNC0xLTEtNTk3NDA_178c4f31-e352-46f8-a9b2-38fec933d2c8"
      unitRef="usd">529000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0d1e565782ba4f77b615f220541630b5_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAtNi0xLTEtNTk3NDA_c989731f-e238-4c69-9b70-0c5d15fb1123"
      unitRef="number">-0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i106a09af4412484ab101b4dff6f6060a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEtMi0xLTEtNTk3NDA_0e05e384-f8b8-41fa-ab73-2d00a12a4a6f"
      unitRef="usd">1012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30c0af8ca15849f8888a804c0a76e8f5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEtNC0xLTEtNTk3NDA_97b23d9e-0717-438f-89c2-c6cc482d38ff"
      unitRef="usd">1163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i106a09af4412484ab101b4dff6f6060a_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEtNi0xLTEtNTk3NDA_26999e3b-49bf-4381-9002-fae74a0ffcd9"
      unitRef="number">-0.130</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cfa95d8a78b40e4a7dfc45c287e5d8a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMtMi0xLTEtNTk3NDA_9cdf2387-28e2-4224-a927-fb53e2909c9c"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08c6944ea87e4a3dafff3f45a308061f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMtNC0xLTEtNTk3NDA_cc3f4ad0-566b-45af-b476-78a89e052be8"
      unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1cfa95d8a78b40e4a7dfc45c287e5d8a_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMtNi0xLTEtNTk3NDA_df14d5b3-6da7-498e-a3e3-96f6d7efc4b4"
      unitRef="number">-0.126</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46c50a0f6783436cb25640408523922e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQtMi0xLTEtNTk3NDA_48a26bc2-4653-4454-aecc-0b075e8cc37c"
      unitRef="usd">223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e793e0192504c92a6fb0cb90815740a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQtNC0xLTEtNTk3NDA_9fe3377e-757a-48a4-8ff2-06bf95b30e0c"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i46c50a0f6783436cb25640408523922e_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQtNi0xLTEtNTk3NDA_b058d6d6-c8a0-4889-9a1b-61b7a5b197a4"
      unitRef="number">-0.120</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i908ec40014fe4b879088ba1b344b5a37_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUtMi0xLTEtNTk3NDA_73bbbe55-1ac0-441a-935a-19a69e78b7f4"
      unitRef="usd">366000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3aa331b4f344986bd6aefd2d877917a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUtNC0xLTEtNTk3NDA_d945756e-2a0b-436e-92fc-b92d51cb54c8"
      unitRef="usd">417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i908ec40014fe4b879088ba1b344b5a37_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUtNi0xLTEtNTk3NDA_d76895f7-6505-478f-b03b-88409af4cf81"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c161740da694af9a2557994290040f0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTctMi0xLTEtNTk3NDA_471dc47c-0eea-4095-96bf-2a968e51b9ea"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b056bd57be1420eb472b82a9ad65490_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTctNC0xLTEtNTk3NDA_a8cce880-0d44-4699-a275-42a61aded944"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4c161740da694af9a2557994290040f0_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTctNi0xLTEtNTk3NDA_e1a55253-a3e9-4e78-afa1-3abfa0f15301"
      unitRef="number">-0.115</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cd2d0c278fd4ccb9e5f826f44c15a6b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgtMi0xLTEtNTk3NDA_688b271f-a44b-457f-bfb1-f7688417b8ca"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdd5fd3ed29041aeba59bb41d9957e8e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgtNC0xLTEtNTk3NDA_42950506-659a-4bf5-9cec-f977d1462869"
      unitRef="usd">293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9cd2d0c278fd4ccb9e5f826f44c15a6b_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgtNi0xLTEtNTk3NDA_412433bf-8a3f-481c-b79c-e7bc0fa6d404"
      unitRef="number">-0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43ceb1cef02743f1b6c9be2aa05040b3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTktMi0xLTEtNTk3NDA_3286727f-87db-4862-8791-a57604f59c09"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4acd3aa5bee74304878a6f9cbf1956ec_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTktNC0xLTEtNTk3NDA_7492ccf7-3a46-40b6-9f42-a3c38edc28f1"
      unitRef="usd">389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i43ceb1cef02743f1b6c9be2aa05040b3_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTktNi0xLTEtNTk3NDA_05778f8c-297f-4349-aa60-61bf7c111597"
      unitRef="number">-0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie77366e1975a48bd8912cb5972f077ca_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEtMi0xLTEtNTk3NDA_ac93c4b2-9593-48e3-8350-d1bdabace9b4"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45ceadbf51b24faa9f04ba01b0a27b54_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEtNC0xLTEtNTk3NDA_61295424-c86d-42ad-8404-8154d5b63e14"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie77366e1975a48bd8912cb5972f077ca_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEtNi0xLTEtNTk3NDA_99650182-a6ce-4c9a-8b13-02f91b22b0f8"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d4e3ae4eef749e986b5c6bd8d739748_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjItMi0xLTEtNTk3NDA_d8538e52-0566-475e-b717-de18084b8db6"
      unitRef="usd">224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84d71c2b7b4544b1a58237715b2b3c42_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjItNC0xLTEtNTk3NDA_4627dbac-49a7-47cf-9cdc-8120dfbfc9ab"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4d4e3ae4eef749e986b5c6bd8d739748_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjItNi0xLTEtNTk3NDA_bd95cf60-ab34-4a67-b53f-75421acde98a"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i678bfbf7014e416f8aa38a66f366d4be_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMtMi0xLTEtNTk3NDA_e5208ea9-ebdf-44cf-859b-1e88d350828d"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib688bd3f296d41f0b14572e3064b458d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMtNC0xLTEtNTk3NDA_a058c63c-508c-4836-b0e9-754801d3b387"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i678bfbf7014e416f8aa38a66f366d4be_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMtNi0xLTEtNTk3NDA_75c5e1bf-7300-465d-b21f-2402ce32154a"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4627a516050411dbd08c0de6091128b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjUtMi0xLTEtNTk3NDA_43025c11-013d-412d-ad94-e3400b43b8fe"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d275cd215484120b60ac1c7626e17a7_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjUtNC0xLTEtNTk3NDA_703dd018-f9f0-4472-b088-dfddf3e52f21"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia4627a516050411dbd08c0de6091128b_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjUtNi0xLTEtNTk3NDA_d6b12e10-86fe-4675-989a-6b9783101da1"
      unitRef="number">-0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i932bcfc6315d438f826521020670f715_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjYtMi0xLTEtNTk3NDA_27219204-7304-451e-8867-3281cf8e4cf7"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7411eebec7264351bf377981afe68c71_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjYtNC0xLTEtNTk3NDA_84b7f3d1-c65e-47a2-a19b-47d730852046"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i932bcfc6315d438f826521020670f715_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjYtNi0xLTEtNTk3NDA_def1c44e-555f-44c5-9017-95f0e396e89a"
      unitRef="number">-0.153</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41f0f05017af45e3863ccf8b056567cb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjctMi0xLTEtNTk3NDA_833df720-86a1-4967-86e7-161d37900970"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c3d886ec05249aab4e1f0ce7760f1c8_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjctNC0xLTEtNTk3NDA_38d3f10b-a06e-45b6-a85d-af83ae70ab07"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i41f0f05017af45e3863ccf8b056567cb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjctNi0xLTEtNTk3NDA_f80ddef3-c5e8-472a-a47e-3f67a5adf125"
      unitRef="number">-0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a5159ea7ea34a9486f467d8b275261c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjktMi0xLTEtNTk3NDA_8ef4accc-75b0-4982-ad61-822543a5517f"
      unitRef="usd">1557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b965aef16c049ca90d08a094faafdcd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjktNC0xLTEtNTk3NDA_1e9b541e-b8db-4069-ae3c-cc5677a6cb0c"
      unitRef="usd">1611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7a5159ea7ea34a9486f467d8b275261c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjktNi0xLTEtNTk3NDA_c11252f2-a7b9-4e82-a1dc-3e558366d08c"
      unitRef="number">-0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cbacfe0de454d4fa786ace56cada354_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzAtMi0xLTEtNTk3NDA_7f4f623a-91e1-453b-adca-3e8a3965bbe9"
      unitRef="usd">2029000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dd509ce95fe400781462e4ad6cfa01f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzAtNC0xLTEtNTk3NDA_0606b9f7-9d8d-4742-9247-b76b739edfd8"
      unitRef="usd">2030000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6cbacfe0de454d4fa786ace56cada354_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzAtNi0xLTEtNTk3NDA_a9be7090-09b0-4f3b-bb68-24c9a52020e5"
      unitRef="number">0.0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzEtMi0xLTEtNTk3NDA_ff50784b-673a-4ec6-bf49-e0aaae4bfd42"
      unitRef="usd">3586000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d4fd750dd7840a1bd8f81d424809f1a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzEtNC0xLTEtNTk3NDA_e9fa37f2-632f-4a06-bcd2-7bf53d0c6f4b"
      unitRef="usd">3641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i243e3137307243b2b0f7cdfef2676e28_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzEtNi0xLTEtNTk3NDA_1a5ca81d-1e9c-43c1-84db-c8772c12a1bf"
      unitRef="number">-0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac6c831f375741cd86628f708528bbc4_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzYtMi0xLTEtNTk3NDA_be50017a-fbe9-4cde-947c-ad4a7892a97e"
      unitRef="usd">2501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i378ba8c96ec94703a6594ef190bcf501_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzYtNC0xLTEtNTk3NDA_2724975b-0fb1-4dca-ae6b-0a9aca977e9d"
      unitRef="usd">2413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iac6c831f375741cd86628f708528bbc4_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzYtNi0xLTEtNTk3NDA_6deb535f-c836-42df-9e4c-b341da429756"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i770e070317374dd9bbc2d03a76164315_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzctMi0xLTEtNTk3NDA_113b5543-b7f2-4859-98f9-d3901577611b"
      unitRef="usd">1617000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id00933be305c4a70bc5ab93fcafbfa34_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzctNC0xLTEtNTk3NDA_b194d787-7f4e-4e46-8ac8-429a59a72954"
      unitRef="usd">1501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i770e070317374dd9bbc2d03a76164315_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzctNi0xLTEtNTk3NDA_20b9b330-9ae5-4b9d-9560-00a6fc0db3a4"
      unitRef="number">0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30ecdf550ad642faad28a0a3da3a0c49_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzgtMi0xLTEtNTk3NDA_ba9639a3-a6a2-4663-80bc-5369c6d8b95e"
      unitRef="usd">4119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic914d835318f4ac59e6afec0dc209943_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzgtNC0xLTEtNTk3NDA_882be0b4-a7f8-4009-85bc-19e1787b657e"
      unitRef="usd">3914000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i30ecdf550ad642faad28a0a3da3a0c49_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMzgtNi0xLTEtNTk3NDA_4c308ae3-3d40-4390-8e34-57d2cc47a7d4"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ea83d16b7bb4bb4852dde662d6d8a03_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDAtMi0xLTEtNTk3NDA_e4cbd040-ef1c-4772-a990-38f0714048fa"
      unitRef="usd">358000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i355c4b8323c94982a0e7d8ad5ef02138_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDAtNC0xLTEtNTk3NDA_f4eacda8-7342-4044-acf8-346d38697d2f"
      unitRef="usd">489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9ea83d16b7bb4bb4852dde662d6d8a03_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDAtNi0xLTEtNTk3NDA_2d6e59de-0e29-4f92-9241-b38159ccd010"
      unitRef="number">-0.268</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5fe9781715b43f6b43d02d8a29fdd61_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDEtMi0xLTEtNTk3NDA_a8f02b5f-f6f9-452b-b384-e593854ca103"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1de5e9029e04a3088baa1a08b8ee842_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDEtNC0xLTEtNTk3NDA_7ca271aa-606c-4b1a-827d-86981f336999"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id5fe9781715b43f6b43d02d8a29fdd61_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDEtNi0xLTEtNTk3NDA_d3e31da8-dd19-4f4d-b691-115d82f0ef9d"
      unitRef="number">0.405</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i919b94882de1475288644c1f41c738db_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDItMi0xLTEtNTk3NDA_44a45c1a-25b8-4e32-8a51-4e8d6cc99a0b"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id74ae7d88be64d3c866359475a6b9e4d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDItNC0xLTEtNTk3NDA_ffe6f391-d267-4ba4-8523-0bfbdce609ba"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i919b94882de1475288644c1f41c738db_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDItNi0xLTEtNTk3NDA_9defe84a-a8af-4a7f-b762-3f620ff383e0"
      unitRef="number">-0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64b27662b65c465dbfc102823591a764_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDMtMi0xLTEtNTk3NDA_0022d349-155b-4cec-8da8-c625f09d171a"
      unitRef="usd">663000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i275f4a59164a4f3cb58fd6b37c979201_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDMtNC0xLTEtNTk3NDA_d5056e88-4e9d-4cc3-b69a-d11e34317377"
      unitRef="usd">777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i64b27662b65c465dbfc102823591a764_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDMtNi0xLTEtNTk3NDA_a98c59bf-0385-4bcf-9ef4-3f1c85adcf69"
      unitRef="number">-0.147</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d196ab07bb74237905594d14817fae6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDUtMi0xLTEtNTk3NDA_2fa2c70a-94fe-4323-a755-2e407251162a"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea6e2e05dd264470bda927b1746471f2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDUtNC0xLTEtNTk3NDA_63706bee-58d0-428e-9998-9db827fe0c3a"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9d196ab07bb74237905594d14817fae6_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDUtNi0xLTEtNTk3NDA_e448d8c4-7b7b-4bca-b299-4606c51885fa"
      unitRef="number">0.125</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5baa35e48631478bb99da941854cbc28_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDYtMi0xLTEtNTk3NDA_da494422-8335-4c1c-beee-e8b188228813"
      unitRef="usd">283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5218805bf34a4f8f9bca9cd6f32c57b2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDYtNC0xLTEtNTk3NDA_e6abe4ad-625e-46f3-99a0-b4b159d970c5"
      unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5baa35e48631478bb99da941854cbc28_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDYtNi0xLTEtNTk3NDA_a3822aae-ad9a-4508-848a-db6f9f959f07"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f43191ea7584ff5a4538caed79690b3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDctMi0xLTEtNTk3NDA_167865f5-4bde-4f9a-849c-8f2da8b1a7fe"
      unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80675b68ae0443c09f1f157dcafd38b5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDctNC0xLTEtNTk3NDA_e69ebc55-d0c4-4d76-a7ad-0b38d52c7cba"
      unitRef="usd">562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3f43191ea7584ff5a4538caed79690b3_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDctNi0xLTEtNTk3NDA_6ea4b2f7-b70f-4d96-853b-4f2063a2587e"
      unitRef="number">0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d5eb90c90324a6c99251bc1ef4cd0b0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDktMi0xLTEtNTk3NDA_5d785131-8149-4972-a5cb-8528265c3c2d"
      unitRef="usd">1379000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a3a53a0ad9046aca93e6a7542cd2283_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDktNC0xLTEtNTk3NDA_8e5a84b6-0134-43d3-9c86-ee1e60705b5c"
      unitRef="usd">1331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9d5eb90c90324a6c99251bc1ef4cd0b0_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNDktNi0xLTEtNTk3NDA_4efbe509-2d5a-47f6-baca-0b00acea54ed"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bae0a6534fb41dfa209ab28eb17aac8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTAtMi0xLTEtNTk3NDA_5788dfa0-22b3-49d9-8954-9a610e792e75"
      unitRef="usd">909000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbb41835a7214d6cbbc92d58157fea67_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTAtNC0xLTEtNTk3NDA_f7335adb-78b5-48fe-bd0d-c7f16a350b50"
      unitRef="usd">817000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3bae0a6534fb41dfa209ab28eb17aac8_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTAtNi0xLTEtNTk3NDA_a57a7736-2c68-4a53-8f95-f3ccb6b26d75"
      unitRef="number">0.112</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7211490fa1584a8e8f0474626afbda8b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTEtMi0xLTEtNTk3NDA_b9c63713-9406-462c-b3ac-b7409c3731e4"
      unitRef="usd">2288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if075bf0d83ea40f880b89b7f1b810a39_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTEtNC0xLTEtNTk3NDA_7512e13f-20fd-425a-9e6a-90d328a39473"
      unitRef="usd">2148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7211490fa1584a8e8f0474626afbda8b_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTEtNi0xLTEtNTk3NDA_75faa9ec-7074-4beb-a4f8-94e40f13bb78"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6904e2c80904427fb7a581c5096e57a2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTMtMi0xLTEtNTk3NDA_f2f9c663-982c-4775-9a02-99663bda94f4"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb39ed1f03bf4875b56192f82a2d67c8_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTMtNC0xLTEtNTk3NDA_645b60cc-dcac-4545-b1e3-5dacd34206a6"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6904e2c80904427fb7a581c5096e57a2_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTMtNi0xLTEtNTk3NDA_9810b18c-ad92-4af4-b364-59339a9d8ffe"
      unitRef="number">0.427</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f8d1cf7d44f47e6b575833e5e6f0d05_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTQtMi0xLTEtNTk3NDA_3aa230f8-b4ef-42a8-ba7b-13b0938b50f0"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff32341c0bbe4b5ea9b566ba153fbf51_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTQtNC0xLTEtNTk3NDA_8e8e14d4-c327-4fe6-ac12-4b6b92aa6d62"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8f8d1cf7d44f47e6b575833e5e6f0d05_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTQtNi0xLTEtNTk3NDA_4b2f80ae-ce0a-479a-a51f-2c8cd49c4be9"
      unitRef="number">0.388</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11ac62a4e6cb4f948252748f571a1ff6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTUtMi0xLTEtNTk3NDA_686bc5c5-5d2d-4ab7-a7e8-0621ace31f16"
      unitRef="usd">590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab0aa5e7ee2b48aba645333335c83702_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTUtNC0xLTEtNTk3NDA_15a2a560-6923-41ed-b6bf-82e0197e1169"
      unitRef="usd">418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i11ac62a4e6cb4f948252748f571a1ff6_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTUtNi0xLTEtNTk3NDA_75d8f29c-cfe5-4892-9be1-1b9f4f1f4507"
      unitRef="number">0.413</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9efb7452eea34bc9898890c0842597d0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTctMi0xLTEtNTk3NDA_fb4cb15c-ed60-40af-808c-6492bafdc601"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1665d864d98a4d47962732594b5b38f9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTctNC0xLTEtNTk3NDA_848bec08-9142-4e2d-8b6c-59cc2a94c6dd"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9efb7452eea34bc9898890c0842597d0_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTctNi0xLTEtNTk3NDA_a9af4b7d-a0da-4e63-a0c6-bf45b23d9baa"
      unitRef="number">-0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc4d03da8ff94f98aab51935db754a84_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTgtMi0xLTEtNTk3NDA_3dcf68b9-489d-4787-aed6-260ce70d18a3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb131415d3694db89b4c3cc631aebfad_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTgtNC0xLTEtNTk3NDA_13621bab-fb17-4a25-88bf-713ee37aa930"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04b92c4c34a94ef0a8c83ea08eee3b04_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTktMi0xLTEtNTk3NDA_88af2fce-e666-4695-a488-6cdc8963cdea"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05d97f7b5e9e411796b79b2aed308f49_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTktNC0xLTEtNTk3NDA_286a7b67-c673-4106-bb8c-ac47872c55bd"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i04b92c4c34a94ef0a8c83ea08eee3b04_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNTktNi0xLTEtNTk3NDA_9f08de1d-348a-4096-ac9c-4459d5c9f3fe"
      unitRef="number">-0.220</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd4c0bdbeb7e481486ce84464add9cec_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjItMi0xLTEtNTk3NDA_5fa3eb28-c593-426f-8033-9235c2af5cf6"
      unitRef="usd">461000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8f65547983b48f38c56effa03744e71_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjItNC0xLTEtNTk3NDA_b0ba0484-3a02-4c6a-9483-8b6a746224e5"
      unitRef="usd">512000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifd4c0bdbeb7e481486ce84464add9cec_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjItNi0xLTEtNTk3NDA_e641f5ec-db8b-4069-966f-639ae334cc87"
      unitRef="number">-0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42a180a67aa34f04985a9c36da5181f4_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjMtMi0xLTEtNTk3NDA_e4492dd6-5101-4886-aead-5067d3474208"
      unitRef="usd">836000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i726bc4433398439cae78ea7e13f10dd7_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjMtNC0xLTEtNTk3NDA_e6ac2055-77c4-4944-8a3e-a3d19de25741"
      unitRef="usd">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i42a180a67aa34f04985a9c36da5181f4_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjMtNi0xLTEtNTk3NDA_3b37fac1-3642-4725-80d1-b500fd05fc7a"
      unitRef="number">0.723</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic26e429353e64268acab78bb090eb6ee_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjQtMi0xLTEtNTk3NDA_f3334be9-95ba-4e37-85dd-53e4470d8f09"
      unitRef="usd">1297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41cfcf4ec4d349ac965bd4f72a911528_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjQtNC0xLTEtNTk3NDA_069fd7fe-c337-40d5-becc-cb53604a7083"
      unitRef="usd">998000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic26e429353e64268acab78bb090eb6ee_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjQtNi0xLTEtNTk3NDA_f80809a3-dabe-4706-9936-4b2e912c9a8c"
      unitRef="number">0.300</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d87460fbbce401e9e230c449de32a04_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjYtMi0xLTEtNTk3NDA_670b8e45-f319-4d38-b611-ac39114be807"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7518353c94d148b98920a57e3c13f558_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjYtNC0xLTEtNTk3NDA_4ec25e74-7352-44c7-89f2-dfe8b1025121"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8d87460fbbce401e9e230c449de32a04_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjYtNi0xLTEtNTk3NDA_d863304c-8166-40a8-aeb7-f3149748a3db"
      unitRef="number">-0.249</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72f3a3fff4b64c42b7391f6783fc86d0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjctMi0xLTEtNTk3NDA_290a5805-3323-4efe-820a-d73b6e2e4be9"
      unitRef="usd">382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i283ab968a33a4019bbca8dd07bb73fb5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjctNC0xLTEtNTk3NDA_186be3e1-60aa-4ee9-b0fc-b5a78d233854"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbe04729f6a041dcbcc8950cffbd70ad_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjgtMi0xLTEtNTk3NDA_a2bb6869-9f7c-4031-b4c5-ad9699bd7362"
      unitRef="usd">457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d850d220f25461faec903dbc0514f8c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNjgtNC0xLTEtNTk3NDA_5cca2e36-f8a8-4557-996c-3705c86b32e3"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0520f0e2ba8d45dbbb23db3edcb3b1ec_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzAtMi0xLTEtNTk3NDA_6e7ade17-94d2-49ef-9273-268518a59432"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9fba2a4e93645948a9ff0513bb728e3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzAtNC0xLTEtNTk3NDA_d5764ebd-d33b-4036-8491-853b23e66095"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0520f0e2ba8d45dbbb23db3edcb3b1ec_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzAtNi0xLTEtNTk3NDA_537cab0b-4539-45de-9565-26ee5bdbba1d"
      unitRef="number">-0.126</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78f85b561077441a8f29c95efc82e1ff_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzEtMi0xLTEtNTk3NDA_98ce671d-b9ee-4cab-986c-4050486a0ca8"
      unitRef="usd">239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb33e483487440ffb0cfd196244dae1e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzEtNC0xLTEtNTk3NDA_cd0b1476-8e7d-46a8-a587-b6fd5d6820bd"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i78f85b561077441a8f29c95efc82e1ff_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzEtNi0xLTEtNTk3NDA_423520d3-38ff-42b0-ab2a-a24a80b007e4"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2104212889d4866a172b2ffa3412b5b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzItMi0xLTEtNTk3NDA_4492c5fb-c361-4c78-982c-88e68533580f"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69d54355525c45a48dcc9d5a2c07b492_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzItNC0xLTEtNTk3NDA_8c55f454-6302-4152-8d88-4932f3da5c0d"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic2104212889d4866a172b2ffa3412b5b_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzItNi0xLTEtNTk3NDA_fa7197a2-0169-4914-a635-3f0a4699c9ed"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic73699a20bfe4592ab11597b967e3e81_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzQtMi0xLTEtNTk3NDA_94946ab4-f6da-4749-98d6-059a0dfe1bd9"
      unitRef="usd">369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43632776d7d241d6acebca744803b602_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzQtNC0xLTEtNTk3NDA_a5373a0c-83de-4988-bbb9-5c6a170ac8aa"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic73699a20bfe4592ab11597b967e3e81_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzQtNi0xLTEtNTk3NDA_8bff0da5-0d0e-4747-b724-c0a8cf0185ac"
      unitRef="number">-0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8041af648d74844acd07d971cac9b88_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzUtMi0xLTEtNTk3NDA_a037e7b5-dcec-4956-8a4f-9790c33570ed"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3003caab41114b89887d780481856b8f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzUtNC0xLTEtNTk3NDA_0450bb4f-458c-4734-8444-55573fb06b85"
      unitRef="usd">166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie8041af648d74844acd07d971cac9b88_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzUtNi0xLTEtNTk3NDA_3262d955-64d4-45bc-aea1-25d4064b77ab"
      unitRef="number">-0.203</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieefaab0fe06d4a1d8825a8a2912d415d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzYtMi0xLTEtNTk3NDA_0a2f4ca6-c8f9-4265-8c25-9f075dcf0172"
      unitRef="usd">501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c1c0146fd1e40afb97e83e53dac0b3c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzYtNC0xLTEtNTk3NDA_5f605593-55a9-4dae-83c4-88d711ed3883"
      unitRef="usd">546000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieefaab0fe06d4a1d8825a8a2912d415d_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfNzYtNi0xLTEtNTk3NDA_4436578e-4f6d-473c-80bb-c422c11c54e3"
      unitRef="number">-0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i113143b999484cd6b7094f5ffb7f6934_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODAtMi0xLTEtNTk3NDA_758a492b-3bb3-4ea1-b7b4-7a6d1e0c0f9e"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6df7baa0a5740ee8592ff53dd67a1be_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODAtNC0xLTEtNTk3NDA_9b0ae23f-ab1c-4de2-bf2d-9abdabaa2e38"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i113143b999484cd6b7094f5ffb7f6934_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODAtNi0xLTEtNTk3NDA_c8dc9a3e-1d3e-492a-b0a4-250c10a2c12d"
      unitRef="number">-0.625</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dc562abb9fc439a87f2465b603dc878_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODEtMi0xLTEtNTk3NDA_22768fbf-b3f2-4fdc-a8b2-d76f7b597b77"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie870e747ed874ff9a84adcffcef46376_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODEtNC0xLTEtNTk3NDA_80aedf41-ca7c-4c53-b84e-e9a9bf6d69d6"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4dc562abb9fc439a87f2465b603dc878_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODEtNi0xLTEtNTk3NDA_74ba15c9-9e5f-438b-a82a-6e8d5eab31ab"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23204760220240d9910ea175d94d29aa_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODItMi0xLTEtNTk3NDA_9da19b5f-f7b5-4b14-81fd-3c7d516f3e0a"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i337ee039b35a4dd29e3fda93f8888073_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODItNC0xLTEtNTk3NDA_83b9f636-ac1b-428f-8790-94fa256493c2"
      unitRef="usd">108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i23204760220240d9910ea175d94d29aa_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODItNi0xLTEtNTk3NDA_c8c13ccf-2050-4c98-b307-13f4cce6e135"
      unitRef="number">-0.153</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i060264da9f6d465d94d5b31aa47981f0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODUtMi0xLTEtNTk3NDA_1cbc67cb-2b12-4927-8ae0-d32dea02a166"
      unitRef="usd">843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e6a826272dc41a88d80ad0ce8b56bc4_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODUtNC0xLTEtNTk3NDA_164078cc-2d6d-46d1-92be-aa6b10b53911"
      unitRef="usd">771000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i060264da9f6d465d94d5b31aa47981f0_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODUtNi0xLTEtNTk3NDA_f3ce7595-273c-402d-ab1b-947ba9cdb683"
      unitRef="number">0.093</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26d3e119c5794d36acde2361b37d9315_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODYtMi0xLTEtNTk3NDA_28b8e91e-b43c-4a99-bbcc-84972f069ddc"
      unitRef="usd">898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i371b019e1643431bbc3c4121387c7e9f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODYtNC0xLTEtNTk3NDA_fd98acd2-ceba-4bdb-b7b8-c796956cd9c2"
      unitRef="usd">943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26d3e119c5794d36acde2361b37d9315_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODYtNi0xLTEtNTk3NDA_41d0c586-4497-4350-9ab4-d5073c04e1e4"
      unitRef="number">-0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d4ebc5182ee44909c1d020a6781ee9b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODctMi0xLTEtNTk3NDA_66118e80-5408-4d52-acbf-a51b196edeab"
      unitRef="usd">1741000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide5e99b0b04b4efeaf8272a60bfe9724_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODctNC0xLTEtNTk3NDA_c981db91-c8fb-4a4c-a35d-8b26a365b92e"
      unitRef="usd">1715000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3d4ebc5182ee44909c1d020a6781ee9b_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODctNi0xLTEtNTk3NDA_f6943179-c3b8-4fa6-9992-4fb4c02d8da1"
      unitRef="number">0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1470034f0eb141a98c1afe534e4076cd_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODktMi0xLTEtNTk3NDA_c21f1cfd-7b83-46e5-945e-4b62768b348a"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37a067e9da7f41b8a982801bb0a850bf_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODktNC0xLTEtNTk3NDA_3fc96922-ea41-40dc-918c-7d8495fad04e"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1470034f0eb141a98c1afe534e4076cd_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfODktNi0xLTEtNTk3NDA_3179bfab-8b0f-4be2-914f-8cc923aa0a16"
      unitRef="number">-0.265</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dcdb3a4cc9d45ba8da97ec07cd15b51_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTAtMi0xLTEtNTk3NDA_1e9ec652-5143-4dbc-b50f-7976d77e067d"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf27b40739cc4a25b5ec694c5b8c000a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTAtNC0xLTEtNTk3NDA_2ddc37cd-7792-4c8a-94da-6c74c8021ecf"
      unitRef="usd">123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0dcdb3a4cc9d45ba8da97ec07cd15b51_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTAtNi0xLTEtNTk3NDA_69a2ba4c-4655-4970-aed0-07890162e478"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b61e2b815e447c49c894f30ace4c7a6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTEtMi0xLTEtNTk3NDA_9d9bd0cb-f8c1-4672-bf8d-802e99256549"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaa838e3db72457496cc39435fbf78f1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTEtNC0xLTEtNTk3NDA_2340a83f-d90b-4701-989d-b3ef0cf9b6b0"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4b61e2b815e447c49c894f30ace4c7a6_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTEtNi0xLTEtNTk3NDA_f260bdb1-97d6-474f-9284-074654290bd9"
      unitRef="number">-0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic91a06bb3ee246aa9b6beeac53b5b676_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTMtMi0xLTEtNTk3NDA_84894f8d-23d4-4ddf-9beb-fb157095c15a"
      unitRef="usd">661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie69adf3622ff4db8a081d1405d03154b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTMtNC0xLTEtNTk3NDA_4c48bd9b-3318-480b-b20d-1c53adb97b06"
      unitRef="usd">589000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic91a06bb3ee246aa9b6beeac53b5b676_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTMtNi0xLTEtNTk3NDA_c540abee-744c-45d4-bd9f-ceffccc27f0f"
      unitRef="number">0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8b076947d8349c4991ca5f8d983bb95_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTQtMi0xLTEtNTk3NDA_59b7a608-9acc-44ce-aa1b-9f1488f380b3"
      unitRef="usd">387000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic57498e999f848169b4085103b58e794_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTQtNC0xLTEtNTk3NDA_6269ec32-3ba9-496c-9f91-3c331fedc047"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib8b076947d8349c4991ca5f8d983bb95_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTQtNi0xLTEtNTk3NDA_dedbe8f3-634d-4c26-9e42-22c8623e187d"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie49109641ba840d7ab935c9251557fcc_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTUtMi0xLTEtNTk3NDA_8d03df07-d0bc-4e99-ae10-4897888b3794"
      unitRef="usd">1048000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4d7ac479b54426c9c4da3f1551137ba_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTUtNC0xLTEtNTk3NDA_0716e895-8e29-49ed-89f9-6fd9a070d803"
      unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie49109641ba840d7ab935c9251557fcc_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTUtNi0xLTEtNTk3NDA_e0989afd-7a8e-4ccf-8dde-c69069657823"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80e016b979bf4274a83e021809fededc_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTctMi0xLTEtNTk3NDA_25c1c78d-b24b-4b5e-82b9-804f8d1aa88a"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04a88fda6b614cf0bc0a0b4fcc001282_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTctNC0xLTEtNTk3NDA_54305ac4-d3e1-449b-a5bc-53efc4003dd6"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i80e016b979bf4274a83e021809fededc_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTctNi0xLTEtNTk3NDA_a58629dd-85cb-4b3a-956f-2ac3f55b4562"
      unitRef="number">-0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2982a107598a4da5a6e1a03aedec047e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTgtMi0xLTEtNTk3NDA_94e6a1c8-84d2-4de7-8226-2bcca8b584a4"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1e34ced22b4405fbd24f5ec2c767132_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTgtNC0xLTEtNTk3NDA_2a3f886d-d251-4946-bef5-117712534006"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2982a107598a4da5a6e1a03aedec047e_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTgtNi0xLTEtNTk3NDA_2b2f9177-5ded-4bc8-86bf-bc434960615e"
      unitRef="number">-0.261</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide41d96049794347b667732daaad5f29_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTktMi0xLTEtNTk3NDA_2f58b519-a33a-4edf-a95e-d140b1efc721"
      unitRef="usd">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice792ebb5db345a282d8d06424353702_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTktNC0xLTEtNTk3NDA_090f5957-0608-40d0-affd-26ef4b289664"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ide41d96049794347b667732daaad5f29_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfOTktNi0xLTEtNTk3NDA_2a2d42bc-ff58-4a5f-bd0a-5918a84c28d6"
      unitRef="number">-0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46ba5f0fbf984535b145a1eb04807f5a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAxLTItMS0xLTU5NzQw_14aa2edc-4627-4919-a2dc-d38ebb3c6d8a"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d2ba44f06524718a59342b7ecc0be0a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAxLTQtMS0xLTU5NzQw_7083a40f-28a2-4d93-bfdb-551809511851"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i46ba5f0fbf984535b145a1eb04807f5a_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAxLTYtMS0xLTU5NzQw_f357c3f1-696c-45d0-9942-3e346a4693e2"
      unitRef="number">0.255</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd97dd4e710848aa948f66ce61e79d4e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAyLTItMS0xLTU5NzQw_0b2e6c40-c8af-43f9-aa0b-97417157103a"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i756b031800b74f1088dc4e2c1b95636e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAyLTQtMS0xLTU5NzQw_1c7aa7ad-6ef5-4e36-bfca-2e1f7c8ccd49"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibd97dd4e710848aa948f66ce61e79d4e_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAyLTYtMS0xLTU5NzQw_d30a6c80-aec5-413e-8ddb-00503f9c6fe3"
      unitRef="number">-0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i002baa7993ed4772b35c50223b4dcc36_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAzLTItMS0xLTU5NzQw_4909ff78-9739-4818-9dcd-d9d6c8a489dd"
      unitRef="usd">408000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic38731cd692a4b1c87ff4416775e7a6d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAzLTQtMS0xLTU5NzQw_2dfaed66-8bfa-452b-af5c-f39c4f6ea540"
      unitRef="usd">422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i002baa7993ed4772b35c50223b4dcc36_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTAzLTYtMS0xLTU5NzQw_eff589d7-ffca-4166-8bc4-8035029d76f5"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b7974a50c1c4182af2999542e8fdf1d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA2LTItMS0xLTU5NzQw_e39ddb9a-a04e-4eb9-be85-08bdb148bf7a"
      unitRef="usd">1582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e49e3349adb4e589300bc5c59272da4_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA2LTQtMS0xLTU5NzQw_ce3a816b-05e8-486b-958f-e9e13ed5d721"
      unitRef="usd">1377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2b7974a50c1c4182af2999542e8fdf1d_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA2LTYtMS0xLTU5NzQw_20139e09-35cc-4366-bff2-f410f9eac5e7"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9457829763fe4b90be78ca6d38abd305_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA3LTItMS0xLTU5NzQw_a5cac74a-cd62-48eb-8898-bf5fe59ef19d"
      unitRef="usd">2369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eaa50ccd6ea42d1be79c5484c2037fa_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA3LTQtMS0xLTU5NzQw_99434c46-5922-4475-ad69-59934d7ec592"
      unitRef="usd">2193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9457829763fe4b90be78ca6d38abd305_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA3LTYtMS0xLTU5NzQw_c8be07c1-1707-419b-a67f-dd1197c47e26"
      unitRef="number">0.080</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4a95b9177eb4a48b5fd6f019f635f7c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA4LTItMS0xLTU5NzQw_8b5ee9df-51d4-4484-8b96-f1e51b2a68d0"
      unitRef="usd">3950000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd9a1c9e24cc4521a4e8fd258ab91323_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA4LTQtMS0xLTU5NzQw_f8ff73f4-5e42-408c-938d-e30552fbd878"
      unitRef="usd">3570000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie4a95b9177eb4a48b5fd6f019f635f7c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTA4LTYtMS0xLTU5NzQw_b9613500-9996-4ec5-8440-6cd30980abe8"
      unitRef="number">0.106</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7caf84ee3bdf4518b4c9c4166e4f8887_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEwLTItMS0xLTU5NzQw_a60709bb-751c-4426-900d-d2cc8be4daf8"
      unitRef="usd">953000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib49af7ebdc1b4c46b17b462113ef14c1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEwLTQtMS0xLTU5NzQw_7d693f86-bacb-4909-9d81-ec9d45b0ac89"
      unitRef="usd">691000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7caf84ee3bdf4518b4c9c4166e4f8887_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEwLTYtMS0xLTU5NzQw_b904c77e-afed-48a2-94d9-c37d5ee60525"
      unitRef="number">0.379</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i602a6924da2441d3ab9cf85ee12fbb06_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTExLTItMS0xLTU5NzQw_e3a60734-6d57-4951-bdfc-373fff6afca7"
      unitRef="usd">903000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dc426c53b2a430092d248e6084cd03e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTExLTQtMS0xLTU5NzQw_c295dd9f-a599-4cbc-83c0-77298c4bf7f8"
      unitRef="usd">674000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i602a6924da2441d3ab9cf85ee12fbb06_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTExLTYtMS0xLTU5NzQw_370a5221-da5a-49ac-962a-67ac24173734"
      unitRef="number">0.340</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf7d6e57e38d42b4b47bd10b91df04e7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEyLTItMS0xLTU5NzQw_354aad3b-1d33-4293-bb62-80f827968967"
      unitRef="usd">1856000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7798838f313f4f9e83d9c4854b30c499_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEyLTQtMS0xLTU5NzQw_542e4286-5f26-4abc-a5ee-2db6f98c72de"
      unitRef="usd">1365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaf7d6e57e38d42b4b47bd10b91df04e7_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTEyLTYtMS0xLTU5NzQw_8a6335c0-e6bb-4ed9-b92e-ca9eeea9a1d9"
      unitRef="number">0.360</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idff12de1146540caa7c4f80581344a74_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE0LTItMS0xLTU5NzQw_3d7675c6-af0f-473c-a1e0-13fa1d55151c"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia86c98d81e2a4e789e3c6e3880743868_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE0LTQtMS0xLTU5NzQw_5cca7e6c-ff4e-4248-921b-3315107eb783"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idff12de1146540caa7c4f80581344a74_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE0LTYtMS0xLTU5NzQw_c6999825-e401-4d48-963b-7c61d308893d"
      unitRef="number">0.203</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1acbda17e2e04d3f9f18cad52f4e5d80_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE1LTItMS0xLTU5NzQw_df87efe0-7fe8-44ad-b3c0-39c7939e9df8"
      unitRef="usd">194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if25efb856b06413aacf054618e7f99bd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE1LTQtMS0xLTU5NzQw_9c45f23a-6a27-46fe-81b8-3293fbddea26"
      unitRef="usd">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b5a6d2f7e6f47649ada40e475d62200_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE2LTItMS0xLTU5NzQw_1662748a-5cdd-46e8-827b-08c119245981"
      unitRef="usd">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia56ec1f9700b4dec9314c88e00ec7a74_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE2LTQtMS0xLTU5NzQw_2a2ba94d-20d7-4c44-8df1-cd8b96fdab75"
      unitRef="usd">261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6b5a6d2f7e6f47649ada40e475d62200_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE2LTYtMS0xLTU5NzQw_d7541497-8f1d-4d07-a881-97d6e67b6d09"
      unitRef="number">0.530</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03297ccd7c91439abd458f48a7b57605_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE4LTItMS0xLTU5NzQw_7787aa0c-483f-4ed7-9692-3ebbf3f5b158"
      unitRef="usd">370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33e589a7b70e4b8c9ec8c56de960196c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE4LTQtMS0xLTU5NzQw_d8a681fe-098f-4fcf-8a50-2801392fbadc"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i03297ccd7c91439abd458f48a7b57605_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE4LTYtMS0xLTU5NzQw_e1fa2859-13a1-4221-a13f-972769e593fd"
      unitRef="number">-0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92068e5088f447999d216d73ce8cdb46_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE5LTItMS0xLTU5NzQw_92282f23-ef10-4c7f-90de-710607b1bdd2"
      unitRef="usd">668000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9791432463c54215891a18b29d7d056c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE5LTQtMS0xLTU5NzQw_69b6cbcf-b159-4749-bfe9-f3e9b3bb4e6d"
      unitRef="usd">680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i92068e5088f447999d216d73ce8cdb46_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTE5LTYtMS0xLTU5NzQw_268ba9ad-69e4-43cb-843b-6702119b0335"
      unitRef="number">-0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1074a5e410494804aa84259fe458782f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIwLTItMS0xLTU5NzQw_482d431b-220a-4879-bacd-378e94606b30"
      unitRef="usd">1038000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fadc8348894481296db094bdc2eda3c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIwLTQtMS0xLTU5NzQw_4e500311-eff4-46bb-93ba-f05e358ad063"
      unitRef="usd">1125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1074a5e410494804aa84259fe458782f_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIwLTYtMS0xLTU5NzQw_226a8673-764e-4b05-a558-7c30d9820034"
      unitRef="number">-0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d635d3f096e49c9b21f9616e12851e5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIyLTItMS0xLTU5NzQw_f6d8d068-3ee8-4530-9cab-740e365d478b"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic28be830ce4b48dcb3d8a7b426fae4d6_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIyLTQtMS0xLTU5NzQw_0869f643-6009-454e-9ef3-a09bb5861e75"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8d635d3f096e49c9b21f9616e12851e5_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIyLTYtMS0xLTU5NzQw_0f38c4fe-7bdd-4dd0-be6a-50f8ad6436fe"
      unitRef="number">-0.621</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i379186cc31f04dbb9749d2943a0e1ed9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIzLTItMS0xLTU5NzQw_8f03f357-d3dd-45aa-b646-c9c0af74af5d"
      unitRef="usd">520000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida711057f67c47f1b72ad683127c4a91_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIzLTQtMS0xLTU5NzQw_b473be17-4294-4622-85cf-6142db987853"
      unitRef="usd">588000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i379186cc31f04dbb9749d2943a0e1ed9_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTIzLTYtMS0xLTU5NzQw_8d042f6f-d4ba-4061-943a-f3c422e77bd8"
      unitRef="number">-0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5cb6c1da36a4a4d8766dfa0e1727ff5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI0LTItMS0xLTU5NzQw_55955f7f-ecdc-45d3-a85f-56ce0d913c6e"
      unitRef="usd">539000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c47976576a747deb5a1820cec87eb07_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI0LTQtMS0xLTU5NzQw_4e838905-a10a-413b-bf40-368d3d3a3bd2"
      unitRef="usd">638000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if5cb6c1da36a4a4d8766dfa0e1727ff5_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI0LTYtMS0xLTU5NzQw_4859eeea-8d2c-4280-943c-3e574bd8108d"
      unitRef="number">-0.156</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i802b2a8cc9be4de697db22398b60df0e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI3LTItMS0xLTU5NzQw_f44b5c75-1854-49fb-aa37-ba73fd56ae44"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5df3d2e7456f46cd95f6b08a1c33601d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI3LTQtMS0xLTU5NzQw_749a8cac-a85a-4cae-90e6-cf5833077b5d"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i802b2a8cc9be4de697db22398b60df0e_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI3LTYtMS0xLTU5NzQw_a6a23461-aef1-41b0-83b4-c2fe86e10886"
      unitRef="number">0.631</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc87f78159374d8bbc9c762e4102e794_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI4LTItMS0xLTU5NzQw_7431998a-628c-444d-b0c3-5ebf209b8566"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if926194c123b420385c4516a85ca9777_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI4LTQtMS0xLTU5NzQw_c8cd8d72-5cc9-4a66-85d9-e35dbb469347"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibc87f78159374d8bbc9c762e4102e794_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI4LTYtMS0xLTU5NzQw_fa9ee8e1-efbb-4c91-8e4f-ecf4c78ad577"
      unitRef="number">-0.477</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d59f0918fbc414a8a87e6ccf2473d9b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI5LTItMS0xLTU5NzQw_b4b37090-0032-4969-8c3c-fccb674b8995"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id48f03c674f5473cb05d01f5147b5df3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI5LTQtMS0xLTU5NzQw_0e83fac2-4cfc-4075-a999-125be9dd7f53"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7d59f0918fbc414a8a87e6ccf2473d9b_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTI5LTYtMS0xLTU5NzQw_941b9399-29ff-435f-9de0-3bfd7284f45d"
      unitRef="number">-0.351</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fb5e19b994341e19c1180af2eb7b115_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMyLTItMS0xLTU5NzQw_264719a4-2b29-4d3c-a913-20b827891087"
      unitRef="usd">572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bea0dc705a44771a477c405cdd10da9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMyLTQtMS0xLTU5NzQw_d622f849-aa4c-4229-a643-be20b09b20a6"
      unitRef="usd">573000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3fb5e19b994341e19c1180af2eb7b115_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMyLTYtMS0xLTU5NzQw_3668bc2b-9ac3-4798-935e-58e496d9b7f9"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadbad500e92547ec9a836181ccd9e6c3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMzLTItMS0xLTU5NzQw_81c75a31-e82f-49d9-8d53-f6fc27a70be9"
      unitRef="usd">279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e6d7f1b310549b0a446ef5d8d0aaea2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMzLTQtMS0xLTU5NzQw_2149c384-9341-4491-ad5e-146a820ff383"
      unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iadbad500e92547ec9a836181ccd9e6c3_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTMzLTYtMS0xLTU5NzQw_abc16b66-26d1-4eb3-a4fc-77d78f4b54ce"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6498d554bec346f290453c23da02bd60_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM0LTItMS0xLTU5NzQw_becf258a-bb6b-43a3-9223-a4397b430e04"
      unitRef="usd">852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb99ff4ae20743c7b4a1bc974a427a75_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM0LTQtMS0xLTU5NzQw_d2c1328c-9621-4c06-9103-63df93687eed"
      unitRef="usd">861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6498d554bec346f290453c23da02bd60_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM0LTYtMS0xLTU5NzQw_af66a973-d0f2-4fed-9fa0-a8cfa94a159f"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie79b08d56cce40828e2c38bf848ff8fd_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM2LTItMS0xLTU5NzQw_fb857140-162f-46e1-ba81-e085324ad962"
      unitRef="usd">273000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52cdeb0271e2486999508f7150d31fe2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM2LTQtMS0xLTU5NzQw_0faabfef-8468-4d28-9c55-b47cabdabdca"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie79b08d56cce40828e2c38bf848ff8fd_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM2LTYtMS0xLTU5NzQw_de230850-fa72-4825-80a4-ea23669fcb08"
      unitRef="number">0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7068d970c8e44a1ab1a0f2f2c4db613_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM3LTItMS0xLTU5NzQw_bd936952-9510-4d2a-95fc-223bfbed544d"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5887b0c29a144ebaa712e90100c41c32_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM3LTQtMS0xLTU5NzQw_fd2a30d2-eaa4-4eff-ae08-37a78f307e21"
      unitRef="usd">179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if7068d970c8e44a1ab1a0f2f2c4db613_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM3LTYtMS0xLTU5NzQw_75208c52-005e-40a3-87e3-08ea03a0fa72"
      unitRef="number">-0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08831d99e88b4248b1d03a755ae3c76b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM4LTItMS0xLTU5NzQw_ff24a7b9-7936-4c50-a321-a1af05e3b978"
      unitRef="usd">443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b566c9ea6ee4374bb5e2d126e55db93_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM4LTQtMS0xLTU5NzQw_483c3a3f-fe86-4fa3-842d-90d4b1a1924e"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i08831d99e88b4248b1d03a755ae3c76b_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTM4LTYtMS0xLTU5NzQw_baad295c-3165-4f8c-bc5e-e157fcd7ca3e"
      unitRef="number">-0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55dd11d66bb94525afadc67611182a00_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQwLTItMS0xLTU5NzQw_e34330e4-1ba6-4636-9ec5-3510634c3f57"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62a96b70190a426784c40cbc850a392d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQwLTQtMS0xLTU5NzQw_767160de-4509-4b60-b805-2eb29274a725"
      unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i55dd11d66bb94525afadc67611182a00_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQwLTYtMS0xLTU5NzQw_d3861ed3-8d5c-4ac4-a8f5-2acf6f1a3133"
      unitRef="number">0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26fe8d48a8184400b9c1e5dce618bf41_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQxLTItMS0xLTU5NzQw_a06c2d66-4358-411e-8eee-6e3e771bd37e"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ca7c88cc02d4eaf88560c8548ee94ef_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQxLTQtMS0xLTU5NzQw_cf1a510c-221d-4af4-bb44-22af21bcdcd8"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26fe8d48a8184400b9c1e5dce618bf41_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQxLTYtMS0xLTU5NzQw_19c60adb-e9c1-415c-ac72-19643ea2a0b3"
      unitRef="number">0.209</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0812afd8e2b348de81fda97685ddef59_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQyLTItMS0xLTU5NzQw_05614449-3c81-488f-8601-b7c77c726dfd"
      unitRef="usd">325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bf731f09e014c3d94757d58a2be8657_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQyLTQtMS0xLTU5NzQw_da25d7a5-0a43-4461-86d9-81afc9b18b87"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0812afd8e2b348de81fda97685ddef59_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQyLTYtMS0xLTU5NzQw_0b5aecbf-3a42-4015-8e26-ca3177a0ca50"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c940a55fb57493188d86966342836e0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ0LTItMS0xLTU5NzQw_22dfb9da-db07-46eb-baff-de37ecaf702c"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b96b154e0074943b4b122886b03054d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ0LTQtMS0xLTU5NzQw_e1c4411b-051b-4c9e-83b7-e116fd155250"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6c940a55fb57493188d86966342836e0_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ0LTYtMS0xLTU5NzQw_306566dc-607d-4e9d-a2dd-2fb6b3b5c3a4"
      unitRef="number">-0.290</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i787149c50a1840428285fe2906bb98f1_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ1LTItMS0xLTU5NzQw_2e595ca7-5bcc-44c2-a71a-20befa4ef549"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3a0ca8ea65246758d0aea04a19962b9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ1LTQtMS0xLTU5NzQw_518a6d73-e239-4e7a-aca3-79576034ad81"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i787149c50a1840428285fe2906bb98f1_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ1LTYtMS0xLTU5NzQw_cc28b1d9-8a8f-413e-b3e2-487cbfba2358"
      unitRef="number">-0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife5cdc6b13e543ce8b0e1c2f9ffa25d3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ2LTItMS0xLTU5NzQw_afa9f392-1ae3-41bf-83bd-894d366a2733"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a5a3f74e1d54099823fc731564879ce_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ2LTQtMS0xLTU5NzQw_b64c1c15-cba7-485f-8418-9dda723ca3bc"
      unitRef="usd">105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ife5cdc6b13e543ce8b0e1c2f9ffa25d3_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ2LTYtMS0xLTU5NzQw_e42da077-1196-43d3-868d-471ef0ac299b"
      unitRef="number">-0.208</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c342b6c1941447a8365ead0b83ea272_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ5LTItMS0xLTU5NzQw_7a9880df-7f7f-43a3-a868-04817e76eb1e"
      unitRef="usd">672000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc76581373f04f5aa51d38fcdda40da3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ5LTQtMS0xLTU5NzQw_db1f1cfb-1bfe-490c-a3eb-8a0e48b95b4e"
      unitRef="usd">799000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5c342b6c1941447a8365ead0b83ea272_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTQ5LTYtMS0xLTU5NzQw_72926043-529f-416e-9815-7fde80bdabcd"
      unitRef="number">-0.158</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie045af3f8e52486eb07c7ba39e98e056_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUwLTItMS0xLTU5NzQw_d17b20b2-e6a9-4492-b59f-a31efcdd615d"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e8eea6eeee44e8a8748c5f8411ca6a8_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUwLTQtMS0xLTU5NzQw_53e00622-04d0-4dc8-984d-79a643c90e4a"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie045af3f8e52486eb07c7ba39e98e056_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUwLTYtMS0xLTU5NzQw_2ab0d097-ee67-40c9-a1f7-7f99b7dc7b85"
      unitRef="number">-0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i658cc2fee1f04efda949f70dfc908648_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUxLTItMS0xLTU5NzQw_0e03551a-4d6c-4d8e-a740-04c479204511"
      unitRef="usd">910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1105c10c9a2445a198e98e2af0ac9d83_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUxLTQtMS0xLTU5NzQw_8dafb3c4-442b-4269-bc58-f11bac5fe6f1"
      unitRef="usd">1044000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i658cc2fee1f04efda949f70dfc908648_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUxLTYtMS0xLTU5NzQw_fba0e8c4-46c3-474d-8fcd-cad91d1ada26"
      unitRef="number">-0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dadb8ca74864bdda389d9aa76f05723_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUzLTItMS0xLTU5NzQw_10368b89-03d6-4300-9905-427cc7965ad7"
      unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d7e2f6cd3d9401f9fda49c75afe417f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUzLTQtMS0xLTU5NzQw_225814f8-ec6e-4853-ab14-a122a4492a56"
      unitRef="usd">589000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3dadb8ca74864bdda389d9aa76f05723_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTUzLTYtMS0xLTU5NzQw_e3c5ee9c-2595-45a8-a312-539271d97c9c"
      unitRef="number">-0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21f9118b127a41df8281a7b4b70328ed_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU0LTItMS0xLTU5NzQw_02e6e3b2-99b4-4b57-adc2-28eb9a437e1c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b44f394b70346ee9c246aae215158bd_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU0LTQtMS0xLTU5NzQw_25835392-2196-4f08-836c-66580ab1c1c1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i21f9118b127a41df8281a7b4b70328ed_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU0LTYtMS0xLTU5NzQw_8f070058-4727-4eca-926d-d5ad6a4bdee0"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic62dc76763e348cbba7e08433976fac4_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU1LTItMS0xLTU5NzQw_8e8d89f1-48bd-4b36-b1df-e120e0d246b2"
      unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c091791d85f44618179b9d279f48c9f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU1LTQtMS0xLTU5NzQw_fdfca982-5843-4a0a-812f-a3263fac771d"
      unitRef="usd">589000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic62dc76763e348cbba7e08433976fac4_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU1LTYtMS0xLTU5NzQw_88dc6c72-34f7-44b4-9497-12eb847b9f6f"
      unitRef="number">-0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd9e9d0ec3a546c8a723d87323ac7ab7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU3LTItMS0xLTU5NzQw_9688b24b-70d6-46ce-bcdc-f044573bb653"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68a1e608de7843568d26a9b8fe5ffb43_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU3LTQtMS0xLTU5NzQw_6cd959fd-a17a-4d46-9121-d5c1049974b2"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibd9e9d0ec3a546c8a723d87323ac7ab7_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU3LTYtMS0xLTU5NzQw_741f632c-f154-46f9-b3ff-454adcb27982"
      unitRef="number">-0.307</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3fe1671e59d4c6a8a3250a87dd2e2cb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU4LTItMS0xLTU5NzQw_162cd91c-411e-4931-a132-40b03304cf69"
      unitRef="usd">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f402cf66c9c43bf9d8b0155d69da95c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU4LTQtMS0xLTU5NzQw_3db2f7a7-7ccd-48b6-a78d-e21f35672891"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id3fe1671e59d4c6a8a3250a87dd2e2cb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU4LTYtMS0xLTU5NzQw_c96f8384-bda9-4729-8ada-7d26ea6d1640"
      unitRef="number">0.075</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29def461faf7492f917e166e064b38d4_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU5LTItMS0xLTU5NzQw_ea669faf-7a01-4da4-95f0-6ebd6192c2c6"
      unitRef="usd">128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0686bf4a5394db3864d38ab25d077e9_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU5LTQtMS0xLTU5NzQw_9ff10e2e-9fb2-4146-83e7-1cc4ef15b091"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29def461faf7492f917e166e064b38d4_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTU5LTYtMS0xLTU5NzQw_26edd692-3e69-4d5a-ba2a-7e6d5dcb63f1"
      unitRef="number">-0.146</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i153a273ca54c4800aa20e3895cc837ed_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY1LTItMS0xLTU5NzQw_4daa4d0f-f831-4794-aa63-45befcbfd9d0"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1154bb4afd9247c784b55466aae7d770_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY1LTQtMS0xLTU5NzQw_a46418ca-88cc-49bf-b570-69820ea167d9"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i153a273ca54c4800aa20e3895cc837ed_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY1LTYtMS0xLTU5NzQw_d1a05f5b-4424-45ab-b3aa-1e1fd220c369"
      unitRef="number">-0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf0009ecb1334c43a265b7735989172d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY2LTItMS0xLTU5NzQw_0e15e964-3ff4-4fe0-8ec3-9ff546b6fb97"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i857d98c87ac0445e9582504c037c4449_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY2LTQtMS0xLTU5NzQw_2cdc09f0-5b6b-4bcd-967a-925b3c4e159b"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf0009ecb1334c43a265b7735989172d_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY2LTYtMS0xLTU5NzQw_4e482576-dbe3-40c9-8ee9-9572d22b3a05"
      unitRef="number">-0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8de874f946f841458bbfbdc60ac530c4_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY3LTItMS0xLTU5NzQw_e7292310-68ab-4f21-bcaf-a1a44b4f9e04"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62ddb318fec741089c74f936f4d258c0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY3LTQtMS0xLTU5NzQw_b990cf9e-9a16-48da-b68f-a7c677309eb3"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8de874f946f841458bbfbdc60ac530c4_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTY3LTYtMS0xLTU5NzQw_4d7cc9ab-ccf7-4536-8321-22cf32429d0c"
      unitRef="number">-0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74673f6468f34983ba990177525051f9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcwLTItMS0xLTU5NzQw_5b45b610-a76f-4311-9f0c-b1b03068c591"
      unitRef="usd">6632000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f7260c372bc4cd69cc06c643d11c56c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcwLTQtMS0xLTU5NzQw_36cb527a-fe75-4032-b9e3-d38f318a0089"
      unitRef="usd">6446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i74673f6468f34983ba990177525051f9_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcwLTYtMS0xLTU5NzQw_45b91839-cca5-457e-96bc-d52f3dd45427"
      unitRef="number">0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ea854374a484fe38540c4f8a7470fe9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcxLTItMS0xLTU5NzQw_1e12746e-d944-48ce-b861-d60ffa718fdf"
      unitRef="usd">6237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ebe25dea81647f0a7c2f6f7eaaa9f12_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcxLTQtMS0xLTU5NzQw_78d9cd39-41da-41f1-b5ca-0934084bfa04"
      unitRef="usd">5655000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ea854374a484fe38540c4f8a7470fe9_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcxLTYtMS0xLTU5NzQw_750a7430-c7d3-43db-bb52-294d039041a4"
      unitRef="number">0.103</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcyLTItMS0xLTU5NzQw_cb9bb189-8bf6-475b-abce-0df96aea996a"
      unitRef="usd">12869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f54f96121d4454b850945a4950be020_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcyLTQtMS0xLTU5NzQw_ce9a31f3-2bd5-4485-a77b-3eca0c24fd3e"
      unitRef="usd">12101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e5fbf0a8c9c4bbc84583953264224ea_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTcyLTYtMS0xLTU5NzQw_c71d7598-4efc-497c-b4b1-3359757450a9"
      unitRef="number">0.063</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dd9e58933a04c87b85bedb0a3a11e3a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgzLTItMS0xLTU5NzQw_1781a1e0-3813-4d37-bd53-c4a7704ea2c8"
      unitRef="usd">494000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5388243b1444a0197156f13c035f594_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgzLTQtMS0xLTU5NzQw_dea11967-cdc3-4b81-ab1f-aaec9ec421ac"
      unitRef="usd">434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1dd9e58933a04c87b85bedb0a3a11e3a_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTgzLTYtMS0xLTU5NzQw_0d368194-be07-4442-9684-bc7900610c1d"
      unitRef="number">0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf14c9d52f00401b9b7af8c1eaaf40a2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg0LTItMS0xLTU5NzQw_e4f9035b-1ca6-44e0-b550-7689d84254a8"
      unitRef="usd">597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2555b2153a3248ee8fd4e5f32f461af3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg0LTQtMS0xLTU5NzQw_f6dc1df9-4365-4248-92fe-bb3a9d84db3f"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibf14c9d52f00401b9b7af8c1eaaf40a2_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg0LTYtMS0xLTU5NzQw_00f420c2-2fde-4a69-8dd5-9b050f6d41e8"
      unitRef="number">0.162</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5167453e1314559964afd83c4a97121_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg1LTItMS0xLTU5NzQw_93e079b8-ffbd-43a0-8b77-7cbe35b2d0b6"
      unitRef="usd">1092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94504e48d701461ab9ef57de03631801_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg1LTQtMS0xLTU5NzQw_4e9c4476-7093-4a5e-adb0-c05ab967aee6"
      unitRef="usd">949000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic5167453e1314559964afd83c4a97121_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg1LTYtMS0xLTU5NzQw_d9ba0058-2a78-4757-b8bc-b5269524d71e"
      unitRef="number">0.151</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd9d91209813438cb5425bacbb2957d7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg3LTItMS0xLTU5NzQw_2d063a4e-f098-4f9d-a735-d38f7ff9e402"
      unitRef="usd">1289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49cc1963139e40a48ba54590e9d558c2_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg3LTQtMS0xLTU5NzQw_718b4a72-a965-4ec9-9d7c-8e1ef6e18845"
      unitRef="usd">1249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icd9d91209813438cb5425bacbb2957d7_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg3LTYtMS0xLTU5NzQw_c5a3ba14-feb3-4519-b85e-7c41cb8f877f"
      unitRef="number">0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic37a5f0e1b4645c18d5404587f248c4e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg4LTItMS0xLTU5NzQw_d0a02cb1-004e-42c4-8806-1a1987cdd047"
      unitRef="usd">899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71825d51651b4f4c94dc7432c265826b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg4LTQtMS0xLTU5NzQw_636e9ce1-c50f-40c8-a0f3-24fee948c690"
      unitRef="usd">864000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic37a5f0e1b4645c18d5404587f248c4e_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg4LTYtMS0xLTU5NzQw_d6aead4f-eb59-44d6-af47-867750782ee9"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26c03d0211654555ae2faaa6bfbef7f0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg5LTItMS0xLTU5NzQw_81bdae81-e365-4ba2-bcc4-9fd9b26d6eca"
      unitRef="usd">2188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8b09f0f2d404dcb90ab77349fb4e6d6_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg5LTQtMS0xLTU5NzQw_aa5835ab-1016-435e-a8d3-13201e9194e8"
      unitRef="usd">2113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26c03d0211654555ae2faaa6bfbef7f0_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTg5LTYtMS0xLTU5NzQw_aec46fde-506d-4940-9323-c57d4b6da09f"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94c393b101be4a43a6732a4be31c57aa_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkxLTItMS0xLTU5NzQw_d21770ed-c2a5-4c5d-adac-8088eabe4a3d"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41cc552be0964064ae3332e0d4c7ef8d_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkxLTQtMS0xLTU5NzQw_4950d14d-27f0-41c7-80d2-b140e227a476"
      unitRef="usd">209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i94c393b101be4a43a6732a4be31c57aa_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkxLTYtMS0xLTU5NzQw_7913733e-5456-4c4d-ae18-8c96fa080010"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4de0d5ad9f549948fe05ce4c2e25b4a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkyLTItMS0xLTU5NzQw_be4ea8ee-4630-4df9-9a2e-ee8494d15928"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83221080ad384b21800f5cd10f1c9fbc_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkyLTQtMS0xLTU5NzQw_f03a2562-5c45-4d73-bcb9-293dc21ec8a7"
      unitRef="usd">146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if4de0d5ad9f549948fe05ce4c2e25b4a_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkyLTYtMS0xLTU5NzQw_58f9bb9f-e809-4ba5-ba2d-bcd37e5a3583"
      unitRef="number">0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a9d112bcae04f66b84e47128a5cc21f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkzLTItMS0xLTU5NzQw_e7d9ae56-1c2a-4b24-9d96-c43db807ce45"
      unitRef="usd">389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52f9480fa6a64211bbaffb8bf7069aa5_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkzLTQtMS0xLTU5NzQw_3f13ef6b-9c16-423b-b7c3-547faa5f55b4"
      unitRef="usd">356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9a9d112bcae04f66b84e47128a5cc21f_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTkzLTYtMS0xLTU5NzQw_d30ef2e7-3050-4c04-a2b1-f88285d27f1f"
      unitRef="number">0.093</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ec92e1bd5064846ace07af1534211f5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk1LTItMS0xLTU5NzQw_8c97dd38-ba89-469b-b378-74b70bb50525"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i761be9058b0d43bf94db251536405133_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk1LTQtMS0xLTU5NzQw_336e0cab-4933-46a6-a018-a18f754e3170"
      unitRef="usd">185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8ec92e1bd5064846ace07af1534211f5_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk1LTYtMS0xLTU5NzQw_3249e294-ce78-4d4f-ad8c-b9395b8bf8ed"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6eddee4e37b042bc9c060f40341f10dd_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk2LTItMS0xLTU5NzQw_16158d14-ca29-4fc4-b90a-74dd4ade272f"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cd8fd20f19644798d62ca131883fb7b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk2LTQtMS0xLTU5NzQw_99313beb-bd99-4961-bb8b-6428326b09d3"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6eddee4e37b042bc9c060f40341f10dd_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk2LTYtMS0xLTU5NzQw_f78396c2-b1fa-4810-a987-d170bb0a7f99"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b87a33ea414436bb9dad4941879ae83_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk3LTItMS0xLTU5NzQw_1e168f6b-391f-4383-bb0a-0fd14e0ca784"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8bb59b5b9cf4f78a4e291ae63400ced_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk3LTQtMS0xLTU5NzQw_5e51d7e8-925d-41a6-8468-8351c57259da"
      unitRef="usd">317000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4b87a33ea414436bb9dad4941879ae83_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk3LTYtMS0xLTU5NzQw_78f767de-5ce3-4054-9592-73b36e96420a"
      unitRef="number">0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd947e6c419b48a4bda0b804eeafe4d6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk5LTItMS0xLTU5NzQw_a2c5db66-df87-4fa5-82bc-d0403fced614"
      unitRef="usd">475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd983febe9574fdfabf56cea42386e21_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk5LTQtMS0xLTU5NzQw_901dd0ea-25b1-4111-86af-bd40dfa57776"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icd947e6c419b48a4bda0b804eeafe4d6_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMTk5LTYtMS0xLTU5NzQw_0b060326-bff5-47f7-8386-2c93ea295fc7"
      unitRef="number">0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc8fed7991104862922245840fbbb6d8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAwLTItMS0xLTU5NzQw_ec622ed3-4cf1-468b-8b5b-84c93900edb8"
      unitRef="usd">273000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaa59186f7b14958a9b1c02f519eb369_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAwLTQtMS0xLTU5NzQw_9a11876a-8da1-47b4-8876-86302543394e"
      unitRef="usd">282000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifc8fed7991104862922245840fbbb6d8_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAwLTYtMS0xLTU5NzQw_47631d65-5474-4d61-95a5-6c605fd620e8"
      unitRef="number">-0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4bf77c080c34fcb8c7da93917014ef3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAxLTItMS0xLTU5NzQw_9d5b762e-fa97-4630-9447-727afd4d9b28"
      unitRef="usd">748000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia86e1d075b324aada06b3181f83ab15c_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAxLTQtMS0xLTU5NzQw_a82c37e4-f83c-4b44-aef6-275f68daff87"
      unitRef="usd">733000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie4bf77c080c34fcb8c7da93917014ef3_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAxLTYtMS0xLTU5NzQw_4b8a023a-4522-4bfa-99b5-49b71ba45943"
      unitRef="number">0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i372a0801e4354df09390de4a1bc1fe8a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAzLTItMS0xLTU5NzQw_65260991-2798-4e16-955d-1f77bdca2130"
      unitRef="usd">387000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b4bbabb621c4b65a1340f25f3b79d25_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAzLTQtMS0xLTU5NzQw_fd74883a-da91-4df9-901d-09078d179328"
      unitRef="usd">404000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i372a0801e4354df09390de4a1bc1fe8a_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjAzLTYtMS0xLTU5NzQw_61e6a15f-e9f5-41be-bb4b-1fd0febefc55"
      unitRef="number">-0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i505f40abf9134ef195fcf3699c50574e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA0LTItMS0xLTU5NzQw_cdd0cafd-f9f2-4118-90ba-5c9eeb67edc3"
      unitRef="usd">324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99e6f27a9bec4c019c8c57696e6bf1e8_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA0LTQtMS0xLTU5NzQw_9474cb0d-ff7c-4f9b-a0b1-788dc2ac1cbc"
      unitRef="usd">303000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i505f40abf9134ef195fcf3699c50574e_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA0LTYtMS0xLTU5NzQw_6dd09916-7585-47e8-a281-1701c482b837"
      unitRef="number">0.070</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa62410b761147768b8c6e1d72541097_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA1LTItMS0xLTU5NzQw_d3ee3048-9521-4594-8096-5b33b5a5bfc2"
      unitRef="usd">712000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8060def9fa5447d9f08d7bf2126beb6_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA1LTQtMS0xLTU5NzQw_675903e1-fdc2-4160-bb1f-dba4929f8873"
      unitRef="usd">707000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifa62410b761147768b8c6e1d72541097_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA1LTYtMS0xLTU5NzQw_2e2c3a80-f18c-492a-8331-8f364fa763ba"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b9dff4050ad4ec1ad3383f53e178b09_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA3LTItMS0xLTU5NzQw_4caa354f-7d5b-4cd7-9bc2-b589c4a164ea"
      unitRef="usd">921000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i402913e98e314dc99d1428cd761b3db0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA3LTQtMS0xLTU5NzQw_219b14e0-b50c-4fd5-af09-e2d52d74134b"
      unitRef="usd">898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4b9dff4050ad4ec1ad3383f53e178b09_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA3LTYtMS0xLTU5NzQw_ac846b26-6c18-41b3-963b-f72a848d3f1a"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd2bfa4745e2435c84b3ff4622725d92_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA4LTItMS0xLTU5NzQw_a8c9a125-0910-4078-8035-80664734e5c0"
      unitRef="usd">1513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34166c04357b40ca861f436c846dbdc3_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA4LTQtMS0xLTU5NzQw_a25ac796-8c7d-49b4-b58c-c3451cdec2af"
      unitRef="usd">1474000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icd2bfa4745e2435c84b3ff4622725d92_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA4LTYtMS0xLTU5NzQw_9f48f88f-01e3-480b-ab69-87c9fb527c7a"
      unitRef="number">0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib41d736c9cbf4af88635765f2162af86_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA5LTItMS0xLTU5NzQw_dbe17c42-829c-4906-b140-5de0612899a4"
      unitRef="usd">2434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica1e5574642c4970ac6c5731d2f54fcb_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA5LTQtMS0xLTU5NzQw_d18f863f-c562-40ad-b5d3-cb5d6f77231b"
      unitRef="usd">2372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib41d736c9cbf4af88635765f2162af86_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjA5LTYtMS0xLTU5NzQw_836d7bc7-606c-440b-b959-d21070b1ab46"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i736971e06954421791a102526ef927cc_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjExLTItMS0xLTU5NzQw_f11c87d4-a81d-4994-af6c-cdfcae18d76b"
      unitRef="usd">417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i462f6596d7e54be4b09bd4bcb7c18bad_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjExLTQtMS0xLTU5NzQw_19efb3fc-407f-4412-8a1d-2396c8952c39"
      unitRef="usd">405000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i736971e06954421791a102526ef927cc_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjExLTYtMS0xLTU5NzQw_5eabec7a-8b81-4aac-b8fb-8373d6c3b1b9"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73eef6d7fd9b4dd2b5426cfa7104e199_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEyLTItMS0xLTU5NzQw_3812bdc3-d429-4140-94c8-1b571d3183f2"
      unitRef="usd">729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i865bbce87767495d83951aa8eb044329_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEyLTQtMS0xLTU5NzQw_4f8e691f-e193-493a-b4f8-7d38452d63d8"
      unitRef="usd">713000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i73eef6d7fd9b4dd2b5426cfa7104e199_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEyLTYtMS0xLTU5NzQw_53d7c92b-0041-4db5-82fa-3682c77c5f4d"
      unitRef="number">0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9ef4bc104ab4018b38aa4cdf80cf5a7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEzLTItMS0xLTU5NzQw_c1189b1e-3d35-4188-907f-8117a08a001a"
      unitRef="usd">1146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i479f5df29cba41dd8ba610461abe4e2e_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEzLTQtMS0xLTU5NzQw_4a0b2809-af9a-4b2f-b5fd-b43c4feaecfd"
      unitRef="usd">1118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia9ef4bc104ab4018b38aa4cdf80cf5a7_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjEzLTYtMS0xLTU5NzQw_364c2af6-72b6-47d1-8e20-49caabf37713"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5794644b54414f8eaa877a9f828a6f9c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE1LTItMS0xLTU5NzQw_2292f232-b8c3-4c23-b0fc-e5b640c186b1"
      unitRef="usd">504000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24a4d5dee1ac4cf28da4e534b4453f02_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE1LTQtMS0xLTU5NzQw_00ece192-d182-4743-acd9-cce3129c2928"
      unitRef="usd">493000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5794644b54414f8eaa877a9f828a6f9c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE1LTYtMS0xLTU5NzQw_bcc3acac-f128-4e22-8931-992138dcda64"
      unitRef="number">0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3342c6f86e341f5ab416482e21b984c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE2LTItMS0xLTU5NzQw_fdaf9085-13ed-444d-bf9c-e66320067b39"
      unitRef="usd">784000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4b1e669d8404534b72479a0f4e7a968_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE2LTQtMS0xLTU5NzQw_5e275c2e-77a8-4bf0-875e-ef22ee2b6f01"
      unitRef="usd">761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic3342c6f86e341f5ab416482e21b984c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE2LTYtMS0xLTU5NzQw_d842f715-b47a-46ab-82d7-22c8072e1f70"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b56dc097e104e6a9d6bf065e10288ee_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE3LTItMS0xLTU5NzQw_6f655861-c2bc-4f32-87b5-e120b0945254"
      unitRef="usd">1288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb28ec2e8cc243329eac4eaf64db5f0f_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE3LTQtMS0xLTU5NzQw_1803cc2f-d4d0-43ac-9a0c-f439159f0b0a"
      unitRef="usd">1254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4b56dc097e104e6a9d6bf065e10288ee_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE3LTYtMS0xLTU5NzQw_1e28d9e5-d636-4d6a-a76b-a8daa8eb2ce2"
      unitRef="number">0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5082af2c38dc4e9b94951ce99a46799d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE5LTItMS0xLTU5NzQw_726d422d-0b0d-443f-8f40-126dbdf81b96"
      unitRef="usd">521000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d44704539114f25b07e12eb55564a99_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE5LTQtMS0xLTU5NzQw_a545e1b4-a2b7-4e6a-8dfd-1dfdf3765e0b"
      unitRef="usd">472000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5082af2c38dc4e9b94951ce99a46799d_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjE5LTYtMS0xLTU5NzQw_ea007548-815c-4c91-b15c-e09457c44c7a"
      unitRef="number">0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f23f5841b48406ab8cda610d6c44c21_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIwLTItMS0xLTU5NzQw_113b467c-6c7e-472f-9818-0e8b79520feb"
      unitRef="usd">736000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if956dbb8930a4658bd499404ec02618a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIwLTQtMS0xLTU5NzQw_8d307620-55ea-46f4-be95-442f35ce4b70"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8f23f5841b48406ab8cda610d6c44c21_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIwLTYtMS0xLTU5NzQw_21e01cb6-606b-461d-a878-252f01fe9ad6"
      unitRef="number">0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a91d5d2384349c3b9f8ba37ce939f63_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIxLTItMS0xLTU5NzQw_5580d04d-7600-466d-b161-fb7ed191a6fe"
      unitRef="usd">1257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i976cfa9383c14f68936e4add9e92c113_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIxLTQtMS0xLTU5NzQw_4740f963-8634-4757-b91e-55694d1c9907"
      unitRef="usd">1145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9a91d5d2384349c3b9f8ba37ce939f63_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIxLTYtMS0xLTU5NzQw_265a1b06-440a-44d1-9332-066867c55b51"
      unitRef="number">0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45d224b06bb144ad871048ad6fc1df0b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIzLTItMS0xLTU5NzQw_d30c0efe-5eae-4252-ac9b-23bdaa723738"
      unitRef="usd">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd7a59ebb6304063a306b51e19b294ca_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIzLTQtMS0xLTU5NzQw_fc8cd768-2666-4247-9fd5-5baeb10c8a2f"
      unitRef="usd">371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i45d224b06bb144ad871048ad6fc1df0b_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjIzLTYtMS0xLTU5NzQw_123f8e65-6fbb-4c69-b44c-7c2dbeeed820"
      unitRef="number">0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0b42f4cd0274c2cadf3f13f4563f625_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI0LTItMS0xLTU5NzQw_08e66514-07cd-4046-b49d-d8e7239c7fee"
      unitRef="usd">511000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i281dec684941496ba9be125acb8ea3a6_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI0LTQtMS0xLTU5NzQw_aa1762ea-720e-411a-8b76-e9b7faf04048"
      unitRef="usd">486000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic0b42f4cd0274c2cadf3f13f4563f625_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI0LTYtMS0xLTU5NzQw_eccea045-9526-48e2-91fb-9131870dfbf4"
      unitRef="number">0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9207f2f3c7994a8a8ecfaf008603423f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI1LTItMS0xLTU5NzQw_c5c65d80-0bf5-41c3-a796-c3c10970e945"
      unitRef="usd">910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7bcbf2c88c141309a3b412412019b86_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI1LTQtMS0xLTU5NzQw_107d0c0b-e2a8-4393-a092-15d3f06f1432"
      unitRef="usd">857000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9207f2f3c7994a8a8ecfaf008603423f_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI1LTYtMS0xLTU5NzQw_fd070124-44cb-44c5-a11e-35619c7e7899"
      unitRef="number">0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf66e290093647d2ac7eef16e4827efc_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI4LTItMS0xLTU5NzQw_6fc9b39e-f443-43f8-b1da-f8cc1b83eb3b"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8cbe17fae384b13888b74cd6b1ec015_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI4LTQtMS0xLTU5NzQw_46b01893-6f0c-41f0-a984-34cb6cb6c24f"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idf66e290093647d2ac7eef16e4827efc_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI4LTYtMS0xLTU5NzQw_959fab59-42ec-4a10-a151-389614c9ba77"
      unitRef="number">0.202</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i769786328e84403f83835f16dd6077be_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI5LTItMS0xLTU5NzQw_5813f506-37d5-4e3b-87ad-2c843ba645a3"
      unitRef="usd">226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied814a23dede4859b4dd10f99d05cfb6_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI5LTQtMS0xLTU5NzQw_877dc40f-8fb2-46fb-adef-f54c1f1938a5"
      unitRef="usd">187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i769786328e84403f83835f16dd6077be_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjI5LTYtMS0xLTU5NzQw_02c31548-86a9-4f38-9993-0e21a326149a"
      unitRef="number">0.205</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8addd19a2534d7298a26e3173b6a863_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMwLTItMS0xLTU5NzQw_e0648171-16d3-4933-8c52-0cf5639692d3"
      unitRef="usd">347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25e78ffd9d9242b9b0cd697326116473_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMwLTQtMS0xLTU5NzQw_010c51dc-a8f2-47a1-b63b-0a0fefb7359d"
      unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia8addd19a2534d7298a26e3173b6a863_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMwLTYtMS0xLTU5NzQw_60664fbd-5508-44c7-9b5d-b48d97c59cbb"
      unitRef="number">0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d97d2295755409ca589230c611d4a1c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMzLTItMS0xLTU5NzQw_f31eac28-b928-4dba-b716-3b4f9ea9f5a1"
      unitRef="usd">3225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib19f1a5dbe744c66ae815743a7372c8b_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMzLTQtMS0xLTU5NzQw_2b610965-fc76-42df-8735-48b4a577e31b"
      unitRef="usd">3054000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1d97d2295755409ca589230c611d4a1c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjMzLTYtMS0xLTU5NzQw_4d50ce3e-f57c-41b6-962d-c76af6a8c573"
      unitRef="number">0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic394e1061f43492797075bd9f149992c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM0LTItMS0xLTU5NzQw_e1ffee1a-906d-49c7-bff2-275017aeee38"
      unitRef="usd">3746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddf6412609614f56bce482cc6a3e294a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM0LTQtMS0xLTU5NzQw_bf236c13-b3a6-41f7-8690-a67d0d6caef8"
      unitRef="usd">3525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic394e1061f43492797075bd9f149992c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM0LTYtMS0xLTU5NzQw_857b6ba8-ec42-45cc-a082-0e869d79ba54"
      unitRef="number">0.063</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM1LTItMS0xLTU5NzQw_16894f52-cebc-4b56-8240-13011aabb76c"
      unitRef="usd">6971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i307797df24904531853ec0fc2169f7e0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM1LTQtMS0xLTU5NzQw_0b595376-6bdc-481c-a46a-c6b6867d26e1"
      unitRef="usd">6579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM1LTYtMS0xLTU5NzQw_b791742c-27d0-43dc-a280-146d676fd2c1"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM4LTItMS0xLTU5NzQw_16a73af4-57c1-4675-93f2-8b5326b07a74"
      unitRef="usd">11414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i045574b786544774882db0b6a4f87c00_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM4LTQtMS0xLTU5NzQw_f371b304-7a22-4d2c-9657-91bafe2e8b48"
      unitRef="usd">11111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM4LTYtMS0xLTU5NzQw_b431352b-8b30-4473-a8e9-972f0d75faf5"
      unitRef="number">0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dd0ee7f3ac94e1093e3d7ad447b4526_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM5LTItMS0xLTU5NzQw_143a7330-14e8-4941-8ab7-7648f892d94c"
      unitRef="usd">12012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie83976fce48a46b3b8d46aa9df8aa8b1_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM5LTQtMS0xLTU5NzQw_3a9cdfd1-50c8-4e0b-81c8-013204aea1cb"
      unitRef="usd">11210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0dd0ee7f3ac94e1093e3d7ad447b4526_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjM5LTYtMS0xLTU5NzQw_9be4e34a-7778-44ff-aa08-4adc52535bb5"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjQwLTItMS0xLTU5NzQw_4699138b-1ff4-424e-8d16-e00f44f79764"
      unitRef="usd">23426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjQwLTQtMS0xLTU5NzQw_0579bbad-dca5-46cc-8033-068fdbc46658"
      unitRef="usd">22321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOmU3ZGQ2OGY4YTVhNzQxNmZhOTMzOGQ3OWZjMWYxY2RmL3RhYmxlcmFuZ2U6ZTdkZDY4ZjhhNWE3NDE2ZmE5MzM4ZDc5ZmMxZjFjZGZfMjQwLTYtMS0xLTU5NzQw_1d968fb0-d0f2-41c9-bbca-b331e1e9b27b"
      unitRef="number">0.050</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53a2d3e56a004f59a45bdb87953ecc0a_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMjc0ODc3OTA4MDI0OQ_0e24f868-ec32-4767-bd28-5bd355622abc"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzczMQ_8eb97d55-a432-4a55-b1b0-f86d680bedfb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.5)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.1)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*Fiscal first quarter 2021 earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2022 and 2021&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Divestiture gains of $0.6&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.8&#160;billion and $0.9&#160;billion in the fiscal first quarter of 2022 and 2021, respectively&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A loss of $0.4&#160;billion related to the change in the fair value of securities in the fiscal first quarter of 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2022 and 2021 &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.3&#160;billion in both the fiscal first quarter of 2022 and 2021 &lt;/span&gt;&lt;/div&gt;(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzczMQ_9d0ab5a7-df88-480c-b6a2-843c49a0103a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.5)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.1)%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*Fiscal first quarter 2021 earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2022 and 2021&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Divestiture gains of $0.6&#160;billion in the fiscal first quarter of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.8&#160;billion and $0.9&#160;billion in the fiscal first quarter of 2022 and 2021, respectively&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A loss of $0.4&#160;billion related to the change in the fair value of securities in the fiscal first quarter of 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9&#160;billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2022 and 2021 &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.3&#160;billion in both the fiscal first quarter of 2022 and 2021 &lt;/span&gt;&lt;/div&gt;(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMi0yLTEtMS01OTc0MA_b40fc36c-8bd0-4ec1-80ff-2fdd0db8f6e0"
      unitRef="usd">686000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7ef3242829b546d9957de36a60faad96_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMi00LTEtMS01OTc0MA_cd0337ba-d2da-45b7-bfa9-1f7aab99f810"
      unitRef="usd">842000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMi02LTEtMS01OTc0MA_38a47b79-01ca-41a0-a160-c4ad2d880799"
      unitRef="number">-0.185</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMy0yLTEtMS01OTc0MA_ebd663df-6705-4d81-b04b-447c0c5d557c"
      unitRef="usd">3924000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7cf2d6ac264147d5bc7eea61f5da1000_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMy00LTEtMS01OTc0MA_91191794-07fa-4e50-a9db-17cdbe5a1d6e"
      unitRef="usd">5169000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfMy02LTEtMS01OTc0MA_ba1331d8-17ee-43b1-b8b2-b8d45496dc5e"
      unitRef="number">-0.241</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4649418b20f44a60bfb39416a9fe963b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNC0yLTEtMS01OTc0MA_04e38c98-2907-4fe0-becb-cec86cf91a1d"
      unitRef="usd">1477000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7614bac3435145d3a723efd9bb087597_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNC00LTEtMS01OTc0MA_787c4016-246c-434a-9bb0-14cca2e16355"
      unitRef="usd">1629000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i4649418b20f44a60bfb39416a9fe963b_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNC02LTEtMS01OTc0MA_a93554a9-3f5f-4384-ace9-7739334a573b"
      unitRef="number">-0.093</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0d9f1ecfd5c34f7a9fd27206d4b69544_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNS0yLTEtMS01OTc0MA_73d1a520-4f40-4ef7-a153-c07f98f04f5e"
      unitRef="usd">6087000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i01abbe2b4f24422780127bb041f28468_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNS00LTEtMS01OTc0MA_ad27c00a-0063-4df4-994f-4eea6640e79e"
      unitRef="usd">7640000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i0d9f1ecfd5c34f7a9fd27206d4b69544_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNS02LTEtMS01OTc0MA_95d8b8c7-ed93-4ae9-8cf9-426b12972de5"
      unitRef="number">-0.203</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9aa048d8675b4238a8d76e97c5690aef_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNi0yLTEtMS01OTc0MA_d6c72718-3374-484b-8193-62d79eab19ca"
      unitRef="usd">123000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7843d84472f449c3bef37bc9121ca5f0_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNi00LTEtMS01OTc0MA_7e56606b-005c-4bf9-bbb2-98b94a0d4137"
      unitRef="usd">211000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:BusinessExitCosts1
      contextRef="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy0yLTEtMS02NjIxOQ_132c9cc7-487f-4804-ad78-59e08088dfef"
      unitRef="usd">102000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i7ef3242829b546d9957de36a60faad96_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy00LTEtMS02NjIyNg_4e19606e-c57e-42ca-9627-d7414c683ece"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy0yLTEtMS01OTc0MA_485ba0a5-46af-4273-a90c-1f8dc53c9717"
      unitRef="usd">5862000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy00LTEtMS01OTc0MA_1d2db8bb-4f62-476c-8f8f-f607a110516f"
      unitRef="usd">7429000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjFkNjk4NjUyMDc2MzQ0ZmY5NmI3YzI4ZDc1NTliZGNlL3RhYmxlcmFuZ2U6MWQ2OTg2NTIwNzYzNDRmZjk2YjdjMjhkNzU1OWJkY2VfNy02LTEtMS01OTc0MA_c9b76f1d-4d1b-4544-acb4-1b78b3e914c7"
      unitRef="number">-0.211</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="i5abb6938c82147379c4baaa1620e6993_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzY5_d651d87d-c36c-4c37-8610-9d0962bca2c4"
      unitRef="usd">100000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i7ef3242829b546d9957de36a60faad96_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzY5_e728ffc5-a14b-4ff1-8e62-9ae9d10a7d87"
      unitRef="usd">100000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfODU2_30b2f794-0704-45bf-b660-8b1b0f40c104"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AdjustmentForAmortization
      contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfOTc2_42c5bfe8-b097-4492-a23e-011ce2cd2e10"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i7cf2d6ac264147d5bc7eea61f5da1000_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfNDM5ODA0NjUxOTEzMw_1e5e6f4c-bb00-44e9-b42f-712fe8b53f08"
      unitRef="usd">900000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1a3ed337e07c472b931ca6aecf7946c3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfNDM5ODA0NjUxOTE0Nw_7a2a1f4d-07e1-4f5b-aa58-2aab0e5b95c1"
      unitRef="usd">600000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i0c6203a1892848c893e4f4eb90b125b9_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMTQ3NA_b9316760-dbb2-4790-9f6b-01af4a197212"
      unitRef="usd">400000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <jnj:AmountPrepaidAndDueToManufacturers
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMjE4Nw_568dab4a-e4db-442a-ac17-ba04040dd3c6"
      unitRef="usd">900000000</jnj:AmountPrepaidAndDueToManufacturers>
    <us-gaap:RestructuringCharges
      contextRef="i9e15e6b4775a401e8f6c7963623e17b8_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMjgxNg_32b33118-0ebe-4697-b97c-bc789d22baea"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i307797df24904531853ec0fc2169f7e0_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMjgxNg_b9a9a365-0137-4636-91e9-83060ff629f3"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:AdjustmentForAmortization
      contextRef="i4649418b20f44a60bfb39416a9fe963b_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzAyMQ_4c6d8479-26ba-43df-895d-f7914cc487aa"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i7614bac3435145d3a723efd9bb087597_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzAyMQ_748ab3f8-f635-4e79-8abc-f99eb149fa62"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RleHRyZWdpb246YTdmY2Y1MjBlZWE3NDRmOWJhN2U4MDA2OTQ2ODkwMjlfMzcxNg_a39706af-15f4-4e0c-83b9-adc874311706">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 4, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMi0yLTEtMS01OTc0MA_2a0d06e2-a16e-4379-8a80-9e592c50a00b"
      unitRef="usd">11414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i045574b786544774882db0b6a4f87c00_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMi00LTEtMS01OTc0MA_6f5340af-9a05-4125-8a17-3e685c79057d"
      unitRef="usd">11111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i849ac74f789a48d3853868c27081a1ba_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMi02LTEtMS01OTc0MA_1d75fdfc-af99-4447-becb-72c5f21683fe"
      unitRef="number">0.027</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i447684ff42fa4bd582534e7299148f49_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMy0yLTEtMS01OTc0MA_8a08780c-e6fc-437a-ac27-fbe8f2158b90"
      unitRef="usd">6024000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i431d8a724aa54139ab3b857d81e71735_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMy00LTEtMS01OTc0MA_8c275727-70b3-42a3-8f24-3bffa4517ebe"
      unitRef="usd">5414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i447684ff42fa4bd582534e7299148f49_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfMy02LTEtMS01OTc0MA_7a1c6f92-94fd-4e62-8a71-e70048bcd8fc"
      unitRef="number">0.113</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic04865d6630d448b86af337d00e81758_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNC0yLTEtMS01OTc0MA_07b39fb4-8bc7-499b-81d2-1521b549c920"
      unitRef="usd">1482000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6511d5e0bf74508adf0aa6bdedfe8bc_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNC00LTEtMS01OTc0MA_b163fa53-25d7-4bcd-9cf6-f0b1a3790200"
      unitRef="usd">1424000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ic04865d6630d448b86af337d00e81758_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNC02LTEtMS01OTc0MA_ad8bdeff-3882-4744-bb5d-7d37609d2109"
      unitRef="number">0.041</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09018b2d45d249cd8716cb425feef71d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNS0yLTEtMS01OTc0MA_3f002c0f-859d-4a41-aee9-2b7907d76844"
      unitRef="usd">4506000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13abd60e97db49d09d10b6d9a10a6b80_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNS00LTEtMS01OTc0MA_548ab5d6-7fd6-4b4c-af45-2e656882633c"
      unitRef="usd">4372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i09018b2d45d249cd8716cb425feef71d_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNS02LTEtMS01OTc0MA_ec825972-ac71-451c-93a3-107f60097c18"
      unitRef="number">0.031</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNi0yLTEtMS01OTc0MA_bd928573-92ff-4a1f-bf4b-e1e96c04d0f7"
      unitRef="usd">23426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i097d20859fcc4351ba03a3fa7849b6da_D20210104-20210404"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNi00LTEtMS01OTc0MA_4aebbd80-8516-45b5-a585-49d079b02500"
      unitRef="usd">22321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84Mi9mcmFnOmE3ZmNmNTIwZWVhNzQ0ZjliYTdlODAwNjk0Njg5MDI5L3RhYmxlOjQ3MjQyNWE4YjlhNjRjZTc5ZWQ0YzA0MzUzNDFjNmQ3L3RhYmxlcmFuZ2U6NDcyNDI1YThiOWE2NGNlNzllZDRjMDQzNTM0MWM2ZDdfNi02LTEtMS01OTc0MA_026fddce-e1f5-4381-89af-8b9a38bb9a97"
      unitRef="number">0.050</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84NS9mcmFnOjdiNDA5OTdiN2VlMTQwOTBhNjJiNTRjYmQ0MTgzNTg1L3RleHRyZWdpb246N2I0MDk5N2I3ZWUxNDA5MGE2MmI1NGNiZDQxODM1ODVfMTUxMw_40339ce8-d6c4-4728-b20a-c2a703730876">ACQUISITIONS AND DIVESTITURESThere were no material acquisitions in the fiscal first quarter of 2022. During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion.</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="if894d62118864420a5c2c56cb58ec015_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84NS9mcmFnOjdiNDA5OTdiN2VlMTQwOTBhNjJiNTRjYmQ0MTgzNTg1L3RleHRyZWdpb246N2I0MDk5N2I3ZWUxNDA5MGE2MmI1NGNiZDQxODM1ODVfMjky_f0008236-581d-41d0-bdb4-fbf43e696417"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfOTUyMDk_fb6b9487-2d7f-4610-8b73-f5da8538377b">LEGAL PROCEEDINGS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of  April&#160;3, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Company&#x2019;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#x2019;s balance sheet, is not expected to have a material adverse effect on the Company&#x2019;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#x2019;s results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;PRODUCT LIABILITY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of April&#160;3, 2022, in the United States there were approximately 230 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 3,900 with respect to the PINNACLE Acetabular Cup System; 9,800 with respect to pelvic meshes; 8,600 with respect to RISPERDAL; 4,300 with respect to XARELTO; 40,400 with respect to body powders containing talc; 80 with respect to INVOKANA;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and 4,800 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp;amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp;amp; Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson arising out of Ethicon&#x2019;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#x2019;s accruals. In addition, class actions and individual &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#x2019;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. In March 2022, the Court appointed a barrister to prepare a written report and recommendation on the form and mechanism of the individual case assessment process, due by August 2022, with a court hearing on those findings later that month. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement is expected to be filed with the Court by May 2022. The Company has established accruals with respect to product liability litigation associated with Ethicon&#x2019;s pelvic mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. The deadline for issuance of Individual Allocation amounts by the Special Master was March 2022. Plaintiffs requested an extension of the deadline. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of April 2022, there are approximately 105 active cases subject to these orders which are being reviewed and evaluated. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;Claims have also been filed against Ethicon and Johnson &amp;amp; Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Discovery is underway in the MCL proceedings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Ethicon and Johnson &amp;amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp;amp; Johnson; and JPI&#x2019;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp;amp; Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp;amp; Johnson Consumer Inc. and Johnson &amp;amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham v. Johnson &amp;amp; Johnson, et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;No. ED 207476 (Mo. App.), reducing the overall award to  $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, Johnson &amp;amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#x2019;s direct parent, Johnson &amp;amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#x2019;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#x2019; compensation statute or act (the Talc-Related Liabilities). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, notwithstanding the Company&#x2019;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp;amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay, and also asked the New Jersey Bankruptcy Court for leave to pursue direct appeals to the Third Circuit Court of Appeals, which was granted. In April 2022, claimants filed a request with Third Circuit Court of Appeals to hear the case, and LTL filed its opposition to the request. While the New Jersey Bankruptcy Court&#x2019;s order effectively stays all of the Company&#x2019;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#x2019; Committee (TCC), and the Future Claimants&#x2019; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#x2019;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn as improperly voted. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#x2019;s insurers (the Mediation Parties) have since agreed to engage in mediation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys adversary proceeding). The Imerys adversary proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#x2019;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys adversary proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2020, Cyprus Mines Corporation and its parent (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus adversary proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan. The Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against Talc Claims asserted against it. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus adversary proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2021, several of the Company&#x2019;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the stay applied to the Coverage Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2018, a securities class action lawsuit was filed against Johnson &amp;amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp;amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder, and that purchasers of Johnson &amp;amp; Johnson&#x2019;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs&#x2019; motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#x2019;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson &amp;amp; Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. In February 2022, the Court granted Johnson &amp;amp; Johnson&#x2019;s cross motion to dismiss. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp;amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Baby Powder, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;&amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2020, a report was delivered to the Company&#x2019;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp;amp; Johnson&#x2019;s motion to dismiss pending a decision on Plaintiff&#x2019;s motion for discovery. In November 2021, at the Court&#x2019;s request, the parties submitted supplemental briefing on Plaintiff&#x2019;s motion for discovery. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp;amp; Johnson Savings Plan against Johnson &amp;amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp;amp; Johnson stock as a Johnson &amp;amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#x2019; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#x2019; motion was complete. In February 2021, the Court granted Defendants&#x2019; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#x2019;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#x2019;S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp;amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#x2019;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases also have been filed in various state courts. In addition, three class action lawsuits have been filed in Canada. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;INTELLECTUAL PROPERTY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain subsidiaries of Johnson &amp;amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#x2019;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (&#x2019;200); 6,491,701 (&#x2019;701); 6,522,906 (&#x2019;906); 6,800,056 (&#x2019;056); 8,142,447 (&#x2019;447); 8,620,473 (&#x2019;473); 8,801,601 (&#x2019;601); and 9,452,276 (&#x2019;276) based on Auris&#x2019; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#x2019;200, &#x2019;056, &#x2019;601 &#x2019;701, &#x2019;447, &#x2019;276 and &#x2019;906 patents. Intuitive subsequently dropped the &#x2019;200, &#x2019;473 and &#x2019;701 patents from the suit. In December 2019, the USPTO instituted review of the &#x2019;601 patent and denied review of the &#x2019;056 patent. In February and March 2020, the USPTO instituted review of the &#x2019;200, &#x2019;447, &#x2019;701 and &#x2019;906 patents and denied review of the &#x2019;276 patent. In December 2020, the USPTO declared all of the challenged claims in the &#x2019;601 patent to be invalid. In March 2022, the U.S. Court of Appeals for the Federal Circuit affirmed the finding of invalidity of the &#x2019;601 patent. In March 2021, the USPTO ruled that the challenged claims of the &#x2019;447 and &#x2019;906 patents are not invalid. Auris has appealed that decision. Auris filed a request for reexamination of the &#x2019;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in January 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713,537 by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. Trial is scheduled to begin in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 and 10,517,583 (&#x2019;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#x2019;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#x2019;180 patent, and awarding damages in the amount of $20 million. DePuy is challenging the verdict in its post-trial motions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes lawsuits the Company&#x2019;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp;amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#x2019;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#x2019;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZYTIGA &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in January 2019, Janssen Inc. and Janssen Oncology, Inc. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#x2019;s Laboratories Ltd. and Dr. Reddy&#x2019;s Laboratories, Inc. (collectively, DRL) in response to those parties&#x2019; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#x2019;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#x2019;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#x2019;310). The following generic drug companies are named defendants:  Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#x2019;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. No trial date has been set in this lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2022, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Micro Labs Ltd. and Micro Labs USA Inc. (collectively, Micro) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#x2019;310 patent. In March 2022, the case against Micro was consolidated for all purposes, including trial, with the consolidated Delaware lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#x2019;310 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Parties Review with the United States Patent and Trademark Office, seeking to invalidate the &#x2019;310 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, Janssen Pharmaceuticals, Inc. (JPI), Bayer Intellectual Property GmbH and Bayer AG filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Changzhou Pharmaceutical Factory, which filed an ANDA seeking approval to market generic a version of XARELTO (10 mg, 15 mg, and 20 mg) before expiration of U.S. Patent No. 9,539,218 (&#x2019;218). In this lawsuit, JPI, Bayer Intellectual Property GmbH and Bayer AG are seeking an order enjoining Changzhou from marketing its generic version of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#x2019;218 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVOKANA/INVOKAMET/INVOKAMET XR&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, Janssen Pharmaceuticals, Inc., Janssen Research &amp;amp; Development, LLC, Cilag GmbH International and Janssen Pharmaceutica NV (collectively, Janssen) and Mitsubishi Tanabe Pharma Corporation (MTPC) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories Ltd (DRL), who filed an ANDA seeking approval to market a generic version of INVOKAMET before expiration of MTPC&#x2019;s United States Patent No. 7,943,788 (&#x2019;788) relating to INVOKAMET. In this lawsuit, Janssen and MTPC are seeking an order enjoining DRL from marketing its generic version of INVOKAMET before the expiration of the &#x2019;788 patent. In January 2021, Janssen and MTPC filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Macleods), which filed an ANDA seeking approval to market a generic version of INVOKAMET XR before expiration of MTPC&#x2019;s United States Patent &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Nos. 7,943,582 (&#x2019;582) and/or 8,513,202 (&#x2019;202) relating to INVOKAMET XR. In February 2022, the case was dismissed by stipulation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2020, Janssen Inc., Janssen Pharmaceutica NV and MTPC initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of INVOKANA before the expiration of the Canadian Patent Nos. 2,799,204, 2,534,024 and 2,671,357. Janssen Inc., Janssen Pharmaceutica NV and MTPC are seeking an order enjoining Sandoz from marketing its generic version of INVOKANA before the expiration of the relevant patents. The trial is scheduled to begin in August 2022. In February 2022, the case was discontinued.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of Canadian Patent No. 2,659,770 (&#x2019;770). Trial against Sandoz concluded in February 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the &#x2019;770 patent. Trial against Apotex concluded in March 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against JAMP Pharma Corporation (JAMP) in Canada in response to JAMP&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg before the expiration of the &#x2019;770 patent and Canadian Patent No. 2,621,273 (&#x2019;273). In April 2022, the parties entered a confidential settlement agreement, and the case was discontinued. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of United States Patent No. 9,439,906 (&#x2019;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#x2019;s favor. Teva has appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent. A trial is scheduled to begin in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#x2019;629) and 2,655,335 (&#x2019;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#x2019;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#x2019;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#x2019;335 patent and that the claims of the &#x2019;335 patent are not invalid. Teva Canada appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#x2019;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. The action has been consolidated with the November 2020 action for trial, which is scheduled to begin in July 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA TRINZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of United States Patent No. 10,143,693 (&#x2019;693) relating to INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(546 mg). Trial is scheduled to begin in October 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(819 mg) before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#x2019;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. The trial is scheduled to begin in July 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of United States Patent Nos. 10,039,718 (the &#x2019;718 patent) and 10,786,518 (the &#x2019;518 patent). Janssen is seeking an order enjoining Lupin from marketing its generic version of SYMTUZA before the expiration of the &#x2019;718 and &#x2019;518 patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#x2019; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#x2019; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in responses to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;GOVERNMENT PROCEEDINGS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp;amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Wholesale Price (AWP) Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;amp;J AWP Defendants were ultimately dismissed. The J&amp;amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp;amp; Johnson and ALZA Corporation. All other cases have been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Opioid Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in 2014 and continuing to the present, Johnson &amp;amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp;amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Johnson &amp;amp; Johnson, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp;amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#x2019;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp;amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp;amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#x2019;s judgment and directed entry of judgment for Defendants. In October 2019 Johnson &amp;amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp;amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#x2019; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of  $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and up to one-third of the all-in settlement is expected to be paid within the next 12 months, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022 and initial payments are set for July 2022. In April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There are approximately 100 cases remaining post-settlement in various state courts. There are approximately 1,000 remaining federal cases coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp;amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp;amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Johnson &amp;amp; Johnson received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From June 2017 through December 2019, the Company&#x2019;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.  By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted Johnson &amp;amp; Johnson&#x2019;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp;amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#x2019;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#x2019; motion to dismiss with prejudice, unsealed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint, and denied the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators&#x2019; request for leave to file a further amended complaint. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#x2019;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#x2019; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#x2019; second amended complaint; the District Court denied DePuy&#x2019;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#x2019;s July 2021 ruling. In November 2021, the District Court granted DePuy&#x2019;s motion for reconsideration and dismissed the case with prejudice. The District Court&#x2019;s order was unsealed in December 2021. The Relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#x2019;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#x2019; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#x2019;s dismissal of the case to the First Circuit, and the Relators&#x2019; brief is due in May 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp;amp; Development, LLC, and Johnson &amp;amp; Johnson (collectively, Janssen) were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in December 2017 in United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. At this time, the federal and state governments have declined to intervene. The case has been transferred to United States District Court for the District of New Jersey. Janssen&#x2019;s motion to dismiss was denied in December 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2012, Johnson &amp;amp; Johnson was contacted by the California Attorney General&#x2019;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp;amp; Johnson&#x2019;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp;amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp;amp; Johnson and Ethicon settled the Washington case. In October 2019, Johnson &amp;amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for May 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#x2019;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#x2019;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. The Company is pursuing an appeal to the Supreme Court of California.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp;amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#x2019; use of talc contained in JOHNSON&#x2019;S Baby Powder and JOHNSON&#x2019;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp;amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#x2019;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp;amp; Johnson and JJCI&#x2019;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#x2019;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting and in January 2022, the Court granted plaintiff&#x2019;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#x2019;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#x2019;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#x2019;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to enter into negotiations to determine if they would resolve their claims through the LTL Bankruptcy Case.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2016, Johnson &amp;amp; Johnson and Janssen Products, LP were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Daubert&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April and September 2017, Johnson &amp;amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, Johnson &amp;amp; Johnson received a subpoena from the United States Attorney&#x2019;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hospitals. Johnson &amp;amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp;amp; Johnson to cooperate with these inquiries by producing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GENERAL LITIGATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp;amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. This case was settled in March 2022, subject to Court approval. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re REMICADE Antitrust Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022, subject to Court approval.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The complaint seeks damages and injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decision. This case was settled in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#x2019;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#x2019;s decision. In February 2022, defendants petitioned for rehearing en banc. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2019, the Court granted Actelion&#x2019;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2019, a class action antitrust complaint was filed against Janssen R&amp;amp;D Ireland (Janssen) and Johnson &amp;amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#x2019; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#x201c;Opt-Out&#x201d; complaints containing allegations similar to the original complaint. Discovery is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#x2019;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#x2019;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#x2019;s motion for summary judgment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, Johnson &amp;amp; Johnson received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp;amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp;amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp;amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp;amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp;amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp;amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp;amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#x2019; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in May 2021, multiple &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;putative &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;class actions were filed in state and federal courts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(California, Florida, New York, and New Jersey)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; against various Johnson &amp;amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and the affirmative promotion of those products as &#x201c;safe&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; and, in at least one case, alleging a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strict liability manufacturing defect and failure to warn &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;claims, asserting that the named plaintiffs&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; suffered unspecified injuries as a result of alleged exposure to benzene.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In March 2022, the Court granted preliminary approval of the settlement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson (subsequently substituted by Johnson &amp;amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="if8404f4966e9457699f55005e32abc65_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDYxNA_4c92a201-368c-40b0-96ae-ed0a92614853"
      unitRef="claimant">230</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="iefcbb252e7bb4f458a41283b135a86ec_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDc3OA_ff2a333d-d189-41d2-9ca4-407bff8921c8"
      unitRef="claimant">3900</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ib22b3a738c7e4ab29b10ad29e3acd8a9_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDgzNA_ee9f80b5-19c6-4699-84c1-3804ba398ce9"
      unitRef="claimant">9800</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ice23be6cbe2746dd8d736fa8da0659cc_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDg2OA_1a6985f8-e953-4b81-bc2c-a95c7390b70c"
      unitRef="claimant">8600</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i37533ea8707341c89db72e8585de3a87_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDg5OQ_64adfb6f-afa1-40b1-b31b-26c89175c378"
      unitRef="claimant">4300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="if5e5fa8d553d4bdfac44b45081a72bad_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDkyOA_55da0cf6-ab53-47dd-8357-2edea964eeec"
      unitRef="claimant">40400</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i4f89bd9fe89d4fdc8e39741b72fb0768_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDk3Nw_b12720d3-5df6-489a-a0d1-5a46c9970729"
      unitRef="claimant">80</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ifeab3c5384914043b5f61dde75cfbcfc_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNTAxMg_a36e9bef-d840-40c4-a9cc-a973b3d77672"
      unitRef="claimant">4800</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="if160682b2ae54bd29b1935327968059a_I20220403"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjQwMg_415eb85a-e468-4d02-a383-be58d53b8838"
      unitRef="patient">10000</jnj:Numberofpatientsinsettlement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iaecd09df5a17466f94617abfae776151_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTIxMTg_76a287e9-2710-47ac-8912-f0283ca9cd15"
      unitRef="cases">3600</us-gaap:LossContingencyPendingClaimsNumber>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="iaecd09df5a17466f94617abfae776151_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDM5ODA0Njk3MjM3Mg_2b0ea660-089e-430d-88d4-20cc8687faca"
      unitRef="claimant">4300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement
      contextRef="i1b15385aca15402cb972e9d0c02e804f_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDM5ODA0Njk3MjM3OQ_b6ca6dba-bd8d-44fd-9391-db0f5931eb06"
      unitRef="cases">3729</jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i0487ffe3bd6846938c1d7cb60790531d_I20220403"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDM5ODA0Njk3MjM4Ng_576ab563-b5c8-49c7-9584-3c57184c89e1"
      unitRef="cases">105</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i812c90cdefa246e3bcebf7398bdb44f4_D20191001-20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTQ0MDg_aee6390d-f0fd-453e-b64e-5a2b779c3a05"
      unitRef="usd">8000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i5421e9f4d1234869a6e154317b70cd16_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTQ0OTA_b4e6f6a4-ca34-4400-b66e-39348eb41a66"
      unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i339e763d52094be9ae4c3c2454a17c00_D20180701-20180731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTY3NzQ_44764696-a61d-4a12-8f64-b60b395258bb"
      unitRef="usd">4700000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i14361e93fcc9401dad202a5affb4254d_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTY4NzM_584421b0-43d5-4107-829e-2f0362e39e5f"
      unitRef="usd">2100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="if0ab2dba81b64612b4248a3cd41c97e2_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTcxOTQ_26510f1b-9552-4174-8674-80b85b771ed4"
      unitRef="usd">2500000000</us-gaap:PaymentsForLegalSettlements>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i1508c05368864604ae6acac4ed5e0fe4_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTk1NTQ_13751d39-c0a6-4113-9be1-c405d6f4103c"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i1508c05368864604ae6acac4ed5e0fe4_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMTk2NTE_21b68a9a-b02a-41f6-abf9-b05c0c96ae29"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i876621f6fe4046ebafa49eee939aae65_I20220403"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjIzNzg_34235476-2ea3-44a5-8501-602e3a9d9da0"
      unitRef="claimant">3500</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i1ba7f11cf3c6444fb13f272778b14648_D20181231-20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjU2OTE_4aaae1d0-32cd-4ef0-828e-b0815e7895c8"
      unitRef="usd">465000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ibc133ce8aefa43cbbac33e0c79222c18_I20191031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjkzOTA_5275fb97-6735-47ab-90fe-d6f750be5608"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:LossContingencyEstimateOfAdditionalPossibleLoss
      contextRef="ic211f008f0c343b9b6dbe0257a30891d_I20201031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjk0OTU_6ca7c639-7121-4a79-a74d-6726a2224a8f"
      unitRef="usd">1000000000</jnj:LossContingencyEstimateOfAdditionalPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ic211f008f0c343b9b6dbe0257a30891d_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNjk2NTU_6dd36b0a-7048-47fb-b5d3-14ffacea085f"
      unitRef="usd">5000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i2e490e1b4676470caee65dbdb296781b_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMjc0ODc3OTQ1NTMyOA_250b3f2d-6c31-4b51-996a-49f342862b1e"
      unitRef="claim">100</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8843c5f5a5344884a0b6d6b1eabc68b6_I20220403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMjc0ODc3OTQ1NTM0Nw_996d5604-e9cd-4ff1-874b-d9033dd63c63"
      unitRef="claim">1000</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="idb0be9010ee64ef5a74536a9b8bf4b5e_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNDM5ODA0Njk3MjM5MQ_55d64c7e-585e-4f2c-ada0-8078626b6358"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="idb0be9010ee64ef5a74536a9b8bf4b5e_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfNzY0OTk_9d855644-69b6-4a15-bb6e-da098a94c84c"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i7bf5bf7a3b0c4bcdba8ba036de5060bd_D20220401-20220430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfMjc0ODc3OTUyNjQyMQ_d0fbb3ff-7c7c-48e4-8ea6-d87602d24eab"
      unitRef="usd">302000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iab1eb6318e4a48a59682988b2dc916e0_I20150430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF84OC9mcmFnOmUzNzYyZDc1MWExMTRkMGNhMWFkYzJhMmMxNTMyMzdlL3RleHRyZWdpb246ZTM3NjJkNzUxYTExNGQwY2ExYWRjMmEyYzE1MzIzN2VfODM2OTk_fe4168d8-a97d-42d4-8120-3a5ad0e89530"
      unitRef="claim">30</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMjU2NQ_da7a38f9-9c5d-4e2b-9955-f7b9498c2350">RESTRUCTURING&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal first quarter of 2022, the Company recorded a net pre-tax charge of $72 million, which is included on the following lines of the Consolidated Statement of Earnings, $70 million in restructuring, $16 million in cost of products sold and income of $14 million (from property sales) in other (income) expense, net. Total project costs of approximately $1.8 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.1 billion to $2.3 billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, April 3, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents gain on sale of assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="ic71f1704f9cc4887aecf9df02c808339_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfNjYw_a5d34c0a-3175-4647-a41c-9602bdaa817d"
      unitRef="usd">72000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i429a51537c514c5d901ca9e7b22c4175_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfNzQ4_7e19f47a-4687-45b8-a738-99b037fb8d23"
      unitRef="usd">70000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i77698652b7224cc1aa4d7e90f3dc8d52_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfNzY5_580756cc-fb22-406f-8a6c-8b42707e733c"
      unitRef="usd">16000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i3c5ffba5806541d5ba6376f4fc012752_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfODAx_91e2fcf1-e076-4192-857c-3ebf07c19e68"
      unitRef="usd">-14000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i9829b5b0fbb446f5a0b0c27c4eb65328_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTEwOQ_c3e8068b-b711-442e-822e-fe4d687dc032"
      unitRef="usd">1800000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i8c4ee00cbdf34df08cf085ad78a22765_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTMzNw_aee8b364-b171-435e-9c5a-f2ebd8627af3"
      unitRef="usd">600000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="ide55be3475194704afb071efa17c609a_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTM0Mw_813d4b04-3829-4a56-9fc3-66ea7cd0915e"
      unitRef="usd">800000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i8c4ee00cbdf34df08cf085ad78a22765_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTUwMA_e33a2133-6619-4268-8f60-85071089e406"
      unitRef="usd">2100000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ide55be3475194704afb071efa17c609a_I20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMTUwNg_66fe8503-7548-4081-9b95-169f66d276bb"
      unitRef="usd">2300000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RleHRyZWdpb246MjMyN2RhMTg3YjM4NDA3NWE3ZDJjNDdhYjQ0MDQxZWRfMjU2MQ_dbdf782f-a263-4777-bf84-d83e8672ec50">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal first quarter of 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, April 3, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents gain on sale of assets&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i5135a58860bc4428aa25ef065e2d9395_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfMS0xLTEtMS01OTc0MA_f320e07e-e17f-4e6e-a3d8-fa2fc85b395b"
      unitRef="usd">112000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id8c4ef8d93674a29b417806bb3af7d59_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfMS0yLTEtMS01OTc0MA_19fc4a67-08fb-478f-94c5-7813cc0ee84c"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i964e0dcb3290414a948e1f7f5b6a98f0_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfMS0zLTEtMS01OTc0MA_e51554d0-4c18-4a09-9f96-e0caa1954d96"
      unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i1e4afcfd6d8e427c8043eca9ef363498_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfMS01LTEtMS01OTc0MA_7d035790-7e95-4cc7-8607-97fdf5b42226"
      unitRef="usd">137000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i55870fa5009d42c29ee665e83387efd6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNC0xLTEtMS01OTc0MA_52f34de6-89a1-4f06-9ff6-98a3fae92c5c"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i84f8b7c83d8e4a408decca1a1e440fef_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNC0yLTEtMS01OTc0MA_ff08dd66-16b6-49e0-97db-099a6ee712cc"
      unitRef="usd">-23000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i947a2e9e4d9745a88afc0f03c30a4835_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNC0zLTEtMS01OTc0MA_7f8d88ff-1f6d-48bb-af94-5480fdadd8e1"
      unitRef="usd">95000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ifad79f71187349d286755258d2aaae39_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNC01LTEtMS01OTc0MA_cb6d4128-d5df-4346-a234-e056724d43a8"
      unitRef="usd">72000000</us-gaap:RestructuringCharges>
    <jnj:PaymentsForRestructuringNet
      contextRef="i55870fa5009d42c29ee665e83387efd6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNS0xLTEtMS01OTc0MA_d2e2e314-725d-4127-a63c-bebb0184f83b"
      unitRef="usd">10000000</jnj:PaymentsForRestructuringNet>
    <jnj:PaymentsForRestructuringNet
      contextRef="i84f8b7c83d8e4a408decca1a1e440fef_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNS0yLTEtMS01OTc0MA_db63d08d-8cc6-4da9-b247-b6355c048d0f"
      unitRef="usd">-35000000</jnj:PaymentsForRestructuringNet>
    <jnj:PaymentsForRestructuringNet
      contextRef="i947a2e9e4d9745a88afc0f03c30a4835_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNS0zLTEtMS01OTc0MA_ceea4eae-1e76-424b-befb-76ed8bcc23a1"
      unitRef="usd">107000000</jnj:PaymentsForRestructuringNet>
    <jnj:PaymentsForRestructuringNet
      contextRef="ifad79f71187349d286755258d2aaae39_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNS01LTEtMS01OTc0MA_7a8ccbd6-4b6d-4d31-a5b2-351aa5444690"
      unitRef="usd">82000000</jnj:PaymentsForRestructuringNet>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i55870fa5009d42c29ee665e83387efd6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNi0xLTEtMS01OTc0MA_841ea045-0231-4d67-8ac2-1ce832868f93"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i84f8b7c83d8e4a408decca1a1e440fef_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNi0yLTEtMS01OTc0MA_18f2626c-8a32-4b40-99ea-c2a526fb79d5"
      unitRef="usd">12000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i947a2e9e4d9745a88afc0f03c30a4835_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNi0zLTEtMS01OTc0MA_d0f3d77c-ec92-4dd7-8fa5-94fbe0ecafb6"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="ifad79f71187349d286755258d2aaae39_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfNi01LTEtMS01OTc0MA_b157d43f-af9e-40ea-bf80-92f755ea9b4a"
      unitRef="usd">12000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="i3dd52c3fe3994d508717b89e90774fc7_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfOS0xLTEtMS01OTc0MA_8955a0ab-af1e-4462-a0e8-9b2b7b1bfefe"
      unitRef="usd">102000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i7d132ccbcb6c479395ae1351d7e61a30_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfOS0yLTEtMS01OTc0MA_766ab0b5-06ec-4366-8e88-fae8b5ab1092"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib2eb914c66f44b7eacd607705a3c6eff_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfOS0zLTEtMS01OTc0MA_d8b9fb64-67cd-40bd-ae67-842f575deff3"
      unitRef="usd">13000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="icd1e6b53d4a34fa48ef408b420626ba5_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5YjU0Nzk5YzYxNjQ4YzA4OTJkNjY0Njk2Mzg3YjI4L3NlYzo4OWI1NDc5OWM2MTY0OGMwODkyZDY2NDY5NjM4N2IyOF85MS9mcmFnOjIzMjdkYTE4N2IzODQwNzVhN2QyYzQ3YWI0NDA0MWVkL3RhYmxlOmM4YWM4OTAwNmEyNDQ0ZmZiMjc5ZmY1NzU5YjQ4MTA2L3RhYmxlcmFuZ2U6YzhhYzg5MDA2YTI0NDRmZmIyNzlmZjU3NTliNDgxMDZfOS01LTEtMS01OTc0MA_619f11a9-605a-435c-87bf-454bf82fdcd6"
      unitRef="usd">115000000</us-gaap:RestructuringReserve>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"(9^19GPLM2-3566RL9P)F"JB&ZJBJJ7&^!R/?;ZWNO /5N6Q@[X65K3)<S
M/-13A3V_8RE8!4(S*8B"Q=B[[E]-$EOO"OXP6.NM-K%.YE(^VL[/8NP%5A!P
MR(UEH/A8P00XMT0HXVG#Z7536N!V^Y7]N_..7N94PT3ROZPPY=A+/%+ @C;<
MW,OU#]CX&5B^7'+M_LFZK1UB<=YH(ZL-&!543+1/^KS)80O0CX\ P@T@_"@@
MV@ B9[15YFS=4D.S5,DU4;8:V6S#9>/0Z(8)^Q5G1N%;ACB33:30DK."&BC(
M#>54Y$!FEDZ3WI0J$*8$PW+*S\@W\C"[);TO9^0+88+<,<[Q2^C4-RC$TOGY
M9M*;=M+PR*37M;H@071.PB ,#\ GI^&_J$!X> CNH_TN@[#+('1\T;$,&F5]
M$JHUVKXZP1AUC)%CC(\9Y+@[;)2:X$8CA6SF9M%P7+2Y;(0Y&%G+.'2,=N^M
MLC"*4W^UG<NAFJ"KV9$:=U+CD^9G)7[D4O("E/Y*X*EAYN54!(..=W R@HFL
M*MRFN(#SQW-24T56E#= :L SQ,Y)>EWS[% >@SVO_3=IG*K8T3SL- \_H=E)
MTX0VII2*_</]T<-5WXX>5-R2#[;TQ!&>IN[W1OJ'2G<\C#H/H\][8%HW[^L?
M[8F*^OW+)([V]7^H=$=_TNE/3NK_C7>1;M3+&P?O2$_V\[P,XL'EOO*#E<DH
MV1?N;YVJ]D:[HVK)A"8<%H@-+D9(HMI;HNT86;N#=BX-'MNN6>+%"LH6X/N%
ME.:U8\_N[JK._@-02P,$%     @ !X&=5.4H !GS!0  ]QL  !@   !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6RE65USFS@4_2L:3SN3SB0828#MC.,9Q\FV
M>6CJB9/NP\X^$)!CIAAY)3E)]]>O!!0(2()T7VP^[KV<<R]71TCS%\I^\!TA
M KSNTXQ?C'9"',['8Q[MR#[D#CV03-[94K8/A3QE3V-^8"2,<Z=].D:N&XSW
M89*-%O/\VIHMYO0HTB0C:P;X<;\/V<]+DM*7BQ$<_;IPESSMA+HP7LP/X1/9
M$/%P6#-Y-JZBQ,F>9#RA&6!D>S%:PO,5]I5#;O$](2^\<0P4E4=*?ZB3F_AB
MY"I$)"614"%"^?=,5B1-522)XY\RZ*AZIG)L'O^*_D=.7I)Y##E9T?3/)!:[
MB]%T!&*R#8^IN*,O7TA)* <8T93GO^"EM'5'(#IR0?>ELT2P3[+B/WPM$]%P
MD''T#JAT0&T'S^" 2P><$RV0Y;2N0A$NYHR^ *:L931UD.<F]Y9LDDR5<2.8
MO)M(/[%8T8S3-(E#06*P$?)/UDAP0+?@.F19DCUQ< 8>-E?@Y,,GP'<A(QPD
M&?B:I*DL S\%'YJG\[&0H%3H<50"N"P ( , #+[23.PXN,YB$K_U'TLR%2/T
MB]$EL@9<'I@#7'P*D(N0!L]JB+N7NT,+'%PE&.?QL"'>31;1/:E3"_Y:/G+!
MY.O[MR6Z5T7W\NB>(?HF3&4]!"U?%<*T%2AB!'D,U=?/"X0]%,S'S\V\:*P0
M5CEXU@#T*X#^.P&" V&12H2\R-5='6)[4.BZCNM^U!7W-QS?\ HJ7H$UTHIR
MH9KDP&A\C&3#R"Z*=4R"3E8G_FS:2KW&R VP/O.3"N'D_0@')=\>%R/'T^>^
MQP\Z$VOJIQ6QJ3709T8Y5[2VB=#!GW:2"?TI:J=<9X7\J3[GLPK:; "T=0X-
MK,M4WU.P,:7:'BZ8.($^U3U^4P=;4PW=6AY<>_]*@94B<"HUA_T@0AZ",(M!
M&$LM2M0XIE08D%<YK>!ZBN4#FIGV9[A=#IV5AY&^'+"A;G (_&'H!S5'SP.1
M;^J./D>OKV:H)HVLH>X()R&+=CG7F#S+N=HAEYZ2J)86ZN0?>P%J5TEC!2>&
MIH&U1$+\OP /*XS]&=!SIH;"]#HB>V%JL89VM;[)SN2P%1$Y1C #92VSKC('
MT&V7IFOD&NI2:S>TR^4 O,-*8W\,,HUR/7Y]6@YK,8=V-;_)!)$,A9S*JMF:
MED-7H\]0IS\T1M WE*$6<FA7SA:Z82FWASQQ'>A^_*1-^F]XOB56"SFT*WE%
MK.SS4Y"18LY"6?Z1%X6'1(1I\F_[RZ DJ1'Q3E]T;4PS*UC+/+0+['N #RN7
M_7G&Z6ZOGUU34#T/0/9YP#>Q(PR<%&_@IS>\=7Q05\[/H-MN%YW5=&H0?52+
M/K)+J07KH&+TA)<=X!EZI\\3.S-[[Z!:Y%&OR LFY_5'IF8U)[=4$ "1#M4E
MZJKVI-TF&AO?T":HUG74J^L-C-$N9$_#1J^>N)K7NF31YV=7<E0K.;(K>;4V
M\DBVE!'U-?*<Y$M;\A2(\%7.)N6)64Y05Z[]:6>^I;&:>&AFJ$NMZ\@NG.]"
M/ZQ@/0KOFP:P'D>,^T:P6N.17>/75I)% _GZ_M%\GD/<+E77""+3!PRJM1_9
MY=:.>E!I>C[+C96Q^_F.;R],/0M ]EG K1R62?E&:@ET%=R'WJR=?XW.P]G$
MD/]:Z9%=09O@AJ7;'@\A8[Y['"?=[Y>W"Y*UEF/7NB1Y>WT/KI=WMS>WGS=@
M?7T'-E^6=]>VT+7T8KO"788\B<")3%2Q5JSMIS+&I-DJSJR]'*FQ0@XV3*9Q
MK9O8KIM727I4:]U]&)$.8[OI-582HZ'I<6/)V+YFO/S^V2F*L@'?'NXW]\O;
M*UDL6X5JY<)VY2HK5*SDZZD7 :9-4@&:.6UQTMIAZ 0&^K4\8?N@7Y7(!M+7
M/#P('+\-4F<W04Y[8!@WME#V1,Y3U,X2!Q$]9J+8>ZBN5KM7RWS/IG7]$IZO
MBCVH.DRQ)?953G^2C(.4;&5(UYE(:*S892I.!#WD&S6/5 BZSP]W)(P)4P;R
M_I9*C2I/U .JO;[%?U!+ P04    "  '@9U40V0+Z!,$  ">#@  &    'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;*U776_;-A3]*X11%"W01*(DVW'F&$B<
M;NM#UB!!MH=A#XQ$6T0I4B,9.^FOWZ6D2+),,=VP%TNB[\>YAY>'Y'(OU3>=
M4VK0<\&%OICDQI3G0:#3G!9$G\J2"OAG(U5!#'RJ;:!+14E6.14\B,)P%A2$
MB<EJ68W=JM52/AG.!+U52#\5!5$O5Y3+_<4$3UX'[M@V-W8@6"U+LJ7WU#R4
MMPJ^@C9*Q@HJ-),"*;JYF%SB\W446H?*XG=&][KWCFPICU)^LQ]?LHM):!%1
M3E-C0Q!X[.B:<FXC 8Z_FZ"3-J=U[+^_1O^Y*AZ*>22:KB7_@V4FOYB<35!&
M-^2)FSNY_Y4V!4UMO%1R7?VB?6T[CR8H?=)&%HTS("B8J)_DN2&BYP!QW Y1
MXQ -'9(1A[AQB*M":V156=?$D-52R3U2UAJBV9>*F\H;JF'"3N.]4? O S^S
M6DNA)6<9,31#]P8>,$=&([E!:UE 9^1VRG84?1&I+"@Z00_WU^C#NX_H'6("
MW3#.83;T,C  QH8,TB;Q59TX&DD<HQLI3*[19Y'1[- _@"+:2J+72JXB;\#+
M4IVB,/Z$HC"*''C6/^*>5.[8 R=NB8VK>/%(O);+42K_O'S41D$?_^5)E[3I
MDBI=,I+N-UCQE"C!Q-8Y&;7WK/*V2WNWFN)DL0QV?8:.C69X,6^-#H!-6V!3
M+P]?34X52@\(8#4!'[C4^N,G)&A%DB'/'B)F;;Z9EPA8W+!T!:P=I:A(7Q!0
M+#0G5C1<Q-31IKV:3Z;39$#,L5$TG[EYF;<XY_[^H("0&4;UN:?JLS;:F;?J
M!P$:SMEW6,2YY!ET =J"AC<4(Z*8MF,9I(1'2163F8N-LV,V<#P@X]@F=%.Q
M:,$OO.#O:,J)UFS#TFJ:-#+2V\P+#X(:H\_B ",..Z$,WUQA:4[$ECK%+OP!
MYAQ&8[!Z^HV]??2Y*+E\H10]4D$WS*"20[_[>@I'7>S(6_(MM EL^53M6$IA
M#6N#2"&58=^K>7J[G9KXAZOKB!6'48)'>.GD%\=>[+_TV__?@8Z/5SN>#T$[
MC.;)".A.Q/';*N[IL>0H)YX-I<IA%,7Q"+!.Q+%?Q:^!K1VQ)RZ-WI.B_ GE
M--OZM0MWDHW]FMU3K_^D6M@AXG@Q'3+CDGI[5'!2T^DXGO^_ZM7$.T0;XB%:
MA]5\;!Z[;0+[]XDW&LPA_]%B-D3FL)KVV#Z$UFT"V+\+O'E0<"(^%OJ3V6)X
MKG%9G8WLWU&W(43^#6'M@.K"V(3I'ZN29#K<L1Q6,XR',ACT3OH%5=OJ J2!
MM2=AZJ-R.]I>LBZKJ\5@_ HN7_55J0M3W]QNB-HRZ&).-Q R/)T#;:J^#-4?
M1I;5?>)1&KB=5*\Y7""IL@;P_T9*\_IA$[17TM4_4$L#!!0    (  >!G51!
MZ;(7M0(  /0&   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULC55M;]HP
M$/XKIZB:6FEM(.&EZP ):*?V0R54UNW#M \F.8A5Q\YL ^V_W]D)&:4![4O\
MDGN>>^[./@^V2K^8#-'":RZD&0:9M<5-&)HDPYR9*U6@I#]+I7-F::E7H2DT
MLM2#<A%&K58OS!F7P6C@]V9Z-%!K*[C$F0:SSG.FWR8HU'88M(/=QA-?9=9M
MA*-!P58X1_M<S#2MPIHEY3E*PY4$C<MA,&[?3/O.WAO\X+@U>W-PD2R4>G&+
MAW08M)P@%)A8Q\!HV. 4A7!$).-/Q1G4+AUP?[YC_^9CIU@6S.!4B9\\M=DP
MN X@Q25;"_NDMO=8Q=-U?(D2QG]A6]FV DC6QJJ\ I."G,MR9*]5'O8 Q-,,
MB"I = CH' '$%2#V@9;*?%BWS++10*LM:&=-;&[B<^/1% V7KHISJ^DO)YP=
M394T2O"464QA;FF@$ED#:@E3E=/!R%S%-@@/,E$YPOF,:3+(T/*$B0NXA.?Y
M+9R?7< 9< F/7 BJCAF$EL0Y%V%2"9F40J(C0F)X5,1KX$ZFF+['AQ14'5FT
MBVP2G20<%_H*6O%GB%I1U*!G^C_PCH>W3\B)ZT3'GB\^PE?G]FAJ?XT7QFHZ
MU[]/N.O4[CK>7>>(.SKC=((E3->:ZI6\P7?-I!',W9VFXI1L/<_F;OYF=-GN
M= ?A9C]C#49Q^TMM]$YHMQ;:/2ETCLE:<\NQ\<R4V.X[C\W^>K6_WDE_=WDA
MU!LB3%#BDEN8"=9\7GL??._%6B;DH\EEK]>LKU_KZY_4=XN:;YCK;08^L;SX
M"O>8KIJST_]8C_[U@<0&FW:W?Z QW&L@.>J5[ZL&$K66MKQQ]6[=NL>^8QWL
M3ZBEEQWX'TWY'CPRO>+2@, E4;:N^I0U7?;8<F%5X=O40EEJ>GZ:T;.$VAG0
M_Z52=K=P#NJ';O074$L#!!0    (  >!G53JFE6%400  ( 0   8    >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&ULK5A;;Z,X&/TK5C0/,]*D8',+HS12FXNV
M(\UNU>[L/KO@-*B &6R:]M_OQZ4TV(9HM_M2+CGG^/BS?6RZ//+R21P8D^@E
M2W-Q.3M(67RS+!$=6$;%!2]8#K_L>9E1"8_EHR6*DM&X(66I16S;MS*:Y+/5
MLGEW6ZZ6O))IDK/;$HDJRVCY>LU2?KR<X=G;B[OD\2#K%]9J6=!'=L_DS^*V
MA">K5XF3C.4BX3DJV?YR=H6_[;!7$QK$7PD[BI-[5'?E@?.G^N$FOIS9M2.6
MLDC6$A0NSVS-TK16 A^_.M%9WV9-/+U_4]\UG8?./%#!UCS].XGEX7*VF*&8
M[6F5RCM^_(UU'6H,1CP5S5]T;+$>@*-*2)YU9'"0)7E[I2]=(4X(V!DAD(Y
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M<1!&[;+$94:BH2?2APU5P^Y':,<5:M>CLJ-G9=V@NV&I1+!^VZ.+_T.UZW2
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M_9;2O2P:5]A6@11KA52?T+5Y_2$5P$0NM'>6=>!HEEAD5;0AT(N=#3EA%#4
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M/LF/_;?['R7\NZJ-D15R#&:M;--;_2^>K$ZCR8#);13R.,&0C-/N$<3C@#'
M831@@&GD 3*7)OA+!CZ)6W]*Y>1AB\>A^YA/L>,IG?NL;YZG?)1Q%/O\M6>
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M%4@R%1>K5496*,GSQPG3L ?X&*18)RGP!M+9DA2Y?.P-9_@=J-?9 R[XE8L
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M:(-O^CB5E:1T8;]B&L9S_A<%@?B1\WS8.,J<G"H1914P 5!Z7NAK%%0)A=I
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M %U-SWYS8! \?$7(1*PW*2*U1 XY*<?,VS...QG400YX;[(M;[A)Q/T^O38
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MTL.(/6[B;1P1S6B#/6X&%*-,HS=]<*E.$M)GO(" ##D  BT1LB[#!;@]Q"?
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M$)7ZA2-UTY0[_E6AV[)IRBU?;F2RDA4-P'OZ@KJYH0WLSTR]_C]02P,$%
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M^6(B7%HTTR'8-BYW^ 1@58R/-79S<BR ]Y7%UZ0_L(-QVS__%U!+ P04
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MIAA4VW(-VV:FYH@!:',=/KZT9+H6\VRAC-63"!_I'K9S!DY'H&4QPX4%KC0
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M*!WG!RBCB>5QS[Y/"CA4WFM7BJ YRU'>N&YK=6E1MSME8Z6QCH8C[X8OLE!
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M!]UBT9=-UZB7E7L!^.8@IVS+#IC:<$9> 0R/9C\OY:JKMDH5N40&C9V^()M
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M 8*M;>Y;@.;8N!LQ:W2;R4@*WU\>$D>@+J]/1L[_*N%]GFPS8>C.LD47$,9
M<@RT1>2<;[;UM<&]1OO!34_"?]<(TG03+DQG?2@YBF?O)R/L$ /Q596\N3J_
M/AF-^7JG0"?KD/V*?-[X'E^;.PZCI5"ZRR-+J?Y2.^)(C%[;$@MKFU"13__<
MH%)TT#OW2;ACGY(L&RZ9&AG)]]'[X]QHR#")0WP N\3F2\^5>#+W\[PK+7-V
MF=ZAE\&(5'P40,__443;U;;Y\T/:WDU#\GLT_5MEQ4)(6I@;YBGM-8I>SP+O
MMR;P^^'=T1A6#<,,@CPZT><>\BV4W HQK-%LFIM2'APW?@$H1$L8-7<;@[@;
MCOIF.-;QK<N)8].Q1.S#.2,K<4]%BQ_A4AQ:7\;.6J^7"[,ZG8+"Y'*BC#+O
M<LDG<74'4Z,\@?])(X%XC5ZLL(1O[C*^N^\\OA-MQ%&$D-S=TNHK W$#ZS"Z
MWQA)S$ %AT [PUODC%"_$U;%8GB'Q(9XRX ^Y<HC>J'JIS6W$$-1WEI>'%X/
MI&%<G[+1^.^DE^K;<:S/K79P;Q 8&T[:>Y.K=PSARVM#>-#>5L'<2J+.H97P
MMG=C_D"5_%#]%9VR(9M[0H=E3B^N3OH_4['3/IUK*E]7J4XV,EIL)A^<5Z39
M!TE$UZ7K?W>/FWHTQ?/M,_IE[U)NE HB-DS#;4IK;1=<_!H]7_ E%R!&N\,-
M#9LJ D1*C9T;VDB)ZYK:X$.'P$A0?V\V<>OP1+:Z+LW[4"91ZAF27Y>*M]9*
M].<-XW9UKSW,I>B<03JVSI:U8<0(;TM5[EC4EK&^PIIVN[?11.E.W_;R4?OJ
MY:.\P3^F^']=K?!/OOSQS+3FU4OHV:T]M46AM[/_N/=X+_J4+H3Y<>_D\0\G
MQWN/\&9X_-7+)5P\<#J4FIS%#*\>'7[W;$]J1>Z/MEK2D$ ;;5LM^#]AB*";
M] "^GU55Z_Z@">C@')/WZK\!4$L#!!0    (  >!G50CON,0I08  #</   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;)U7VV[<-A#]%6)K%#9@[T5K
MQZYK&["=-$V!M,%NTCP4?:"DT8H-12HDY?7VZWN&U-Z<6Y&775'DW,Z<&8ZN
MEM9]\#51$(^--OYZ4(?07HY&OJBID7YH6S+8J:QK9,#2+4:^=23+*-3H438>
M/QLU4IG!S55\]\;=7-DN:&7HC1.^:QKI5G>D[?)Z,!FL7\S4H@[\8G1SU<H%
MS2F\:]\XK$8;+:5JR'AEC7!470]N)Y=WIWP^'OA3T=+O/ N.)+?V R]>E=>#
M,3M$FHK &B3^'NB>M&9%<.-CKW.P,<F"N\]K[;_$V!%++CW=6_U>E:&^'EP,
M1$F5['28V>6OU,=SQOH*JWW\%<MT]A2'B\X'V_3"\*!1)OW+QQZ''8&+\1<$
MLEX@BWXG0]'+YS+(FRMGE\+Q:6CCAQAJE(9SRG!2YL%A5T$NW,S(!]<5H7/*
M+*Y& 2IY8U3TXG=)//N"^%2\MB;47KPP)97[\B.XLO$G6_MSEWU5X6WKAF(\
M/1;9.,N^HF^ZB6\:]4W_3WQ"FE+,2,M I;AE/JB@R(N_;G.< D'^_HK%TXW%
MTVCQ]'L1_8;XB_G;V;O[M^]FKWY_*5X9$6H2E?*%U,)381'!QTZZ0$[8"BA-
M+N*)>]NTTJP0H;&=*1!?JZ7Q(EBAFE83ZB@("0V. X:DC%7A\>^L]T(%+UYJ
MF\/*O&M;O1+W-4H:NB7D' EE G&.66-EP4R4I+>=*Z".856F0%/P?/ !"+ ]
M:$WN%PXX<P"%;&6N=$3]6 0J:F.U7:A>A[>Z2UX9@EZ/+L'F&FFZ2C*BE(XE
M!]GEUMD26(O6NE!9K>RQ(%-+ "#D@@VMHD3I4/IB@4R&>BC>PJ7/Q;J&9*FT
MYGAT5Y*@1^!:,GDXD@X! CQF2Z"%*@3J3\O<8IG0A+$<)8GTL(@R"%5RWXF9
M< 1G 8?EC#S"N6-.CK,/_,Z'$]Z@H/B\0?C;6'9QBS9L&U2C_J7HU%X0A@+W
MP>$3ZE3*^;#/G"P[WJ.. [L<9UBR$D!+)T$^BJ*6;A&C/CC/T((T4#;'8EFK
MHA;*KX&"3[U!(&*7'#U3.W(M63%(KRIC[<T#_B(EL?M".H/C"/?@?+PVP-1Q
MNY6$W<FSW5U&C,5["GAF3[FFHFV2QY/3C<AAY6S#IUMRH(67FOP1*[)PSXG#
M)'7$"<>=0\<, KAB ]"#U#^X1J+-5#TM7CTJW H$Y \FPPN1]W9JB73F1&8+
MJ%><1$9A+R2QE'Y;L$,Q)WJ"8)"YYK43LBP54PS.E!2DTGZ-][Y*N+5PLDGI
M9]_W<\S!,5;A&R4 LB[ 06;YTUC'PV>;6'$,ZVWLK,&8+B+6LX>SY.4#)S@U
MDUA=.:&*T72E07UHJ"U)@_4H$)&OHG?$+$\T317[20BV!WAC:Q^)Q-O/92L;
M3O8BR(;3S;JWGDHTS@T]?WM@.<3G:$Y-#LYLG//44X,[I?3>%BKR?*E"O:[(
M=<VF3H':1@-82R%6610855P4*PDAL8HXM_!F@_[6BR8TGG(D#57H""FWG@!F
M;!VNO^X #KF'OGWPD1TW]X'K"X 5.=LMZF^VD4MQ^)S;H(L-_W5"$K4UWSAQ
MZSTZRGM< W1BJ\J/YEQ]XH]4>=E17V:SY"/&+,UBQ^(W='Z^!+(T#X@#,9ED
MXL<?+K))]K/(SL1D>B[N.^>XE:Q(NC3EH;->,J%C_M>G#[/ID?CI3*")W4M?
M Z(0TKWHQ>%D?"2F9^(01_!\CM^+C /@(Z4P2$/!,AM=$^SN+3YQ'8.,TJ(?
M9'#FB)T?;YV?3!'+6=R([O# +%<^%OLV>\RG1/AT\WY2-ZU4)<M^#W$9^)2"
MOH?[3:/K.0!C:/+H4NB6,DX.[![!A%T15GP3,S/3[1@O_^V%QT3#O.(Q'^_2
M:AA1GC'%?01_P8T'_G)'CM7*9/%[-0\UT-'9SFN^I^A!Z@[,36/++M=[CJ])
M'WO$TP&00>%*Q)*O#[E*'"@[XO,1,N30Q+K0<:1)3J5J8>4+Z>)$D"QKH:U9
MD#M!231K!/U^T\K1WBA. =P"8W][5#YLE>RYSUGW756I0C&QX56!&<%]L6NG
M46_!8T/R'].'!2U8)MW3L>!WQYL@/\0X"]IW-&[V<$<\.!L^);-A&5G^TZW'
M.[D[J*EJ]Y)"Q^KX2$[Q+@8J>>Q3K <902_&:OBY<7NT\S'3$$J8/]D\?(*^
M]%VS>;OY*KQ-'T/;X^F3\C4Z@$+$FBJ(CH?G9P/ATF=:6@3;QD^CW 9\:,7'
M&E^VY/@ ]BMKPWK!!C;?RC?_ 5!+ P04    "  '@9U43/$7#S$&  ">$
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M/3Q#8_'Y-9PGT37I!;IP$>_9-,2=&_=5WH#OI7.QG[""X5\2E_\!4$L#!!0
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MT.1L.H[ M%/8&DY7H?,WVM$<A6U!#Q<:[T#W6ZW=WO !^J<P_0M02P,$%
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MPP*UEW\)XQV9QRK/DE(K,)URD%$ ,Y%XZ("6_2H/+*T>'DGLY2^+V[\(8T\
M>XK<XSW"Y7.0+\F9("BFQ)I-D*[YL1R/ R&B553Q4AX$ LPJ_D]T]PQ*;)PQ
MPVR46O?.F.XRT\)0-QO]-K^*8?!9$]\Z8V8+L@MH$_K3??IUG08X$/YUFO;:
MN0])2C>T@W.^\4UZ,^(\=,-[W7E,3,UM5AT(5$7M/HFH ;/^QH"D_.J\5-B/
M62AUDW"\KPZNIC[M\SP,=\E.14GE]!=9@HB[H3STB4*$E,0M2:4<MW%U +XC
M@,,A;RQ(CLU=\\<"LG$\W/JM>!65@8F7@:DO#J6CBS$=/66VHS'3T;\"[$BB
M9->)DCV>**',6.Z@#]U,Z5V4!FD80>*WK:!" EZ4#*Z$FD)"J<CB:"F%=A7$
MV(BX3QGQ4)XU3LZE#.0=$4PEVK\'Z8Y2*J-Z6'1T6@4!P9[!.6E/.2DFB*-E
MAPEL9V2EXM'I4690'K?\SZXT!K*"7G( V_@(XF6P)^5Z!1%6/&^B<"/7;9H\
M@>P08E:A:Q'D^0L=IW$5M+Q,*SY&P6,44QZY:$AM5K;2Z@]E6)"F41G;;86E
M(O9(9,=84$\ZK\Q^S-+UC]#Q1-F3/S5U$[^N;[*)0\Y_HEO&V8AR.[5R.T<K
M]TWMZ-J)5)H5N&\G4Q7O6GH_I,;CB(]RN,L>':\G=<<XXQ%//"S)/?_<<J:M
ML'1;YUX=-R$)>2<)^8<B1-6='2[_? R71QWONS*5N:E2F445TJO:H.\K3YGA
M0Y&<,3UR:SURCZTFJQ(2W*D]Q\T?.WIR6P?/08T91_%G:DFN\#?!&WG.L*S'
M[;3V",J++"2G)826;_G$5]3144KQ,SS;;944EI7DG-WO<DA)8%C*!IEB#_;/
M%#=D."Q* 5X*P2'-?5ZRYZC8,.IX1?$+C(0<!Z(3,4AYXU.F3ST/::>E&90H
M:LA#IY9ME+\'(&:[8ARHK6E(<@%+P]"6?W3&3U5PP?$5Y8H!\ZHHI=.JB=*O
M@X/)-E V7Z6I(TKIU4KIC6I,$Z)+UI'15VX[HK9"T9+;D$:.P_\L QHH3U]D
MON'^)!B9L(S]%!-K_$&#/V[A3U0_:TF$M()GL!_BAR*\"N6!**U"]#L;_>4'
MG!M_XC'3RZM17DWV.2M N/HEJ7Y5<7U><OR82JN5R;N6T1G;J/"Z#85F%RE1
M74*X=F?L^DY)>5V 3%T40MT[?6J:3EL?CJ*V@:'97N_.\_2CZ-6GCFWT[GS7
M[]%L@$JM=P<[1@[<C\]_K3SJLM1I#PWKFUGE>.VAX=5>H>6-;_8\M"QHE8/:
M*R=+YT4^329(@L-M*)N:6"T^^U/;,_NWN+B&6Q+1=@<4,<$X\K@XA(B0?JBX
M3TYNO]ZT/$?^V:C$W\OR!9&&_'TK_),OA N T4M WV*@2BD4@M*/D3]W;9,T
M&-JP@ >)"O:PVVZSO&"7ZYS+%CF;+!XN*56$?MGR:GAV!8_HE-"8[S&83!M+
MFR=0.]>3K/9>182UFB\1>78'41L@:D.?>A<J8RAS)_7N1KX#>:2P$S:!M>TO
M*;L+#PF)<H&#OO"8+N\5A]FD9#E587(J90N*\=N*]=0K2Z2UM9SVQ,')+1<J
M:[/+)?A$0/=TYCYXZ78?)Y9W1OE@%RVI%=!2?(7KE30?""$!A8 X9JVJ'ERH
MG+E,#&1._27DVRJ'W<^&Z.FILJ=$\6-:%F,$?PBVKAK&AX1!\(AW-;0A&.9,
M>L7;*@D(7^]3$=*!YS/I+!8='&F6_AB6"50F;5VQ<"9=1&LM,2DJ>X;$&LBS
MKN4K %#5W[G*.1M?,Y..H2;_U()FEP>6FT]M0SO$@7WJ.E(]+@.8(C\36]7&
MC5]F+5(0WCJ4Z+4H>G14-/QY[",)FU\G;/YH0G77</FAYO)07C8.II67_2"D
M7*??(-U!-H34:XL$7QZJ'_H] U5=,E4OWM2.HU4N+(@R^9Y'#6]:1%8%P"!C
MU/)3T*8;3815=]UGJ"5^_'7V,&,B>^(J7+<C)ER,B5*PAM ;RYTY+#87U#G:
MEK4+"RK_+R@@6WX[/..N^VR1Y0@:9+#+?L F]%/;=J4+I9$N$S]SJD&+[[*4
MOY0"8JM=NB1DMMM&1G?=9Y^CA/!L,Q$5"H'K-&D C=OW#[O'0H8J79MZ5,,X
M5-),7=]G+A(-1*NI:3GLUQ3%4"P#%DE3L>5]]O1#YS1(+DR;&OP(A#0V;9B+
MC[1'=Q"LJZQC4 X-1>W18<89($J&!\N6"9KF-T<)GH(HEOI",5- G=1V\K>G
M1)BCF;C1SJJD"-S6+"+2KO/0;S8<J*0VM30/"$BBVM3T#.*HY<CDRS=4G?B!
MQ[(XAT70SFY "F27DO(,51X%"8:2^2&]*24BZ!V!H%XYO2/@O2T4IH.<HKE0
M4>;R $?:!M_#V8KN,I#N&@U0N&4P5LCK?<V;9I4L*.<>=GKTJA,SYC%UK?DZ
M0CNZ@]<](_4:VN[B3O'Y@$L=1W/X]7Z5[N^@,4F-H6[&['/]%0\;]&K: VZ6
ME.!*-J';'TN4DB*VIYR]0 .4MMN>+2^.)=<$*^K"U4N*39[MUAO4ZT_J"9DQ
M_6_6MJ:JU05/RR?])$^93U^[2K.S*HL;DW[KVQC]R!9'.\>FFO"NU5L8;W*,
MHQB6_/#;#\*;#.(][[UA:UHC_61V0UX!>\,JD)9OK\LW%6'[!<)CF3"KK\,&
MM.G8*#T8F(=Y6X7D\D67-35\5_YZ,LQVIIV9:WY'0SR17_ L 19TF<RP-68X
M#E)@T[6_H_9O>];3#.8A=]1FCJWU9A%;7%N[NV,WNSQC^DPW=?A2#\\]Q&I[
M-K2!&G78\?[J'AM,BZI !T'*159HS!RC3X#-7$1NUS% @+T_Z8-V#P6*,;/Z
MDPX"L>_;].OI6.#W%[C,-S7\60 ],(F<P208IN;2[OY1J!"U?%I@>3Z=?>^P
MW@'N.)([SCY.GY'D3$HA9F8/FDG]%L>5;5*J]>7N/6FBRK$ PO8UK-B3)F91
M#(-GA&!/FB9%PIE]U267"G:+?CT7"M*7 !CD(S'R+1?2[I_'Q(1/C0$#];JY
M+UM3\EB7+$0T-F=6GR(/  S\D2YY@^?U4,$#C:;CO'2@O15(WBB!<W02HMY#
M@ E?A^ZYL!J)H#,)I?'I"PFCA-V9)$8[S':0[LS<_J14/9>R+8T@S/J"L(AD
ML(ZZ#_N@/:@\986DU7V>V27%$.&^RCND(SI)&#2KY,[%O[+WT7<(I\SPIIY-
MIT2:Z S&@'GK4\F$YVOY02A]H0%'I;Z:K)_6'YU>JD\MF^7JBU64#6O*4V*^
MPE8-/#EAN?H(5-T4V59^>/F8%466R.&&!ZCB:0'F5QF.6MX0@OI3W(O_ 5!+
M P04    "  '@9U4)R-(M3<#  #;!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6Q]56UOVC 0_BNGK)I::6H2!RAM 0E8J_5#-];NY<.T#R8YP)IC
M9[93NOWZG9V0,JD@%-MGWSWWW/E\C+;:_+(;1 ?/I51V'&V<JZ[BV.8;++D]
MUQ4J.EEI4W)'HEG'MC+(BV!4RI@ER2 NN5#19!3V%F8RTK630N'"@*W+DIL_
M,Y1Z.X[2:+?Q(-8;YS?BR:CB:WQ$][5:&)+B#J40)2HKM *#JW$T3:]F/:\?
M%+X)W-J]-?A(EEK_\L)=,8X23P@EYLXC<)J><(Y2>B"B\;O%C#J7WG!_O4._
M#;%3+$MN<:[E=U&XS3@:1E#@BM?2/>CM!VSCZ7N\7$L;1M@VNCT605Y;I\O6
MF!B40C4S?V[SL&<P3 X8L-: !=Z-H\#R/7=\,C)Z"\9K$YI?A%"#-9$3RE_*
MHS-T*LC.319-?BUP5< GMT$#,U2X$@X6DM/^Z1>^E&C/1K$C=]XHSEOH60/-
M#D!G<*^5VUBX4046_]O'1+/CRG9<9^PHX+0RYY!D[X EC!W!R[K8LX"7'<![
M0"<,4H6Y7<P6?DR7UAFJE9]''/0Z![W@H'? P5R7E5:$;T&OX",]L04:H0N1
M=TF>:^M>2^U18/]2KVS%<QQ']!0MFB>,)AZ_VN$O6_R<\"W0XP6Z6_"$N/KS
M]LV0I1?7UI<O(1>=MGG)2!5NWU>%#E6Q4VGVA<IE76  76E)3UNH-3G;Q7L%
MM\+F7-)DK(//-3>.0$(EP%[>FQI[M>[>$RPWWA7<"RE]D9X!E8"0T)9 *_6"
ME!X]>Z04B1Q#.N $,MK*^AD,$[BX@#M%W- VR0*6)9!>9L &9 HWSQ7U#R)-
MJ:F- FHD/@/ K45*[.G@\O*,QF%"(VN^::F-$W]YZ#IT[T2$TF_W&,2GN<%"
M.-+O#?S0IR&E;WA&R<GU6HF_Y)*JD/(F*(M2DSL+Z8!!EO: &&9#F-?&<2'+
M4%_^HHB1D]C(*?W"-;/K;CY8("]\3N T(R)I-J O@Y3UX;5W$.\UG!+-.K15
M2UBU<DWOZ7:[SCUM&M:+>M/V[[E9"[IOB2LR3<XO^A&8II4V@M-5:%]+[:@9
MAN6&_GW0> 4Z7VGM=H)WT/V?3?X!4$L#!!0    (  >!G509[H3ZUP(   \&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)55;4_;,!#^*Z=HFEJI
M(FG2M,#:2BVPP30& K9]F/;!32Z-A6-GMD/IO]_9:;M6 K1]2&*?GWONQ7>7
M\4KI1U,B6GBNA#23H+2V/@U#DY58,7.D:I1T4BA=,4M;O0Q-K9'E7JD281Q%
MP[!B7 ;3L9?=ZNE8-59PB;<:3%-53*_G*-1J$O2#K>".+TOK!.%T7+,EWJ/]
M5M]JVH4[EIQ7* U7$C06DV#6/YT/'-X#OG-<F;TUN$@62CVZS54^"2+G$ K,
MK&-@]'G",Q3"$9$;OS><P<ZD4]Q?;]D_^M@IE@4S>*;$#Y[;<A(<!Y!CP1IA
M[]3J$C?QI(XO4\+X-ZQ:;)H$D#7&JFJC3!Y47+9?]KS)PY["<?2*0KQ1B+W?
MK2'OY3FS;#K6:@7:H8G-+7RH7IN<X])=RKW5=,I)STYG6=94C6 6<[BQ)6HX
M4Q5=;^GR_H1P)3-5(70>V$*@Z8Y#2T:=:IAM#,Q; _$K!A*X5M*6!BYDCOFA
M?DC.[CR.MQ[/XS<)9[4^@BCI01S%\1M\R2X#B>=+7N&[^-UPNX:?LX6QFHKD
MUQN<@QWGP',.7N%T.502I36@"OBW'+^4VO^QHCQS=L#,-[<GE#%=.B.IL0Y,
M6"B4H);D<GD*5.!4OA(^41>'G2\>?5'50JT1#X0/RC)Q$-!9HS7*; TW$N8H
ML>#6+<]1\R?F.LZ\&'/GG*PS;<A%N.9"4(<Z>LVD(5[7K_>8-9I;3@2W@L3P
MGE7U![C$?$FB;5VV;GUFLJ&1 G%;%? ..OVH%_5'7>@D],2]412[=3*D=S_I
M1>EQ%[[2S,M*)I?$DZ8#?]*%_G! "B<..#PYZ0+5&Q>0'#"GH[Y##SUUFAP[
M;!*WU*-TU'VIA,*])JU0+_TH,G0IC;1MO^ZDNVDW:YO\+[P=E==,+SEE1&!!
MJM'1* U M^.GW5A5^Y9?*$L#Q"]+FMBH'8#."Z7L=N,,[/X!TS]02P,$%
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M!M6F7,.VF:DY8@#:7 6KIX9,UV)]6RAC=23"1GH?RSD]IR70LICA8@>NW !
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M#:L&648*2D:G+3X$84AGQ!7UT98>(T$04;9FX//BZ7NRTFR+\DL&7=YCRQU
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M.C8&PF1U=W"'O @!"SI(SU'_=AOHM\PO,Q2&5+*+?D".4U<._, V* KW47Y
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M6JU .V]B<Q>^-AY-V7#IVGAK-=WEA+/#2VF9G/,'@3 R!JT!)A/XHE2RXD+
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M,_H:0.T<Z'ZJE%T?G$#]?3'\"U!+ P04    "  '@9U4XZECI3L"  "U!0
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MFV#6MT+H4V#/>G=3I[\!4$L#!!0    (  >!G51OD**"Z00  -H1   9
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MQ^AL#MS[TYF,#O0&YPLRI0]4?EU\X>I=+YUE[,]I*'P6(DXG%YU+XVSH>=&
M..*;3U<B\QI%I3PR]C-Z<SN^Z/2CC&A 1S*:@JA?3W1(@R":2>7Q[WK23GK.
M:&#V]6;VF[AX5<PC$73(@G_\L9Q==+P.&M,)60;RGJT^TG5!=C3?B 4B_HE6
MZ]A^!XV60K+Y>K#*8.Z'R6_RO+X0F0%JGMT#S/4 <WN 53( KP?@N- DL[BL
M:R+)X)RS%>)1M)HM>A%?FWBTJL8/HS8^2*[^ZJMQ<G!#?(Z^D6!)T1TE8LFI
MZI$4J(L>DL8B-D'7E/M/)+K>Z#*Z[+[\A4ZNJ21^(-ZJT*\/U^CDS5OT!ODA
MNO.#0#5(G/>DRB\Z2V^TSN4JR<4LR06C.Q;*F4 ?PC$=Y\?W5%UI<>:FN"M3
M.^'E@K]'??P.F7W3W)'/<)_A5CS<T*2#TVN-X_FLDOD^RQGEZ,0/1VQ.WR+Z
MK#Z+@FHFMM*)K7AB7#)QIC^WH9!\&??P'?I+?8S1R2<F5)>^?U*#T*VD<_%#
M<TH[/:6MK>5RSI:AC,0QC4["5%U!?!Y.1P$1PI_X=(PFG,W1Y>?AK1*&9"BI
M?)<PDI,Y\<FB.\_3H'_>>\JV2A>1J\!)*W"T%0RYRE=]Q#BGX>A7E"#E5$C$
MB:1(K,A"H/]0[9:YZ=G=MEKFI:?TVFQ9<C);TS)=1*Z"T[2"4VT%F9O51SJ>
M^N%4M>AVT[C[J'$/JG'JX ,)J$ J_^062KG07$"C#S?+?EM=,S)W:*-QW]@T
M]'^KKJGC2:>00N,8LB3)6/H\"I;C37?I9$)C>H94?0*DNG;J2NZ\71N5/=:&
MY LVH6#S$ 5'(MV9M5F=M2XDGS7<W W]W7U_<0Z9B*M;<#9>CA1L!0MTN#.
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M&GCAMNI>W.K%(7U"T5Z;,[$@(WK162C-4/Y$.P.DZU#F.?'Z!F<OI;[ X+B
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M]F;_K07,WPXPNY'$AT7 Q[M.J%XV'\WNIO]-P B/&3P-BX5O7RTLACEF;S/
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M21H B(-^('9FBN:NE<$V('&PS\*I .Z* 0NGH@M70Y $@%4,5#4578UJB((
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M+KJ\(O9Z-UEV#JJU>\WG"FDV.#.G:0S:'J#]3"G<.W9 ^/D^_ M02P,$%
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M_?^G35?#^V]V'R%_OVE^[5_C\O]02P,$%     @ !X&=5.[D8^9G @  QP4
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M&W;U^ 1S)8S_PJ:-'9-BOC96U1V8[)K+]L^V71_V ,1S&!!W@/@E8/0*(.D
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MHG8!M%\J97>&$^AG=_874$L#!!0    (  >!G50KCA3\V@,  -$.   9
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M/W74K&SZIG27^-9EU7!##^<Z]SF)WL?A\QL2AJV$X44)<X5@%'<*N*2&16&
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MY>9SI(!62B* YRB!STF21$)U83SWIXQ-!5A'9:%UE _7H=J91/<!.T2AN3%
M=E1N9D<*2,*.3 7(CA*8G51E)-<3P'=4&7Y' <"CLA \RH/PM)6C$ _#TX3
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M<7!R?# Z?1@&WTP6EU^O[RXGMU>?QHMH20%,2W,98PJ(E1:(J%2=>/9QN9W
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M#)):U]V:4)--#829%MI4/4$@PJPOB?,S0*=I@4[KKX^$B@/@F6[+>%:@Q[1
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M/*5;UG?GI_OO#Z/O"YFV+>):#5!*1NB7E2:/391MA&CWV*C-55OH2!78"V"
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MD"HN@U0Q(%6<!:EB#U+ESD^QAZG25:AF %/%N9DJ*6 M2@(2K !4)4@BN70
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M("Y#!#$009R%"&(/$<0.7LX>(,BTH>0 0!#G!H*D@.(2&?! W(<'\@DBN6P
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MW$+Z.I>&"FD3/$8A7S%P&WK$JXF_/Q,/-0(]T<ZRL7#?V&NH51RMXRY QD<
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M6+RFTAO$]444\?U!^H#R&[:K_P!02P,$%     @ !X&=5.%@O=6K P  Y@\
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M&J8\>YG"(,ZD.0#WUT+HEX5)T([VBW\!4$L#!!0    (  >!G50/F7W!^ ,
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M >;^1@A].LD-ZH\[R_\ 4$L#!!0    (  >!G50.8)5M&@,  &81   -
M>&PO<W1Y;&5S+GAM;-U8;4_;,!#^*Y&9)I FTC80FM%4VBHA3=HF)/BP;\AM
MG-228V>.RUI^_7QQDK[@0XP/&RQ5B7V/[[G'=Q<<=5*;C6 W2\9,L"Z%K%.R
M-*;Z&(;U8LE*6I^JBDF+Y$J7U-BI+L*ZTHQF-3B5(AP-!G%84B[)=")7Y55I
MZF"A5M*DY*PW!>[V)4O),#XC@:.;J8REY.[X_<^5,I?O G<_^G!T-+@[N3RT
M'S? "0F]I.?/(#T=X+P6PZCC?>IVN67J/#''BV=I>D)20QRV69U.<B6WR8V(
M,]C(M&3!/14IF5'!YYJ#5TY++C;./ +#0@FE V.K:J4,P5(_.'CH9E#PEJ?D
M4NDFMHO@_L[;Y0= -P.!7(A>X(@XPW1246.8EE=VTBQNC(^@H!W?;BJKL-!T
M,QR=DZU#<[-!YDIG3/=AAJ0S32>"Y2!'\V()=Z.J$$!C5&D'&:>%DK31T'FT
M TN[8$+<P-/P(]_C7N<[-1U 164_M(+:H:-Q$^#?97/<N[2#%_$&%;]7YO/*
M;D<V<^@5=JU9SM?-?)WW C#V(<Y.JTIL/@E>R)*YS3\[X'1".[]@J31_L-&@
M51;6P#0)[IDV?+%K^:5I=<O6IFNG=8YK'KU!S7\WSP633%.Q*]KV_FO.\HL5
M1Q?_2G+S7^50L%=C>\2]=I'G;T%D_!9$OLZ>#-MC9^=LVSO9>FL ;Q I^0[O
M*F(;-)BON#!<MK,ESS(F'QUPEM[0N7V)W..WZS.6TY4PMSV8DNWX&\OXJDSZ
M5=>0B';5=OP5MC>,^]<7&XO+C*U9-FNGNI@WP\ .;-3V H=#Y*JY_ CFXS _
M A@6!U. ^3@O+,[_M)\QNA^'8=K&7F2,^HQ1'^?E0V;-!XOC]TGLY=]IDD11
M'&,9G<V\"F98WN(8OGXV3!MX8'$@TI_E&J\VWB%/]P%6TZ<Z!-LIWHG83O%<
M ^+/&W@DB;_:6!SPP*J ]0[$]\>!GO+[1!%4%=.&/<$XDB08 KWH[]$X1K(3
MP\=?'^PIB:(D\2. ^15$$8; TX@CF +0@"%1U)R#!^=1V)U3X?:7E>EO4$L#
M!!0    (  >!G527BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,
M0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BD
MMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G
M<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^
M=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"
MR0_L?@!02P,$%     @ !X&=5-H<*PYI!   !28   \   !X;"]W;W)K8F]O
M:RYX;6S%FMMNVS@00'^%T%,*;-?6+6V#ND 2;[H!NJT1%WDM&&EL$Z5(+TDY
M;;^^I%QWR<8>[,M43[(H63H:7@Z'TNM';3X_:/V9?>FDLK-LX]SV8C*QS08Z
M;O_46U#^R$J;CCN_:]83NS7 6[L!<)V<%-/I^:3C0F5O7A^NM3"3>$<[:)S0
MRA>&@GL!C_:_XV&7[805#T(*]W66#;\E9*P32G3B&[2S;)HQN]&/?VLCOFGE
MN%PV1DLYR_+]@7LP3C1/BI<!\B-_L$.)XP]WW(/,LO.IO^!*&.N&,X;K<\^X
M W_R?J]W^D9(!V;.';PUNM\*M0Z7\4\QB1YCB,-ANP_BA?D_8=2KE6A@KIN^
M ^7V<30@ Z"R&[&U&5.\@UEVK7=@PO/X&]RV^V=S'BJ*E+D0_H"Y;0<\2A1E
MM12MOWO+KKCDJ@$VA-!&@ 4"6(P&R,X6/((L$<CR-T(N T3X@V5ZQ?[B1D60
M%0)9C09YK;MM!%DCD/6(D)^*"/(<@3P?K[K_[44$^0*!?#$B9!+)EPCDR_&J
MF]M-!/D*@7Q%"[GLNXZ;KP%J*=9*^+]QY=AET^A>N;BZ\RDVDD]I,6_5SI_@
M?0KQT)VC<B&VRZT7NUJ'F[)+:\.0S57+WFK=/@HI8TK,,#FQ8FZX,.R>RQ[8
M/\!M;_:-,,;#W)(3R^56-;H#]I%_22L64TE.[)(%*!O*AOK\X#9@V!4H6 G'
M%E[1,28FDYS8)KZ+]ETOA]%E3QE,9V 3\'<08V(ZR8E]$N8(?BYJV<(3+C?<
M)&280W)BB2QA_7- ONJM4&!_]&'0:Q//OG+,(CFQ1BX;KUTKW,\F.?>U:YUP
MOB\G?0:S2$ZLD7>PYI+YY*D!:$-UQQ-L3!P%L3CN?*A,W_A@>:H8"E-'0:P.
M5+K)]*5 LQ-B=T3296<^U91@G\5LF#@*<G%@]F4Q)N:2@M@E)_1["&>,B;FD
M('8)JKRT06(N*8A=@BHOQ<3$4A"+Y:GRCG8?3"H%L510]Z61Q+12$&LE&;V/
M!;'$W%+^OJ2$G<W!<2%3.,PQY9CI25+#)>:8DMPQ&&898Z)K8&/JYE,58V*Z
M*8EU@V/6,2:FFY)8-Z>L^)R]YR:9>9>8;DIBW9S&'"9P,2:FFY)8-Z<QYV#$
M+L;$E%,2*P>)IK]Z&V-BRBF)E8-B)N-FA;FG(G8/VC933,Q"%;&%3F/>")6L
MI528A:IQ5LD\9EBI_2/&Q"Q4$5L(;YNQ+"OT7<Q(2<]0Z6G;Q"Q4$5LH7GL\
M.G^K,/E4Q/+!4[*DKC'Y5,3RP3'CB5&%R:<B7T3#,L<DFIA\*F+Y',L<CS3,
M&C-/36P>/'6,0UECYJFIU]A0S+AAUIAY:F+SX)CQC+W&S%,3FP==A&;/8TS,
M/#6Q>9XL0Q_O/N@W ,3629<T?F0\X5N>/6J,B>FG)M;/KYC#'+WW>:5OIW?)
MPF6-Z:<>]#,Y?';4>C$H:-_[6UA?WG#9+ P+F_V+TJH.;S%6O937ONR#>J=Y
M>_B*Z? %UIOO4$L#!!0    (  >!G53S((MYZ0$  !(B   :    >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'/-VCM.PT 4A>&M1%X D_N8\%!"14.+V( 5
M)@^1Q)9G$,GNB4(1CD5!@^94UMCR]5]]LL:>OZ1=6[;=(6^V?9X<][M#7C2;
M4OJ'$/)RD_9MONGZ=#A?677#OBWGY; .?;M\;]<IZ'0Z"\//&<WC_.?,R>NI
M3W^9V*U6VV5ZZI8?^W0HOPP.G]WPGC<IE6;RV@[K5!9-..ZNIW.X'.3F/+F9
M/+\MFN'Y39I0.T@A2.L'&019_2"'(*\?%"$HU@^:0="L?M M!-W6#[J#H+OZ
M0?<0=%\_2*8HXY0@:80U@=:"7 N!UX)@"X'8@F0+@=F": N!VH)L"X';@G +
M@=R"= N!W8)X"X'>BGHK@=Z*>BN!WCIZV2;06U%O)=!;46\ET%M1;R706U%O
M)=!;46\ET%M1;R706U%O)=#;4&\CT-M0;R/0VU!O(]#;1ILE!'H;ZFT$>AOJ
M;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>OMH
MLYM ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0.^(>D<"O2/J'0GTCJAW)- [
MHMZ10.^(>D<"O>/H8R6!WA'UC@1Z1]0[_J?>N9QV*5][OM?X_/^DNISO3=?'
M7Y;?)T?L7' .\ O(XQ=02P,$%     @ !X&=5+)H2=C5 0  OR$  !,   !;
M0V]N=&5N=%]4>7!E<UTN>&ULS=I=3X,P% ;@O[)P:T;7K_D1YXUZJU[X!RJ<
M#3*@3=O-^>\M3$TT2EQFXGL#@;;G/;3)<\7EXXNC,-FU31<6616CNV L%!6U
M)N3649=&EM:W)J9'OV+.%&NS(B9FLSDK;!>IB]/8U\BN+F]H:39-G-SNTNM0
MVVZ1>6I"-KG>3^RS%IEQKJD+$],XVW;EEY3I6T*>5@YS0E6[<)(F9.S;A'[D
MYX"W=?=;\KXN:?)@?+PS;9K%=@T+\:6AD(^7^*9'NUS6!96VV+1I21Z<)U.&
MBBBV3;XO>C*>'-,.T_[*C\X?RHP%IID/WKJ03LS3X7'O1]*OGKI4B'RLQS_Q
M(S&5/OK[J#_MDLI?9J?M?;9^/9Q'8,/M^#W^?,8?]0_L0X#T(4'Z4"!]:) ^
MYB!]G(+T<0;2QSE('WR&T@B*J!R%5(YB*D=!E:.HRE%8Y2BN<A18.8JL D56
M@2*K0)%5H,@J4&05*+(*%%D%BJP"15:!(JM$D56BR"I19)4HLDH4626*K!)%
M5HDBJT215:+(JE!D52BR*A19%8JL"D56A2*K0I%5H<BJ4&15*+)J%%DUBJP:
M15:-(JM&D56CR*I19-7_*>N3M>N__J6@O^>MJ;OW?#;\MW'U"E!+ 0(4 Q0
M   (  >!G50'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ !X&=5, 93E?O    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    (  >!G52UU^K;N0(  +8'   8
M  " @;@5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  '
M@9U4Y2@ &?,%  #W&P  &               @(&G&   >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ !X&=5$-D"^@3!   G@X  !@
M         ("!T!X  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   (  >!G51!Z;(7M0(  /0&   8              " @1DC  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  '@9U4ZII5A5$$  " $
M&               @($$)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ !X&=5!<SDOE- @  -04  !@              ("!BRH  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  >!G516</OW50@
M , A   8              " @0XM  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    "  '@9U4:E7F)ED&  #)#P  &0              @(&9
M-0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  >!G512
M[:3K: (   X%   9              " @2D\  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ !X&=5'ZZ<W*=!@  M@\  !D
M     ("!R#X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M"  '@9U4Y*9?2)P6  !R2@  &0              @(&<10  >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  >!G51,LC_P: 4  /D+   9
M              " @6]<  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!
M A0#%     @ !X&=5.,(>P68!   . H  !D              ("!#F(  'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  '@9U4) 5Y;!($
M   T"0  &0              @('=9@  >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;%!+ 0(4 Q0    (  >!G51O00)!70,  ' '   9              "
M@29K  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ !X&=
M5,V7S3:A#P  >"4  !D              ("!NFX  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    "  '@9U4Q]"PI,4"  #*!0  &0
M        @(&2?@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   (  >!G52*YP\%#2<   "&   9              " @8Z!  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ !X&=5".^XQ"E!@  -P\
M !D              ("!TJ@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    "  '@9U43/$7#S$&  ">$   &0              @(&NKP
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  >!G527>.:I
M:P(  !8%   9              " @1:V  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ !X&=5+F/*2A\!0  [@P  !D
M ("!N+@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  '
M@9U4DC4D?1<-  "6*P  &0              @(%KO@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  >!G50G(TBU-P,  -L&   9
M          " @;G+  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#
M%     @ !X&=5!GNA/K7 @  #P8  !D              ("!)\\  'AL+W=O
M<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  '@9U4I;M+]?D"  "L
M!@  &0              @($UT@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;%!+ 0(4 Q0    (  >!G50Y8_<J\P\  %LF   9              " @675
M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ !X&=5&06
MM%^& P  3 <  !D              ("!C^4  'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6Q02P$"% ,4    "  '@9U4:U%#VVH"   [!@  &0
M    @(%,Z0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M  >!G5028#0E%00   P0   9              " @>WK  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ !X&=5+M]E;>/ P  30X  !D
M             ("!.?   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    "  '@9U4%N:9WM8"  !K"   &0              @('_\P  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  >!G53CJ6.E.P(
M +4%   9              " @0SW  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ !X&=5&^0HH+I!   VA$  !D              ("!
M?OD  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  '@9U4
M)@A^P9T'   2/   &0              @(&>_@  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    (  >!G51(W[9-L0(  !4'   9
M      " @7(& 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ !X&=5#@2S.2P @  ) 8  !D              ("!6@D! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  '@9U4CE]^"SH#  !""@
M&0              @(%!# $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    (  >!G51PXP+WB ,  &(,   9              " @;(/ 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ !X&=5([)&VPG
M"   ?#8  !D              ("!<1,! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    "  '@9U4AO_H]Y4'  "%-P  &0
M@('/&P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  >!
MG53LDCXZE@(  .L'   9              " @9LC 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ !X&=5-4<!P?5#@  /X   !D
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M=#0Y+GAM;%!+ 0(4 Q0    (  >!G50!NGVQ70,  +<)   9
M  " @35# 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M!X&=5$H1)^(/)   @$T! !D              ("!R48! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    "  '@9U47.Q"QDH%  "8%P  &0
M            @($/:P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    (  >!G50U3!0@I@,  -<-   9              " @9!P 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ !X&=5+(P:5\Y @
MT00  !D              ("!;70! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    "  '@9U4=25D<28'  #/)@  &0              @('=
M=@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (  >!G53A
M8+W5JP,  .8/   9              " @3I^ 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ !X&=5 ^9?<'X P  Z!$  !D
M     ("!'((! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M"  '@9U4#F"5;1H#  !F$0  #0              @ %+A@$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    (  >!G527BKL<P    !,"   +              "
M 9") 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (  >!G53:'"L.:00   4F   /
M              "  7F* 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  '
M@9U4\R"+>>D!   2(@  &@              @ $/CP$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  '@9U4LFA)V-4!  "_(0  $P
M            @ $PD0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     00!!
+ +X1   VDP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>634</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>178</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1008009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124105 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Pensions and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlans</Role>
      <ShortName>Pensions and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - Segments of Business and Geographic Areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</Role>
      <ShortName>Segments of Business and Geographic Areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2141110 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2146112 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</Role>
      <ShortName>Pensions and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables</Role>
      <ShortName>Segments of Business and Geographic Areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2347308 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Restructuring</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill By Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails</Role>
      <ShortName>Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2425416 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Pensions and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/LegalProceedings</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="jnj-20220403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="jnj-20220403.htm">jnj-20220403.htm</File>
    <File>a20221qex311ceocertificati.htm</File>
    <File>a20221qex312cfocertificati.htm</File>
    <File>a20221qex321ceocertificati.htm</File>
    <File>a20221qex322cfocertificati.htm</File>
    <File>jnj-20220403.xsd</File>
    <File>jnj-20220403_cal.xml</File>
    <File>jnj-20220403_def.xml</File>
    <File>jnj-20220403_lab.xml</File>
    <File>jnj-20220403_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20220403_g1.jpg</File>
    <File>jnj-20220403_g2.jpg</File>
    <File>jnj-20220403_g3.jpg</File>
    <File>jnj-20220403_g4.jpg</File>
    <File>jnj-20220403_g5.jpg</File>
    <File>jnj-20220403_g6.jpg</File>
    <File>jnj-20220403_g7.jpg</File>
    <File>jnj-20220403_g8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1150">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "jnj-20220403.htm": {
   "axisCustom": 0,
   "axisStandard": 32,
   "contextCount": 634,
   "dts": {
    "calculationLink": {
     "local": [
      "jnj-20220403_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20220403_def.xml"
     ]
    },
    "inline": {
     "local": [
      "jnj-20220403.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20220403_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20220403_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20220403.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 627,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 39,
   "keyStandard": 260,
   "memberCustom": 109,
   "memberStandard": 61,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20220403",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.jnj.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Inventories",
     "role": "http://www.jnj.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Measurements",
     "role": "http://www.jnj.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124105 - Disclosure - Income Taxes",
     "role": "http://www.jnj.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Pensions and Other Benefit Plans",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlans",
     "shortName": "Pensions and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Accumulated Other Comprehensive Income",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome",
     "shortName": "Accumulated Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Earnings Per Share",
     "role": "http://www.jnj.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - Segments of Business and Geographic Areas",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas",
     "shortName": "Segments of Business and Geographic Areas",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141110 - Disclosure - Acquisitions and Divestitures",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Legal Proceedings",
     "role": "http://www.jnj.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146112 - Disclosure - Restructuring",
     "role": "http://www.jnj.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Inventories (Tables)",
     "role": "http://www.jnj.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables",
     "shortName": "Pensions and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.jnj.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables",
     "shortName": "Segments of Business and Geographic Areas (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347308 - Disclosure - Restructuring (Tables)",
     "role": "http://www.jnj.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Inventories (Details)",
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "if6d5ec7bb88b49bb9225ff6447a06091_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails",
     "shortName": "Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2a4f1c2e35354c268ad4b4f0c299f46c_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
     "shortName": "Fair Value Measurements - Summary of Derivative Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i75b7f48faa4c44dd8729fef7add9958e_D20220103-20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
     "shortName": "Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i92ed1d2317744e2fbc2c3b45e1b4d2e2_I20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i0dc14e7b1e2e4a29877dd2b95650a3ac_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i0dc14e7b1e2e4a29877dd2b95650a3ac_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Earnings",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "shortName": "Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:SalesRevenueGoodsNetPercentToSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i6f4dbad0006c47f48dad1e81741750fc_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i80cc25f225c142c9b2e51f9cc136f5e5_I20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425416 - Disclosure - Income Taxes (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "ib26b9864809e47f28ea10c1582de92e6_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "ifd9afdfa4aab43f5aec11564a7a210ec_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Pensions and Other Benefit Plans (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
     "shortName": "Pensions and Other Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "ifd9afdfa4aab43f5aec11564a7a210ec_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "if6d5ec7bb88b49bb9225ff6447a06091_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i655ff821171a4447a9788502f3181ca5_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.jnj.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInOperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesByGeographicArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "if894d62118864420a5c2c56cb58ec015_D20210104-20210404",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "if894d62118864420a5c2c56cb58ec015_D20210104-20210404",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Legal Proceedings (Details)",
     "role": "http://www.jnj.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i2e490e1b4676470caee65dbdb296781b_I20220403",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.jnj.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "ic71f1704f9cc4887aecf9df02c808339_D20220103-20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)",
     "role": "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
     "shortName": "Restructuring - Schedule of Restructuring Reserve (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i1e4afcfd6d8e427c8043eca9ef363498_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "iccce36176b41451cb72ade5fd7acd620_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Equity",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "idab9077c64f34317815b7b3af8096958_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20220403.htm",
      "contextRef": "i7a528fe6cb5a4967834d097595692bdb_D20220103-20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 178,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "CHINA"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.650% Notes Due 2024 [Member]",
        "label": "0.650% Notes Due 2024 [Member]",
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.1311)",
        "verboseLabel": "0.650% Notes Due May 2024"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0550NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.550 Notes due 2025",
        "label": "0.550 Notes due 2025 [Member]",
        "terseLabel": "0.55% Notes due 2025"
       }
      }
     },
     "localname": "A0550NotesDue2025Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A095NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "terseLabel": "0.95% Notes due 2027"
       }
      }
     },
     "localname": "A095NotesDue2027Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.150% Notes Due 2028 [Member]",
        "label": "1.150% Notes Due 2028 [Member]",
        "terseLabel": "1.150% Notes due 2028 (750MM Euro 1.1311)",
        "verboseLabel": "1.150% Notes Due November 2028"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.650% Notes Due 2035 [Member]",
        "label": "1.650% Notes Due 2035 [Member]",
        "terseLabel": "1.650% Notes due 2035 (1.5B Euro 1.1311)",
        "verboseLabel": "1.650% Notes Due May 2035"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1300NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.300% Notes due 2030",
        "label": "1.300% Notes due 2030 [Member]",
        "terseLabel": "1.30% Notes due 2030"
       }
      }
     },
     "localname": "A1300NotesDue2030Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2026 [Member]",
        "label": "2.45% Notes due 2026 [Member]",
        "terseLabel": "2.45% Notes due 2026"
       }
      }
     },
     "localname": "A2.45Notesdue2026Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.625Notesdue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.625 Notes due 2025 [Member]",
        "label": "2.625 Notes due 2025 [Member]",
        "terseLabel": "2.625% Notes due 2025"
       }
      }
     },
     "localname": "A2.625Notesdue2025Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.900Notesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.900% Notes due 2028 [Member]",
        "label": "2.900% Notes due 2028 [Member]",
        "terseLabel": "2.90%\u00a0Notes due 2028"
       }
      }
     },
     "localname": "A2.900Notesdue2028Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Notes due 2027 [Member]",
        "label": "2.95% Notes due 2027 [Member]",
        "terseLabel": "2.95% Notes due 2027"
       }
      }
     },
     "localname": "A2.95Notesdue2027Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A210NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "terseLabel": "2.10% Notes due 2040"
       }
      }
     },
     "localname": "A210NotesDue2040Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2250NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "terseLabel": "2.25% Notes due 2050"
       }
      }
     },
     "localname": "A2250NotesDue2050Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2450NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "terseLabel": "2.45% Notes due 2060"
       }
      }
     },
     "localname": "A2450NotesDue2060Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.375Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes due 2023 [Member]",
        "label": "3.375% Notes due 2023 [Member]",
        "terseLabel": "3.375% Notes due 2023"
       }
      }
     },
     "localname": "A3.375Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.400Notesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.400% Notes due 2038 [Member]",
        "label": "3.400% Notes due 2038 [Member]",
        "terseLabel": "3.40%\u00a0Notes due 2038"
       }
      }
     },
     "localname": "A3.400Notesdue2038Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.500Notesdue2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.500% Notes due 2048 [Member]",
        "label": "3.500% Notes due 2048 [Member]",
        "terseLabel": "3.50% Notes due 2048"
       }
      }
     },
     "localname": "A3.500Notesdue2048Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2036 [Member]",
        "label": "3.55% Notes due 2036 [Member]",
        "terseLabel": "3.55% Notes due 2036"
       }
      }
     },
     "localname": "A3.55Notesdue2036Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.625Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2037 [Member]",
        "label": "3.625% Notes due 2037 [Member]",
        "terseLabel": "3.625% Notes due 2037"
       }
      }
     },
     "localname": "A3.625Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.70Notesdue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes due 2046 [Member]",
        "label": "3.70% Notes due 2046 [Member]",
        "terseLabel": "3.70% Notes due 2046"
       }
      }
     },
     "localname": "A3.70Notesdue2046Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.75Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.75% Notes due 2047 [Member]",
        "label": "3.75% Notes due 2047 [Member]",
        "terseLabel": "3.75% Notes due 2047"
       }
      }
     },
     "localname": "A3.75Notesdue2047Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.375Notesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Notes due 2033 [Member]",
        "label": "4.375% Notes due 2033 [Member]",
        "terseLabel": "4.375% Notes due 2033"
       }
      }
     },
     "localname": "A4.375Notesdue2033Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Debentures due 2040 [Member]",
        "label": "4.50% Debentures due 2040 [Member]",
        "terseLabel": "4.50% Debentures due 2040"
       }
      }
     },
     "localname": "A4.50Debenturesdue2040Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Notes due 2043 [Member]",
        "label": "4.50% Notes due 2043 [Member]",
        "terseLabel": "4.50% Notes due 2043"
       }
      }
     },
     "localname": "A4.50Notesdue2043Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.85Notesdue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.85% Notes due 2041 [Member]",
        "label": "4.85% Notes due 2041 [Member]",
        "terseLabel": "4.85% Notes due 2041"
       }
      }
     },
     "localname": "A4.85Notesdue2041Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Debentures due 2033 [Member]",
        "label": "4.95% Debentures due 2033 [Member]",
        "terseLabel": "4.95% Debentures due 2033"
       }
      }
     },
     "localname": "A4.95Debenturesdue2033Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Notes Due 2024 [Member]",
        "label": "5.50% Notes Due 2024 [Member]",
        "terseLabel": "5.50% Notes due 2024 (500 MM GBP 1.3485)",
        "verboseLabel": "5.50% Notes Due November 2024"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.85% Debentures due 2038 [Member]",
        "label": "5.85% Debentures due 2038 [Member]",
        "terseLabel": "5.85% Debentures due 2038"
       }
      }
     },
     "localname": "A5.85Debenturesdue2038Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.95Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes due 2037 [Member]",
        "label": "5.95% Notes due 2037 [Member]",
        "terseLabel": "5.95% Notes due 2037"
       }
      }
     },
     "localname": "A5.95Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.73Debenturesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.73% Debentures due 2023 [Member]",
        "label": "6.73% Debentures due 2023 [Member]",
        "terseLabel": "6.73% Debentures due 2023"
       }
      }
     },
     "localname": "A6.73Debenturesdue2023Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.95Notesdue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.95% Notes due 2029 [Member]",
        "label": "6.95% Notes due 2029 [Member]",
        "terseLabel": "6.95% Notes due 2029"
       }
      }
     },
     "localname": "A6.95Notesdue2029Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ADVANCEDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVANCED [Member]",
        "label": "ADVANCED [Member]",
        "terseLabel": "ADVANCED"
       }
      }
     },
     "localname": "ADVANCEDMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.",
        "label": "Accrued Rebates Returns And Promotions",
        "verboseLabel": "Accrued rebates, returns and promotions"
       }
      }
     },
     "localname": "AccruedRebatesReturnsAndPromotions",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AmountPrepaidAndDueToManufacturers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Prepaid and Due to Manufacturers",
        "label": "Amount Prepaid and Due to Manufacturers",
        "terseLabel": "Amount prepaid and due to manufacturers"
       }
      }
     },
     "localname": "AmountPrepaidAndDueToManufacturers",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AsiaPacificAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia-Pacific, Africa [Member]",
        "label": "Asia-Pacific, Africa [Member]",
        "terseLabel": "Asia-Pacific, Africa"
       }
      }
     },
     "localname": "AsiaPacificAfricaMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASR.",
        "label": "ASR [Member]",
        "terseLabel": "ASR"
       }
      }
     },
     "localname": "AsrMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AssetWriteoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-off [Member]",
        "label": "Asset Write-off [Member]",
        "terseLabel": "Asset Write-offs/Sales"
       }
      }
     },
     "localname": "AssetWriteoffMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AurisHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auris Health",
        "label": "Auris Health [Member]",
        "terseLabel": "Auris Health"
       }
      }
     },
     "localname": "AurisHealthMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Care [Member]",
        "label": "Baby Care [Member]",
        "terseLabel": "Baby Care"
       }
      }
     },
     "localname": "BabyCareMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyPowderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Powder [Member]",
        "label": "Baby Powder [Member]",
        "terseLabel": "Baby Powder"
       }
      }
     },
     "localname": "BabyPowderMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BeautyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beauty [Member]",
        "label": "Beauty [Member]",
        "terseLabel": "Skin Health/Beauty"
       }
      }
     },
     "localname": "BeautyMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BermekimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bermekimab [Member]",
        "label": "bermekimab [Member]",
        "terseLabel": "bermekimab"
       }
      }
     },
     "localname": "BermekimabMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONCERTA/Methylphenidate [Member]",
        "label": "CONCERTA/Methylphenidate [Member]",
        "terseLabel": "CONCERTA / methylphenidate"
       }
      }
     },
     "localname": "CONCERTAMethylphenidateMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONSUMERHEALTHAndPHARMACEUTICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONSUMER HEALTH and PHARMACEUTICAL",
        "label": "CONSUMER HEALTH and PHARMACEUTICAL [Member]",
        "terseLabel": "CONSUMER HEALTH and PHARMACEUTICAL [Member]"
       }
      }
     },
     "localname": "CONSUMERHEALTHAndPHARMACEUTICALMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONTACT LENSES/OTHER [Member]",
        "label": "CONTACT LENSES/OTHER [Member]",
        "terseLabel": "CONTACT LENSES / OTHER"
       }
      }
     },
     "localname": "CONTACTLENSESOTHERMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular/Metabolism/Other [Member]",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "terseLabel": "Cardiovascular / Metabolism / Other"
       }
      }
     },
     "localname": "CardiovascularMetabolismOtherMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Total cash, cash equivalents and current marketable securities, Unrecognized Loss"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ConsumerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer.",
        "label": "Consumer [Member]",
        "terseLabel": "CONSUMER HEALTH"
       }
      }
     },
     "localname": "ConsumerMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ContactLensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contact Lenses",
        "label": "Contact Lenses [Member]",
        "terseLabel": "Contact Lenses"
       }
      }
     },
     "localname": "ContactLensesMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CostOfGoodsSoldPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods sold percent to sales.",
        "label": "Cost Of Goods Sold Percent To Sales",
        "terseLabel": "Cost of products sold percent to sales"
       }
      }
     },
     "localname": "CostOfGoodsSoldPercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_DARZALEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARZALEX [Member]",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX"
       }
      }
     },
     "localname": "DARZALEXMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DePuyASRU.S.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy ASR U.S. [Member]",
        "label": "DePuy ASR U.S. [Member]",
        "terseLabel": "DePuy ASR U.S."
       }
      }
     },
     "localname": "DePuyASRU.S.Member",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EDURANTrilpivirineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EDURANT/rilpivirine [Member]",
        "label": "EDURANT/rilpivirine [Member]",
        "terseLabel": "EDURANT / rilpivirine"
       }
      }
     },
     "localname": "EDURANTrilpivirineMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ERLEADAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ERLEADA",
        "label": "ERLEADA [Member]",
        "terseLabel": "ERLEADA"
       }
      }
     },
     "localname": "ERLEADAMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityFairValueAdjustmentImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Impairment Loss",
        "label": "Equity, Fair Value Adjustment, Impairment Loss",
        "terseLabel": "Equity, fair value adjustment, impairment loss"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentImpairmentLoss",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "terseLabel": "Equity Investment [Roll Forward]"
       }
      }
     },
     "localname": "EquityInvestmentRollForward",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "terseLabel": "Sales/ Purchases/Other"
       }
      }
     },
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments with Readily Determinable Value [Member]",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments with readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments without Readily Determinable Value [Member]",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments without readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EvraAndDoxilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evra and Doxil",
        "label": "Evra and Doxil [Member]",
        "terseLabel": "Evra and Doxil"
       }
      }
     },
     "localname": "EvraAndDoxilMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExcessOfFairValueOverCarryingValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of fair value over carrying value of debt.",
        "label": "Excess Of Fair Value Over Carrying Value Of Debt",
        "terseLabel": "Excess of the estimated fair value over the carrying value of debt"
       }
      }
     },
     "localname": "ExcessOfFairValueOverCarryingValueOfDebt",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "terseLabel": "Changes in estimated fair value (6)"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_GENERALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GENERAL [Member]",
        "label": "GENERAL [Member]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "GENERALMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GrossProfitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross profit percent to sales.",
        "label": "Gross Profit Percent To Sales",
        "totalLabel": "Gross Profit Percent To Sales"
       }
      }
     },
     "localname": "GrossProfitPercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_HIPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIPS [Member]",
        "label": "HIPS [Member]",
        "terseLabel": "HIPS"
       }
      }
     },
     "localname": "HIPSMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IMBRUVICAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMBRUVICA [Member]",
        "label": "IMBRUVICA [Member]",
        "terseLabel": "IMBRUVICA"
       }
      }
     },
     "localname": "IMBRUVICAMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "terseLabel": "INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA"
       }
      }
     },
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVOKANAINVOKAMETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVOKANA/INVOKAMET [Member]",
        "label": "INVOKANA/INVOKAMET [Member]",
        "terseLabel": "INVOKANA / INVOKAMET"
       }
      }
     },
     "localname": "INVOKANAINVOKAMETMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales",
        "totalLabel": "Earnings before provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_IncomeTaxExpenseBenefitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense benefit percent to sales.",
        "label": "Income Tax Expense Benefit Percent To Sales",
        "terseLabel": "Provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitPercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Diseases [Member]",
        "label": "Infectious Diseases [Member]",
        "terseLabel": "Infectious Diseases"
       }
      }
     },
     "localname": "InfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterestExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense percent to sales.",
        "label": "Interest Expense Percent To Sales",
        "terseLabel": "Interest expense, net of portion capitalized percent to sales"
       }
      }
     },
     "localname": "InterestExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Expense Net Member.",
        "label": "Interest Income Expense Net Member",
        "verboseLabel": "Interest (income)/Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Solutions [Member]",
        "label": "Interventional Solutions [Member]",
        "verboseLabel": "Interventional Solutions"
       }
      }
     },
     "localname": "InterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InvestmentIncomeInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income interest percent to sales.",
        "label": "Investment Income Interest Percent To Sales",
        "terseLabel": "Interest income percent to sales"
       }
      }
     },
     "localname": "InvestmentIncomeInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InvokanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invokana [Member]",
        "label": "Invokana [Member]",
        "terseLabel": "Invokana"
       }
      }
     },
     "localname": "InvokanaMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_KNEESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KNEES [Member]",
        "label": "KNEES [Member]",
        "terseLabel": "KNEES"
       }
      }
     },
     "localname": "KNEESMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalProceedingTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Proceeding Textuals Abstract.",
        "label": "Legal Proceeding (Textuals) [Abstract]",
        "terseLabel": "Legal Proceeding (Textuals)"
       }
      }
     },
     "localname": "LegalProceedingTextualsAbstract",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Axis]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesAxis",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Domain]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesDomain",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LossContingencyEstimateOfAdditionalPossibleLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Additional Possible Loss",
        "label": "Loss Contingency, Estimate of Additional Possible Loss",
        "terseLabel": "Loss contingency, estimate of additional possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfAdditionalPossibleLoss",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Claims within Settlement Agreement",
        "label": "Loss Contingency, Number of Claims within Settlement Agreement",
        "terseLabel": "Number of claims within settlement agreement"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimsWithinSettlementAgreement",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyReserveEstablishedWithinTrust": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reserve Established within Trust",
        "label": "Loss Contingency, Reserve Established within Trust",
        "terseLabel": "Reserve established"
       }
      }
     },
     "localname": "LossContingencyReserveEstablishedWithinTrust",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_MedicalDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Devices [Member]",
        "label": "Medical Devices [Member]",
        "terseLabel": "MEDTECH(3)",
        "verboseLabel": "MedTech"
       }
      }
     },
     "localname": "MedicalDevicesMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NetIncomeAttributableToParentPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income Attributable to Parent Percent to Sales",
        "label": "Net Income Attributable to Parent Percent to Sales",
        "totalLabel": "Net earnings percent to sales"
       }
      }
     },
     "localname": "NetIncomeAttributableToParentPercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neuroscience [Member]",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NotesDuePeriodFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes due period fifteen.",
        "label": "Notes Due Period Fifteen Member",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "NotesDuePeriodFifteenMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Numberofpatientsinsettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "terseLabel": "Number of patients in settlement"
       }
      }
     },
     "localname": "Numberofpatientsinsettlement",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_OPSUMITMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPSUMIT [Member]",
        "label": "OPSUMIT [Member]",
        "terseLabel": "OPSUMIT"
       }
      }
     },
     "localname": "OPSUMITMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTC [Member]",
        "label": "OTC [Member]",
        "terseLabel": "OTC [Member]"
       }
      }
     },
     "localname": "OTCMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTHER NEUROSCIENCE [Member]",
        "label": "OTHER NEUROSCIENCE [Member]",
        "terseLabel": "OTHER NEUROSCIENCE"
       }
      }
     },
     "localname": "OTHERNEUROSCIENCEMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "label": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "terseLabel": "Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI"
       }
      }
     },
     "localname": "OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpioidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid",
        "label": "opioid [Member]",
        "terseLabel": "Opioid"
       }
      }
     },
     "localname": "OpioidMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OralCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Care [Member]",
        "label": "Oral Care [Member]",
        "terseLabel": "Oral Care"
       }
      }
     },
     "localname": "OralCareMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OrthopaedicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orthopaedics [Member]",
        "label": "Orthopaedics [Member]",
        "terseLabel": "Orthopaedics"
       }
      }
     },
     "localname": "OrthopaedicsMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "negatedTerseLabel": "Prior service cost amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "negatedTerseLabel": "Gain (loss) amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "OTHER IMMUNOLOGY"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense Net [Member]",
        "label": "Other Income Expense Net [Member]",
        "terseLabel": "Other (income) expense",
        "verboseLabel": "Other Income Expense Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Infectious Diseases [Member]",
        "label": "Other Infectious Diseases [Member]",
        "terseLabel": "OTHER INFECTIOUS DISEASES("
       }
      }
     },
     "localname": "OtherInfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherNonOperatingIncomeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non operating income expense percent to sales.",
        "label": "Other Non Operating Income Expense Percent To Sales",
        "terseLabel": "Other (income) expense, net percent to sales"
       }
      }
     },
     "localname": "OtherNonOperatingIncomeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "OTHER ONCOLOGY"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "terseLabel": "PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA"
       }
      }
     },
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And Trademarks [Member]",
        "label": "Patents And Trademarks [Member]",
        "terseLabel": "Patents And Trademarks"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PaymentsForRestructuringNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Restructuring, Net",
        "label": "Payments for Restructuring, Net",
        "negatedTerseLabel": "Cash settlements"
       }
      }
     },
     "localname": "PaymentsForRestructuringNet",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_PelvicMeshesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pelvic meshes.",
        "label": "Pelvic Meshes [Member]",
        "terseLabel": "Pelvic Meshes"
       }
      }
     },
     "localname": "PelvicMeshesMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PercentageChangeInOperatingIncomeLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in operating income loss.",
        "label": "Percentage Change in Operating Income Loss",
        "terseLabel": "Percentage Change in Operating Income Loss"
       }
      }
     },
     "localname": "PercentageChangeInOperatingIncomeLoss",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesByGeographicArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by geographic area.",
        "label": "Percentage Change In Sales By Geographic Area",
        "terseLabel": "Percentage Change In Sales By Geographic Area"
       }
      }
     },
     "localname": "PercentageChangeInSalesByGeographicArea",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by segment of business.",
        "label": "Percentage Change In Sales By Segment Of Business",
        "terseLabel": "Percent Change (as a percent)"
       }
      }
     },
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical.",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "PHARMACEUTICAL"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PhysiomeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physiomesh [Member]",
        "label": "Physiomesh [Member]",
        "terseLabel": "Physiomesh"
       }
      }
     },
     "localname": "PhysiomeshMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Acetabular cup system.",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "terseLabel": "Pinnacle Acetabular Cup System"
       }
      }
     },
     "localname": "PinnacleAcetabularCupSystemMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability contingency number of claimant.",
        "label": "Product Liability Contingency Number Of Claimant",
        "terseLabel": "Product liability contingency, number of claimants"
       }
      }
     },
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_PulmonaryHypertensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pulmonary Hypertension [Member]",
        "label": "Pulmonary Hypertension [Member]",
        "terseLabel": "Pulmonary Hypertension"
       }
      }
     },
     "localname": "PulmonaryHypertensionMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased In-Process Research And Development [Member]",
        "label": "Purchased In-Process Research And Development [Member]",
        "terseLabel": "Purchased In-Process Research And Development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RISPERDALCONSTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RISPERDAL CONSTA [Member]",
        "label": "RISPERDAL CONSTA [Member]",
        "terseLabel": "RISPERDAL CONSTA"
       }
      }
     },
     "localname": "RISPERDALCONSTAMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member]",
        "label": "Remicade [Member]",
        "terseLabel": "REMICADE"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense excluding acquired in process cost percent to sales.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost Percent To Sales",
        "terseLabel": "Research and development expense percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ResearchAndDevelopmentInProcessPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "research and development in process percent to sales",
        "label": "Research and development in process percent to sales",
        "terseLabel": "In-process research and development percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessPercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RestructuringandRelatedCostExpectedFutureSavings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Expected Future Savings",
        "label": "Restructuring and Related Cost, Expected Future Savings",
        "terseLabel": "Cost savings expected"
       }
      }
     },
     "localname": "RestructuringandRelatedCostExpectedFutureSavings",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_Restructuringchargepercenttosales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring charge percent to sales",
        "label": "Restructuring charge percent to sales",
        "terseLabel": "Restructuring charge percent to sales"
       }
      }
     },
     "localname": "Restructuringchargepercenttosales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RisperdalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risperdal.",
        "label": "Risperdal [Member]",
        "terseLabel": "Risperdal"
       }
      }
     },
     "localname": "RisperdalMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPINEOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINE &amp; OTHER [Member]",
        "label": "SPINE &amp; OTHER [Member]",
        "terseLabel": "SPINE, SPORTS &amp; OTHER"
       }
      }
     },
     "localname": "SPINEOTHERMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SURGICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SURGICAL [Member]",
        "label": "SURGICAL [Member]",
        "terseLabel": "SURGICAL"
       }
      }
     },
     "localname": "SURGICALMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales by segment of business.",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "terseLabel": "Sales By Segment Of Business"
       }
      }
     },
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SalesRevenueGoodsNetPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales revenue goods net percentage to sales.",
        "label": "Sales Revenue Goods Net Percent To Sales",
        "terseLabel": "Sales to customers percent to sales"
       }
      }
     },
     "localname": "SalesRevenueGoodsNetPercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SellingGeneralAndAdministrativeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling general and administrative expense percent to sales.",
        "label": "Selling General And Administrative Expense Percent To Sales",
        "terseLabel": "Selling marketing and administrative expenses percent to sales"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "negatedTerseLabel": "Less: shares which could be repurchased under treasury stock method"
       }
      }
     },
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_SimponiSimponiAriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi/Simponi Aria [Member]",
        "label": "Simponi/Simponi Aria [Member]",
        "terseLabel": "SIMPONI / SIMPONI ARIA"
       }
      }
     },
     "localname": "SimponiSimponiAriaMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StelaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stelara [Member]",
        "label": "Stelara [Member]",
        "terseLabel": "STELARA"
       }
      }
     },
     "localname": "StelaraMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SupplyChainMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Chain",
        "label": "Supply Chain [Member]",
        "terseLabel": "Supply Chain"
       }
      }
     },
     "localname": "SupplyChainMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery [Member]",
        "label": "Surgery [Member]",
        "terseLabel": "Surgery"
       }
      }
     },
     "localname": "SurgeryMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgicalMeshProductsMarketingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Mesh Products Marketing",
        "label": "Surgical Mesh Products Marketing [Member]",
        "terseLabel": "Surgical Mesh Products Marketing"
       }
      }
     },
     "localname": "SurgicalMeshProductsMarketingMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TRAUMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRAUMA [Member]",
        "label": "TRAUMA [Member]",
        "terseLabel": "TRAUMA"
       }
      }
     },
     "localname": "TRAUMAMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TalcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Talc [Member]",
        "label": "Talc [Member]",
        "terseLabel": "Talc"
       }
      }
     },
     "localname": "TalcMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfaya",
        "label": "Tremfya [Member]",
        "terseLabel": "TREMFYA"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UNITEDSTATESExportsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES Exports [Member]",
        "label": "UNITED STATES Exports [Member]",
        "terseLabel": "U.S. Exports"
       }
      }
     },
     "localname": "UNITEDSTATESExportsMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UPTRAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPTRAVI [Member]",
        "label": "UPTRAVI [Member]",
        "terseLabel": "UPTRAVI"
       }
      }
     },
     "localname": "UPTRAVIMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision[Member]",
        "label": "Vision [Member]",
        "terseLabel": "Vision"
       }
      }
     },
     "localname": "VisionMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Hemisphere, excluding U.S. [Member]",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "terseLabel": "Western Hemisphere, excluding U.S."
       }
      }
     },
     "localname": "WesternHemisphereExcludingUSMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WomensHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Women's Health [Member]",
        "label": "Women's Health [Member]",
        "terseLabel": "Women's Health"
       }
      }
     },
     "localname": "WomensHealthMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WoundCareandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care and Other [Member]",
        "label": "Wound Care and Other [Member]",
        "terseLabel": "Wound Care/Other"
       }
      }
     },
     "localname": "WoundCareandOtherMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XareltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xarelto [Member]",
        "label": "Xarelto [Member]",
        "terseLabel": "XARELTO"
       }
      }
     },
     "localname": "XareltoMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ZYTIGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYTIGA [Member]",
        "label": "ZYTIGA [Member]",
        "terseLabel": "ZYTIGA / abiraterone acetate"
       }
      }
     },
     "localname": "ZYTIGAMember",
     "nsuri": "http://www.jnj.com/20220403",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r137",
      "r191",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r211",
      "r215",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r137",
      "r191",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r211",
      "r215",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r334",
      "r354",
      "r454",
      "r459",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r656",
      "r659",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r334",
      "r354",
      "r454",
      "r459",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r656",
      "r659",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r218",
      "r362",
      "r363",
      "r605",
      "r655",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r218",
      "r362",
      "r363",
      "r605",
      "r655",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r334",
      "r354",
      "r395",
      "r454",
      "r459",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r656",
      "r659",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r334",
      "r354",
      "r395",
      "r454",
      "r459",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r656",
      "r659",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r362",
      "r364",
      "r658",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r362",
      "r364",
      "r658",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r46",
      "r591"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r27",
      "r224",
      "r225"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, trade, less allowances for doubtful accounts and credit losses $234 (2021, $230)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r21",
      "r616",
      "r641"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued taxes on income (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r23",
      "r616",
      "r641"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term taxes payable (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r75",
      "r81",
      "r90",
      "r91",
      "r92",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r44",
      "r281"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r81",
      "r90",
      "r91",
      "r92",
      "r93",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r81",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r78",
      "r80",
      "r81",
      "r643",
      "r664",
      "r667"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss) (Note 7)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r77",
      "r81",
      "r90",
      "r91",
      "r92",
      "r138",
      "r139",
      "r140",
      "r505",
      "r660",
      "r661",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r69",
      "r81",
      "r90",
      "r91",
      "r92",
      "r505",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r123",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r31",
      "r226",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r123",
      "r266",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense of amortizable intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "negatedTerseLabel": "Accumulated other comprehensive income on derivatives, after tax"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r123",
      "r279"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r133",
      "r199",
      "r206",
      "r213",
      "r249",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r502",
      "r506",
      "r567",
      "r589",
      "r591",
      "r614",
      "r640"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r59",
      "r133",
      "r249",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r502",
      "r506",
      "r567",
      "r589",
      "r591"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r231",
      "r256"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale Securities - Carrying Amount"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r234",
      "r237",
      "r635"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r234",
      "r236",
      "r634"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r234",
      "r238",
      "r636"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r234",
      "r238",
      "r632"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r234",
      "r235",
      "r633"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r230",
      "r232",
      "r256",
      "r619"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale Securities",
        "verboseLabel": "Available-for-sale Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r518",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits(1)"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r450",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r450",
      "r455",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r495",
      "r496",
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Business Exit Costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "verboseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r41",
      "r125"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Carrying Amount"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r119",
      "r125",
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "periodStartLabel": "Cash and Cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r119",
      "r574"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r131",
      "r133",
      "r160",
      "r164",
      "r165",
      "r167",
      "r169",
      "r177",
      "r178",
      "r179",
      "r249",
      "r316",
      "r321",
      "r322",
      "r323",
      "r329",
      "r330",
      "r352",
      "r353",
      "r355",
      "r356",
      "r567",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral already posted, aggregate fair value"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r55",
      "r300",
      "r622",
      "r647"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r138",
      "r139",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued Amount",
        "verboseLabel": "Common Stock, Par Value $1.00"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26",
      "r591"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock \u2014 par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r86",
      "r88",
      "r89",
      "r99",
      "r626",
      "r651"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r98",
      "r108",
      "r625",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r396",
      "r444",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities(1)"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r215",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r104",
      "r605"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r396",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross Currency Interest Rate Contract",
        "verboseLabel": "Cross currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r132",
      "r137",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r587",
      "r615",
      "r617",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r52",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r53",
      "r132",
      "r137",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale and Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Available for Sale Securities Maturities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r123",
      "r134",
      "r476",
      "r484",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r372",
      "r411",
      "r438",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r372",
      "r412",
      "r439",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost/(credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r372",
      "r410",
      "r437",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r372",
      "r377",
      "r409",
      "r436",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r407",
      "r434",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "verboseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "auth_ref": [
      "r373",
      "r414",
      "r441"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "negatedLabel": "Curtailments and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r375",
      "r408",
      "r435",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r123",
      "r194"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization of property and intangibles"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r61",
      "r67",
      "r522"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r62",
      "r63",
      "r65",
      "r564"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Total Net Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r528",
      "r544"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r60",
      "r65",
      "r66",
      "r522",
      "r602"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Total Gross Assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r60",
      "r65",
      "r66",
      "r522",
      "r602"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Total Gross Liabilities",
        "verboseLabel": "Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]",
        "verboseLabel": "Financial assets and liabilities at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r65",
      "r519",
      "r523",
      "r530",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r516",
      "r519",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r516",
      "r519",
      "r530",
      "r537",
      "r538",
      "r543",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r62",
      "r63",
      "r65",
      "r564"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total Net Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r61",
      "r64",
      "r67",
      "r522"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Fair Value, Gross Asset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r510",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r509",
      "r511",
      "r512",
      "r516",
      "r517",
      "r526",
      "r530",
      "r541",
      "r542",
      "r546",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.",
        "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)",
        "verboseLabel": "Reclassification of foreign exchange contracts into earnings, period"
       }
      }
     },
     "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "NET EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r100",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r158",
      "r160",
      "r167",
      "r168",
      "r169",
      "r173",
      "r174",
      "r553",
      "r554",
      "r627",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (per share)",
        "verboseLabel": "Basic net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r100",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r160",
      "r167",
      "r168",
      "r169",
      "r173",
      "r174",
      "r553",
      "r554",
      "r627",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (per share)",
        "verboseLabel": "Diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Worldwide effective income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r621",
      "r648"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Employee-related Liabilities",
        "verboseLabel": "Employee related obligations (Note 6)"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r90",
      "r91",
      "r92",
      "r138",
      "r139",
      "r140",
      "r144",
      "r152",
      "r154",
      "r176",
      "r250",
      "r357",
      "r358",
      "r461",
      "r462",
      "r463",
      "r477",
      "r478",
      "r552",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583",
      "r660",
      "r661",
      "r662",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Changes in Fair Value Reflected in Net Income"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Available-for-sale Securities, Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r15",
      "r20",
      "r247",
      "r639",
      "r681",
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r340",
      "r348",
      "r349",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r555",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r555",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r555",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "verboseLabel": "Financial Liabilities not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r340",
      "r348",
      "r349",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r444",
      "r556",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r340",
      "r348",
      "r349",
      "r555",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r340",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r340",
      "r396",
      "r398",
      "r403",
      "r444",
      "r556",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets and liabilities Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r340",
      "r348",
      "r349",
      "r396",
      "r398",
      "r403",
      "r444",
      "r556",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r340",
      "r348",
      "r349",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r444",
      "r556",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r558"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r558"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r340",
      "r348",
      "r349",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r444",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r518",
      "r526",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Liabilities"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Finite-Lived Intangible Assets, Weighted-Average Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r267",
      "r269",
      "r272",
      "r276",
      "r606",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r272",
      "r610"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r267",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r272",
      "r606"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets with definite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r65",
      "r396",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Forward foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r449",
      "r453",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "verboseLabel": "International retirement plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain (loss) on disposition of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Net gain on sale of assets/businesses"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r259",
      "r260",
      "r591",
      "r613"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill End of Period",
        "periodStartLabel": "Goodwill Beginning of Period",
        "terseLabel": "Goodwill (Note 3)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, related to acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Currency translation/Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r103",
      "r133",
      "r199",
      "r205",
      "r209",
      "r212",
      "r215",
      "r249",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r567"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r516",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r227",
      "r239",
      "r253",
      "r255"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Held-to-maturity Securities - Carrying Amount"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r241",
      "r243"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held-to-maturity Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r240",
      "r242",
      "r619"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Fair Value",
        "terseLabel": "Held-to-maturity Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-maturity Securities [Member]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r123",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r199",
      "r205",
      "r209",
      "r212",
      "r215",
      "r611",
      "r623",
      "r630",
      "r653"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings before provision for taxes on income",
        "verboseLabel": "Worldwide income before tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r283",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r472",
      "r474",
      "r475",
      "r482",
      "r487",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r153",
      "r154",
      "r197",
      "r470",
      "r483",
      "r488",
      "r654"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income (Note 5)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Decrease in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Decrease in other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Increase/(Decrease) in other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r169"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Potential shares exercisable under stock option plans"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r268",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets with indefinite lives:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r268",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r265",
      "r270"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Total intangible assets - net",
        "verboseLabel": "Intangible assets, net (Note 3)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r94",
      "r193",
      "r585",
      "r586",
      "r628"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net of portion capitalized"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r65",
      "r396",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r32",
      "r257"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r58",
      "r591"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories (Note 2)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r34",
      "r35",
      "r257"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "verboseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r33",
      "r257"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Goods in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r106",
      "r192"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r48",
      "r133",
      "r207",
      "r249",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r503",
      "r506",
      "r507",
      "r567",
      "r589",
      "r590"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r133",
      "r249",
      "r567",
      "r591",
      "r618",
      "r645"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r51",
      "r133",
      "r249",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r503",
      "r506",
      "r507",
      "r567",
      "r589",
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-Current Debt",
        "verboseLabel": "Long-term debt (Note 4)"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Non-Current Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate on non-current debt"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r310",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r310",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Product Liability Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r300",
      "r303",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r300",
      "r303",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Litigation contingency"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r304",
      "r309",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r310",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r10",
      "r49"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Maximum length of time for hedge exposure"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r6",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "verboseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH USED BY FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH USED BY INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r119",
      "r121",
      "r124"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r84",
      "r87",
      "r92",
      "r97",
      "r124",
      "r133",
      "r143",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r166",
      "r199",
      "r205",
      "r209",
      "r212",
      "r215",
      "r249",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r327",
      "r329",
      "r330",
      "r554",
      "r567",
      "r624",
      "r649"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net earnings",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r2",
      "r141",
      "r142",
      "r145",
      "r146",
      "r155",
      "r156",
      "r157",
      "r228",
      "r229",
      "r251",
      "r252",
      "r365",
      "r366",
      "r367",
      "r368",
      "r464",
      "r479",
      "r480",
      "r481",
      "r551",
      "r568",
      "r569",
      "r570",
      "r588",
      "r607",
      "r608",
      "r609",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New and Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net cash paid for acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "verboseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed and noncontrolling interests"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r199",
      "r205",
      "r209",
      "r212",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "verboseLabel": "Total Segment Operating Income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Non Current Other Assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]",
        "terseLabel": "Derivatives &amp; hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r68",
      "r78",
      "r571",
      "r572",
      "r575"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r72",
      "r73",
      "r78"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r70",
      "r78"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Derivatives &amp; Hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r70",
      "r78"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r78",
      "r82"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r71",
      "r78",
      "r527",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "verboseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r71",
      "r78",
      "r527",
      "r532",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r68",
      "r79",
      "r573",
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r85",
      "r88",
      "r90",
      "r91",
      "r93",
      "r98",
      "r357",
      "r576",
      "r581",
      "r583",
      "r625",
      "r650"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net change",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r76",
      "r78"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r76",
      "r79",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "negatedTerseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r78",
      "r82",
      "r83",
      "r246"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r72",
      "r78"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r73",
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Customer relationships and other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "terseLabel": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title.",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the information about other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.",
        "label": "Other Investment Not Readily Marketable [Table]",
        "terseLabel": "Other Investment Not Readily Marketable [Table]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r422",
      "r425",
      "r429",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "verboseLabel": "Other Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r287",
      "r288",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r110",
      "r113"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other (primarily licenses and milestones)"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired (Note 10)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r395",
      "r397",
      "r403",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r444",
      "r446",
      "r447",
      "r448",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pensions and Other Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Contribution to pension plans"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r369",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r422",
      "r425",
      "r429",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r455",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r11",
      "r39",
      "r40"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r115",
      "r118"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net (Note 10)"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "verboseLabel": "Proceeds from short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r43",
      "r280"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r282",
      "r591",
      "r637",
      "r646"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r101",
      "r254"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Credit losses and accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayment of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r466",
      "r604",
      "r696"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "In-process research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r286",
      "r288",
      "r291",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r287",
      "r290",
      "r294",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring charges recorded to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r287",
      "r290",
      "r294",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring estimated cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r123",
      "r285",
      "r292",
      "r294"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring (Note 12)",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r292",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r287",
      "r288",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r288",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Reserve balance ending",
        "periodStartLabel": "Reserve balance beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r288",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Settled non cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r358",
      "r465",
      "r591",
      "r644",
      "r663",
      "r667"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r138",
      "r139",
      "r140",
      "r144",
      "r152",
      "r154",
      "r250",
      "r461",
      "r462",
      "r463",
      "r477",
      "r478",
      "r552",
      "r660",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r449",
      "r453",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r449",
      "r453",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r422",
      "r425",
      "r429",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r422",
      "r425",
      "r429",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r190",
      "r191",
      "r204",
      "r210",
      "r211",
      "r218",
      "r219",
      "r222",
      "r361",
      "r362",
      "r605"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Sales",
        "terseLabel": "Sales to customers",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r81",
      "r581",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r428",
      "r429",
      "r432",
      "r433",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r519",
      "r530",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r267",
      "r271",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r288",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r102",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r95",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r199",
      "r202",
      "r208",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r199",
      "r202",
      "r208",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Operating Profit by Segment of Business"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities that an institution sells and agrees to repurchase at a specified date for a specified price, net of any reductions or offsets.",
        "label": "Securities Loaned or Sold under Agreements to Repurchase [Member]",
        "terseLabel": "U.S. reverse repurchase agreements"
       }
      }
     },
     "localname": "SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r222",
      "r290",
      "r297",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "verboseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r199",
      "r203",
      "r209",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments of Business and Geographic Areas"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]",
        "verboseLabel": "Sales by segment of business"
       }
      }
     },
     "localname": "SegmentReportingInformationRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments, Geographical Areas [Abstract]",
        "verboseLabel": "Sales by geographic area"
       }
      }
     },
     "localname": "SegmentsGeographicalAreasAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, marketing and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r18",
      "r591",
      "r615",
      "r642"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Current Debt",
        "verboseLabel": "Loans and notes payable"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Non-U.S. sovereign securities(1)"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r4",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r222",
      "r263",
      "r284",
      "r290",
      "r297",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Statement, Business Segments"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r131",
      "r133",
      "r160",
      "r164",
      "r165",
      "r167",
      "r169",
      "r177",
      "r178",
      "r179",
      "r249",
      "r316",
      "r321",
      "r322",
      "r323",
      "r329",
      "r330",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r567",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r57",
      "r90",
      "r91",
      "r92",
      "r138",
      "r139",
      "r140",
      "r144",
      "r152",
      "r154",
      "r176",
      "r250",
      "r357",
      "r358",
      "r461",
      "r462",
      "r463",
      "r477",
      "r478",
      "r552",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r583",
      "r660",
      "r661",
      "r662",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r176",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r25",
      "r26",
      "r357",
      "r358",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r91",
      "r133",
      "r138",
      "r139",
      "r140",
      "r144",
      "r152",
      "r249",
      "r250",
      "r358",
      "r461",
      "r462",
      "r463",
      "r477",
      "r478",
      "r499",
      "r500",
      "r508",
      "r552",
      "r567",
      "r576",
      "r577",
      "r583",
      "r661",
      "r662",
      "r704"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r584",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r584",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r584",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r56",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock Amount"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r56",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "verboseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r56",
      "r359",
      "r360"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "verboseLabel": "Less: common stock held in treasury, at cost (490,459,000 and 490,878,000 shares)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r357",
      "r358",
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r287",
      "r288",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r396",
      "r631",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Gov't securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r467",
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r159",
      "r169"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Average shares outstanding \u2014 diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "AVG. SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r158",
      "r169"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Average shares outstanding \u2014 basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6284393-111563"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e14981-108350"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r697": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r698": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r699": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r700": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r701": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r702": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r703": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0000200406-22-000048-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-22-000048-xbrl.zip
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M-X&U[U_FCH&R5J7=YM*%!T;)PJZ[?.:3F?+H/^!QGQ*=_0E02P,$%     @
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M+OG&-;/J:2Z]Z>MWH_\ 4$L#!!0    (  >!G538;,K,]@4  ,(G   >
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MEH&'*JHI- GJM8 VAHN[ ].'HG=B'^H-B\B@("5P*&0]<0LMIUX[9=H;^^R
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MR*C+&AP?UT"2?$E\:Y;DQE(LN<;$'AE&2BP%L7%)W!%[%-C]R#F%;YW7]#2
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M&R0JRXC>,HD/BH5%! J%KK$VE9G'Z?,']56@S+)^JH-E3BFS$D$GE)&I!13
M6)GCU W/_J!%5II_&U:L13#OQ7EX;XDB(SU+@_HCQ^@X=0_4K6-EKVC>S:U;
MY=*6!J@ID&=<&AB/]"!0P G*M=X$E%?UU2P%L R],64?&3U"6:B]FK*4D=%
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M.R?;'[V)G @I,LLTSYAQ,M.PW!DR6BJFA"02/7F^<9IWNBVZUDI+_DO87/S
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M%D,0X"X;G1F:>G5*,)R68!,P,%35:K+U7Z9W^JQ5O;L^?]V_SKJ:GW[;^FI
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M8OV-QK!0CKM[V/9BG.= A3+5 TA3GGCRZ-29^_+1,!*H!T-C*?89XXQG.@B
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M''PB[72_D^VOA]]@)*_>GOW?MR/VT2NL(U(NDX8K4 F@#73P.M/16F0=C\J
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MYZ/!]EOV?'^G >-XXOV./C6[KTGCVZ?S:)><-]Z_^'3T3J+&U@<+17#6N92
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M'$*@F,9 (^Z-PMYJ%%DS01O3I?B7O@1+K3T!+\O^8)#\ *$]7$30YZDZ3Q_
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M6=*#0DN<JC-%0X.M*Y)S 58&VHL_!'(K8&<.,Q.4)WT&B"@=6+(WJ". "FR
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MCEA=K,?GQ?<&,G57E/?MHIT7ZF,NU+VO^ZU/7QHGC?B];VFT*S\HB(7CPH/
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MTW4B<^7=K&\64WE7*!:"PD(AJBB16".'N19&TN ]\>QFA9,K[RZ+YIGTV>!
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M?WUB$>@'MI)O"%U5$OJAHO'WHWY-/]P/+?TU[R-WV$?VIS-[(7%.>T& -S8
MBKR/MG'<5J"*)K+$3@1OUC8E7_5@U2JA-\=-ED),=\H/L(X:8XGR2%/,E"*,
M*D@(T09B(G%6LG52LI-E^+PC" H+ ?%8 :JE SJ@ )!4VA#K.+(J*]GE0F]6
MLEE,3R^Z^(O>"57GKH+FS@E/JG."H=%XL)YY1QT-6DJ#B(2,,^V@=3B,:_[=
M+IDCE_JK#Y.9SE964;S.1B8C&),@&HJ1R2 K@7 L*(P5YE2O;7*V+@G--49S
M-&,1ZB95S,?4:FD=H5H'*3!4!EHO&+5*TZQNEE;=3'5.0 19'3PP1%E '>+
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M**"<I:/X% $E(]GV4G$>>.I<)&1NOKJB8%Z8RSZ#><%@GC3%O$:"0,4!1,P
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M77O%U]F#JB(7I7&!0?[DM<T+R!\9Y%-Y7(P:+9P":-. .)$160G*) W226G
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MVO#:8K+/CW=.ETDR,?@$1("8DP9QRR0H3L$B84VTQLL4F,E^.?R@(Z 28+;
MC.+QE*7"*):744QUTA! $\82Q'"N6<*U0D;#GXHJ$['V4NBZ+#4C"\(H7H*O
MZ?58MWH]H5NM5RX>M+O=G#G82]5QC:7B77I,[U*2042OG-/: >-TAE*1DN1<
M62RQ(5^V1_H6_;E3Z8&V9.&!<^*!>]-UF[ W.GC%D,2)("Z40P;,3<2-%9A*
MQT3,<6]\G<_H#5;\2RL#=0^S9)(HZ3CA@GBGJ U1I*"L#Y+B&NI98[K!?UR@
MOC!0GZKR))6W.F#DJ<6(AQ@0Z#\"*:(HLX:YF+(;F:V;&0$+)=WPT7L+;[:V
MFJBM-^__VOY[\X\WK;V/Z]4;^'3W;?7GFP_;NUN/X5]ZL*FX<*OYOQZBF]^!
M/!><I=/(#8[$<:DD5]C;&*4(+CB:76?$C;2W&X\$"TM?$)8^7>'*>TH4BP1I
M'$!G Z4-.4,<HC%Z^ 2^,018.E[G\L$M#8K#:W&A[GAT(')%##SP9,%<(TQC
M(84-V >:1MK;C=6M"M07!NI3@6B<\L"(0DI3C[BC'#GE(A(B&4.L49)E9Q5=
ME^K!55_F[[)Z4#C:;8VX\HP;M>70'AQW[%DFCOCSUR[>E65JBS/@,K478IEN
M>A#P@W9= >I1HQN6_1DOX6SFK6WW*]#V3NH*CW8PB'5!)*"0?GR4HY@'^V07
M;@EO[YN8-<65,5CF'K?<ZG5S,-9N_T_;'X[^N,2[_LY$NYLV:Y+='%$L*4;)
MG8R2Z<CDX!1U3(-1XCU%G$6*3-(&44:=B8(YE_T/5"R2/[D<'2UJ.:<'8KET
M]ID+QJ="D:,!$A$!&6MD#D5VR.5*3]IPGX1R.!J[B)U]7H)V?E4AZ[2M:W?J
MI-"LG)T<Q5!'TL!^9,#V>YU.#IYI W;[\;[=S5ZV3_99NXC<CB_^<4$%FPT1
M%#WG;CQP.J18)R]IG?OK&$$\$HT<51K%X .&W914Y$;OBQ$E6)"\&@K.3" 7
M)6<N )]4<CC30&Y*(!=U;M<:0+]1TB#+;,*4!:MIF)N24R*"[U;-* Z;1*MC
MVPX9 (W+Z2%.R>)V*FZGIU#)@'3APZ->-PYM_^RJQ5KTM >R\:_3T<R.<^P"
MSV4[HT><F("<,00YZ8,*,1J5HYFI>' MXN*/6ER0/[6Z=F>0%QUN+N"?U.%$
MTI@*[%$T6&0=CB/'$D.$1*<LHY0[LH2.JL4[]RZ'_^.I_7MH72?"OZ'][=7_
M@1_C.RY1@(_9W_;T;)-FMODQQJK5&\(#A[WJ-:C+O4X[V&$,U:B2G.U4'X?P
MP=&5\@63TQD]DRIXZ7&O87N_]F/'#MO?XG].VV%X..;3E^YJR/Q7?'&+=3"
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M4Y:"P(1'T/2H<Y9;PZCR.GA^^S*.!=O/ANU)G5U[&:3.YQ,A)-#9&4<Z< \
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M?_#.N]^/=K8.VZVCW[_N;KW_L7]4YW^?3@;5R!!Q#JH)U$O$O<5(,YH0)U'
MMIODE5][Q=<EGCZ>?]0\V)5#W\*#KP7OWSN-G6]Q!P9S>$MO:L'=K7 W&8!*
M@_ IA(08"3E[QWFD@X#?J+5: O2<E05W+P)W6<;MG?8*W.8(M\G8T2!R.9/D
M8#V51IR'B$Q4#B7OO7. M^A)AALO<'L1<#OLQU@ -T? 3<9]!FT"$$1$// <
M^6(\<MY11'E2(1BK S%KKUB1;R\#<&][)\6.FR?>)D,VN2:YPFU 6N%\NB\5
M,L$2A$.D5G$=B8T9;_@FO"UM$&7U,<:JU1O&BN!Q9^/<#[#7:8?Z_!6HUG9]
MVW:JCT/XX*B.HJS/7R^:+8<XM.W.X+HJW$W#Z';=_WEXTH^#&6V*,^+:W1/;
M+.U-:S5>I=%4.-U0^>QTNLG]N,ME#?E+-XX.7/'%+=;!G$^&U]\RZ^3W.79,
M32S>I9^'_0N?XT%$KA_M/\@F&.NOMG-JSP9K_[YZGM7NHHDEG)S],X4 U"?J
MO91),<?MSIKRC312,T1M7&Y8;[PDDFN/M:%!2BZ-9%HYJK](OO;L(&SM[KVI
M>#4JR_O3X-)YA-;8=O]OVSF)6^V![_0&&9$+$CM#6^=RY)^SSS_>?H7W?/],
MW[9WOGXX^KSWMKV_=\#W]SQM[8$LV=MO[[S[_'TR=@;&\G7GTP[;W7O[]?.G
M[;/6N_W#G4^_=W:W#CNM'R"?Z'O2.MH^W?_Z-D<<G^[N'7S!1&OC"6A:GC+$
MF>3(*N\093C7!8DI$-ZH!<"D8MC,XCAR'@-.AGNBN!3:R:!DPO"$I!AS4\$V
M;S>W/U1_;_[QUYMJY\WFQ[\^O-EYT]K[."4H[A2"=9EO-EMW\["FID&=LX9*
M++A5%$1AP(SFTN_>^EPN^GE#_%_WCN#-9]7)(-:"Y]3VZ\AMN"X'!/E#T*1B
M/:<LF0=9^,![<\AW&_Z*WX]K"A_+MF^VW[:NW6D/SS)_\79P6*7<D'R].NZ#
M2M6'25R68W4(T>3+^O!MU?Q>MT-/)UFLY=#@V/>CX8ZBDIJ$@\-V/Z!CVX>7
M'I_TX<Y!<V,./H+Q@.@,L=L#=ER_MMVM[/E+_:B@8A.A?&4Q?+\W&)Q?T+P>
M9&PSO,&I/;Z\&.>7]=N#?V;/U?7Z_=XIZ/"#C>JWWO"P&IX=-^,,,,IOM41M
MX@E#S$50FOBLP<4B5H<QP)+<*8SPV6AK\UQ_Z9RMC_2>2XL[:S5SBWM 67<
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M(-8'P;E21JV]DNRZNFM'8VL\+S8:VN^UIGDY:+G=;9:_5ET'<7PB>"GT^5+
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M&2\(P 3]N)UR=(@=S X^'HSTPXWJP_@)!U.F+*#RTJM"A$T[JJ-"0+V$09V
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M4+6"YN5 \V1,&Z<^:>D#TI$8D,WY#-YZCJP,AA/X3Z+S.X@O:%Z2F+:"YN5
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M8I<V1JV(Y&7!]H11;6+ 61O+H:<2<6<ELC0F9!VGU''/K"T-KY</X',/9BL
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MU5X+RRT/B6K+O$S,J21"PK@$*A<:TJ.!2F69]"E99((!;TE1C&RD%&66":M
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MECJH3((IA"*YS($BQTE"*AFM? +%*G%I-5\!<,^%_*6X4;-'>&.TH]5Q3US
M* EK$1=2(&LY 9B[%#1X6,+A[$=)\63BS(+OQ<7W7!ABBO*>+;1'E'=RX$<I
M@#;UV".>DD<Z9&I-$90QP9L@=%'>JP#N>?#$%.4]>X3OC"CO8 -FU!GD9$:X
MQ )I'1BBC I%P?-RB1;EO?3XG@N93 F"3L?#SO]_RC#^+!H7'\Z^*J,"-U8C
M;YE&>;V0E4DA&BB(ZQ 59B;309D%0G"AE%G*3RY7G6RAE%EJ2IGB3,Y03VV/
M18(CD]PQ%Q 6(?>RFH2<IA8%)UG"G*0D"[',*H![+L0RQ9F</<)'(\%2\N@E
M<2B:&!'GS".G .LX)? D0:9;+]<VZ"M%%ND8EH+OET@O4Y3W;*$]HKRMM-8D
M&F!SB9S&=199*N&'38)2'^!G(9E9!7#/A62F*._9(WPT$JR"!O$L'!(T)L1]
MRJ<?PJ\:"\R]!:,=DZ*\EQ[?<Z&:*?B>@_L]&B:.@FFE$@/K/ # HV;($6>0
M35YYX6SBFN=4CY:+!/!5()RYQDJOUN[T 5<]&)/MQU"SO=HA0 :>I-:\QE&A
MI2D$&&7&RHR5&5OM&5N%=-N EO!Q&F]2J__%3MG4L55FK,Q8F;$R8XLZ8\OE
M#LZ7B*U40\Z9B.W=8 '?G':[L>W/[PR)-3K]K2MW?[/WKX&S?^,#E?U34ES3
M#I!]'JM/(9'9:'A"@6F%>*(&P6\*.1\=BR;H)&AI=E@!^$^+JVU&\"\P?Q#,
M1XM4/ CVH(1 QBN*.(\:&2TITMX$R1(EQIFUC:>3KA>$+R["IT775A3\0B-_
M1,$'4.DQ<HZ8U09QZR+*G1.($F;!U*,1Y$)1\"L _VDQNA4%OP@P'RUDP28P
M'KQ!D@J)N *8:ZTMDL$(Z7VTP;FBX)<;X=,B=2L(7P2$CY6RB&A2Q&"Y2Q(T
MXF"V(9<]=\*)Y3%I(0E;VZ!\@2"^"JFZ)Q^<5.+<9<;*C)49*S.V+#-6\G4E
M7[=:^;I+(^B\A/2F[0GXL9R=%,)1'S%R- C$J95(,^N03XI8Y4AT+I:0W@J(
M@(7*V=TM @K4'P3UT;R=\$:D:"AB&-Q]'K!%UC"-"!7&"<F$MVEM0S[YK(:"
M\L5%^4+E[8JBGR7Z1\EC9!222H64(AJ!D<>0Y5(@3;7!1"H>7*$17P41L%"Y
MNZ+HIP#UT?R=3M038S#"RG,$QIQ$1A@P[(T$R:^M=:(H^B5'^4+E[PK*I^&Y
MC^;P"*64Y_(;'U0^7Y$G9"Q-R%(AI."$$<_7-N@BP7P5<G@[_</8K6VWO\=>
M_PF]YC.(@)=KE&M,?(V5.67M[7]/03/5FM> ?8D'K+'?ROEJ+X=5=[#G/D5_
MVJV*/=Y];S0+><_TK*5OXWD.&WG@5**D*$.<88(L<1PY&CUX28FZ6)VQQ,LQ
M#<L,X&DQY_X:P"5T^6CLCC4<@:S%/@5$M B W420D=XC)IQB&"2R]Z&$+E<
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MDTQJPF4$G&K%$-<N &*Q0$FHH"1-D9&X[$J^H'5*:"VEB3- [-C)3XX&Y91
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M%:],J5<J:"X%B N'Z+$"1!FIP$KDD^P<XN#A(YLD1U8H%4,BG*BPMJ%><5$
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MZ1_&;JW7@3'!G]M/#1RN1%*>XY 48=Y29;C522>LM18IGVVI"6>S"QP60?0
M050?BPT*98(WC* @HT,\X @BB$O$=!0VL"BH2&L;3VZK6^""FE($_W+EP:11
MP=+4-Q7A,1HMM$8)%XE&'@<*PB-F(\9HQ+%0&$?OX-]%Y!,K-7DO!.[WQPT+
M<A^&W-'08'0F<9(Y>:E$^2QR9$0DR%'C%-;""ZV66^T7S$X)LX^("A85_&@@
MCP8$G1 !>YA-Y5+FJPL*6<DX\E0KS:E)7M*B@@N<)X;S3T."!:P/<[;'HGY8
M<<*41BF93,";++*).V2L,\3KZ"QE9=67;=65M]HX1E%0,3M'E(",QABE0(P0
M*K) S5W&U@*)ZU6H%7W3Z9YTNK:?&9A=J1>=1/P8[7!D$G8T-]S$7%! )-/<
MJ #N/]$E[+L0,NG#6-B7:4E5]!9A SJ(^T"0B3H3ET89$JQB(G9M@SZ] VN!
ML\BE'G06]:!S$@FE'G0F<F(TPJL,"=((@PQA^= 719$1B2&C/.5.$YV46ML8
M/\*]E(,N+)@7 ,LEK#LMN(Z$=:UE"MQ(@Y0,H-:YC,B:7/%IC7>"I\0$RVJ]
ME'L6U!9BXV>![%@ -UBA@\2(.1L0E\(B;21%23IN%5&.*K#$V3(;X@6Q4T)L
MB>)-T6,>C>*9Q((12B$6=,ZTQ(AT"@[%I$&K.F4]RZ77^,GD0R^X7//9#D[[
M"86QO30^<PJRU@,05/&]%WBZ&KWG=+4G)[X6+A3[CZ?$N!\ D@77"T%K&[$2
M."K&A2#:XB"55\DS2P.-I1U_\37)Y['8*^94:*X)<LPXQ"TFR"2?4/#6,&)4
MPEY6;7D2+W,!3JF[G47X=4XBHX1?9R(J1L.OA/JD,'%(<LT1)\(CBTTF\C#>
M2$^%(CC;G(6)^N6@>0' 7-KQYP+FD>"L-M0P'DR.]/!<(Z^1RS$?JG5TF/$H
M6:KTOM#+K/<+JJ>$ZM*./W=(CP9OI35$<5UQUWK$I=+(QGRDI+24<N9QPCI3
MV6+\9&*M@NCE1W1IQY^72SX:W+4Z!:\50<%(#(8V3<BIG(\1D0LC+6"95.WX
M0BT2N?PJE&7N5E%<#UKN5?6S%J^57<VVX<$'"*D=7Z'G)[6;3TXT+=S\3!XK
MO>L1ET8&T\@-CL2!$I9<86]CE"*XX*@!M4S<0ZRJ49.J'3X==KK]W=@]WFY_
MC[W^<?YS$<G3$\E[8U%2;4.4G$0DJ '32CF)+(X,Z>AE<J!H60")S/ KCI>9
MZJ@4J<XB2OI487'4/GJ H/AYM+1(B@=*BM$@J7?"QZ!S/U5NKPD!(YLT15@'
M*Z.D1,A<]/:4X_H66$ L)Y@7%LMO>WVX B"YG.(W&W"/!$VY)XS[RB<C &Y-
M+#*4@U4@E;*22^8PKLP IND2FP$%Y5,T[TO0=*Z0'@V:AFB%LY@B0AU%W&46
M$@M*VX'6QA'[X&VJ3N8$=!=(%TB7J.F" /F.QG8<J64">2$MXM%Y9"-52 @I
MB:!,8.&JC*:AB]1Q4D5-?Z]VS&4IY?0+5R<H!:6/+P4EO]5F4L#Z:Y33C/)\
MM'6MWZD=#P^WKC6O+>2:[<9:-YZ [1Q#S?9K]K*^$.#?ZU<AVP/;;/=JG6ZM
M!0YP'/E*LUV+MMN&5>ZMUVY7O+ZT9:+/NTR;=Y<^WPB/CRU6 K>F]CT;0;6S
M9O\0Y/?5P6Z#1<O+-URUJ^^U8[_62;6^_0%_A>7K5 RZOG-\THV'L=V#^8(_
MP^]Q?:2">2 3&J?'\(!^\'O6$<WVJ1U08%RM^,;_NN[O&V/;X7)*A\_-Z;K*
M2S*^7F?-T#^\5%(WOC@0#7_@ZZ]8U^NT3OOW?V7L*+[YZ]IJ>0D;F<T;/P^O
M3BH]L0<1.5C%;\@F&.P?MG5FSWMKO]]ZIN-F&XW,X>CC/\]#[E;[%W;7FVP[
MM/MW/?)/-\G(EAJH>HRY24Z#]\@LI\P[$EUBBI)D=/(6#TP5^$X,F]EZ4 R'
M9)EU-&HN)'<:OAN]#%83L&?)<\[09J\"WR&@O)DMFMHYB,]:; = YE\6'KM[
M/M"U]%4M6U351_W0W\G2^;3=KYU9@/;)2;?SHPIOM,ZK3_7 T*K!._EUO(Q\
MW) 1Z_>(YWO ^CSS\^Y:I,$\'61>[W;65+?$($BUC@-(5WMDF%>\CP^FFJSK
MZ3CMY7G\[VDG_^*ZG6\@^TY G TOVP,YT4R@'^". \'8<? DWZM]W6R?G/9[
M#YS&.^30T2D,)YT_DR#ZWUMB_+:5KZR@.D7IG; \&_:,!VR4,$(:"L;^UZW*
MRB>8H6MS?Q*?_3^=5M.?[\*-7K<Z_MO+M.%;\5\?S_>_A!-'N=S)MOB7.MO9
M?7>T]R7;[/N']2]_M7:V#EN-BSW2H!](XWC[;/_H73Y4 ,;R^2MAPE-*$XK:
M)W"F$T%66(,T,X';((3C>@TVJ[<G><=T3\$LV04TOP'E;-OG-=^RO1YLS[Q9
M6ZW:(:PJ8+_5A'D.MZRZRAKH]:L=/S3[\I<JR=.-L78,BWXXL.EBKU=+W<YQ
M+63PP"=.3KO^$*RB+$KN3.$_]M8'H-9 I<$08-/?&D=U_RRV[AS#SRH&UFMW
MF$TWP3_9:#KM.!#$/QD)V%[7W6E@3J?3&^4,G9/8O2&-\H>O%BO<.Y,_?[1Q
M@VMBN3-;B(^T%XS4*U<VP"HCO7YT ,ZV=C0QAUC"&G'O-+*4*Z2$2SQ::3!3
MHTA_1K,MVQCPJ>SMGX)-,BHRXEU]F3<5<O6Y3="CK8'QPH;&2P4:P'>GU>J<
M]?ZX5SD"  [ ILUNFJ@"<$,P7%K]W1"[.;;0LB>]^,?EBS\O<^?-=O5,U9?^
M'%YKZ"K<X?)5FGCP]M!L5GR=$Y%UX[ \:WCCH5&]7JG-D:#'X#W.U@GF][Z-
MU\F][_WLLG1=4S/]J])UJAYWV9^]1]>)4-,?K%C';+(!_:*P;B'JY_1D91%;
M>6MW*[^\WFRULD(92WS_Y!$GJ$QY64?5YR[76M7FNLJS4#E%5;+KUBRL0D'I
MUC"VU;PVTB;8"0].])1*TU)I^H2NO/J5P?2EVJL[[;@'._56L_XJI+>V+W:^
M[,-GWM*=K3VVO_OAO'%<A[$=X)VMQK>=W;>DOO7A;(]NL]'T5OVH+O:/_VK!
M^'CC*+0:6]MT[^) [&Q]X'7Z0=1W/Y\UMEX?[1V%5/^$S_\]2&^1G5V/ZYM?
M/>'18&>18MG>)M7!N=8A+#EQ(B;ADQVVZRU2<JNDJ9<)[BM5938WJ.,1J"N'
MB0F2(192+C+3'IF .>*6,$E-LL&P =3ED_OX7C"[TW,9:U7:ZCJ@UC^$ASHX
MK*6<5LQ_F<20+]V-+T8 ;N;E!OFW.UCG=[#,613V1DR?(O(F%WG-,>N&"2=3
M$A))13.SB X(%MDCZHPGUGE'&,XB;X&:'0NPEQ38-XR< NJ'@'K4CDDD1,R2
M1\*PBOY9(F<)1H10P9@B.)%% _6J!)P&-LRUR7)EQ?1C^PE&3/'B%EG690DW
M%':[L7V7$;/4IR+.20Z>CQDWEBMCB?<(<YM/K<@GK(4D$"8)%IO;H+F8VJ&(
M)7934/\KU-\3QBF(?RSB1RT?*2G11EODM0#$:R61CKD,2G*B;+166;Z(B%^%
M$,Z P&72,_6>X-D5'NR2<9N*&/\$4]B*P]_/MVP_KB9']GS$>>/-F $GL5$T
M:(Q""OFLA:2048DC)J-0WII ,!U29!=BO6*_S1#X!>93A/FHU89-2EXGAC2C
M/F?;.#)$$J22QS(IKAU>1$;<._I')VID6^E>-5YZU1[9J_;+WK.17C5!@J:6
M$V:PX90GPP7&GAOA?/!!B)GWZUQYNZ_/7]N6;?OXZ3#&_GO XPE@;X4+^7^
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MDV <]9EGB#D6^-:ZAX\8ODOP0E7XW@E\M^:TKS;1)JHU$4F5)'/9$Y>H(UR
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MYWZ3MHG;5$Y]: ).>V)DU$2)X)U5P@64OFO27A:X6X'\X(!\U)RSOUNE_%T
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M_I,C(B9<6LJ^@DEK0,,'@'":=<_HB).ZHGQU$_!D*K:PXN[!(WE$:MB(D7@
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M)K8%T,L%<-YETMAHA&9"[$B5*43IC2+G$=_O7L'WRR4\/1ZM21PJH3<8RZ=
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MOKJ)^>3LP\(UI </Y6!-72W9127*V>OX4<C%4JMW564G$I>$\D$BL:809E,
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M#)1O3?.<Z)BW^/EL #X4/R,GWRK.EI\%2 N!<A\ UM)3]XH>\>H&;VDS=CD
M7IE5K9OB68]_;?'S^89WI-ZX$BM[IG$VD^);K*4ES];);R*VGO'_MR,BIBZ5
M,)SVG!K*0-XWX-8:I(8M9V\5\S O\3BSOP63%X-D+IH+<RDN5&K:F6-R@X71
MN!.$6M\\;$DD'_"P,D*UZ-W<M^#K".,Z@1F-)0O:@[=22YW2F8WDBT'RK33L
M1+>\:=C9\'M P[R4Y+0:M+%BPQ,/+J8E!_"2")L."FVS<;L[G8<MC."5V=6N
M@VW9\W*QFV,__'OE%@R):V/?JTI.'&MM/<IF8>O9_N-IJ"XF3T0"6'C8?N8.
MG)P'RR6/?R'57J]N,%QR_X$'#^5L/:/O3IKS5+ *Y9AK9 W6.,6\:=B24#[L
M^:PAUJP1G!("4?(#RG.>EM=>Q$80/@<;H]M0OA@H_XCJ^23'O'G8V0!\P,.<
M16W%.J!2 '(^PEC$!$71YZRN:'17-VGW EK^R(>N>%Y8]_S%\]\^>?;H=U]]
M^MD7GS]^]H='O_W#[YX\>_[D\R^??O'YED'O<RQH37;Z9\N@UR&+J0@YC;%;
MS"3HF2LG20DI,*:V9= +QIK'L[Y"J-VD*E1S>?: -C#M?3A-S*UHSRZ4218O
M.-1\\$A&DV0^4G-N()G0R'P(S,D<NDA;!;TFD@_2/LT7(N\-7!P_J$@#1LO0
MO$^]^AC#9(VT.T#?-R3?==+7:7YY;W8_/Y(/\C_H4DRI%D@N5Z F%334"J%;
M,K18_G_VWK:YK1M)&_XK*M7N\\QL&0H:: #=SI:J-+%FDKUC>V([,YOYDFJ\
MV4IDRS<E)W%^_0U04F*3]$0R;?J(0DU*(XN'AX< KNZ^^M4*[NX;WEO6RJ/:
M?3)7CE3HD0J]N<@=!4!.3@M0,\\,&7*U&-:]%H;J2(6>H."'93)6'+LD0;F8
MDD),1DD :5L62Q4LU2'O[KNU6X]-./WJUB.YVA[@H2+>&?3!4=921*, LS>1
M!QF;))(7R)@#$I^#5<58;B9<$"5)K KL@M<6)1/L[ON!Y)N&Y&N2L37U\B!C
MFT?R AE+R?1^<:Q(J"H$6U2TI8_H"2G6*,8ZVMT'M[?L6!EMH"=SY0B(C7SH
M31EPQ:6<?&R2PJ%-A:(ND$SE6GMBWAC),T&QOSP;5:IPM6P42+%-[,?:O>E9
M$6.VWHL)O24!C2[06XQD$B>V!BR0'6IF,K:F8,'YIOPYE4'%)HGD!2H6/29(
MX%2*$IK9YOJ05"#%.4LPMK&RF)H!-]*A;QR4KSN19SW%/+C8YJ&\P,4*FBPZ
M! 7 O5]$[QCD*2L,4*J69)CCO$!UG9$\$X;QE!G6M;G8Y267D#[_SM/."1WW
MF.8]IG?(;ZMK(JS4U%_(+!^=_"2GZ=6QS'8^V[E?SB2>'!^=/F__>'CVK,P^
MJE-BW&/J]Y@>+D>FQP:R[6]W,.DZ3<>311-] D9 #$+6NR)91^J=68(97L7I
M$1BWY%4,PD0Z5Q5JJ(W B%72&(S22!!*\"5"DRH^K)VD.^& TJV'<D[!.P(;
M;-58G8B#;*FFG 5UEC%<;II07NRR$*%"JE%!K$4AZZ3$EJA(=$&*[&(?+A=X
MFWME;2>4K^E67%,S#[?BYJ&\..C;L/$:K7*&>XJ'+XH)7%/2N9".66+*\Q2/
M,>E[PE=NEQ_ET^3;W^YXTC5LN*+12;65BC-(S6[7(84HE@M3T<X/.C8YP?_M
M\@RH#"$:'8TJ7E@ALE'1-14@%DJWQSVX)OB-79;[(S2\-5#6A<I\T'<IB(6$
M E)RE1 @B1<:=&R24%Y,N+=%:V^,TIBUPIRHV7"856#Q:!,W4B8-RCBR/&X:
ME*])Q];4S(..;1[*"W3,2-19<U"E^*!0)U8"-30ZQAQ#;KM)KD^#&M7/$[YR
MQ,363;B_W4ZXZS2B<I22J:5 U5AZCU/D&G2N3>N31QI<;'I2?WD,E"[:.@?2
M;#>?V@\J2@+J9L\E#-QVS0'L[C.LW8EJPHZX6P]E .T2-(TO!IL9!\UD:_\9
MZ<F=G&E#H;%Z,GLN9^UQ?CF[VVQ,E4_F343[APR<7QOG"T2-LM1H$RI$$Q4:
MSRHF1ZH"M$/O:O&UX1SN:,2!]!N&].MVJEI/<0^JMGDP+U"U&D47ZF#VR2H,
MF%5/9%!),D,&R6)\ [,9D;,I7[GIR-GH4G[E+N7_>_#H\.LG#]=H2'YS4X+'
M/:8N.(8[:*1(3X<\VBPY]DG"V(S'F+-8XLPBP5?M@AF-%R9H4OZZY =JV^,I
M$BMM<Z_QU%HQ:]>88D@IL'>2P^Z^TVO'Y"=L5@XHYU!,]2GW&70:*C=RB)R"
MDUH0PI@'/DTH?[,X6\ 18"55DB^]\X)5$@&5@#'2LVW$-7;H:*1(WS0H7]/1
MLZ9F'HZ>S4-YL?."3:X43LHX;KK8"?4D.:.<91,@<TC<FZC8X>B9\I4C17JD
M2&_,AC/-; .@""8(0JYD""1$C$%;0R5OAHZ]&<NK1[^4K'XMLY-AVUU/(2S/
MC=*F^&*C:>0LHL+H@I*<C&H[&UG0A@*I@Y$,F,]'SN7VPMQ'Q&IY#FOTW48P
MZ$6* 0>.XH:&1PV8?R"8+U(X1[;;>,K,.VY538JL3\I[1[J1N=Y9;\!\ZV"^
MDL6MJ=#M^Y*W/\#V('57!O<"J:.J@]:.% 83%)8DBHW/*CO)7AI1+T7?!G!/
MF;*-$-O(N)Z<S9>\Z4U,@K?%(J48)11-:"T'7R7AB+1-3_PO3YNB0IFX@L)F
MIC<*9[V*3:VK D87G9L9'\V(M&TYE#EIAL"0R55$#]3^$3F;P+4AFT>D;9I0
M7J!I-=<D3$:Y)H45BA9%8'HAN_&V2>00((](VTV$\C4C;6MJYA%IVSR4%TD9
MY>13,,IB;:0,(RI&#@I,B80A<O5U1-JF?N5(J9YL2O57#_[Q\/\</#C8^6SG
M_-?[AT]&?O6XQP2ER'#^C/SJZ5#%F+EPUB59<>@3]>E)F8(UMA$,B6%X?:9G
M7]HEKP][HF@PJJ![?K5/1<64DZH:T04;HW=V=]^/,OLM1K(G@>(UY1(:-W2>
MLO'"D6IQM48<':BGB>0%IX]/F1W7K 1";YN!7C$84+FW4$#F@-U_2V$@^88A
M^9H^GS7U\O#Y;![)BPVH$:JWIBEA<+V6OK**ME:%#B6G: )30[+5>\M8'CZ?
MR5PYLJM'=O7FAHC86L '*(XS)B\DUC@M%'(VQ:0XR-CT!#\N%[MZTXPX2 H!
M^A 1"\V8LT:ACMI:C:EZ;F1L])_>8B2'BMJTC?:)$]I8.5/4X%SVG(5=&F1L
MDDA>(&,V1U.#!!52RCVCQBL)E%4Q4!O##H88&I+M0/*V('DE%UM3+;]WCO2@
M8-?%[P(%2^PK64(5<Q\%$0PKDBPJ9..+^ P>]>Y^V-OF_O%3)E<C%#;RH"=G
MNAG.I:*'*C4@F\H0FO3W17N,EO+(@YZ@Z%\>RMK$N^>VA2J(!H594+&K6OD2
MLP<VR:1Y$\N1![W%4!;MR<>*XBQC;NCUF"U)-"[K$ H/%C9)*"^P,*X5=#%%
M<8U&(:!79$M0D!*6"B[JSL+ C>CV38/R-6-B:VKF$1/;/)07IP#YDK-GHVSQ
MC9!E)RJ*:82L^.QRBM[.^\3CGA\QL>E>^0=D;'H//*X<1V5<.?$KQU$95XZC
M,JZ\V?D[HV;KRC5;#Y]\>?CHHSR9VR-WE8=[>7)Z-'^J63ENC_=3^?SLY.5=
M9?>@OWUQB^6TG#_XG^".^?.H+AOWF*"\&R&U45TV'0<\."LFV"0.$Y+6(D87
M2^Q2(ALVU2YV.."OX;7[;KFG$&81S+JJ2A84!D8EXJU"%TM-L6;.>G<?])CM
MN,U0!H<QHK3=-AA2((S.H>]=84,.08]8VB2AO!!+$_0(E$01I:208U71!:T\
M4Y/, CYD[F%Q,Z!\PZ!\S5C:FIIYQ-(V#^6%6%H&T:ZZV&<N8Y_>$56T(@H*
MU-QV+-E>9@"XM]P?;,32)G/EJ"\;]66;:_%:VZ-P21&L;6*_:0#O8@C6,3$$
M,^C8! 6_69[24< 5]JALK4WPUZ(5E605U]H,\NAKY- $?U@['VK"6>VW'LKD
MFJ5.B8*DWN.EL"/C-"9M0T+$D=HX32@O3N)(.6FN6KGHFR$74U;L0^_8[Z)-
MV(#.L4&9UJ9C \K3IF-K:N9!QS8/Y04ZA@6;! Y>Y5BL0IVX:>7"BEW;/F,:
M-=-N=]^OE=DX811/F6.-F-@H,YN> 9<+!:R,OA(".HJQQIR\EN2L'N,VIBCU
MEQLOEF#86-#*DS0#KAI0,4E5 M*[?%<NS>[>-V&$QK88RM[D'"U0+2D@:.+4
M@6U]Q6P<I1$:FR:4%[A89-:I 5:Q@%=(653TU* <DF^6>+/.H^W]VM9N%C"@
M/&TNMJ9F'EQL\U!>Y&(YI,1-(:?4QVTXVRM&FVHV)E5KT'#6?;"]WEMVD8[0
MV&2NO"!CEY=<0MK-O_.T\T+'/:9YC^D=\EOBFUBL%0@K%?63AT\.OM[Y^Y<'
MC^X??''X[9.OOCCX^J-Z(6[*\EW+M3-6[*:NV(;N,3W9-O)E-E"U<+L#<M=I
MWHH^V.JQL7^+3#8*LX80G'':0>7-N&;KR>RYG+7'^>7L;N.I*I_,"^GZAPQG
MS[488OIYR6_K(KKH02L)OBJT (JK3BI"U%9[2F[>V?6.MR/TOL5(QQJ,U\D&
M$Q.F[#DE[9-'FP&2\QMJTSR0_B&1OMC#V:?H3!!52W"JB6JC(A>KLFW2'4BT
MIMZ-_0[B<F1^(/V&(GVE7W=-M6Z'.W=3$%YTY[K(0)952M(@[$)1[&-2V9EJ
M<T:')NSNFQ6%#ML#X"ESLEOBPYI(M</MCN5=IY%S$7)H PH2UF+;/W3"2A(P
MZ%H&C;MIFN&7Y5$[!4Q3ZT5E1E1(?>XI>5#9ZUHE -5<NW%G[!B8N-5(C\6X
MW/ .'D/5$I*IOH8B(ES!#!IW\Y"^0.,"94ZYV8 (6=J/"BJZ)$JS14T8J_1$
M.W?'NY&?LS5(7]T%>CVU/FC<QB"\.!#5-<&,5JL4LE5H<U0Q.J,,8]:6-8+@
M/"MG[7E:$T;PE-G9B,)MKDYB..ZN:-OIXFIL)AWU28HQ)D)'EITU'HW!(H/%
MW3#%\'J)Q:7(,0*QHEB]PN"BDMBHG,Z5O13A]K,W);I#?IM=? /JU6';<3"0
M$1U&<IK1";+3L6BSH3J* ?4/"?4%&I<*BX7:9'7,3B&24Q)"5+8DT<E@S;;,
MH=ZV>4!]6Z"^DL>MJ=@'C]L8AA>GJ@;(P3$I++7W$ Q)18R@K'4<7,!&\WI$
M?7T:-V$ 3YF<;;C"XN;FP8Y[#*_&'\,!<10<C7O<5NWPV9G$X[(_5^7=?#MZ
M\6J>O+#R+_-1&.W'(H+,7N@#-9;';?Q\E,^>75J/;[SQ7'G?U;^_1>+IR?&K
MLW>_Y0U[H)N"S=S<N!%L^C/UULD7]LWY9) W?C[[3;:\;*:JBK,B/RJI[6'O
MRO'/\OIT][.WOM/SHQ=J80T7O_ZG^9)/^J'8.:D[G5:WU5[UE=_\'C)[VKY*
M'ZYR;ELL')US0YQ]PN)2!D"#64<R/KD2FT'IC<[(Y_RAO:?D@\[/=0(MD$OO
M=8NF()N2@33'3. CX+L^I]FH,:440LT5+09)WG&L!L47YRDO?DXB)UGG2M4T
M.S<(4RI4VV.ER*%XZ,IAOAZ_'=Y9+K,N,X[EY6FY>_G+YY<@.WHQ7]'YFSZ_
M6)N+$[]B[LS\8)^_?+'[P>T!^GX +ESP%Q]\<3;VYF=CP;H^?PUYSP=ZY\MZ
M#][SM1#,>[WSWSTLV#VB=[\\L8=U>QK#37E8NP?Z_6[[1P][Y26X$2IPNIF-
M'W_.V.H2W?N']YX<?O'EIL9VK7J(]Q[;9=<9VG5S*=FXQ]2%QP<3,]-[X''E
M."KCRHE?.8[*N'(<E7'E."KCRG%4QI53OG(<E7'E."KCRD_LOIUT0<-JU^V\
M]/RG\N*\]GSG<8^GME]//VK]PKC'U.\Q/3!^1-AN73^)]^X&.$I.7UQQ\'G.
M7!RQM:(Q48CD8LE1BQ6 8C=4@#0*#ZZ1M/STU^5.$8% H&AE":S";(.*V5F5
M4$+06,0DVMU''H-:MAC*XBR101L!$44#!W"^@DW:NNH8QZ"624)YH88HER9X
MV0>5<FI0C@1*(E0E4A*7A 8D-2C; >6M@?+* J(U%;,=!42; O!" 9'.UA,P
MJEAT4$T4&\6>VC]38*T]Z 1Y=[^G_VTQ@J=,JVZKW^33-/0;1:-7--]B!4S<
MNW[J)LPA<@Q2*4$1J:C%#"8V/>FOET=F8N5F;T<%27R3_HV31>>T"IXX$QJ'
MTIB8X[4[]DVX?/360]DXYZ(!9\4:I%*H9BRN6E/1@U0[F-@DH;S Q*K/S52K
MK-!ZI[#MI&)3BXK12L=RCK8V*,/:3&Q >2I07LG$UE3,@XEM#,"+3$Q7-#H9
M96HN"L6SHIR=XJB=;NA&*$T7@]_;YBDH4^97(Q2VN99\P_=V1>,M.? !G2U@
M 9UC]B@UDTTH',# :,EWPQ0#+)$TMD4'CJ1JC;F9=Z(5Q1!42+$T[F:RCKXI
MACN:U]8,$_;1W7JD,SJ-!2D'#9V812[5A5RT]19(PZ!IDP3S DW#P@DQ>!4T
MVV;EN:(D1ZV2=FU'?9!2&I@9UVZN.: \%2BOI&EKZNU!TS8&X 6:ECF*UHZ4
MD4"]06Y0D6)2T1G/SF .T'@ N+VU>V9.&,%3)E^W-6"V.M'XX>SLV<E+*?DH
MC>3BVWV/Z0%P>%1&<O%T"%;*G!F,9@*+EE)T:%Q;BQ@--Z(5ABOEAAEO=LF5
M8K+V5K"HJGO/Y,I92;!N/H XU,H%M>FN%$.#?VTQTI%3 O86;-]Q08KBT+$N
MG)VC-&;4W4"D+\ZH XHHP2CA'@XOB17GD!05*-47($(W1_KPM&P/TE=[6M93
MZ\/3LC$(+\XV<&*C *I:HE7H@%4D5U1(""E2I1#J[KY=/QX^80!/F9/=5D?+
MR$R>D,A?0>-L$%=U@8@>70+*KMEOCD(U2 G+R$R>GO#')::6M6B3(BBM&UU#
MDU 1::] @"FDG#6&W7WB,81NBZ'<C'CCL@/O&I@K)L:< EJ3C'=D?!PA[TE"
M>8&*>>L+IP(J.5T5ZD1*=!\[A[44;C+9LVY0]B,S>6N@O)J(K:>8!Q';&( 7
M0]Y]\&O&JDITK!"S5U(Q*/(A.!W(-!CO[N/Z$>\) WC*]&J$T49B\N1L-^.3
MMKE99<UZ0^><%%-%Q,<:2PU5CVC:#=,+;HFC$<0LA4"5><E9%*-B:D2-:^9H
M?/8ER>Z^N0.TS<T#;CW2(T7-55>3FSF74V0M,02+7".6=@I&-.WF(7V!PHDX
MLDZB:MOH%=J>M4S9*K!-@A<&QEZ;UI .:P\:'DB?"M)7DK@UU?H@<1N#\ *)
MDY+0]\I2IWU6R*@56V-5<B%C]%F:#._1-+?% )XR-9MN-.WCC[=['R+W4:;>
M7>7!SM>MB;23V3R>=[>M=)F=C[7[\JN_/UYCKMW-S2T>]YBZU!A.HI%K/1W.
MR)@LV]CH1"PH:,4':P1CL= ,$AF-G*=G4_[XRW*0WD (NK2C:\0I3"XKR9(4
M::(B?6=M[E/8M]FFO/501DC).1.+9H_:HQ1KK2DZ8PJE4AY!^DE">;$NG9W.
M@%F91N)5V]/04)R-BH"Z&!,$@V]0UB-;>FN@O-*_LZ9B'OZ=C0%XP;\3&&RP
MMBB'SC==W* L!4A18E]%DVY[MKL?]K;903ME5C5=_\[T^-?(EMZ8]58Q-U/-
M2>;JD!FI%NU2P62*<1$'$9N@\'^]1,2:KBY"I2CTMEEOO0TLBRFJ%$+&#([-
MO'?D2+'<8BB3-8U>D99L":.!IO*K2QETA<0UID'$)@GEQ3[.VHIQWBB7T#4H
M!ZMBBJP,VYP,E$02&I31#RAO"Y17$K$U%?,@8AL#\ (1<U0Y1JZJD.:>%>=4
M%),;BK,-Q8EU9!N S>CC//DK1R1LI$MO*B FG %,3%(T5N\C8<$ AL2EIO;K
MX&'3D_W+DTU+R"S%>07)2)/]!A5G]BJAS9%T:/K;[>[;T5UHFZ'L3&WFFJ[B
MQ:,!B%%JC11KT)Y%W.!ADX3R @^S%6RI/BI./>79V*AB2%8Y#+5M8G7-"&]0
M=FOSL 'EJ4!Y=4!L/<4\>-C& +Q8M6IUJ:8$9;73"E,3MV(BJ$IDR&43*M3=
M?1X!L<E?N7T)SZM[-=_ A.?_\^#P<&0\CWM,46P,/\_(>)X.*Z22V!2(V6F/
MA%Y2T4$J.-LY8G7#P3,]HW)Y%A<E#CE;4E&(%7INK- &4@%CT#$Z[8SK:9+;
M//SCUD,Y>(B%M:.H,]I8&7,TKB'9HW9@Q\#D:4)YT<%C?=%)HD*VMD%9O!(-
MI 2H!H?%0M"[^T"C>&%KH+S2P;.F8AX.GHT!>,'!8PUR,8PJE3Z)JS<HDTQ)
M1;;LNK^=2M[=I[UM]M!.F55-U\$S/?XU,IXW9KWYDG,I3;^'J-'$Q$E[79M4
M1ZB@<QY$;'K"WRP1,?#@*$,3_F(:$:L)56\\U8A8SBBYF&!JL][LVIW')IQD
M=>NA[%*FFHVNP!XQ,&5ODH %(EMC&/VAIPGE!2+&;,'&$E7,W*#,'E1LYIOR
M:,@:'S7GGC!IMSE?\I9!>2416U,Q#R*V,0 O$+$:R+)/O5B\BD("K80IJ S=
M)ZHE5![]H6_$E2,0-A*>-]4V)%(0:XL@(%H?(V?)R @46 K90<.F)_J7!ZI"
M 4\]2](R5(66K.H27^G:N%EWKP?J69)V)#QO,90+Q>@XNLBI8C,&!(MAD.)M
MNW4JHP/0-*&\0,-<<9!#(<7&984@7A%Z4F1=;_UB7!/0#<H0!I2W!<HK:=B:
MBGG0L(T!>+$#$-7@0^_PG(I5J!TJ=FQ4L+%/X/)H= .PW]MF $^97$TW'C82
MGJ^<\/SDT<&W]P]&QO.XQP3EQG#TC(SGZ=#"E!E#\0F!(S92&+/H2!I+D5KP
M8B[0\/!,RJI<'O(E)KD<O5>Y4E!8Q2DR,:G<]ZLV=N\!=_<QC#3)[88RV5IB
M81>PYBJQ.I\:1326?#$P/#R3A/)BH%U#SKJ(,BZ"0@!0Y*6JF%&W/74A]![/
MZ/2 \K9 >?4@YO44\_#P; S "QX>';77UG@5:W4*0PV*F@!6)K$M8MC5%';W
MW9CA-?DK1\;SR'C>7(_G1+7DP S-,B-OV!B#CE#7&*//-(C8U(3_#P<_+_<6
M2]Z8DJW"5)OUYBDJBJ[]P";]6>N28Y_!&M;N9S+A+*M;#^4BXAC(UQ !V9%P
MA*1-=< E6L^#B$T2RHM$3  H>%&4I4$Y1%34_MW8F-7&H;6,S5(P-#*>;QJ4
M_W3-)L_K:>:^#^TK-UP/2K8I*"]0,@S>0O:N]P5$U<@S*';BE$]>NYJ]T7TR
MNEW19>S/VX#B*7.L$0T;:<_3,^ PUA"2)ITLUA0IA2S-?H>@ 4L=:<\3E/K+
M@T\YNQB\*>TX<3@?NL.(0043I&;,'/N\G8!K5Y].V!%WZZ$LY MD'5RT!D6R
M:!\M$%2R$L&->3O3A/("%Q,RR8:"JFU;4A@1E93JE0FN^L;/:J70H&RWN4WL
M+8/R2BJVIF(>0;&- 7B1@442;:PH=,8T %=1S-$IY!@@"CI&N[MOUJ\^G3"
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M$LH+-,P'Q]H64+6Q+H4-G2I&J"I'039<B8)M4-8COKTU4%Y=E+J>8AXT;&,
M7J!AIIADFRQ6%2BIAEE19"TH:B0:JP1OH^SNZS$0=?)7;E<\;'7SY\>O9D_+
M[/5'C76->TS]'M/#WG"6C-3AZ5 KC)QK1>VT9"P))%M+MKIFIP>*FH>79'J6
MV?*8+$PBUF%5(;NH,.6@./:!B8XXH8#'TBPS-MM<HS:@K V#+4S% N;$G $-
MM;/@(=H<]?"23!+*"UX2 QS[:+N&7=V#U=DIJ9I5,=F9'! LQMU]XM'Z86N@
M_(XQ66LIYN$EV1B %[PDD@A]-%[Y!-03AJUB;Z.JP0@A95M!>KWX:*(\]2NW
MRTLRLH8G)/)7C< PL0H&=,6@=4V(1-ODOS<F&)?9;(:(U9/9<SEKC_/+V=VF
MEE0^F5?L]P\9IMWU- ,NC[JAQ +&*<V@%>I BK1U[8?W&"P6E_3N/MQQ,#(1
MMQCI%L'[I!O(0T2=A#Q4M+Z;#3GF9#?#TP;2/R32%YM^&2<IL%>]RU/O%(3=
M%9-4LN@@M64V4CO2F[@?2-\6I+]C%LY::GW0N(U!>('&<46J1%5IZ-..24<E
MT;.BD+A&9T(*<QJW=K;*A $\97(VPF@CYWARIEU$R*&9<IQB16GBPS<CS[MJ
MP#>-3QL:23I,NP^F%Y;GE>98("0TB@SW)"CM5034RN6B/1AB%FQZX0[:T=QC
MBY&>!(IS 3V:A!RT))]<L)!-=;V]ZR!Q-P_I"R0N0S, O:TJ.6\4:LF-Q&6K
M4OOI:PC&0NQ(MV$4'VP-TE>2N#75^B!Q&X/P HDCZW.(*2BO?5/6V$A<9,<J
M-XD<= 2)Z#N)&QG+4[]R]&Z>;._F@WO_.'CPQ>&]T:IYW&."DF,XBD:^]71X
M8S,C.4#1GAVB@< @H(TSOE0V(:61;STYN_)P>3Y7!4@4,BHAZ/$];K_59F&F
M7),4H!Q\HX8(HY1UBZ&,WE3ON#&,XC 6C)ICQIAB2$!1\LBWGB24%[P\P*5&
M6U//QZF-(H)1) W4QK)/Q,XDR[U5\S:G:]XR**_T\:RIF(>/9V, 7O#QN"*Q
MI""*(H%"D:0BU:C(!IM]LA$B]PG):S<'FS" I\RJINOCF1[_&OG6&R1B#5K-
M=JN9(^9LHD/C4Y70#+4"/ I?)RC\7R\1,4M@>LZLRFA880_$,R92$%V ;(%L
M[>W!#&]QEM:MAS)Y%V,J%((/R"Z390<B5*)&M(8'$9LDE!>(&%8JGJ&J)GVM
M0K:B8ON;"MD2.I.]S7WF^:B-V!XHOX.(K:68!Q';&( 7B9C-(;&)2FOL0Z^B
M4V2J*.O)I!"2JYA[L'WM;)D) WC*]&H$PD;&].1L-^%2,:8FVR6B!HJ61##E
M2CI5)QOJTCSR*#^87EB>:YH B",49;/M$]2H3]()51% $$VB=6^( '< MSD-
MZ]8C'0-7EZOA% 4A9XKB&^P]2"Q83!D9TS</Z8L43G0TI%E)95$83571U=QX
MG$U8BY14\QSI,+H7;0W25Y*X-=7Z('$;@_ "B;,>>W&Z5\%$KS!D4%2,5LA)
M)%8; MC1O>@F7'GS,Z;='KFKY":_/#D]FB<ES\JQG!W]5#X_.WEY5]D]Z&]?
M?%XY+>=YRS<PU?IOAP\.'QU\/3*MQSTF*'&&@VED6D^';[K Z!&C0X0>6Q*A
M$(0K&1)?>61:3] >79[_90R;:JQ1D9)5S3:U*NJ:5''1HTY /L+NOM.CV'Z+
MH6Q0,+M<"DC"5 UEP>(L1D1GJS8CP#])*"]XA[0NJ0 ;E8%,HY9HE:3,JAUA
M"X930SKM[B.O'> ?4)X*E%>/85Y/,0_?T,8 O. ;BBE929)4!4,*BS&*V()B
M-F IIRR^M[[9V^8I$U-F5=/U#4V/?XU,Z\VU2K(63?*5?+$(U4E$\$BF&(A,
M.(C8!(6_62YYS5)9DU-@2U:(F%5LREH5[ZW1VH?8Z^0"C8:V6PSE@A':AG.F
M1K$Z 0L& XNN6)H%YVD0L4E"^9O%BCD37#)%-;.[V7&Q:D7!%56J,:68Z*N&
M!F6_MATWH#P5**_N3;V>8AY$;&, 7B!B3?R:&L"IB$$4>HF*3 [*F$0ZF (U
MZ%[RNLT GC*]&H&PD6D].=L-H_,Y:0ZE%])XX>R;YO>N_=,0E3(RK6^87E@>
M ^NK=XX\J&1BGQUI33/LHE,%C(Z:T1F'/?^R[?<6N^AN/=)C-%2:?4\I&;36
M<)&$1:KO-5E5UY%I??.0OMBUB+1MNUM5QJP56DFJT?"D*EH&Q[7!?5Y3T0 _
MD+XM2'_'G-BUU/H@<1N#\ *)@V(H<W$J>^L59B]*@H]**,][%YA4S <9,#1A
M $^9FMW6:%I8*93^<73:CMY'#92->TS]'M.#WO"TC)3CZ1 OI\E(-:DGPV#A
MR,@.4NDCH7Q@SB/2/3W#;'G"5S ^HS%9-1+5(]VV*JJH%9@^G[<21/:[^\YL
M<YK3K8=R.P(8>HR; ; :%W4C6*9$YYQ'X=%3;)I07IS#[+ 1X8A*3 RJTV-%
MN68%[4>UH;%DW?NTCP%>VP/EU2G'ZRGFX239&( 7G"1%M X.21&XI# QJ-A_
M*SV:$1+B? HSZ+UM=G-.F5;=5B_)R#F>D,Q?T1*V&EL=8=/]A-I+I%Z= #K[
M+C,,#"8V.>G_U<]+3 S QJ:@D_(I%-7,M*J8@)0N% ,[HVMIYENP:_<-FW">
MTZV'<F77>'<DMKI9:XYB[O.6-):DC0>2P<0F">4%)D;9ZN"-5LZ5GK)84<7"
M3B&::ETJ&'O*H@^CN_/60'DE$UM3,0\FMC$ +S Q T5#BKZ/4HX-P)"54"!E
MG*D::F')?G>?UR=B$P;PE.G5B(2-G./)V6XL#-EE8PDM<K*1*T6Q(16V7+T=
M.<<W3"\LCT)UCG36F%7P6C>]X+.*X$'5&$H&!O&UG&<B;G,BTT!ZZ#,ZV))-
M@-4WMN8+MF_,A4UJ/'[D'-\\I"]V=PZH*WNKR%M4&%Q0D:$T1N<9,R1F'<[[
MN&]S<]A;AO25)&Y-M3Y(W,8@O$CBO!.(VBM$+>U'!L76&J6])Q^2<]%!)W';
M7!XT96HVW6C:Z.[\\;L[?_'PP9.#+Y[L?'WXX/'AXYW/=AX^^?+PT6CV/.XQ
M00$T_$TC\WHZ]!.;-6JP638Q C;>27U:)$GV-4&N.HYX__3,T^5)8=GJI$MM
ME+)(46B<49(X*F-C%@G&!ML[Q&J]Q>;IK8=RRD$<EQB];3#U5FQ#M8,"' UC
M&O'^:4)YP5E4$[6-]*2,]XUN&@R*:W;*12D1="(Q=7??AE%$L3507EV>OIYB
M'JZBC0%XL3S=V#Z0W2E?8U28/*N(F%1()L=22B:C=_?#*$^?_)4C\7HD7F_.
M>M,13<64M0F83))<;05;T7E;O7&#B$U/^.LE(J:;Y/<.4.F0LFH6MF_"G[/*
M5!H+XQ1J:>+%P38WF+SU4#8$#9B>D!&0?12.!8R3%*F(%3^(V"2AO%@"*Q"\
M*:*"T44A@"B*P:O",52I?=>Z3X5&#<760'EUL^?U%/,@8AL#\&();&,KHM$I
M=L8KI&(40XWMAP4*.M=8L>GBT>QY\E>.0-A(O-Y4.J;1H9IJ4V!&(:&2NK+7
MY+5%8^N@8=,3_<O#3Y-+WF722L?JFNV6K)+ 7B6;0'/0A='M[C.,>-@60SF&
MF&(UB2@!@M4L-B*8]I\&CC1HV#2AO-BP68>LFPVNBNDS=RPW*&LV"ERV5?L*
M:,WN/HTBB>V!\NK4Z?44\Z!A&P/P=XOS[W303>PJQ!3[#Z<$H"CK/' *)1#S
M[K[?V^968E,F5]>F89>77(#9X/P[3SL-=-QCFO>8WB&_)AP^.Y-X7/;GLJOK
MJZ,7K^;ATI5_F2>BMQ\+"$*S%WI*_G+"?F/\9\\NU>4;;SR75G?U[V^1>'IR
M_.KLW6]Y0P!VW=?TZ\:UONG/9.Q"7OX;/Y_])EM>-MVLXJS(CTIJ>]B[<ORS
MO#[=_>RM[_3\Z(5:6,/%K_]ION23?BAV3NI.YPEMM5=]Y87C<6Y=Z,9/!7)I
M!DQ"4Y!-R4":8R;P$?#<*&KO*?F@EVN&]FJ5&$UBCV0;UY&*@J0;W4W-<-Y]
MQ^<D<I)UKE1-Q!B$*16J 5V*'(J'M\_.<YD];4O=RT?<N;"??[_?#N,LEUF7
M <?R\K3<O?SE\TO0'+V8K]#\39]?W.OB!*^H1)D?U/.7+W8SN#U WS?TP@=X
M\<$7>[TWW^L%\^#\->0]'^B=+^L]>,_70C#O]<Y_][!@]XC>_?+$'M;M:0PW
MY6'M'NCWN^T?/>R5E^!&J+3INN1'&=W'+Z-[_.VCOWWUQ<'7:Q3.79\0C7M,
M\Q[3$SDC<7,#A7,C,^2*T85<O2^&M6;K,60C*32(@2]()I3Z1S/ 1W3A$S@G
M<<7@U\31<E$5T2JTE52$+*I22A#)EFCC[CZL/[)DPCDB \J48H%0I5C""):(
M8L"4&^$N28,;@<))0GFQRY*/&HBM\E4GA5"U$B94%E/T_3^#M4\\&%#>&BBO
M#!2NJ9A'H'!C %X(%++C*M&Q0E,:@ 4:@,&!LL0>L.EI"6%WW^CU(X431O"4
M:=5TO4/3(V#K5\Z-Y) KFF_!<R!O#17")LPK6;*N"?R<O0XA_M$@[V&^?0+I
MOSP\TA'8ZK17-F2GL-BH*$A6)A':*!Z=V";]S=KE-A-.$[GU4"Z9 ,787'(S
MUQQ'S!ET9<[:I1I'RN8TH;PXLB2$G%#WZ:_1])$E44DN556'"2JP)7&-B=%(
MV=P:**]D8FLJYL'$-@;@!2:F3;(P'Q[II=&Q:DDQLU6Z&!!K&AMCF3.Q;>Y7
M/65^-4)AFRN=&[ZW*QIO0NWK96 QSF(.ADF,+Q:"C5YH4S-+AO%V#=E_?WET
M9-$>"0*HIJ>M0K9647)&Z52=M^S9Y,;#+*YMO$W8"7?KH6Q<"51KYLP&3>2H
M4V[&7%?]X#%L:"C)@/(UH;S P]K^) <Y*:':>%@04-';J+3H6FH,UG%N9ARM
M/;1@0'DJ4%[)P]94S(.';0S "SS,:^^QQJR<T]1+YX+BZ+**2)E#<IQBG/.P
M,3MRZE>NKIT#<ZW:N9N;33KN,=P26^.66,RS#RMU]).'3PZ^WKE_>._)X1=?
M?E3/PTU9MVNY<\:*W=05&Z7#(S]F3/;YY#X<:!0A&\,N.(>:DSAB8W7R !D%
M-E2@, ;+?C!^N#SVIUHHD@RIR.T'YB@J!O#*1JQ<A*L3V-VW=XS9YD#=K4=Z
M!*X@+L<2$)/W4@A<0"O!!I,HCA'2-P_I"ZY<$SUH]D[5%/I4H%P5!>L44D1Q
M(10+L2-=N[5=00/I4T'Z2F?NFFI].',W!N$%9RYFIU.Q1547>GU2](J]:><W
M>*E>*+E@>SOJ;4YPG3(GNR7.JXE4-XSXW57G EG& MI#18ML @<=7,S-XD-F
M-H/&W33-L#PTJ$"MI8 HUCXKY!14K-4H$YR&(*64/KW5W@DX9HUL,=)SKA[!
M>-W+':OS,?62U92\V&(8-S2_=2#]0R)]@<;%:JQ/8%6TXGN->E#D62OQ(>OL
MDY0Z1[I;WV$SD#X5I*^>*K2>6A\T;F,07J!QY$+T44B5A$:A2TF))J-T:4C.
M@:,X[.VL[18#>,KD; 3AQE2AR9EV7, 5'S$$)ZBA4/4IL+?>V (ATB!Q-TPO
M+(\< D_<K':C4HE)871>D4&MP&H D1B#3TTOW.&P=@.B"3OX;CW2K0[-ELO5
M(&MT%LC9DG1-!CS74/0@<3</Z8ME%=&QL\$K'W-#.D&S -&+2CYZ:D3.^ (=
MZ2[P0/JV('WU3*+UU/H@<1N#\ *)BX$AH$G*A*P5VEXC9:@I:_39!U^S2=!C
M<=L,X"E3LW7K*FB,)!KW&"Z-F^72N%I9Q3\?/OKZWC^_NG?X43T6-V7-/GZ!
MP%BQL6+36['IB=Z1/C2F4TS'#47(D@+60"Q(V9*SY"F9H D$H@R'\PWCL,NC
M*\!+L%)1N9! H0].L:U&4736^*B#!-S=![B#L,WM 6X]U#4Z%S &\@XQ!"0R
M.>KH!2N%I(?'^09"_9O%.J\ T;8-#&*,PFR28N^"XB;):S&%(M(<Z@!CNL76
M0'VERWE-Q3Y<SAO#\*++&2U89V+3SU:K)JFM$BJL.)BJ<W!5JMO=-WO;W%=O
MRJSLECC9)E+^,:*,5[7N<M:EA&HES1-&V1:;@^0F0"(ZXP>1NV&:87GR!<PK
MM6V//A92R B*) 85/%(E-IDQ]1F$=S2L/?EHPO'(6P_U0I:#K[WJ0]!'&RFC
M%^%<280B#")W\Z"^0.2L<,HU@W(Z-:@7W<Q!:+]IL$UT2Q%(<4[DVO8.J&\+
MU%<2N345^R!R&\/PXIC"6+!8%!5"Z$U9:U4BO3VKY.2,LR[&1N3"^E,*)PS@
M*=.S$8B;S&R,M;UUDUO._UC'#7,-U$Y*?ZT8N2C.4"T^12?(/I#%K#DX=IY-
MS'&PTINEYKY9G@."GADL106UHD*#15$&KXK6M2F]T*@*[NX;>P?7'\DX89?E
M+8LYK'! ]793FAS7E- ZB**MV"J!D*//HRO!#83Z8D&+"QRC9)63.(4^)47:
M6J4]U1P3>N^HCUZ]8\T(+VX-U%>/;%Q/L0]6NC$,+[!2R-S0&K7*NL_Z@<0J
MQB0J6@L%"D<38J]H6=NM]&$ _"F0\)\;:I ^/:)[34K\V9G$X]+^/Q_]M/_?
M\Q\?-=%_:;M,WZ[_^EU^[#R=%3DKLYVS)DAV^F[NG,QV7IR<[3PO\J)M2WWU
M>QCRDS[T;S3Z@WZVWW-7^/3/7YZ<'G5(WYV58SD[^JE\?G;R\JZR\W<O(E%.
M2[_![OZ?X,\?Y:&ON&!?O6B[6G;J45<![?]FIV<[__>5S/IVG]2=;E/>V9&7
M+V<GOS0E<U:.7^_\QS7,5V?%9%N<%ZVQ.A9T38U1X%Z7G?2$S%>^F:KON'SY
MZ/6__IE?1H.^7?/\._,=W/_A+\?_FJNQ1\\?_O-_GCTPW^+]>P?FX9.F'N_]
M^//]'XZ;&DOZX;UD'SXY:*]]I1]^\[TN!BOYWEO']H%U/JB8#:FV9=8Y;XS$
MM+NO]]YEA<:CX^-^'MJY2>VXR]&+G:,W4Q5V'C[Y8J>=I/PJG9W>:;^U#9BU
M(]VNVOGBV=$+N;/S<YF5G5E)QW)Z>E2/2MZI;:?G1_3OSZ3M8BJOYCC:.3VW
M8G;.3N:OML-P^JH=@)TOBQR?/?OMY0ZTO-,?ZF6973Y'FAM$IT-FO:_,,A]'
M9KD]6N^IX=\^]L=9Z:OM\E<OFF Z;8_:T;'S]T</OWCTU9.=SW8.__[H\'_'
M8EYO,7]^=I2>[?PLITV&E)^.3EZ=-B'2[*ET?-+1?EI>RFRNJP;"WQ?A]I-:
M)7__?5MGI9;9K.UJ$_1MP^^7/!?_]]H%:5&$=[74S8^C%Z_FHOZ-+=__[SC[
M;/_MR\^5V(.N-H[2!R#B;ULJC].SDE\=EX?U@G _*B]/VG*_>/K5BW.#I#WA
M;VS\2?OHOQR?I!]OFQGR:_KU_C??4XD<LG-*L)L>TGZ+T.AT,T>R)QU+KO'<
MM&Q[6_)!-^8J2HR% C!I!)/89$K),5A&#1%V=TJS[5ZV+3F;O2J[8[\GM-^<
MM;2E#BI7(H6DDXI>C"*T"5GZ0LOB?OO8W@4Y6@B,(5![D_<((9-D4RHO[?>'
ME_=_[.J8RZ_#@T</OGKPM\<[?SG\Z\-'AUW=_^.KQU\]?+#3_KGSY.!_#]M+
MW^T\/OS;_<,'3_[KC>COI9ZZ?.)F(#\]>J&ZR';G336Z;^ W=\G)+)=9=Y4<
MR\O3<O?RE\\O?0M'+^8/-W_3YQ?W.G<"W5TA_N?NH_.7/__Y*)\]N^O#GG'0
MW9@7<?J+#SY_%?;F'LX%G]7Y:\[NH7?O?+F1B/=\C<B_USO_W<,"[#':F_*P
M=H_UNU^>V,-^M)7E*[_S1GC^;O.5?Y (-(E\'_JP31C^T)\-[BK?OSMHRVQ*
M*_#7<T?B7^>.Q&\N'(F'+W+)'V)51NK9E3?B3_>Z,3 [[<ZU^^>.N=,_;R@$
M\S[K-[VC?/!R=G2\8^_,F6.W^L?J77OU\+?5@[%ZUUB]B^#;?/'.P_<C>GH+
MK]QTK>NG8,SS\[X8OOE4'E/](>*X%\[(#YCYOW:YS@W.Y%[U%:>=Z7*=^+C$
MZ-E2(@,8;."$443 &UT\L[UV)O?#\S!G=SJFD^?EZY,WTKMN=(;F#W]MS_ C
M/OCAV]?W[Z7V'.T]S]O]GW]EO_OUJYZE!0^>'!_]ZV\/CA>SN^[_\QOS\,E3
MTS_OP:_?_=K]D_]JW^6['_(/]W]X]N.#7[^%A__\GQ^_,_^H]X_TZZ^?'/;L
M+GCX).G[!]]'U#59GQ3%WJVX)%"D:U6FYJQSI.J+WMWWM,V30V]9R>"*DHM2
MK4%#AJ-#GYE=R,5Z\;J*9/;73F090%T;J'H!J"EK:T,4E4T6A2[V08[""FH0
MB<R5H &5\':4!KZ/<;A)(G1%C/[I>AG4:RK4OGSM*S? _OM4ZG^'WIN=1;TY
M^)H%^%H2##&PTI :?$&T:ONF54)I@";2@7EW'VAO>3CCG]\ON?AVU=MNWY4?
M*7#PR5CPVRF.-Y #FW4X\"@4NFI-8&K:S H0&\*FZ=@6K%@BZPC&1?XPI''K
M:_XVI>E>+S'*$K/W-E?E@W8*,X&*&F-O2YAT<MFYD/H<8C:C=? 6XSBD:K*7
M9#PV6S6[F$(IXJ&Z+.UFUV\=/'#\<7&\2#@9@'LRFM*A-HNUN&:Q<HX*0LJQ
M.('LFU9T=\"O/<EJPCB^.;&WCT,YUU3'@W)N#L"+E#,*6 N9&F)+46AC4\04
MC>J]_QRRS\DU !M<4?*TJ5R*Z;&NVWSEK0G(WB_Y24G/;B 'M1\Q#COB(9=*
M#WWOE-MD96]')%['&FW[@Q>NA;V]?@NJ8;M^1-7WX(LE#JJQ6$I,RK ."FO1
M*I8452J)?*H,S7K=W8<[&-9NB3_A<,FMQW'P@.VKV]Y;"EVV$HPM-7.,FH+C
M,#CHQ'"\R$$#A80:O#+H4S-A453?/ 68DI@"WCK7<>S-[9BF?#O#GFNJX\%!
M-P?@10XJW!"*PLI65QN "96DPBH$R[;!V04;=_=YSWX@"CJ"GC?[RAM=NW)%
MZ7=1)+U39-;[2YWNQ-),B-*;Q_QT=-K%8?OGSIG\\D8'@!&B^"CS;[A"236[
M9B+6T-1)-L%HGS%Z=HB#YDU*NSQ>HGG!9A!G=&-XV)-7:U "SJJD0V6JO2E7
MDRS^3K/VMSA$,7 ,O5>&B5@-HC&!-)C0: )"-82>!LV;&(X7:9XTN9NT%J6U
MMPIS1<6,S5[L$6./N@1N. YWVJ];C.-;'VI<3QT/FK<Y "_2/':9(J6@2N8&
M8&D,CU)EA<9',!Q,+GT J?Y@/&^$&F_VE;<FU/AU.3V]NW/XR\ORXK3,VPK+
M\?%)DK/SIF\7G3Q/;UXH<N=/.&*1&S!N640C9?+!1326A'+PA4-RGK64.HHH
M-ZW^EHLHLT_!!"!E;4"%A'WT8E.$WN1FN4H$3M*GK"YKO^T)4MQZH 9"FPDQ
MF(K(R<92;8B)P4 25S]0PNL ZG6 NA1/+,Y[[6,CFBXIC+5/LHA&,45&T1G!
MAF:GPMJC:"8,U/6LK.E!],IMR4:T:-NNO W1HG,"L3P!8-X%O*ND=')Z=OI1
M1FP.#_-'ZV1R.9WJ\)>CLR_Z!L)0[==1[;^7G9D'/WSUR\-OO@=K$J<4FOD=
M:F^ZC$IR(.6X:-)$N9;:;'"]=G^$"7N0;SU./W@CDU4X?3,05(]^*5G]6F8G
M [_7PZ]^ [^O'SS]'@MP,\V+2BX4A2:)8F^"R@$!DR=;4NG&7I/ YO,MQO#T
M[C$]N^\V7[EIS_FGD/B_CXX_FKL^+C.DSN27C\'SUO9;36X!1P/"CS-*_G=/
MW.6,OJ,7K]JZ/;R<OW;ZE_E)/;_N24_A._SE;"8GL[:Z,GO]U5EY?OK@Y$5_
MRMG)\?'<N7=69N7T;"28? 1R<.GW0W)1]'P M31R8()5PCHIJ)23LXD#A%[+
M3GZ;VZ?=>A?]!Y\W/^3!S9 'BW$ R"9'BE%A]?-AH$E1I:JJUT$ M -?>\(9
MCKJB+4XX6W\@_4@XVQ" %Q/.$L?@*V2%&1J*'?:ZHH@*8J!H"P.F>2!O56^+
MT4[Q-EZYD>GS'W5LZ7_]==4<\VZH7*64:.>9])?+B[<G4+<_CG'6'WW@+'R<
M@;-7G-BXM.!'?5YS+J=WWSF:\4+,J>[9N&O]I>8_>I';1MU50'/A=\4O<S [
MDN/W_@K@_O/<[VO\YY]H%=LC?/[6B@#NS2=6-F.]G<ZC/K52GO=YJ+^>QV3+
M1;[G2=WYCPV&&6F1GQSD'UZ=GG5P_?5D=O#&$UZ-7?#--$[6F-_ZG?L^>P>9
M0E/\?2P")AL4>="*FVWH34QB$FXT*#5V]0/L:@G-U*_)*8'>B[164%0:]V,I
MG$%+:%N^NZ]7V(M+?]B)YQ/GNBIL=.?97*?55;JYP;_C=$=>Y)VWIH1])"5V
M16&Z8B3OC=*FYM-JTP7C9L/*](-^ET^K5N='8)5:O=>.PNG9T=FK9F ^;:;I
MZ745Z;I-I)=$[M_:4W3B_O#%O<8M+H[MPWIP>EJ6<@*&W#V7NP_O?6N^MSJ:
M>MY%MNDW=+&JZ+U6%"'JBCHU?=?E[KOF"[TA:_] S,+.7(J<U]6<_7RR$V=-
M[K:C\^KLM(<2^]N_W7N\=Q-LWBF#\P/;O!\<JL,ZNAY*GR3S/9K4D%E(1<U!
M(;)18FQ1&B 5D[(I?;B0WJ,_0&DW=*ZS^>LV"1^;O][F/[AWW[7[M7M]^\O#
M)X>_WO_Y>RBN^(I)Q:AU.PJ%541350#3#DATMFKJ1^%=@9&K"^S?[>([372?
MOBRIFX#'KR=E1YD;*:KM'IV+ZC_<@SL7'KGG[9%?=V_>R2QWM^#<'?B;G.]F
MSLY1N^9H-O?4I68"/YV+>GGY<G;R2P/16=NY:V$?Q)9L;2@Z) PFLH4D7DKJ
MYH)/U\^I?E1.B\S2LX,7^5YI!^GD97_6B]+;@?\KX%\_^/G[($:@8FX&6X%&
ME%U4(HZ4$8FZ-(7L$ES%8'O#&)L?)M7.22JGIQWJ\VV:HS__OE'GI^S.3BSM
MC/W8MB7N_.E_7OR/"@$#HC=_OG-^HSDU>'KI'LZS5T_/G=SM&)_-BLR%?S^9
M!XU+'J6=>Z5O>[/73W?^='#OS_-/_?(HSZ0)C?E?'[]Z^?)5=S?_)#M_^O+Q
MG_=V#AJ4+FY_].+\V)Q_HZ?2X_9/=TJMC?JEU_UC^N<>W&L7YO:G^76QI'8N
M=^0G.3KNX8:=GY\=M:][W!?C#:Q=.,/[$9Q[ZON_V[,>O6C+=O'*[VO3/NB-
M=>G?]^#>L&37M&0/=HX;I?OD!NM]F?U8YH&IQR6]FK6C5TX?%3ENWRY?\LXA
MOE9Z]IY\8Q\<?-]5AP^-5.9>RXF!M>+:BSQ!*@IP,&"ZR'K7O*$5(JOC[SSR
M])LATW3?SD]R_&JN]DY_VZFK&#KO<+?M_W><?;8_ :>@^<^YK7#Q%>9<^L(T
MTV_;!_.4C[9"S39H8GVG?U29 VB>P-06=:<]QZO:?FFKTP2ES&9]#><M+N92
MZR=)J7WT962QK_K/1W,7ZM$L[[QLJ_;Z7?<ZF3V5%Q?6_.G>SI-G38^\_0'S
MJ.<%T[]\XOG=ZZNY*^FT2?KC^;4]KGCR_'F9I:/^J[R4=-0^^1U/V-?BY<E9
M>U^[NEDY[>E>G-8RFPOW>=[.Z;R7QZLFY=]XVU']_<Y-S_3>'[/R?U\=M05L
M.N;YR:OY,\M1GG]N6\N?CIJ"['>*7?@?-V-X-C?%\F]+\FK^^2?QN"O \Y/:
MKIW?X_S0MB6YRO*M9[FMFU9+;^;+G"_$WV>E?XMNNKTJ3T[N__;H939DWVK9
M]\,A-G/-><H2453!W&>L&5&2(*@HG2SKG&WR5Z%K,H_EU^-&PN;XGH/HY?FN
M7+IV3N=G\:2],KMS_G_G-MMIL\Q2FKUJ;SP^DG;'<\'XV\5O_76A9\SY0SWH
MT>FCM/K?Z3RM4LZC,6^8.1?R"\U>Z &#Y6C"ST?Y[-EEFN@;;SQ/4KNK?W^+
MQ-.3XU=G[W[+4N+;)_+8]Z%Y;RW@&S^?S7XW )\6%9LU_*.2VA[VKAS_+*]/
M=S][ZSLU6U,MK.'BU_\T7_+)7+(V&=4S:MMJK_K*"P?C'/PA U5I5D!BCV03
M4;< D+0$3B'KW7>\KUT48Z$ 3!JAO=MD2LDQ6$8-$<X%8'M/R0==#A71&AP8
MZQ.UZRUE+,YIPE@=2\%W?8Z/G#7D:/M@M1"(FC'I$4(FR:947OR<H$D[+#::
M]B!12WL3:0M-T K;&OPGVJ2YP= @?Z["+H3%A<;]_T_[=VAH.LIS%17E6%ZD
MIGR?E7*V\^KEW%/<K*?YHK0M+M*IX--9F2OF-\G7\>NWC8^>P/26 7*9N'2I
MLM\D3+TJOGVF+)LA<XO@Z4E3KB_F5UY:?<OVQ6^??+DI<^5<NA%XR=&>'I_$
MSD++\R[M+GGH%P__\=4]!?S;D_47C\Y.?_NLN27R>IG ;=(N_+@Q6OOGG4\9
MI+V8\#2"LQ^#-??RA-FK2\/R\DS_[A.\CBW)!5SQL0G#9DMJ*%1]"NRM-[9
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MW=?":#BK8(UK]*6#F%"4"J97C1UQQ6M:._0:)P#WXOUU<25D$ER*ZT)'!SV
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M']!E2& Q4O$-O:_17[>.+W:W24-M<2MXZ@6?S1OK1_HD"853/XY-.8D3>%$
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MA0X$K\)#@  "C'G#*137/X:F M]U>)S[F>-Z?A3&+.1.X'O.".NK9$Y('7Z
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M#.RH;4>9&X#HR^+(SD:I[7'N^+G#V(\L:IWHLZB9E/""URI<UO$JF6*#\+O
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MQ6=T^L;>_:P"1>:8',X*YJ.T1T,)W)J75]2"1-VR/=#)(B# [Z:&#%0:!/E
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M][A'-G>TDIXE;?!DNQT!?0*77C<"^J$B64MQU1O-Y%]H8:BZ?+>\N<D4N#T
MN&:0%XNK*W0Y"O2> 6)HX%*K)@!<V8"E(]1!JO:E;'[0 6]TP^-CY9684:%L
MEJ&H)#]FPN\QW6I5N'QE!MAT93FH9V/9-KV23(:(H4+MKBVF*/6HR!E8_K.2
M3UFM^M^2=T E,F*_2+"NTH6 ^E<@VJNF_*.JU*"VI0^22+A3U2_V"GT$TPX0
MJ.AKMR/?G1DOEU#1!I9AS )_NRO&XQ9Z-2TQ,0_9!=%?\_+FSJ>N[5&\ZO%M
MDLUF)_WZD5'FKJGI^2>[*P_6]-,Y//GM]-^[)[M4KAYV+ZT*8<NC=JBR/AIY
M58I\2NSK,KZ'HU^(&J-523VA6+88*V3PY?T,K%-@M'#45::GJ0^$@\9[\ZBF
M?^3J>6R_O[_@=5&="5<U8C>;FZWJ$+:F.=AS;;TLJTO#TE'VWEU1\Z:AE^J[
MHVQ@B:QIP=.7NU$+'_"*3ETU_^>V WWR7.3@Z/CP_/3D84Q$'3>I$&)3KS'(
M1"K?B;@KZ:V>Y!B6[5("-6>H,34,Z?>>/@GRK+G1LTNHG*89*H?XP\!.P;,#
M.R%1ZKPU;M3&O.7C<J:*] &MPEM$T8EY8?:P!4(2E7\)!#[H8X))B2485K55
M6]TIL@,;MO^D+#%/Q6PA"W:T @R">2D7L2#G,:;U%?-2U$O]4>)H5=-)I<JU
MQ5)'[<3B]/V!E#62Z@6:M58+].P7:-9J:-9&J%4'FA7EMI/Y-H_\E/E.X"?9
MR$YB.PI\AT<Q_V$EC9 I/E.5;66'5-5NL5_WDH+S3S8_U13-JBL@:GF^<:%?
MK=7!-M[W]VWZJ$]V$Y?),+. )OH3H6J%@#X\N3PX.CK8N_RP>V2=G9^>'9Q?
M?OSQ2J4P364L6G?RD-BQ56U7.5Z)0)>!3$B%P9#@AW\'E'%*P8.9D2EI:/8&
M8AUI$J-C\XHA1*:Z$=X[-!5(AZ-J6 OQ*% A@(JTLV))RRPJ*UG46'&A7FX3
MW52CI#3BIGB15EAT4C&,X%] [K<@+#+9:5A@+.9D4I2-\%0=%&0A[P:A)XJW
M-Z5]^JP.?3.<:-01>/LMN71SSU3V^NX8RQA=:2O'W*I6BR)R%(OB0'#-G F.
M($^OFF[=6H+N^+N,!8MZFJV Y2@'(CJ!)9&0C4VQD+FJL-9428<= C6=+^T%
M^@VI>&<AFHYT6GJG(@>6,MVQ^BZC M^"GTF.HN]H+0;!I; **9%$T^5"8NF+
MJ:PAFELU&\/UF4R2EE\B%?*Y[D4"[QFH\)+<(5W5>L; O#(! ;DH]E91=QWM
MT4)?=O-R##1-AS#':ZK-BJT;$&X%5I8NW7!O<E<X!FQZ1;5/J?3-CG5A[$1S
M'%#E1I,J07 +J-YW3]V<!<ZSCE\>\^R2I]<_?IS*(=NDFT5H!,]!DJ- OEB
MZ$FQ:7%31W7I1^N47)@B/-9;4E7=TE0F$(=,LP<B$PH6*\-^=P$\T/J% ZU=
MJZ?2=U0]]='&@ZJ;*N.VW!(QVV8RJB C>FCSQ;@],GC AYV+'>M,C/JDA/,=
M#EP?_M^VK2W)]N#S]FOXWH^=P<AV]/?PF;X/7'<0VZ'^'C[3]Y%M#^R@^1X^
MP_?1P/'=@>^/]/?PF;X/P=CS1U[S_<BC[R/;&83&>T-Z+^Y9// #=^".FG?
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MGG.0H<U<T9-:-V71-F-NC<.H9(S&U;7R!2AN4O'AG Z;; DBA;1J#M9/@PU
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M!AR]\TOS_*7 A+CR[P^[+'<\-OLG#-8U3QA8QQ<G[?#,657<8B5?-+/DS]1
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M;K3,/ES!M$!I0D[*^X<Y.C71B:?6/X%H8@G#:>U6Q==R2A_4PN\!@P5M!Z8
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M5;GX7)Z=F>C!,ET4-2K?1NX?I;=8MT4Y5@@HX*U\1IH<HUP8F)_Q:O%"E2&
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M25YHDLDA43,KS6*,\'S?\B-&ETR!6F9)F4?>1/+7;")#2O+"K)/;K"UBHX?
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MF?%.H3E1&:HCB]&(%*4QE@JS_Z6R'EEB)SRV'9OST.=YP$9^X(4L3J(D]Y.
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M&RYZ"_.Q..-8GYU%H;S*T;_?GU43%E?H"<LR%Q?G%%;#V^8$T;0F54D=@_>
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M9'68;-8KYO><P-(-KQW80;]MF9;3)H9IM:EF.ZYA!99)O(5E#G;'9"_!P;+
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M=HJ@HK,'-AV9ZW<S(F& SV[2DN*Y^X@]-]8F18QW@#2%E7XN>MQF96=!T:L
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M8#:?EB.S9;#?-NTN8[!=\-!LU%%M5G(WDWX+,<V?2_IP:O'WY&1$ITX\$B6
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M==?9&-;PQ$4\BB%>(RRF>>5AXO]W'/*25AE[5Z7(8(9EIU=4KJXNFV]S,*G
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MU\K[TP^75Z?*IRM0]Z_/+B\4^%.YZ?[G%)ZY4$ =NSP_W0M)!+@!G@D#=G*
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M[U@6/ F3C4C*R1C'CV 1*5\"+AK^')(4X*\$*;!IC,UYV+2LS0[*PZ6-=H3
M;*/:_]9TBA,EC -8Y]NV[K%S;DWD=].01,M0KC^&<MT6MT>&\VY'$@26\&X*
M(KK%XK->_=2-$:<ECGLIB@@ ^E>:P^!"(F3;@?,3;K>)$&< /TZ&PR0(\P<
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M#AX7G)^AT @*Z8,:-*Y8M\I'COII,L31H$D#_S,E^C5.E.1H&L[>*;<0".M
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MTDQ/3[_^NCMR8VIV? (^C$<7?:"\P&47*E8W&?R=#1^=_>?YW=5:TT$Q3S"
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M26\'"(<]Z]]PP>3=BNCV+)CB]=M6#AUN&NAPY\_WW:/N]7/A@(?#I:V?Y<4
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ME#C\(P8!FB'H,P\((+?Q#D#NZPB0.8SZ8 GI"GA0KH2/OU@6MPI:KC")K+"
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M#V6 #PX("/B&D2(8[$$9P+C;LG/]6CE5J8 V0)!O+ D*Z1<(@DB1,I5!&B#
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MW8*'*2^>BM*+%Y9+.*=7^9MG;66J7PYN@/5%Q^IW'T:#<:?795F08C6B"MP
M44:]\; [NG7O^#ZFZNA8!; !8MRA",U%$]O-G9LU?U8<A(@%=D&F2BQ-9 /$
M'!+LLS3U#H$I"E"TKMKH I+5^EHT_N+%^Z](G4KMPAA@I'',I@]$,?/= S*
M;;&MR)V>P 7/1Y_@]N[=$?3XD()FR!-,;(]1\N<-W4&G-TQ2V.QTRQ SH6&$
MDCOGLZ*6 (1TADD?1I\92YPP^Q7/W"4F$?I34!8?3,"S_,ID@]@TM&)6IB9M
M)3 IATP.,H:$'RKAI3S)">J"/ES">F$XOQ43Z.2P^:LL^>]FT5 K\BC!#_7P
M,O0T;M-[0!XAC]CJ *-$-2#LZ-^:5^/AB]<1-;3DAR(P!!X/;NZ,,-,J\N<J
M< -L[EZ<7K;WEO&5]?!2' .$4F21[C.J+(#70GV;B9R/EDEH??E$;@27S)U\
M16'"/I0!%AI#\2) >@,<"PBNOV1S:<X]?W&LWD;FRXB9L(K\I3=4G+C+0QA@
M-];U\]7?+<7-<97@)HC2VN5-5?=>!6Z *!.6C,W6BE%H#\@ MCN#?J<[XHL7
MT6(=K%CFB7PV_BN7565(!H@EXDOZYKPHMN>)L68DTT U(6[M;-*QF<$(BAN4
M><K/HZW'D[B8)P=C\)2\7:RSVZ=%R- '+0J//[$)%-]0AK<P^2FFO=MWT+DQ
M\_,?Q:U)KR%LZ(1JF.V^;ZIPRXMT5;MW]:@8$!_<]JG3S.VF*.\3J(0W0)C>
M_<WHX6NOH[KI;!_, -9=UDNT2DI+ $U@GV\S?2.,")[-5!/0$E 31& Y5=ZS
ME468E?!F"./D$T35EFH5N &B9)6A]>XH4V&9(%C_Z^ ?;M]-?MYW%;=F5((;
M((K;3*<CMUJSEPIH P0I7K:R]P2C]!"A)K8)2;,X"9[;1E<7V):#&V"SP0IA
MY"NVVG=@#& ZNX>6WS_;?6960Q0.9J+<<[#B;?&%Z>1ELPEX3G<VU-?:UB5G
M:CK.YEW)VOR$ !\N 7E4G.R081A@[N3*S.4R#G4/<A:!#1!CN !D"3S(Z'JJ
MJV?+80T0X@[.09!V&!:9^5L%,>M+;BI%Y6*\"NTO/@75?2* 3S/Q,U)8I@S2
M +OPZ[>#-1LYD:*RHP30 /8'DXZJW*MC$+NZP<C(..2V63J2ST?4JQ85\ 8(
MP^_K51_HW8?ZMS+^_HSQ3;T%&U<__O+_4$L#!!0    (  >!G51TW4@2/R0
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MX)V,E#+:IF+T<6Q/(<7>RBVN)+'][Q3>-R' ,.3F,1+4BYY(HR.Q5#@BI [
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M;\_9M*0*9_DW6+R!;CQ+XWCQEC*$[7.C=9Z[8UJTP>"K5;WG\132"J#[,8Q
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M=%>#BNBP)I.9>,38;OWP0>5+]D&O_8AI3??LXO7R)>"S__6/_P]02P,$%
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MIDLUF&+ZX>/X\X_T%N).\/]2]9>P^.6"O*WO7\CV<:M:'I4?Z&<'*=D226K
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M4Q6905R8*&0A#_(NX?<Z76Q[_K-EL3>A]?C9SC'I']9"*D+DZ(PCC5+D%*J
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M= J\<04$;=X9$^T#LHW]LQ76T1KT]L'[IDZ]G>7?P&9:^HB+J,,N8)H&:N_
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MY)B%*+Q-%& 7=$^J..-Q6K-[W=\C26G1<_]6O[C[S2@&Q=0AS)K7>%P&95.
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M9\Q:1IXHNC8MR1\-^33TZ3",-?#B%\!O0%VG?PQ83,IX6VBS]1QHFV4D#JU
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M?MG!UEDT*4S2('E@P(0E!\QJ^O*T8<!LKN-\6<F-YO'M"/"D;<46)#6(HN\
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M<64/\)XX@XY]\%0K:ZV6K(G7_'C50R>NA8S6T+5SM*.\W/V E._CN_U@WKR
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M?MB'N]M=B2\:2^&48PP0HU&X!W!T%@/ZB)$)Q-AD#%Z#1[V! '<70JUL7+X
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M 6/BI3D8"A-\[\NX.L%27X![7_9"^WE]MSZX/!HJ%?&5YFS%W;9;''HH4#X
MPH2_Z-I;S!)T(+$AV9QGHBR02LQ$; !%EJ3QE&[Z>R.2*MB'4J-^+['P*MQ4
MS,8%/,KS6(AK"!A?XMELBBB^?^^AMLIX/4=S,D,7+.4@<]X,FL!AR(VQ/9PL
M]Q)TD$,T?GR/3[,ICG\Y*CA0;+(8%;/#M_FL1,ME25#-6?OFJ9B+O M2[C]L
M^Z"@F2"I-0E]-3P%"SA5</J\ME+/T*469_X$:/55<*1#B^>5#KL-R;"'H2&^
M%*&8VT=+SMSCJ?JV=4^+Z0M&D[$B#&<PX3GR I#<.U(!YMHT3QFU7W>HH>V(
MZ]37[T^W=<F9Y&H\(W61Z[^!\)*@#"4_CL'KS&==\NCNDY82G"B^@0X(3U&H
MRXYB0[A6S81_]>6*!)FDD/[.-95.MJ7\N7;1Z^SU>Z<-Q&#1/ZI-/Z^Y;#CB
MPEF"CG1>4)"FS$D,P>C['%+2>K_3_?5*F=Q#4+#GO4RS\$!]]<K$:;?Q_AM.
MV3TCOPQTTCXI''CK(YS2]:EN!#8?R.*3)L%E6/B_C@QI>Q;_$/VT!U(#[ ]$
MZ?T9,;_\#;=S>D;CR".-_#/IA43#4R-*'WDEUG4LV@7-(7&C#(5RCA$58"WG
M"#*?,H+ISJ@I%+2X9Y$SGL*OYBS,JW,UR*?'=$\W:"_L&RS0&=6*R6[/5LF,
MF=:KWH*F<71VG/N#)6P[R)+&&:% /5#951(UU'G1>#7RE?H\PB ^@K\=OW1S
M:^'JP,:?U,!%$C82'1C%K"KNN8W!?4:GCKZ]:<4'QDIOXJYP=[;.RW79=4.B
ME"060K\%[3&W[_"F>]35W/0KX2_W5"G1%,I7D1>JN&7%*4,V15DBFIP@64*-
MX!MW,G1AA-)B,TRZL7="G!0CJOBC^Y&7S_U?G"W%UE\MLKV40J+R><*+4G V
M/<6/SZ/?<09PZ1=#TH4E( FXLP2CZ2:,:\QTF/_&7 F9".^!"R&5+47\I[P.
M4D>J.1/(VSI\?X?4V:NMB0'(HIA@57JI7<'6,/$FI@;)S2DI;Z*#'4$-S7YO
MU9=(I&-NT1V]8J#B74*X6U&8M56)E@[%?:?XXM#^#\,5]=6J-3J?SPZ@*P5>
MF:8V"6:'0"4<G\]UE8<+GME+GU<I.S;JZJYZR^4[=P:$44,=I:02X:#)((O/
M#R@@%.?BOFZ0U18E\^=[?<5$&OT\WQ?9SR\O"?0FU%;,A+<G<6GSD86Z;BYM
MZH,'80Q941J<.MJ_P8/NMD3[;<SE#HR#9%)@YOJ?T72,%.J@KY?%WX5OB:%,
M]TOOZ89%<3_.*A\K_SPH W[\+NG'6G0Z"4U! SZBH/ZO-;O7J*EIS+O8/I@@
M6$SB[8'M"7D31_4[#URGD?2E5V,:JKM?C.@T'#*1V7R=3] [/W$Z#UFM6,P4
MX0R0.6=>.#;](QC=&]*,># :<"9_9'$#.VDD8":EQOBX>)V>9N*XUKK_5?'-
M?#&],'*VF%*<L\3@K=-__V9 =B-9 I?H<:/T/6 2(37;N%;1#0OD9J(TAXAL
MB)+M\]^;<)]Y#\L\]+%.\=.Y*F<U$N4K9DWC[#2XCO%N<6*$,RT34>CNPYQ
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ME8<YXO5,:VLA$Z#R0Z>]4L1KU],^>[GO0O;O-;L+>\J&@(=$^W.3_V(8"OR
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M6)J*Z<^4]YA-^ETR.",X>C#SMO63,XI#3_RN%2V/P('1?ZO1B%%:]@SLNJ,
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MH\&(<['!!:D=MX7C.YS$-DRY_!L+(;,ADA'BM2XZG[US=2=7;FQ,6;>"K>B
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MEXIO0??N [JZZF<128[N!;V^*AZ-ZD_Z;F?G^,I^%"GK3I&W^K?WFP7G[3K
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MNB"",*;N QK+L-)WK^BF*,Y-9$NPTT-!01UA?59F[IFH ;[%QHKJ4L]Z5SK
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M?&WD2.8;.UX2^U*M!B0T(YKM47-;^37KLZ"Q^G%[H[UV_<R"$DS4(J[M8W1
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M"U1X.44'+VR,;ZTM,BYU9RBX=MT*0W=G+]%UR<9TUYC+1@9U*Y9)03@W=C;
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MD77XTPBC,M=6ZU0U+2O->/:-/_.64?HRTT8$T?:C_(BKFTG8?:*.9$$%")O
MIZ&7KZ#V"%5$RMKA2F0N.$RM]?)=B: H(XS\34B/5E/H- ^()-P#+4_35E(D
MP%_()W1N2GLAMD*R'5I(9M,A9-)!&?<TMY!C#>3P72_P?4CNI:U6FL_0<QDV
M[)?Z+Q"/+:]31O<+<C8SOI4I3^'KA3B**JP%*I^G(!),$M2,CCZN?I?FM?><
ML]<3K\9XUTBE&TE['G6IQXX6'UPW'B5;!LNU;#LGNQ(VDV:L'%=P,OA'6),5
MCK/_Y;&7)3^ZN*O=U_P?L5HF$E/JU3I"ES+1!1LK*E)S[&I**T\"G=MA.[[L
M>X(J7C_HLR&S*69ZX,V!S]D<NVA&A6=7B$)9<X9>,WUMM_X+A\-'DG@&V9/[
M4:!E,@6T[T_7WB8& HU)A*K8-$F4$NZX [[&;+H0S_&RAKPQN*G[PS"[UK.5
MPIJ].EYX08]<?,-@/UVO5 [;6Y"(=1EB3.53U QA-Z$QE#\CR 1GB8+(P:]_
M^:A $2?$0+MMU@)[S'!,Q+3TV[?O:I19?\:;U2=PH,1* [SPGQA:6-.$4U ]
M_\8@KTTBEYUCL,4_\*$2Z/I4\U!9&;4EQ^)O'FME8!Y!,+@VOG6;^:;&;::I
MDVS7AO&_B:2/?!KWS;1$G43!GY(1B1-08K EPCA!E^.X&SK7ICU:'UMJND_I
M=;#V8F;><FLJ4JFV*=[G:M*J(9DKZB-4.+X7 _?9M1EDH0M\9K,08_RFN;XM
M'D'<*$EI,@8_+0B,%++G.GMKZNB,9^,Z9HB6_?/A 1HHO<U/&_G_RX\,\]J0
M 8/+YZ<)7FRF\_ J\$Z0()AGF#TT_,6O0O2IOJ[G4B,R[/MNFV?2YI-9XT>_
MK:M.YLPL!WBD& ;H/2O]8'<HWMMB.?!Y2]!4K\G&\3IOMZT>M2AR5)BGX"XN
MFBER@+=(XH%#A+:+E@MC8F!U;8#PP^0MXCX;M*% /QD_P/\$W>S(97,YLQXX
MD4X5O2E/I*RPMZFA\+GZN'R<77M2I-2A6OS*@"_U,C_Y]V"7R.B@L3<): F(
M$><?PQJ<5%<59O#(13&@<H(P<;@@U6 U:_W%OPD3VG.,GU =O@B6K&27BUAB
MH$H,=-Y#G!W&1' T%&2F$2FP-V>,QCT:4W$G][U 78>>9._U,&?:/0\;^JM-
M:ZB-1O] M)-L.A0BP$-,#@E(L!Y9P9OCPO@A7749U_D%<?;A3PL=54N3VG2&
M\CEC*U/''U.K&^WUJH_$N+D/EI>!]H*:09&A)^P#:J^H<Y[ZY[6B?)*G?7=!
MR6UHNX!2MF?_;72P$P99V9Q5V7A];CJ )5UG>\XQ7"+58$A5J  [;>:V:(5<
MT=Z&MPAB^:9A[O';'1]2E->SIA*'4116T7W?1<&5P-F\ YFLS_K.@3DXU>RB
M&]Q94E'0_W^AR/]908IX[#]02P,$%     @ !X&=5",=9C8!>   B(@  !,
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M\S C;?9+<]08AQ*VW\GO#:S19?6DW]F!=$@0]R 9QC:BL\@#(]CZHLM";.T
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M^;WW^SY_/'^<Q_PSQ[76=:US?<[/9ZUSG:O,SIX" R[[48X!](.-OX.56#N
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MKF[9G>-JE@^&]-K^^'.:8KN\2_;6V[$/+8SJ:7C9$W)$W&/+A4)AA:0S\%L
M9#>?'^&XT$P.BKWFYJVMANT;\U]<?=$"7O9%4O2SCQZ=: UEO,(/"JH(HQVB
M^ZV+8$Z*!5"&GDGUT$[H),.1Z,-!WM,N2NPQ*[T1)+;$DX5+V*BUO9\%A;H6
M_YQ^./6PVR7$F]3/^2KS_-U2R<.1'\2OL2>9R?^A#W9=_G]<B]Y"ST1KSO+2
ML]&'"=V/IQ1143N+N;[#9IXQ3!!Y?@Q(+72SM-Y N;U_4+&\J>00R;NRT:J_
MXK%;?Z>R;G@'4.M5G^:JD1>X,60.@EZ#90)OK$>?C#9^@S;T_G%9:18::O(T
M]NZ1W_1BO,AFT>UNDXFV?Z+*\OK8/,$);8L@BJUX7S//IK0W+Z1X/Z#D+>&.
MDEG@K:]FN5:?6FVK=2QR(\^EM>-!5V2:1 F;;8H?=7PZ*OVP-Q[/%2 8LML[
MY:S 2+LT1),J#8$HH7S[-M"R7[CG[#!W,O8:W[/HCR/4%34=-P]^H8!YS/,"
MQDWC(FP>8PQ96V+-HSKRA/(?CM46O;X--L\3:*JU,>(0OWR+>+M?]M72P+.2
M&UMO,@-79$UXWJ_L8^[,O?GSQOMFB;HE?^GO!F4[)BAU_R7H,,B>^YDI3!$N
M2/_,!'F;\-% 0"I[.VK*Y$864?D9XVPO?EWU.FGVVR77"(G4<@7O]0!?7VVG
MM3(1T<6TOV<]7U1>5=I+P,+8>ID@-C.6?TPSL%"2)4\TIBJ?)F#4Q@0=UX81
MH,FXF=R4I @AMUU.MN@@R^NC_5YJK4JJ7I*%/5G']A*E'SAJ[F&73::RY5!)
M+*4+7!C;;!G$^;3"2'?R)UFBKQS9[H/CGS\>0K%6*OZD4X<D>&G+-[I;EPW%
MOM2KZI**/-;U^G?THE&[%(AZ.8' 8 .4B8AHFN8(/ *8\"**1:R;5J0@"9]J
MRB_U=P8IEHD6O3TO>V30]Z*6I6C(H.^_+S;]BX&O1DS!2+?!4W&4_OH<:[)E
M'/?S^4Z3GT#CM62';\Z'D3H7ORR&\KSU 3VR]=@:I!R0P"L1$]!J, ZN6P"$
M,?@Q)VYD,G"DCD8TJ1.:$';'$9F49M:G>SA+D(K2#9_C"HYO?WBYT)"?\LIR
M,J]$>:.)N%R?2M(V(71QD54SK+!3]Q'>(I>9('1=5NDN>G"1,$1\FE)D=>>8
MY!$10T8<PHT'D$6NQ5/-RW;S!9M//D!X]/'0S$,UJ>+O1*G]:@^V?2<-Q<)+
M"28I&)(W*L'S-JYX;8:,&V=<3#^%)'*:'7D7ROGZL'S5;CP[IGA]3SD1?O&-
M]!DS?UGZNL-6&BSIE4G;-H8=*%;P?G"SZB1C(VVOTX24F+J7HQM6W#$(R.2O
M#Y),?R&$(_H9Y_+&^8S<1;@J1]_AH$E-)>F/F2!,O5B+.F$W,R@T?#13@_+E
MFO;M^P^<KY<E78WDD9CX/:F-/?3:;*EM+/G6;M*K+/S47H6&4M^EE;Q!(3WS
M19RI+R)!/YPJ'>R+MJ+>A4-^P,N7-9+\*;F^XU)?]=.9H#/W4=.?:2P B7P(
M^*)O4+T 79SBD-MR>(A&W?25R'PJT U#6>S)QJM_JW8WQV0*41>8H._T*.Q5
M[6^Z[IA^K? AV*\#=3Z '/[O,%']J' %5[H7ZOQ&IW7PUF-%6FGA,(0KN,OT
M[.:YA '5T4$9&_!&!>*AI8[G?5%N3(A:,Z)@2)\COATZTXK)6GD:X'/K1VUX
MZ(+U[WUX/<]<KYW02BA/9Q/T.G">D*M9ABL;GKMUM12>R@3-2>;W3=BX.+D4
M3Y>7QY0]:<<$:KZ4 S]#"?&WJSTJ.KT-V=1E(%+7"<&!Z#\H)8LI=R:H=UN3
M%9QY4B[;8$[9LNM$='MW@4DRC*CM"DJ72=6(XOW>.S4IIU_"JSK?'3(SA6DD
M=,[[IC59P7J+?X9?%CH<V]HY6N@#P01;XI5II[(8QS*(F"E]XBR2!08LZ19Y
MDV;84$>&QD.DIGO!S]1J4I8"&[6_#,B,)'HGF+N]?SK^M.3N0K248 PBHG1[
MNBN?=$<9D*O'ED.Q&&[&$<:X.#?9)TJ-"4*: G/7:\E=V.4[A83314T-C9E0
MB-@]P5&O<VF+4X_."[2KZ+Z\\ Q=;/4#T?H7%%^6=_Z@HC*CVSH_.4(1$)_^
M&XC!ZR"H[)V!^W 3L?*?S?>ZQ7Z:?E/D)ME:G[LS$4\*_/)\[Z#.58$)<#Z(
MQK?).(XA13&.9\S[)#8H=V XW!L: !-LI@:$J[Z.T5:7@3.H\4_<S3,?N3Y2
M$S2D^:;G%BK:%KFK.T$[F=.1?P+QV ,UM4W1I#?3_$B-\_>KR;=H?Y.1'?WG
M1GISVAM*RR*-PA(]0@HX'AN5V#B]?/]Z].NKS)D57!"-?X)8O,ZA@15% >>1
MZVP$DW@R7(:L)BY#HB )/'&;!=/NH>OH2S>\2MSUC*93GPPI?&FX\9?-C5]7
ME+[(F=_E*5_=.\A]\:=QC1TDS\V1GFRN5[N1]8F(=I/#P5G&R';*5? +^*'Y
MDIUD2Y/8.9OZD?*Z05[N>W+GZFV?Q=A_YC9_B3#%N X"4M DB#8K -DPA!"M
MQFM03QC?[ZLNV*9S\@;-XM93U?K!#F[=MY;X/V./, )ED]H7VW@;E\0?1K#&
M*_*:>QZ(]9/E#B:98R:1Q,OI>(0(4(VM%]%HAW$"A6U;*Z&7T6EEL&7#2EL;
M(Q^5M%F<_J$WCJ[7SG)JJ; /@DGNK/#!0ZFAET%$:2[T'";( _/".B[I3WXD
M0WID76U3:)5?&.5MWZ@Q5(L>J>^_DF+$[I1V?9@7PGGR,_NJ.AS+"JL'*36V
M-+F#V4P[/8X^C!\\-0N4MC,ND4\T;"*UW3[AI-$-353RUO68&/0Q3L]$OW6E
MA>I3,LUY_]^?[/Z&$J,) ]?(AJI"[7,Q=J)DOE?3];8_UC<ZYTQF"WUM%06+
MKM:Z#N:]S0X?J58M-<QPU31/2%L;FY@/88]"V",FJ83!%-%Y*';N&4XIIJRV
M=)I>>FM;<51OT4@N_HR>:HU?O;:EDT:KSY&>IZDS^FM9X'FN@!I+I]O3:J5*
M[AE+LG5??.[@ZGS->BY]OKA8?)W79EF@=O.]_NFYOV@2H3!WR>5+"++  @#&
M+U[Q2/Q%447M6*^YEC!&NEC,NM.28@=C@B!#?38T"=*9(T+#"UG@[>%%)JA
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MAF"&Q-14[:<X,N[WP\E+S-WF/= (& D,;7.(OVZ2,W#* +9BC2G"!M:MZMC
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M=E/2 HN-@]# S<ECOQN98+"P>F&S6]H*GU9CC4 #=7>BK=C  P0]G@U40W"
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M"A*'M 6M%[4ISKK?JI'?X=(GU7K7C0K4^10_7M:T_1BF:K+*\=G.C0U$LW9
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M4%NP9[!"2)=0G+R<UR/)G2Q=V!UCYPD<!^AYBHI/U*6?5+/HO?JMKO^GVOK
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M^C"O0>Y^K+/R^NOERYZ-EU/6Y+(VRA.:G?B-CSV3Z4UP<"M)'3BG&Y5J6U:
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MD3B20GVP2&R04>)I></#5M,#WIZN\:%A/F.G#4R-7&>N[NQ0<D3:N7\=\G'
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MP"3J-K6O2/XEVUD>36A9%'8-FG=[?/GK.ORQA:%8S/N_@\/? &)U8^D[&U#
M1;&!JWF@DM>U\G7CU%4V\&3\#!MX9PGJZ77:!:\CYS&2AM#&FV6;]#C\5'93
M$):IQ"UJ 3\=,O$[=;\*QQ"K"[]JS] &$]]N83F(YDP-!=-^D(BE\[7"?0>G
M,O>Q@4^?$VA0&U0]L8L1IXI.8 ->IPS!4MLZ>]]0]"+'/Q(G$_I-L'R+(NA\
M(VQ@L7_!;PI3B64\,0)G7(QG=3AU"8)J-P18QUAN,4V8U7U@];G/,OYD96&(
M/H7IK/\KO7\7GEG(??34N6[\HAB"#62E5'BJ_K+.C-YHEAX3/HTV)^)'7\WB
M08^HBMS^'7?B_+XRTLXR#A5BU8/<(=L,:1B,_]-"XX.)L$WE=ZR$-;>UC3WH
M-N/H'_"M\WP'LG /-C_^5*+3XJ326RM$%+!MJ:Z]4_<ZX757Z-UW^V<TFZ7.
MU1O[1AR3K:#,?$P EZR29\F5)]Q )T23UDA4$T8V$JD?BF<S!=(;5YT\4J;'
M+4K#5!W:4HA**2&ZAY):OV_>NG+H[#:I):F*BN#+ES:=?]L[=$&)\]H%WQH]
M9QE?>!I^#_Z&1CR$?$&(X,'2 0NK_BU8=(@2-$([/K@9P_,CO7)5K4B^^AW=
MC>JPZNP_OO,^BBP^@:)Y12,#FRBB5P[.SVG$)5<H^1<KIA0KW>U9"=8::_,@
M+N3W^%O#&Z:2XDH#XA#G*A=[0XO]?)<T)%"]>^#\>.="*.$,*2!JJ;SNYF1#
M=6@[#34]>S+<KO:18FQCR(-;V^==HLM"NU-N 6:!H-];K[$!;CB.EIJ[@"D?
M;$+?VQCC"/9PK88(O>S+Q57OUYK:A)TX=#[]<]E1N^1+P&:IKJZ:%-6%#82]
M8'W.W$M!/&( >F<FND3MZXOL/4X4)9XEFXM]+7SF>"[QJ(?PXR:7W3LF!KOP
MW'@WN#"Z_B@4L<+)$*$)D):<UB:Z6DP%W*'A?IXSU;"=\_[B>,^UI=&V:])Q
MT9N*B:V!UQ7D-46:#AGR?>NT@A^L=74+/)+TU,M-G. P1^A(C8J4(2YT?[<H
M^C":*U5HZ/CF\\;#Q$M!Q?YUBZ&#<'5TO17:JTL*]0E>UEF5'R+4\[)/#R&>
MJ UL[(J1ZS["!LJ;O0=[\XEEA_)%+3(=A]-W/FY/>&5PD'&RA&9!;FV"BVKK
MR],O5I&78_SR8==>GW3]\,%.WF.GA1R]Y^AH@6ZBZBJ>VL9\;\"+W&#MF*,X
MG.DOQTBU4W1)>C9[4')X/%D\V]/Y5K?32.V)$%N1LP4IE=VJQA)>..?G2G)Z
M*VE=9;S$W_SV2<:*W$Z"O8TS#:S*VL3%KC5NWBUY1O!-UCFFTJSMI7US8]74
M=MRPS)]YA>R4%U",U#490'P[LA'D(G+A\WMN@O9UGY%$3_/:=NH9VMP$EB R
M810WB>6POTD>/N.=(I@VEJ#]<.R6A=P=A>=G1&<B6X1NKA.H!ZSB[35?./::
M6C9CS>]ZGM]MXU&W+?9 \86PV ,O!5O_B"Z-D+(51@I> &Q?3M S\8H4(9:1
M%;I^JXPJ)(B>NNS 0--O@MF&-X">!;_=^X?RQPX(ZX!59%:@IV)UF!%>(.F_
M244&L(S?(RBM:WKF(.5_(JC,$%HU. W"P=9.EO]?:OV[0$\RP.Y!W@CD15<+
MT4S1BL++3MR@%H6?0&:-9\7:]V.G7QA39N;9@-96@ !K2<AP$T1=N_0(48N3
MW'\7B 9J#+ZJ.XNF\J&9DIX-JJ-L *&Q*;,.I7-#6?':1#'Z.!^Z33]J'9T.
MQ;RO89W7,RY@ ST7P6*PKMSY4\7>\5TA4IX4*2*UADS=6C5UUUZ27#!/(XEQ
MDTQ([G$']'9SNKCUX+Q!SG9#: 1]A2*>/-$10(T@CPYD0!HS;!M3\;ODR+ZM
M^8&V(D-^59[3"4L)TH*&'[<KN=[0="G %+QY>\5(\)'26,#FT?*Z+73CVW@9
MY"VO6P?+U=9,%CS]X&2(51</Q6TQE^))W*C'1(WSXJ\+)3QF'"LG"Z7R#&LG
M"!@6CGC:Q,GVBGV]\<CP^O#C-BF50TM?EU0'0X[2I$AQ&M*G*$F3F(1B/=M)
M?D=U1]T+Z1>ZS3->SXFOENHM>-Q:@\G7%HLZN92:*?P6(^:O;K5E+6K,'?5@
M,S'(_O-*LH.G$=5F?>V;4GR3N:!:,2+ ]<M*86WQEY5I1J7>3#UT)TYG%E[N
M]I"U'UDX.96&#].N,VB![$3NG"TY6RW=+7<Y=P^PG/KE:D<8S]87R/L*4^H0
M2""))5#7%7%4!YZ<Q@8:=-G #L.*6O@(?!CO2==)]MVYN1KR:6/F\\C&H%19
MYV^AYK'YU]P['\RVZ4@X;2"6G.8WJNWGO*KMHDF%9W;Q=7N<EZXL-2569!3?
M6.^OV_J62RR&L':M"'IL\1#T5MX-&R)F;HW@KW.//GSA)M%BYI@5.ZJ8_"3<
MJ^9=5JQ*]$\"O8AV&]]40TF"T57DMZ$?HDDW ,NH)WF0&>&,_;"P"A,&FU57
M8P:D$'J5/,,R3,:W@J7E)^E8FUP_^5>/"7Y)B1_5O^2,6Q1Z*CB2#4BCM9I(
ML$UA$OHC6 BG#H*9][)KYNK_YBG$OTG._]TDYR_]7L+$H*<J:)ZLAI+!;S_(
MK8MT-J"$;813Q1[A9K!M>J#GGB1#R*@B9G@C9E/<A@U 6 2P#&"[$KK!DO#R
M'\JO?>? PB^=::8,J'99BN'#Z!*)@4Z=B6$#G(R$QV^R8EGAT(RPO]+[=Q'Z
M"MT&.N4)&/L'P=@W5+LY8/O+*F_F[6($;N&_L#(:T35GNE%@&-CL)_[>,>WC
M5:F,1UL09AB&#1BED6,WT+\L,VJC ;,*N\:$3'?-+*N#]B3LFL>O/Q6U, S=
ML?:7 ?53M_,?,YZ8,+S!,H5'XA=594*[X(E(T'$*!Z$3S,MTGBCHZJ%B%I19
M\3,#,) L[M^5G#](H/)2(1M0M "5@#:6V18/)J((^%5#*59#)1N@:P?K@<BG
M\$V'-KF9J;P;_2E*A,6S"=D'9BES.UKW+]7^S^KV$O5+22S"_K+&@VOF"K2U
M'^CG3%T09ORCLAB@GXK,&G[OF%3\'TOB,AOX9969*Q'0J<S&+6@'INN;(QAK
ML@K]Z+D#(&YNB<S\9T[_-^WX[]*.OQ*9A#\F>R3T#W4+94*",!Z^80/A/]P6
M9:7!8"BMHH'+T@<F "H$%0U^ _Z1B/T"H%6_0NPB>861<'M\,F$:^<($7"%I
M& TR%1(! O6Z!&/Q/]1@2'@Q&N+CF%0=!1WWHS!4]T)O,2%X9"1_6^O.F\=!
M?YCG3 B:N=M&L<:AI>,QT)OXL'BB$"^R8=*\;WTAH7+X\I'O7MH28LA('S;P
M4L?0^US]!.<$&QC19?&94""3J4W!,)J5).L5<7PG,N"B0[S(8L^SO)H,H7:_
MHU#*4.?I\$X3;6K4H@ ]A(:@%I()M#/-JR-S8R=ZB]>"77(.!3V\>?S]/?2L
MSP_+3YLP2!)+E9P7HR= ,AWG1>(-W_=6Z)\@OJPKK7Y8]/A3WF/C'[-&O!.#
MW6BR.78(2XIJQ<HXA-B64[:_(B*$W'50+D[[RI24,[\'&7HC.X7&O>^Y!BH#
MG#]28F<8:D2$^"Q:4(Z<4D+A"[6TCX.Y0YK*AEH2335Y1)ZE3GU2E*D3/$"N
MBJSUS XY%MY V&@R[O>;+:=&PD5,7AN+F!X'+Q-=W*LH\[R^M0ZX*VH+!<>D
M;1C1?'BB](PIW'Z8789YY9;()^O/EIHVN&3*I)"=S<"35<Y'^K-D7 *%WXSF
MLSV&E"#A<--)*0'F/C,H8FYW/66&YQ;N_(N#X0E/9?LXOEI<80,1Z_CH2HB@
M7$^()2E=E0V(O,YL,\ *)"1SI1[3=5F]3SS5VKYD'+'(4B*$Z(2U-J=UI@:0
M<GJ'W7 55<@EQ>IZ0KT!^<+2IX6!>R?X5#'D6HC(2QJ"&Q^WLN[!L*OVY8^+
M.Y!C*@Y>=[JJ4Z'SVT:+.[F:81%%K.6?5#ERO-:^VC<TMYQX<&[)+[S*FPV,
M\:Y5'9^1>"G4\VO!&,2$B+^G@;FTL^O5%=IJ8R.<G"G$KV#FE6,*I5ZN74UX
M6M"#VOBL?(,42!]:LI?=AJ<M:=3SFQF3;H03/Z'VH:]_VB!XQ_MI>5QGJ-Z*
M5TS:R+3P>EDRPS6XYBV?3NT-@(LX;-:%ZG7-O= V7%0IA$;HUZ9DXHR=#7UP
MVP9P.J,,X?)!E")2U:B<0NEV2:&?ZJG8G]@$Y_9ZE[.H];V,6RIZ4KDG]2-*
M@=;]!KR6 FV"1DGZIT^^[G9)6VN@GOB8-JQQNL3![X/<MIP(*<K]%]2B#!75
M^7+_4;3-VM"PS</B['ZXVP84JM;9$CM9RT/"/@S"U//#]H:<HEEXYM)&RR^K
M:^C)N+UMU3,)$HLE%(]M$VXZN/GLXVAF'U*H95Q<>R5,/%.?,E-O1-YXZ-KM
M4EU+ED3&\O<B_,&K^8<^QK0+9W_A=!]=.I.M%&KS: 2[UA^X-//FX%?_[GEL
MV4B7&21IL-W(_XBMS 14-L2,(@0.'HW2IFGZ$-F 6'M6W>C@??,*@;[*C?-%
M-KU+%O>ERH2WDX\RQL#A2<J/&"9D@T$2(@XG>-.>)QH<O[:&K%=5<L71X=O!
M$KIR&D;APT'@6OVW W=O8"L?C12SF+9IO5_$W,^/_!Q]N7NA;/#3HOM;W8]H
M$3U;$C9,'"-6>X8<9?^U(F;=%H>IMXV7&J\_6/A;A9)Y[SX"4-]B9S$!B[5G
M W$H'@+#<8"U&QEUIL^MVXF%V YOR+.\WW\9]]G"O%>%   3*:(GM!6"U_U'
M$4R_(;&;=RJJ"Q>IK,R13 @]$/UIY14;&%)A ^L>6%[L>68!Z^ 5QBERZ@.6
M^EC(88IQU!2.G)/:130+OB \/]"DBY$_QRE3)GUU_W*.KY,J$1/-3X)%DD/.
MH;<O;+FGFWLVOIJO1B2_:1(5^:XG]4CIV,<K/^3Q2"+RLP0W;UT/>LL2RD'Z
M8!1RRLEBN((-Y&2_S/H AC7C3"E%H]'=8#]$8.%$B(A'!Y+@E)?W#)MES?5L
M3#I1<7)YYNT!\F!3**09(C!!>^69.^\_H#77$:2F462O6AYOE5B\:\J 8S-H
M'1NR.?DWG0(A)F0V$(N2JJ>8MQ!8,D=#CV-M5&N4'Q&O6Q\Z<Q9U=8CG^X)Q
M)$X9:=R,%B#22G)&S8]<7I_&F>25)1[GXLN-T7PW)BA*>4B_R'/*T)<E27LU
M@1%G'(TBC<44U,SND?2$MP8J%3VI&NXWW:-9&B6M<FP$<Q/.SX"1-1ZRI$<8
M]N3I:G4]?;\\[77).(>VO9ZW^?<,S4O?WE%_$3EW4NI'%]C^]=- M.>'L,1X
M&/O3T RP3 RS 6]6$_WD&N/A)&I\4,:G4[,C9(-^C0W4F^(D0R1IU]Q\R0B'
M<@I/3(A)7ES\SH-5R1Z<4VI]GS_N&G=QV=;D0@QB7?N;ZH2_J19G Z#NJ)^Z
M"1!OU@C]U!J#,8-:Z971;-%L!E!D"[@.Z^-X51=(DV[B!; /].!JN(S)XA/C
M.I7G3[>^:<E.C^9A14&L]1*>4M8C_E \_:&_9S6XO7]@YYO*T>C5P]DLH7[,
M.Z0O6#D_CT^"]>QGJ=^D;,G]5?-D^T>B&#3Z*Y4L:\2OZC>B'T&?DWR4&=$^
MT GTDU4QD(]^=5M[]_L6#,S<"N5% ;(EM9"R/X'$!O8T^^3=#/)KND[=N,!7
M>O-H;&#54[#-.QSZ78(SO/4=TK(A4XJL$[E8NX\H(#YNWGMDP2_L\^>!WTH:
M)1\!D,'\X\I)]O_"35/.71/A5OGM-ER'WWU2Z$F)!3;+J!0V$(9&6E)?DK$,
M1=;V\O*>6J_<$:_>Y60N'WA+=IS'NV-@E\,&'KR /*5LNK(!OD(2E'$(3;."
MD"/F(>0D-N >&D4769SI6EN+3T=?66\]WJI-KP?+)^,@-@I"+F$#1-#LACW@
M+!M@3 P5LH0O2X!^ZO3W9FH-2KM)7^2) L/KG0X87JXP 6P< RZ&RYXL-AK?
M4U7 :9QGU)B.%&)%*=OH"3WU78_X_T=K$KB/60=UYJ:!_N53PGMT;1<2CQLO
MR=B[\ 1!-_=G8OS] VMP< U_YKBZ5G.06VRYB9X9,=ZT\?'"GB#?>7$1!_57
M5XENE8?W61QR">-\&Z B-W$?#@%3_"+>16,8<1ITVEU:>CU*G";QTFYLKK*R
M<@R(,^I1,.TN,O41/?KDX[Q>:\IE1XM--;D M4RSP,WXD!NR#PJ^6I1;(M*V
M1K(JQ]XRCX3J2U=&"HE$QQ]<-FE[\];!(U1]!9]5Y6@++U-7EZNXO_SV]3E2
M/'^;XL-M!?<33?0!F87/+"G6*+2DM45#\C+C!,V:?@&IU72"^@J_:&^4\+91
MOXF^*R?TS8.D"K%G6]S*%;?QY6S@'MHS'WU50&=BID%(\#(-WUIEOSTYFU9(
M-W5T,*RILK/P$YDI4[?W,]GWR55AB;N>V[,#.I$)W0NV,%YND[A<LG$+G Q+
MV,'@H,V]G(/=WG*-BBC:=R(^7+C4S#48P2?AK+PBI[CK<_G]*UC]D)8BS?(W
MBEFY7BZYA>@;:L&U;6KI ULRHH?GM3[VOQU)BE^/>Q03FF](_U9<U]-#J(-5
MJ7*2HIHA47CN6N[\D(NT0M*(/G_CEMXV+U-K?-*MB_NN9NNW'?K\$C Y!' ]
M5D7A]=C !'8P %^.632A.) >Z-S!WJOE>FQ/L[C^^,'@C_MO1D9&;_) 4&/?
MCE1^3:A>U6YZOT\N:.X+)?'CQ(P-WZI%DFFW8]44OLV[NRMY(CNAI>'I^*$K
M6>D@ORPU[6 #Z<-:RUU[&5:T + \U>=3>%HR-4I[[P9>X.=>ZDL_VZ5I'7EL
M<,5$\>'G?,FP+U\ KA>6.&FPJ/ T=PE"Q$-T*-9OBZ]6W2%TJ)7)?+URMEDI
MS.JJI(K%?0&I"%<]8=5IQ(A"PYA:9B_U!BU?H+BY]4&M"(7?M$_/Y5U+9^7%
MNKAZ 48!1]/%-N5.IL)NQ#'K&Q)LH#3OX0W:*1*48$E]-; ^>I(&:4:+7$WZ
M>/0H>9=RM'H*0>IHXN>CK>G4&JSZ@1<AI6([!<?3/HPY7SK6Y7: H ]WN+/F
MBXYDK6"=HDZW>[1S+SFKMF>MS7P'(4RL;L4\ U:4WL(2E=6!1W':QU2T]#S*
MN3O%G:'&%;9/=>*:V(MDQR;Q W3?DI)")SA9J,&#3#7-,";A8\KS#?8CERT*
MD+%CJM\/O1(MLCE:T*1K3VBEY\@)?%%*OA>(,7CEE"S1F7,\IXCNOX3613"U
MOF!Y+3&'' =1S*7OH?@<L$S=O/ZS5J'NT_ZXTZ:T]I>&%]YQ+&&RJY_EMKXL
MQ23(QJV"V%JB\_LFV<")68N?"O@*]H6BH)(C@P]L:UA_;'@W<. GB<%"LVS@
M*!KJ$\!XBDRP!HG.SP>FL[ 7? ?>&D^B6]#\(5RT0#^*2',0*A_UQ%2L+C+A
ME9WV*"LO0)4K<H# /7W9,1JX#;1K6MM<TWJA4M]IWN9MM>]$V<6PFF 9/['5
M\08$3845 [I,Q)CY' 1IR'!5*WR'G@GI329L.SYN(J)8.RQ\OV+:GH-ESA!E
M!465JU]BQ\T\TZ83B!GB:TV9\OUR);WK],OJ"*QW[@ZQ6LU\MR=#Y(*"'8ID
M0#L2(A'9?.KST[=)9:-'&+UE<*ULD? FXOY7-D>]'&_U.IDY&A#\U"R<].GB
MJ&%9/F852L9S7!0%02(N]I87*[38$@1*^EJ&O9O?1\?%/]LN1[H84KF9NE>/
MXA1/D6IE06B.$S4K,LAGCOJYL1I;^A&%,!]?U>I64>&F>^6E;0J*[K&'.^=Y
M[*OMTL1 BIX\T;_2,_JI,!)K+#QK?C3-O\J!>G06^QSW$S'/9>.9.>60X?3)
MKL7Z24S$5M7#5YDPSG':\^+]%?U?5.N(A^W;Y9M_NP+14 L[G<B_?[E]$KH4
M=8T\2;J11P[XB!;X(;07&=?(VI':G*E06H*+';U5WG\G^M44R?3Y>6BJ(+!O
M1\!#,;4'OM+2<Q_RW3,R'VV,#52L>/F/.,9_3YF\9G&JU>9MA4WE8-V2YQQN
MRSM87^P+8Q^M9@+^"+IC'1(/%ZJ E[O+*O3(]]U=>&[KS.MB-G0;]JG]<RFF
M^K/QS? )?',P(MYI5Q)),.:5F6>6(_Q+IC0N\Z1YL<N#@W#YR:E8&\%NET1*
MX)W;BGPGG.V??@ATW$P>3%N9*Z!W>E@4"GJ[>MNZ3=&#9EF3Q6"0G9'[5WY0
MNK-+@M;5@!%D*+^AK;0Z[2OON>LEWVE:![N$>V8L4'X@]_EH @"H$F4T6'QL
M@ UP#=-R*?+CDSPM:,+1L788N6(J[R-*)*G1/J>#:\@]W>;#+OO2BO;L$XU[
MU:8,%7:'M%V^SN3(>N_S+,0UT'C87-/4[\ 'QW6"STA5J#E#5H'G]&%JW_?]
MZ^9:%J4+M4IX%$%V'PE*.V"[V$[>("+NL0Z'7*&X#CZX*Q2CY=Q B*S*[2S1
MN_7ZG%)&MX27C9W_.9S'%9X9*3A"*3 W1(]9C/;"1T#+8?5FYKWVW0;B<R?6
M;F8>[7EFXOS&!'TKY9T'^0JVS=_V;N^'T^T[#+DB4\76*U^]GB-4%-K-5PI?
M:6@2CR3)S9\[+L%U/2?V #'^6J3V64.^Z&R.D[/ TGFD_8^T> ]E41)+2K<Y
M#Z\%WXT;\9@6;K[X\L6;^GQMI:*WQ8H#W_(9ZB,KV"=3!@JT87(A]0$EKUEH
MZ.?K%!%MKSVMDLH19X-&J9B\=NGJ\^,CJ&G2CN>G]:)+6R8%ZA7>WPHQ80/<
M2LP(EDX()\@Z[M &IA>H5 H^NE:#V+$'5AE5;ULMGH%P5JL><S 456S<ZV+U
M^1V?\3?.7%2ZL:N;0%]JM_W9LB\%91=*[JUR=WZ%7=INKM6K/)!;I/G!2HM/
M)-XCN..\REM7EQ7/7-7S!*<MW5N/'@IZZ577*AD9S/LDP9)'"YTZ6BBXRLH"
M>MD7O LT<DR;=IFL8$@>3T =GF<=KTL<5;>\/+#T*M:=A'R<^][NI&/,0\Z^
MF;0F6B@;D-"B>!D<<T)M?&0)UF0.$A<%O@2]?LEYRJ_8.=OH99O7K2 Q'1&!
M]B,7<!U'?OO60-T0+GKR*=<EOD_,58%+."@VSK2GO$/H0F7W$;,3_+JJQW;S
MFYK:V1Q[&2-Z,$O^GMA) -@.[!4;>M=F)-J[X3R_/#"(J&15;E+T+.]DF ;W
M+&29Z"\F5XWTL &-]O$$'8-]5<Q,M&>Q9_-^0UJS%]UH2*-Q3NQ4?^*W*QX8
M<D(<=-,C? ?FJCG?\QH$MD_MM_'*=&]"@?SH7I$E58G-L^E&$_IE::_0$U#.
M^<P#Y11<WD3'_AG[=P];G0N[\LYNV'SR37YTJ>:K=":'C)FG[5%.C13!HJGO
MP3FXN?.V*$1:5P_S5G79SI9CA(MA\44C]$G>X4!U!ZS#W9H#6;'K77_;1LKD
M_&6WWY]VH*;Y0%HQA8RNN6\Z]'+]/5-@];SN_?NV+Z3N3P\. OY4&%="P,\4
MJ9!NUBT6BK2R>8 B"])NDY]ON+YBCHG9TXU[*G33=4>-S2,#RQ>2?*XIED1Z
M!EZ [;JKO%R5>BCF"4.]L>XR5H/Y5B^4?H[&213KF%G,):LP B:E/G#71:0O
M'+6QH<J%I^>G+;N'1\@H7$BYSD'X<"WYYI-<DTZ3\HI2,WRB?:6GT8M"ZXMQ
M)G7J!-/IL1A9./UBB'8E\PT;\(*'CW%WJZ68(L*W1I"#+2>JU0T?1OY6[9\I
MQ0KJDM,Z[&=7W C!RRZ'D[H2:KDI*Y.'\$!%@M0L-7,GV:MO#UR8>SI7%#TB
M>8]?NS(^\EJUZ';=N,PO.X4SVA7G<<[D<!*:(1K0<,(?0VYM1),O'"5_'="^
MBQ!FG*1HM(1*628>SWMBV%GHQ_W^LOH4?\KJUS<-BNYB8A>#9IH@M/V810C%
MMJ4ZM0D1C2D3BO3S\K6K]LR 7:JY_R7U<)7M=>D[GDVO"TC9Q[\^*DWTM;0,
MNSE@81L_6H3-S:Q;K",\>B1^,2*0_B[NXNW;Z68U'W3/?][P'U@P'T09@J#J
M0%&.0J#VACCTW*I84/'.H;$!4N&;I:QJHR<O#W_D>G6J[<R3M;LSQ:$O/CT"
M[G)MX_VT?$*2ML#: 3(9+GHOVJ40(8N<;,%ONSLN2,/16].F9*7[]M5&>L ;
M+[5SI;R+C+2U>OBL=->[A:KI;7701@@$?^LYWC4=$X=294:/HO8YS/><Q@@<
M8B#<L?K/WN^8R1U1B;L=7?9 #]?).P;TJN1;\J?T1LH+F!C6*"EGK;S>FJT*
M57=-[\F-_3(/$SI"^F8]$MO_-I-*N$EUO(5$+QVGGW:BV;+XH.0;, *&>FV@
M'+9M^&:JO5LC7"K>B3 ]!A,>+SA9ZMB\ Z%T]J;-$3>N/8'G;F.JU_%QT++4
M%A@/JV_L.#,')T!S&F^*HP@1+]%N3EY(MXSM7V=>&AU?'%3O>2S9G7A:<;C:
M2C.LI W/#VW"<C+.,FMX[AW1D$5U$38:V8  #=ZRA8ZM&*1$3&=N!%@.K2!O
M+5TO_8#Y'F@7F'3>N>GF:56)PYE$2G S2X4,;:0S S[B^-Y3Q-^?=IBM/@M$
M9,[;VI&TCO&TW;\<;JI"?U)8N0.0R(V@/BJ?-WF_IM)B4XYM=\M-[K%7+5SO
M+TRUW;/8O_=2[*7OMY\BD"-I"PXU1W_X^^.JE9VGNR+PW$*-B'MC.T%41]@C
M6XZO)_ @+TEA'[*4(RU%-8=J3%0]/LULUT)..PXW&M](%"EY'5$XR!)D#4$!
ME,J"/4]8"']PL M.H3NO3V\G(3)!*:,2GS=R.*?,+A4X(>?>V2#&J+HL=L%%
MV[H/[.QKYJ N&&D&;P4E@*!G,3DN<)."C&HN:[' ^@73C2--6SB5=IG*M^Y5
M_AQY(-M)V+8+RH7C8MRF)#0)#:N>'<")>1KL@0VOU*=%Y"7XR5SB$-WM)*,N
M<UC5\SB'JK^2^]B-1/WN(B1W>$:89=.$F[DH,=O"9JP]3?,[WMRN:O]63=T3
MLVL^Y/P3R=KFYENJ51*F::.!KY]>FBVJ"C"8^TF]A3)^$GA=R!\>(.Q$_>$E
M/2.I";HI8<$&>.:[AO2.@US&%4%A TMO0-QDT)C"_Q_OIO\+^=< [+]Z?_8O
M_QCP'^[.^"=L@=\,_M-F$:>5/RWS&,V29;((S68,,YC-XZL6)'U;5N)/GOW*
MX/9_YO1_[\KYU]^5PR-"J:(^IDG0CWGXGQAOU8@)0D1Z::M&AK6$F@S;>(@%
MB%WA_"0]^((--/9 )S#0=;],,3;P,09*BZ5B=R.UZEF'PU01>VB69OW.$>UG
M9'.=I1>D=H59'3MV;%E5@27J5J^QI8 #;VD(&F$#T2^%#K&!J!QTO0%Z=D%/
ME0W<WXVFB*+_I/L'E&:!X<+//J+9LH$="PB6?,*O)^[IE;%DGX"U?),-9!>1
ML2PNL UHLLU ];(!\L65H022<@.5O!*.]TC@&W.2.2UQ%HI895F/)J7RZ3[Z
ML=[*.- 5!E\W#@$G\> 'Z.M=QG\ZXWCLD/4%0?6]L1['3[W&5F90C_L,G4<R
M%,D_I"S2/$9"@Q&;D'0XN0=?-L@4'P=[O0FJ$.M@ LT#/KS BD-$H,G!/&Q
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M,L2_N_TVX=NYGM*6EWL.1O,[*[MC>\XSFFC6]%,,'CQH<):!'.%RB!NY"!M
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MWGOFS/F?N?]SSKVG?+YZ+*AZO[76M\*[OJ*87YC3 /_E2\:7 )8]+, U\!_
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M:C=7P#*$^Y R?5&";W=+*]V\GE;JE/8L7<:@_ZF%H'@?@$5B;,.(=$QX@5T
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MYYCL;5%1P]NB@.>W:+9TS!$H_=U$D/!$<21;-O\/YSF2P>]+9^96^EG>Q.J
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MY=BY9YC2>Z7?W\N(U41U"8:J_9C7PTX2:3WQO]S/"?E>HOU*[?_ZWJ(_PKS
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M'*M*"6N<1[M[,0B9^#X%RYKN/DJ<IN?%BT^2;COH_#24"5,-6M#QX%U-UUU
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M_UC-ZOD4*YV5O$5".+1J@SM-$2>&(H"]<LLST$Z9XUU.SSS /4QX6I=>+/.
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M>'OYZJVJI7G%CS&C%9297NFGBAWVXI]4GR>ZW)(G9STNUCC78/^9 L=1J0)
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MIVG;X%COU)->N:GIA\),]X@&QN:DQ08?7ETI@ES^*R>+2"W%"4*8.9$(F3*
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M1K2&_5:-T'#+L:K,;[VV?W;64+)I66V"&'=?QQ)RPD0EX#17"%$-B Q06N1
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MLW"FWTF7 +V]_>?K[0]?CG#KC#B]9#(W+3F&V(PN<D6&BO/15]*CH(TMPY$
M#*KMG@#(XQF>X2[RP-#2=84AF3W:S<61YX?*))19<Z=RSAK_2D]'B*/YNC=@
M\A@G9MW1(0]0!B5/]B:'D<OS']XBD_6N&WQ*2I.N<3)>TN*LOERYQD/7_)_1
MJF7AH49>H(@TXQY)]':)VXQ>9-67\\<6^5Y3U\==F!:@B!^;!R,_\NM@ 'UE
M*9[J(NZ#OGLTW8TQN]Q29Q.YI294?\_[;:Q5<]&]^R[VL6_DIZ-\@7Y0_/I0
M8YXT]BV^<2R1+KZ+O-Z]QB(PRQ6:O6[H/_]RA.7KWA&5+=+V7$M>/4E"'!)
M71<0LH 9M;#];T<09E2_'7DV#-R2 _6]Z)'<BTHS+YJO>F\_U G#VM]0VW)A
M^!KB)W!YTU&&>PVKCR[=O&"7($8:I:XWMU<M@8,?:SLN!+!^U/:+SDXV/O(Q
MG@R[]_5*)BMS57+R*FO;9K66!SA84]W$3U8V0SZWMC(LSOWQ_2<.83F7'TW)
M;[=XYV _)3;4K"BOOEO >V_#3F >%,_@/D.8@A^1]5Y9"'[L$$&OE2F8A17
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MGX4$!04$-PAMV/"/(2PJ @_A#1M$Q$5$Q7X?\'<;Q<4V_O[A]R3_="F_D("
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MR4@=:2I"3P;L/D]R=R]LT\2'7;'NRG"\4V"8:;*DH(9BCM%MNA&IH(SE+MP
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MOU/](Z+1S/K'/:E53Z]>E+F52:R 14&<5,0"'.!>X'GSTT,G" %#ZA?PX^<
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MRGSC*(I10!?_'/M)..3VC&F-C9=8Z6_5#B33.I+8B4LF;;,P AW@FKR=(+$
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MW(8>8.NB$X#W74>5EZ>X!QX^0W?D&[!//;1XADPSMSZ4;J/SGM%X/NO5J%W
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M7MU5OA\+ AZRD,,P<"E$(7$@#F2P02+,A$5L.R"^;IQQK)&I?=X53E "!1]
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MJ\!2F07RRBZ0*</ <V&9OJ/6K0?;7>KA.F2DW ,E_84!H+  ?%3IL]?T%T:
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M\E8L)'Z)OJ0\7I#T[3)^C;E8\&PFL&U9H<^A1U11.]OA,,0R[/2)(,*3;IO
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M%O=/LJT'D3XKI9Y9EH<B5::$.Y$-$:-,%2SQH>]QGW.+AA[QS3:#'&UK>CM
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MC_-QP_=,K^H_(-Q1QX[A:=\=>49HL=NXI1(4DNSI2WI+TKSZQSG[QU(.DRJ
MJN8EZO2HZBQ5ELGXBMNS*'!"HC:\"R\B4+K, 22NAR&E!/D.QK[/65WO3&]@
MZHQ%2X:VBYD-//(4LW"OQ8YNJ4?S-61 2LR%!BVDC<DBE[CF*JEGO)"O@\A,
M9S^[=Z'>\#%LMXPS.E2PU1X'906H_[UAQUFU U_VUX8MH#*F/\T_F<Y>);T[
MFE$5^V32=@7Y] =VT]M?DH3_&<_G=_*;EU'(GR3ELQ!YE(<!@RZ.5$X^.X1A
M2%T8N<R) B*HU%D3!_] &U/SS&N(X'<%$E0H#0\,'>)23]).9&A@L3(EQUB"
M&LSO55P.M3.J;#08NBL(39=VV:6=/BJ'[;/(GF[3A"^9JF6;_B%4.?!Z^X<5
MV8A8#/HV4=L8(P>&#L/005[@,SN(G$@[L9-&>U.3@!HR4)A!#1JL4)ML9VXG
MNWVIIF<*APYW6]CKM"N\G4:3?>*]TCG:SO&.+Z7A;G)M;AKWE[<_9<0=Y]HF
M;>]!U[_MQ+/<91603^ILCEV]S0&. D$\ 7E@2\>+APABGV#(L73'+(<1X5"S
M-:"&UJ:W!/2?RT1MWGU)8R8#G7@!""MVDCP7'9"!2$9+,9<?7?%%D&(^HHA;
M-^/9PD1@=SSJ?:!3]#RXGH@>6*4W-^.40,]JP@;8W:?!R3"'N@^T]WW.<A\W
M_.@1[H9;.LZHB?R"%&KV*C\>_O'M:R;X]>)Z\2HRI6KGZB,K0\HZBQD1'@M1
M2*!P;"1UB'%(A6.I WV>< /&F>6:Z9 YB.G)T\7Y_:_@YT]?_GH/?K[[\AE<
MW_QV=?]P??,+.+]XN/[M^N'ZZMYPILR\:S2GR :E>^BY,9$#A1[4\-5"R#ME
M@1P3?@0K(\#:BD'RO'4GL=\9,7,8XTZ%=:9I;PZL^Y.Z26-YV.*!?%OGS5A7
M18L"ST).!"ES"$0$AQ 3]<_0938-F.=86OL2-=J:6B1<)6:46,$:K,XG9DRR
MGIKU1-W LM69-6-ATN"C5P5J:F]4J=$P?%=3=&XQ$P\NXMF5C$'RM_MG,I]_
M7&;Q0F39#&/D^RY5FV$B!R(WP)"XH8"!BRT?<SNDEJTC&$>>/S61*"&" B.H
M0>HIPS$&F]6@!UX&5@ S2K0_^Q;##WSJF6#O'Y/7#_+.XBO_!U(_PO+'XM,^
M]LQ1/N<6@^I/N.VR;F/^_UGR6!VKNEO.U].(GNO[S*<A)-B3@[W@/L0T\*!P
M(X2HVCX0&J7G/M3(U#[@&B,H09H-Z@=9U!O-3^5FX(]XAY8!ID6:".AUW#[8
MT*@#=I.INR-UX[4=YUKC!5FH9VX<QE[];F,MO2KE?O\D1/Y+FBQ?)(!UR!U0
MXEI.9$.'V19$'$>0,"Z@A7D0(.;9@3"JC]P+JJFIR<J S<TJAI.PO?26YG3M
MV'TP],3NBOZM=!H'>^4,5%:!PBRPLFN08*57ION=+NX%V;@3RWV2N3<%W>O#
M.RMVG(MBO^GU(I=O>$SGY=G3[)/T_E16TVQF^;;#'<N#OHU]B%2J)1(&"(8>
MI2'W*?-\HSP5.HU.4&\EYFK#^!IUM7<<_*Z @P*Y:=9CG1[0%ME>>1U>0T^F
MM(L\:G/4M_JU-SRVN&E3<4"[]._M)DV;>R\7_#Y/V!]/R5S>GUW]8RF#U)D=
M4F8+1*#+BVV3CJ\2'W/HN59(2""8?.PL5ZDE]&2IK4$C25HU.]SW4V;-V-I;
MON @>R*IJ'#_+R *Y&:*U$J\GAKU2>? 2O1IA\.K9M:,14>7BEX%I[714<5&
MEX)=H=&^K^,1<;'@L3IPD\>/Q=:R:FI%B,!S',^'KN]05=S!@2'Q'<FU\!QL
M$VIC;N+R'&EG:EY.!1.L<1H>^SY"IYYB]$#2P$*QS\\ \U4M-/1[GOM(6^,>
MY6XV>.\4=\OE/6:OO5[\*OAC<?A#>C;G^6K7T"P(4$BMT(&4N-+YL"SI?"#D
MPRCP0V$S!PENN&7'#,#TMNNL\6> BRQ^7!2I04D&GJ0)Y?FVE5W@IQ,3?6EU
MDI[L#$?\P&IT.*FKVLA98C];G6PF^49>L($3LK8R-WQ:U>,0OG]RU%9ZM%*<
MMC^EW_J\*I.)VBOT\SSYLVBYSK%Z'DF_9#?1JO34'LBW&;5<8E.ID3P(;(@P
M%A"+B$%DN\2+"'>%XYH$:'V"FUHPIS;AL2?Y&\/4VKUVF)Y>?J]N&%A--4KF
M%KLDE7FEP&ZESY8BJ\S<SZ*M DIIZ?#U<$_A?Y2BMYT 3J*R[2G4ZI:O/:F-
M#@DB;=>RUO7=7:L^$V-;D6=1"]H6E:+MA1:D@8R!78;#4""'($>[FLR1-J86
M]=KO76LGE9]ED/?P")'-8MH3/0-KHF)FCYHNN2&/<&20&O)TKD8Z0GB0LYX2
M0C:3T)0/\LB=XZ6#;(:^E0VRY5)SK5L+K,JZ<Y$L\GBQE!'IEQ>1%F]#]E$5
M#1>KS:LBN]E*S7)=96;9J3_G^2XFGO1M0ZQ2X 2(0X+"  :<(M>C'D>8Z#BX
M V*<FI][1=)%L?>!%M:HXG5E2K[BM&&NS +R'V65F1,*"0[5Y>VJ/H&.''A4
MV/**RR1K:S/!VLZZC]<[]=6<Q+:QH+865.:"AP3<3Z.O]4>G"?3Y2*-;U9<J
M;6S9\VS=\\E>SU>?<?E9/\>+)%4;MNL\5T5H%.\^L%RR!,\B?TK4G]5AI')B
M:U<-WO<SJ@[<>0VC\E MCS:J#TS=IE<P=%/]SY?=JE\4D5IQU6V2Y:G(X[*X
M]T>Q$%&<W\J/*U-3+\A52XN!@+ZG#OZZPH<X""P9=A%?^$Z(.7/K;'H/^NN.
M?>'34J+M#'L/8QR*>7Z9)V]"@ HN*/#V-X-FU(6GSY[UWB/?;^;L76G5CT4.
M[#-P*:$O!-_JIZ,S9N?\[\M2\\_&FSGKPOUHLV9&X"8S8]:%4I/9LD[/'V8S
MVFH[O/!M$E'*8&3; B*$D=1QCJ!M(2]TA!<R+,S6A76;GMZ*\*?K\X_7GXH\
M#>#\YA+<_WI^=_7KET^75W?W__K/H6,'_P:N_O/K]</?^MV@9G@V80B"!U;<
MPQO6!CE/8,K.J'O8OL^I %-*3/>TG;BW7WG+%R3E<?)*,K:<D_2SR E-YG'V
M7 AE-?EJ,\$=$460"D]*%?8%)+Z2*H1LX@7<=WQ/=Z9?H[VIS?IO0P8?P!JU
M_$<!7'\*0H?O]JFCGED<6(2VT7Y8P_U0.H3FRP0Z+.I/RO3,YD@3+">S:C3W
M8<!1PSR&SE-&FY,P,&ES?L'DMA,S$7X61.7%4"_37^/\Z>LBH9E(B])!938R
M&1%).^404;QK\E_+-(T7CQ])%F?UX/%V*]^X)Y*);":(*R(6N9"&:NZ 8@J)
M97F06C0(<&A%S'6-SF<-!'1J(\ YYT6R;]-SLT/UHYZ[.H7>&7ADV4R;N&$E
M^%.:"3;MK)(J@FU+S\#*5E 8>[8ZCOMV!E8&#Y!X<: N&29K8]]@OT_*QX$H
M/YHO<JCVNHTIOY9;J^_$O)P#?XI?+I-G$B]FC-J"V-2"Q&.JKG0D(*6N!>V
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M-RB/T<YZNYSWR^3 .EY36*$%%5P@\8+;81@TJ#72*Y,CZ?6=B.;2_\] _B2
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MS),7-795+UUD"Q%Z'H.^[X80A9Q ZH<$$H0IXA'E+M=>6S)K>FI?[PH]N%[
M"C^H#2B\F T3]-T8P_YH=PJ'8WE@E3 BN$.X;\BTOO,X'.,C.9(],V_D;W4C
MK\'W,GS@:'Y8-T,W?;*.3S ?(SX2^G9!4E%]"0@)CC 3$-. 061%\B<9_T,_
ML (7>0'V]=*&[3]Z:AJOT($+[9.Z![AJU^?N# RLOROC.VCK#@OZVMF=C9&T
MT8 5(]T[;'B#KNW<,)IN'0:ZJ4M'KNC@F\:+!6%S<<Y4+FZ5E/MB^7+_EN6B
MCH&DS^G0R'.E]K@"(IL(2+W AQ&/PA SV_<"K6-Y6JU-39UJP&"-&$C(H,1L
MX BUTJSA9?9)WM".92-O73S)5@(-G,<^B1S+7SQ *).$9@7LGB;BM(EI\@5;
MGS&>^Z=KSI;'IWU3M\U/GTGZAWKR7-RKI-5%?9KZC"YC@J+ M:6O1ZNT3M06
M%#IA2"ERI$.(M")_C;:F)K1KJ"!;837;U]3$;+.Z]LS7T%-[:ZK6,,_Z._]L
MP$:ONXR:VAMU*Y&&X;O[A71NZ:87OZ1JWWR:1'$^\SAVF>5258+$@8B&&%+$
M&+0YMZ47QFR',)U*Z >>;:0'(U0P+Z"IA2:)S4P&-@G3^^P[TC#P9UXR<-O,
M@/%'?<#67C_BS>>/^M$>,&SW(SUT2<?T:U$D6/XENOK&GF2?"959]LOB@F1/
MZG^JOMPKF:MJVD5ZR%AM&%5_.%_P[5]L7#F+'(H=1W[20D57"&/YF?O,A0Q'
M+HX0$31 AHG;^D<YO6TBI9%J_5I49H)4)5HN?\Y L@!,VE"L:A<_B+4UALGA
M!NAT/8'ZSATYL-"M>["VKTR5+7M.@3XK_A]L8%>5AVJSRC^JSMW]W95&/YOG
MM!NN)_K-AC< SG'SZ U']%X&O@&;ZICVEST)OIR++]&=>!6+I<A^E@1=?2O2
MP\POEEF>/,N83"+XE"P>BUWJY=[T!^6!SAS?(93:J,KJ1WT;AB$*8<@<3 AE
M*.*A47;@D^!,+=*LK5&"4]L#U L(:HO RJ1"6)11U7F0TBSP>V&8:<+ATSI5
M;Z08KZL&'A1&Z"7S5,>]D-MO1N33((V;.+D7^O;R*_?SU&Y"_9'(EY:)^R<A
M\D_J_8F3195'W+,QPZ$KH.=94H2Y$T J77CH.@&2#KT(+614^.EX4U,3V HI
M**""&FO'-.T-#.LI8C^\#;X.W(TR8PEK9Z-7>6IH;E3I:3=[5U8T[NCHVXFY
M_.OC+V(A4C*7LG3.G^-%K Y6J\W5U8G"F>4YV'5<#-W $A Y%$&I)P'TD8>"
M$ 4X)):1#Z?5[-2DI$)]!IZ+^55UX%^-]60+N]KHKL ;AO.:':'I=_5.[]#^
M5<UL!;G@=1LTJ%#WZ$ 9L=2OHZ37]+@.D1$=>XZ/V=U=Z]QQ$1T_"_WQ[3/Y
M>Y)>S$F6G7^+LYG@/@Z0RV&(N0^10#XD!,N? B?R(A19OFL4>AJV/S7]6L.'
M\X,)!624HG ;.D6FO:*G80-R/;"8G4YSAX)[G<CJN1*?&8:12_1U(FB_=E^W
MQW23NR+G6)E$[$XP]= XBDOG[YS_7<:2:J?/I<A8&K\4VXP8MG 4N!9D(9)N
M6H <2%5NALBCF(2V3PVC/%, 4Q.\7=!FNF9,OYZP#4GJP,JVB_>LR$-)TJK
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M0Y]J%41N:VAJ[HJ"^B]@#;;(_:+@&B3U:>*U65;Z9&M@,3E*5(>S2(V,&21
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M3D=<8A]$TG&Y?TBPCY:'00?S3[I\8VAJ.9_)RG:ORCM5)8!R3+-"40HD*R#
ME!: 48D *CC*TC2#R*W'1_<04]M;.)"R+BOF562I!\Q^"HX#T<#\&8".5]9F
M/P 7IV]V/'ZT/,Y^]=H)G6>N#.QSK3:;N260S>RN>G"SPTYSR14I,D!(:?QD
M7## =)$"B9 L!8580Z_NC1WC3.U3;\1,]G)Z]K?N@-/-U(H TL ?^S$^ X0J
MSL 0MYMUQUCCMK/N5_BHG_69R_W3):ZS7PF$GY<;M9:/"D%<;@.84F*8PQ)
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M05+C#6("B?3LX7UZI.GMS#<=1M=UA]&J.^LZF57"5KU;ZY^$-VP]P-G-%XR
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MGIHE^KX_EL*MJVCDWZ;\!C1"]ID8-P(<".XQPXN7(NV?6NV/6=QL:8_QQTV
M]@?F**<YX!&7G*6_87^]^^M!+=:JZ6=P2P2"2F8E8"(M <X% [P@!!0L0XJ6
MG&8T]3]+?S3.U,C+V-H_9VM;24B;#V?#_K*-'1?&2:M.CK^R6[P)<0R]G(/8
MU3:[&+C!3; *'"-BTLB8O&JDC&IG]>(PP+GZX[%>X%Q]I\*GS]5W7QY:1?QY
MY5\S3FUE?5VN;(CJ>K-9S?ACO6.X_&QTLV7CEG/ST+MM-;E;(5*J,"H 9"0%
M&)<8E!DF "-,4\1U 96XW2PW;.[&)G'$\B*?G7##?4@W=HQD_8.M5*/;O_U+
MB=+B[XFJ=/2M/1YEZBBAHB#4&+5:Y&;J& 4LESG((#+_EQ-4I/CV0:UF2_E]
MPU:;J4[@<Q&'F\;7ZFZVL#T1D]=L;NO>O,B\95!(6[\?I-694:8Y8)AQ8!9U
M6J:L5)KES;R]6\AIS]I6P.'FS(SPTA/F9@Z,/P4#6P^G.@-<)3NEDD:KI*U6
MLEDFAXKMRL_&["00$^G(K0:BB#9R+X*8<!XW*XCZ]#!C:;OOU,16Q4JQM7JK
MZO_>9I(5,$TID%(:&X@B8P-)6 (DRAS2LE!0.U7S<!IM:G[5KDRTK;6PGE?)
M37^K)/?CVGZ(W2@T&G #,^-6SJMDFWA1BYB\V@H;T;UR B4JB?6/."HW.2G_
MG'+<;@ICDB:PM_ZFA)I51]8_JTW]#6UND8(\S7$*:$J-1:ZA!!1IVRZEA!I#
MF9),^@7:^H:;7E!M*VVRVHE[97E%FO_,;4%H-I\O_[1VW+K:Q9'+1[[1C_.$
M;6^TX7=1GUR;+]=K<]V_H@PGK^R;>F7_#CVW>'KGRXV58LW!.%D-Z^1;"WRF
MS1J27&]AKU!O3@;:PJ!739> B,:9"UI1V:IWP%')RD7UYUSE=(]_U;+K>[60
M-BOA_9S=W0J1,9XQ!0P9<8!)R4%IRZ\BAC*-92FD*%S+E1T\>6K&S$ZXQ$KG
M7I_L$*Y^6K@(A*$YP$U_KTID)W4-+D%V^+31:H^=5*)==.ST!?Y'D=Z]_?W;
M]>>;U6S^,/LY6\T6V_J:C!**I)" E<I\@P7. 4N5 (01E$N,)"+.)V:Z!IG:
MY]C(F?PM:8GJ?NZC$\O^#S060@-_JXV(?VO)&' VIA,C][,Q,; :Z6Q,$&9>
M)V/.@=%S,J;SUM%.QIP3OGTRYNRU8?[1MD"!+4SP8;U^M%;G%_UQN;B[4:O[
MMXIO;E4NLA+* FC*#1.R(@5<H1P0DN=4,:RU0#[;+>>'G!HO[BIW5.4ZYD92
M8(:]3Z21M:IS8Y/%9XTJB5BN?;,1'6;!S?>)B^W C'H(ZU9<B^7''<16Y'C.
MCCL\45T>AV%'=7S<87CN_GC<>6&S[7KO^<WR_F&YJ+*U;0Z:D&F!>%$ C(6M
M^<=+:Y390RPLETP@)+E322ZGT:;&0DVOY[V002E__0"[ALXBP3:TR>:+6'B3
M[#XDAFF.?7+$EVF*W:=\9S/LWIN"-WL?[Q_GM@E#M9=L'[Y2/]1B7?79L6D]
M=A>M/EQ*!"^TSBE(-3-F32F-69-!"K@N4ZDI1"*%/ESB,_C4J*4E>Q,B.9 ^
M:1+3#OI=>?*.U]PX;_0.@OCP&[\1P0[9\/5&+?8&L+L 8V\(>T-S8H/8_QF7
MMG!\P]8_[/];3OW)YLWIMN\_EJN-M<OVIY/K<??G23.N\U)B#2#BQ/AV6!H2
M1!00X]?)(I<:^M7#OURDJ5%CZS3^=UL&VZ-D9L1Y<K3+1D5_8)JTXE\E]L^D
MI445<6R)/U+SQ4OQ'*C;8K!8+]1>\5(8N_LI7OSDT$Y#-^RO#](\MZH38'=3
M/S]6^[F9RK HM0(IDA)@4:2@%&4.2JDY2C,DL<K\6@YUC#0UPFRZ[-A##(?B
M)K6\OEV(N@ ^'_6+!MO0;FHH8@$=BLZ@<6&KHJZGC]RSZ(R2Q\V+SMT04.(0
M_IH?%++"VQ*'F*HR+17@2AJW4ZC"6ES<_%%JD1)69CCS*''8,<ST<HTJ0=ME
MTCZQ)ULJ#7O4E>O"5$-&(4LYR+3* -99!AAC&A20LZPH>8Z4DRL?"]$Q:/8
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M&Q[[H:-TC0955\X&[)T224N+J_9TC',V+ C3@0Z$^<GR0J? @@#K/OH5]KB
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M*^!Y6O&>..>S&T8+;YX6M!W5[+@B@'>^?O_]TX>;YB6"!&LIA 0X1X9V!)&
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M.99$9<:0T%BZ$S)&1R65FN#O8*-I>.S6*2";^:(C>'KFB%K#OV]4;-$Y]!1
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M!86YH+;WR@?H'RMEX8T&?Q8FMNV&V_UK$>;VC6.P>^;/0<>Y?4??WH:@GY;
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MEO6?T],6ZT%R=Z*5&T6.3EM(0W-Q6C\_WCG\(M:^U>+U7#\LA39/8OFO3=6
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MW/$'531/,0FMWM$H:6S\42OKD[>\MD4],!_@[Y<GOC^6$L_3M9@5]=F?2U/
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M$83&>([C=PX8S]&H^GX\1_.E;6M!?C>KM1__!_> #VYE]+A83O]O\3)4;Z-
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M3N!<3^>/$Z-UQADN>EHXQY0PY1W3##I:8!IKFVJ1Q^SY1<H?&VE4>H)W1=&
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MHK .MM_;B_!6C+XYN]G&'K?$3<X)'&?$GM0"?/5UO14NY>Q1VM#<$=R!T)T
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M&_GX%JLW3;:GNC^K%&;_&T.=PR(C67X#,M13(-H):'-P$8))6!,#1C9J/3T
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M G>W>7GW1_AT-3E1ZJ"59B"PUF=E+."](HYX],5;IY-O<U]S.SV]N%@#HVH
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MKM/ $VYU(']/0"''G[Q 6@K>&PU>)E:"YL'(1F'9KB3VD@8X$ SW;%$+S70
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M0#EW 9(7B]7Z3;G- N-!$[<1=*D=MK7W$+Q+X%*T5@AC(VM3Q7N/E'$S#>T
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M6F%ZW.ND=R/:@<SC,:6[(&R[*>U;<R-(K]Q)K;)S3O_6ZJT52B%D5IR)4.I
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M',]P_GV2L+)U8;*TP2A@@=>G%$X98J?VJ2K1!2&]++9-;/$L66-#79^8^"D
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MY"HN[GL^J$3T7"2FE*@]85U@T:%BWLA2I,A 'E ;W_ A(0.;D9<.-P[0PKA
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MX.A;JH-[@[3.=Y(+*0(NSV;U%=ILNG9I<KVG35DPDS4)*2K#(D0R@D*K8J(
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M%3,[5$H#J_97A*OEVK]!R"%[*UE&29Q+8C_62#8;,I(I>D+\SYXI/5YSF'N
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M$*U-_<VAV4S#P%AJK?99KSH8'8INLE-1V2@D!6A:U'Z@1#8#[A7+H 3$:%+
MU!!'0U_H]:'99X&RAYA'D#:Y=3?6OLEMP7(N6//1'+(BO]-(%ATZ%B1 "!!
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M3%9E#+MX1N[>. E40Z*H"^\GO:M<#T5\'(&QMYE?<#53LB0KR2'0B3'B#*,
M1)##B'04A";5K=DI_86.+-%0YE-/R.B3I^>#PV_ <8O7U<'[?5!+M1F6LIYT
ML;A?_13NOHB9SA)CL HLYZ$.K>/@,"!P)1F+=#"2':$MT>L$-I3D-((]NU1"
M;>-O9HKQG!L/FEQ*4-I+<(QV9DP.4FB9/<:V/*7!:A]&]Y3.X?V%GM*'VWQ*
MIMSV'^J7&.[PKW_Y#U!+ 0(4 Q0    (  >!G52R[3?TJ <  /0@   >
M          "  0    !A,C R,C%Q97@S,3%C96]C97)T:69I8V%T:2YH=&U0
M2P$"% ,4    "  '@9U4ZCZ44J@'  "E)   '@              @ 'D!P
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M   0              "  0)( P!J;FHM,C R,C T,#,N>'-D4$L! A0#%
M  @ !X&=5'3=2!(_)   _&<! !0              ( ! 5\# &IN:BTR,#(R
M,#0P,U]C86PN>&UL4$L! A0#%     @ !X&=5,P=)$&N>   /  % !0
M         ( !<H,# &IN:BTR,#(R,#0P,U]D968N>&UL4$L! A0#%     @
M!X&=5*28URDZCP  ?*$  !,              ( !4OP# &IN:BTR,#(R,#0P
M,U]G,2YJ<&=02P$"% ,4    "  '@9U4(QUF-@%X  "(B   $P
M    @ &]BP0 :FYJ+3(P,C(P-# S7V<R+FIP9U!+ 0(4 Q0    (  >!G52_
M0'L813\  !=9   3              "  >\#!0!J;FHM,C R,C T,#-?9S,N
M:G!G4$L! A0#%     @ !X&=5-S$VH7S.P  BU0  !,              ( !
M94,% &IN:BTR,#(R,#0P,U]G-"YJ<&=02P$"% ,4    "  '@9U4MJY*=6HZ
M  !/3P  $P              @ &)?P4 :FYJ+3(P,C(P-# S7V<U+FIP9U!+
M 0(4 Q0    (  >!G53YYW='$%H  ,IN   3              "  22Z!0!J
M;FHM,C R,C T,#-?9S8N:G!G4$L! A0#%     @ !X&=5-=$HV9&<0  L8@
M !,              ( !910& &IN:BTR,#(R,#0P,U]G-RYJ<&=02P$"% ,4
M    "  '@9U4TNK=&[97  " ;@  $P              @ '<A08 :FYJ+3(P
M,C(P-# S7V<X+FIP9U!+ 0(4 Q0    (  >!G52K74*)VRD! ,,+#  4
M          "  </=!@!J;FHM,C R,C T,#-?;&%B+GAM;%!+ 0(4 Q0    (
M  B!G51T\7\JUZH  +V.!P 4              "  = '" !J;FHM,C R,C T
@,#-?<')E+GAM;%!+!08     $@ 2 +P$  #9L@@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
